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A B S T R A C T
Background
Researchers have suggested that omega-3 polyunsaturated fatty acids from oily fish (long-chain omega-3 (LCn3), including eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA)), as well as from plants (alpha-linolenic acid (ALA)) benefit cardiovascular health.
Guidelines recommend increasing omega-3-rich foods, and sometimes supplementation, but recent trials have not confirmed this.
Objectives
To assess effects of increased intake of fish- and plant-based omega-3 for all-cause mortality, cardiovascular (CVD) events, adiposity and
lipids.
Search methods
We searched CENTRAL, MEDLINE and Embase to April 2017, plus ClinicalTrials.gov and World Health Organization International Clinical
Trials Registry to September 2016, with no language restrictions. We handsearched systematic review references and bibliographies and
contacted authors.
Selection criteria
We included randomised controlled trials (RCTs) that lasted at least 12 months and compared supplementation and/or advice to increase
LCn3 or ALA intake versus usual or lower intake.
Data collection and analysis
Two review authors independently assessed studies for inclusion, extracted data and assessed validity. We performed separate random-ef-
fects meta-analysis for ALA and LCn3 interventions, and assessed dose-response relationships through meta-regression.
Main results
We included 79 RCTs (112,059 participants) in this review update and found that 25 were at low summary risk of bias. Trials were of 12
to 72 months' duration and included adults at varying cardiovascular risk, mainly in high-income countries. Most studies assessed LCn3
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supplementation with capsules, but some used LCn3- or ALA-rich or enriched foods or dietary advice compared to placebo or usual diet.
LCn3 doses ranged from 0.5g/d LCn3 to > 5 g/d (16 RCTs gave at least 3g/d LCn3).
Meta-analysis and sensitivity analyses suggested little or no effect of increasing LCn3 on all-cause mortality (RR 0.98, 95% CI 0.90 to
1.03, 92,653 participants; 8189 deaths in 39 trials, high-quality evidence), cardiovascular mortality (RR 0.95, 95% CI 0.87 to 1.03, 67,772
participants; 4544 CVD deaths in 25 RCTs), cardiovascular events (RR 0.99, 95% CI 0.94 to 1.04, 90,378 participants; 14,737 people expe-
rienced events in 38 trials, high-quality evidence), coronary heart disease (CHD) mortality (RR 0.93, 95% CI 0.79 to 1.09, 73,491 partici-
pants; 1596 CHD deaths in 21 RCTs), stroke (RR 1.06, 95% CI 0.96 to 1.16, 89,358 participants; 1822 strokes in 28 trials) or arrhythmia (RR
0.97, 95% CI 0.90 to 1.05, 53,796 participants; 3788 people experienced arrhythmia in 28 RCTs). There was a suggestion that LCn3 reduced
CHD events (RR 0.93, 95% CI 0.88 to 0.97, 84,301 participants; 5469 people experienced CHD events in 28 RCTs); however, this was not
maintained in sensitivity analyses – LCn3 probably makes little or no difference to CHD event risk. All evidence was of moderate GRADE
quality, except as noted.
Increasing ALA intake probably makes little or no difference to all-cause mortality (RR 1.01, 95% CI 0.84 to 1.20, 19,327 participants;
459 deaths, 5 RCTs),cardiovascular mortality (RR 0.96, 95% CI 0.74 to 1.25, 18,619 participants; 219 cardiovascular deaths, 4 RCTs), and
CHD mortality (1.1% to 1.0%, RR 0.95, 95% CI 0.72 to 1.26, 18,353 participants; 193 CHD deaths, 3 RCTs) and ALA may make little or no
difference to CHD events (RR 1.00, 95% CI 0.80 to 1.22, 19,061 participants, 397 CHD events, 4 RCTs, low-quality evidence). However,
increased ALA may slightly reduce risk of cardiovascular events (from 4.8% to 4.7%, RR 0.95, 95% CI 0.83 to 1.07, 19,327 participants; 884
CVD events, 5 RCTs, low-quality evidence with greater effects in trials at low summary risk of bias), and probably reduces risk of arrhythmia
(3.3% to 2.6%, RR 0.79, 95% CI 0.57 to 1.10, 4,837 participants; 141 events, 1 RCT). Effects on stroke are unclear.
Sensitivity analysis retaining only trials at low summary risk of bias moved effect sizes towards the null (RR 1.0) for all LCn3 primary out-
comes except arrhythmias, but for most ALA outcomes, effect sizes moved to suggest protection. LCn3 funnel plots suggested that adding
in missing studies/results would move effect sizes towards null for most primary outcomes. There were no dose or duration effects in
subgrouping or meta-regression.
There was no evidence that increasing LCn3 or ALA altered serious adverse events, adiposity or lipids, except LCn3 reduced triglycerides
by ˜15% in a dose-dependant way (high-quality evidence).
Authors' conclusions
This is the most extensive systematic assessment of effects of omega-3 fats on cardiovascular health to date. Moderate- and high-quality
evidence suggests that increasing EPA and DHA has little or no effect on mortality or cardiovascular health (evidence mainly from supple-
ment trials). Previous suggestions of benefits from EPA and DHA supplements appear to spring from trials with higher risk of bias. Low-
quality evidence suggests ALA may slightly reduce CVD event and arrhythmia risk.
P L A I N   L A N G U A G E   S U M M A R Y
Omega-3 intake for cardiovascular disease
Review question
We reviewed randomised trials (where participants have an equal chance of being assigned to either treatment) examining effects of
increasing fish- and plant-based omega-3 fats on heart and circulatory disease (called cardiovascular diseases, CVD, which include heart
attacks and stroke), fatness and blood fats (lipids, including cholesterol, triglycerides, high-density lipoprotein (HDL – 'good' cholesterol)
and low-density lipoprotein (LDL – 'bad' cholesterol)).
Background
Omega-3 fats are essential – to stay healthy we must obtain some from food. The main types of omega-3 fats are alpha-linolenic acid (ALA),
a fat found in plant foods, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both found in fish. There is a common belief that
eating more fish or taking omega-3 supplements reduces our risk of heart disease, stroke and death.
Study characteristics
The evidence is current to April 2017. The review included 79 trials involving over 112,000 people. These studies assessed effects of greater
omega-3 intake versus lower or no omega-3 intake for heart and circulatory disease. Twenty-five studies were very trustworthy (well-
designed so as not to give biased results). Participants were adults, some with existing illness and some healthy, living in North America,
Europe, Australia and Asia. Participants increased omega-3 fats, or maintained their usual fats for at least a year. Most EPA and DHA trials
provided capsules, few gave oily fish.
Key results
Increasing EPA and DHA has little or no effect on all-cause deaths and cardiovascular events (high-quality evidence) and probably makes
little or no difference to cardiovascular death, coronary deaths or events, stroke, or heart irregularities (moderate-quality evidence, coro-
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nary events are illnesses of the arteries which supply the heart). EPA and DHA slightly reduce serum triglycerides and raise HDL (high-
quality evidence).
Eating more ALA (for example, by increasing walnuts or enriched margarine) probably makes little or no difference to all-cause, cardiovas-
cular or coronary deaths or coronary events but probably slightly reduces cardiovascular events and heart irregularities (moderate/low-
quality evidence). Effects of ALA on stroke are unclear as the evidence was of very low quality.
There is evidence that taking omega-3 capsules does not reduce heart disease, stroke or death. There is little evidence of effects of eating
fish. Although EPA and DHA reduce triglycerides, supplementary omega-3 fats are probably not useful for preventing or treating heart and
circulatory diseases. However, increasing plant-based ALA may be slightly protective for some heart and circulatory diseases.
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Summary of findings for the main comparison.   High versus low LCn3 for preventing cardiovascular disease and mortality (primary outcomes)
High versus low LCn3 for preventing cardiovascular disease and mortality (primary outcomes)
Patient or population: adults with or without existing CVD
Setting: participants were living at home for most or all of the duration of their trials. Most studies were carried out in high-income economies (World Bank 2018), but four
trials were carried out in upper-middle income countries (Argentina, Iran, Turkey and China). No studies took place in low- or low-middle income countries.
Intervention: higher intake of long-chain omega-3 fats
Comparison: lower intake of long-chain omega-3 fats
The intervention was dietary supplementation, a provided diet or advice on diet. Supplementation may have been in oil or capsule form or as foodstuffs provided, to be
consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuffs or supplements must have been: oily fish or fish oils as a food, oil, made into a
spreading fat or supplementing another food (such as bread or eggs). Refined eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or concentrated fish or algal oils,
were also accepted.
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
lower LCn3
Risk with
higher LCn3
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Certainty of
the evidence
(GRADE)
Comments
All-cause mortality –
deaths
Assessed with: number
of participants dying of
any cause, whether re-
ported as an outcome or
a reason for dropout
Duration: range 12 to 72
months
90 per 1,000 88 per 1,000
(83 to 92)
RR 0.98
(0.93 to 1.03)
92,653
(39 RCTs)
⊕⊕⊕⊕
Higha
Meta-analysis and indications of bias suggest risk re-
duction of less than 2%. Long-chain omega-3 fat intake
makes little or no difference to all-cause mortality.
Cardiovascular mor-
tality – cardiovascular
deaths
Assessed with: deaths
from any cardiovascular
cause. Where this was
not available, cardiac
death was used instead
where known.
69 per 1,000 66 per 1,000
(60 to 71)
RR 0.95
(0.87 to 1.03)
67,772
(25 RCTs)
⊕⊕⊕⊝
Moderateb
Meta-analysis and indications of bias suggest risk re-
duction of less than 5%. Long-chain omega-3 fat intake
probably makes little or no difference to cardiovascular
deaths.
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Duration: range 12 to 72
months
Cardiovascular events
– cardiovascular events
Assessed with: number
of participants experi-
encing any cardiovascu-
lar event
Duration: range 12 to 72
months
165 per 1,000 164 per 1,000
(155 to 172)
RR 0.99
(0.94 to 1.04)
90,378
(38 RCTs)
⊕⊕⊕⊕
Highc
Meta-analysis and indications of bias suggest risk re-
duction of less than 1%. Long-chain omega-3 fat intake
makes little or no difference to risk of cardiovascular
events.
Coronary heart disease
mortality – CHD deaths
Assessed with: coronary
deaths, or where these
were not reported, IHD
death, fatal MI or cardiac
death (in that order)
Duration: range 12 to 72
months
22 per 1,000 21 per 1,000
(18 to 24)
RR 0.93
(0.79 to 1.09)
73,491
(21 RCTs)
⊕⊕⊕⊝
Moderated
Meta-analysis and indications of bias suggest risk re-
duction of less than 7%. Long-chain omega-3 fat intake
probably makes little or no difference to coronary heart
mortality.
Coronary heart disease
events – CHD events
Assessed with: num-
ber of participants ex-
periencing the first out-
come in this list report-
ed for each trial: CHD or
coronary events; total
MI; acute coronary syn-
drome; or angina (stable
and unstable)
Duration: range 12 to 72
months
68 per 1,000 63 per 1,000
(59 to 65)
RR 0.93
(0.88 to 0.97)
84,301
(28 RCTs)
⊕⊕⊕⊝
Moderatee
Meta-analysis and indications of bias suggest risk re-
duction of less than 7%. Long-chain omega-3 fat intake
probably makes little or no difference to risk of coronary
heart events.
Stroke
Assessed with: number
of participants experi-
encing at least one fatal
or non-fatal, ischaemic
or haemorrhagic stroke
20 per 1,000 21 per 1,000
(19 to 23)
RR 1.06
(0.96 to 1.16)
89,358
(28 RCTs)
⊕⊕⊕⊝
Moderatef
Meta-analysis and indications of bias suggest increased
risk of less than 6%. Long-chain omega-3 fat intake
probably makes little or no difference to risk of experi-
encing a stroke.
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Duration: range 12 to 72
months
Arrhythmias
Assessed with: number
of participants experi-
encing fatal or nonfa-
tal, new or recurrent ar-
rhythmia, including atri-
al fibrillation, ventricular
tachycardia and ventric-
ular fibrillation.
Duration: range 12 to 72
months
68 per 1,000 66 per 1,000
(62 to 72)
RR 0.97
(0.90 to 1.05)
53,796
(28 RCTs)
⊕⊕⊕⊝
Moderateg
Meta-analysis and indications of bias suggest risk re-
duction of less than 3%. Long-chain omega-3 fat intake
probably makes little or no difference to risk of arrhyth-
mia.
Harms: bleeding
Assessed with: number
of participants experi-
encing bleeding events.
Duration: range 12 to 72
months
8 per 1,000 8 per 1,000
(5 to 11)
RR 1.06
(0.73 to 1.52)
45,562
(8 RCTs)
⊕⊝⊝⊝
Very lowh
The effect of long-chain omega-3 fat intake on bleeding
is unclear as the evidence is of very low quality.
Harms: pulmonary em-
bolus or DVT
Assessed with: num-
ber of participants ex-
periencing pulmonary
embolus or deep vein
thrombosis
Duration: range 18 to 36
months
5 per 1,000 6 per 1,000
(2 to 18)
RR 1.25
(0.41 to 3.78)
3,011
(4 RCTs)
⊕⊝⊝⊝
Very lowi
The effect of long-chain omega-3 fat intake on pul-
monary embolus or DVT is unclear as the evidence is of
very low quality.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CHD: coronary heart disease; CI: confidence interval; DVT: deep vein thrombosis; IHD: ischaemic heart disease; MI: myocardial infarction; RCT: randomised controlled trial;
RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
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Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aAll-cause mortality, LCn3• Risk of bias: effect size moved closer to no effect (RR 1.0) when analysis was limited to studies at low summary risk of bias and low risk of compliance bias (adding weight to
the suggestion of little or no effect) but did not alter with fixed-effect meta-analysis or results in the analysis limited to larger studies. It was further noted by the WHO NUGAG
Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern
for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded.• Inconsistency: I2 was < 60% and I2 reduced when analysis was limited to studies at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not
downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD
as well as non-CVD health problems. Low- and middle-income countries were represented but underrepresented. Not downgraded.• Imprecision: tight confidence intervals, very large numbers of participants have taken part in RCTs in long-term studies with consistent results. Given the lack of a statistically
significant effect in this very large set of participants, any effect appears too small to be individually relevant. Not downgraded.• Publication bias: the funnel plot suggested that some small studies with higher numbers of events in the intervention group might be missing. If such missing studies were
added back in, the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded.
bCardiovascular mortality, LCn3• Risk of bias: effect size moved closer to no effect (RR 1.0) when analysis was limited to studies at low summary risk of bias and low risk of compliance bias (adding weight to
the suggestion of little or no effect) but did not alter with fixed-effect meta-analysis or results in the analysis limited to larger studies. It was further noted by the WHO NUGAG
Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern
for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded.• Inconsistency: I2 was < 60% and I2 reduced when analysis was limited to studies at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not
downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD
as well as non-CVD health problems. All studies were conducted in high-income countries. Not downgraded.• Imprecision: Although very large numbers of participants have taken part in RCTs in long-term studies, with consistent results, the 95% CI includes the null. Given the lack
of a statistically significant effect in this very large set of participants, any effect appears too small to be individually relevant. However, as 95% confidence intervals do not
exclude important benefits or harms. Downgraded once.• Publication bias: the funnel plot suggested that some small studies with higher numbers of events in the intervention group might be missing. If such missing studies were
added back in, the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded.
cCardiovascular events, LCn3• Risk of bias: effect size moved closer to no effect (RR 1.0) when analysis was limited to studies at low summary risk of bias and low risk of compliance bias (adding weight to
the suggestion of little or no effect) but did not alter with fixed-effect meta-analysis or results in the analysis limited to larger studies. It was further noted by the WHO NUGAG
Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern
for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded.• Inconsistency: I2 was < 60% and I2 reduced when analysis was limited to studies at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not
downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD
as well as non-CVD health problems. Low- and middle-income countries were represented but underrepresented. Not downgraded.• Imprecision: very large numbers of participants have taken part in RCTs in long-term studies with consistent results. Given the lack of an important effect in this very large set of
participants, any effect appears too small to be individually relevant. However, as 95% confidence intervals do not exclude important benefits or harms, we downgraded once.• Publication bias: the funnel plot suggested that some small studies with higher numbers of events in the intervention group might be missing. If such missing studies were
added back in, the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded.
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d Coronary heart disease mortality, LCn3• Risk of bias: effect size moved closer to no effect (RR 1.0) when analysis was limited to studies at low summary risk of bias and low risk of compliance bias (adding weight to
the suggestion of little or no effect) but did not alter with fixed-effect meta-analysis or results in the analysis limited to larger studies. It was further noted by the WHO NUGAG
Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern
for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded.• Inconsistency: I2 was < 60% and I2 reduced when analysis was limited to studies at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not
downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD
as well as non-CVD health problems. All studies were conducted in high-income countries. Not downgraded.• Imprecision: very large numbers of participants have taken part in RCTs in long-term studies with consistent results. Given the lack of a statistically significant effect in this
very large set of participants, any effect appears too small to be individually relevant. However, as 95% confidence intervals do not exclude important benefits or harms we
downgraded once.• Publication bias: the funnel plot suggested that some small studies with higher numbers of events in the intervention group might be missing. If such missing studies were
added back in the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded.
e Coronary heart disease events, LCn3• Risk of bias: effect size moved closer to no effect (RR 1.0) when was analysis limited to studies at low summary risk of bias. This adds weight to the suggestion of little or no
effect. However, effect size did not alter with fixed-effect meta-analysis or limiting to studies at low risk of compliance bias or larger trials. It was further noted by the WHO
NUGAG Subgroup on Diet and Health that there was a significant effect observed in main analysis but the effect moved closer to a non-significant, null effect when analysis
was limited to studies at low summary risk of bias. Downgraded once.• Inconsistency: I2 was < 60% and I2 reduced when analysis was limited to studies at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not
downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD
as well as non-CVD health problems. Low- and middle-income countries were represented but underrepresented. Not downgraded.• Imprecision: 95% CI did not include the null. Not downgraded.• Publication bias: the funnel plot suggested that some small studies with higher numbers of events in the intervention group might be missing. If such missing studies were
added back in, the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded.
f Stroke, LCn3• Risk of bias: effect size moved closer to no effect (RR 1.0) when analysis limited to studies at low summary risk of bias (adding weight to the suggestion of little or no effect), but
did not alter with fixed-effect meta-analysis or limiting to larger studies. Limiting to studies at low risk of compliance problems resulted in the suggestion of greater harm. It was
further noted by the WHO NUGAG Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation
of effect. This is less of a concern for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded.• Inconsistency: I2 was < 60%. Not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD
as well as non-CVD health problems. Low- and middle-income countries were represented but underrepresented. Not downgraded.• Imprecision: very large numbers of participants have taken part in RCTs in long-term studies with consistent results. Given the lack of a statistically significant effect in this
very large set of participants any effect appears too small to be individually relevant. However, as 95% confidence intervals do not exclude important benefits or harms, we
downgraded once.• Publication bias: the funnel plot did not suggest any small study bias. Not downgraded.
g Arrhythmias, LCn3• Risk of bias: effect size remained similar in most sensitivity analyses, but moved closer to no effect (RR 1.01) when analysis used fixed-effect meta-analysis (adding weight to
the suggestion of little or no effect) and suggested harm when limited to studies at low summary risk of bias. Not downgraded.• Inconsistency: I2 was < 60% and I2 reduced when analysis was limited to studies at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not
downgraded.
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• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD
as well as non-CVD health problems. Low- and middle-income countries were represented but underrepresented. Not downgraded.• Imprecision: As 95% confidence intervals do not exclude important benefits we downgraded once.• Publication bias: funnel plot not interpretable as studies all of a similar size and weight. Not downgraded.
h Bleeding, LCn3• Risk of bias: effect size changed direction (from harmful to protective) when analysis limited to studies at low summary risk of bias. Downgraded once.• Inconsistency: I2 was < 60%. Not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD
as well as non-CVD health problems. Low- and middle-income countries not represented. Not downgraded.• Imprecision: 95% confidence intervals do not exclude large and important benefits or harms. Downgraded twice.• Publication bias: insufficient studies for funnel plot. Not downgraded.
i Pulmonary embolus or DVD, LCn3• Risk of bias: effect size suggested greater harm when analysis limited to studies at low summary risk of bias. Downgraded once.• Inconsistency: I2 was < 60%. Not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD
as well as non-CVD health problems. Low- and middle-income countries not represented. Not downgraded.• Imprecision: 95% confidence intervals do not exclude large benefits or large harms. Downgraded twice.• Publication bias: insufficient studies for funnel plot. Not downgraded.
 
 
Summary of findings 2.   High versus low ALA omega-3 fats for preventing cardiovascular disease (primary outcomes)
High versus low ALA omega-3 fats for preventing cardiovascular disease (primary outcomes)
Patient or population: adults with or without existing CVD
Setting: participants were living at home for most or all of the duration of their trials. Most studies were carried out in high-income economies (World Bank 2018), but four
trials were carried out in upper-middle income countries (Argentina, Iran, Turkey and China). No studies took place in low- or low-middle income countries.
Intervention: higher intake of ALA
Comparison: lower intake of ALA
The intervention was dietary supplementation, a provided diet or advice on diet. Supplementation may have been in oil or capsule form or as foodstuffs provided, to be
consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuffs or supplements must have been: refined ALA, linseed (flax), canola (rapeseed),
perilla, purslane, mustard seed, candlenut, stillingia or walnut as a food, oil, made into a spreading fat or supplementing another food (such as bread or eggs). For ALA
sources the product consumed had to have an omega-3 fat content of at least 10% of the total fat content.
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
lower ALA
Risk with
higher ALA
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Certainty of
the evidence
(GRADE)
Comments
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All-cause mortality
– deaths
Assessed with: num-
ber of participants
dying of any cause,
whether reported as
an outcome or a rea-
son for dropout
Duration: range 12 to
40 months
25 per 1000 25 per 1000
(21 to 29)
RR 1.01
(0.84 to 1.20)
19327
(5 RCTs)
⊕⊕⊕⊝
Moderatea
Meta-analysis and sensitivity analyses suggest risk increase
of less than 1%. ALA intake probably makes little or no dif-
ference to all-cause mortality.
Cardiovascular
mortality – cardio-
vascular deaths
Assessed with:
deaths from any car-
diovascular cause.
Where this was not
available cardiac
death was used in-
stead where known.
Duration: range 12 to
40 months
12 per 1000 12 per 1000
(9 to 15)
RR 0.96
(0.74 to 1.25)
18619
(4 RCTs)
⊕⊕⊕⊝
Moderateb
Meta-analysis and sensitivity analyses suggest risk reduc-
tion of less than 5%. ALA intake probably makes little or no
difference to cardiovascular mortality.
Cardiovascular
events – cardiovas-
cular events
Assessed with: num-
ber of participants
experiencing any car-
diovascular event
Duration: range 12 to
40 months
48 per 1000 47 per 1000
(39 to 57)
RR 0.95
(0.83 to 1.07)
19327
(5 RCTs)
⊕⊕⊝⊝
Lowc
Meta-analysis and sensitivity analyses suggest risk reduc-
tion of 5% to 10% (9% reduction in trials of low summa-
ry risk of bias, 10% in trials at low risk of compliance prob-
lems). ALA intake may reduce the risk of cardiovascular
events but by a very small amount (from 4.8 to 4.7%). One
thousand people would need to consume more ALA to pre-
vent a single person experiencing a CVD event (NNT=1000).
Coronary heart
mortality – CHD
deaths
Assessed with: Coro-
nary deaths, or
where these were
not reported, IHD
death, fatal MI or car-
11 per 1000 10 per 1000
(8 to 14)
RR 0.95
(0.72 to 1.26)
18353
(3 RCTs)
⊕⊕⊕⊝
Moderated
Meta-analysis and sensitivity analyses suggest risk reduc-
tion of 5% to 8%. ALA intake probably has little or no effect
on risk of CHD mortality.
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diac death (in that
order)
Duration: range 12 to
40 months
Coronary Heart Dis-
ease – CHD events
Assessed with: num-
ber of participants
experiencing the first
outcome in this list
reported for each
trial: CHD or coro-
nary events; total
MI; acute coronary
syndrome; or angina
(stable and unstable)
Duration: range 12 to
40 months
22 per 1000 22 per 1000
(17 to 28)
RR 1.00
(0.82 to 1.22)
19061
(4 RCTs)
⊕⊕⊝⊝
Lowe
Meta-analysis and sensitivity analyses suggest risk reduc-
tion of 0% to 9%. ALA intake may make little or no differ-
ence to CHD events.
Stroke
Assessed with: num-
ber of participants
experiencing at least
one fatal or non-
fatal, ischaemic or
haemorrhagic stroke
Duration: range 12 to
40 months
2 per 1000 3 per 1000
(2 to 5)
RR 1.15
(0.66 to 2.01)
19327
(5 RCTs)
⊕⊝⊝⊝
Very lowf
Meta-analysis and sensitivity analyses suggest risk increase
of −15% to 23%. The effect of ALA intake on stroke is un-
clear as the evidence is of very low quality.
Arrhythmias – AF,
VT, VF
Assessed with: num-
ber of participants
experiencing fatal or
nonfatal, new or re-
current arrhythmia,
including atrial fib-
rillation, ventricular
tachycardia and ven-
tricular fibrillation
33 per 1000 26 per 1000
(19 to 36)
RR 0.79
(0.57 to 1.10)
4837
(1 RCT)
⊕⊕⊕⊝
Moderateg
Meta-analysis and sensitivity analyses suggest risk reduc-
tion of 21%. ALA intake probably reduces the risk of ar-
rhythmias a small amount (from 3.3 to 2.6%). 143 people
would need to consume more ALA to prevent a single per-
son experiencing an arrhythmic event (NNT=143).
Cochrane
Library
Trusted evidence.
Inform
ed decisions.
Better health.
  
Cochrane Database of System
atic Review
s
O
m
ega-3 fatty acids for the prim
ary and secondary prevention of cardiovascular disease (Review
)
Copyright ©
 2018 The Cochrane Collaboration. Published by John W
iley & Sons, Ltd.
12
Duration: 1 trial of 40
months
Harms: bleeding
Assessed with: num-
ber of participants
experiencing bleed-
ing events
The effect of ALA intake on bleeding is unclear as no studies reported this outcome.
Harms: pulmonary
embolus or DVT
Assessed with: num-
ber of participants
experiencing pul-
monary embolus or
deep vein thrombo-
sis
Duration: range 24
months
3 per 1000 1 per 1000
(0 to 23)
RR 0.32
(0.01 to 7.80)
708
(1 study)
⊕⊝⊝⊝
Very lowh
The effect of ALA intake on pulmonary embolus or DVT is
unclear as the evidence is of very low quality.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
ALA: alpha-linolenic acid; CHD: coronary heart disease; CI: confidence interval; DVT: deep vein thrombosis; IHD: ischaemic heart disease; MI: myocardial infarction; RCT:
randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
a All-cause mortality, ALA• Risk of bias: there was little or no effect in the main meta-analysis or when data were limited to RCTs at low summary risk of bias, low risk of compliance problems or larger
trials, though a suggestion of increased risk of death with fixed-effect meta-analyses. Not downgraded.• Inconsistency: I2 was < 60%; not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD
as well as non-CVD health problems. All studies were conducted in high-income countries. Not downgraded.• Imprecision: large numbers of participants have taken part in RCTs in long-term studies with consistent results. However, as 95% confidence intervals do not exclude impor-
tant benefits or harms we downgraded once.• Publication bias: funnel plot not useful as fewer than 10 trials included. Not downgraded.
b Cardiovascular mortality, ALA
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• Risk of bias: there was little or no effect in the main analysis, or when data were limited to RCTs at low summary risk of bias, larger trials or fixed-effect meta-analysis, though
a small benefit was suggested when studies were limited to trials with low risk of compliance bias. Not downgraded.• Inconsistency: I2 was < 60%; not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD
as well as non-CVD health problems. All studies were conducted in high-income countries. Not downgraded.• Imprecision: large numbers of participants have taken part in RCTs in long-term studies with consistent results. However, as 95% confidence intervals do not exclude impor-
tant benefits or harms we downgraded once.• Publication bias: funnel plot not useful as fewer than 10 trials included. Not downgraded.
c Cardiovascular events, ALA• Risk of bias: there was a small effect in the main analysis, with larger trials and in fixed-effect analysis, and a larger effect when data were limited to RCTs at low summary
risk of bias or at low risk from compliance problems. Downgraded once.• Inconsistency: I2 was <60%; not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD
as well as non-CVD health problems. All studies were conducted in high-income countries. Not downgraded.• Imprecision: large numbers of participants have taken part in RCTs in long-term studies with consistent results. However, as 95% confidence intervals do not exclude impor-
tant benefits or harms we downgraded once.• Publication bias: funnel plot not useful as fewer than 10 trials included. Not downgraded.
d Coronary heart disease mortality, ALA• Risk of bias: while ALA reduced CHD mortality by 5% in the main analysis, fixed-effect analysis and in larger trials, limiting data to RCTs at low summary risk of bias and low
risk of compliance problems resulted in 7%-8% reductions. Not downgraded.• Inconsistency: I2 was < 60%; not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD
as well as non-CVD health problems. All studies were conducted in high-income countries. Not downgraded.• Imprecision: large numbers of participants have taken part in RCTs in long-term studies with consistent results. However, as 95% confidence intervals do not exclude impor-
tant benefits or harms we downgraded. Downgraded once.• Publication bias: funnel plot not useful as fewer than 10 trials included. Not downgraded.
e Coronary heart disease events, ALA• Risk of bias: there was little or no effect in the main analyses, in fixed-effect meta-analysis, or in larger studies, but some risk reduction (8 to 9%) when data were limited to
RCTs at low summary risk of bias or low risk of compliance bias. Downgraded once.• Inconsistency: I2 was < 60%; not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD
as well as non-CVD health problems. All studies were conducted in high-income countries. Not downgraded.• Imprecision: large numbers of participants have taken part in RCTs in long-term studies with consistent results. However, as 95% confidence intervals do not exclude impor-
tant benefits or harms we downgraded. Downgraded once.• Publication bias: funnel plot not useful as fewer than 10 trials included. Not downgraded.
f Stroke, ALA• Risk of bias: the main analysis, fixed-effect analysis, and larger trials suggest increased risk of stroke with more ALA, but there was little or no effect when data were limited
to RCTs at low summary risk of bias, and a suggestion of benefit when limited to trials with low risk of compliance problems. Downgraded twice.• Inconsistency: I2 was < 60%; not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD
as well as non-CVD health problems. All studies were conducted in high-income countries. Not downgraded.
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• Imprecision: large numbers of participants have taken part in RCTs in long-term studies, but only 49 participants experienced strokes. 95% confidence intervals do not exclude
important benefits or harms, downgraded once.• Publication bias: funnel plot not useful as fewer than 10 trials included. Not downgraded.
g Arrhythmias, ALA• Risk of bias: there was a 21% reduction in risk of arrhythmia in the main analysis, when data were limited to RCTs at low summary risk of bias, in larger trials and when data
were limited to trials at low risk from compliance. Not downgraded.• Inconsistency: only one trial, no inconsistency. Not downgraded.• Indirectness: a single trial, which included adults with previous MI in a high-income country and only assessed new arrhythmia. Not downgraded.• Imprecision: large numbers of participants have taken part in this long term study. However, as 95% confidence intervals do not exclude important benefits or harms we
downgraded once.• Publication bias: funnel plot not useful as fewer than 10 trials included. Not downgraded.
h Pulmonary embolus or DVD, ALA• Risk of bias: the single trial was not at low summary risk of bias. Downgraded once.• Inconsistency: with one trial no inconsistency. Not downgraded.• Indirectness: healthy men and women, no participants with CVD risk factors or previous CVD; low- and middle-income countries not represented. Not downgraded.• Imprecision: only one event included in a single trial. Downgraded twice.• Publication bias: insufficient studies for funnel plot. Not downgraded.
 
 
Summary of findings 3.   High versus low omega-3 fats for modification of CVD risk factors (adiposity and lipids): key outcomes
High versus low omega-3 fats for modification of CVD risk factors (adiposity and lipids)
Patient or population: adults with or without existing CVD
Setting: participants were living at home for most or all of the duration of their trials. Most studies were carried out in high-income economies (World Bank 2018), but four
trials were carried out in upper-middle income countries. No studies took place in low- or low-middle income countries.
Intervention: higher omega-3 intake (LCn3 or ALA)
Comparison: lower omega-3 intake (LCn3 or ALA)
The intervention was dietary supplementation, a provided diet or advice on diet. Supplementation may have been in oil or capsule form or as foodstuffs provided, to be
consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuffs or supplements must have been: oily fish; fish oils; linseed (flax), canola (rape-
seed), perilla, purslane, mustard seed, candlenut, stillingia or walnut as a food, oil, made into a spreading fat or supplementing another food (such as bread or eggs). For
ALA sources the product consumed had to have an omega-3 fat content of at least 10% of the total fat content. Refined eicosapentaenoic acid (EPA), docosahexaenoic acid
(DHA) or alpha-linolenic acids, or concentrated fish or algal oils, were also accepted.
Anticipated absolute effects* (95% CI)Outcomes
All in trials of 12 to 72 months' dura-
tion
Risk with low
omega-3
Risk with high omega-3
№ of partici-
pants
(studies)
Certainty of
the evidence
(GRADE)
Comments
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Measures of adiposity – LCn3 – Weight,
kg
Mean body
weight was 81.2
kg
MD 0.01 kg lower
(0.84 lower to 0.82 higher)
15812
(12 RCTs)
⊕⊕⊕⊕
Higha
LCn3 intake makes little or no difference
to body weight.
Measures of adiposity – LCn3 – BMI, kg/
m2
Mean BMI was
27.3 kg/m2
MD 0.04 higher
(0.16 lower to 0.24 higher)
15234
(14 RCTs)
⊕⊕⊕⊕
Highb
LCn3 intake makes little or no difference
to BMI.
Serum total cholesterol – LCn3 – TC,
mmol/L
Mean TC was
5.61 mmol/L
MD 0.01 lower
(0.05 lower to 0.04 higher)
37281
(28 RCTs)
⊕⊕⊕⊝
Moderatec
LCn3 intake probably makes little or no
difference to serum total cholesterol.
Serum triglyceride, fasting – LCn3 – TG,
mmol/L
Mean TG was
1.59 mmol/L
MD 0.24 lower
(0.32 lower to 0.17 lower)
35534
(24 RCTs)
⊕⊕⊕⊕
Highd
Increasing LCn3 intake reduces serum
triglyceride.
Serum high density lipoprotein – LCn3 –
HDL, mmol/L
Mean HDL was
1.32 mmol/L
MD 0.02 higher
(0 to 0.04 higher)
37237
(27 RCTs)
⊕⊕⊕⊕
Highe
Increasing LCn3 intake has little or no ef-
fect on serum HDL.
Serum low density lipoprotein – LCn3 –
LDL, mmol/L
Mean LDL was
3.27 mmol/L
MD 0.01 higher
(0.01 lower to 0.03 higher)
35035
(23 RCTs)
⊕⊕⊕⊝
Moderatef
LCn3 intake probably makes little or no
difference to serum LDL.
Measures of adiposity – ALA – Weight, kg Mean weight
was 80.9 kg
MD 0.17 higher
(0.61 lower to 0.96 higher)
664
(4 RCTs)
⊕⊝⊝⊝
Very lowg
The effect of ALA intake on body weight
is unclear as the evidence is of very low
quality.
Measures of adiposity – ALA – BMI, kg/
m2
Mean BMI was
27.4 kg/m2
MD 0.12 higher
(0.06 lower to 0.3 higher)
1581
(3 RCTs)
⊕⊕⊝⊝
Lowh
ALA intake may make little or no differ-
ence to BMI.
Serum total cholesterol – ALA – TC,
mmol/L
Mean TC was
5.02 mmol/L
MD 0.09 lower
(0.23 lower to 0.05 higher)
2164
(6 RCTs)
⊕⊕⊝⊝
Lowi
ALA intake may make little or no differ-
ence to serum total cholesterol (low-qual-
ity/certainty evidence).
Serum Triglyceride, fasting – ALA – TG,
mmol/L
Mean TG was
1.48 mmol/L
MD 0.03 lower
(0.11 lower to 0.05 higher)
1776
(6 RCTs)
⊕⊕⊕⊝
Moderatej
ALA intake probably makes little or no dif-
ference to serum triglycerides (moder-
ate-quality/certainty evidence).
Serum high density lipoprotein – ALA –
HDL, mmol/L
Mean HDL was
1.49 mmol/L
MD 0.02 lower
(0.08 lower to 0.03 higher)
1776
(6 RCTs)
⊕⊕⊕⊝
Moderatek
ALA intake probably has little or no effect
on serum HDL.
Serum low density lipoprotein – ALA –
LDL, mmol/L
Mean LDL was
2.88 mmol/L
MD 0.05 lower
(0.15 lower to 0.04 higher)
2201
(7 RCTs)
⊕⊕⊝⊝
Lowl
ALA intake may make little or no differ-
ence to serum LDL.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
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BMI: body mass index; CI: confidence interval; HDL: high-density lipoprotein; LCn3: long-chain omega-3 fatty acids; LDL: low-density lipoprotein; MD: mean difference; RCT:
randomised controlled trial; TC: total cholesterol; TG: triglycerides.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
a Measures of adiposity, weight, LCn3• Risk of bias: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.• Inconsistency: I2 was < 60%; not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low-
and middle-income countries were underrepresented. Not downgraded.• Imprecision: large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% confidence intervals exclude important benefits or harms.
Not downgraded.• Publication bias: funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.
b Measures of adiposity, BMI, LCn3• Risk of bias: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.• Inconsistency: I2 was < 60%; not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low-
and middle-income countries were underrepresented. Not downgraded.• Imprecision: large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% confidence intervals exclude important benefits or harms.
Not downgraded.• Publication bias: funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included. Not downgraded.
c Lipids, serum total cholesterol, LCn3• Risk of bias: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.• Inconsistency: I2 was < 60%; not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low-
and middle-income countries were not represented. Not downgraded.• Imprecision: when we ran fixed-effect analysis, a statistically significant effect was suggested. The 95% CI included null but excluded important benefits or harms. Downgraded
once..• Publication bias: funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.
d Lipids, serum triglycerides, LCn3• Risk of bias: there was a statistically significant effect overall and in all sensitivity analyses, including when data were limited to RCTs at low summary risk of bias. Not
downgraded.• Inconsistency: I2 was < 60%; not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low-
and middle-income countries were not represented. Not downgraded.• Imprecision: large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% confidence intervals exclude harms. Not downgraded.
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• Publication bias: funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.
e Lipids, HDL, LCn3• Risk of bias: the suggested increase in HDL with increased LCn3 was apparent in all sensitivity analyses. Not downgraded.• Inconsistency: I2 was < 60%; not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low-
and middle-income countries were not represented. Not downgraded.• Imprecision: large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% confidence intervals exclude harms. Not downgraded.• Publication bias: funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.
f Lipids, LDL, LCn3• Risk of bias: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.• Inconsistency: I2 was < 60%; not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low-
and middle-income countries were not represented. Not downgraded.• Imprecision: large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% confidence intervals included the null but excluded
important benefits or harms. Downgraded once.• Publication bias: funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.
g Measures of adiposity, weight, ALA• Risk of bias: no included trials were at low summary risk of bias. Downgraded once.• Inconsistency: I2 was > 60%, downgraded once.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low-
and middle-income countries were not represented. Not downgraded.• Imprecision: large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% confidence intervals include some benefits or harms.
Downgraded once.• Publication bias: funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.
h Measures of adiposity, BMI, ALA• Risk of bias: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.• Inconsistency: I2 was > 60%, downgraded once.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low-
and middle-income countries were not represented. Not downgraded.• Imprecision: large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% confidence intervals include some benefits and harms.
Downgraded once.• Publication bias: funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.
i Lipids, serum total cholesterol, ALA• Risk of bias: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.• Inconsistency: I2 was > 60%. Downgraded once.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low-
and middle-income countries were not represented. Not downgraded.• Imprecision: when we ran fixed-effect analysis a statistically significant effect was suggested, but main analysis includes some benefits and harms. Downgraded once.• Publication bias: funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.
j Lipids, serum triglycerides, ALA• Risk of bias: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.
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• Inconsistency: I2 was < 60%; not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low-
and middle-income countries were not represented. Not downgraded.• Imprecision: large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% include benefits and harms. Downgraded once.• Publication bias: funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.
k Lipids, HDL, ALA• Risk of bias: there was a statistically significant effect with fixed effects analysis and when data were limited to RCTs at low summary risk of bias, but the main analysis and
other sensitivity analyses also suggested reductions om HDL. Not downgraded.• Inconsistency: I2 was < 60%; not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low-
and middle-income countries were not represented. Not downgraded.• Imprecision: large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% CI includes benefits and harms. Downgraded once.• Publication bias: funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.
l Lipids, LDL, ALA• Risk of bias: apparent effect altered from slight benefit to slight harm when data were limited to RCTs at low summary risk of bias. Downgraded once.• Inconsistency: I2 was < 60%; not downgraded.• Indirectness: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low-
and middle-income countries were not represented. Not downgraded.• Imprecision: when we ran fixed-effect analysis a statistically significant effect was suggested. For main analysis 95% CI included benefits and harms. Downgraded once.• Publication bias: funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.
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B A C K G R O U N D
Description of the condition
Cardiovascular diseases (CVDs) are disorders of the heart and blood
vessels. They include cerebrovascular disease (including stroke
and transient ischaemic attack), coronary heart disease (including
heart attack or myocardial infarction and angina), peripheral arter-
ial disease (diseases of the blood vessels to the arms and legs), deep
vein thrombosis and pulmonary embolism (blood clots formed in
the legs which can move to the heart and lungs), as well as rheumat-
ic and congenital heart disease (WHO 2017); these last two are not
discussed in this review. Globally, 31% of all global deaths are due
to CVD, more than from any other cause (WHO 2017). Of the 17.7
million people who died from CVDs in 2015, 7.4 million were due
to coronary heart disease and 6.7 million due to stroke. Of 17 mil-
lion premature deaths in 2015 caused by non-communicable dis-
eases, 82% were in low- and middle-income countries, and 37%
were caused by CVDs (WHO 2017).
Description of the intervention
Omega-3 fats (also called Ω3 or n-3 fats) from fish sources include
eicosapentaenoic acid (EPA, or 20:5), docosahexaenoic acid (DHA,
22:6) and docosapentaenoic acid (DPA, 22:5), the longer chain
omega-3 fats (LCn3). Alpha-linolenic acid (ALA or α-linolenic, 18:3)
is the shorter chain omega-3 fat found in plants and grass-fed,
which is partially converted to longer chain omega-3 fatty acids
within our bodies. There is some debate about the effectiveness
of this conversion, which may differ depending on whether it is as-
sessed over the short or long term as well as on other dietary fac-
tors (Li 1999; Pawlosky 2001). For this reason the effectiveness of
ALA may differ from that of the longer chain omega-3 fats.
Since Bang and colleagues first suggested that the abundance of
omega-3 fatty acids in the diet of the Greenland Inuit people was
responsible for their low mortality from ischaemic heart disease
(Bang 1972; Bang 1976), there has been considerable interest in the
protective role and possible mechanism of action of marine unsat-
urated fats. This interest has spread to encompass plant seeds and
oils rich in omega-3 fatty acids, including chia seed, flax (linseed)
and rapeseed (canola) oils (Nettleton 1991), their derivatives (e.g.
margarines), purslane leaves (Simopoulos 1992), and nuts (espe-
cially walnuts).
How the intervention might work
Proposed mechanisms for the protective role of omega-3 fats
against cardiovascular diseases include: lowering the blood pres-
sure; altering the lipid profile, especially reduced serum triglyc-
eride concentration; modulating arterial lipoprotein lipase levels;
reducing thrombotic tendency; producing anti-inflammatory ef-
fects and anti-arrhythmic effects; improving vascular endothelial
function and insulin sensitivity; and increasing plaque stability and
paraoxonase levels (Bhatnagar 2003; BNF 1999; Calabresi 2004;
Chang 2013; Geelen 2004).
Given that most omega-3 fats are ingested in the form of oily fish
or fish oil (often fish liver) capsules, reports of high levels of vari-
ous toxic compounds such as mercury, dioxins and polychlorinated
biphenyls (PCBs) in oily fish and fish oils are concerning (FSA 2000;
Liem 1997; MAFF 1998A; USFDA 1995). These are all fat soluble and
accumulate over time in the body, so harms may be exhibited on-
ly after long-term fish consumption or supplementation with fish
oils. Animal intervention studies and human cohorts who have suf-
fered accidental exposure to dioxins and PCBs suggest that pre-na-
tal exposure may cause sub-fertility problems, and adult exposures
may lead to an excess of total cancers (JECFA 2001). Human cohorts
exposed to high levels of mercury exhibit neurological problems
(USFDA 1995). As many people eat oily fish once or twice a week or
take fish oil supplements, it is important to explore the potential-
ly harmful effects of fish-associated omega-3 intake. It is also pos-
sible that omega-3 fats themselves may exhibit harm, for example
through extension of bleeding times or suppression of normal im-
mune responses (USFDA 2000).
Cardiovascular effects of eating more oily fish may differ from those
of taking a fish oil supplement because fish (not fish oil) is a rich
source of nutrients including selenium, iodine, zinc, calcium and
protein. Fish in the diet may also displace a variety of other foods
including sources of saturated or trans fats, so it could alter CVD in
other ways.
Why it is important to do this review
There is a great deal of public belief in the cardiovascular bene-
fits of omega-3 fats. Analysis of US National Health and Nutrition
Examination Survey data from 2003 to 2008 suggests that in the
USA, adults' mean long-chain omega-3 intakes were greater from
dietary supplements (0.72 g/d EPA and DHA) than from foods (0.41
g/d, Papanikolaou 2014). But public health advice differs across
countries. For example, the National Institute for Health and Clin-
ical Excellence in the UK now encourages fish intake but discour-
ages supplementation: "people with or at high risk of CVD should
be advised to consume at least 2 portions of fish per week, includ-
ing a portion of oily fish". However, it advises that omega-3 fatty
acid compounds "should not be offered for primary or secondary
prevention of CVD" (NICE 2016). The American Heart Association
(AHA) also "recommends eating fish (particularly fatty fish) at least
two times (two servings) a week". Although the AHA suggests that
omega-3 intake via foods is preferable, the AHA is more positive
about omega-3 supplements: "those with coronary artery disease
may not get enough omega-3 by diet alone. These people may want
to talk to their doctor about supplements. And for those with high
triglycerides, even larger doses could help" (AHA 2016). These rec-
ommendations are balanced with a warning about potential ex-
cessive bleeding in those taking doses of > 3 g/d omega-3 fatty
acids (presumably long-chain omega-3 fats). Such recommenda-
tions, and resulting increased fish consumption, have potential-
ly negative long-term consequences for our marine ecosystems
(Brunner 2009).
Epidemiological studies have supported the relationship between
high omega-3 intake and lower cardiovascular disease (CVD) rates
(Ballard-Barbash 1987; Burr 1993; Kris-Etherton 2002). However,
these associations could be due to some other characteristic of
people who choose to eat fish. In many societies eating fish is asso-
ciated with better social status and a health-conscientious life view
(Cade 2007), so eating fish is highly confounded by dietary quali-
ty, socioeconomic status and other markers of healthy lifestyles. As
an example, the global attributable burden of eating a diet low in
seafood omega-3 fats was estimated as 1.1% of global disability-ad-
justed life-years (DALYs; 95% CI 0.8 to 1.5), "with 22% of ischaemic
heart disease DALYs attributable to low seafood intake" (Engell
2013). The data sources are not described, but when the estimate
was derived from RCTs alone, rather than cohort studies and RCTs
combined, the estimated global attributable burden was much
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smaller, 0.5% (95% CI −0.5 to 1.4). Information concerning cause
and effect is more reliably supplied by intervention trials in which
participants are randomly allocated to receive fish oil or advice to
eat more fish.
Systematic reviews of randomised controlled trials (RCTs) have had
various findings. An earlier version of this review found no effects
for omega-3 fats on all-cause mortality or cardiovascular outcomes
in trials of at least six months' duration (which included > 36,000
participants) (Hooper 2004). Since Hooper 2004 was published, sev-
eral other systematic reviews have suggested a lack of effect for
omega-3 fats on all-cause mortality or a variety of CVDs (Campbell
2013; Chowdhury 2012; Khoueiry 2013; Kotwal 2012; Kwak 2012;
Mariani 2013; Rizos 2012; Zheng 2014). However, others have high-
lighted particular outcomes or circumstances in which CVD preven-
tion was evident: after heart surgery (He 2013), for preventing sud-
den cardiac death (Zhao 2009), for reducing CVD mortality and sud-
den cardiac death (although with no effect on all-cause mortality)
(Trikalinos 2012), for CVD mortality (Sethi 2016), and for reducing
the risk of stroke in women (albeit with no effect on stroke overall)
(Larsson 2012). Kwak 2012 reported marginal effects on cardiovas-
cular death, though these were lost when a poor-quality trial was
removed, and a few others have reported only positive effects in
their abstracts (reductions in cardiovascular events, cardiac death
and coronary events) (Delgado-Lista 2012). These disparate find-
ings have fuelled both debate and confusion. A recent extensive
Agency for Healthcare Research and Quality review meta-analysed
risk factors extensively but suggested there was only limited RCT
data to assess the effects of omega-3 fats on clinical CVD outcomes
(Balk 2016).
This systematic review and meta-analysis aimed to assess the ev-
idence on the effects of omega-3 fats (long-chain and ALA sepa-
rately) on all-cause mortality and CVDs. It also aimed to assess
potentially harmful effects of omega-3 fats or compounds associ-
ated with consuming long-chain omega-3 fats such as excessive
bleeding. A related review has formally systematically reviewed po-
tential harms such as excessive cancers, rather than simply exam-
ining studies included in this review for cancer outcomes (Han-
son 2017b). We assessed mechanisms of action such as lipid and
body weight changes and antiarrhythmic effects as primary or sec-
ondary outcomes in this review, and we have systematically re-
viewed these outcomes in a formal way by including trials that as-
sessed adiposity, lipids and arrhythmic events even where no CVD
events occurred or were reported. Sister systematic reviews have
assessed anti-inflammatory effects and effects on inflammatory
bowel disease (Thorpe 2017), as well as effects on insulin sensitivity
and glucose metabolism (Brown 2017).
The World Health Organization (WHO) is currently updating its
guidance on polyunsaturated fatty acid intake in adults and chil-
dren. The update and expansion of this review was commissioned
by WHO in order to inform and contribute to the development of
updated WHO recommendations. The results of this review includ-
ing GRADE assessments were discussed and reviewed by the WHO
Nutrition Guidance Expert Advisory Group (NUGAG) Subgroup on
Diet and Health as part of WHO’s guideline development process.
O B J E C T I V E S
To assess the effects of increased intake of fish- and plant-based
omega-3 for all-cause mortality, cardiovascular (CVD) events, adi-
posity and lipids.
The primary review question was, 'Do long-chain omega-3 (LCn3,
fish-based omega-3 fats) or ALA (plant-based omega-3 fats) fats al-
ter risk of all-cause mortality, cardiovascular deaths, cardiovascu-
lar events, coronary heart disease deaths, coronary heart disease
events, stroke, arrhythmia, adiposity and lipids?'
Secondary questions include the following.
• If omega-3 fatty acids confer protection:* does protection occur equally in those at low and at high risk
of cardiovascular disease?* does protection depend on the dose of omega-3 fats taken
per day?* do effects differ between dietary and supplemental omega-3
sources?* does protection depend on study summary risk of bias?• Is protection or harm stronger with longer trial duration?
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled clinical trials that included di-
et advice or dietary supplementation to promote omega-3 fatty
acid intake versus placebo, no supplementation, usual diet or low-
er dose omega-3. One of our outcomes had to be measured and
available (through publications or contact with authors), and tri-
als had to follow participants for at least 12 months (52 weeks or
360 days) for mortality and cardiovascular outcomes. For advice tri-
als, follow-up must have been at least 12 months following advice,
and for trials where participants received food or supplementation,
provision must have continued for at least 12 months). We accept-
ed randomisation of individuals or of clusters as long as there were
at least six clusters randomised.
Careful work by Browning suggests that supplements of EPA and
DHA equivalent to one weekly portion of oily fish results in 95% of
maximal incorporation by 5 days for EPA in plasma phosphatidyl-
choline (95% CI 0 to 18 days) to 273 days for DHA into blood
mononuclear cells (95% CI 0 to 670 days) (FISH 2012). While this
suggests individual variability, on average all compartments ex-
cept blood mononuclear cells had equilibrated by 117 days (both
EPA and DHA into plasma phosphatidylcholine, plasma cholesteryl
esters, plasma nonesterified fatty acids, plasma triglycerides, ery-
throcytes and platelets). The authors stated "EPA and DHA reached
a maximum in platelets in 3–4 weeks and 1–2 months, respectively,
and in blood mononuclear cells in 6–9 months". For this reason we
chose 12 months as the minimum duration of intervention, as it al-
lows equilibration of most body compartments with EPA and DHA
as well as time for this change in body composition to have some
effect on cardiovascular risk or mortality.
In previous reviews of dietary effects on cardiovascular outcomes,
we limited trials to at least two years' duration (Hooper 2015), as
the proposed mechanism of effects was via LDL cholesterol, ather-
osclerosis and its sequelae, and this takes time to develop. The 4S
trial showed separation of the survival curves at around two years
(Scandinavian Simvastatin Survival Study Group 1994). Potential
mechanisms for effects of polyunsaturated fatty acids (PUFAs) are
broader, including what could be rapid effects on arrhythmias or
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inflammation, so we decided to include trials of at least 12 months
to ensure we did not miss these effects.
Types of participants
Studies in adults (18 years or older, men and/or women) at any
risk of cardiovascular disease (with or without existing cardiovas-
cular disease) were eligible, including those in participants with in-
creased risk of cancer, those undergoing or who have undergone
coronary artery bypass grafting or angioplasty, and those with cur-
rent or previous cardiovascular disease, nephritis in systemic lupus
erythematosus, breast cysts, diabetes mellitus, rheumatoid arthri-
tis, multiple sclerosis, psoriasis, hay fever, asthma or ulcerative col-
itis. Including these populations allows us to understand both de-
velopment and progression of cardiovascular disease (primary and
secondary prevention). We excluded participants who were preg-
nant or acutely ill (with acute-stage cancer, undergoing heart or re-
nal transplantation, with HIV or AIDS, on haemodialysis, with IgA
glomerulonephritis, or any other renal problem except in diabetes).
Types of interventions
The intervention must have been dietary supplementation, a pro-
vided diet or advice on diet. The foodstuffs or supplements must
have been: oily fish (including mackerel, dogfish, salmon, herring,
trout, tuna, sturgeon, stablefish, anchovy, sprat, coho, capelin, sar-
dines, swordfish, sild, pilchard, brisling, menhaden, bloater, white-
bait, crab and conger eel); fish oils (made from any of the above or
a mixture of fish, or cod liver oil); linseed (flax), canola (rapeseed),
perilla, purslane, mustard seed, candlenut, stillingia or walnut as
a food, capsule, oil, made into a spreading fat or supplementing
another food (such as bread or eggs). For ALA sources the product
consumed had to have an omega-3 fat content of at least 10% of
the total fat content. Refined eicosapentaenoic acid (EPA), docosa-
hexaenoic acid (DHA) or alpha-linolenic acids, or concentrated fish
or algal oils, were also accepted. Supplementation may have been
in oil or capsule form or as foodstuffs provided to be consumed by
mouth (excluding enteral and parenteral feeds and enemas).
We excluded studies using multiple risk factor interventions on
lifestyle factors (such as weight reduction, smoking or physical ac-
tivity goals), or differential dietary interventions not involving di-
etary fats, except where that other intervention was a direct re-
placement for polyunsaturated fats or the effect of diet or supple-
mentation could be separated out from the other interventions.
Studies were eligible if they compared the effect of dietary advice
or supplementation to increase omega-3 fats with the usual diet,
no advice, no supplementation, placebo or lower dose omega-3.
Types of outcome measures
Primary outcomes
Primary outcomes included numbers of participants experiencing:
• all-cause mortality (deaths);• cardiovascular mortality (cardiovascular deaths);• cardiovascular events (cardiovascular events);• coronary heart disease mortality (CHD deaths);• coronary heart disease events (CHD events);• stroke; and• arrhythmia (atrial fibrillation).
We analysed coronary heart disease using the first of the following
to be reported: number of participants experiencing CHD or coro-
nary events, total myocardial infarction (MI), acute coronary syn-
drome or angina (stable and unstable). This meant that if trialists
reported CHD events, we used these in analysis and ignored the
other outcomes; where trials did not report CHD events but did re-
port total MI, we used that (and so on). Combined cardiovascular
events included fatal and non-fatal myocardial infarction, angina,
stroke, heart failure, peripheral arterial disease, sudden death and
non-scheduled cardiovascular interventions – coronary artery by-
pass surgery or angioplasty. We included all available outcomes
where we could be sure that the same participant was not being
counted twice.
At the request of WHO NUGAG Subgroup on Diet and Health, we
added CHD mortality post hoc as a primary outcome. Data used
were the first of the following list reported: coronary death, is-
chaemic heart disease (IHD) death, fatal MI, cardiac death. We only
used cardiac death when no other outcomes in this category were
available, and we ran a sensitivity analysis omitting cardiac death.
The reason for excluding cardiac death in sensitivity analysis was
that it goes slightly outside our area of interest, including other
causes of death in addition to CHD, such as cardiomyopathies and
congenital and valvular heart diseases. We wanted to include car-
diac death in the main analysis as we felt that otherwise we would
be missing some important cases of coronary heart mortality, but
we decided to exclude it in sensitivity analysis as we were potential-
ly including a few outcomes that CHD mortality did not encompass.
Secondary outcomes
Secondary outcomes included:
• major adverse cerebrovascular or cardiovascular events (MAC-
CEs) or individual cardiovascular events (total, fatal or non-fa-
tal MI, sudden cardiac death, angina, heart failure, revasculari-
sation, peripheral arterial disease or acute coronary syndrome);• body weight and other measures of adiposity; and• lipids (total, LDL or HDL cholesterol and triglycerides).
We defined MACCEs as participants experiencing MI, unstable angi-
na, stroke or death. We did not consider studies that did not provide
data on all these health events for this outcome.
The review included studies if any of their participants experienced
or were assessed for any primary or secondary outcome. These
could have been reported in publications (as outcomes or reasons
for dropout or adverse events), supplied by study authors, or which
clearly happened even if exact numbers were not available. How-
ever, as almost all trials note if a death or cardiovascular event oc-
curs in a study participant (so ALL trials assess for our primary out-
comes) we only included trials where at least one event occurred,
or where a continuous outcome was measured.
Tertiary outcomes
We extracted the following outcomes where available within in-
cluded studies.
• Blood pressure.• Serious adverse events (any other reported illnesses).• Side effects.• Dropouts.
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• Quality of life measures.• Economic costs.
We originally intended to assess type 2 diabetes diagnoses, mea-
sures of glucose metabolism, cancers, breast cancer, neurocogni-
tive outcomes such as dementia, depression and anxiety within in-
cluded studies. However, as part of the larger set of reviews we
formally systematically reviewed effects of omega-3 fats on type 2
diabetes diagnoses and measures of glucose metabolism (Brown
2017), cancers including breast cancer (Hanson 2017b), neurocog-
nitive outcomes such as dementia (Jimoh 2017), irritable bowel dis-
ease (IBD) and inflammatory factors (Thorpe 2017), depression and
anxiety (Hanson 2017a), and functional outcomes (Abdelhamid
2017), so a partial assessment within this review would be unhelp-
ful and potentially misleading. For this reason we exclude these
specific outcomes from our reporting of serious adverse events.
Key outcomes
When the World Health Organization (WHO) Nutrition Guidance
Expert Advisory Group (NUGAG) Subgroup on Diet and Health re-
quested this review update they named the following as key out-
comes to inform their planned dietary guidance.
• All-cause mortality.• CVD mortality.• CVD events.• CHD mortality.• CHD events.• Stroke.• Arrhythmia (atrial fibrillation).• Serum lipids including total cholesterol (TC), fasting triglyc-
erides (TG), high-density lipoprotein (HDL) and low-density
lipoprotein (LDL).• Measures of adiposity (body weight and body mass index).
We were not able to make all of these outcomes into primary
outcomes. However, because WHO NUGAG Subgroup on Diet and
Health will use these outcomes to underpin guidance, we carried
out sensitivity analyses, subgroup analyses and GRADE assessment
of quality of evidence for them, even when they were not primary
outcomes.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases on 27 April 2017 to
identify reports of relevant randomised clinical trials.
• Cochrane Central Register of Controlled Trials (CENTRAL; 2017;
Issue 3) in the Cochrane Library.• Epub Ahead of Print, In-Process & Other Non-Indexed Citations,
MEDLINE Daily and MEDLINE (Ovid, 1946 to 27 April 2017).• Embase Classic and Embase (Ovid, 1947 to 2017 week 17).
We applied date limits to the terms from the original strategies so
that the search included only new records, but we did not apply any
date limits to newly added terms. Appendix 1 shows the MEDLINE
search strategy for the original version of this review, and Appen-
dix 2 shows the updated searches. We de-duplicated the results
against each other. The RCT filter for MEDLINE was the Cochrane
sensitivity and precision-maximising RCT filter, and for Embase, we
applied the terms as recommended in the Cochrane Handbook for
Systematic Reviews of Interventions (Lefebvre 2011).
As we were also running searches for a new systematic review of
the effects of polyunsaturated fats on cardiovascular disease (Ab-
delhamid 2018), as well as updating and extending a Cochrane Re-
view of the effects of omega-6 polyunsaturated fats on health out-
comes (Hooper 2018), we also ran searches for these reviews us-
ing the same RCT filters (Appendix 3). The results of these search-
es were de-duplicated against the omega-3 searches, and all the ti-
tles and abstracts assessed as a single set for all three reviews. We
created a dataset of RCTs that lasted at least six months and com-
pared higher versus lower omega-6, omega-3 or total polyunsatu-
rated fatty acids (PUFA) in adults. We used this dataset as the wider
study pool from which we selected included studies for all reviews
(Abdelhamid 2018; Abdelhamid 2017; Hooper 2018; Brown 2017;
Hanson 2017a; Hanson 2017b; Jimoh 2017; Thorpe 2017; Hooper
2004).
We searched two trials registers, ClinicalTrials.gov (clinicaltrial-
s.gov) and the WHO International Clinical Trials Registry Platform
(ICTRP, www.who.int/ictrp/en) on 23 September 2016 for registry
entries for relevant completed and ongoing studies.
Searching other resources
We assessed titles and abstracts retrieved during these electron-
ic searches for relevant RCTs and also relevant systematic reviews.
We handsearched the included studies in all relevant systematic re-
views for new trials and additional publications of included trials.
We contacted authors of all large included studies (at least 100 par-
ticipants) and some smaller trials for further study data, method-
ological details and references to studies not yet identified, includ-
ing published, unpublished or ongoing studies.
Data collection and analysis
Selection of studies
At least two reviewers independently assessed titles and abstracts
resulting from the electronic and bibliographic searches. We com-
bined the search results for this review and two others, Abdelhamid
2018and Hooper 2018, de-duplicating and assessing them at the
same time. We rejected titles and abstracts on initial screen only if
the reviewer could determine from the title and abstract that the
article was not a report of a randomised controlled trial; did not
address omega-3 intake (or total polyunsaturated fat or omega-6
fat for the other two reviews); were exclusively in children or young
adults (less than 18 years old), pregnant women or the critically ill;
were of less than 12 months' duration; or if the intervention was
multi-factorial and we could not separate out the effect of dietary
fat.
We rejected studies only when it was certain that no primary or sec-
ondary outcome events occurred, and none of the secondary out-
come risk factors were measured. When we could not reject a ti-
tle/abstract with certainty, we obtained the full text of the article
for further evaluation. We made attempts to obtain full-text transla-
tions and/or evaluations of all potentially relevant non-English ar-
ticles.
We used an in/out form to assess full-text papers and studies for
inclusion (or otherwise) into the review. We contacted the authors
of all potentially included RCTs for further information on trial
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methodology and outcomes. Two assessors independently decid-
ed on inclusion of full-text RCTs, resolving any differences by dis-
cussion and, when necessary, in consultation with the review team.
Data extraction and management
We designed a data extraction form for this review, which each of
the reviewers tested on a common 'training' study (SCIMO 1999),
and we adapted it as appropriate. We extracted data concerning
participants, interventions, and outcomes, as described above in
the selection criteria section. We extracted dichotomous data from
dietary advice studies at the latest point available in the trial (re-
gardless of the amount of reinforcement of the original dietary
message), while for supplement studies, we extracted dichoto-
mous data to the point that supplementation or the trial ended,
whichever was earlier. We extracted continuous data at the nearest
time point to 12 months and also the latest point available in fixed-
term trials, but in studies where participants were followed up for
varying durations (aside from dropouts), we extracted the partici-
pants' data from the first time point following the mean trial dura-
tion. We never used data from periods following the end of a trial
in meta-analysis.
We also extracted data on risk of bias, assessed using the Cochrane
'Risk of bias' tool, along with data on potential effect modifiers, in-
cluding existing cardiovascular disease (primary or secondary pre-
vention), trial duration, intensity of intervention (dietary advice, di-
et provided, supplemental foods, supplements (capsules) and any
combination), long-chain omega-3 fats or ALA and dose, replace-
ment, medications used (including statins, antihypertensive, an-
tiarrhythmic or antithrombotic medication), fatty acid data (from
plasma, platelets or adipose tissue) and smoking status.
For primary and secondary dichotomous outcomes, we extracted
numbers of participants experiencing an outcome and total num-
bers of participants randomised (or in whom the outcome was
assessed where known) for each study arm. For continuous out-
comes, we extracted the number of participants assessed, means
and standard deviations of the final readings in each treatment
arm; we calculated standard deviations from other variance data
where appropriate. Where data were available on both change and
final readings, we used data on change.
Two reviewers independently extracted original reports of trial re-
sults. We resolved differences between reviewers' results by discus-
sion and, when necessary, in consultation with a third reviewer or
the review team.
Assessment of risk of bias in included studies
Two reviewers independently assessed risk of bias for each includ-
ed study, using Cochrane criteria (Higgins 2011), including in the
domains of sequence generation; allocation concealment; blind-
ing of participants and personnel, blinding of outcome assessors;
incomplete outcome data; and selective outcome reporting. Addi-
tional review-specific criteria included similarity of type and inten-
sity of intervention in both arms (attention) and evidence of appro-
priate moderate to high compliance (to establish that the interven-
tion group were receiving a different intake of omega-3 fats than
the control group). Table 1 presents specific details of how we in-
terpreted these criteria for this review.
We considered a study to be at low risk of attention bias when par-
ticipants were given the same amount of time and attention from
study staC and health professionals whether they were in the inter-
vention or control arms, and at low risk of compliance bias when
adherence was assessed, results of that assessment were clearly re-
ported for both intervention and control arms, and where most par-
ticipants appeared to have taken at least 75% of the intended PUFA
dose.
Summary risk of bias
Schulz 1995 found that poorly concealed allocation was associat-
ed with a 40% greater effect size, so randomisation and allocation
concealment are core issues for all trials. Lack of blinding is associ-
ated with bias, though smaller levels of bias than lack of allocation
concealment (Savovic 2012), especially in studies with objectively
measured outcomes (Wood 2008), such as those we primarily used
in our review. Although we originally planned to assess summary
risk of bias for all included trials in the same way across this review,
the omega-3 review and the total PUFA review (Abdelhamid 2018;
Hooper 2018; Hooper 2004), we adopted a different approach after
discussing the different nature of supplement trials compared to
dietary advice or food provision trials with the WHO NUGAG Sub-
group on Diet and Health.
We considered supplement or capsule type trials to be at low sum-
mary risk of bias where we judged randomisation, allocation con-
cealment, blinding of participants and personnel, and blinding of
outcome assessors to be adequate. We considered all other trials
to be at moderate or high risk of bias (a single category).
We considered dietary advice or all-food-provided type trials to be
at low summary risk of bias where we judged randomisation, allo-
cation concealment, and blinding of outcome assessors to be ade-
quate. We considered all other trials to be at moderate or high risk
of bias (a single category).
Measures of treatment e2ect
We pooled dichotomous data using risk ratios (RR) to describe ef-
fect sizes and continuous data using mean differences (MD). Where
effects were described by different but comparable measures or
scales in different studies, we combined them using standardised
mean difference (SMD).
Unit of analysis issues
We considered that we could reduce patient numbers in clus-
ter-randomised trials to an effective sample size, as described
by Hauck 1991; however, we identified no such trials. For com-
bined outcomes (e.g. combined cardiovascular events), we made
attempts to add numbers of individuals experiencing specific out-
comes within studies, but only where we could be certain that we
were not counting individual participants more than once within
any one of our review outcome categories.
For studies with intervention arms providing different omega-3
doses, we combined data for the intervention groups for binary out-
comes and used data on higher dose data versus control for con-
tinuous outcomes. We used arms with different doses separately
when subgrouping by dose. Where factorial trials ran more than
one intervention included in this review (AlphaOmega - ALA 2010;
AlphaOmega - EPA+DHA 2010), we did not pool both comparisons
in the same meta-analysis.
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Dealing with missing data
We sought trials registry entries and study protocols to help us as-
sess which studies measured each outcome. Where trials appeared
to have collected – but did not report – data, we wrote to study au-
thors to ask for information. We wrote to authors of all studies that
randomised at least 100 participants as well as to those of many
smaller studies (although not to all due to limited resources), pri-
oritising our efforts on larger studies that would tend to provide
more information to the review. For larger studies where we found
no trials registry entry or protocol, we wrote to study authors to ask
whether they had collected information on any outcomes of inter-
est that we had not yet located. Where it was clear that data exist-
ed but could not be located to use within the review, we noted this
and assessed the potential effect of this missing data on effect sizes
narratively.
Assessment of heterogeneity
We assessed heterogeneity using the I2 test and assumed it to be
important when I2 was more than 60% (Higgins 2003).
Assessment of reporting biases
We used funnel plots to assess for evidence of bias for primary out-
comes where at least 10 studies contributed to the meta-analysis
(Egger 1997).
Data synthesis
Primary measures of interest were effects of dietary advice or sup-
plementation of fish-based (long-chain, LCn3) omega-3 fats, and al-
pha linolenic acid (ALA), on primary outcomes. We separated out
effects of LCn3 and ALA in all analyses and thus present two sepa-
rate sets of results: one for ALA and one for LCn3.
We combined treatment/control differences in the outcomes
across studies using relative risks (RR) or mean differences (MD) in
random-effects meta-analysis. For combined outcomes (e.g. com-
bined cardiovascular events), we made attempts to add numbers
of individuals experiencing specific outcomes within studies, but
only where we were certain that we were not counting individual
participants more than once within any one of our review outcome
categories. However, individuals may have been counted for more
than one of the review outcomes (in separate forest plots).
Subgroup analysis and investigation of heterogeneity
We explored the effects of LCn3 and ALA separately on all prima-
ry review outcomes and also on key review outcomes where these
were secondary outcomes in our review and included at least six
studies by subgrouping. The planned subgroup analyses were:
• type of intervention – dietary advice, supplemental foods (for
example margarine fortified with rapeseed, tins of sardines or
oils to use in cooking) provided by the study, supplements (cap-
sules or oils) provided to take as medicine or any combination;• replacement of saturated fatty acids (SFA), mono-unsaturated
fatty acids (MUFA), omega-6 fats, fat mixture, carbohydrates or
sugars, non-fat or no placebo, or unclear, with LCn3 or ALA;• primary prevention versus secondary prevention of CVD;• LCn3 dose: at least 150 mg/d, 250 mg/d, 400 mg/d from all
sources including supplements (above or below each threshold)
– low dose 0.4 g/d to 2.4 g/d, medium dose 2.5 g/d to 4.4 g/d,
and high dose ≥ 4.5 g/d of combined long-chain omega-3 fats,
• ALA dose: higher versus lower levels of intake (≥ 5 g/d versus <
5 g/d);• trial duration – studies with medium follow-up (12 to 23
months), medium follow-up (24 to 47 months) and long fol-
low-up (≥ 48 months);• statin use (< 50% of control group on statins, ≥ 50% of control
group on statins, use of statins unclear);• baseline long-chain omega-3 intake, and baseline ALA intake.
There were insufficient data on baseline omega three intake (or in-
take in control groups which could have been used as a proxy) to
subgroup by baseline omega-3 intake.
Meta-regression
We used meta-regression to further explore effects of LCn3 dose,
ALA dose, omega-6 dose, total PUFA dose (looking for evidence of
dose response for each), duration, primary or secondary preven-
tion, food or capsule intervention (food included dietary advice
and supplemental foods), and risk of bias (summary risk of bias
low or moderate to high) on primary outcomes. We performed ran-
dom-effects meta-regression using the STATA command metareg
(Berkley 1995; Sharp 1998): log(e) relative risk versus (dose or pri-
mary/secondary prevention or type of intervention or risk of bias or
duration), weighted by the standard error of the log(e) relative risk.
Where there were no events in one arm, we added 0.1 to the num-
bers for both groups (so a trial with 10 people experiencing stroke
in one arm but none in the other arm would be entered as 10.1 and
0.1). We analysed all included trials (of at least 12 months' duration)
that reported each outcome from this review and its sister reviews
(omega-3 trials from this review, omega-6 trials from the update of
Hooper 2018, and total PUFA trials from Abdelhamid 2018). We car-
ried out meta-regression of each variable singly, then a multivari-
ate meta-regression of the three variables with lowest P values in
single regression for each outcome. Given that we generally includ-
ed data from around 35 trials and there were some missing data for
some trials, we did not run meta-regressions with more than three
variables at one time.
Sensitivity analysis
We carried out sensitivity analyses on all primary outcomes (re-
gardless of the number of included trials) and on key outcomes that
were secondary outcomes in this review.
We used sensitivity analyses to assess robustness of results to:
• trial quality (removing trials at moderate or high summary risk
of bias);• study size (retaining only trials that randomised at least 100 par-
ticipants across all study arms);• fixed-effect analysis; and• compliance (retaining only trials where we assessed compliance
as conferring low risk of bias).
We tabulated the type and frequency of side effects and adverse
effects (with the other extracted data on adverse effects) and com-
pared between different studies and designs.
'Summary of findings' tables
Outcome data were interpreted as follows:
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
24
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
1. Is there an effect? (options were ‘increased risk’, ‘decreased risk’,
or ‘little or no effect’). Our main outcome measure was RR so we
decided on existence of an effect using RR. RR < 8% (RR < 0.92
or > 1.08) for the highest quality evidence suggested increased
or decreased risk (otherwise little or no effect). The presence or
not of an effect was decided on the RR for the main analysis and
sensitivity analyses.
2. For continuous outcomes increasing ALA or LCn3 was consid-
ered to have little or no effect unless effect sizes represented at
least 5% change from baseline (or 2% in the case of cumulative
outcomes such as adiposity).
3. Quality of evidence was assessed using GRADE assessment
(GRADE Working Group 2004) for key outcomes. We used the five
GRADE considerations (risk of bias, consistency of effect, impre-
cision, indirectness and publication bias) to assess the quality of
the body of evidence as it related to the studies that contributed
data to the meta-analyses for the prespecified outcomes. We
used methods and recommendations described in Section 8.5
and Chapter 12 of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011), plus GRADEpro GDT soft-
ware (GRADEpro GDT 2015). We justified all decisions to down-
grade the quality of studies using footnotes and made com-
ments to aid reader's understanding of the review.
4. Where there was a suggested effect the size of effect was as-
sessed using the NNT or ARR.
We included three 'Summary of findings' tables: for effects of LCn3
on primary outcomes, effects of ALA on primary outcomes, and for
key outcomes that were not included in the review primary out-
comes (measures of adiposity and serum lipids).
R E S U L T S
Description of studies
Results of the search
The electronic searches for the full set of reviews (populating the
dataset of all trials that assessed effects of higher versus low-
er omega-6, omega-3 or PUFA over at least 6 months) generated
37,810 titles and abstracts, which we de-duplicated to 19,772 hits.
We assessed these along with 53 studies previously included from
Hooper 2018 and Hooper 2004, to reassess for inclusion; 986 poten-
tially relevant trials registry entries; and 35 new references gained
from systematic review reference lists. In total, we assessed 20,846
titles and abstracts in duplicate to decide whether to retrieve full
texts. We ultimately assessed 2155 full-text reports, of which 226
were systematic reviews. Two review authors independently as-
sessed the remaining 1929 papers for inclusion and grouped them
into studies. Of these, we included 364 RCTs in a wider set of tri-
als that underpinned the full set of reviews (this review and sev-
eral others including Abdelhamid 2018; Abdelhamid 2017; Hooper
2018; Brown 2017; Hanson 2017a; Hanson 2017b; Jimoh 2017; Thor-
pe 2017). This wider set of trials included RCTs of omega-3, omega-6
or total polyunsaturated fatty acids (PUFA) interventions with a du-
ration of at least six months and regardless of outcomes reported
(Figure 1). This database of 364 trials comprised 1020 documents
(papers, abstracts and trials registry entries), plus additional data
from 121 authors.
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Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
 
Of these 364 RCTs in the main dataset:
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• 27 RCTs (51 documents) assessed effects of omega-3 fats over
at least one year but were ongoing (without published outcome
data);• 258 RCTs (581 documents) did not assess effects of omega-3 fats
or had a duration of less than one year or had not assessed rel-
evant outcomes for this review, so we excluded them from this
review; and• 79 RCTs (388 documents) were eligible for inclusion in this re-
view.
Of these 79 RCTs, 76 were included in meta-analyses. Three trials
clearly collected relevant data but did not report them in a format
that could be used in meta-analyses (Gill 2012; Ramirez-Ramirez
2013; Reed 2014; Figure 1).
Included studies
The 79 included RCTs randomised 112,059 participants, tripling the
number of participants in the original version of this review (36,913
participants, some of whom were followed for only six months).
The number of participants in included studies ranged from 11
to 18,645. Twelve trials randomised at least 1000 participants (Al-
phaOmega - ALA 2010; AlphaOmega - EPA+DHA 2010; AREDS2 2014;
DART2 2003; DART 1989; GISSI-HF 2008; GISSI-P 1999; JELIS 2007;
Norwegian 1968; OMEGA 2009; ORIGIN 2012; Risk & Prevention
2013; SU.FOL.OM3 2010), of which one was a 2 × 2 factorial trial
where both interventions were included (AlphaOmega - ALA 2010;
AlphaOmega - EPA+DHA 2010). Most of these larger trials assessed
effects of longer chain omega-3 fats, but two studies/arms assessed
effects of ALA (AlphaOmega - ALA 2010; Norwegian 1968).
Participants had cardiovascular disease at baseline in 33 of the tri-
als (secondary prevention), and the remaining 46 trials were of pri-
mary prevention.
Most studies assessed effects of long-chain omega-3 fats.
• Sixty-two studies increased LCn3 intake using supplementary
capsules or medicinal oils (ADCS 2010; AFFORD 2013; Ahn 2016;
AREDS2 2014; Baldassarre 2006; Bates 1989; Berson 2004; Brox
2001; Caldwell 2011; Derosa 2016; Deslypere 1992; Doi 2014;
DO IT 2010; EPE-A 2014 (as two different doses); EPIC-1 2008;
EPIC-2 2008; EPOCH 2014; Erdogan 2007; FAAT 2005; FORWARD
2013; Franzen 1993; Gill 2012; GISSI-HF 2008; GISSI-P 1999; HARP
1995; JELIS 2007; Kumar 2012; Kumar 2013; Lorenz-Meyer 1996;
MAPT 2017; MARINA 2011; Mita 2007; NAT2 2013; Nodari 2011
AF; Nodari 2011 HF; Norouzi 2014; Nutristroke 2009; Nye 1990;
OFAMI 2001; OMEGA 2009; OPAL 2010; ORIGIN 2012; ORL 2013;
Özaydin 2011; Proudman 2015; Puri 2005; Raitt 2005; Ramirez-
Ramirez 2013; Reed 2014; Risk & Prevention 2013; Rossing 1996;
Sandhu 2016; SCIMO 1999; Shinto 2014; SHOT 1996; Sianni 2013;
SOFA 2006; Sofi 2010; SU.FOL.OM3 2010; Tande 2016; WELCOME
2015; Zhang 2017).• Two trials used supplemented or supplemental foods, such as
enriched margarine or juice to increase LCn3 (AlphaOmega - EPA
+DHA 2010; FOSTAR 2016).• Four increased LCn3 fats using dietary advice (DART2 2003; DART
1989; DISAF 2003; THIS DIET 2008).• Three provided some combination of these interventions to in-
crease LCn3 (DIPP 2015; SMART 2013; Weinstock-Guttman 2005).
Doses of LCn3 ranged from 0.5g/d of EPA and DHA to > 5 g/d (17
RCTs had a dose of LCn3 < 1 g/d, 26 a dose of 1 to < 2 g/d, 11 of 2 to
< 3 g/d, 16 RCTs had a dose of 3 or more g/d LCn3, 1 did not clearly
state their dose).
Fewer studies assessed the effects of ALA on health outcomes.
• One trial used supplementary capsules or medicinal oils to in-
crease ALA (Norwegian 1968).• Six increased ALA using supplemented or supplemental foods,
such as enriched margarine, bread, walnuts or other enriched
food products (AlphaOmega - ALA 2010; Dodin 2005; FLAX-PAD
2013; HERO 2009; MARGARIN 2002; WAHA 2016).• One used a combination of these to increase ALA (MENU 2016).
One trial provided an intervention combining LCn3 and ALA as cap-
sules (DIPP 2015). However, trialists did not state the ALA dose, so
we treated the study as an LCn3 intervention.
Control groups received olive, corn, sunflower oils, other types
of fats (including medium-chain triglycerides and fat replicating
the composition of an average European diet), other 'inert' or ill-
defined substances (liquid paraffin, aluminium hydroxide, 'place-
bo' not described), different dietary advice or foods without the
omega-3 enrichment, or no treatment/no placebo.
The main study outcome was cardiovascular in 48 studies. Eighteen
studies (19 comparisons) aimed to measure death or cardiovascu-
lar events (AlphaOmega - ALA 2010; AlphaOmega - EPA+DHA 2010;
DART2 2003; DART 1989; Doi 2014; FAAT 2005; FLAX-PAD 2013; GISSI-
HF 2008; GISSI-P 1999; JELIS 2007; Norwegian 1968; Nye 1990;
OFAMI 2001; OMEGA 2009; ORIGIN 2012; Risk & Prevention 2013; SO-
FA 2006; SU.FOL.OM3 2010; THIS DIET 2008).
Thirty studies aimed to measure various cardiovascular risk factors
or progression of cardiovascular health.
• Atrial fibrillation recurrence or sinus rhythm (AFFORD 2013;
DISAF 2003; Erdogan 2007; FAAT 2005; FORWARD 2013; Kumar
2012; Kumar 2013; Nodari 2011 AF; Özaydin 2011; Raitt 2005;
Sianni 2013).• Atherosclerosis progression/regression (Ahn 2016; DO IT 2010;
HARP 1995; SCIMO 1999).• LeW ventricular function (Nodari 2011 HF).• CABG graW patency (SHOT 1996).• Lipids and other CVD risk factors (Brox 2001; Deslypere 1992;
Franzen 1993; MARGARIN 2002).• Diabetes, insulin or glucose-based outcomes (Derosa 2016;
Rossing 1996).• Endothelial function or carotid intima-media thickness (IMT)
(Baldassarre 2006; Gill 2012; MARINA 2011; Mita 2007).• Body weight and adiposity (HERO 2009; MENU 2016; SMART
2013).
Thirty-one RCTs assessed effects on other health states.
• Cognitive measures (ADCS 2010; EPOCH 2014; MAPT 2017; OPAL
2010; Shinto 2014; WAHA 2016; Zhang 2017).• Eye health (AREDS2 2014; Berson 2004; NAT2 2013).• Multiple sclerosis outcomes (Bates 1989; Weinstock-Guttman
2005).• Cancer or pre-cancer outcomes (DIPP 2015).• Bone health (Dodin 2005).
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• Liver health (Caldwell 2011; EPE-A 2014; Sofi 2010; WELCOME
2015).• Gastrointestinal health (Crohn's EPIC-1 2008; EPIC-2 2008;
Lorenz-Meyer 1996).• Arthritis outcomes (FOSTAR 2016; Proudman 2015; Reed 2014).• Functional status (Nutristroke 2009).• Neurological function after spinal injury or in Huntington's dis-
ease (Norouzi 2014; Puri 2005).• Safety outcomes and adverse events (ORL 2013; Tande 2016).• Breast health (Sandhu 2016).• Inflammatory markers (Ramirez-Ramirez 2013).
Most studies took place in high-income economies (World Bank
2018), but four were in upper-middle-income countries: Argentina
(FORWARD 2013), Iran (Norouzi 2014), Turkey (Özaydin 2011), and
China (Zhang 2017). No studies took place in low- or low-middle in-
come countries.
We identified a further 27 ongoing trials, which we describe in the
table of Characteristics of ongoing studies. At the time of writing
this review, all of these trials were unpublished, and some were re-
cruiting or delivering interventions or had recently been complet-
ed, and trialists were presumably analysing data and writing up re-
sults. Others appear overdue for publication, and their status is un-
clear – they may constitute missing data.
Excluded studies
We read full texts of over 1000 papers, so the full list of excluded
studies is too extensive to add to this review. The main reason for
exclusion of full-text papers was duration of less than 12 months
(this was often unclear in abstracts, so we collected full-text papers
to check).
We initially included several studies into our wider data set (Singh
1992; Singh 1997a; Singh 1997b; Singh 2002), but we later exclud-
ed them due to expressions of concern published by the BMJ and
The Lancet (BMJ 2005; Horton 2005; White 2005). These expressions
of concern followed extensive examination of the conduct, results
and publication of these studies and questioned the veracity of da-
ta behind several studies published by RB Singh. Another trial was
retracted and so not included (Matsuyama 2005).
Risk of bias in included studies
We assessed summary risk of bias as low in 25 RCTs (26 com-
parisons: ADCS 2010; AlphaOmega - ALA 2010; AlphaOmega - EPA
+DHA 2010; AREDS2 2014; Berson 2004; Caldwell 2011; Derosa
2016; EPOCH 2014; FLAX-PAD 2013; FORWARD 2013; FOSTAR 2016;
Lorenz-Meyer 1996; MAPT 2017; MARGARIN 2002; MARINA 2011;
NAT2 2013; OMEGA 2009; OPAL 2010; ORIGIN 2012; Proudman 2015;
Puri 2005; Reed 2014; SCIMO 1999; SOFA 2006; SU.FOL.OM3 2010;
WELCOME 2015), and we deemed it to be moderate to high in the
remainder. Our definition of low summary risk of bias is in the sec-
tion Assessment of risk of bias in included studies. Figure 2 itemises
risk of bias by domain and study.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 2.   (Continued)
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Figure 2.   (Continued)
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Figure 2.   (Continued)
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Allocation
Of the 79 RCT arms described in the 'Risk of bias' summary (Figure
2), 64 studies described randomisation well enough to merit an as-
sessment of low risk (the remainder were unclear), and 45 study
arms described adequate allocation concealment (the remaining
34 were unclear).
Blinding
We considered blinding of participants and personnel to be at low
risk of bias in 37 of the 79 comparisons (Figure 2). Lack of blinding of
participants put 22 trials at high risk of bias while the remaining 20
arms were at unclear risk. Blinding of outcome assessors put trials
at low risk of detection bias in 53 studies and at high risk in 6 trials;
this aspect was unclear in the remainder. We found that 33 studies
were at low risk of both performance and detection bias.
Incomplete outcome data
We found that 53 trials were at low risk of attrition bias, 14 at high
risk, and the remaining 12 at unclear risk.
Selective reporting
We determined that 17 trials had a pre-published trials registry en-
try or protocol and reported all planned outcomes appropriately so
were considered at low risk of selective reporting. Twenty-three tri-
als were at high risk of selective reporting omitting reports on either
pre-stated outcomes or time points. We judged the remaining 39
trials to be at unclear risk of reporting bias as we could not find any
protocol or prospective trial registry entry (often trials were pub-
lished prior to trial registration availability).
Other potential sources of bias
We assessed risk of bias from lack of compliance and attention bias
and also noted other sources of bias. We found four studies to be
at high risk of compliance bias (FAAT 2005; HERO 2009; Proudman
2015; SMART 2013), while 34 studies provided evidence of good
compliance, and the remaining 41 studies were unclear. We noted
a high risk of attention bias in three studies where intervention par-
ticipants potentially had more dedicated time for dietary advice or
follow-up (DART2 2003; DART 1989; MARGARIN 2002). Nine trials did
not provide enough details to assess so we considered them to be at
unclear risk of attention bias (Ahn 2016; Erdogan 2007; Gill 2012; Ku-
mar 2012; Kumar 2013; Risk & Prevention 2013; Sianni 2013; SMART
2013; WAHA 2016), while we thought the remaining 67 were at low
risk of attention bias. We judged three studies to be at high risk of
other potential biases: Ahn 2016 because it is unclear whether it
was placebo-controlled, and there was concern over reported stan-
dard deviations, DISAF 2003 because the study stopped early, and
Kumar 2013 due to concerns over design. Three studies were at un-
clear risk due to insufficient methodological detail being provided
(Gill 2012; Sianni 2013; Zhang 2017).
E2ects of interventions
See: Summary of findings for the main comparison High ver-
sus low LCn3 for preventing cardiovascular disease and mortali-
ty (primary outcomes); Summary of findings 2 High versus low
ALA omega-3 fats for preventing cardiovascular disease (primary
outcomes); Summary of findings 3 High versus low omega-3 fats
for modification of CVD risk factors (adiposity and lipids): key out-
comes
Primary outcomes
See Summary of findings for the main comparison for a GRADE
summary of our evidence on effects of long-chain omega-3 (LCn3)
fats (including eicosapentaenoic acid (EPA), docosahexaenoic acid
(DHA) and docosapentaenoic acid (DPA)) on our primary outcomes.
Eects of long-chain omega-3 fats on primary health outcomes
All-cause mortality (LCn3)
High-quality evidence showed little or no effect of LCn3 on all-cause
mortality.
There was little or no effect of increasing long-chain omega-3 fats
on all-cause mortality, despite 8189 deaths in > 92,000 participants
(RR 0.98, 95% CI 0.93 to 1.03, I2 = 12%, Analysis 1.1). The funnel plot
suggested that some small studies with higher numbers of deaths
in the intervention group might be missing (Figure 3), indicating
small study bias. If such missing studies were added back in the RR
would rise (towards the null value of 1.0).
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Figure 3.   Funnel plot of comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes), outcome: 1.1 Aall-cause
mortality (overall) – LCn3.
 
Sensitivity analyses using fixed-effect meta-analysis did not alter
the lack of effect on all-cause mortality (RR 0.97, 95% CI 0.93 to 1.01,
Analysis 1.2). Removing RCTs not at low summary risk of bias leW
us with 15 RCTs involving over 33,000 participants, 3059 of whom
died, suggesting no effect of LCn3 on mortality (RR 1.01, 95% CI 0.94
to 1.08, I2 = 0%, Analysis 1.3). This lack of effect was also evident in
sensitivity analyses limited to studies at low risk of compliance bias
and to larger studies (Analysis 1.4).
The lack of effect for LCn3 on mortality did not differ by replace-
ment with mono-unsaturated fatty acids (MUFA), omega-3 fats or
other types of placebo compounds (Analysis 1.6). There was no sug-
gestion of any dose effect for long-chain omega-3 fats on mortality
(Analysis 1.5), and subgroups with RRs further away from 1.00 had
wider 95% confidence intervals. The lack of effect did not differ by
primary versus secondary prevention (Analysis 1.9) or mode of in-
tervention (dietary advice, supplemental foods, or capsules, Analy-
sis 1.7). While there was some suggestion of a small risk reduction in
total mortality with LCn3 in studies with medium to long duration
(2 to < 4 years, RR 0.91, 95% CI 0.86 to 0.96) and this subgroup was
clearly different from other durations (test for subgroup differences
P = 0.007), the effect was not evident in shorter (1 to < 2 years) or
longer studies (≥ 4 years, RR 1.03, 95% CI 0.98 to 1.09). Because of
the lack of effect in longer studies, we did not assume any duration
effects (Analysis 1.8).
As there was no suggestion of any effect of LCn3 fats on all-cause
mortality, we did not carry out meta-regression.
GRADE assessment suggested that the finding of little or no effect
of LCn3 on all-cause mortality was supported by high-quality evi-
dence (not downgraded, Summary of findings for the main compar-
ison).
Cardiovascular mortality (LCn3)
Moderate-quality evidence suggests that long-chain omega-3 fat
intake probably makes little or no difference to cardiovascular
deaths.
Twenty-five trials in at least 67,000 participants, 4544 of whom died
of CVD, reported on cardiovascular mortality (RR 0.95, 95% CI 0.87
to 1.03, I2 = 24%, Analysis 1.11). The funnel plot suggested that
some smaller studies with more cardiovascular deaths in the inter-
vention group were missing (some small study bias, Figure 4) – if
this were the case then adding the missing studies would increase
the relative risk towards the null (no effect).
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Figure 4.   Funnel plot of comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes), outcome: 1.11
Cardiovascular mortality (overall) – LCn3.
 
Fixed-effect meta-analysis suggested a 6% reduction in CVD mor-
tality risk (RR 0.94, 95% CI 0.89 to 1.00, Analysis 1.12). However, sen-
sitivity analyses removing RCTs not at low summary risk of bias leW
nine RCTs in over 29,000 participants, 1539 of whom died, suggest-
ing little or no effect of LCn3 on CVD mortality (RR 0.99, 95% CI 0.90
to 1.09, I2 = 0%, Analysis 1.13). Removing trials not at low risk of
compliance bias had a similar effect (Analysis 1.14).
There were no statistically significant differences between sub-
groups and no differential effects by replacement (Analysis 1.16),
mode of intervention (Analysis 1.17), duration (marginally signif-
icant difference between subgroups, P = 0.06; effects seen only
in medium- to long-term trials and not in shorter or longer stud-
ies, Analysis 1.18), primary or secondary prevention (Analysis 1.19),
statin use (Analysis 1.20) or omega-3 dose (Analysis 1.15). There was
no suggestion of a dose-response effect.
Meta-regression to assess effects of LCn3 dose (or alpha-linolenic
acid (ALA), omega-6 or total poly-unsaturated fatty acid (PUFA)
dose), duration, intervention type, primary or secondary preven-
tion and risk of bias (as well as a single multiple regression of the
three factors with the smallest P value) showed no association be-
tween these factors and risk of cardiovascular mortality (all P val-
ues were > 0.60, Table 2). We saw no suggestion of dose-response
or duration effects.
The suggestion of a protective effect disappeared in studies at
low summary risk of bias and at low risk of compliance problems.
The funnel plot suggests that the true risk ratio is higher than the
main estimate, and there was no suggestion of dose or duration ef-
fects; thus we summarised the evidence as showing little or no ef-
fect of LCn3 on CVD mortality. GRADE assessment suggested mod-
erate-quality evidence that long-chain omega-3 fat intake proba-
bly makes little or no difference to cardiovascular deaths (moder-
ate-quality/certainty evidence, downgraded once for imprecision).
Combined cardiovascular events (LCn3)
High-quality evidence suggests that LCn3 intake makes little or no
difference to risk of cardiovascular events.
There was little or no effect of increasing LCn3 fats on cardiovas-
cular events (RR 0.99, 95% CI 0.94 to 1.04, I2 = 37%, Analysis 1.21).
Analyses included 14,737 participants with cardiovascular events
in more than 90,000 participants in 38 trials. The funnel plot sug-
gested that some smaller studies with more participants experi-
encing cardiovascular events in the intervention group were miss-
ing (some small study bias, not shown) – if this were the case then
adding the missing studies would increase the relative risk.
Sensitivity analyses removing trials at moderate to high risk of
bias leW 14 trials, including more than 31,000 participants, 6695 of
whom had CVD events, with no suggestion of any effect of LCn3
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fats (RR 1.00, 95% CI 0.96 to 1.05, I2 = 0%, Analysis 1.23). Sensitivity
analyses including studies at low risk of compliance bias, at low risk
of small study bias and using fixed-effect meta-analysis did not sug-
gest any effect of LCn3 on CVD events (Analysis 1.22; Analysis 1.24).
In subgroup analysis, there was no suggestion of a dose-response
effect (Analysis 1.25). Effects did not differ by replacement (Analysis
1.26), baseline CVD risk (Analysis 1.29), type of intervention (Analy-
sis 1.27), statin use (Analysis 1.30), LCn3 dose (Analysis 1.25) or
study duration (Analysis 1.28), and there were no important differ-
ences between subgroups.
Meta-regression to assess effects of LCn3 dose (or doses of ALA,
omega-6 and total PUFA), duration, intervention type, primary or
secondary prevention and risk of bias (as well as a single multiple
regression of the three factors with the smallest P value) showed no
association between these factors and risk of cardiovascular events
(all P values were ≥ 0.24, Table 3). We saw no suggestion of dose or
duration effects.
GRADE assessment suggested high-quality evidence that LCn3 in-
take makes little or no difference to risk of cardiovascular events
(high-quality/certainty evidence).
Coronary heart mortality (LCn3)
Moderate-quality evidence suggests that long-chain omega-3 fat
intake probably makes little or no difference to coronary heart mor-
tality.
There was a suggestion that increasing LCn3 fats reduced the risk
of coronary heart mortality by 7% (RR 0.93, 95% CI 0.79 to 1.09, I2 =
35%) in 21 trials reporting 1596 events in more than 73,000 partici-
pants (Analysis 1.31). Sensitivity analyses using a fixed-effect mod-
el suggested a 6% reduction in CHD mortality (Analysis 1.32).
However, retaining only RCTs at low summary risk of bias, meta-
analysis of seven trials with more than 16,000 participants and 283
CHD deaths suggested no effect of LCn3 fats on CHD deaths (RR
1.00, 95% CI 0.72 to 1.37, I2 = 18%, Analysis 1.33). Sensitivity analy-
ses retaining only trials with low risk of compliance bias suggested
a 5% increase in risk with LCn3, but retaining only larger trials sug-
gested a 7% reduction (Analysis 1.34). The funnel plot suggested
that some smaller studies with higher RRs were missing (Figure 5),
and if added back these would increase the RR.
 
Figure 5.   Funnel plot of comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes), outcome: 1.31 Coronary
heart disease mortality (overall) – LCn3.
 
When we added this outcome we had pre-specified that we would
use the first of the following list reported in any trial: coronary
death, ischaemic heart disease (IHD) death, fatal MI and cardiac
death. We used cardiac death only when no other outcomes in this
category were available, and we ran a sensitivity analysis omitting
cardiac death as it potentially includes other causes of death in ad-
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dition to CHD, such as cardiomyopathies and congenital and valvu-
lar heart diseases (though numbers are likely to be small). Omitting
cardiac death resulted in a 17% reduction in CHD deaths with LCn3
(RR 0.83, 95% CI 0.74 to 0.94, I2 = 0%, 16 trials including 65,325 par-
ticipants, Analysis 1.35).
There were no statistically significant differences between sub-
groups for type of intervention (Analysis 1.38), dose (Analysis 1.36),
baseline CVD risk (Analysis 1.40), statin use (Analysis 1.41) or base-
line coronary artery disease status (Analysis 1.42). There were im-
portant differences between subgroups for study duration, with no
effect in shorter trials (1 to < 2 years), a significant protective effect
of LCn3 fats in medium- to long-term trials (2 to < 4 years) and an al-
most statistically significant harmful effect in long trials (≥ 4 years,
Analysis 1.39), so we did not assume any differential effect by du-
ration. The differences between subgroups for replacement disap-
peared when we omitted the 'replacement unclear' category (alter-
ing the test for subgroup differences to P = 0.46, Analysis 1.37).
Meta-regression to assess effects of LCn3 dose on CHD mortality
found no relationship (P = 0.94, Table 4). Similarly we saw no rela-
tionships between ALA dose, omega-6 dose, total PUFA dose, du-
ration, intervention type, primary or secondary prevention or risk
of bias and CHD deaths (all P values were > 0.40, Table 4). Multiple
regression of the three factors with the smallest P value found no
factors associated with risk of CHD deaths. We saw no suggestion
of dose or duration effects.
The suggestion of a protective effect disappeared in studies at low
summary risk of bias, the funnel plot suggests that the true risk ra-
tio is higher than the main estimate, and there was no suggestion of
dose or duration effects, so we summarised the evidence by assum-
ing little or no effect of LCn3 on CHD mortality. GRADE assessment
suggested moderate-quality evidence that long-chain omega-3 fat
intake probably makes little or no difference to coronary heart mor-
tality (moderate-quality/certainty evidence, downgraded once for
imprecision).
Coronary heart disease events (LCn3)
Moderate-quality evidence suggests that long-chain omega-3 fat
intake probably makes little or no difference to risk of coronary
heart events.
The main meta-analysis suggested a 7% reduction in people expe-
riencing CHD events with higher intake of LCn3 fats (RR 0.93, 95%
CI 0.88 to 0.97, I2 = 0%, 5469 events, > 84,000 participants, Analy-
sis 1.43). The funnel plot suggested that some smaller studies with
more cardiovascular deaths in the intervention group were missing
(some small study bias, Figure 6) – if this were the case then adding
the missing studies would increase the relative risk.
 
Figure 6.   Funnel plot of comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes), outcome: 1.43 Coronary
heart disease events (overall) – LCn3.
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Sensitivity analyses using a fixed-effect model did not alter the re-
sults (RR 0.92, 95% CI 0.88 to 0.97, Analysis 1.44). The protective ef-
fect was lost in studies at low summary risk of bias (Analysis 1.45),
and the effect was smaller when studies were limited to those with
good compliance and to larger studies (Analysis 1.46). Removing
RCTs not at low summary risk of bias leW 12 trials with more than
30,000 participants, 2228 of whom developed CHD (RR 0.97, 95% CI
0.90 to 1.05, I2 = 0%, Analysis 1.45).
There were no statistically significant differences between sub-
groups (Analysis 1.47; Analysis 1.48; Analysis 1.49; Analysis 1.50;
Analysis 1.51; Analysis 1.52; Analysis 1.53).
Meta-regression to assess effects of LCn3, ALA, omega-6, total PU-
FA dose and duration, intervention type, primary or secondary pre-
vention, and risk of bias (as well as a single multiple regression of
the three factors with the smallest P value) showed no association
between these factors and the risk of CHD events (all P values were
> 0.20, Table 5). We saw no suggestion of dose-response or duration
effects.
Because a protective effect was only apparent in studies at higher
risk of bias, we were concerned that the reduction in CHD events
is residual and arises from methodological weaknesses in some
of the studies (there was a marginally significant difference be-
tween the group of studies at low risk of bias, and those at moder-
ate to high risk of bias, P = 0.09, Analysis 1.45). GRADE assessment
suggested moderate-quality evidence that long-chain omega-3 fat
intake probably makes little or no difference to risk of coronary
heart events (moderate-quality/certainty evidence, downgraded
once for risk of bias).
Stroke (LCn3)
Moderate-quality evidence suggests that long-chain omega-3 fat
intake probably makes little or no difference to risk of experiencing
a stroke.
There was a suggestion that increasing intake of LCn3 results in a
6% higher risk of stroke (RR 1.06, 95% CI 0.96 to 1.16, I2 = 0%, 1822
reported strokes, Analysis 1.54), and the funnel plot did not suggest
any small study bias (not shown).
Sensitivity analyses removing trials not at low summary risk of bias
leW 12 trials with 888 participants experiencing strokes, suggesting
little or no effect of LCn3 fats on stroke (RR 0.98, 95% CI 0.86 to 1.12,
I2 = 0%, Analysis 1.56). Using fixed-effect meta-analysis also sug-
gested a 6% increase in risk (Analysis 1.55), while sensitivity analy-
sis removing trials with risk from poor compliance and smaller trials
suggested there may be harm from increased LCn3 (Analysis 1.57).
When studies reported stroke type separately, the risk of both
haemorrhagic (RR 1.20, 95% CI 0.85 to 1.69, I2 = 0%, 130 participants
with events) and ischaemic stroke were increased (RR 1.09, 95%
CI 0.89 to 1.33, I2 = 13%, 556 people with events, in 8 trials each,
Analysis 1.58). Five trials reported only 40 participants experienc-
ing transient ischaemic attack (TIA), suggesting a 26% reduction in
risk but with very wide confidence intervals (TIAs were not included
in any other stroke categories, Analysis 1.58). Subgrouping did not
suggest important differences by intervention type, replacement,
statin use, trial duration or dose (Analysis 1.59; Analysis 1.60; Analy-
sis 1.61; Analysis 1.62; Analysis 1.64). There was a suggestion of in-
creased stroke risk in people with CVD at baseline (RR 1.21, 95%
CI 1.05 to 1.40, I2 = 0%, with differences in effect size between sub-
groups by primary or secondary prevention, P = 0.02, Analysis 1.63).
Meta-regression to assess effects of LCn3 dose did not find any
clear dose response on risk of stroke (P = 0.42, Table 6). Univariate
meta-regression suggested that trials of shorter duration showed a
greater effect on reducing stroke (P = 0.012) and that LCn3 fats may
be more protective against stroke in secondary prevention than pri-
mary (P = 0.04, Table 6). There were no clear relationships between
dose of any PUFA type, risk of bias, or use of food or capsules, and
no significant relationships in multivariate meta-regression.
Given that studies at low summary risk of bias suggested little or no
effect of LCn3 on stroke risk, and there were no dose-response or
duration relationships, we assumed little or no true effect. GRADE
assessment suggests moderate-quality evidence that long-chain
omega-3 fat intake probably makes little or no difference to risk of
experiencing a stroke (moderate-quality/certainty evidence, down-
graded once for imprecision).
Arrhythmia (LCn3)
Moderate-quality evidence suggests that long-chain omega-3 fat
intake probably makes little or no difference to risk of arrhythmia.
There was no effect of LCn3 fats on incidence of new or recurrent
(fatal and non-fatal) arrhythmias (RR 0.97, 95% CI 0.90 to 1.05, I2 =
43%, 3788 events in > 53,000 participants, Analysis 1.65). The funnel
plot was not interpretable as studies were clustered (not shown).
Sensitivity analyses removing trials not at low summary risk of bias
leW 10 trials with 1146 events (> 25,000 participants), suggesting a
10% increase in risk of arrhythmia with increased LCn3 (RR 1.10,
95% CI 0.98 to 1.23, I2 = 0%, Analysis 1.67). Restricting the analysis
to studies at low summary risk of bias removed heterogeneity, and
there was a statistically significant difference in effect size between
subgroups at low versus moderate to high risk of bias (P = 0.03,
Analysis 1.67). Using fixed-effect methodology did not alter the ap-
parent lack of effect of LCn3 on arrhythmia (Analysis 1.66), and sen-
sitivity analysis by compliance and study size also suggested little
or no effect of LCn3 on arrhythmia (Analysis 1.68).
Subgrouping by new or recurrent arrhythmias suggested differ-
ences between subgroups, with LCn3 increasing the risk of new ar-
rhythmias and reducing the risk of recurrent arrhythmia (Analysis
1.69). There were also statistically significant differences between
subgroups by fatality, with a suggestion that LCn3 increased the
risk of fatal arrhythmias but reduced the risk of non-fatal arrhyth-
mias (Analysis 1.70). Subgroup analyses by type of intervention, re-
placement, baseline CVD risk, statin use, dose and study duration
did not suggest any statistically significant differences between
subgroups (Analysis 1.71; Analysis 1.72; Analysis 1.73; Analysis 1.74;
Analysis 1.75; Analysis 1.76).
Meta-regression suggested a marginally significant negative dose-
response relationship with LCn3 fats, such that lower dose was as-
sociated with lower risk of arrhythmia (P = 0.06, Table 7). The effect
remained marginally significant when we controlled for primary or
secondary prevention and study duration (P = 0.09). Because of the
negative direction of this apparent dose-response relationship, we
assumed it was likely to be a chance occurrence resulting from run-
ning a large number of statistical tests. There was also a marginal-
ly significant relationship for arrhythmia with primary versus sec-
ondary prevention, suggesting greater reduction in arrhythmia risk
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in primary prevention (P = 0.07, Table 7). There were no other sug-
gested relationships.
GRADE assessment suggested moderate-quality evidence that
long-chain omega-3 fat intake probably makes little or no differ-
ence to risk of arrhythmia (moderate-quality/certainty evidence,
downgraded once for imprecision).
Eects of ALA on primary health outcomes
See Summary of findings 2 for a summary of our evidence on effects
of ALA on our primary outcomes.
As there were fewer than 10 studies for all ALA analyses we did
not use funnel plots, though we did run sensitivity analyses and
subgroups. We assessed ALA dose-response and duration effects in
meta-regression of all included LCn3, ALA, omega-6 and total PUFA
trials (but not of ALA trials alone as there were too few studies to
carry out meta-regression with any reliability).
All-cause mortality (ALA)
Moderate-quality evidence suggests that ALA intake probably
makes little or no difference to all-cause mortality.
There was little or no effect of increasing ALA omega-3 fats on all-
cause mortality, with 458 deaths in more than 18,000 participants
involved in four studies (RR 1.01, 95% CI 0.84 to 1.20, I2 = 0%, Analy-
sis 4.1).
Sensitivity analyses removing RCTs not at low summary risk of bias
leW three trials with 375 deaths, again suggesting little or no effect
(RR 1.02, 95% CI 0.72 to 1.45, I2 = 3%, Analysis 4.3). Using fixed-effect
meta-analysis suggested a 6% increase in risk of all-cause mortality
with increased ALA (RR 1.06, 95% CI 0.84 to 1.34, Analysis 4.2), while
limiting the analysis to studies at low risk of compliance problems
showed a 5% increase, and including only larger trials showed little
or no effect (Analysis 4.4).
Subgrouping by ALA dose, trial duration, statin use, replacement,
primary or secondary prevention, or intervention type did not re-
sult in any significant differences between subgroups (Analysis 4.5;
Analysis 4.6; Analysis 4.7; Analysis 4.8; Analysis 4.9; Analysis 4.10).
As there was no suggestion of effect in any subgroup, we did not
carry out meta-regression.
GRADE assessment suggested that ALA intake probably makes little
or no difference to all-cause mortality (moderate-quality/certainty
evidence, downgraded once for imprecision).
Cardiovascular mortality (ALA)
Moderate-quality evidence suggests that increasing ALA intake
probably has little or no effect on cardiovascular mortality.
Four studies contributed data to this outcome. There was little or
no effect of increasing ALA omega-3 fats on cardiovascular mortal-
ity (RR 0.96, 95% CI 0.74 to 1.25, I2 = 0%, Analysis 4.11), but confi-
dence intervals were very wide. Analyses included 219 CVD deaths
in > 18,000 participants.
Sensitivity analyses using fixed-effect meta-analysis did alter the
lack of effect (RR 0.96, 95% CI 0.74 to 1.25, Analysis 4.12). Removing
studies not at low risk of bias leW three trials with 165 cardiovascu-
lar deaths, suggesting a 5% reduction of cardiovascular death risk
with higher ALA (RR 0.95, 95% CI 0.70 to 1.28, Analysis 4.13). Sensi-
tivity analysis by compliance or study size again suggested 6% and
4% reductions, respectively, in CVD mortality risk (Analysis 4.14).
Subgrouping by ALA dose, study duration, replacement, inter-
vention type, statin use or primary/secondary prevention did not
suggest important differences between subgroups (Analysis 4.15;
Analysis 4.16; Analysis 4.17; Analysis 4.18; Analysis 4.19; Analysis
4.20). Meta-regression to assess for effects of ALA dose on cardio-
vascular mortality did not suggest dose effects (P = 0.91, Table 2).
GRADE assessment suggested that increasing ALA intake probably
has little or no effect on cardiovascular mortality (moderate-quali-
ty/certainty evidence, downgraded once for imprecision).
Cardiovascular events (ALA)
GRADE assessment suggested that increasing ALA intake may re-
duce the risk of cardiovascular events by a small amount.
There was a 5% reduction in risk of cardiovascular events in five tri-
als with increased ALA intake (RR 0.95, 95% CI 0.83 to 1.07, I2 = 0%,
884 out of > 19,000 participants experienced at least one cardiovas-
cular event, Analysis 4.21).
Sensitivity analyses removing studies at moderate to high risk of
bias leW three trials in which 691 of > 5,000 enrolled participants
experienced at least one cardiovascular event, suggesting a 9% re-
duction in risk of CVD events with higher ALA (RR 0.91, 95% CI 0.79
to 1.04, I2 = 0%, Analysis 4.23). Fixed-effect analysis suggested a 5%
reduction in risk (Analysis 4.22), while studies at low risk of compli-
ance bias suggested a 10% reduction in risk, and larger studies a
5% reduction (Analysis 4.24).
Subgrouping by ALA dose, study duration, replacement, inter-
vention type, statin use or primary/secondary prevention did not
suggest significant differences between subgroups (Analysis 4.25;
Analysis 4.26; Analysis 4.27; Analysis 4.28; Analysis 4.29; Analysis
4.30). Meta-regression to assess for effects of ALA dose on cardio-
vascular events did not suggest any dose effects (P = 0.70, Table 3).
GRADE assessment suggested that increasing ALA intake may re-
duce the risk of cardiovascular events by a small amount (low-qual-
ity/certainty evidence, downgraded once for risk of bias and once
for imprecision).
Coronary heart disease mortality (ALA)
GRADE assessment suggested that increasing ALA intake probably
has little or no effect on CHD mortality.
Three studies reported 193 CHD deaths in > 18,000 participants,
suggesting a 5% reduction in CHD mortality with increased ALA (RR
0.95, 95% CI 0.72 to 1.26, I2 = 0%, Analysis 4.31).
Sensitivity analyses using fixed-effect meta-analysis did not alter
the effect (RR 0.95, 95% CI 0.72 to 1.26, Analysis 4.32). Studies at
low summary risk of bias suggested a 7% reduction in risk of CHD
mortality (including 2 trials with 4947 participants, RR 0.93, 95% CI
0.67 to 1.30, I2 = 0%, Analysis 4.33), with similar effects in studies at
low risk of compliance bias, or low risk of small study bias (Analysis
4.34).
Subgrouping by ALA dose, study duration, replacement, interven-
tion type, statin use, primary/secondary prevention or previous his-
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tory of coronary artery disease did not suggest important differ-
ences between subgroups (Analysis 4.35; Analysis 4.36; Analysis
4.37; Analysis 4.38; Analysis 4.39; Analysis 4.40; Analysis 4.41). Meta-
regression to assess for effects of ALA dose on CHD deaths did not
suggest any dose effects (P = 0.93, Table 4).
GRADE assessment suggested that increasing ALA intake probably
has little or no effect on CHD mortality (moderate-quality/certainty
evidence, downgraded once for imprecision).
Coronary heart disease events (ALA)
Low-quality evidence suggests that ALA intake may make little or
no difference to CHD events.
Three studies contributed data to this outcome, with 396 out of
over 18,000 participants experiencing at least one CHD event. There
was little or no effect on CHD risk with increased ALA (RR 1.00, 95%
CI 0.82 to 1.22, I2 = 2%, Analysis 4.42).
Sensitivity analyses using fixed-effect meta-analysis did not alter
the lack of effect (RR 1.00, 95% CI 0.82 to 1.21, Analysis 4.43). Re-
moving studies not at low summary risk of bias leW two studies with
almost 5000 participants, suggesting a 9% reduction in risk of a CHD
event (RR 0.91, 95% CI 0.71 to 1.15, Analysis 4.44), similar to sensi-
tivity analysis omitting studies with potential compliance problems
(Analysis 4.45), though no effects were seen when restricting analy-
sis to larger trials (Analysis 4.45).
Subgrouping by ALA dose, study duration, replacement, interven-
tion type, statin use, primary/secondary prevention or previous his-
tory of coronary artery disease did not suggest important differ-
ences between subgroups (Analysis 4.46; Analysis 4.47; Analysis
4.48; Analysis 4.49; Analysis 4.50; Analysis 4.51; Analysis 4.52). Meta-
regression did not suggest that there was a direct relationship be-
tween ALA dose and CHD events (Table 5).
Given the differences in sensitivity analyses, GRADE assessment
suggested that ALA intake may make little or no difference to CHD
events (low-quality/certainty evidence, downgraded once for risk
of bias and once for imprecision).
Stroke (ALA)
The effect of ALA intake on stroke is unclear, as the evidence is of
very low quality.
Five RCTs involved 51 people out of more than 18,000 participants
experiencing a stroke, suggesting a 15% increase in stroke risk with
increased ALA (RR1.15, 95% CI 0.66 to 2.01, I2 = 0%, Analysis 4.53).
Sensitivity analyses removing studies not at low summary risk of
bias leW three studies with 27 stroke events and no suggestion of
effect (Analysis 4.55). Using a fixed-effect model suggested a 23%
increased risk of stroke (Analysis 4.54), while removing studies at
high risk of bias due to compliance suggested a 15% reduction in
stroke risk, while larger studies suggested a 15% greater stroke risk
(Analysis 4.56).
Subgrouping by ALA dose, study duration, replacement, interven-
tion type, statin use or primary/secondary prevention did not result
in significant differences between subgroups (Analysis 4.57; Analy-
sis 4.58; Analysis 4.59; Analysis 4.60; Analysis 4.61; Analysis 4.62).
When examining data reported by type of stroke, only three stud-
ies reported on 28 ischaemic strokes, with no clear effects, and no
studies reported on haemorrhagic stroke (Analysis 4.63). Meta-re-
gression did not suggest any relationship between ALA dose and
risk of stroke (Table 6).
The effect of ALA on stroke is unclear as the evidence is of very
low quality (downgraded twice for risk of bias and once for impre-
cision).
Arrhythmia (ALA)
Moderate-quality evidence suggested that ALA intake probably re-
duces the risk of arrhythmias.
Only one study reported effects of ALA on arrhythmia, with 141 new
arrhythmias in 4837 participants, suggesting a 21% reduction in ar-
rhythmia but with wide confidence intervals (RR 0.79, 95% CI 0.57
to 1.10, Analysis 4.64). The results were identical when sensitivity
analysis retained only studies at low summary risk of bias (as we
judged the single included study to be at low risk of bias, Analysis
4.65). As there was only one trial, we did not carry out further sensi-
tivity analyses or subgrouping. There was no suggestion of a dose-
response relationship between ALA and arrhythmia risk in meta-re-
gression (P = 0.67, Table 7).
GRADE assessment suggested that ALA intake probably reduces the
risk of arrhythmias (moderate-quality/certainty evidence, down-
graded once for imprecision).
Secondary outcomes
See Summary of findings 3 for a summary of our evidence on effects
of long-chain omega-3 fats and ALA on serum lipids and measures
of adiposity.
Eects of long-chain omega-3 fats (EPA, DHA and DPA) on
secondary health outcomes
We did not carry out sensitivity analyses or subgrouping on sec-
ondary outcomes, except for adiposity and lipids (which were key
outcomes). We did carry out some post hoc sensitivity analyses to
further assess effects of LCn3 on MI, to ascertain whether the sug-
gested protection was stable to sensitivity analyses.
Major adverse cerebrovascular or cardiovascular events (LCn3)
Five trials reported on major adverse cerebrovascular or cardiovas-
cular events (MACCEs) in more than 34,000 participants, 4232 of
whom suffered from a MACCE, suggesting little or no effect of LCn3
fats (RR 1.03, 95% CI 0.97 to 1.09, I2 = 0%, Analysis 2.1).
Myocardial infarction (LCn3)
Twenty-three studies (> 72,000 participants) reported on total (fatal
and non-fatal) myocardial infarction (MI). Meta-analyses suggest-
ed that increasing LCn3 fats resulted in a small reduction in total
MI (RR 0.95, 95% CI 0.88 to 1.03, I2 = 0%, 2200 MI events, Analysis
2.2). This was confirmed in sensitivity analyses limited to studies
without compliance problems and to studies that randomised at
least 100 participants (Analysis 2.4), but analyses limited to studies
at low summary risk of bias suggest little or no effect of LCn3 on
MI (RR 1.03, 95% CI 0.92 to 1.15, I2 = 0%, > 30,000 participants in 11
trials, and reporting on 1154 people experiencing at least one MI,
Analysis 2.3). This suggests little or no true effect of LCn3 on MI.
We ran subgroup analyses by fatality at the request of the WHO NU-
GAG Subgroup on Diet and Health, finding no significant difference
between fatal and non-fatal MI subgroups (P = 0.23, Analysis 2.5).
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Sudden cardiac death (LCn3)
There was little or no effect of LCn3 fats on sudden cardiac death
(RR 0.97, 95% CI 0.80 to 1.18, I2 = 38%, 1274 deaths, 14 studies in >
65,000 people, Analysis 2.6).
Angina (LCn3)
Meta-analysis of 11 studies involving more than 39,000 partici-
pants, 2418 of whom reported new or worsening angina, suggest-
ed little or no effect of increasing LCn3 fats (RR 0.99, 95% CI 0.92 to
1.07, I2 = 0%, Analysis 2.7).
Heart failure (LCn3)
Meta-analysis suggested a small effect for LCn3 fatty acids on heart
failure diagnosis in 15 trials with 4098 people experiencing events
(RR 0.93, 95% CI 0.85 to 1.03, I2 = 31%, Analysis 2.8). Because of this
suggested effectiveness, we ran a sensitivity analysis limited to the
six studies at low summary risk of bias, which suggested little effect
(RR 0.97, 95% CI 0.89 to 1.06, I2 = 0%, 1809 participants experiencing
heart failure). For this reason we concluded that there was little or
no effect of LCn3 on risk of heart failure.
Revascularisation (LCn3)
Meta-analysis suggested little or no effect of LCn3 fats on revascu-
larisation (all types combined, RR 0.98, 95% CI 0.94 to 1.03, 6558
participants experiencing revascularisation, I2 = 0%, Analysis 2.9).
Data on angioplasty alone were similar (RR 0.96, 95% CI 0.74 to
1.24, 215 events), and there were insufficient reported CABGs to
give meaningful results (9 events, Analysis 2.9).
Peripheral arterial disease (LCn3)
Meta-analysis suggested that LCn3 reduced the risk of peripheral
arterial disease (PAD) by 7% (RR 0.93, 95% CI 0.74 to 1.18, I2 = 0%,
282 events in > 49,000 participants, 7 trials, Analysis 2.10). All rele-
vant studies had randomised at least 100 participants, so this sen-
sitivity analysis did not alter the effect, but limiting the analysis to
studies at low risk of compliance bias suggested little or no effect of
LCn3 on PAD, and limiting analyses to studies at low summary risk
of bias suggested an increase in PAD with increased LCn3 (Analysis
2.11; Analysis 2.12). The effect of LCn3 on peripheral arterial disease
is unclear – there may be increased, decreased or no effect.
Acute coronary syndrome (LCn3)
There were limited data on effects of increasing LCn3 fats on acute
coronary syndrome (RR 1.19, 95% CI 0.71 to 2.00, I2 = 0%, 55 events
in > 2000 participants, 2 trials, Analysis 2.13).
Body weight, body mass index (BMI) and other measures of adiposity
(LCn3)
Body weight
High-quality evidence shows that LCn3 intake makes little or no dif-
ference to body weight.
Twelve studies, 11 of which were included in meta-analysis, report-
ed on the effect of increasing LCn3 on body weight, suggesting lit-
tle or no effect in > 15,000 participants (mean difference (MD) −0.01
kg, 95% CI −0.84 to 0.82, I2 = 49%, Analysis 2.14). Sensitivity analysis
limited to studies at low summary risk of bias, low risk from compli-
ance, larger trials or fixed-effect analysis (not shown) did not alter
this lack of effect (Analysis 2.15; Analysis 2.16).
Subgroup analysis by intervention type, primary or secondary pre-
vention, statin use and trial duration did not suggest important dif-
ferences between subgroups (Analysis 2.19; Analysis 2.20; Analysis
2.21; Analysis 2.22). There was a marginally significant difference
between dose subgroups (P = 0.06, Analysis 2.17) and increased
body weight when participants received very high LCn3 doses (>
4.4 g/d LCn3, MD 1.51 kg, 95% CI 0.28 to 2.75, I2 = 0%, 2 trials in-
cluding 261 participants, Analysis 2.17). Subgrouping by replace-
ment suggested differences between subgroups (P < 0.001, Analy-
sis 2.18, with reduced body weight when LCn3 replaced saturated
fatty acids (SFA) or carbohydrates but increased weight when LCn3
replaced nil or low LCn3 (Analysis 2.18).
Several studies clearly measured body weight but did not report it
in a useable way (Baldassarre 2006; Caldwell 2011; Deslypere 1992;
EPE-A 2014; MARINA 2011; Nutristroke 2009). Body weight is com-
monly measured in healthcare settings, so there may be consider-
ably more missing data than these.
GRADE evidence suggests high-quality evidence that LCn3 intake
makes little or no difference to body weight (high-quality/certainty
evidence).
BMI
High-quality evidence shows that LCn3 intake makes little or no dif-
ference to BMI.
Fourteen trials, 12 of which were included in meta-analysis, re-
ported on BMI, suggesting little or no effect of LCn3 on BMI (MD
0.04 kg/m2, 95% CI −0.16 to 0.24, I2 = 40%, > 15,000 participants,
Analysis 2.23). This lack of effect was also apparent in sensitivi-
ty analyses limited to studies at low summary risk of bias (Analy-
sis 2.24), with good compliance or with large study size (Analysis
2.25), as well as fixed-effect analysis (not shown). Subgroup analy-
ses by primary or secondary prevention, LCn3 dose, intervention
type, statin use and trial duration did not suggest important dif-
ferences between subgroups (Analysis 2.26; Analysis 2.28; Analy-
sis 2.29; Analysis 2.30; Analysis 2.31). There were significant differ-
ences between subgroups when subgrouped by replacement, sug-
gesting lower BMI when LCn3 was replaced by SFA and carbohy-
drate, but increased BMI with LCn3 in other replacements (P = 0.04,
Analysis 2.27).
Several studies clearly measured BMI but did not report it in a use-
able way (Caldwell 2011; EPE-A 2014; Nutristroke 2009; Ramirez-
Ramirez 2013; Sofi 2010), suggesting that missing data may be an
issue with this outcome.
GRADE evidence suggests high-quality evidence that LCn3 intake
makes little or no difference to BMI (high-quality/certainty evi-
dence).
Other measures of adiposity
Few studies reported on other measures of adiposity (percentage
body fat, percentage visceral fat, waist circumference, waist/hip ra-
tio, abdominal circumference and hip circumference) with some
suggesting higher adiposity and some lower adiposity in groups
with more LCn3 (Analysis 2.32).
Serum lipids (LCn3)
Several studies clearly measured lipids but did not report them in
a way that we could include in our meta-analyses. These general-
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ly included Baldassarre 2006, Gill 2012, Ramirez-Ramirez 2013 and
Reed 2014, plus Ahn 2016, Caldwell 2011, Franzen 1993 and Rossing
1996, which assessed but did not report triglycerides, and Franzen
1993, which measured but did not provide useable data for HDL and
LDL cholesterol. For this reason missing data may potentially bias
these outcomes.
Serum total cholesterol
Moderate-quality evidence shows that LCn3 intake probably makes
little or no difference to serum total cholesterol.
Twenty-eight trials provided data on long-term effects of LCn3 fats
on serum total cholesterol, suggesting little or no effect in more
than 37,000 participants (MD −0.01 mmol/L, 95% CI −0.5 to 0.04, I2 =
19%, Analysis 2.33). Sensitivity analyses limited to trials at low sum-
mary risk of bias, low risk of compliance issues, and larger trials al-
so suggested little or no effect of LCn3 on serum total cholesterol
(Analysis 2.34; Analysis 2.35), but fixed-effect meta-analysis sug-
gested that LCn3 reduced serum total cholesterol (MD −0.04 mmol/
L, 95% CI −0.06 to −0.02, I2 = 19%, not shown). Subgrouping by dura-
tion did not suggest any differential effects of LCn3 (Analysis 2.39).
There were significant differences between subgroups by dose but
no logical sequence suggesting a true dose-response effect (P =
0.03, Analysis 2.36). There were also subgroup differences for re-
placement and intervention type (Analysis 2.37; Analysis 2.38), with
reductions in serum total cholesterol when supplemental capsules
were used and when LCn3 replaced carbohydrates (Analysis 2.36;
Analysis 2.37; Analysis 2.38).
GRADE assessment suggests moderate-quality evidence that LCn3
intake probably makes little or no difference to serum total choles-
terol (moderate-quality/certainty evidence, downgraded once for
imprecision).
Serum triglycerides
High-quality evidence suggests that LCn3 intake reduces serum
triglycerides in a dose-dependent manner.
LCn3 fats significantly reduced serum triglycerides in > 35,000 par-
ticipants in 23 trials (MD −0.24 mmol/L, 95% CI −0.31 to −0.16, I2
= 48%, Analysis 2.42). This effect was not lost in sensitivity analy-
sis excluding studies at moderate to high risk of bias, those with-
out clear compliance or small studies (Analysis 2.43; Analysis 2.44),
or using fixed-effect analysis (not shown). Subgrouping suggested
that the reduction of serum triglycerides did not differ between
subgroups by primary or secondary prevention, statin use, replace-
ment, intervention type or trial duration ( Analysis 2.46; Analysis
2.47; Analysis 2.48; Analysis 2.49; Analysis 2.50). There was a sug-
gestion of a dose-response relationship with greater reductions in
triglycerides at higher LCn3 doses, with significant differences be-
tween subgroups (P = 0.04, Analysis 2.45).
GRADE evidence suggests high-quality evidence that LCn3 intake
reduces serum triglycerides in a dose-dependent manner (not
downgraded).
HDL cholesterol
High-quality evidence suggests that LCn3 intake has little or no ef-
fect on HDL cholesterol.
Twenty-seven trials including more than 37,000 participants sug-
gested a small increase of less than 5% in serum HDL cholesterol
with increased LCn3 (MD 0.02 mmol/L, 95% CI 0.00 to 0.04, P = 0.03,
I2 = 48%, Analysis 2.51). There was still a suggestion of a small HDL
increase when we limited analysis to the eight studies at low sum-
mary risk of bias (MD 0.03 mmol/L, 95% CI −0.01 to 0.07, I2 = 66%,
> 14,000 participants, Analysis 2.52) where heterogeneity was very
high. Limiting analyses by compliance and study size (Analysis 2.53)
and in fixed-effect analysis (not shown), results suggested increas-
es in HDL with LCn3. There were no significant differences between
subgroups in any analysis except by duration, where shorter trials
suggested HDL increases, with no effect in longer trials (P = 0.05,
Analysis 2.57). There were no important differences between oth-
er subgroups and no suggestion of a dose-response relationship
(Analysis 2.54; Analysis 2.55; Analysis 2.56; Analysis 2.58; Analysis
2.59).
GRADE assessment suggests high-quality evidence that LCn3 in-
take has little or no effect on HDL cholesterol (not downgraded).
LDL cholesterol
GRADE assessment suggests moderate-quality evidence that LCn3
intake probably makes little or no difference to LDL cholesterol.
There was little or no effect of increasing LCn3 on serum LDL cho-
lesterol in over 35,000 participants from 23 trials (MD 0.01 mmol/
L, 95% CI −0.01 to 0.03, I2 = 0%, Analysis 2.60). This lack of effect
did not alter in sensitivity analyses limited to trials at low summa-
ry risk of bias, to trials with good evidence of compliance (Analysis
2.61) , larger studies (Analysis 2.62) or in fixed-effect meta-analysis
(not shown). We saw no statistically significant differences between
subgroups except for with regard to statin use, where there was an
increase in LDL cholesterol in nine trials where statin use was low
(Analysis 2.63; Analysis 2.64; Analysis 2.65; Analysis 2.66; Analysis
2.67; Analysis 2.68).
GRADE assessment suggests moderate-quality evidence that LCn3
intake probably makes little or no difference to LDL cholesterol
(moderate-quality/certainty evidence, downgraded once for im-
precision).
Eects of ALA on secondary health outcomes
We did not plan any sensitivity or subgroup analyses on secondary
outcomes, except for adiposity and lipids (key outcomes). As fewer
than 10 ALA trials were available for these outcomes, we carried out
only sensitivity analyses.
Major adverse cerebrovascular or cardiovascular events (ALA)
One trial reported on MACCEs in 110 participants, 9 of whom expe-
rienced an event. There were insufficient data to suggest any effect
of ALA on MACCEs (RR 1.12, 95% CI 0.32 to 3.95, Analysis 5.1).
Myocardial infarction (ALA)
Three studies reported that 333 out of more than 18,000 partici-
pants experienced a fatal or non-fatal MI, suggesting little or no ef-
fect of ALA on MI (RR 1.00, 95% CI 0.76 to 1.32, I2 = 26%, Analysis 5.2).
We carried out subgroup analyses by fatality at the request of the
WHO NUGAG Subgroup on Diet and Health, and these suggested no
significant differences between fatal and non-fatal MI subgroups (P
= 0.36, Analysis 5.3).
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Sudden cardiac death (ALA)
No studies assessed effects of ALA on sudden cardiac death.
Angina (ALA)
Two trials assessed the effects of increasing ALA on diagnosis of
new or worsening angina (39 of > 13,000 participants experienced
this). There were insufficient data to suggest any effect of ALA on
angina (RR1.41, 95% CI 0.75 to 2.64, I2 = 0%, Analysis 5.4).
Heart failure (ALA)
No studies assessed effects of ALA on heart failure.
Revascularisation (ALA)
Only one trial (3 events in 266 participants) reported on the effects
of increased ALA on revascularisation (RR 0.72, 95% CI 0.07 to 7.84,
3 events, Analysis 5.5) or CABG specifically (RR 0.29, 95% CI 0.01 to
5.93, 2 events, Analysis 5.5). There were insufficient data to suggest
any effect of ALA on revascularisation.
Peripheral arterial disease (ALA)
Meta-analysis suggested no clear effect of ALA on PAD in a single
study (RR 0.25, 95% CI 0.05 to 1.17, 10 of the > 13,000 participants
experienced PAD, Analysis 5.6). There were insufficient data to sug-
gest any effect of ALA on the outcome.
Acute coronary syndrome (ALA)
There were no trials assessing effects of ALA on acute coronary syn-
drome.
Body weight, BMI and other measures of adiposity (ALA)
Low-quality evidence suggests that ALA intake may make little or
no difference to BMI, but the effect of LCn3 intake on body weight
is unclear as the evidence is of very low quality.
Four studies reported on the effect of ALA on body weight in 664
participants, suggesting some weight reduction in those taking
more ALA but with extremely high heterogeneity (MD −1.49 kg, 95%
CI −4.17 to 1.18, I2 = 73%, Analysis 5.7). Sensitivity analysis us-
ing fixed-effect meta-analysis suggested a slight increase in body
weight with ALA (Analysis 5.8), while no studies were at low sum-
mary risk of bias (Analysis 5.9). Retaining only trials at low risk
for compliance bias or only larger trials suggested weight reduc-
tion with ALA (Analysis 5.10). There were no significant differences
between subgroups by intervention type, dose, duration, replace-
ment, statin use, or primary or secondary prevention of CVD (Analy-
sis 5.11; Analysis 5.12; Analysis 5.13; Analysis 5.14; Analysis 5.15;
Analysis 5.16). GRADE assessment suggests that the effect of ALA in-
take on body weight is unclear, as the evidence is of very low qual-
ity (downgraded once each for risk of bias, inconsistency and im-
precision).
Three trials reported on BMI, suggesting a reduction in BMI with in-
creased ALA (MD −0.42 kg/m2, 95% CI −1.53 to 0.69, I2 = 65%, 1581
participants, Analysis 5.17), again with high heterogeneity. Sensi-
tivity analyses using fixed-effect analysis or only retaining studies
at low summary risk of bias suggested a small increase in BMI with
ALA (Analysis 5.18; Analysis 5.19), while limiting to studies at low
risk of compliance bias or eliminating smaller studies suggested
a small reduction in BMI with increased ALA (Analysis 5.20). There
were no statistically significant differences between subgroups dif-
ferentiated by replacement or statin use (Analysis 5.23; Analysis
5.25), but there were differences by dose – subgrouping by dose
suggested greater reduction of BMI in studies giving more ALA (P =
0.03, Analysis 5.21). All included studies gave supplemental foods
(Analysis 5.22). There were greater reductions in BMI in shorter
studies (P = 0.02, Analysis 5.24) and in primary prevention studies
(P = 0.03, Analysis 5.26), but the inclusion of Dodin 2005 in any sub-
group tended to differentiate that group from the others. GRADE as-
sessment suggests low-quality evidence that ALA intake may make
little or no difference to BMI (low-quality/certainty evidence, down-
graded once each for imprecision and inconsistency).
One study reported on visceral adipose tissue, suggesting no clear
effect, but three trials reported on waist circumference. Meta-
analysis of two of these suggested that increasing ALA resulted in
reduced weight circumference (MD −1.59 cm, 95% CI −3.10 to −0.07,
I2 = 0%, Analysis 5.27). However, the single trial that we could not
include in the meta-analysis due to lack of information on vari-
ance suggested effects in the opposite direction. Sensitivity analy-
ses (only retaining studies at low summary risk of bias, not shown)
removed all trials.
Serum lipids (ALA)
Serum total cholesterol
Low-quality evidence suggests that ALA intake may make little or
no difference to serum total cholesterol.
Six trials provided data on the long-term effects of ALA on serum
total cholesterol, suggesting that increased ALA intake leads to a
small reduction in total cholesterol, but with high heterogeneity
(MD −0.09 mmol/L, 95% CI −0.23 to 0.05, I2 = 63%, in > 2000 partic-
ipants, Analysis 5.28). Restricting analyses to studies at low sum-
mary risk of bias suggested no effect of ALA (Analysis 5.30), but
fixed-effect analysis suggested that the intervention led to a reduc-
tion (Analysis 5.29), as did sensitivity analyses limited to studies
at low risk of compliance bias or larger studies (Analysis 5.31). All
studies provided food supplements (Analysis 5.33), but subgroup
analyses suggested greater reductions in total cholesterol in short-
er duration studies (P = 0.02, Analysis 5.35). Other differences be-
tween subgroups resulted from effects groups where ALA replace-
ment or statin use was 'unclear' (Analysis 5.34; Analysis 5.36), or
there were no differences (Analysis 5.32; Analysis 5.37). GRADE as-
sessment suggests low-quality evidence that ALA intake may make
little or no difference to serum total cholesterol (downgraded once
each for imprecision and inconsistency).
Serum triglycerides
Moderate-quality evidence suggests that ALA intake probably
makes little or no difference to serum triglycerides.
There was little or no effect of ALA on serum triglycerides in 1776
participants in six trials (MD −0.03 mmol/L, 95% CI −0.11 to 0.05, I2
= 0%, Analysis 5.38). There was little or no effect of ALA in sensitiv-
ity analysis removing trials of moderate to high risk of bias (Analy-
sis 5.40), in fixed-effect meta-analysis (Analysis 5.39), or limiting
by compliance bias or study size (Analysis 5.41). Subgrouping sug-
gested no important differential effects by dose, duration, replace-
ment, intervention type, statin use, or primary or secondary pre-
vention (Analysis 5.42; Analysis 5.43; Analysis 5.44; Analysis 5.45;
Analysis 5.46; Analysis 5.47). GRADE assessment suggests moder-
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ate-quality evidence that ALA intake probably makes little or no dif-
ference to serum triglycerides (downgraded once for imprecision).
HDL cholesterol
Moderate-quality evidence suggests that ALA probably has little or
no effect on HDL cholesterol.
There was little or no effect of ALA on HDL cholesterol in 1776 par-
ticipants of 6 trials (MD −0.02 mmol/L, 95% CI −0.08 to 0.03, I2 =
53%, Analysis 5.48), although there were small reductions of HDL
in both analyses by risk of bias and using fixed-effect meta-analy-
sis (Analysis 5.49; Analysis 5.50) with similar effects in studies with
good compliance and in larger trials (Analysis 5.51). A further trial,
WAHA 2016, also measured HDL but did not provide data in a use-
able format for meta-analysis. There was a suggestion of greater
HDL reduction with greater ALA dose (P = 0.09, Analysis 5.52), but
no other subgrouping effects were evident (Analysis 5.53; Analysis
5.54; Analysis 5.55; Analysis 5.56; Analysis 5.57). GRADE assessment
suggests moderate-quality evidence that ALA probably has little or
no effect on HDL cholesterol (downgraded for imprecision).
LDL cholesterol
Low-quality evidence suggests that ALA intake may make little or
no difference to LDL cholesterol.
There was a small reduction of LDL cholesterol with ALA in 2201
participants of 7 trials (MD −0.05 mmol/L, 95% CI −0.15 to 0.04, I2 =
46%, Analysis 5.58), with similar effects in studies with good com-
pliance and in larger trials (Analysis 5.61). While fixed-effect analy-
sis suggested marginal statistical significance of this reduction (P
= 0.06, Analysis 5.59), there were no effects when we limited analy-
ses to studies at low summary risk of bias (MD 0.02 mmol/L, 95% CI
−0.05 to 0.10, I2 = 0%, Analysis 5.60). Subgrouping suggested no dif-
ferences in effect by ALA dose or primary or secondary prevention
(Analysis 5.62; Analysis 5.67), but shorter studies, those with un-
clear replacement and unclear statin use suggested reductions in
LDL with ALA (Analysis 5.64; Analysis 5.65; Analysis 5.66). All studies
provided supplemental foods (Analysis 5.63). GRADE assessment
suggests low-quality evidence that ALA intake may make little or
no difference to LDL cholesterol (downgraded once each for risk of
bias and imprecision).
Tertiary outcomes
Eects of long-chain omega-3 fats (EPA, DHA and DPA) on
tertiary health outcomes
We extracted these outcomes from studies that we included for
other outcomes, so we did not assess them completely or system-
atically. We did not carry out sensitivity analyses or subgrouping for
these outcomes. We are aware of missing data for some of these
outcomes, including blood pressure in Ramirez-Ramirez 2013.
Blood pressure (LCn3)
Fifteen included trials (> 34,000 participants) contributed data on
effects of LCn3 fats on blood pressure. Meta-analysis suggested lit-
tle or no effect of LCn3 on systolic (MD 0.02 mmHg, 95% CI −0.32
to 0.35, I2 = 0%, Analysis 3.1) or diastolic (MD −0.02 mmHg, 95% CI
−0.22 to 0.17, I2 = 0%, Analysis 3.1) blood pressure in trials of at least
one year.
Serious adverse e2ects (LCn3)
As part of the larger set of reviews we formally systematically
reviewed effects of omega-3 fats on type 2 diabetes diagnoses,
measures of glucose metabolism (Brown 2017), cancers includ-
ing breast cancer (Hanson 2017b), neurocognitive outcomes such
as dementia (Jimoh 2017), irritable bowel disease (IBD) and in-
flammatory factors (Thorpe 2017), depression and anxiety (Hanson
2017a), and functional outcomes (Abdelhamid 2017), so we do not
present these outcomes here.
We did collect data on the following potentially important health
outcomes (Analysis 3.2).
• Any serious adverse event (RR 1.05, 95% CI 0.78 to 1.41, I2 NA,
126 events in > 400 participants in 1 trial).• Bleeding (RR 1.06, 95% CI 0.73 to 1.52, I2 = 49%, 374 events in >
45,000 participants in 8 trials).• Gastrointestinal hospitalisation (RR 1.75, 95% CI 0.53 to 5.79, I2
NA, 11 events in 200 participants in 1 trial).• Pulmonary embolus or DVT (RR 1.25, 95% CI 0.41 to 3.78, I2 =
11%, 18 events in > 3000 participants in 4 trials).• Progression to advanced age-related macular degeneration (RR
0.96, 95% CI 0.90 to 1.02, I2 NA, 2049 events in > 4000 participants
in 1 trial).• Thrombophlebitis: no data identified.• Urolithiasis: no data identified.
Side e2ects (non-serious, LCn3)
To assess side effects we collected data on the following potential
side effects (Analysis 3.3).
• Withdrawal: the data suggest more participants taking LCn3 fats
dropped out because of side effects (RR 1.16, 95% CI 0.99 to 1.36,
I2 = 1%, 620 dropouts in > 16,000 participants, 23 trials).• Increased abdominal pain or discomfort: data suggest an asso-
ciation with higher LCn3 (RR 1.10, 95% CI 0.84 to 1.45, I2 = 24%,
303 events in > 14,000 participants, 7 trials).• Diarrhoea: the data suggested an increased risk with increased
LCn3 (RR 1.15, 95% CI 0.92 to 1.43, I2 = 0%, 284 events in > 2000
participants, 10 trials).• Nausea: risk increased with LCn3 (RR 1.76, 95% CI 1.25 to 2.48, I2
= 0%, 140 events in > 1000 participants, 6 trials).• Any gastrointestinal side effect: risk also appeared to increase
with LCn3, albeit with very high heterogeneity (RR 1.12, 95% CI
0.94 to 1.34, I2 = 74%, 2545 events in > 65,000 participants, 29
trials).• Skin problems, including itching or rashes: these were not af-
fected by LCn3 in a meta-analysis with high heterogeneity (RR
1.04, 95% CI 0.47 to 2.30, I2 = 72%, 290 events in > 36,000 partic-
ipants, 8 trials).• Headache or worsening migraine: there were limited data on
this outcome (RR 0.81, 95% CI 0.48 to 1.36, I2 = 0%, 55 events in
996 participants, 3 trials).• Reflux: there were limited data (RR 1.42, 95% CI 0.71 to 2.81, I2
NA, 29 events in 202 participants, 1 trial).• Joint lumbar and muscle pain: one study provided data suggest-
ing that LCn3 reduced the risk of such pain (RR 0.80, 95% CI 0.64
to 0.99, 324 out of > 18,000 participants experiencing pain).
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• All adverse effects: there was no suggestion that LCn3 increased
or decreased all side effects combined in a meta-analysis with
very high heterogeneity (RR 1.01, 95% CI 0.95 to 1.08, I2 = 81%,
9534 people with at least one side effect in > 38,000 participants,
13 trials).
Dropouts (LCn3)
Included studies reported 5515 dropouts over > 31,000 participants
in 30 trials, suggesting no difference in dropout rates between in-
tervention and control arms (RR 1.02, 95% CI 0.95 to 1.09, I2 = 11%,
Analysis 3.4).
Quality of life, economic costs (LCn3)
We found no data on quality of life outcomes or economic costs.
Eects of ALA on tertiary health outcomes
We extracted these outcomes from studies that we included for
other outcomes, so we did not assess them completely or system-
atically. We did not carry out sensitivity analyses or subgrouping for
these outcomes.
Blood pressure (ALA)
Four included trials (1671 participants) contributed data on effects
of ALA on blood pressure. Meta-analysis suggested little or no effect
of ALA on systolic (MD −0.87 mmHg, 95% CI −4.48 to 2.75, I2 = 58%,
Analysis 6.1) or diastolic (MD −1.42 mmHg, 95% CI −4.40 to 1.57, I2 =
74%, Analysis 6.1) blood pressure in trials of at least one year. The
heterogeneity in these results reflect a single trial, FLAX-PAD 2013,
that showed large diastolic and systolic blood pressure effects. The
other (larger) trials did not suggest such effects.
Serious adverse e2ects (ALA)
As part of the larger set of reviews we formally systematically re-
viewed effects of omega-3 fats on type 2 diabetes diagnoses and
measures of glucose metabolism (Brown 2017), cancers includ-
ing breast cancer (Hanson 2017b), neurocognitive outcomes such
as dementia (Jimoh 2017), irritable bowel disease (IBD) and in-
flammatory factors (Thorpe 2017), depression and anxiety (Hanson
2017a), and functional outcomes (Abdelhamid 2017), so we do not
present these outcomes here.
We did collect data on the following potentially important health
outcomes (Analysis 6.2).
• Any serious adverse event: no data identified.• Bleeding: no data identified.• Gastrointestinal hospitalisation: no data identified.• Pulmonary embolus or DVT: only one event was identified in a
single study, so there were insufficient data to assess effects• Progression to advanced age-related macular degeneration: no
data identified.• Thrombophlebitis: there were insufficient data to assess effects
(RR 1.59, 95% CI 0.72 to 3.51, I2 NA, 26 events, > 13,000 partici-
pants, 1 trial).• Urolithiasis: there were insufficient data to assess effects (RR
0.80, 95% CI 0.47 to 1.36, I2 NA, 54 events, > 13,000 participants,
1 trial).
Side e2ects (non-serious, ALA)
To assess potential side effects, we collected data on the following
(Analysis 6.3).
• Dropouts due to side effects: data suggested that ALA increased
the risk of withdrawal, although there was high heterogeneity
(RR 2.10, 95% CI 0.66 to 6.71, I2 = 62%, 68 events, > 3000 partic-
ipants, 5 trials).• Abdominal pain or discomfort: no data identified.• Diarrhoea: a single study identified 10 participants with diar-
rhoea, suggesting a higher risk of diarrhoea with greater ALA in-
take (RR 3.82, 95% CI 0.82 to 17.88).• Nausea: there were insufficient data to assess effects of ALA (RR
6.29, 95% CI 0.33 to 118.93, I2 NA, 3 events, 110 participants, 1
trial).• Any gastrointestinal side effect: there were insufficient data to
assess effects of ALA (RR 1.79, 95% CI 0.48 to 6.69, I2 = 69%, 46
events, > 3000 participants, 3 trials). The very high heterogeneity
suggests that gastrointestinal side effects may be collected in
different ways in different trials.• Skin problems, including itching or rashes: no data identified.• Headache or worsening migraine: no data identified.• Reflux: no data identified.• All side effects combined: no data identified.
Dropouts (ALA)
Included studies reported 558 dropouts over > 3000 participants in
6 trials, suggesting slightly higher dropout rates in participants tak-
ing higher ALA (RR 1.08, 95% CI 0.92 to 1.25, I2 = 0%, Analysis 6.4).
Quality of life, economic costs (ALA)
We found no data on quality of life outcomes or economic costs.
D I S C U S S I O N
Summary of main results
We included 79 randomised controlled trials (112,059 participants),
of which 25 were at low summary risk of bias (randomisation, al-
location concealment, selection and detection bias all at low risk
for supplementation trials; randomisation, allocation concealment
and detection bias all at low risk for dietary advice trials). Trials of
12 to 72 months' duration included adults at varying levels of car-
diovascular risk, mainly in high-income countries. Most studies as-
sessed LCn3 supplementation with capsules, but some used LCn3-
or ALA-rich or enriched foods or dietary advice compared to place-
bo or usual diet.
Pooled trial results suggested there is probably little or no ef-
fect of increasing long-chain omega-3 fats on risk of our primary
outcomes: all-cause mortality, cardiovascular deaths, cardiovas-
cular events, coronary heart disease deaths, coronary heart dis-
ease events, stroke or arrhythmias (moderate and high-quality evi-
dence). For all of these outcomes except arrhythmia, limiting LCn3
analyses to trials at low summary risk of bias moved the effect size
towards 1.0 (the null value) whether initial analyses suggested a
protective effect (for example, for CHD mortality, whose effect size
moved from RR 0.93 to RR 1.00) or a harmful effect (for example,
stroke, whose effect size moved from RR 1.06 to RR 0.98). We found
no suggestion of dose response (in subgrouping or meta-regres-
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sion), or important effects regardless of sensitivity analysis, sub-
grouping or meta-regression. These results apply to supplemental
LCn3 intake. We did not see important differences in LCn3 trials be-
tween those providing oily fish (dietary source) or EPA/DHA cap-
sules (supplemental source), but as few trials provided whole fish
health effects may differ.
On the other hand we found moderate-quality evidence that in-
creasing ALA probably reduces risk of arrhythmia (from 3.3% to
2.6%), and low-quality evidence that increasing ALA may reduce
risk of CVD events a little (from 4.8% to 4.7%). However, there is
probably little or no effect on all-cause or cardiovascular mortal-
ity, coronary heart disease mortality or events (low and moder-
ate-quality evidence), and effects on stroke are unclear. For ALA,
limiting analyses to studies at low summary risk of bias tended
to reduce the RR, or increase the suggested protection. Data were
more limited than for LCn3, and there were too few studies for infor-
mative funnel plots or subgroup analyses. These suggested bene-
fits of ALA need to be considered with caution, as effects were small,
and few trials (though often at low summary risk of bias) addressed
the outcomes.
Meta-analyses suggested little or no effect of long-chain omega-3
fats or ALA intake on secondary outcomes: major adverse cere-
brovascular or cardiovascular events, fatal and/or non-fatal my-
ocardial infarction, sudden cardiac death, new or worsening angi-
na, heart failure, revascularisation, peripheral arterial disease or
acute coronary syndrome.
There was no evidence for effects of LCn3 or ALA on measures
of adiposity, but LCn3 did reduce serum triglycerides by ˜15% in
a dose-dependant manner. We did not see this effect in trials of
ALA, and no omega-3 fats altered total, HDL or LDL cholesterol in
these long-term trials. Within the included studies we assessed ef-
fects on blood pressure, serious adverse effects, side effects and
dropouts. There was no suggestion that blood pressure or risk of
adverse events such as bleeding differed by LCn3 or ALA intake.
Thus, proposed mechanisms for omega-3 activity, including lower-
ing of blood pressure, reduced thrombotic tendency and anti-ar-
rhythmic effects are not apparent in adult humans, but LCn3 does
lower serum triglyceride levels a little.
The review has provided some answers for its secondary questions.
• If omega-3 fatty acids confer protection:* does protection occur equally in those at low and at high risk
of cardiovascular disease? There is no evidence of differential
effects on mortality or cardiovascular health by primary or
secondary CVD prevention.* does protection depend on the dose of omega-3 fats taken
per day? We ran subgroup analyses for primary and key out-
comes and meta-regression for primary outcomes but found
no evidence of differential effects by LCn3 or ALA dose on any
outcomes except LCn3 on serum triglycerides, where there
was a statistically significant difference between different
dose subgroups and greater effects with higher dose.* do effects differ between dietary and supplemental omega-3
sources? We assessed this question by looking for statistically
significant differences between subgroups but found no evi-
dence of differential effects by dietary or supplemental LCn3
or ALA sources. However, few of the LCn3 trials advised or
gave fish, most gave supplemental fish oils, so our ability to
assess effects of eating more oily whole fish are limited.* does protection depend on study summary risk of bias? Some
analyses suggested a protective effect of LCn3 fats, but these
effects disappeared when analyses were limited to studies at
low summary risk of bias. The stronger studies with higher
internal validity suggested few or no effects of LCn3 on mor-
tality or CVD outcomes. On the other hand, for most primary
cardiovascular outcomes, ALA trials at low summary risk of
bias suggested greater protection with higher ALA than in the
main analysis (including trials of all levels of summary risk of
bias).• Is protection or harm stronger with longer trial duration? In
subgroup analyses for primary and key outcomes and in meta-
regression for primary outcomes, there was no evidence that
longer trials increased the effect of LCn3 or ALA.
Overall completeness and applicability of evidence
We searched very carefully to find all studies relevant to this review
and located 79 trials randomising 112,059 participants to higher
and lower omega-3 fats (LCn3 or ALA) for at least 12 months.
To reduce selection bias, we contacted authors of trials that ap-
peared to have randomised appropriate participants to appropri-
ate intervention and comparator but may not have published rel-
evant outcomes. If trialists had assessed any of our outcomes, we
requested data and included the study. This enabled us to include
several additional trials. We also contacted authors of all includ-
ed trials that randomised at least 100 participants (and most small-
er trials) to request data on any further outcomes (as well as on
methodological issues) that may have been recorded but not re-
ported. We tried to contact 72 of the 79 included studies (all except
Baldassarre 2006; HERO 2009; Mita 2007; Nutristroke 2009; Özaydin
2011; Shinto 2014; Sofi 2010). This allowed us to collect useful addi-
tional data on outcomes such as deaths and cardiovascular events
that we would not have had access to otherwise.
We identified 27 trials that appeared to be unpublished at the time
of writing (Characteristics of ongoing studies). We have labelled
these trials as ongoing, although some appear overdue for publica-
tion, and their status is unclear – they may constitute missing da-
ta. We tried to contact authors of all 'overdue' ongoing studies, and
some stated that publications are forthcoming; others did not re-
ply. We suspect that if trialists have not published outcomes, it is
likely that any protective health effects did not reach statistical sig-
nificance. Given that existing studies suggest no effects of omega-3
fats on cardiovascular health outcomes, any missing data may not
affect outcomes greatly; however, for completeness we would pre-
fer to include all available data.
Post hoc, we followed advice to assess differences in effects be-
tween EPA and DHA within the review. However, most LCn3 trials
provided or advised changes resulting in increased intakes of both
EPA and DHA (as in natural fish oil), though in different ratios. On-
ly three trials provided data on DHA only (ADCS 2010; Berson 2004;
Zhang 2017), and five provided data on EPA only (Doi 2014; JELIS
2007; Mita 2007; Nye 1990; Puri 2005). Unfortunately for any single
outcome only two or three of these trials were represented, so our
ability to assess differential effects of the DHA-only and EPA-only
interventions was very limited, and we have not presented these
analyses or attempted to draw any information from them.
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Quality of the evidence
Figure 2 displays risk of bias of included studies. Of the 79 RCTs,
25 were at low summary risk of bias (at low risk of selection bias,
performance bias and detection bias, plus low risk of performance
bias in supplemental trials). We assessed the validity of evidence in
meta-analyses by running sensitivity analyses that removed trials
not at low summary risk of bias. When sensitivity analyses removed
LCn3 trials at moderate to high summary risk of bias, effect sizes
moved closer to no effect (RR 1.0) for all primary outcomes except
arrhythmias, where the RR rose to 1.10. Funnel plots for LCn3 tri-
als suggested that there may be missing studies for all primary out-
comes except stroke and arrhythmia, and in all cases adding such
studies back in would move effect sizes closer to no effect (RR 1.0).
This lack of effect in the studies at lowest risk of bias (with sugges-
tions of effect in studies at moderate to high risk of bias) was an
important finding from this review and supported our interpreta-
tion of lack of effect of long-chain omega-3 fats on our primary out-
comes.
As there were fewer ALA trials, funnel plots were not useful, but sen-
sitivity analyses retaining only trials at low summary risk of bias
were more variable, often suggesting lower risk of a cardiovascular
outcome.
Potential biases in the review process
Potential adverse effects include cancers and neurological prob-
lems associated with polychlorinated biphenyls (PCBs) or mercury
in fish oils, and bleeds associated with reductions in clotting (see
How the intervention might work). Any data on bleeds, including
haemorrhagic stroke, have been collated in this review, though we
did not ask authors specifically for additional data on these out-
comes. Unfortunately there were insufficient data on serious harms
(bleeding and pulmonary embolism or deep vein thrombosis) to as-
sess these potential harms. We have not collated data on cancers
and neurological problems within this review but have formally sys-
tematically reviewed them elsewhere (Hanson 2017b; Jimoh 2017).
This approach is preferable to including data on these outcomes
from within included studies, which would be incomplete and po-
tentially underpowered to show important effects.
One problem with CVD outcomes is that they are collected togeth-
er in a variety of ways, depending on the study. For example, in as-
sessing CHD mortality, we pre-specified that we would include the
first of the following list reported in any trial: coronary death, is-
chaemic heart disease death, fatal myocardial infarction, cardiac
death. Each included trial includes outcome data in its own way, so
we had to adapt to this in our analysis. One way to get around this
problem would be to use individual patient data, as in one recent
meta-analysis that included fewer trials than this review but was
able to formulate their outcome data to match precisely between
trials (Aung 2018). The next section discusses similarities and differ-
ences between this review and Aung 2018, but their findings were
highly similar. For CHD mortality, our meta-analytic estimate of ef-
fect of LCn3 was RR 0.93, (95% CI 0.79 to 1.09, I2 = 35%) in 21 trials
reporting 1596 CHD deaths, while theirs was RR 0.93 (95% CI 0.83 to
1.03) in 10 trials reporting 2695 CHD deaths.
While we tried hard to locate all available trials and collect addi-
tional outcome data where possible, there was evidence from fun-
nel plots of some small study bias. Some smaller studies showing
increased risk of CVD outcomes with omega-3 fats may be miss-
ing from some of the meta-analyses. If these studies were replaced
they would tend to increase risk ratios. This suggests that there is
some underlying small study bias within the review.
Given that the many LCn3 studies at moderate to high risk of bias
appear to be inflating any protective effects, and that small study
bias is also inflating any protective effects, it is justified to view with
skepticism the occasional suggestion of a protective effect. Given
the very large number of subgroup analyses we carried out, it is also
important to treat the occasional subgroup analysis that throws up
a statistically significant difference between subgroups very cau-
tiously.
A secondary question asked by this review was about differential
effects of dietary and supplemental LCn3 fats. LCn3 interventions
included dietary advice (advice to eat more oily fish), supplemen-
tal foods (LCn3 fats incorporated into other foods such as mar-
garine) and supplements or capsules (by far the greatest propor-
tion of studies). Dietary fish is likely to have different health effects,
as it may take the place of less healthy foods in the diet (leading
to reduced saturated fat intake, for example) and provides many
nutrients in addition to omega-3 fats (such as protein, selenium,
iodine, calcium, magnesium, etc.). There were only four LCn3 di-
etary advice trials with event data (DART 1989; DART2 2003; DISAF
2003; THIS DIET 2008), and two of these also provided fish oil cap-
sules when participants did not want to eat more fish (DART 1989;
DART2 2003). We found no statistically significant differences be-
tween dietary advice subgroups and supplemental foods or cap-
sule subgroups for primary outcomes. This may mean that health
effects between the two types of intervention are not different, but
It is likely that our analysis was underpowered to see any such dif-
ferences if they exist.
Population LCn3 status varies widely across the world, from over
8% of fatty acids in Japan, Scandinavia and other areas with non-
Westernised dietary patterns to less than 4% in North, South and
Central America; Europe; the Middle East; Southeast Asia; and
Africa (Stark 2016). We hypothesised that additional LCn3 might
have greater health effects in people whose usual LCn3 intake was
relatively low, but unfortunately we were not able to ascertain
baseline LCn3 intake or status for most of our included trials. How-
ever, most of the included studies were carried out in areas of the
world with lower LCn3 status, so we would expect to see effects of
increasing LCn3 in most included trials if such effects exist – the fact
that we did not see them suggests that any such effects may not be
important in the populations included in this review.
Agreements and disagreements with other studies or
reviews
One potential difference between the findings of this review and
some other trials and reviews is our running sensitivity analyses as-
sessing effects exclusively in studies at low summary risk of bias.
This clarified the lack of effect of LCn3 fats on CHD mortality, CHD
events and heart failure, which otherwise appeared slightly protec-
tive, and on stroke, which otherwise appeared slightly harmful. On
the other hand, these sensitivity analyses suggested some protec-
tive effects for ALA (on CVD events and arrhythmia), though effects
were small and evidence limited.
The effect of LCn3 on arrhythmias was unclear. There was a sugges-
tion that LCn3 was harmful regarding development of new arrhyth-
mia (where trials were not set up with arrhythmia as a primary out-
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come), but protective of recurrent arrhythmia. However, trials at
low summary risk of bias suggested harm, and other trials (at mod-
erate to high risk of bias) suggested benefit. Eight of the 10 includ-
ed studies at low summary risk of bias were trials assessing new
arrhythmia. It is possible that the apparent difference between ef-
fects on new and recurrent arrhythmia are related to summary risk
of bias.
There was no suggestion that blood pressure or risk of adverse
events such as bleeding differed by LCn3 or ALA intake. This sug-
gests that possible mechanisms for omega-3 activity, including
lowering of blood pressure, reduced thrombotic tendency and
anti-arrhythmic effects are not important in most adult humans,
though LCn3 does appear to lower serum triglyceride levels. We did
not systematically review blood pressure data so may have missed
a few long-term studies (though not many) – missing data from in-
cluded studies is likely to be a bigger issues. Of the 15 included tri-
als that reported blood pressure outcomes, nine reported numbers
of hypertensive participants at baseline, ranging from 5% in MARI-
NA 2011 to 79% of participants in ORIGIN 2012. Effects did not dif-
fer by proportions of hypertensive participants (I2 was 0% for both
systolic and diastolic blood pressure, Analysis 3.1).
Nearly 20 years ago, the GISSI-P 1999 trial suggested that LCn3 had
its primary effects in reducing sudden cardiac death. However, the
forest plot clearly shows that subsequent trials have not seen this
effect individually or in aggregate (Analysis 2.6).
The scope of this review is similar to that of the extensive Agency
for Healthcare Research and Quality review (Balk 2016), so we have
compared our results with theirs. Given that our review included
79 RCTs randomising more than 112,000 participants, who experi-
enced over 8000 deaths and upwards of 4000 CVD deaths, we were
surprised to read that Balk and colleagues characterised the body
of evidence as having "limited data ... from RCTs on the effect of n-3
FA on clinical CVD outcomes" (Balk 2016). This appears to be be-
cause the Balk review excluded RCTs of people with non-CVD and
non-diabetes related diseases at baseline, while we included them.
While Balk 2016 excluded some studies we included, it did not in-
clude any studies providing all-cause mortality data that we ex-
cluded. This meant that in analysing effects on all-cause mortality,
Balk 2016 included 18 RCTs randomising 81,027 participants expe-
riencing 8480 deaths, while we included 112,059 participants ran-
domised to high or low LCn3 or ALA experiencing 8648 deaths. Balk
2016 excluded studies that we included, such as AREDS2 2014, a
high-quality trial with 368 deaths in more than 4000 participants
with age-related macular degeneration. This sort of population ap-
peared ideal to us for assessment of omega-3 fats on primary pre-
vention of CVD, as these people tend to be elderly but there is no
clear reason why omega-3 fats would affect CVD differently in this
population than in other older adults at usual CVD risk.
Despite these slight differences in approach, we obtained very sim-
ilar effect estimates to Balk 2016. We meta-analysed effects of LCn3
and ALA trials, finding an RR for all-cause mortality of 0.98 (95% CI
0.93 to 1.03, I2 = 6%), compared to a pooled RR for all-cause mor-
tality of 0.97 (95% CI 0.92 to 1.03) in Balk 2016. While that review
seldom pooled their results, we can compare our results with theirs
where they did. Despite our slightly different inclusion criteria, our
results are very comparable (Table 8).
A recent individual meta-analysis of 10 large trials in almost 78,000
people at high risk of CVD found no associations of LCn3 with CHD
mortality (RR 0.93, 99% CI 0.83 to 1.03), nonfatal MI (RR 0.97, 99%
CI 0.87 to 1.08), CHD events (RR 0.96, 95% CI 0.90 to 1.01) or major
vascular events (RR 0.97, 95% CI 0.93 to 1.01, Aung 2018). Aung 2018
included individual patient data from the participants of large, long
trials (randomising at least 500 participants and following them
for at least one year) (AlphaOmega - EPA+DHA 2010; AREDS2 2014;
DO IT 2010; GISSI-HF 2008; GISSI-P 1999; JELIS 2007; OMEGA 2009;
ORIGIN 2012; Risk & Prevention 2013; SU.FOL.OM3 2010), and this
review includes all their trials. Their review had the advantage of
being able to ensure that they had complete and equivalent data
for all of their key outcomes from all the trials, reducing the risk
of publication bias, but the disadvantage of missing all the data
from many large LCn3 trials such as DART2 2003 DART 1989 FOR-
WARD 2013, MAPT 2017 SHOT 1996 and SOFA 2006 (all LCn3 trials
randomising at least 500 participants). It also missed large trials of
LCn3 in lower risk participants such as OPAL 2010, and large trials
of ALA such as MARGARIN 2002, Norwegian 1968 and WAHA 2016,
as well as all the smaller trials. However, though taking different
approaches, the results of this review and Aung 2018 are also very
similar (Table 8). LCn3 has little or no effect on major cardiovascu-
lar outcomes. This review, Balk 2016 and Aung 2018 addressed the
analysis of the data in slightly different ways, creating sensitivity
analyses for each other. The fact that they came to the same con-
clusions reassures us that our conclusions are solidly based.
Our results, suggesting high-quality evidence of no clinically useful
cardiovascular health effects of either LCn3 or ALA, are consistent
with many further high-quality recent systematic reviews (Camp-
bell 2013; Chowdhury 2012; Enns 2014; He 2013; Khoueiry 2013;
Kotwal 2012; Kwak 2012; Mariani 2013; Rizos 2012; Zheng 2014),
and they confirm and expand on the findings of earlier versions of
this review (Hooper 2004; Hooper 2006).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
We found high-quality evidence that long-chain omega-3 fats do
not have important positive or negative effects on mortality or CVD
events and moderate-quality evidence that they have little or no
effect on other measures of cardiovascular health in primary or
secondary prevention. Most evidence on long-chain omega-3 fats
came from trials of capsules of fish oil or EPA/DHA mixtures. While
we did not see important differences between trials of supplemen-
tal capsules and trials of oily fish, there were few trials of oily fish.
We found moderate-quality evidence that increasing ALA proba-
bly slightly reduces risk of CHD mortality and arrhythmia, and may
slightly reduce risk of CVD events. However, there is probably lit-
tle or no effect on all-cause or cardiovascular mortality or coronary
heart disease events (low and moderate-quality evidence). Effects
of ALA were very small - 143 people would need to increase their
ALA intake to prevent one person developing arrhythmia, and 1000
would need to take more ALA to prevent one person experiencing
a CVD event or dying from CHD. Trials of ALA gave ALA-rich or en-
riched foods such as walnuts or enriched margarine.
Supplemental long-chain omega-3 fats are probably not useful for
preventing or treating cardiovascular disease, although long-chain
omega-3 fats can help to reduce serum triglycerides and raise HDL
a little. Fish and seafood are nutrient-dense and rich in a variety of
other nutrients (such as vitamin D, calcium, iodine, selenium) so are
useful foods even without cardiovascular benefits. In light of the ev-
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idence in this review it would be appropriate to review official rec-
ommendations supporting supplemental LCn3 fatty acid intake.
ALA is an essential fatty acid, an important part of a mixed diet, and
increasing intakes may be very slightly beneficial for prevention or
treatment of cardiovascular disease.
Implications for research
There are several large ongoing trials of supplemental long-chain
omega-3 fats (see Characteristics of ongoing studies). We suggest
that given the lack of convincing effects suggested for omega-3 fats
in the large number of trials to date, no further trials should be initi-
ated until the ongoing trials have reported. Further large and high-
quality trials of ALA carried out in lower and higher income coun-
tries and that assess baseline ALA intake and use biomarkers to as-
sess compliance would be helpful to clarify the cardiovascular ef-
fects of ALA. Similarly trials of dietary fish would be helpful.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Alzheimer's Disease Cooperative Study (ADCS)
RCT, parallel, (n-3 DHA vs n-6 LA), 18 months
Summary risk of bias: low
Participants Individuals with mild to moderate Alzheimer's disease
N: 238 intervention, 164 control
Level of risk for CVD: low
Men: 52.9% intervention, 40.2% control
Mean age in years (SD): 76 (9.3) intervention, 76 (7.8) control
Age range: unclear
Smokers: 24.4% intervention, 21.9% control
ADCS 2010 
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Hypertension: not reported
Medications taken by at least 50% of those in the control group: cholinesterase inhibitor, memantine
Medications taken by 20%-49% of those in the control group: none
Medications taken by some, but less than 20% of the control group: none
Location: USA
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: DHA vs omega 6
Intervention: 2 × 1 g algal-derived DHA capsules (Neuromins) per day for a total daily dose of 2 g, each
capsule contain 45% to 55% of DHA and does not contain EPA (950 mg soW-gel capsules which contain
approximately 510 mg DHA). Dose: +DHA 1.02 g/d.
Control: 2 × 1 g placebo capsules per day (made up of corn or soy oil)
Compliance: measured by pill counts at every visit
Length of intervention: 18 months
Outcomes Main study outcome: change in the cognitive subscale of the Alzheimer's Disease Assessment Scale
(ADAS-cog) and change in the Clinical Dementia Rating (CDR)
Dropouts: 67 intervention, 40 control (discontinued treatment but included in main analyses)
Available outcomes: mortality, measures of cognition, baseline & change in plasma DHA, adverse
events
Response to contact: no data provided
Notes Study funding; quote: "grant UO1-AG10483 from the National Institute on Aging. The National Institute
on Aging was not otherwise involved in the design and conduct of the study, or in the analysis of data
or preparation of the manuscript". "The placebo and DHA study drugs were provided by Martek Bio-
sciences. Martek also provided plasma and cerebrospinal fluid measurements of fatty acids, as well as
partial financial support for the magnetic resonance imaging sub study. (Martek Biosciences produces
nutritional supplements from cultivated fungi and microalgae). Martek employees participated in de-
sign of the study and in revision of the manuscript, but were not involved in data management or data
analysis." (Quinn 2010, p. 1910).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was achieved with a centralised interactive voice response sys-
tem, using a block design with a block size of 5 (3 in the DHA group and 2 in the
placebo group.
Allocation concealment
(selection bias)
Low risk Randomisation was achieved with a centralised interactive voice response sys-
tem, using a block design with a block size of 5 (3 in the DHA group and 2 in the
placebo group.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Placebo capsules (made up of corn or soy oil) were identical in appearance.
The adequacy of blinding was assessed by questionnaires completed by care-
givers, study coordinators, and site physicians.
ADCS 2010  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The adequacy of blinding was assessed by questionnaires completed by care-
givers, study coordinators, and site physicians with results showing no differ-
ence between groups and the majority did not know.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Intention-to-treat analysis. At 12 months data were available for > 80% (ITT
analysis)
Selective reporting (re-
porting bias)
Low risk Prospectively registered February 2007, study started February 2007, complet-
ed May 2009. Primary outcomes were rate of change in ADAS-Cog11 and CDR-
SOB, which are both reported in main report. NPI and ADL were secondary out-
comes also reported.
Attention Low risk Both study arms had the same follow-up and care.
Compliance Unclear risk Measured by pill count at every visit. 28% intervention and 24% control dis-
continued supplement with a minority discontinuing due to adverse events. A
further 8% were excluded for < 80% compliance in both intervention and con-
trol arms.
Other bias Low risk None noted
ADCS 2010  (Continued)
 
 
Methods Multi-center study to evaluate the effect of n-3 fatty acids on arrhythmia recurrence in atrial fibrillation
(AFFORD)
RCT, parallel, (n-3 EPA + DHA vs n-6), 12 months
Summary risk of bias: moderate or high
Participants People with symptomatic paroxysmal or persistent AF
N: 165 intervention, 172 control. (analysed, intervention: 153 control: 163)
Level of risk for CVD: high
Men: 69% intervention, 65% control
Mean age in years (SD): 60 (12) intervention, 62 (13) control
Age range: not reported
Smokers: not reported
Hypertension: 45% intervention, 42% control
Medications taken by at least 50% of those in the control group: oral anticoagulant
Medications taken by 20%-49%: beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin
receptor blockers
Medications taken by some, but < 20%: none
Location: Canada
Ethnicity: not reported
Interventions Type: supplement (fish oil)
AFFORD 2013 
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Comparison: EPA + DHA vs omega 6 safflower oil
Intervention: 4 × 1 g enteric-coated fish oil capsules/d (1.6 g/d EPA + 0.8 g/d DHA, Genuine Health,
Toronto, Ontario, Canada). Dose: +2.4 g/d EPA + DHA,
Control: 4 ×1 g matching placebo capsules, 4 g/d safflower oil
Compliance: omega-3 index increased in intervention group, but not control, over the study
Duration of intervention: 6 to 16 months
Outcomes Main study outcome: AF recurrence
Dropouts: 21 intervention, 19 control
Available outcomes: all-cause mortality, stroke, AF recurrence,TIA, CV events, CRP (not usable)
Response to contact: no
Notes Authors contacted about QoL, resource use and dietary habits
Study funding: Canadian Institutes for Health Research and the Heart and Stroke Foundation of Quebec
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "[R]andomised"
Allocation concealment
(selection bias)
Unclear risk Not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Described as double-blind, but blinding not described or tested
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk An independent events committee adjudicated AF recurrences, bleeding,
strokes, transient ischemic attacks, and deaths, but unclear if blinded to allo-
cation.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Participant flow well described. ITT analysis
Selective reporting (re-
porting bias)
High risk NCT01235130 registered July 2010, recruitment March 2009-March 2012, fol-
low-up finished December 2012. Results published 2014, but no data on quali-
ty of life, resource utilisation, or dietary habits (stated in registry) found
Attention Low risk No problem with attention bias
Compliance Low risk Omega-3 index measured
Other bias Low risk None noted
AFFORD 2013  (Continued)
 
 
Methods RCT, parallel, (EPA + DHA + statins vs statins), 12 months
Ahn 2016 
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Summary risk of bias: moderate to high
Participants Statin treated CAD patients undergoing PCI
N: 38 intervention, 36 control
Level of risk for CVD: high
Men: 63.2% intervention, 72.2% control
Mean age in years (SD): 59.6 (9.1) intervention, 60.7 (0.8) [sic] control
Age range: unclear
Smokers: 36.8% intervention, 58.3% control
Hypertension: 50% in both groups
Medications taken by at least 50% of those in the control group: aspirin, clopidogrel, ACE in-
hibitors/ARB, beta-blockers, atorvastatin
Medications taken by 20%-49% of those in the control group: cilostazol
Medications taken by some, but less than 20% of the control group: rosuvastatin, nitrates, calcium an-
tagonists
Location: South Korea
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs unclear (nil)
Intervention: 3 g of ω-3 PUFA containing 1395 mg of EPA and 1125 mg of DHA per day. No further de-
tails. Dose: +2.52 g/d EPA + DHA
Control: unclear whether control group were given placebo or only statins
Compliance: unclear how it was measured but reported good compliance with no numbers
Length of intervention: 12 months
Outcomes Main study outcome: change in atherosclerotic burden
Dropouts: none
Available outcomes: lipids (TG reported as median, IQR so not used), atheroma volume, neointimal vol-
ume index
Response to contact: no
Notes Study funding: the study was supported by clinical research grant from Pusan National University Hos-
pital
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Simple randomisation was carried out using random number tables to assign
each participant to the intervention or control group
Ahn 2016  (Continued)
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Allocation concealment
(selection bias)
Low risk Participants were assigned randomisation numbers sequentially on recruit-
ment to the study, and the randomisation codes were retained by the clinical
research coordinator.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk No details
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The personnel responsible for randomisation as well as those performing lab-
oratory measurements were blinded to the randomisation assignments.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No dropouts reported
Selective reporting (re-
porting bias)
Unclear risk No protocol or trial register entry found
Attention Unclear risk No details
Compliance Unclear risk No details on how it was measured and no fatty acid levels reported
Other bias High risk It's unclear whether the study was placebo controlled or the control group had
no intervention. Also, some of the SDs appear to be incorrectly reported.
Ahn 2016  (Continued)
 
 
Methods RCT, (n-3 ALA vs MUFA), 40 months
Summary risk of bias: low
Participants 60-80 year-olds with previous MI
N: 1197 ALA intervention, 1236 control (1212 ALA + EPA/DHA intervention group)
Level of risk for CVD: high
Men: 77.9% intervention, 78.7% control
Mean age in years (SD): 69.0 (5.6) intervention, 68.9 (5.6) control
Age range: 60-80 years
Smokers: 17.4% intervention, 18% control
Hypertension: unclear
Medications taken by at least 50% of those in the control group: lipid lowering medication, antihyper-
tensives, antithrombotics
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: antiarrythmic drugs, antidiabetic
drugs
Location: the Netherlands
AlphaOmega - ALA 2010 
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
83
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Ethnicty: not reported
Interventions Type: supplementary margarine
Comparsion: ALA vs MUFA
Intervention 20 g of enriched margarine per day incorporating: 2 g ALA. 8 × 250 g margarine tubs deliv-
ered every 12 weeks. Dose: average achieved +1.9 g/d ALA
Control: 20 g of margarine per day. No additional n-3 PUFAs. Identical margarine (oleic acid) placebo.
Compliance: unused margarine tubs were returned- daily intakes of margarine and n-3 fatty acids were
calculated on the basis of the amount unused. Adherence was measured by levels of fatty acids in plas-
ma cholesteryl esters, margarine and questionnaires. 90.5% of patients adhered to the protocol and
consumed 20.6 (SD 2.8) g of margarine/d.
Length of intervention: 40 months
Outcomes Main study outcome: cardiovascular disease events
Dropouts: 91 died, 98 discontinued intervention, 93 died, 93 discontinued control
Available outcomes: deaths, MI, cardiovascular events, ventricular arrhythmia, Incident cardiovascular
disease
Response to contact: yes (data provided)
Notes The study has 3 intervention arms (ALA margarine, EPA/DHA margarine, mixture of the two interven-
tions). This table represents the ALA only intervention. Outcome data is used for the ALA group where
reported separately or for the combined (ALA arm, ALA + EPA/DHA arm)
Study funding: Netherlands Heart Foundation, National Institutes of Health and Unilever R&D (latter
provided unrestricted grant for distribution of trial margarines)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk On the computer by a random number generator before the start of the trial
Allocation concealment
(selection bias)
Low risk Author confirmed allocation was concealed from clinicians/ researchers
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk The 4 types of margarine were "similar in taste, texture and colour". A trained
test panel did not perceive a fishy taste or odour. Randomisation tables were
stored safely under supervision.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Randomisation tables were stored safely under supervision. There was an in-
dependent statistician for data analysis. Quote: "Events were coded by three
members of the end-point adjudication committee who were unaware of the
identity of the patient, the identity of the treating physician and the patients
assigned study group".
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients were followed up for events computerised linkage with municipal
registries. 2531 patients were only followed up for baseline anthropometric
and medical measurements.
Selective reporting (re-
porting bias)
High risk Sudden cardiac death endpoint omitted. Registered in August 2005, recruit-
ment was from 2002 to 2006. Outcomes papers published in 2010
AlphaOmega - ALA 2010  (Continued)
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Attention Low risk All participants appear to have had similar frequency and quantity of attention
and follow-up
Compliance Low risk Unused margarine tubs were returned; daily intakes of margarine and n-3 fatty
acids were calculated on the basis of the amount unused. Adherence was mea-
sured by levels of fatty acids in plasma cholesteryl esters, margarine and ques-
tionnaires. 90.5% of patients adhered to the protocol and consumed 20.6 (SD
2.8) g of margarine/d
Other bias Low risk None noted
AlphaOmega - ALA 2010  (Continued)
 
 
Methods RCT, (EPA + DHA vs MUFA), 40 months
Summary risk of bias: low
Participants 60-80 year-olds with previous MI
N: 1192 EPA/DHA intervention, 1236 control (1212 ALA + EPA/DHA intervention group)
Level of risk for CVD: high
Men: 78.1% intervention, 78.7% control
Mean age in years (SD): 69.1 (5.6) intervention, 68.9 (5.6) control
Age range: 60-80 years
Smokers: 16.8%, intervention, 18% control
Hypertension: unclear
Medications taken by at least 50% of those in the control group: lipid-lowering medication, antihyper-
tensives, antithrombotics
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: antiarrythmic drugs, antidiabetic
drugs
Location: the Netherlands
Ethnicty: not reported
Interventions Type: supplementary margarine
Comparison 1: EPA + DHA vs MUFA
Intervention: 20 g of enriched margarine per day incorporating 400 mg EPA-DHA (240 mg EPA and 160
mg DHA). Dose: average achieved 376 mg/d EPA + DHA
Control: 20 g of margarine per day. No additional n-3 PUFAs. Identical margarine (oleic acid) placebo
Compliance: unused margarine tubs were returned; daily intakes of margarine and n-3 fatty acids were
calculated on the basis of the amount unused. Adherence was measured by levels of fatty acids in plas-
ma cholesteryl esters, margarine and questionnaires. 90.5% of patients adhered to the protocol.
Length of intervention: 40 months
Outcomes Main study outcome: cardiovascular disease events  
Dropouts: 95 died, 119 discontinued intervention, 93 died, 93 discontinued control
AlphaOmega - EPA+DHA 2010 
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
85
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Available outcomes: deaths, MI, cardiovascular events, ventricular arrhythmia, incident cardiovascular
disease
Response to contact: yes (data provided)
Notes The study has three intervention arms (ALA margarine, EPA/DHA margarine, mixture of the two inter-
ventions). This table represents theEPA/DHA only intervention. Outcome data is used for the EPA/DHA
group where available or for the combined (EPA/DHA arm, EPA/DHA + ALA arm)
Study funding: Netherlands Heart Foundation, National Institutes of Health and Unilever R&D (latter
provided unrestricted grant for distribution of trial margarines)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk On the computer by a random number generator before the start of the trial
Allocation concealment
(selection bias)
Low risk Author confirmed allocation was concealed from clinicians/ researchers
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk The 4 types of margarine were "similar in taste, texture and colour". A trained
test panel did not perceive a fishy taste or odour. Randomisation tables were
stored safely under supervision.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Randomisation tables were stored safely under supervision. There was an in-
dependent statistician for data analysis. Quote: "Events were coded by three
members of the end-point adjudication committee who were unaware of the
identity of the patient, the identity of the treating physician and the patients
assigned study group".
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients were followed up for events computerised linkage with municipal
registries. 2531 patients were only followed up for baseline anthropometric
and medical measurements.
Selective reporting (re-
porting bias)
High risk Sudden cardiac death endpoint omitted. Registered from August 2005, recruit-
ment was from 2002 to 2006. Outcomes papers published in 2010
Attention Low risk All participants appear to have had similar frequency and quantity of attention
and follow-up
Compliance Low risk Unused margarine tubs were returned; daily intakes of margarine and n-3 fatty
acids were calculated on the basis of the amount unused. Adherence was mea-
sured by levels of fatty acids in plasma cholesteryl esters, margarine and ques-
tionnaires. 90.5% of patients adhered to the protocol and consumed 20.6 (SD
2.8) g of margarine/d
Other bias Low risk None noted
AlphaOmega - EPA+DHA 2010  (Continued)
 
 
Methods Age-Related Eye Disease Study 2 (AREDS2)
RCT, parallel, 2 × 2 factorial (n-3 EPA + DHA vs nil) also randomised to lutein and zeaxanthin vs nil), 5
years
AREDS2 2014 
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Summary risk of bias: low
Participants People aged 50-85 years at high risk of progression to advanced age-related macular degeneration
(AMD)
N: 2147 intervention (1068 DHA/EPA, 1079 DHA/EPA + lutein/zeaxanthin), 2056 control (1012 placebo,
1044 lutein/zeaxanthin)
Level of risk for CVD: low (however ˜20% had previous CV event)
Men: intervention 42.1%, control 44.4%
Age in years: intervention median 74.6 (IQR 11.1), control median 74 (IQR 11.1)
Age range: 68-79 years
Smokers: intervention 6.3%, control 7.2%
Hypertension: unclear
Medications taken by at least 50% of those in the control group: multivitamins
Medications taken by 20%-49% of those in the control group: cholesterol lowering drugs, aspirin
Medications taken by some, but less than 20% of the control group: NSAID, paracetamol
Location: USA
Ethnicty: white 96.5% intervention, 96.6% control; Hispanic: 2.6 intervention, 1.3 control
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs nil
Intervention 350 mg/d DHA plus 650 mg/d EPA added to the standard AREDS supplement of Vitamin C
(500 mg/d), Vitamin E (440 IU/d), beta-carotene (15 mg/d), zinc oxide (80 mg/d) and cupric oxide (2 mg/
d). Dose: +1 g/d EPA + DHA
Control: standard AREDS supplement of Vitamin C (500 mg/d), Vitamin E (400IU/d), beta-carotene (15
mg/d), zinc oxide (80 mg/d) and cupric oxide (2 mg/d).
Compliance: assessed by pill count – 84% of participants in each group took at least 75% of study med-
ications
Length of intervention: 60 months
Outcomes Main study outcome: development of advanced AMD
Dropouts: intervention 200 died, 165 discontinued, 80 were lost to follow-up; control 168 died, 140 dis-
continued, 61 were lost to follow-up
Available outcomes: deaths, cardiovascular death, MI, stroke, angina, heart failure, revascularisation,
cognition, eye health, (authors provided data on diabetes diagnosis, depression diagnosis, breast can-
cer)
Response to contact: yes (data provided)
Notes Study funding: National Eye Institute/National Institutes of Health, Department of Health and Human
Services
Risk of bias
Bias Authors' judgement Support for judgement
AREDS2 2014  (Continued)
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Random sequence genera-
tion (selection bias)
Low risk Quote: "random block design was implemented using the AREDS2 Advantage
Electronic Data Capture system by the AREDS2 Coordinating Center"
Allocation concealment
(selection bias)
Low risk Each treatment was assigned 5 bottle numbers. Bottle numbers were issued
via an electronic randomisation system for each participant once study eli-
gibility was verified. The assigned bottle number was used to distribute the
study treatment(s). AREDS2 Coordinating centre personnel involved in creat-
ing the randomisation system had access to the bottle number/treatment as-
signments.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk "Participants, investigators, study coordinators, and all other study personnel
are masked to treatment assignment". However, no information was given re-
garding the taste, smell, or appearance of the active or placebo capsules.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The coordinating centre randomly assigned the event to a study adjudicator,
who made the final determination of these study endpoints through review of
the medical records and applying the endpoint criterion defined a priori. All
adjudicators were masked to study assignment.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk < 20% attrition over 5 years, balanced reasons for dropouts
Selective reporting (re-
porting bias)
Low risk Outcomes in trials registry entry appear to all be reported (NCT00345176). En-
try received June 2006, recruitment September 2006 – October 2012
Attention Low risk Participants, investigators, study coordinators, and all other study personnel
are masked to treatment assignment, so attention bias not feasible
Compliance Unclear risk Assessed by pill count – 84% of participants in each group took at least 75% of
study medications
Other bias Low risk None noted
AREDS2 2014  (Continued)
 
 
Methods RCT, (n-3 EPA + DHA vs MUFA), 24 months
Summary risk of bias: moderate or high
Participants 45-70 year olds with combined hyperlipoproteinaemia
N: 32 intervention, 32 control
Level of risk for CVD: moderate
Men: 29% intervention, 29% control
Mean age in years (SD): 53.7 (7.2) intervention, 53.7 (6.9) control
Age range: 45-70 years (inclusion)
Smokers: 28.1% intervention, 28.1% control
Hypertension: none (exclusion criteria)
Medications taken by at least 50% of those in the control group: not reported
Baldassarre 2006 
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Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported (patients on HRT, an-
ti-hypertensive drugs, lipid lowering drugs, or who smoked > 10 cigarettes were excluded)
Location: Italy
Ethnicty: not reported
Interventions Type: capsules
Comparsion: LCn3 vs MUFA
Intervention: 1 g × 6 soW gelatin capsules/d of fatty acid mixture (19% EPA), 13% DHA, 19% palmitic
acid, 18% oleic acid, 2% LA and 29% other minor components) providing 1.08 g/d EPA, 0.72 g/d DHA,
0.01 g/d tocopherol acetate, divided to three doses. Dose: 1.8 g/d EPA + DHA
Control: 1 g × 6 opaque identical soW gelatin capsules/d of olive oil divided in 3 doses.
Compliance: assessed by counting returned capsules at each visit and by measuring EPA and DHA lev-
els at month 24
Length of intervention: 24 months
Outcomes Main study outcome: carotid atherosclerosis measures
Dropouts: 2 intervention, 5 control
Available outcomes: deaths (nil), MI (lipids, weight, BP and heart rate reported but not in a usable for-
mat; lipid data were presented at various times without clear numerical data, suggesting falls in TGs in
the intervention but not control arms, and rises in LDL and HDL cholesterol in intervention but not con-
trol arms. For the other outcomes the text states "a rise in body weight (+ 3%, P < 0.01) was observed
at the end of the study in both groups. Blood pressure and heart rate were unchanged". Effects on IMT
and platelets also reported but not used)
Response to contact: not yet attempted
Notes Study funding: supported by Institut De Recherche Pierre Fabre, Departement Recherche Clinique
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk An appropriate software was used to obtain 2 groups balanced for sex, age and
smoking
Allocation concealment
(selection bias)
Unclear risk No further details
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Double-blind and placebo capsules were opaque and identical looking to in-
tervention. However no information provided on capsules taste or smell
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No details
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All dropouts are accounted for. "One patient leW the study after 3 months be-
cause he moved to another city and was therefore excluded from statistical
analyses. Two patients were excluded because of major deviation from the
protocol during the follow-up (anti-hypertensive assumption) and four be-
Baldassarre 2006  (Continued)
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cause of non-compliance on the basis of returning capsules (compliance <
70%). The final analysed group included 57 patients (30 on active treatment)."
Selective reporting (re-
porting bias)
Unclear risk No protocol or trial register record
Attention Low risk Both groups had the same contact and number of visits.
Compliance Low risk Pill count, we know they excluded 4/64 who returned > 70% of capsules. So
60/64 had > 70% compliance with significant increase in serum EPA and DHA in
the intervention group.
Other bias Low risk None noted
Baldassarre 2006  (Continued)
 
 
Methods RCT, parallel, (n-3 EPA + DHA vs MUFA), 24 months
Summary risk of bias: moderate or high
Participants People with multiple sclerosis
N: 155 intervention, 157 control. (analysed, intervention: 145 control: 147)
Level of risk for CVD: low
Men: 34.2% intervention, 30.6% control
Mean age in years (SD): 34.0 (6.6) intervention, 33.7 (6.3) control
Age range: not reported but 16-45 years inclusion criteria
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49%: not reported
Medications taken by some, but < 20%: not reported
Location: UK
Ethnicity: not reported
Interventions Type: supplement (fish oil capsule)
Comparison: EPA + DHA vs MUFA
Intervention: 20 × 0.5 g/d capsules MaxEPA fish body oil (10 g/d fish oil providing 1.71 g/d EPA +1.14 g/d
DHA +10 IU/d vitamin E), plus all advised to reduce animal fat and ensure plentiful omega-6 fats. Dose:
+2.85 g/d EPA + DHA
Control: 20 × 0.5 g/d capsules olive oil (10 g/d olive oil), plus all advised to reduce animal fat and ensure
plentiful omega-6 fats. All capsules contained 0.5 IU vit E and 100 ppm dodecyl gallate to minimise per-
oxide formation
Compliance: serum EPA and DHA rose in intervention group but fell in controls
Duration of intervention: 24 months (5 years mentioned but outcomes not reported)
Bates 1989 
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
90
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Outcomes Main study outcome: multiple sclerosis progress
Dropouts: 10 intervention, 10 control
Available outcomes: all-cause mortality, progress of MS, rate of MS relapse
Response to contact: yes (no data provided)
Notes Study funding: Multiple Sclerosis Society of Great Britain and Northern Ireland, but Marfleet Refining
provided fish oil and placebo capsules
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomised"
Allocation concealment
(selection bias)
Unclear risk No further details
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Paper states research was "double blind" and control capsules "had the same
appearance and flavour as the fish oil capsules and were packed and dis-
pensed in identical fashion"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not stated
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Low risk at reported time points
Selective reporting (re-
porting bias)
High risk No protocol or trials registration entries found. Study was intended to run for 5
years, but outcomes only appear to be reported for the first 2 years.
Attention Low risk Unlikely as each had capsules
Compliance Low risk Serum EPA and DHA rose in intervention group but fell in controls
Other bias Low risk Not noted
Bates 1989  (Continued)
 
 
Methods RCT, parallel, (n-3 DHA vs n-6 LA), 48 months
Summary risk of bias: low
Participants People with retinitis pigmentosa aged 18-55 years
N: 221 randomised overall, analysed 105 intervention, 103 control
Level of risk for CVD: low
Men: 48% intervention, 54% control
Mean age in years (SD): 37.8 (6.5) intervention, 36.0 (7.2) control
Berson 2004 
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Age range: unclear (18-55 inclusion criterion)
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: vitamin A
Medications taken by 20%-49% of those in the control group: multivitamins
Medications taken by some, but less than 20% of the control group: not reported
Location: USA
Ethnicity: unclear (6% of the study population were minorities)
Interventions Type: supplement (DHA capsules)
Comparison: DHA vs omega 6
Intervention: 6 × 500 mg capsules/d of DHA (1.2 g/d DHA plus 1.8 g vegetable oil) plus < 0.0006 mg/d to-
copherols plus 15,000 IU retinyl palmitate (vitamin A). Dose: +1.2 g/d DHA
Control: 6 × 500 mg capsules/d of soy and corn oils (half each) with 120 mg/d ALA, plus < 0.0006 mg/d
tocopherols plus 15000 IU retinyl palmitate (vitamin A)
Compliance: 92% of capsules taken by both intervention and control groups (assessed by monthly cal-
endars), Plasma DHA much higher in intervention than control
Length of intervention: 48 months
Outcomes Main study outcome: retinal degeneration
Dropouts: 5 or 6 intervention, 7 or 8 control
Available outcomes: mortality, cancer diagnoses, lipids, eyesight
Response to contact: yes (no data provided)
Notes Study funding: National Eye Institute and Foundation Fighting Blindness
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random numbers
Allocation concealment
(selection bias)
Low risk Random numbers available only to programmer who provided assignments to
data manager, all staC in contact with patients were masked to group assign-
ment
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk States that all staC in contact with participants were masked to group assign-
ment, as were participants. However no information was provided regarding
the taste, smell and appearance of the active and placebo capsules
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk All assessments were performed blind to study allocation. Each ocular exami-
nation was performed without review of previous records. All serum samples
were analysed without knowledge of treatment group assignment.
Incomplete outcome data
(attrition bias) 
Unclear risk Numbers of dropouts and reasons for dropouts not stated. 221 participants
randomised, data presented on 208 participants
Berson 2004  (Continued)
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All outcomes
Selective reporting (re-
porting bias)
Unclear risk No trials registry entry or protocol found.
Attention Low risk StaC in contact with patients were masked, so unable to bias time, etc.
Compliance Low risk 92% of capsules taken by both intervention and control groups (assessed by
monthly calendars), Plasma DHA much higher in intervention than control
Other bias Low risk None noted
Berson 2004  (Continued)
 
 
Methods RCT, parallel, 3 arms (n-3 EPA + DHA from cod liver vs n-3 EPA + DHA from seal oil vs nil), 14 months
Summary risk of bias: moderate or high
Participants Subjects with moderate hypercholesterolaemia
N: 40 seal oil (SO), 40 cod liver oil (CLO), 40 control (numbers analysed vary by outcome)
Level of risk for CVD: moderate (dyslipidaemia)
Men: 53% seal oil, 50% cod liver oil, 48% control
Mean age in years: 53.2 seal oil, 55.0 cod liver oil, 55.8 control
Age range: 43-66 years
Smokers: unclear
Hypertension: unclear
Medications taken by at least 50% of those in the control group: none allowed
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Norway
Ethnicity: not reported
Interventions Type: supplement (oil)
Comparison: EPA + DHA vs nil
Intervention: Intervention: seal oil – 15 mL/d (2.6 g, 1.1 g/d EPA + 1.5/d DHA) (total n-3 3.9 g/d, total PU-
FA 4.2 g/d): SO dose: EPA + DHA 2.6 g/d
Cod liver oil – 15 mL/d (3.3 g, 1.5 g /d EPA + 1.8 g/d DHA) (total n-3 4.1 g/d, total PUFA 4.35 g/d): CLO
dose: EPA + DHA 3.3 g/d
Control: nil, no supplement
Compliance: serum omega-3 fatty acids, rose from around 1 mmoL/L to 2.4 (seal oil), 2.1 (cod liver oil)
and 1.2 mmoL/L (control)
Length of intervention: 14 months
Outcomes Main study outcome: serum lipids
Brox 2001 
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Dropouts: 8 seal oil, 2 cod liver oil, 1 control
Available outcomes: total and cardiovascular deaths, MI, combined CV events, lipids, adverse events
Response to contact: yes (author provided methodological details)
Notes Data of two intervention groups combined for dichotomous outcomes and CLO vs control data used for
continuous outcomes
Study funding: the study was supported by the programme Medical Research in Finnmark County, Uni-
versity of Tromsø
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk J Brox stated (personal communication, January 2017): "The randomization
of the 120 participants was done by first generating 3 groups (seal oil, cod liv-
er oil, control), then giving each participant a number (1-120), "'putting all the
numbers into the same hat' and blindly drawing one number at the time from
the hat. The first 40 numbers (1-40) were allocated to the seal oil group, the
next 40 numbers (41-80) to the cod liver oil group and the rest (81-120) were al-
located to the control group."
Allocation concealment
(selection bias)
Low risk J Brox stated (personal communication, January 2017): "The researcher/clini-
cian who invited the participants had no knowledge of to which group the par-
ticipants would be allocated."
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "controls were aware – not given a supplement"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk J Brox stated (personal communication, 2003): "All the persons involved in
the drawing & analysing of blood were unaware of treatment. The technicians
analysing the blood did not have any personal contact with the participants
except K. Olaussen who did the FA analysis … she only had access to the sam-
ple numbers not names and code. The participants did not know their number
(says elsewhere that K Olaussen did not know allocations). The only outcome
assessor was J Brox who did not have personal contact with participants, ran-
domising, collecting results or analysing process." "The only assessor was J
Brox who did not have any personal contact with the participants, had nothing
to do with the randomising or analysing process, or the collecting of results."
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Control group 3 dropouts, seal oil group 10 dropouts, cod liver oil 3 dropouts.
So substantial differences in rates of dropouts between the groups
Selective reporting (re-
porting bias)
Unclear risk No study protocol or trials register entry was found
Attention Low risk No suggestion of differential attention
Compliance Low risk Serum omega-3 fatty acids, rose from around 1 mmoL/L to 2.4 (seal oil), 2.1
(cod liver oil) and 1.2 mmoL/L (control)
Other bias Low risk No further bias noted
Brox 2001  (Continued)
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Methods RCT, parallel, (n-3 EPA + DHA vs n-6 LA), 12 months
Summary risk of bias: low
Participants Participants with non-cirrhotic NASH (non-alcoholic steatohepatitis)
N: 20 intervention, 21 control (analysed 17 intervention, 17 control)
Level of risk for CVD: moderate
Men: 35.3% intervention, 41.2% control
Mean age in years (SD): 46.4 (12.1) intervention, 47.2 (12) control
Age range: 25-72 years
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: USA
Ethnicity: intervention, 100% white, control 94.% white, 5.9% other
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs omega 6
Intervention: 3 × 1 g fish oil capsules/d (Nordic Natural) for a total 2.1 g/d n-3, each capsule contained
70% of n-3 (1050 mg EPA, 750 mg DHA + 300 mg other n-3). Dose: 1.8 g/d EPA + DHA
Control: 3 × 1 g identical placebo (soybean) capsules per day containing 8% fish oils
Both groups had dietary counselling on caloric intake and physical activity
Compliance: unclear (measured n-6-n-3 ratio due to its link to hepatic lipid composition)
Length of intervention: 12 months
Outcomes Main study outcome: NASH activity score
Dropouts: 3 intervention, 3 control
Available outcomes: lipids (TG too unbalanced at baseline to use), measures of adiposity (weight, BMI,
visceral fat – all unbalanced at baseline so not used), fasting glucose, insulin, HOMA-IR, QUICKI (also
NASH progression, hepatic fat, ALT, VO2 max, activity level, markers of cell injury, adiponectin not used)
Response to contact: yes, change data supplied for BMI and body weight, confirmed no deaths, cardio-
vascular events, diabetes, depression, breast cancer or IBD diagnoses
Notes Data on; BMI, weight, visceral fat, TG and glucose were not used as they were different between groups
at baseline.
Study funding: study was supported by NIH NCCAM Grant 5R21AT2901–2 and 5 M01 RR00847. Study
medication and identical appearing placebo was provided at no charge by Nordic Natural. RBC phos-
pholipid profile was performed by Metametrix (www.metametrix.com). M30, M65, adiponectin, and IGF-
Caldwell 2011 
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BP-1 electro chemiluminescence assays were performed by Wellstat Diagnostics (www.wellstatdiag-
nostics.com).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were randomised to n-3 or placebo using a stratified block 1:1
randomisation scheme. An independent biostatistician generated the ran-
domisation list which was confidentially forwarded to the Investigational
pharmacy
Allocation concealment
(selection bias)
Low risk As above
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All staC and subjects were blinded to therapy assignment throughout the
study period. Both capsules were identical. However no information provided
on capsules taste or smell
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Blinded for main outcome
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 15% dropouts explained and equal in both groups
Selective reporting (re-
porting bias)
Low risk The trial was prospectively registered
Attention Low risk Both groups had the same attention
Compliance Unclear risk No details on compliance measurement
Other bias Low risk None noted
Caldwell 2011  (Continued)
 
 
Methods Diet And Reinfarction Trial (DART) – oily fish advice (or capsule) arm
RCT – parallel, 2 × 2 × 2 factorial (n-3 EPA + DHA vs nil or fat advice vs not, oily fish advice (or capsule) vs
not, dietary fibre advice vs not)), 2 years
Summary risk of bias: moderate or high
Participants Men recovering from myocardial infarction
N: 1015 intervention, 1018
Level of risk for CVD: high (post-MI)
Men: 100%
Mean age, SD: 56.7 intervention, 56.4 control (SDs not stated)
Age range: unclear
Smokers: 61.7% intervention, 62.2% control
DART 1989 
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Hypertension: 22.7% intervention, 24.6% control
Medications taken by at least 50% of those in the control group: none reported
Medications taken by 20%-49%: beta-blockers, other antihypertensives, antianginals
Medications taken by some, but < 20%: anticoagulant, aspirin/antiplatelet, digoxin/antiarrhythmic
Location: UK
Ethnicity: not stated
Interventions Type: dietary advice (to eat more oily fish)
Comparison: EPA + DHA vs SFA + MUFA (by dietary achievement below)
Intervention: advised to eat at least 2 weekly portions of 200-400 g fatty fish (mackerel, herring, kip-
per, pilchard, sardine, salmon, trout). If this was not possible, given MaxEPA capsules, 3/d (0.5 g EPA/d).
191/883 participants were taking MaxEPA at 2 years. Advice was reinforced 3-monthly. Dose: aimed for
0.5 g/d EPA
Control: No such dietary advice or capsules
Compliance: 7 day weighed food diary of a random sub-sample indicated intake of 2.5 g/week EPA in-
tervention, 0.8 g/week EPA control
Dietary achievements
Total fat intake, %E (through study): control 35 (SD 6), intervention 31 (SD 7) (MD −4.00, 95% CI −4.57 to
−3.43); significant reduction
Saturated fat intake, %E (through study): control 15 (SD 3), intervention 11 (SD 3), (MD −4.00, 95% CI
−4.26 to −3.74); significant reduction
PUFA intake (through study), %E⁑: control 7 (SD unclear), intervention 9 (SD unclear), (MD 2.00, 95% CI
1.57 to 2.43 assuming SDs of 5) significant increase
PUFA n-3 intake: EPA, control 0.6 (SD 0.7) g/week, intervention 2.4 (SD 1.4) g/week
PUFA n-6 intake: not reported
MUFA intake (through study), %E⁑: control 13 (SD unclear), intervention 11 (SD unclear) (MD −2.00,
95% CI −2.43 to −1.57 assuming SDs of 5); significant reduction
CHO intake (through study), %E: control 44 (SD 6),intervention 46 (SD 7) (MD 2.00, 95% CI 1.43 to 2.57);
significant increase
Protein intake (through study), %E: control 17(SD 4), intervention 18 (SD 4) (MD 1.00, 95% CI 0.65 to
1.35); significant increase
Trans fat intake: not reported
Length of intervention: 24 months
Outcomes Main study outcome: total mortality, reinfarction, CHD death
Dropouts: none for mortality
Available outcomes: total and CV deaths, MI, CHD events, lipids, blood pressure, cancer deaths
Response to contact: yes (data provided)
Notes Some of each group were also advised on low fat and high PUFA and/or high fibre diets, all participants
who smoked were advised to stop and all with a BMI > 30 kg/m2 were given weight reduction advice, re-
gardless of randomisation arm. The low fat high PUFA comparison was included in the omega-6 review.
DART 1989  (Continued)
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Study funding: by the Welsh Scheme for the Development of Health and Social Research, the Welsh
Heart Foundation and the Health Promotion, Research Trust. Seven Seas Health Care and Duncan
Flockhart provided Maxepa capsules
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomised" confirmed by author
Allocation concealment
(selection bias)
Unclear risk Pre-prepared sequentially numbered enveloped opened by dietitian (unclear
if envelopes were opaque)
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Blinding of dietary advice (or lack of it) is not possible
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome assessors were not aware of study allocation (Prof Burr stated he did
not know assignments)
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Hospital notes and death registers were flagged to catch all outcome data
Selective reporting (re-
porting bias)
Unclear risk No study protocol or trials register entry was found
Attention High risk More attention was paid to those given dietary advice
Compliance Unclear risk 7 day weighed food diary of a random sub-sample indicated intake of 2.5 g/
week EPA intervention, 0.8 g/week EPA control
Other bias Low risk None noted
DART 1989  (Continued)
 
 
Methods Diet and Angina Randomised Trial (DART2)
RCT, 2 × 2, (oily fish or capsulesn-3 EPA + DHA vs nil, also no specific advice, also fruit, vegetables and
oats vs no specific advice), 3-9 years
Summary risk of bias: moderate or high
Participants Men treated for angina
N: 1571 intervention, 1543 control (all analysed for events)
Control level of risk for CVD: high
Men: 100%
Mean age in years (SD): 61.1 (NR) intervention, 61.1 (NR) control
Age range: unclear
Smokers: 25% intervention, 23% control
DART2 2003 
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Hypertension: 49% intervention, 47% control
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49%: lipid lowering, beta-blockers
Medications taken by some, but less than 20% of the control group: not reported
Location: UK
Ethnicity: not reported
Interventions Type: dietary advice (to eat more oily fish or take fish oil capsules)
Comparison: EPA + DHA vs unclear (not total fat, SFA or alcohol, presumably CHO and/or protein but
not clear)
Intervention: most (1109) advised to eat at least 2 weekly portions of fatty fish OR take MaxEPA cap-
sules, 3/d (0.5 g EPA/d). But 462 participants were sub-randomised to receive only fish oil capsules, not
dietary fish advice. Dose: aimed for 0.5 g/d EPA.
Control: none specific sensible eating advice that did not include either of the interventions.
Compliance: postal dietary questionnaire suggested dietary EPA intake increased by 2.4 g /week inter-
vention, 0.2 g /week control
Dietary achievements
Total fat intake, (change from baseline to 6 months): control −8.6 g/d (SD 20.9), intervention −5.2 (g/d
SD 21.4) (MD 3.4 g/d)
Saturated fat intake, (change from baseline to 6 months): control −3.5 g/d (SD 9.3), intervention −2.8 g/
d (SD 9.4), (MD 0.7 g/d)
PUFA intake (change from baseline to 6 months): control −1.6 g/d (SD 5.4), intervention −0.1 g/d (SD
5.8) (MD 1.5 g/d)
PUFA n-3 intake (change from baseline to 6 months): EPA, control 0.12 g/week (SD 0.73), intervention
2.65 g/week (SD 1.35) (MD 2.53 g/week)
PUFA n-6 intake: not reported
MUFA intake: not reported
CHO intake: not reported
Protein intake: not reported
Trans fat intake: not reported
Duration of intervention: 36 to 108 months
Outcomes Main study outcome: total mortality
Dropouts: none for mortality
Available outcomes: total and CV deaths, sudden death, stroke, heart failure, cancer deaths
Response to contact: yes (data provided)
Notes Some of each group were also advised on high fruit, vegetables and oat diets, and those who received
neither fish nor fruit advice received 'non-specific' dietary advice. All those whose BMI > 30 kg/m2 in
both groups received weight reduction advice.
Study funding: probably British Heart Foundation, Seven Seas Ltd, Novex Pharma Ltd and the Fish
Foundation (these were acknowledged)
DART2 2003  (Continued)
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly allocated"
Allocation concealment
(selection bias)
Unclear risk Pre-prepared sequentially numbered enveloped opened by dietitian (unclear
if envelopes were opaque)
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Dietary advice, so not possible for participants to be blinded to intervention
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome assessors were not aware of study allocation (Prof Burr stated he did
not know assignments)
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Hospital notes and death registers were flagged to catch all outcome data
Selective reporting (re-
porting bias)
Unclear risk No study protocol was found, or trials registry entry
Attention High risk More attention was paid to those given dietary advice
Compliance Unclear risk Postal dietary questionnaire suggested dietary EPA intake increased by 2.4 g/
week intervention, 0.2 g/week control
Other bias Low risk None noted
DART2 2003  (Continued)
 
 
Methods RCT, parallel, (n-3 PUFA capsules vs placebo), 18 months
Summary risk of bias: low
Participants White overweight/obese patients with impaired fasting glucose (IFG) or impaired glucose tolerance
(IGT)
N: 138 intervention, 143 control (analysed 128 intervention, 130 control)
Level of risk for CVD: low
Men: 50.72% intervention, 48.95% control
Mean age in years (SD): 53.4 (11.2) intervention, 54.8 (12.1) control
Age range: unclear
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Derosa 2016 
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Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Italy
Ethnicity: white
Interventions Type: capsule (n-3 PUFA)
Comparison: EPA + DHA vs CHO + SFA
Intervention: 3 ×1 g capsule/ day n-3 PUFAs (ethylic esters, each 1-g capsule of n-3 PUFAs contains high-
ly concentrated ethyl esters of omega-3 fatty acids, primarily EPA, and DHA in the proportion of 0.9–
1.5). Dose: unclear (approx 2-3 g/d)
Control: placebo (a capsule containing sucrose, mannitol and mineral salts, magnesium stearate (a sat-
urated fat) and silicon dioxide, used as anti-caking agents)
Both groups were given diet advice to follow a controlled-energy diet based on AHA recommendations
(50% of calories from carbohydrates, 30% from fat (6% saturated), and 20% from proteins, with a maxi-
mum cholesterol content of 300 mg/day and 35 g/day of fibre). Individuals were also encouraged to in-
crease their physical activity by walking briskly for 20 to 30 min, 3 to 5 times per week, or by cycling
Compliance: measured by counting the number of pills returned at the time of specified clinic visits
Length of intervention: 18 months
Outcomes Main study outcome: insulin resistance
Dropouts: 23 across arms (no details on groups but stated that there were no difference between
groups)
Available outcomes: mortality, CV mortality, CHD event, stroke, combined CVD events, MI, AF, weight,
BMI, lipids, diabetes mellitus
Response to contact: yes (data provided)
Notes Study funding: "The authors have no relevant affiliations or financial involvement with any organiza-
tion or entity with a financial interest in or financial conflict with the subject matter or materials dis-
cussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or op-
tions, expert testimony, grants or patents received or pending, or royalties"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was done using a drawing of envelopes containing randomisa-
tion codes prepared by a statistician.
Allocation concealment
(selection bias)
Low risk Author stated that allocation was concealed from clinicians and researchers,
but no methodology provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Both n-3 PUFAs and placebo were supplied as identical, opaque, white cap-
sules in coded bottles to ensure the blind status of the study. However no in-
formation provided on capsules taste or smell
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk A copy of the code was provided only to the person performing the statistical
analysis
Derosa 2016  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk An intention-to-treat analysis was conducted for patients who received 1 dose
of study medication
Selective reporting (re-
porting bias)
Unclear risk No trial registry or protocol found
Attention Low risk No difference reported
Compliance Unclear risk Measured by counting the number of pills returned at the time of specified
clinic visits
Other bias Low risk None noted
Derosa 2016  (Continued)
 
 
Methods RCT 4 arms, ( n-3 EPA + DHA (3 different doses) vs MUFA), 12 months
Summary risk of bias: moderate or high
Participants Healthy monks
N: 14 high, 15 medium, 15 low dose intervention, 14 control
Level of risk for CVD: low
Men: 100%
Mean age in years (SD): 56.2 (16.5) (not reported by arm)
Age range: 21-87
Smokers: none
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported (no medications influ-
encing lipid metabolism or non-steroidal anti-inflammatory drugs were allowed)
Location: the Netherlands
Ethnicity: not reported
Interventions Type: capsules
Comparsion: LCn3 vs MUFA
Intervention 9 capsules (9 g vol.) per day, of which 3, 6 or 9 were fish oil (Labaz, Brussels, Belgium) and
any remainder were placebo (providing respectively 1.12; 2.24 or 3.37 g n-3 FA/day). Dose: 1.12 g/d;
2.24 g/d or 3.37 g/d EPA + DHA)
Control: 9 placebo capsules made up of olive oil (Puget Marseille, France) and Palmoil (Loders-Kroklaan
Wormerveen, the Netherlands) with the same SFA, cholesterol and vitamin E as the fish oil capsules.
Compliance: assessed by counting remaining capsules every 2 months and by measuring EPA concen-
tration. Excellent compliance reported and shown by the EPA concentration results
Deslypere 1992 
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Length of intervention: 12 months
Outcomes Main study outcome: effect on coronary risk factors
Dropouts: none
Available outcomes: deaths (nil), CVD events (nil), lipids, BP, HbA1c, weight (measured but only text
suggests "no significant changes in the anthropometric parameters (weight, length, waist, hip and
thigh circumferences) during the study"), IL-6, TNF-alpha and several IL-1s (IL-6 reported as below de-
tection range, for the others there was "no significant difference between the two treatment groups at
any point in time")
Response to contact: yes
Notes Study funding: capsules supplied by Labaz (Brussels Belgium). The placebo capsules contained olive oil
(Puget) and palm oil (Loders-Kroklaan, Wormerveer). Financial support by Sanofi-Labaz.
Data entered for high fish oil versus placebo groups
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote (author correspondence): "The manufacturer provided envelopes con-
taining numbers corresponding with boxes of capsules. For each enrolled sub-
ject, random envelope was opened."
Allocation concealment
(selection bias)
Low risk Allocation concealed from all this way
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Although double blind, the fishy taste of the active treatment was not matched
(author states that the fishy taste was clear in the intervention capsules)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Authors confirmed outcome assessors were unaware until afterwards.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No dropouts
Selective reporting (re-
porting bias)
Unclear risk No protocol or trial registry record
Attention Low risk No difference between groups
Compliance Low risk Significant difference in EPA concentration
Other bias Low risk None noted
Deslypere 1992  (Continued)
 
 
Methods Dietary Intervention for Patients Polypectomized for tumours of the colorectum (DIPP)
RCT, parallel, 2 arms (n-3 EPA + DHA + n-3 ALA vs nil), 24 months
DIPP 2015 
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Summary risk of bias: moderate or high
Participants Patients previously polypectomised for colorectal tumours
N: 104 intervention, 101 control
Level of risk for CVD: low
Men: 73.1% intervention, 74.3% control
Mean age in years (SD): 58.3 (9.5) intervention, 59.7 (8.9) control
Age range: 35-75
Smokers: 65.4% intervention, 61.4% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: supplements
Medications taken by 20%-49% of those in the control group: none
Medications taken by some, but less than 20% of the control group: oral contraceptive pills
Location: Japan
Ethnicity: not reported
Interventions Type: advice + supplement (fish oil capsules)
Comparison: EPA + DHA + ALA vs omega-6
Intervention: advice to reduce total fat intake, decrease consumption of n-6 PUFAs, increase intake of
n-3 PUFAs from fish/marine foods, increase intake of n-3 PUFAs from perilla oil rich in ALA, take 8 cap-
sules of fish oil/day (equivalent to 96 mg/day of EPA and 360 mg/day of DHA). Dose: 456mg/d EPA +
DHA and unknown dose of ALA
Control: advice to decrease intake of fats/oils as a whole
Compliance: measured via semi-quantitative food frequency questionnaire, plasma fatty acid concen-
trations, fatty acid compositions in the membranes of red blood cells and the sigmoid colon. Reported
satisfactorily high compliance with protocol in both groups but no figures provided.
Length of intervention: 24 months
Outcomes Main study outcome: number and size of colorectal tumours
Dropouts: 3 intervention, 5 control
Available outcomes: all cause mortality, dietary intake, plasma fatty acids, lipids, side effects, glucose
Response to contact: yes (methodological details provided)
Notes Study funding: all were either government or charity grants
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomly allocated using random digit number for allocation of participants
DIPP 2015  (Continued)
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Allocation concealment
(selection bias)
Low risk Author confirmed "Allocation information was blinded to clinicians and re-
searchers"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk From the 2015 paper, "The attending physicians as well as the participants
were blinded to the assignment information". However in the discussion sec-
tion they say "complete participant blinding could not have been achieved be-
cause free living participants might have exchanged information on their di-
etary intervention, say in the hospital waiting room". Author confirmed blind-
ing
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "physicians, including colonoscopists, a scientist who conducted blood
and specimen analyses, and pathologists were blinded"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All those randomised were accounted for
Selective reporting (re-
porting bias)
High risk The researchers chose not to report data on the number, size and pathologi-
cal type of the colorectal tumours as they said they would in the trials register.
They reported more outcomes in the paper than initially stated.
UMIN000000461 Registered 3 August 2006, recruitment completed 1 March
2007
Attention Low risk Participants were given equal follow-up
Compliance Unclear risk Reported satisfactorily high compliance with protocol was noted in both
groups but no figures
Other bias Low risk None noted
DIPP 2015  (Continued)
 
 
Methods Dietary Intervention Study for AF (DISAF)
RCT, parallel, 2 arms (n-3 EPA + DHA vs nil), 12 months
Summary risk of bias: moderate or high
Participants People presenting for first treatment of acute/persistent atrial fibrillation or flutter, confirmed by ECG
N: intervention 201, control 206
Level of risk for CVD: high (patients with atrial fibrillation)
Men: intervention 64.7%, control 63.6%
Mean age in years (SD): intervention 67.7 (9.4), control 68.7 (9.5)
Age range: unclear
Smokers: intervention 10.9%, control 12.1%
Hypertension: intervention 48.2%, control 40.8%
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: antiarrythmics, antithrombotics
DISAF 2003 
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Medications taken by some, but less than 20% of the control group: not reported
Location: UK
Ethnicity: white British
Interventions Type: dietary advice
Comparison: EPA + DHA vs unclear
Intervention: dietary assistants gave advice and support to eat 2 to 3 portions of oily fish per week (pro-
viding up to 10 g LCn3/ week), plus 2 to 3 portions of fruit and vegetables per day. Dose: 1.4 g/d EPA +
DHA.
Control: dietary assistants gave advice and support to eat 2 to 3 portions of fruit and vegetables per
day. No other health/lifestyle given as part of the trial
Compliance: assessed red blood cell fatty acids and found some increases in EPA and DHA in interven-
tion compared to control (no further intake data)
Length of intervention: 12 months
Outcomes Main study outcome: sinus rhythm after 12 months
Dropouts: unclear
Available outcomes: deaths, AF recurrence
Response to contact: yes (data provided)
Notes Study funding: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was by phone to an independent randomisation office, which
used pre-printed random number tables
Allocation concealment
(selection bias)
Low risk Randomisation was by phone to an independent randomisation office, which
used pre-printed random number tables
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Dietary advice was clear, so allocation known by participants
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Unclear
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Some discrepancies between papers, reasons unclear
Selective reporting (re-
porting bias)
High risk ISRCTN16448451 registered 23 January 2004, recruitment from 1 July 1998 to 1
July 2002; some secondary outcomes were not reported
Attention Low risk Intervention (advice to eat more oil-rich fish, fruit and vegetables) and control
(advice to eat more fruit and vegetables) groups appeared to be given equiva-
lent time and attention.
DISAF 2003  (Continued)
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
106
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Compliance Low risk Assessed red blood cell fatty acids and found some increases in EPA and DHA
in intervention compared to control
Other bias High risk The trial was stopped early
DISAF 2003  (Continued)
 
 
Methods Diet and Omega 3 Intervention Trial on Atherosclerosis (DO IT)
Randomisation: RCT, parallel, 2 × 2 factorial, (n-3 DHA + EPA vs n-6 LA also dietary advice intervention),
36 months
Summary risk of bias: moderate or high
Participants Elderly men with longstanding dyslipidaemia or hypertension (a subset of Oslo Diet heart study)
N: intervention 282 (140 n-3 capsules + 142 n-3 capsules and dietary advice), control 281 (142 placebo
capsules + 139 placebo capsules and dietary advice)
Level of risk for CVD: moderate
Men: intervention 100%, control 100%
Mean age in years (SD): intervention 70.4 (2.9), control 69.7 (3.0) years
Age range: 64-76 years
Smokers: intervention 35%, control 33%
Hypertension: intervention 29%, control 27%
Medications taken by at least 50% of those in the control group: none
Medications taken by 20%-49% of those in the control group: statins and acetylsalicylic acid
Medications taken by some, but less than 20% of the control group: β-blockers, ACE inhibitors and ni-
trates
Location: Norway
Ethnicity: not reported
Interventions Type: supplement/ capsule (also dietary advice as the factorial intervention)
Comparison: EPA + DHA vs omega-6
Intervention: 2 × 2 capsules/d incl 2.4 g/d of omega-3 PUFA (Pikasol, 0.84 g/d EPA plus 0.48 g/d DHA
plus 8.4 mg/d tocopherols). Dose: 1.32 g/d EPA + DHA
Control: 2 × 2 capsules/d inc 4 g/d corn oil (2.24 g/d linoleic, 1.28 g/d oleic acid, 16 mg/d tocopherols)
Compliance: pharmacy records suggested that > 90% of supplements were taken, and plasma EPA and
DHA were raised in intervention compared to control participants.
Duration of intervention: 36 months
Outcomes Main study outcome: atherosclerosis progression.
Dropouts: intervention 14 died, 20 others discontinued, control 24 died, 18 others discontinued
Available outcomes: mortality, cardiovascular deaths, CHD events, CV events, MI, stroke, diabetes, glu-
cose, lipids, cancer diagnosis, cancer deaths, sudden death, BMI (waist circumference reported as me-
dian, IQR)
DO IT 2010 
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
107
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Response to contact: yes (data provided)
Notes The other 2 × 2 intervention was dietary counselling to increase both omega-3 and omega-6 fats as well
as fruit and vegetables.
Study funding: Norwegian Cardiovascular Council, Norwegian retail company RIMI, vegetable oil and
margarine supplied by the Norwegian food company Mills DA and placebo capsules by LUBE
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Permuted block randomisation, no clear mechanism provided
Allocation concealment
(selection bias)
Unclear risk No details provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Capsules of fish oil or placebo taken, but unclear whether blinded and if so,
how well or successfully
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk "Mortality data were supplied from the Norwegian Cause of Death Registry,
and all clinical events were confirmed by hospital records and verified by an in-
dependent cardiologist"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No attrition as deaths and events collected from centralised register
Selective reporting (re-
porting bias)
Unclear risk Trials registry entry submitted after the outcomes papers were published.
Attention Low risk No suggestion of attention bias between verum and placebo supplement arms
Compliance Low risk Pharmacy records suggested that > 90% of supplements were taken, and plas-
ma EPA and DHA were raised in intervention compared to control participants
Other bias Low risk None noted
DO IT 2010  (Continued)
 
 
Methods RCT, parallel, (n-3 ALA vs n-6 LA), 12 months
Summary risk of bias: moderate or high
Participants Healthy menopausal women
N: 101 intervention, 98 control. (analysed, intervention: 85 control: 94)
Level of risk for CVD: low
Men: 0% intervention, 0% control
Mean age in years (SD): 54.0 (4.0) intervention, 55.4 (4.5) control
Age range: 49-65
Dodin 2005 
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Smokers: 8% intervention, 6% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Canada
Ethnicity: French Canadian
Interventions Type: food supplement (flaxseed)
Comparison: ALA vs unclear (probably includes lipids, CHO and protein, but not clear)
Intervention: 40 g/d flaxseed incorporated into diets (providing 21,071 g total lignans, 180 calories, 16 g
lipids (57% ALA), and 11 g total dietary fibre). Dose: 9.1 g/d ALA
Control: 40 g/d wheat germ incorporated into diets (providing 196 g total lignans, 144 calories, 4 g
lipids (6.9% ALA), and 6 g total dietary fibre
Compliance: first morning urine collection was performed at randomisation and at month 12 to mea-
sure urinary lignin levels. In addition, study participants recorded their daily intake of seeds on diary
cards and were asked to return unused bread and packages of seeds at each visit. Good compliance re-
ported
Duration of intervention: 12 months
Outcomes Main study outcome: bone mineral density
Dropouts: 26 intervention, 17 control (but 13/17 had an endpoint evaluation)
Available outcomes: weight, BMI, QoL, blood pressure, lipids, glucose, adverse events, dietary intake,
plasma fatty acids
Response to contact: yes
Notes Auhors replied to tell us that there were no deaths or CV events during the study
Study funding: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk The randomisation schedule was prepared by the clinical unit of the research
centre using computer generated randomisation in blocks of 4-8
Allocation concealment
(selection bias)
Unclear risk No details
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Participants, investigators, staC, and statisticians were blinded to dietary as-
signments for the duration of the study.
Quote: "a local baker prepared loaves of bread. Each week, the loaves of bread
were delivered in sealed, opaque unmarked wrappers to the Department of
Food and Nutrition Sciences at Laval University. The seeds were ground up
and vacuum-packed in the same laboratory. The Department of Food and Nu-
trition Sciences was responsible for labelling the bags of bread and packages
of seeds with the subject's randomization number. Bread and packages of
Dodin 2005  (Continued)
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seeds were provided on a 3-month basis. The foods that both groups received
was similar in appearance and packaging and was kept frozen until consump-
tion to avoid essential fatty acid
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Participants, investigators, staC, and statisticians were blinded to dietary as-
signments for the duration of the study
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Intention-to-treat analysis. Loss to follow-up 10%, reasons given
Selective reporting (re-
porting bias)
Unclear risk No protocol or clinical trial registry entry found
Attention Low risk All participants had same number of visits
Compliance Low risk First morning urine collection was performed at randomisation and at month
12 to measure urinary lignin levels. In addition, study participants recorded
their daily intake of seeds on diary cards and were asked to return unused
bread and packages of seeds at each visit. Good compliance reported
Other bias Low risk None noted
Dodin 2005  (Continued)
 
 
Methods RCT, parallel, (n-3 EPA vs nil), 12 months
Summary risk of bias: moderate or high
Participants Patients having PCI after acute MI
N: 119 intervention, 119 control analysed
Level of risk for CVD: high
Men: 77% intervention, 76% control
Mean age in years (SD): 70 (11) intervention, 71 (12) control
Age range: unclear
Smokers: 28% intervention, 32% control
Hypertension: 71% intervention, 69% control
Medications taken by at least 50% of those in the control group: aspirin, ticlopidine, beta-blockers,
statins (as part of treatment)
Medications taken by 20%-49% of those in the control group: ARB/ACE inhibitors
Medications taken by some, but less than 20% of the control group: none
Location: Japan
Ethnicity: not reported
Interventions Type: supplement (EPA)
Comparison: EPA vs nil
Doi 2014 
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Intervention: purified EPA ethyl esters (> 98%) 1800 mg EPA/day within 24 hours after PCI plus statins.
Dose: 1.8 g/d EPA
Control: statins with no EPA
Compliance: not reported
Length of intervention: 12 months
Outcomes Main study outcome: cardiovascular events
Dropouts: 1 intervention, 2 control
Available outcomes: mortality, stroke, MI, sudden death, CV death, revascularisation
Response to contact: no
Notes Study funding: trial registry state "self-funded". The authors received honoraria from Mochida Pharma-
ceutical Co.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A computer-generated, randomisation plan, which included stratification by
age and sex
Allocation concealment
(selection bias)
Unclear risk Carried out by research technician but unclear
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open label but blind endpoint
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Data on outcomes were collected from clinical charts. Unclear if blinded. Diag-
noses were confirmed by investigator blind to treatment allocation
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Only 3 dropouts, similar rates between the groups and reasons given
Selective reporting (re-
porting bias)
High risk Data collection completed before trial registry entry. Only 1% dropouts
Attention Low risk Timing of follow-up similar
Compliance Unclear risk Not reported
Other bias Low risk None observed
Doi 2014  (Continued)
 
 
Methods EPE-A
RCT, parallel, 3 arms (n-3 EPA, low dose vs high dose vs unclear placebo), 12 months
EPE-A 2014 
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Summary risk of bias: moderate or high
Participants People with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD)
N: 86 intervention-high, 82 int low, 75 control (analysed 64, 55, 55 respectively, ITT analysis for primary
outcomes)
Level of risk for CVD: low (although 35% had type II diabetes)
Men: 33.7% intervention-high, 41.5% intervention-low, 42.7% control
Mean age in years (SD): 47.8 (11.1) intervention-high, 47.8 (12.5) intervention-low, 50.5 (12.5) control
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: USA
Ethnicity: white intervention-low: 94%, intervention-high: 87%, control: 90.7%
African American intervention-low: 3.7%, intervention-high: 2.3%, control: 4.0%
Others intervention-low: 2.4%, intervention-high: 10.5%, control: 5.3%
Interventions Type: supplement (omega 3 capsule)
Comparison 1: high EPA vs low EPA (unclear what replaced EPA)
Comparison 2: EPA vs unclear (placebo contents not reported)
Intervention-high: EPA-E 2.7 g/d, 3 × EPA-E 300 mg capsules. Dose: 2.7 g/d EPA + DHA
Intervention-low: EPA-E 1.8 g/d, 2 × EPA-E 300 mg capsules + 1 placebo capsule
Dose: 1.8 g/d EPA + DHA
Control: 3 × placebo capsules. The pills were identical with respect to size, colour and smell
Compliance: estimated by pill count and measuring the ratio of serum EPA to arachidonic acid. compli-
ance rates for the 3 groups (placebo vs EPA-E 1800 mg/d vs EPA-E 2700 mg/d) were 89.5% (6.8%), 90.3%
(5.7%) and 89.5% (5.3%), respectively
Length of intervention: 12 months
Outcomes Main study outcome: histological response in standardised scoring of liver biopsies and change in ALT
level
Dropouts: 22 intervention-high, 27 intervention-low, 20 control
Available outcomes: cardiac events, deaths (none), angina, adverse events (weight, BMI, lipids, glucose,
HbA1c, HOMA, hsCRP all reported as medians so not useable in meta-analyses)
Response to contact: yes (provided methodological details)
Notes Data combined for the 2 intervention groups for binary outcomes and higher dose data vs control used
for continuous outcomes
EPE-A 2014  (Continued)
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Study funding: supported entirely by Mochida Pharmaceuticals
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomisation using an interactive voice-response system to assign sub-
jects in a 1:1:1 ratio between the 2 arms for each site separately. Participants
were stratified by the presence of type 2 diabetes. The total fraction of such in-
dividuals was capped at 40% of the study cohort
Allocation concealment
(selection bias)
Low risk As above (remote computer-generated randomisation)
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Double-blind stated, but no further details. Author confirmed researchers and
outcome assessors were blinded to treatment allocation and pills were identi-
cal with respect to size, colour and smell
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No details
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Number and characteristics of participants lost to follow-up similar across
arms, however < 80% provided outcome data relevant to this systematic re-
view
Selective reporting (re-
porting bias)
Low risk Registered June 2010, study started June 2010, completed October 2012. All
outcomes in trials registry entry were also reported in the trials registry. Se-
condary outcomes reported were not planned (compared with first version of
clinicaltrials.gov entry)
Attention Low risk All participants had same follow-up visits.
Compliance Low risk Compliance was estimated by pill count and measuring the ratio of serum EPA
to arachidonic acid. Compliance rates for the 3 groups (placebo vs EPA-E 1800
mg/d vs EPA-E 2700 mg/d) were 89.5% (6.8%), 90.3% (5.7%) and 89.5% (5.3%)
respectively
Other bias Low risk None noted
EPE-A 2014  (Continued)
 
 
Methods EPANOVA in Crohn's disease, study 1 (EPIC-1)
RCT, parallel, 2-arm (omega 3 vs MCT), 52 weeks
Summary risk of bias: moderate or high
Participants Adults with quiescent Crohn's disease (CDAI) score < 150
N:  188 intervention, 186 control
Level of risk for CVD: low
Men: 48.1% intervention, 41.1% control
Mean age in years (SD): 40.5 (15.2) intervention, 38.2 (13.1) control
Age range: 18-70 years
EPIC-1 2008 
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Smokers: 30.6% intervention, 34.4% control                                       
Hypertension: unclear
Medications taken by at least 50% of those in the control group: oral 5-ASA therapy, Systemic corticos-
teroids – prednisolone, budesonide
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: antibiotic therapy, topical rectal
therapy, immune-modifying agents, immune modifiers/biologics
Location: Canada, Europe, Israel, USA
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs SFA (medium chain triglycerides of short SFAs)
Intervention: 2 × 2 1 g gelatin capsules omega-3 free fatty acids (Epanova- 2.2 g EPA, 0.8 g DHA). Dose: 3
g/d EPA + DHA    
Control: 4 x1 g capsules medium chain triglycerides
Compliance: pill counts, 79.2% adhered intervention, 75.6% adhered control
Length of intervention: mean 52 weeks
Outcomes Main study outcome: Crohns relapse-free time
Dropouts: 80 intervention, 91 control
Available outcomes: total deaths, non-fatal arrhythmias, cancer diagnoses, cancer deaths, adverse
events
Response to contact: yes (data provided)
Notes Study funding: Tillotts Pharma, authors had extensive financial disclosures
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation by number generator. Used a centralised randomisation pro-
cedure via interactive voice recognition system.
Allocation concealment
(selection bias)
Low risk Centralised randomisation (see above)
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Double blinding stated, identical capsule (slow-release capsules). Neither in-
vestigator nor participant knew the allocation.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Study states double-blind but does not state that outcome assessors were
blinded or provide a mechanism for this
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Number of dropouts and reasons provided. 171 of 187 in intervention group
and 174 of 184 in control group provided data for primary outcome, (7%
dropout), though 80 in the intervention group and 91 in the control group ter-
minated early.
EPIC-1 2008  (Continued)
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Selective reporting (re-
porting bias)
High risk Trials registration (NCT00613197) first received in 2008, but study started in
2003 and was published in 2008
Attention Low risk As investigators were blinded attention bias was not possible.
Compliance Unclear risk Pill counts, 79.2% adhered intervention, 75.6% adhered control
Other bias Low risk No further bias noted
EPIC-1 2008  (Continued)
 
 
Methods EPANOVA in Crohn's Disease, Study 2 (EPIC-2)
RCT, parallel, 2 arms (omega 3 vs MCT), 58 weeks
Summary risk of bias: moderate or high
Participants Adults with a confirmed diagnosis of Crohn's Disease and a Crohn's Disease Activity Index (CDAI) score <
150 who are responding to steroid induction therapy
N:  intervention, 189, control 190 (187 intervention, 188 control analysed)
Level of risk for CVD: low (people with quiescent Crohn's disease)
Men: 48.1% intervention, 41.1% control
Mean age in years (SD): 38.5 (13.8) intervention, 40.0 (13.6) years control
Age range: > 16 years
Smokers: 25.1% intervention, 37.2% control                                   
Hypertension: unclear
Medications taken by at least 50% of those in the control group: systemic corticosteroids – pred-
nisolone, budesonide (but tapered and discontinued during the study)
Medications taken by 20%-49% of those in the control group: only reported for prior 12 months
Medications taken by some, but less than 20% of the control group: only reported for prior 12 months
Location: Canada, Europe, Israel, USA
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs SFA (medium chain triglycerides of short SFAs)
Intervention: 2 × 2 1 g gelatin capsules omega-3 free fatty acids (Epanova) providing total dose ˜2.2 g/d
EPA, 0.8 g/d DHA. Dose: ˜3.0 g/d EPA + DHA                   
Control: 2 × 2 1 g capsules medium chain triglyceride oil
Compliance: measured by patient interviews and pill counts, 75.4% adhered intervention, 81.4% ad-
hered control
Length of intervention: mean 58 weeks
Outcomes Main study outcome: maintain Crohns symptomatic remission
Dropouts: 114 intervention, 112 control
Available outcomes: mortality, CV events (nil), cancer diagnoses, adverse events
Response to contact: yes (data provided)
EPIC-2 2008 
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Notes Study funding: Tillotts Pharma, authors had extensive financial disclosures
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation by number generator. Used a centralised randomisation pro-
cedure via interactive voice recognition system
Allocation concealment
(selection bias)
Low risk Centralised randomisation (see above)
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Double blinding stated, identical capsule (slow-release capsules). Neither in-
vestigator nor participant knew the allocation. However no information pro-
vided on capsules taste or smell
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Study states double-blind but does not state that outcome assessors were
blinded or provide a mechanism for this
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Number of dropouts and reasons provided, however 114 of 189 in intervention
group and 112 of 190 in control group terminated early.
Selective reporting (re-
porting bias)
High risk NCT00074542. First received 2003, study start 2002. Published 2008.  Some
outcomes, such as quality of life, stated in trials registry but not in published
papers
Attention Low risk As investigators were blinded, attention bias was not possible.
Compliance Unclear risk Measured by patient interviews and pill counts, 75.4% adhered intervention,
81.4% adhered control
Other bias Low risk No further bias noted
EPIC-2 2008  (Continued)
 
 
Methods Older People, Omega-3 and Cognitive Health (EPOCH)
RCT, parallel (n-3 EPA + DHA vs MUFA), 18 months
Summary risk of bias: low
Participants Healthy older adults with no cognitive impairment
N: 195 intervention, 196 control (reported by author)
Level of risk for CVD: low
Men: not reported
Mean age in years (SD): not reported
Age range: not reported, but 65-90 recruited
Smokers: not reported
EPOCH 2014 
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Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Australia
Ethnicity: not reported
Interventions Type: supplement (fish oil capsules)
Comparison: EPA + DHA vs MUFA
Intervention: 4 capsules/d (1.72 g/d DHA and 0.60 g/d EPA). Dose: 2.32 g/d EPA + DHA
Control: 4 capsules/d (3.960 g/d olive oil and 40 mg/d fish oil)
Compliance: count of all unused supplements returned at three-monthly intervals, plus self-report cal-
endars, mailed back on a monthly basis. If compliance fell below 85% (re calendars), they were con-
tacted by a researcher who noted the reasons. Compliance also assessed by erythrocyte membrane n-3
LC PUFA status
Length of intervention: 18 months
Outcomes Main study outcome: change in cognitive performance
Dropouts: not reported
Available outcomes: mortality (nil), MI, stroke, revascularisation, arrhythmias, CV events
Response to contact: yes (data provided)
Notes Authors reported some events, but don't appear to be published.
Study funding: EPAX donated the Omega-3 concentrate and Blackmores Pty Ltd donated the placebo
and packaging of the Omega-3 concentrate. The trial was supported by the Brailsford Robertson Award
2007-2008 (University of Adelaide and CSIRO Food and Nutritional Sciences), and is funded by a Nation-
al Health and Medical Research Project Grant (#578800).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Age-stratified, permuted-block randomisation, with mixed block-sizes (2-8,
size unknown to study investigators), 1:1 allocation. Computer-generated ran-
domisation schedule
Allocation concealment
(selection bias)
Low risk An independent researcher prepared allocation to treatment
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk The researchers, project staC, and participants remained blinded to treatment
allocation until the trial was completed and the database locked. However, no
information provided on capsules appearance, taste or smell
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk As above
EPOCH 2014  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No data for each group presented, and no attrition data presented
Selective reporting (re-
porting bias)
High risk Only cognitive functions reported for whole population (not by arm). No sec-
ondary outcomes reported (MMSE; perceived health status, depressive symp-
toms, positive and negative affect, life satisfaction, self-reported cognitive
functioning, and functional capacity; blood pressure; biomarkers of glucose,
glycated haemoglobin, triglycerides, total cholesterol, HDL, LDL, homocys-
teine, CRP, MDA, and telomere length)
Attention Low risk All had the same contact and attention
Compliance Unclear risk Count of all unused supplements returned at 3-monthly intervals, plus self-re-
port calendars, mailed back on a monthly basis. If compliance fell below 85%
(re calendars), they were contacted by a researcher who noted the reasons.
Compliance also assessed by erythrocyte membrane n-3 LC PUFA status but
results not reported
Other bias Low risk None noted
EPOCH 2014  (Continued)
 
 
Methods RCT, parallel (n-3 EPA + DHA vs unclear), 12 months
Summary risk of bias: moderate to high
Participants People with successful external cardioversion
N: unclear intervention, unclear control (54 analysed intervention, 54 control)
Level of risk for CVD: high
Men: 70% intervention, 74% control
Mean age in years (SD): 65.0 (mean for whole group, SD not reported)
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Germany
Ethnicity: not reported
Interventions Type: supplement (probably, not described)
Comparison: high EPA + DHA vs unclear placebo
Intervention: described only as "PUFA" but included in systematic review (Mariani 2013) by Erdogan et
al on effects of n-3 PUFA. Dose: unclear
Erdogan 2007 
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Control: described only as "placebo"
Compliance: not reported
Length of intervention: 12 months
Outcomes Main study outcome: atrial fibrillation relapse
Dropouts: not reported
Available outcomes: recurrent AF (reported in Mariani 2013), mortality (none)
Response to contact: no reply to date
Notes Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly assigned"
Allocation concealment
(selection bias)
Unclear risk Not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Described as triple blind, but no further details provided (only an abstract with
some details in a related trial publication and some in a systematic review by
the same author)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not described, but analysis appears to have been carried out blind to interven-
tion/control status
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Number randomised not described
Selective reporting (re-
porting bias)
Unclear risk Unclear, no trial registry entry or protocol found
Attention Unclear risk Not described
Compliance Unclear risk Not described
Other bias Low risk None noted
Erdogan 2007  (Continued)
 
 
Methods Fatty Acid Antiarrhythmia Trial – FAAT
Randomisation: RCT, parallel, 2 arms, (n-3 EPA + DHA vs MUFA), 12 months
Summary risk of bias: moderate or high
Participants People with implanted cardioverter defibrillators (ICDs)
FAAT 2005 
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N: intervention 200, control 202
Level of risk for CVD: high (patients with ICDs).
Men: intervention 84.5%, control 81.7%
Mean age in years (SD): intervention 65.7 (11.6), control 65.3 (11.7)
Age range: unclear
Smokers: intervention 15%, control 11.4%
Hypertension: unclear
Medications taken by at least 50% of those in the control group: ACE inhibitors, beta-blockers
Medications taken by 20% - 49%: diuretics
Medications taken by some, but < 20%: calcium channel blockers, amiodarone, sotalol, type 1 antiar-
rhythmics
Location: USA
Ethnicity: intervention 95.5% white, control 96.5% white
Interventions Type: supplement/capsule
Comparison: EPA + DHA vs MUFA
Intervention: 4 ×1 g/d fish oil gelatin capsules, 2.6 g/d EPA + DHA (Pronova Biocare, quantities of EPA +
DHA unclear). Dose: 2.6 g/d EPA + DHA
Control: 4 ×1 g/d olive oil capsules, 4 g/d (in identical gelatin capsules, < 0.06 g/d EPA and < 0.06 g/d
DHA)
All were advised to use olive oil rather than the common plant seed oils for cooking, dressings, and
sauces
Compliance: pill counts and platelet phospholipid data suggested greater omega 3 intake in interven-
tion participants. 35% were non-compliers (36.5% intervention, 34.2% control)
Duration of intervention: 12 months
Outcomes Main study outcome: fatal ventricular arrhythmias
Dropouts: intervention 13 deaths, unclear no. of dropouts, control 12 deaths, dropouts unclear
Available outcomes: deaths, cardiovascular deaths, CVD events, deaths from heart failure, fatal arrhyth-
mias, MI, angina
Response to contact: yes (data provided)
Notes Study funding: the study was supported in part by a grant from the NHLBI, NIH (HL62154)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation tables for each collaborating site, strati-
fied by site
Allocation concealment
(selection bias)
Low risk Author confirmed allocation was concealed from investigators
FAAT 2005  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Study referred to as "double blind" and gelatin capsules (verum and place-
bo) were stated as being of identical appearance but no discussion of taste or
smell. Author confirmed that investigators and patients were blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk VT and VF events were assessed blinded to allocation
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Large numbers dropped out so some deaths, etc. may have been missed, 35%
discontinued early due to non-compliance but were assessed at study end, da-
ta censored for some participants
Selective reporting (re-
porting bias)
High risk Trials registry data received September 2005, paper published November 2005
Attention Low risk Time and attention appeared similar between the 2 arms
Compliance High risk Pill counts and platelet phospholipid data suggested greater omega 3 intake in
intervention participants. 35% were non-compliers (36.5% intervention, 34.2%
control)
Other bias Low risk None noted
FAAT 2005  (Continued)
 
 
Methods Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial
Disease (FLAX PAD)
RCT, parallel, (n-3 ALA vs mixed fat), 12 months
Summary risk of bias: low
Participants Patients with peripheral artery disease, over 40 years old
N: 58 intervention, 52 control
Level of risk for CVD: high (all had peripheral artery disease, 80% had hyperlipidaemia)
Men: 74.1% intervention, 73.1% control
Mean age in years (SD): 67.4 (8.06) intervention, 65.3 (9.4) control
Age range: unclear
Smokers: 19.2% intervention, 34.6% control
Hypertension: 81% intervention, 69.2% control
Medications taken by at least 50% of those in the control group: lipid lowering medication, antihyper-
tensives, antithrombotics
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: insulin or blood sugar-lowering
drugs
Location: Canada
FLAX-PAD 2013 
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Ethnicity: unclear
Interventions Type: food supplement (milled flaxseed)
Comparison: ALA vs unclear (mix of wheat, wheat germ and mixed dietary oils)
Intervention: food products (i.e. bagels, muCins, bars, pasta, buns, and milled seeds) containing 30 g of
milled flaxseed daily. Dose: ˜6.8 g/d ALA (calculated based on 30 g milled flaxseed/d)
Control: placebo food products (i.e. bagels, muCins, bars, pasta, buns, and milled seeds) containing a
mixture of wheat, wheat bran, and mixed dietary oils to replace the flaxseed daily
Compliance: plasma levels of enterolignans and the n-3 fatty acid ALA were used as markers of dietary
compliancy
Length of intervention: 12 months
Outcomes Main study outcome: all-cause mortality, cardiovascular mortality, stroke, and myocardial infarctions
Dropouts: 15 intervention, 11 control
Available outcomes: blood pressure, lipids, adverse events, plasma ALA
Response to contact: yes (but no data provided)
Notes Different intervention dropout figures reported in two publications (13 or 15)
Study funding: funded by government organisations but foods created and provided by a company
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomly selected by a computer programme
Allocation concealment
(selection bias)
Low risk Allocation was concealed. The person who determined if a participant was el-
igible for inclusion in the trial was unaware, when this decision was made, of
which group the subject would be allocated
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Product colour and texture were similar to disguise the composition of the
product. Participants, personnel administering the intervention and those as-
sessing the outcomes were blinded to group assignment
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk All personnel that collected or analysed data were blinded to the intervention
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised accounted for in main outcomes
Selective reporting (re-
porting bias)
High risk Prospectively registered October 2008, study start October 2008, primary out-
come data completed March 2011, end date December 2017. Cardiovascular
mortality and measures of adiposity not reported in a useable way
Attention Low risk Both groups had the same care
Compliance Unclear risk 12 in intervention group and 8 in placebo group unwilling to comply with diet
FLAX-PAD 2013  (Continued)
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Other bias Low risk None noted
FLAX-PAD 2013  (Continued)
 
 
Methods Randomized trial to assess efficacy of PUFA for the maintenance of sinus rhythm in persistent atrial fib-
rillation (FORWARD)
RCT, parallel, (n-3 EPA + DHA vs MUFA), 12 months
Summary risk of bias: low
Participants Patients with paroxysmal atrial fibrillation
N: 289 intervention, 297 control
Level of risk for CVD: high
Men: 57.8% intervention, 51.9% control
Mean age in years (SD): 66.3 (12) intervention, 65.9 (10.5) control
Age range: > 21
Smokers: 9% intervention, 6.2% control
Hypertension: 92.2% intervention, 90.8% control
Medications taken by at least 50% of those in the control group: aspirin, amiodarone, 'any antithrom-
botic treatment', beta-blockers
Medications taken by 20%-49% of those in the control group: anticoagulants
Medications taken by some, but less than 20% of the control group: none reported
Location: Argentina
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs MUFA
Intervention: one capsule/ day containing 1 g of n-3 PUFA (Societá Prodotti Antibiotici and SigmaTau,
Italy) (provided 850 mg to 882 mg EPA/DHA). Dose: 0.85 g/d EPA + DHA
Control: identical placebo capsule containing olive oil
Compliance: not reported.
Length of intervention: 12 months
Outcomes Main study outcome: survival free of atrial fibrillation
Dropouts: 20 intervention, 25 control
Available outcomes: mortality, MI, AF, heart failure, stroke, hospitalisation, side effects. Authors sup-
plied further info on CVD events and methodology
Response to contact: yes
FORWARD 2013 
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Notes Study funding: through unrestricted grants provided by companies that supplied study drugs, however
"these companies did not have representatives on the Steering Committee" who terminated the trial
after 1 year
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Participants were centrally assigned to receive either 1 g of n-3 PUFA
or placebo in a ratio of 1:1" – computer generated in blocks of 4 and 6 strati-
fied by study location
Allocation concealment
(selection bias)
Low risk As above, centrally allocated. Communication from authors was ambiguous,
stated that the person recruiting was aware of which arm the individual would
be allocated to, but that the "study was double-blind, placebo-controlled."
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Each study site will be supplied with study drug and placebo in iden-
tically appearing packaging". "Both placebo and active treatment have the
same odour and produce a comparable degree of fishy aftertaste"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Patients, investigator staC, persons performing the assessments, and
data analysts will remain blind to the identity of the treatment from the time
of randomisation until database lock" "The adjudication committee members
are unaware of participant allocation and assess all available data and docu-
mentation with reference to pre-established criteria".
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Quote: "the study was cut short by the trial steering committee due to 'a slow-
er-than-expected recruitment rate and lower event rates'. This 'resulted in an
underpowered clinical trial unable to verify its hypothesis'. Therefore the out-
come data were not as complete as they were initially meant to be".
Selective reporting (re-
porting bias)
Low risk Prospectively registered January 2008, study start January 2008, completion
August 2011. All outcomes in trials registry appear to have been reported.
Attention Low risk Both intervention and control given the same exposure to research personnel.
2013 paper: "Clinical outcomes, adherence, and adverse events were assessed
2, 4, 8, and 12 months after randomization"
Compliance Unclear risk Not reported
Other bias Low risk None noted
FORWARD 2013  (Continued)
 
 
Methods Fish Oil in knee OSTeoARthritis (FOSTAR)
RCT, parallel, (n-3 EPA + DHA vs low n-3), 24 months
Summary risk of bias: low
Participants Adults aged 40+ years with knee osteoarthritis
N: 101 intervention, 101 control
Level of risk for CVD: low
FOSTAR 2016 
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Men: 41% intervention, 60% control
Mean age in years (SD): 60.8 (10) intervention, 61.1 (10) control
Age range: > 40
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: none reported
Medications taken by 20%-49% of those in the control group: not reported at baseline, but 'during' in-
cludes Vit. D ˜ 32%
Medications taken by some, but less than 20% of the control group: not reported at baseline, but 'dur-
ing' includes Glucocorticoid, HRT/anti-resorptive, both ˜ 10%
Location: Australia
Ethnicity: not reported
Interventions Type: supplementary food (enriched orange juice)
Comparison: high EPA + DHA vs low EPA + DHA plus ALA (replacement unclear, but low omega 3)
Intervention: 1-3 × a day drink of fruit juice mixed with day total = 15 mL of fish oil supplement (18%
EPA, 12% DHA, 4.5 g/day total omega 3). Dose: 4.5 g/d EPA + DHA
Control: liquid oral oil 15 mL sunola oil/day (which contains fish oil 2 mL plus 13 mL canola oil) (total
omega-3 fat: ≥ 0.45 g EPA + DHA from 15 mL)
Compliance: assessed by measuring the oil volume in returned bottles, compliance was > 80% in both
groups. Both groups had increases from baseline in plasma EPA and DHA with the high-dose group hav-
ing substantially larger increases, consistent with compliance with study oil
Length of intervention: 24 months
Outcomes Main study outcome: change in pain scale of WOMAC index
Dropouts: 18 intervention, 16 control
Available outcomes: mortality, CVD events, adverse events, analgesic use, bone marrow density,
weight gain and serum fatty acids
Response to contact: yes
Notes Data on quality of life and pain score are presented in a figure and not in a usable format
Study funding: government funding
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random allocation sequence
Allocation concealment
(selection bias)
Low risk A security-protected central automated allocation procedure was used to allo-
cate participants to one of the 2 treatment arms. This was performed centrally
at one pharmacy and then used to allocate and administer the oil at each site
FOSTAR 2016  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Citrus flavouring was added to both oils to achieve comparable taste and op-
timise masking. Both were provided in identical dark 500-mL bottles with sim-
ilar labelling. At the end of the study, 52% of participants were unsure which
group to which they had been allocated (50% high dose, 50% low dose). Of the
remaining who thought they knew which group they were allocated, only 57%
answered correctly, suggesting that blinding had been well maintained
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Participants and staC involved in patient care and assessment of BMD re-
mained blinded throughout the study.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Oil intolerance in 1st year differed, others appear similar, but numbers con-
fused
Selective reporting (re-
porting bias)
High risk Prospectively registered August 2007, recruitment started July 2007, outcomes
published 2016. Variety of outcomes such as quality of life stated in trials reg-
istry but not published.
Attention Low risk Same contact and instruction schedule for all participants.
Compliance Low risk Assessed by measuring the oil volume in returned bottles, compliance was >
80% in both groups. Both groups had increases from baseline in plasma EPA
and DHA with the high-dose group having substantially larger increases, con-
sistent with compliance with study oil
Other bias Low risk None noted
FOSTAR 2016  (Continued)
 
 
Methods RCT, parallel (n-3 EPA + DHA vs MUFA), 12 months
Summary risk of bias: moderate to high
Participants Adults with documented coronary heart disease
N: 15 intervention, 15 control
Level of risk for CVD: high
Men: unclear
Mean age in years (SD): 52 (9) intervention, 54 (7) control
Age range: not reported
Smokers: 87% intervention, 100% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: aspirin, beta-blockers
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Lipid lowering medications were not allowed
Location: Germany
Franzen 1993 
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Ethnicity: not reported
Interventions Type: fish oil capsules
Comparison: EPA + DHA vs MUFA
Intervention: 9 × 1 g capsules/day of fish oils (20% EPA, 15% DHA, 3.15 g/day total omega 3). Dose: 3.15
g/d EPA + DHA
Control: 9 × 1 g capsules/day olive oil (which contains 6.3 g/day MUFA, 1.35 g/day SFA, 1.35 g/d total
omega 6 fat)
Compliance: assessed by pill counts and FA in body tissue analysis
Length of intervention: 12 months
Outcomes Main study outcome: blood lipids and FA in body tissues
Dropouts: 0 intervention, 0 control
Available outcomes: mortality (nil death), CVD events (nil), lipids (only TC used as the others were dif-
ferent at baseline), adverse events, serum fatty acids
Response to contact: yes
Notes Study funding: unclear
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated list
Allocation concealment
(selection bias)
Unclear risk No details. They received their initial allocation in a sealed box in person; sub-
sequent doses arrived in the post
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk No further details beyond stating "double blind"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No details
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No attrition
Selective reporting (re-
porting bias)
Unclear risk No trial register or protocol found
Attention Low risk No difference between groups
Compliance Unclear risk Measured but no results
Other bias Low risk None noted
Franzen 1993  (Continued)
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Methods RCT, parallel, (EPA + DHA vs unclear), 24 months
Summary risk of bias: moderate or high
Participants Adults with Metabolic syndrome
N: unclear, total randomised 101
Level of risk for CVD: low
Men: 47% total, no details by group
Mean age in years (SD): 55 (10) total
Age range: 18-75 years
Smokers: 0% intervention, 0% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: USA
Ethnicity: unclear
Interventions Type: supplement (fish oil capsules)
Comparison: EPA + DHA vs placebo (unclear what)
Intervention: fO3FA capsules 1.8 g of EPA + DHA daily. Dose: 1.8 g/d EPA + DHA
Control: matching placebo supplement
Compliance: not reported
Length of intervention: 12 months
Outcomes Main study outcome: change in carotid IMT
Dropouts: unclear
Available outcomes: lipids, insulin and glucose are stated as secondary outcomes but no usable data
published
Response to contact: no
Notes Results cannot be used as numbers are not reported by study arm.
Study funding: unclear, but mentions that Pfizer, NIH and "Northwest Lipids Clinic" are partners
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details
Gill 2012 
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Allocation concealment
(selection bias)
Unclear risk No details
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk No data
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No data
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No data
Selective reporting (re-
porting bias)
High risk Inadequate detail in reporting as no full text publication found; Gill 2014 does
give detail on carotid IMT, but not on other primary or secondary outcomes.
The trial was prospectively registered (registered July 2006, unclear when re-
cruitment started, final data collection 2011, first data published 2012).
Attention Unclear risk No data
Compliance Unclear risk No data
Other bias Unclear risk No data
Gill 2012  (Continued)
 
 
Methods Gruppo Italiano per la Sperimentazione della Streptochinasi nell'Infarto Miocardico – Heart Failure
(GISSI-HF)
RCT, parallel, 2 arms (n-3 EPA + DHA vs MUFA), 3.9 years
Summary risk of bias: moderate or high
Participants Patients with chronic heart failure
N: 3494 intervention, 3481 control
Level of risk for CVD: high
Men: 77.8% intervention, 78.8% control
Mean age: 67 (11) intervention,67 (11) control
Age range: 18+ years
Smokers: 14.4% intervention, 13.9% control
Hypertension: 54.0% intervention, 55.2% control
Medications taken by at least 50% of those in the control group: ACE inhibitors, beta-blockers, diuretics
Medications taken by 20%-49% of those in the control group: spironolactone, digitalis, oral anticoagu-
lants, aspirin, nitrates, statin
Medications taken by some, but less than 20% of the control group: ARBs, other antiplatelets, calcium
channel blockers, amiodarone
GISSI-HF 2008 
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Location: Italy
Ethnicity: unclear
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs MUFA
Intervention:1 capsule per day of 1 g n-3 mainly EPA and DHA as ethyl esters in the average ratio of
1:1.2. Dose: ˜0.866 g/d EPA + DHA
Control: 1 g/d matching olive oil placebo capsule
Compliance: unclear
Length of intervention: median 3.9 years
Outcomes Main study outcome: time to death or admission to hospital for cardiovascular reasons
Dropouts: 34 intervention, 46 control (1004 intervention and 1029 control stopped study treatment)
Available outcomes: mortality, CV mortality, MI, stroke, new heart failure, incident AF, resumed arrhyth-
mia gatalitis
Response to contact: yes (no data provided)
Notes Study funding: funders included Pfizer, AstraZeneca and others
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomly assigned (with stratification by site) to treatment groups
Allocation concealment
(selection bias)
Low risk Randomly assigned (with stratification by site) to treatment groups by a con-
cealed computerised telephone randomisation system
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Double blinding stated, but taste not reported as masked and blinding of par-
ticipants not checked
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk All events "adjudicated blindly by an ad-hoc committee on the basis of pre-
agreed definitions and procedures"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reasons for attrition and exclusion were stated and addressed. Numbers in
each intervention compared to numbers were similar.
Selective reporting (re-
porting bias)
Unclear risk Published rationale and design (Tavazzi 2004) suggested primary outcomes
were deaths and death or CV hospitalisation (published). Secondary outcomes
not stated and no trials registry entry found
Attention Low risk Scheduled clinic visits at 1, 3, 6 months then 6 monthly until the end of the tri-
al (for both arms)
Compliance Unclear risk No details
GISSI-HF 2008  (Continued)
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Other bias Low risk No further bias noted
GISSI-HF 2008  (Continued)
 
 
Methods Gruppo Italiano per la Sperimentazione della Streptochinasi nell'Infarto Miocardico – Prevention
(GISSI-P)
RCT, 2 × 2 (n-3 EPA + DHA vs nil), 42 months
Summary risk of bias: moderate or high
Participants People with recent (≤ 3 months) myocardial infarction
N: 5666 intervention, 5658 control (99.9% follow-up at study end)
Level of risk for CVD: high
Men: 85.7% intervention, 84.9% control
Mean age in years (SD): 59.3 (10.6) intervention, 59.5 (10.5) years control
Age range: < 50 to > 80
Smokers: 42.6% intervention, 42.3% control
Hypertension: 36.2% intervention, 34.9% control
Medications taken by at least 50% of those in the control group: anti-platelet
Medications taken by 20%-49% of those in the control group: ACE inhibitors, beta-blockers
Medications taken by some, but less than 20% of the control group: lipid lowering
Location: Italy
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs nil
Intervention: gelatin capsules of omega-3-acid ethyl esters 90 (Omacor), 1/d (850-882 mg/d EPA + DHA
daily, ratio 1:2)
Dose: ˜0.866 g/d EPA + DHA
Control: nil (no placebo)
Compliance: capsule counts, 11.6% had stopped taking Omacor by 12 months, 28.5% by the end of the
study
Duration of intervention: median follow-up 40 months
Outcomes Main study outcome: all cause mortality, CV mortality, stroke, MI
Dropouts: unclear (however, all randomised were included in analyses)
Available outcomes: total, sudden and CV deaths, MI, stroke, angioplasty or CABG, angina, CHD, cancer
diagnosis, cancer death, combined CV events, side effects
Response to contact: no
GISSI-P 1999 
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Notes Numbers are slightly different in different publications (Lancet 1999 paper used as main source). Half of
both groups were on vitamin E supplements (300 mg/d synthetic α-tocopherol) as this was the other 2
× 2 intervention.
Study funding: Bristol Meyers Squibb, Pharmacia Upjohn, Societa Produtti Antibiotici, Pfizer
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Telephone/computer network, stratified by hospital, based on a biased coin
algorithm
Allocation concealment
(selection bias)
Low risk Randomisation by telephone with the coordinating centre
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No placebo intervention (capsule vs nil) so participants not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk "validation of clinical events ... was assured by an ad-hoc committee of expert
cardiologists and neurologists blinded to patients treatment assignment"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Clearly described, good follow-up (< 28% dropped out over 3.5 years)
Selective reporting (re-
porting bias)
Unclear risk No study protocol or trials registry entry was found
Attention Low risk Slight as no placebo, otherwise similar
Compliance Unclear risk Capsule counts, 11.6% had stopped taking Omacor by 12 months, 28.5% by
the end of the study
Other bias Low risk No further bias noted
GISSI-P 1999  (Continued)
 
 
Methods Harvard Atherosclerosis Reversibility Project (HARP)
RCT, (n-3 EPA + DHA vs MUFA), 24 months
Summary risk of bias: moderate or high
Participants Patients with coronary heart disease
N: 41 intervention, 39 control (99.9% follow-up at study end)
Level of risk for CVD: high
Men: 93.5% intervention, 92.9 % control
Mean age in years (SD): 62 (7) intervention, 62 (7) years control
Age range: 30-75
HARP 1995 
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Smokers: 0% (exclusion criteria)
Hypertension: 48% intervention, 36% control
Medications taken by at least 50% of those in the control group: beta blockers, antiplatelet agents
Medications taken by 20%-49% of those in the control group: calcium channel blockers, nitrates
Medications taken by some, but less than 20% of the control group: ACE inhibitors, oral hypoglycaemic
drugs
Location: USA
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: LCn3 vs MUFA
Intervention: 12 fish oil capsules/day (Promega, Parke-Davis) in divided doses, preferably after meals.
Each fish oil capsule contained 500 mg of n-3 polyunsaturated fatty acids composed of EPA (240 mg),
DHA (160 mg) and other (100 mg) (mainly DPA) providing total daily dose of 6 g of n-3 fatty acids. Dose:
6 g/d LCn3
Control: olive oil capsules identical in appearance to the fish oil capsules.
Compliance: capsule counts and serum level measurements. Adherence averaged 80% intervention,
and 90% control with significant levels of adipose n-3 fatty acids in the fish oil group.
Duration of intervention: average 28 months
Outcomes Main study outcome: regression of coronary artery lesions
Dropouts: 10 intervention, 11 control
Available outcomes: all-cause and CV deaths, fatal and non-fatal MI, stroke, angioplasty or CABG, un-
stable angina, CHD, cancer diagnosis, combined CV events, side effects
Response to contact: yes
Notes Study funding: National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, Bethes-
da, Maryland, Warner Lambert-Parke Davis, East Hanover, New Jersey; and by an Established Investiga-
tor Award to Dr Sacks from the American Heart Association, Dallas, Texas
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomization" stratified by clinical management regime and to-
tal/HDL cholesterol ratio
Allocation concealment
(selection bias)
Unclear risk No further details
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Quote: "patients and personnel responsible for lab measurements, cardiac
catheterization, and analysis of angiography films were blinded to the treat-
ment assignment". Although capsules were identical in appearance, no infor-
mation on their taste and smell
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "patients and personnel responsible for lab measurements, cardiac
catheterization, and analysis of angiography films were blinded to the treat-
ment assignment"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Low attrition rate over 28 months and all reasons are well documented
HARP 1995  (Continued)
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Selective reporting (re-
porting bias)
High risk Trial registered retrospectively after publication
Attention Low risk Nothing in description implies the arms were treated differently
Compliance Low risk Very clear (P < 0.001) differences between arms for the 3 main n-3 components
in the fish oil
Other bias Low risk None noted
HARP 1995  (Continued)
 
 
Methods Healthy Eating to Reduce Overweight in people with type 2 diabetes (HERO)
RCT, parallel, (n-3 ALA vs low n-3), 12 months
Summary risk of bias: moderate or high
Participants Overweight adults with non-insulin treated diabetes
N: 26 intervention, 24 control (analysed, intervention: 18 control: 17)
Level of risk for CVD: moderate
Male %: not reported
Mean age in years (SD): 54 (8.7), not reported by arm
Age range: 33-70 years
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: lipid lowering drugs, oral hypo-
glycemics
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Australia
Ethnicity: not reported
Interventions Type: food supplement (walnuts)
Comparison: ALA vs nil
Intervention: 30 g/d snack portions of walnuts (provided 10% MUFA, 10% E PUFA, and a P/S ratio of 1.0)
and advised not to take fish oil supplements. ALA dose not reported. Dose: ˜3 g/d ALA based on 30 g/d
intake of walnuts
Control: no supplements
Both groups were given low-fat isocaloric dietary advice (30% E fat (10% E SFA, 15% E MUFA; 5% E PU-
FA, P/S ratio of 0.5), 20% E protein and 50% E CHO) plus advice to brisk walk 30 min × 3 times/week
Compliance: measured by erythrocyte membrane fatty acid levels which were similar in both groups
Duration of intervention: 12 months
HERO 2009 
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Outcomes Main study outcome: change in body weight and % body fat
Dropouts: 8 intervention, 5 control
Available outcomes: all cause mortality (nil deaths), weight, visceral adipose tissue, lipids, glucose, in-
sulin, HbA1c (body fat % and subcutaneous adipose tissue measured but too different at baseline to
use)
Response to contact: not yet attempted
Notes Body fat % was too different between groups at baseline hence data not used
Study funding: California Walnuts Commission
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was conducted using a computerised random number genera-
tor by a researcher independent of the subject interface.
Allocation concealment
(selection bias)
Unclear risk No further details
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "Subjects, but not dietitians, were blinded to the type of overall diet
(a prepackaged 30 g snack portion of walnuts was given to the walnut group
unbeknown to the controls)". However, there was no placebo supplement, so
blinding easily broken
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Paper states "code was concealed from the researchers collecting data, as well
as from subjects." However as participants could not be blinded outcome as-
sessors may not have been (problem for measures of adiposity, not for bio-
chemical measures)
Incomplete outcome data
(attrition bias) 
All outcomes
High risk High dropout rate 35 of 50 analysed (30% attrition rate)
Selective reporting (re-
porting bias)
Unclear risk Trial was registered postanalysis
Attention Low risk Both groups appear to have had same level of attention
Compliance High risk ALA levels almost exactly the same in intervention and control
Other bias Low risk None noted
HERO 2009  (Continued)
 
 
Methods Japan Eicosapentaenoic acid Lipid Intervention Study (JELIS)
RCT, parallel, 2-arm (EPA capsule vs nil), 5 years                                   
Summary risk of bias: moderate or high
Participants People with hypercholesterolaemia
JELIS 2007 
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N: intervention, 9326, control 9319 (analysed intervention 9326, control 9319)
Level of risk for CVD: moderate (Patients with hypercholesterolaemia)
Men: 32% intervention, 31% control
Mean age in years (SD): 61 (8) intervention 61 (9) control
Age range: 40-75 years
Smokers: 20% intervention, 18% control                                               
Hypertension: 36% intervention, 35% control                                               
Medications taken by at least 50% of those in the control group: statins
Medications taken by 20%-49% of those in the control group: calcium channel blockers, other antihy-
pertensives
Medications taken by some, but less than 20% of the control group: beta-blockers, antiplatelet, hypo-
glycemics, nitrates
Location: Japan
Ethnicity: Japanese
Interventions Type: supplement (EPA capsule)   
Comparison 1: EPA vs nil            
Intervention: 3 × 2 × 300 mg capsules/d EPA ethyl ester (total dose of 1.8 g/d EPA), after meals. Dose: 1.8
g/d EPA
Control: nothing (though all in both groups received "appropriate" dietary advice). All patients in both
groups were on statins.
Compliance: monitored by local physicians and measuring plasma fatty acids concentrations. Study
drug regimens, 71% adhered EPA intervention, 73% adhered EPA control, 74% adhered statin
Duration of intervention: maximum 5 years, mean 4.7 (1.1) years
Outcomes Main study outcome: major coronary events
Dropouts: 1766 intervention, 1582 control (but all had endpoint evaluation)
Available outcomes: major coronary events: sudden cardiac death, fatal or non-fatal MI, unstable angi-
na, angioplasty or CABG. Also all-cause mortality, stroke, peripheral artery disease, cancer, lipids, rise
in blood sugar, fasting glucose, HbA1c
Response to contact: no
Notes Study funding: Mochida Pharmaceutical Company
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Statistical co-ordination centre: "permitted block randomisation with a block
size of 4"
Allocation concealment
(selection bias)
Low risk Centralised. Statistical coordinating centre (see above)
JELIS 2007  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not blinded as there was no placebo. Quote: "[o]pen label blinded end point"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk "Clinical endpoints ... reported by local physicians were checked by members
of a regional organizing committee in a blinded fashion. Then an endpoints
adjudication committee ... confirmed them once a year without knowledge of
the treatment allocation"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Well documented, dropout numbers low
Selective reporting (re-
porting bias)
Unclear risk NCT00231738 registered October 2005, recruitment November 1996 to Novem-
ber 1999, main results published 2007. Rationale and design paper published
in 2003 (reported baseline characteristics, so before completed follow-up, but
after data collection began). All reported outcomes appear to have been pub-
lished.
Attention Low risk Slight, as no placebo provided to control group, but only capsules to interven-
tion group. Otherwise 2 groups appeared to be treated equally
Compliance Unclear risk Monitored by local physicians and measuring plasma fatty acids concentra-
tions. Study drug regimens,71% adhered EPA intervention, 73% adhered EPA
control, 74% adhered statin
Other bias Low risk No further bias noted
JELIS 2007  (Continued)
 
 
Methods RCT, parallel, (fish oil vs nil), 12 months
Summary risk of bias: moderate or high
Participants Patients with persistent atrial fibrillation (AF) on warfarin
N: 92 intervention, 90 control (91 and 87 analysed ITT)
Level of risk for CVD: high
Male %: 82.4 intervention, 72.4 control
Mean age in years (SD): 63 (10) intervention, 61(13) control
Age range: 18-85 years (inclusion criteria)
Smokers: 22.2% intervention, 11.5% control
Hypertension: 45.6% intervention, 58.6% control
Medications taken by at least 50% of those in the control group: anti-arrhythmic drugs, renin-an-
giotensin system inhibitors
Medications taken by 20%-49% of those in the control group: statins
Medications taken by some, but less than 20% of the control group: not reported
Location: Australia
Kumar 2012 
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Ethnicity: not reported
Interventions Type: fish oil capsule
Comparison: EPA + DHA vs nil
Intervention: 6 capsules/day of a fish oil preparation containing a total dose of 1.02 g of EPA and 0.72 g
DHA. Participants in the omega-3 group were asked to continue fish oils till a maximum of 1 year or till
return of persistent AF. Dose: 1.7 g/d EPA + DHA
Control: no supplements. Patients were advised not to take any fish oil supplements.
All patients underwent cardioversion following randomisation.
Compliance: was monitored on a weekly basis via telephone and during follow-up by using a pill count
plus serum EPA and DHA levels which were significantly increased
Duration of intervention: 1 year (or AF recurrence)
Outcomes Main study outcome: atrial fibrillation recurrence
Dropouts: 4 intervention, 0 control
Available outcomes: all-cause mortality (nil death), AF recurrence, time to AF recurrence, adverse
events
Response to contact: contact not yet established
Notes Study funding: the study was funded in part by the National Heart Foundation of Australia and the Pfiz-
er Cardiovascular Lipid Research Grant.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Patients were randomised to a control or an omega-3 group in a 1:1 fashion
(no details of method)
Allocation concealment
(selection bias)
Unclear risk No further details
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open label with no placebo control
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Open label
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis was conducted
Selective reporting (re-
porting bias)
Unclear risk Trial registered 2005 but data collection started 2003
Attention Unclear risk Intervention group had capsules, while control group did not. Potential for
greater contact and checking with intervention group on this basis, although
otherwise both groups seem to have had the same care.
Kumar 2012  (Continued)
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Compliance Low risk EPA and DHA levels were significantly higher in intervention group
Other bias Low risk None noted
Kumar 2012  (Continued)
 
 
Methods RCT, parallel, (fish oil vs nil), 12 months
Summary risk of bias: moderate or high
Participants Patients > 60 years with sinoatrial node disease and dual chamber pacemakers
N: 39 intervention, 39 control randomised (18 intervention vs 39 control at 12 months)
Level of risk for CVD: moderate/high
Male %: 46% intervention, 56% control
Mean age in years (SD): 78 (7) intervention, 77(8) control
Age range: not reported
Smokers: not reported
Hypertension: 72%
Medications taken by at least 50% of those in the control group: statin, renin-angiotensin system in-
hibitors
Medications taken by 20%-49% of those in the control group: anti-arrhythmic drugs
Medications taken by some, but less than 20% of the control group: not reported
Location: Australia
Ethnicity: not reported
Interventions Type: omega 3 capsule
Comparison: EPA + DHA vs nil
Intervention: a triglyceride preparation containing a total of 6 g/day of omega-3 polyunsaturated fatty
acids of which 1.8 g/day were n-3 (1.02 g EPA and 0.72 g DHA). Dose: 1.8 g/d EPA + DHA
Control: no supplements
Compliance: measured by weekly dietary history and pill count. Fatty acid status measured at ran-
domisation and between 1-3 months post randomisation (blood samples).
Duration of intervention: median 378 days
Outcomes Main study outcome: atrial fibrillation burden
Dropouts: 1 intervention, 0 control
Available outcomes: all cause mortality, CV mortality, AF (frequency and duration but not recurrence so
not used), adverse events
Response to contact: written but no contact yet
Notes Study funding: unclear
Kumar 2013 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was performed using sequentially numbered, opaque, sealed
envelopes.
Allocation concealment
(selection bias)
Low risk As above
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open label design
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "At each visit, stored AT/AF diagnostic data were retrieved in an un-
blinded fashion"
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Only 1 lost, and reason explained. 21 of the 39 randomised to the intervention
were crossed over to control at 6 months so 12-month outcomes are reported
for 17/18 intervention while baseline characteristics are reported for the 39 pa-
tients.
Selective reporting (re-
porting bias)
Low risk Trial prospectively registered and outcomes stated were reported
Attention Unclear risk As only the intervention group had supplements there was potential for atten-
tion differences. Other contact appears the same.
Compliance Low risk EPA was 3-fold higher and DHA 1.8 fold higher compared with controls. EPA
and DHA did not change significantly in controls upon repeat testing
Other bias High risk Odd design – 21 of the 39 randomised to the intervention were crossed over to
control at 6 months
Kumar 2013  (Continued)
 
 
Methods RCT- parallel, 2 arms (omega 3 vs corn oil), 12 months
Summary risk of bias: low
Participants People with Crohn's disease in remission (but with a recent relapse)
N: 70 intervention, 63 control
Level of risk for CVD: low
Men: 35.7% intervention, 27.0% control
Mean age in years (SD): 29.5 (9.6) intervention, 31.8 (10.9) control
Age range: 17-62 years intervention, 17-65 years control
Smokers: not reported
Hypertension: not reported
Lorenz-Meyer 1996 
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Medications taken by at least 50% of those in the control group: methylprednisolone (all for 1st 8
weeks)
Medications taken by 20%-49%: not reported
Medications taken by some, but < 20%: not reported
Location: Germany
Ethnicity: not reported
Interventions Type: supplement (fish oil)
Comparison: EPA + DHA vs omega 6
Intervention: 2 × 3 1 g gelatin capsules/d of ethylester fish oil concentrate (3.3 g/d EPA + 1.8 g/d DHA).
Dose: 5.1 g/d EPA + DHA
Control: 2 × 3 1 g gelatin capsules/d of corn oil
Compliance: pill count, 5 non-compliant patients, among compliant patients, 18 were censored (for not
using the medication for 3 continuous weeks)
Duration of intervention: 12 months
Outcomes Main study outcome: Crohn's disease duration of remission
Dropouts: unclear
Available outcomes: mortality (nil), Crohn's disease activity and relapses, serum triglycerides
Response to contact: yes (methodological details provided)
Notes There was a third arm of dietary advice (for low CHO diet)
Study funding: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised within the centres in blocks of six (block size blinded to the cen-
tres)
Allocation concealment
(selection bias)
Low risk Author reported allocation was concealed
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double blind conditions were intended for the verum-placebo com-
parisons". Author stated that capsules were identical in appearance (taste not
mentioned).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Primary outcome was relapses "classified in a blind fashion by a primary end-
point committee"
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Participants were accounted for based on the main outcome of the study (re-
lapses), however 20% omitted from analyses and numbers confusing
Lorenz-Meyer 1996  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk No trials registry entry or protocol found
Attention Low risk All patients were seen by their physician in the respective centre after regular
time intervals (1, 2, 3, 6, 9 and 12 months).
Compliance Unclear risk Pill count, 5 non-compliant patients, among compliant patients, 18 were cen-
sored (for not using the medication for three continuous weeks). 23 of 133
non-compliant
Other bias Low risk None noted
Lorenz-Meyer 1996  (Continued)
 
 
Methods Multidomain Alzheimer Preventive Trial (MAPT)
4 arms RCT, parallel, (n-3 ± multidomain intervention vs placebo ± multidomain intervention), 36
months
Summary risk of bias: low
Participants Population: people aged at least 70 years without dementia but with memory complaint, IADL limita-
tion or slow gait speed
N: 840 intervention (arms 1 and 3), 840 control (arms 2 and 4) randomised. Numbers analysed differ by
outcome.
Level of risk for CVD: low
Men: 37.2% intervention, 34.5% control. (combined groups)
Mean age in years (SD): 75.6 (4.7) and 74.4 (4.4) intervention, 75.1 (4.3) and 75 (4.1) control
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: France and Monaco
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs paraffin oil (non-fat)
Intervention
Arm 1: omega-3 (V0137 CA 800 mg/d DHA; 225 mg/d EPA in soW caps). Dose for arms 1 and 3: 1.025 g/d
EPA + DHA
Arm 3: omega 3 (V0137 CA 800 mg/d DHA; 225 mg/d EPA in soW caps) plus multi-domain intervention
(nutrition, physical exercise, cognitive stimulation, social activities)
MAPT 2017 
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Control:
Arm 2: placebo capsules containing flavoured paraffin oil. All capsules were supplied by Pierre Fabre
Médicament (Castres, France)
Arm 4: placebo capsules plus multi-domain intervention (nutrition, physical exercise, cognitive stimu-
lation, social activities)
Compliance: adherence to study interventions was assessed every 6 months. For supplementation, ad-
herence was assessed by counting the number of capsules returned by participants (or based on treat-
ment dates if the number of capsules was missing). Furthermore, biological samples were obtained at
baseline and after 12 months to assess concentrations of DHA and EPA in red blood cell membranes.
Duration of intervention: 36 months
Outcomes Main study outcome: change in cognitive function )
Dropouts: 200 intervention, 194 control
Available outcomes: mortality, CVD events, haemorrhagic stroke, adverse events, functional capacity,
other cognitive functions, safety and tolerability
Response to contact: no
Notes Study funding: Gérontopôle of Toulouse, the French Ministry of Health (PHRC 2008, 2009), the Pierre
Fabre Research Institute (manufacturer of the polyunsaturated fatty acid supplement), Exhonit Thera-
peutics, and Avid Radiopharmaceuticals
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were randomly assigned (1:1:1:1) to the combined intervention
(i.e. the multidomain intervention plus polyunsaturated fatty acids), the mul-
tidomain intervention plus placebo, polyunsaturated fatty acids only, or place-
bo only. A computer-generated randomisation procedure (done by ClinInfo, a
subcontractor) was used with block sizes of 8 and stratification by centre.
Allocation concealment
(selection bias)
Low risk A clinical research assistant, who was not involved in the assessment of partic-
ipants, used a centralised interactive voice response system to identify which
group to allocate the participant to, and which lot number to administer.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk All participants and study staC were blinded to polyunsaturated fatty acid or
placebo assignment – both sets of capsules looked and tasted identical. In
view of the nature of the multidomain intervention, the study was unblind-
ed for this component, but the independent neuropsychologists who were
trained to assess cognitive outcomes were blinded to group assignment.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk All participants and study staC were blinded to polyunsaturated fatty acid or
placebo assignment—both sets of capsules looked and tasted identical. In
view of the nature of the multidomain intervention, the study was unblind-
ed for this component, but the independent neuropsychologists who were
trained to assess cognitive outcomes were blinded to group assignment. Data
analysts were not blinded to group assignment, but two data managers, one
statistician (CC) and two physicians (SA and BV) did a blinded data review.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 1680 participants were enrolled and randomly allocated, the modified inten-
tion-to-treat population (N = 1525), i.e. 155 excluded (9% over 3 years)
MAPT 2017  (Continued)
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Selective reporting (re-
porting bias)
Low risk Protocol registered ClinicalTrials.gov (NCT00672685) – outcomes match re-
port. Because of advances in the field since our trial was designed in 2007, we
decided to modify the primary outcome from one cognitive test to a composite
cognitive score, which is now thought to be a better endpoint.
This protocol amendment was submitted to the local ethical committee on 2
February 2015 and was subsequently approved
Attention Low risk Both groups assessed at baseline, 6, 12, 24, 36 months. Groups 1 and 2 only dif-
fered by content of capsules.
Compliance Unclear risk Adherence to study interventions was assessed every 6 months, by counting
the number of capsules returned (or based on treatment dates if the number
of capsules was missing). Biological samples were obtained at baseline and af-
ter 12 months to assess concentrations of DHA and EPA in red blood cell mem-
branes, but outcomes not reported.
Other bias Low risk None noted
MAPT 2017  (Continued)
 
 
Methods Mediterranean alpha-linolenic enriched Groningen dietary intervention study (MARGARIN)
RCT, factorial 2 × 2 (ALA rich margarine vs LA rich margarine, also nutrition education vs no education
but this is not included), 2 years
Summary risk of bias: low
Participants Hypercholestrolemic adults with 2 or more CVD risk factors
N: total 282 randomised; 114 intervention (51 with nutrition education, 58 without NE) 157 control (52
with NE, 105 without NE)
Level of risk for CVD: moderate (multiple cardiovascular risk factors, 10-year IHD risk ˜20%)
Men: 41.9% intervention, 45.7% control
Mean age in years (SD): 54.4 (9.5) intervention, 53.9 (9.8) control
Age range: 30-70
Smokers: 49.1% intervention, 49.3% control
Hypertension: 52.9% intervention, 45.3% control (on anti-hypertensives)
Medications taken by at least 50% of those in the control group: antihypertensives
Medications taken by 20%-49%: not reported
Medications taken by some, but < 20%: not reported
Location: the Netherlands
Ethnicity: not reported
Interventions Type: supplementary food (ALA enriched margarine)
Intervention: provided with ALA rich margarine (80% fat of which 15% was ALA and 46% LA) to be eaten
ad libitum. Dose: average intake 6.3 g/d ALA (was also 1 g/d ALA in the control group).
MARGARIN 2002 
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Control: provided with linoleic rich margarine (80% fat of which 0.3% was ALA and 58% LA), identical in
taste and packaging. Both margarines contained 0.66 mg vit E/g, 9 micro-g vit A/g and 0.023 micro-g vit
D/g
Comparison: ALA vs omega 6
Compliance: serum fatty acids used to assess, ALA rose by 0.47 mol % (SD 0.04) and 0.36 mol% (SD
0.04) intervention arms (with and without NE) and fell by 0.06 mol % (SD 0.04) and 0.11 mol % (SD 0.03)
control arms (with and without NE), significantly different.
Duration of intervention: 24 months
Outcomes Main study outcome: cardiovascular risk factors and IHD risk
Dropouts: unclear
Available outcomes: total and CV deaths, non-fatal MI, stroke, CABG and angioplasty, BMI, lipids, BP
Response to contact: yes
Notes Study funding: Prevent fund and Unilever Research
Other intervention (2 × 2) was educational, teaching a multifactorial dietary intervention. It was exclud-
ed as multifactorial.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random allocation, allocated by an independent trial co-
ordination centre that organised masked distribution of margarines
Allocation concealment
(selection bias)
Low risk Allocated by an independent trial coordination centre which organised
masked distribution of margarines
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Double-blind; the 2 margarines are described as identical as to taste and pack-
aging (though not reported as checked)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk 2 independent physicians, a cardiologist and a general practitioner validated
and classified results in a blinded fashion
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk The number randomised to each arm was unclear, but one publication clari-
fies (55 randomised to each arm, 51 intervention and 52 control analysed).
Selective reporting (re-
porting bias)
Unclear risk No study protocol or trials registry entry was found.
Attention High risk There was no difference in attention between margarine types, but the dietary
advice group spent more time with study staC than the control group, and
some (not quite randomly allocated) were sent individual motivational letters
(Siero 2000).
Compliance Low risk Serum fatty acids used to assess, ALA rose by 0.47 mol% (SD 0.04) and 0.36 mol
% (SD 0.04) intervention arms (with and without NE) and fell by 0.06 mol % (SD
0.04) and 0.11 mol % (SD 0.03) control arms (with and without NE), Significant-
ly different
Other bias Low risk No further bias noted
MARGARIN 2002  (Continued)
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Methods Modulation of Atherosclerosis Risk by Increasing dose of n-3 fatty Acids (MARINA)
RCT, parallel, 4 arms (n-3 PUFA 3 different doses or olive oil placebo), 12 months
Summary risk of bias: low
Participants Non-smoking men and women aged 45-70 years
N: intervention. 279 in 3 groups (G1 0.45 g/d n = 94, G2 0.9 g/d n = 93, G3 1.8 g/d n = 92); control: 88
(analysed G1 0.45 g/d n = 81, G2 0.9 g/d n = 80, G3 1.8 g/d n = 80, control 71)
Level of risk for CVD: low
Men: 38.7% intervention, 38.6% control
Mean age in years (CI): G1: 55 (53, 56), G2: 55 (54, 56), G3: 55 (54, 57) intervention 55 (54,57) control
Age range: 45-70
Smokers: 0% intervention, 0% control
Hypertension: 5.4% intervention, 5% control
Medications taken by at least 50% of those in the control group: none
Medications taken by 20%-49% of those in the control group: none
Medications taken by some, but less than 20% of the control group: statins, antihypertensives, HRT,
thyroxine
Location: UK
Ethnicity: G1: white 80.9%, black 4.3%, Asian 6.4%, East Asian 4.3%, other 4.3%
G2: white 78.5%, black 6.5%, Asian 10.8%, East Asian 0%, other 4.3%
G3: white 85.9%, black 1.1%, Asian 2.2%, East Asian 4.3%, other 6.5%
Control: white 77.3%, black 10.2%, Asian 6.8%, East Asian 2.3%, other 3.4%
Interventions Type: supplement (fish oil capsules)
Comparison 1: EPA + DHA vs MUFA
Comparison 2: high EPA + DHA vs low EPA + DHA
Intervention: 3 × 1 g oil gelatin capsule/day consisting of blend of EPA concentrate, DHA concentrate,
refined olive oil and 0.1% peppermint oil. Providing a daily dose of: 0.45 g, 0.9 g, or 1.8 g per day (all
with EPA/DHA ratio of 1.51). Dose: 1.8 g/d EPA + DHA (G3 used for outcomes)
Control: 3 gelatin capsules/ day containing refined olive oil + 0.1% peppermint oil
Compliance: measured by capsule counting and erythrocyte lipids for proportion of EPA/DHA @ base-
line, 6 months, 12 months. 88.5% of participants consumed > 90% of capsules provided. EPA and DHA
in erythrocyte lipids increased in dose-dependent manner compared with placebo, indicating long-
term compliance with intervention.
Length of intervention: 12 months
Outcomes Main study outcome: endothelial function, arterial stiffness
Dropouts: 38 intervention (13,13,12), 17 control
MARINA 2011 
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Available outcomes: lipids, dietary intake, CRP, BP (supine and ambulatory – numeric data not provid-
ed, but study states that there were no significant differences between arms). Weight data not used as
baseline is different between groups (FMD, arterials stiffness, carotid intima media thickness, heart rate
variability, heart rate, endothelial progenitor cells reported but not used)
Contact with authors: yes (many outcomes above provided in end of study report from authors)
Notes Outcome data used G3 (highest dose) vs placebo for continuous outcomes and combined the 3 inter-
vention groups vs placebo for dichotomous outcomes
Study funding: Food Standards Agency
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "the random allocation sequence was generated with a computer pro-
gram by using the process of minimisation to balance age, sex and ethnicity
between treatment groups."
Allocation concealment
(selection bias)
Low risk Quote: "We enrolled eligible participants and the study database program al-
located a serious of capsules to the participant. The treatments associated
with the capsule codes were concealed from all investigators and associated
clinical staC until the data analysis was complete. The code breaker was an
employee of MedSciNet who constructed the trial database."
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "We enrolled eligible participants and the study database program al-
located a serious of capsules to the participant. The treatments associated
with the capsule codes were concealed from all investigators and associat-
ed clinical staC until the data analysis was complete. The code breaker was
an employee of MedSciNet who constructed the trial database." "blends of
the test fat with 0.1% peppermint oil to disguise the fish taste of the EPA and
DHA" (peppermint oil in both intervention and control capsules)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "We enrolled eligible participants and the study database program al-
located a serious of capsules to the participant. The treatments associated
with the capsule codes were concealed from all investigators and associated
clinical staC until the data analysis was complete. The code breaker was an
employee of MedSciNet who constructed the trial database."
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 15% withdrawal, reasons for attrition reported
Selective reporting (re-
porting bias)
Low risk Outcomes published match trials register. Registered September 2008, trial
started June 2008, ended December 2010, main publication 2011
Attention Low risk No difference between groups
Compliance Low risk Statistically significant difference in erythrocyte omega 3 fats at 12 months be-
tween different arms
Other bias Low risk None noted
MARINA 2011  (Continued)
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RCT, parallel, (walnut rich moderate fat diet vs moderate fat diet), 12 months
Summary risk of bias: moderate or high
Participants Overweight and obese women, of whom half were insulin resistant
N: 82 intervention, 81 control (analysed, intervention: 65 control: 61)
Level of risk for CVD: low
Men: 0% intervention, 0% control
Mean age (SD) years: 51 (NR) intervention, 50 (NR) control
Age range: 22-67 years intervention, 25-72 years control
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: 10% were on cholesterol medica-
tions
Location: USA
Ethnicity: Hispanic 18% intervention, 14% control; black 9% intervention, 3% control; Asian American
1% intervention, 4% control; white non-Hispanic 71% intervention, 78% control.
Interventions Type: food and advice
Comparison: walnut rich moderate fat diet (ALA) vs moderate fat diet (MUFA)
Intervention: advice to follow walnut-rich higher fat diet (35%E fat with limited SFA, MUFA encouraged,
including 42 g/d walnuts (provided by study), 45%E CHO, 20%E protein). Participants given print mate-
rials on diet and exercise, attended group sessions weekly for 1st 4 months, biweekly for next 2 months,
then monthly to 1 year), provided web-based tracking for dietary constituents, scale, pedometer, mea-
suring cups and exercise videos. Regular dietetic and group leader support. Clinic visits were at 0, 6 and
12 months. Dose: ˜4.2 g/d ALA (calculated based on 42 g/d intake of walnuts)
Control: exactly as intervention for goals, materials and support except higher fat diet did not include
walnuts (35% E fat with limited SFA, MUFA encouraged, 45%E CHO, 20%E protein)
Compliance: walnut consumption reported on form and nuts provided. Red blood cell ALA significantly
higher in intervention at 12 months than control
Duration of intervention: 12 months
Outcomes Main study outcome: body weight
Dropouts: 13 of 82 intervention, 12 of 81 control
Available outcomes: weight, waist circumference, HDL and LDL cholesterol, triglycerides, insulin, glu-
cose, HOMA-IR, HOMA-beta, CRP and IL-6 (estradiol, SHBG, nutrient gene interactions, physical activity
and heart rate also presented)
Response to contact: no reply received to date
Notes Study funding: National Cancer Institute and California Walnut Commission
Risk of bias
MENU 2016  (Continued)
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation stratified by age and insulin resistance
Allocation concealment
(selection bias)
Unclear risk No details
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open study, participants were advised on their diets extensively
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Blinding not mentioned, so unclear for their primary outcome, weight
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Paper states ITT analysis but 25 dropouts (15%) not included in 1 year data,
but dropout reasons clear
Selective reporting (re-
porting bias)
Low risk Pre-registered, all mentioned outcomes reported at 12 months
Attention Low risk Appear very equal
Compliance Low risk Statistically significant difference between intervention and control arms for
ALA in blood cell membranes at 12 months
Other bias Low risk None noted
MENU 2016  (Continued)
 
 
Methods RCT, parallel, (EPA capsules vs nil), 2 years
Summary risk of bias: moderate to high
Participants Japanese type 2 diabetics
N: intervention. 40, control: 41 (analysed 30, 30)
Level of risk for CVD: moderate
Men: 53% intervention, 67% control
Mean age in years (SD): 59 (11.2) intervention 61.2 (8.4) control
Age range: not reported
Smokers: 40% intervention, 43% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: oral hypoglycemics
Medications taken by 20%-49% of those in the control group: insulin, lipid lowering drugs, antihyper-
tensives
Medications taken by some, but less than 20% of the control group: antithrombotics
Mita 2007 
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Location: Japan
Ethnicity: 100% Japanese
Interventions Type: supplement (EPA oil capsules)
Comparison: EPA vs nil
Intervention: 1800 mg/d EPA EPADEL capsules (Mochida Pharmaceutical Co Ltd Japan)- 98% pure eth-
yl-ester EPA (unclear how many caps). Dose: ˜1.8 g/d EPA
Control: no intervention
Compliance: checked during 3 month reviews throughout trial and 5 participants were excluded for
poor compliance but no details on method or results
Length of intervention: mean 2.1 (0.2) years
Outcomes Main study outcome: progression of diabetic macroangiopathy measured by carotid intima-media
thickness and brachial-ankle pulse wave velocity
Dropouts: 10 intervention, 11 control
Available outcomes: BMI, lipids, BP, HbA1c, cancer diagnosis
Response to contact: not yet attempted
Notes Blood pressure data not used as groups are different at baseline
Study funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Patients randomly divided into 2 groups matched for age and gender
Allocation concealment
(selection bias)
Unclear risk No details
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Assessors of main study outcomes were blinded to the treatment
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Dropout rate (26%) over 2 years. All dropouts explained, however, 5 were ex-
cluded for poor compliance but no clear predefined protocol for exclusion
Selective reporting (re-
porting bias)
Unclear risk No protocol
Attention Low risk All participants had the same contact
Compliance Unclear risk Compliance measured but no clear methods or reported results
Mita 2007  (Continued)
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
150
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Other bias Low risk None noted
Mita 2007  (Continued)
 
 
Methods Nutritional AMD Treatment-2 (NAT2)
RCT, parallel, (EPA + DHA vs MUFA), 36 months
Summary risk of bias: low
Participants Patients with early age related macular degeneration
N: 150 intervention, 150 control
Level of risk for CVD: high (92.5% intervention and 79.8 controls had past CVD)
Men: 31.3% intervention, 39.5% control
Mean age in years (SD): 73.9 (6.6) intervention, 73.2 (6.8) control
Age range: 55-85
Smokers: 6.7% intervention, 8.5% control
Hypertension: 58% total (not reported by study arm)
Medications taken by at least 50% of those in the control group: lipid-lowering medication
Medications taken by 20%-49% of those in the control group: agents acting on renin-angiotensin sys-
tem, anti-inflammatory and anti-rheumatic products
Medications taken by some, but less than 20% of the control group: insulin or blood sugar lowering
drugs
Location: France
Ethnicity: unclear
Interventions Type: supplement (fish oil capsule)
Comparison: EPA + DHA vs MUFA
Intervention: 3 daily fish oil capsules containing 1110 total n-3 FAs (EPA: 270 mg/day DHA: 840 mg/day)
and vit E: 6 mg/day. Dose: 1.1 g/d EPA + DHA
Control: 3 × 602 mg olive oil capsules a day containing 0.2 g total PUFA and vit E: 0.09 g/d
Compliance: assessed during visits from unused capsules and serum PUFA levels. Overall compliance
over the 3 years; 69.4% intervention, 70.5% control
Length of intervention: 36 months
Outcomes Main study outcome: time to occurrence of choroidal new vessels (CNV) in the study eye from prospec-
tive assessment of fluorescein angiography
Dropouts: 29 intervention, 34 control
Available outcomes: all cause mortality, plasma lipids, adverse events, serum FAs
Response to contact: yes (no added data)
Notes TG data not used as presented as median (5th-95th percentile)
NAT2 2013 
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Study funding: Laboratoire Chauvin, Bausch & Lomb Inc
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk QL Ranclin software was used to generate the randomisation list before en-
rolment. The patients and the study personnel both were blinded to the treat-
ment assignment
Allocation concealment
(selection bias)
Low risk As above
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk The capsules had the same appearance, the same size, and the same weight
(602 mg) in both DHA and placebo groups. No masking flavour was added to
the capsules, which were otherwise odourless
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Author confirmed blinding of outcome assessors
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Any temporary discontinuation of the treatment was considered to be a de-
viation from the study protocol. Discontinuation for more than 5 months was
considered to be a major deviation from the study protocol. Participants who
dropped out were taken in account in the survival analysis and occurrence of
CNV and were counted at last angiography performed.
Selective reporting (re-
porting bias)
Unclear risk ISRCTN98246501. Retrospectively registered May 2007, recruitment started
December 2003, completed November 2008, key publication 2013
Attention Low risk Same amount of time spend with both study arms
Compliance Low risk Assessed during visits from unused capsules and serum PUFA levels. Overall
compliance over the 3 years; 69.4% intervention, 70.5% control
Other bias Low risk None noted
NAT2 2013  (Continued)
 
 
Methods RCT, parallel, (DHA + EPA vs MUFA), 12 months
Summary risk of bias: moderate or high
Participants Patients with persistent atrial fibrillation with at least 1 relapse after cardioversion
N: 102 intervention, 103 control. (analysed, intervention: 94 control: 94)
Level of risk for CVD: high
Men: 70% intervention, 63% control
Mean age in years (SD): 70 (6) intervention, 69 (9) control
Age range: not reported (18-80 inclusion criteria)
Smokers: 10% intervention, 9.1% control
Nodari 2011 AF 
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Hypertension: 47% intervention, 40% control
Medications taken by at least 50% of those in the control group: beta-blockers, ACE inhibitors, antico-
agulant therapy, amiodarone
Medications taken by 20%-49% of those in the control group: diuretics, antiplatelet, statins
Medications taken by some, but less than 20% of the control group: calcium channel blockers
Location: Italy
Ethnicity: not reported
Interventions Type: supplement (omega-3-acid ethyl esters 90: Omacor)
Comparison: EPA + DHA vs MUFA
Intervention: 2 × 1 g/d Omacor (total 1.7 g/d EPA + DHA at a ratio of 0.9 to 1.5). Dose: 1.7 g/d EPA + DHA
Control: 2 × 1 g/d olive oil (gelatin capsules identical in appearance to Omacor)
Compliance: no details
Duration of intervention: 12 months
Outcomes Main study outcome: probability of maintenance of sinus rhythm
Dropouts: 6 intervention, 5 control
Available outcomes: adverse events, AF recurrence (nil death)
Response to contact: no
Notes Study funding: 'Centro per lo Studio ed il Trattamento dello Scompenso Cardiaco' of the University of
Brescia, Brescia, Italy. The work of Dr Campia was supported by National Institutes of Health grant K12
HL083790-01a1
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random assignment followed a computer-generated randomisation list ob-
tained using blocks of size 4
Allocation concealment
(selection bias)
Low risk The randomisation schedule was kept in the research pharmacy area and was
available only to unblinded pharmacy personnel until after the database was
locked. At that time, the unblinded patient treatment information was made
available to the investigators.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Placebo gelatin capsules identical in appearance to Omacor. However no in-
formation provided as to their smell and taste.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No details
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised were accounted for. ITT analysis for main outcomes
Nodari 2011 AF  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk NCT01198275. Registered retrospectively in September 2010, study started
January 2006, completed May 2008, main publication 2011
Attention Low risk No difference between groups
Compliance Unclear risk No details
Other bias Low risk None noted
Nodari 2011 AF  (Continued)
 
 
Methods RCT, parallel, (DHA + EPA vs MUFA), 12 months
Summary risk of bias: moderate or high
Participants People with heart failure (non-ischaemic dilated cardiomyopathy)
N: 67 intervention, 66 control. (analysed, intervention: 67 control: 66)
Level of risk for CVD: high
Men: 95.5% intervention, 84.9% control
Mean age in years (SD): 61 (11) intervention, 64 (9) control
Age range: not reported (18-75 inclusion criteria)
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: beta-blockers, ACE inhibitors,
furosemide, amiodarone, aldosterone blockers
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: statins, ARB
Location: Italy
Ethnicity: not reported
Interventions Type: supplement (Omacor)
Comparison: EPA + DHA vs MUFA
Intervention: 2 × 1 g/d Omacor (1.7 g/d EPA + DHA at a ratio of 0.9 to 1.5)
Control: 2 × 1 g/d olive oil (gelatin capsules identical in appearance to Omacor)
Compliance: pill counts – participants were withdrawn if < 80% capsules taken (none were withdrawn).
Fatty acid EPA + DHA 0.83% in intervention group, 0.41% in control group.
Duration of intervention: 12 months
Outcomes Main study outcome: leW ventricular function and functional capacity
Dropouts: 0 intervention, 0 control
Nodari 2011 HF 
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Available outcomes: mortality (nil death), combined CVD events, AF, BMI, hospitalisation for cardio-
vascular reasons, hospitalisation for worsening heart failure, lipids, blood glucose (but too different at
baseline to use), serum cytokine
Response to contact: yes
Notes Study funding: Centro per lo Studio ed il Trattamento dello Scompenso Cardiaco, one author was a
consultant for 8 pharmaceutical companies
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomised"
Allocation concealment
(selection bias)
Unclear risk Not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Paper states that placebo and verum were identical and that the study was
double blind, but blinding of participants not checked. Author confirmed in-
vestigators not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Author confirmed assessors not blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear whether all participants were assessed for all outcomes (e.g. hospitali-
sation), but some outcomes report no attrition
Selective reporting (re-
porting bias)
Unclear risk NCT01223703 – study registration October 2010, recruitment November 2007
to June 2009. Retrospective
Attention Low risk No suggestion of this, and investigators appeared blinded (so could not differ
in attention provided by allocation)
Compliance Low risk See characteristics table
Other bias Low risk None noted
Nodari 2011 HF  (Continued)
 
 
Methods RCT, parallel, (MorDHA capsules vs unclear placebo), 14 months
Summary risk of bias: moderate or high
Participants Patients with chronic traumatic spinal cord injury
N: 55 intervention, 55 control. (analysed, intervention: 54 control: 50)
Level of risk for CVD: low
Men: 81.5% intervention, 82% control
Mean age in years (SD): 51.15 (13.43) intervention, 54.12 (11.76) control
Norouzi 2014 
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Age range: 15-74 years intervention, 30-74 years control
Smokers: 0% (exclusion criteria)
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Iran
Ethnicity: not reported
Interventions Type: supplement (n-3 capsules)
Comparison: EPA + DHA vs placebo (unclear what)
Intervention: 2 MorDHA capsules (providing 870 mg DHA and 130 mg EPA) per day. Dose: 1 g/d DHA +
EPA
Control: 2 placebo capsules per day. Both capsules were similar in colour, shape, and taste. Both
groups received one calcium capsules per day consisting of 1000 mg calcium and 400 IU vitamin D.
Compliance: pill counts – compliance averaged 80% in both groups
Duration of intervention: 14 months
Outcomes Main study outcome: professionals evaluation of neurological function
Dropouts: 1 intervention, 5 control
Available outcomes: functional measures (total and sub-scales), BMI, leptin and adiponectin concen-
tration.
Response to contact: no
Notes Study funding: PhD university funding. Omega 3 capsules were provided by Minami Nutrition Co (Aart-
selaar, Belgium) and placebo capsules were supplied by Zahravi Pharmaceutical Co. (Tabriz, Iran). Cal-
cium capsules were provided by Darou Pakhsh Pharm Co. (Tehran, Iran)
Data were collected at the beginning of the study and after 14 months
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised using permuted balanced block randomisation method
Allocation concealment
(selection bias)
Unclear risk No further detail on allocation
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Stated as double blind but content of placebo not stated and no report of at-
tempt to mask n-3 FA taste.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Unclear, few details
Norouzi 2014  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Attrition was 1 in intervention group, 5 in control group, so minor. "the two
most common reasons for dropouts were experiencing GI side effects or diffi-
culty to maintain scheduled clinic visits"
Selective reporting (re-
porting bias)
High risk Some of the outcomes stated in the trial register are not reported. Registered
March 2011, study start November 2010, completion April 2012
Attention Low risk No difference between groups
Compliance Unclear risk Pill counts – compliance averaged 80% in both groups
Other bias Low risk None noted
Norouzi 2014  (Continued)
 
 
Methods Norwegian Vegetable Oil Experiment of 1965-6
RCT, parallel, 2 arms (ALA linseed oil vs omega 6 sunflower oil), 1 year
Risk of bias: moderate or high
Participants Men working in Norwegian companies aged 50-59 years
N: 6716 intervention, 6690 control
Level of risk for CVD: low (working men, though a few had had a previous MI or angina)
Men: 100%
Mean age in years (SD): unclear
Age range: 50-59 years
Smokers: unclear (˜48% non-smokers)
Hypertension: unclear
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Norway
Ethnicity: unclear
Interventions Type: supplementary food (oil)
Comparison: ALA vs omega 6
Intervention: linseed oil, 10 mL/d (55% ALA), 5.5 g/d ALA, 1.5 g/d linoleic. Dose: 5.5 g/d ALA
Control: sunflower oil, 10 mL/d (1.4% ALA), 0.1 g/d ALA, 6.3 g/d linoleic. Vitamin E was added to both
oils.
Compliance: 73% were still taking the linseed oil at 1 year, 72% were still taking their sunflower oil at 1
year (unclear how this was ascertained)
Duration of intervention: 12 months
Outcomes Main study outcome: morbidity and mortality
Norwegian 1968 
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Dropouts: survival status was traced for all but 4 included men, health status was missing for about 80
men in total or 0.6%.
Available outcomes: total and CV deaths, MI, angina, stroke, peripheral vascular disease, combined CV
events, total cholesterol (subgroup)
Response to contact: no
Notes Study funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Paper states "simple randomisation" without clarification
Allocation concealment
(selection bias)
Unclear risk Few details provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Paper states that the workplace doctors who administered the trial locally
were sent bottles for each participant marked only with their trial number, and
that "appearance and taste of the products were so similar that most partici-
pants were unable to identify the type"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Company physicians recorded health status, and were also blinded to inter-
vention (as above)
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Detailed description, and those who leW employment during the study were
followed up for survival and morbidity via the main health system
Selective reporting (re-
porting bias)
Unclear risk No protocol or trials registration found
Attention Low risk As company physicians administered oils and assessed outcomes but were
blind to treatment arm there could not be attention bias
Compliance Unclear risk 73% were still taking the linseed oil at 1 year, 72% were still taking their sun-
flower oil at 1 year (unclear how this was ascertained)
Other bias Low risk No further bias noted
Norwegian 1968  (Continued)
 
 
Methods Nutristroke
RCT, parallel, (diet rich in vitamins and omega 3 plus omega 3 supplement vs diet rich in vitamins and
omega 3), 12 months
Summary risk of bias: moderate or high
Participants People in a rehabilitation unit who had survived a stroke
N: 38 intervention, 34 control. (analysed, intervention: 32 control: 20)
Level of risk for CVD: high
Nutristroke 2009 
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Men: 74% intervention, 56% control
Mean age in years (SD): 61.3 (13.6) n-3, 66.3 (11.4) n-3 + antioxidant intervention, 68.4 (12.6) placebo,
65.1 (12.8) antioxidant – control
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Italy
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: fish oil vs unclear placebo
Intervention: fish oil gelatin capsules including 250 mg DHA + 250 mg EPA. Dose: 0.5 g/d EPA + DHA
Control: "identical to supplement but contained no antioxidants or polyunsaturated fatty acids"
Compliance: appears to have been assessed at meetings or on the phone monthly, but results unclear
Duration of intervention: 12 months
Outcomes Main study outcome: functional status in stroke survivors
Dropouts: 6 intervention, 14 control
Available outcomes: mortality and cardiovascular mortality, lipids (6 months), albumin and lympho-
cyte counts (6 months), Barthel Index (functional status), neurological impairment (not reported by in-
tervention group), mobility, adiposity (no numerical data presented; quote: "there were no statistical-
ly significant differences in body weight, BMI, arm circumference and triceps skin fold at the different
time points")
Response to contact: not yet attempted
Notes 2 × 2 study that also had an antioxidant supplementary focus (supplementary vitamins C and E, beta
carotene and polyphenols)
Study funding: Italian Ministry of Health, Sigma-Tau Health Science provided omega 3 capsules
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized by means of a specific list"
Allocation concealment
(selection bias)
Unclear risk Randomisation methodology not mentioned
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Quote: "the placebo was identical to the supplement but contained no antiox-
idants or polyunsaturated fatty acids; no patient, research assistant, investiga-
tor or any other medical or nursing staC could distinguish the placebo from the
Nutristroke 2009  (Continued)
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supplements during the study". However, only one placebo discussed and un-
clear whether it was a placebo capsule (for omega 3) or pill (for antioxidants)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "assays were quality control checked by internal standard and calibra-
tion curve in a random and double blind way"
Incomplete outcome data
(attrition bias) 
All outcomes
High risk High rates of dropouts
Selective reporting (re-
porting bias)
Unclear risk No protocol or trials registry entry found
Attention Low risk All assessments and treatments appear equal across the intervention groups
Compliance Unclear risk Appears to have been assessed at meetings or on the phone monthly, but re-
sults unclear
Other bias Low risk None noted
Nutristroke 2009  (Continued)
 
 
Methods Randomisation: parallel, 3 groups (omega 3 vs olive oil vs aspirin and dipyridamole), 1 year
Risk of bias: moderate or high
Participants People undergoing PTCA
N: 36 intervention, 37 control (also 35 allocated to arm 3, aspirin and dipyridamole)
Level of risk for CVD: high (people undergoing angioplasty)
Men: 78% intervention, 76% control
Mean age in years (SD): 54 (8) intervention, 55 (8) control years
Age range: unclear
Smokers: unclear
Hypertension: unclear
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: New Zealand
Ethnicity: unclear
Interventions Type: supplement (capsules)
Comparison: EPA vs MUFA
Intervention: MaxEPA capsules 12/d (2.2 g EPA). Dose: 2.2 g/d EPA
Control: olive oil capsules, 12/d, identical to MaxEPA. Both capsules included vitamin E
Nye 1990 
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Compliance: no data
Length of intervention: 12 months
Outcomes Main study outcome: angina, restenosis
Dropouts: none
Available outcomes: angina, interventions, lipids (Nil death)
Response to contact: no
Notes Study funding: Medical Research Council of New Zealand and Scherer Ltd (who supplied MaxEPA and
the olive oil capsules)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly divided without exclusions into 3 groups"
Allocation concealment
(selection bias)
Unclear risk Unclear, no further info
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk States that placebo capsules were identical to the MaxEPA, and "neither
the patient nor the attending cardiologist knew which capsules were being
used" (but no masking of taste was reported, and participant guesses as to al-
location were not reported)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "neither the patient, nor the attending cardiologist knew which cap-
sules were being used" ... "Angioplasty was repeated electively at one year or
before where symptoms recurred, and assessed without knowledge of the pa-
tient's treatment group."
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Some participants were lost to follow-up and reasons for this were unclear
Selective reporting (re-
porting bias)
Unclear risk No protocol or trials registration found
Attention Low risk No suggestion of attention bias, symptomatic patients were reviewed between
scheduled visits, otherwise all on the same schedule
Compliance Unclear risk No data
Other bias Low risk No further bias noted
Nye 1990  (Continued)
 
 
Methods Omacor Following Acute Myocardial Infarction (OFAMI)
RCT, parallel, 2 arms (omega 3 vs corn oil), 2 years
Summary risk of bias: moderate or high
Participants Patients recruited 4-8 days after confirmed MI
OFAMI 2001 
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N: 150 intervention, 150 control
Level of risk for CVD: high
Men: 77% intervention, 82% control
Mean age in years (SD): 64.4 intervention, 63.6 control (no SD)
Age range: 28-86 years intervention, 29-87 years control
Smokers: 39% intervention, 38% control
Hypertension: 29% intervention, 23% control
Medications taken by at least 50% of those in the control group: b-blockers, aspirin
Medications taken by 20%-49% of those in the control group: statins, ACE inhibitors
Medications taken by some, but less than 20% of the control group: diuretics, warfarin
Location: Norway
Ethnicity: unclear
Interventions Type: supplement (capsules)
Comparison: EPA + DHA vs omega 6
Intervention: 4 gelatin capsules of omega-3-acid ethyl esters 90 (Omacor, Pronova A/S, Oslo, Norway),
each is 1 g containing 850-882 mg EPA and DHA as concentrated ethylesters Dose ˜3.4- 3.5 g/d EPA +
DHA
Control: corn oil capsules, 4/d, each contains 1 g of corn oil
Compliance: assessed by questionnaire and capsule count, 82% intervention group had complete com-
pliance after 6 weeks, 86% of controls
Length of intervention: 24 months
Outcomes Main study outcome: CV events
Dropouts: unclear
Available outcomes: total and CV deaths, MI, unstable angina, interventions, combined CV events, BMI,
lipids, BP (authors provided additional data on glucose, AF, stroke)
Response to contact: yes
Notes Study funding: Pharmacia-Upjohn and Pronova
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly assigned" – Pharmacia was responsible for randomisation.
Author response: participants were randomised in blocks of 4
Allocation concealment
(selection bias)
Low risk Author confirmed allocation was concealed
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Identical capsules containing either Omacor or corn oil. Double blinding stat-
ed, but taste not reported as masked and blinding of participants not checked
OFAMI 2001  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Author stated: all later analyses performed without the knowledge of outcome
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Number of dropouts was unclear
Selective reporting (re-
porting bias)
Unclear risk Trials registry NCT01422317. Outcomes reported in trials registry appear to
have been published, but registration was retrospective.
Attention Low risk All participants appear to have been reviewed at the same intervals
Compliance Unclear risk Assessed by questionnaire and capsule count, 82% intervention group had
complete compliance after 6 weeks, 86% of controls
Other bias Low risk No further bias noted
OFAMI 2001  (Continued)
 
 
Methods Effect of Omega 3 fatty acids on reduction of sudden cardiac death after MI (OMEGA)
2 arm, parallel RCT (omega 3 vs olive oil), 12 months
Summary risk of bias: low
Participants People who have had an acute myocardial infarction
N: 1940 intervention,1911 control (analysed for primary endpoints 1919 intervention, 1885 control)
Level of risk for CVD: high
Men: 75.1% intervention, 73.7% control
Age (median): 64.0 years, intervention, 64.0 years control
Age range: unclear (upper and lower quartiles 54-72)
Smokers: 35.9% intervention, 37.5% control
Hypertension: 66.9% intervention, 66.1% control
Medications taken by at least 50% of those in the control group: statins, ACE inhibitors, beta-blockers,
clopidogrel, aspirin
Medications taken by 20%-49%: diuretics
Medications taken by some, but < 20%: AT1 receptor blockers, vit K antagonist, calcium channel block-
ers, digitalis, amiodarone, oral antidiabetics, insulin
Location: Germany
Ethnicity: not reported
Interventions Type: supplement (capsules)
Comparison: EPA + DHA vs MUFA
Intervention: 1 × 1 g/d Pronova BiCare soW gelatin capsule 'zodin' omega-3 acid ethyl esters (460 mg/d
EPA and 386 mg/d DHA). Dose: 0.85 g/d EPA + DHA
OMEGA 2009 
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Control: 1 × 1 g/d olive oil capsule identical to intervention
Compliance: 93.1% of intervention group and 93.2% of control participants took > 70% of capsules
Duration of intervention: 12 months
Outcomes Main study outcome: sudden cardiac death, cardiac arrest
Dropouts: Control: 26 (8-lost to follow-up, 2-withdrew before allocation, 16-excluded.) intervention: 21
Available outcomes: deaths, CV mortality, MACCE, MI, arrhythmias, heart failure, stroke, revascularisa-
tion, lipids, authors supplied information on angina, depression, cancers, AF
Response to contact: yes
Notes Study funding: Tromsdorff Arzneimittel commissioned the research
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation code generated by alpha med PHARBIL, done in blocks of 8.
Randomisation was stratified by centre.
Allocation concealment
(selection bias)
Low risk Appearance of the drugs or the drug containers did not allow patients and
physicians to deduce the study arm. 4-digit number on a concealed container
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Capsules for placebo and intervention looked the same, randomisation code
unknown to investigator (taste and smell not mentioned)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Classification of adverse events blinded to allocation, and there was a blinded
endpoint committee for all pre-specified outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All events were documented by the investigators and reported to the assigned
clinical research organisation and the sponsor. The data safety monitoring
board judged any imbalances between the study arms.
Selective reporting (re-
porting bias)
Low risk NCT00251134 registered in 2005. Study start date: 2003, Completed: 2008,
study design: 2006, Published paper: 2010. All trials registry primary and sec-
ondary outcomes reported
Attention Low risk Capsules for both arms
Compliance Low risk 93.1% of intervention group and 93.2% of control participants took > 70% of
capsules. EAIC 0.65 intervention, and control
Other bias Low risk None noted
OMEGA 2009  (Continued)
 
 
Methods Older People And n-3 Long-chain polyunsaturated fatty acid (OPAL)
2 arm, parallel, RCT, 12 months
Summary risk of bias: low
OPAL 2010 
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Participants Healthy cognitively normal adults aged 70-79 years
N: 434 intervention, 433 control (analysed 376 intervention, 372 control)
Level of risk for CVD: low
Men: 53.4% intervention, 56.6% control
Mean age in years (SD): 74.7 (2.5) intervention, 74.6 (2.7) control
Age range: 70-79 years
Smokers: not reported
Hypertension: 54.9% intervention, 56.9% control
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49%: not reported
Medications taken by some, but < 20%: not reported
Location: England and Wales
Ethnicity: not reported
Interventions Type: supplement (capsules)
Comparison: EPA + DHA vs MUFA
Intervention: 2 × 650 mg capsule/d Ocean Nutrition vanilla flavoured soW gelatin capsule (total daily
dose of 200 mg EPA and 500 mg DHA). Dose: 0.7 g/d EPA + DHA
Control: 2 × 650 mg olive oil capsule identical to intervention
Compliance: count returned capsules.
Capsules not returned:
• Intervention - median: 0.95; IQR: 0.82, 1.00• Control - median: 0.95; IQR: 0.81, 1.00
Fasting serum fatty acids, mg/L, mean (SD)
• EPA: intervention 49.9, (2.7); control 39.1 (3.1)• DHA: intervention 95.6 (3.1); control, 70.7 (2.9)• α-linoleic: intervention 21.5 (0.8); control 22.0 (0.9)
Length of intervention: 24 months
Outcomes Main study outcome: delayed onset of cognitive decline
Dropouts: control: 78 (8 died, 53 withdrew, 17 discontinued intervention but provided data);
intervention: 67 (9 died, 49 withdrew, 9 discontinued intervention but provided data)
Available outcomes: deaths, MI, arrhythmias, stroke, diabetes, lipids
Response to contact: yes
Notes Study funding: UK Food Standards Agency, NHS R&D provided support costs
Risk of bias
OPAL 2010  (Continued)
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were "selected in random blocks". "Research nurses telephoned
a central computerized randomization service to obtain treatment allocation
codes".
Allocation concealment
(selection bias)
Low risk Central allocation via telephone
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Identical capsules (vanilla-flavoured, dark-brown coloured). Supplements
packaged into identical pots, each containing 180 capsules, labelled by staC
not involved in the study. All project staC were unaware of group assignments
until after data analysis.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk All project staC were unaware of group assignments until after data analysis.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Participants who discontinued the supplements invited to an interview at 24
months. Dropouts explained and similar in both arms (intervention 49 with-
drew, control 53 withdrew)
Selective reporting (re-
porting bias)
High risk ISRCTN72331636. Trial registered 2004, before study began. Protocol pub-
lished 2006. Publication of first results 2010. Many outcomes, such as depres-
sion and BP were stated in trials registry entry but not reported.
Attention Low risk All participants had the same review schedule, and staC were unaware of as-
signments
Compliance Low risk Count returned capsules. Capsules not returned (intervention - median: 0.95;
IQR: 0.82, 1.00; control - median: 0.95; IQR: 0.81, 1.00). Fasting serum fatty
acids, mg/L, mean (SD): EPA, intervention 49.9 (2.7); control 39.1 (3.1). DHA, in-
tervention 95.6 (3.1); control 70.7 (2.9). α-linoleic: intervention 21.5 (0.8); con-
trol 22.0 (0.9)
Other bias Low risk No further bias noted
OPAL 2010  (Continued)
 
 
Methods Outcome Reduction With Initial Glargine Intervention (ORIGIN)
RCT, 2 × 2 factorial, (capsule of n-3 fatty acids or placebo), 72 months
Summary risk of bias: low
Participants People at high risk of CV events with impaired fasting glucose, impaired glucose tolerance or diabetes
N: 6319 intervention, 6292 control. (analysed, intervention: 6281 control: 6255)
Level of risk for CVD: moderate
Men: 65.4% intervention, 64.7% control
Mean age in years (SD): 63.5 (7.8) intervention, 63.6 (7.9) control
Age range: unclear, eligible if aged ≥ 50 years
Smokers: current smokers 12.1% intervention, 12.6% control
ORIGIN 2012 
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Hypertension: 78.7% intervention, 80.3% control
Medications taken by at least 50% of those in the control group: ACE inhibitor or ARB, aspirin or other
antiplatelet, beta-blocker, statin, glucose-lowering drug
Medications taken by 20%-49%: calcium-channel blocker
Medications taken by some, but less than 20%: thiazide diuretics, anticoagulant
Location: 40 study locations in Europe and the Americas
Ethnicity: unclear
Interventions Type: supplement capsule (Omacor)
Comparison: EPA + DHA vs MUFA
Intervention: 1 gelatin capsule/d Omacor containing at least 900 mg ethyl esters of n-3 fats (465 mg EPA
+ 375 mg DHA). Dose: 0.84 g/d EPA + DHA
Control: 1 × 1 g gelatin capsule/d olive oil
Compliance: methods of assessment unclear, but reported that "rates of adherence to the study-drug
regimen were similar in the two groups with 96% of patients continuing to receive the study drug at 1
year ... and 88% at the end of the study".
Length of intervention: 74 months mean follow-up (median 6.2 years)
Outcomes Main study outcome: composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocar-
dial Infarction (MI) or Nonfatal Stroke
Dropouts: 38 intervention, 37 control (some of the remainder did not have final outcome status, were
lost or withdrew consent, but were included in analysis)
Available outcomes: mortality, CV mortality, fatal arrhythmia, MI, stroke, heart failure, angina, revascu-
larisation, breast cancer, cancer diagnoses and cancer deaths, BP, lipids (HbA1c given as medians only)
Response to contact: yes but no data provided
Notes The other 2 × 2 assignment was to insulin glargine versus standard care, and is not discussed here. Re-
sults are reported here for the trial duration and not the follow-up post trial (the ORIGIN and Legacy Ef-
fects, ORIGINALE).
Study funding: Sanofi Aventis, Omacor provided by Pronova Biocare
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomized by an automated telephone randomization system (using
randomly varying block sizes)"
Allocation concealment
(selection bias)
Low risk As above
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Study described as "double blind" and placebo described as identical. Blind-
ing of patients, investigators, local and central trials personnel described.
However, no information provided as to the capsule's smell and taste
ORIGIN 2012  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "all primary and secondary outcomes were adjudicated with the use
of prespecified definitions by a committee whose members were unaware of
study-group assignments"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Almost all participants were included in outcomes
Selective reporting (re-
porting bias)
Low risk NCT00069784 – registered October 2003, study started August 2003, final da-
ta collection December 2011. Most outcomes appear to have been reported
in various publications (cardiovascular events only reported by glargine ran-
domisation).
Attention Low risk No suggestion of differences between groups
Compliance Unclear risk Methods of assessment unclear, but reported that "rates of adherence to the
study-drug regimen were similar in the two groups with 96% of patients con-
tinuing to receive the study drug at 1 year ... and 88% at the end of the study"
Other bias Low risk None noted
ORIGIN 2012  (Continued)
 
 
Methods Omega-3 fatty acids randomised long-term (ORL)
RCT- parallel, 3 arms (TAK-085 2 g, TAK-085 4 g, and EPA-E 1.8 g), 12 months
Summary risk of bias: moderate or high
Participants Population: Japanese adults with hypertriglyceridaemia
N: 171 intervention (4 g TAK), 165 control (2 g TAK)
Level of risk for CVD: moderate
Men: 70.8% intervention, 71.5% control
Mean age in years (SD): 55.9 (10.12) intervention, 56 (10.95) control
Age range: 20-74
Smokers (current): 27.5% intervention, 31.5% control
Hypertension: 66.7% intervention, 67.3% control
Medications taken by at least 50% of those in the control group: HMG-CoA reductase inhibitor
Medications taken by 20%-49%: statin
Medications taken by some, but less than 20%: not reported
Location: Japan
Ethnicity: unclear
Interventions Type: supplement (TAK-085 capsules)
Comparison: EPA + DHA higher vs lower dose
ORL 2013 
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Intervention: 1 × 2/d capsule each containing 2 g of TAK-085 (1 g of fatty acid in TAK-085 capsules con-
tains approximately 465 mg of EPA-E plus 375 mg of DHA-E). Total dose of 1.86 g/d EPA + 1.5 g/d DHA.
Dose: ˜3.4 g/d EPA + DHA) (difference of +1.7 g/d from control arm)
Control: 1 capsule/d containing 2 g of TAK-085 (1 g of fatty acid in TAK-085 capsules contains approxi-
mately 465 mg of EPA-E plus 375 mg of DHA-E). Total dose of 0.93 g/d EPA + 0.75 g/d DHA. Dose: 1.7 g/d
EPA + DHA
Compliance: monitored every 4 weeks, mean rate of compliance reported as > 96% in each group
Length of intervention: 12 months
Outcomes Main study outcome: safety outcomes and adverse events
Dropouts: group 1: 8, group 2: 14, group 3 (not analysed): 21
Available outcomes: adverse events (including CVD events, cancers), CRP, waist circumference, weight,
blood pressure (nil death), lipids provided as % change from baseline, but no baseline data available,
so not used in meta-analyses
Response to contact: no
Notes A third arm of EPA-E 1.8 g supplementation is not used here. Outcome data used TAK-4 vs TAK-2
Study funding: Takeda Pharmaceutical Company
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was stratified according to statin use and performed by an in-
dependent registration centre
Allocation concealment
(selection bias)
Low risk As above
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Open label
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All participants were accounted for and analysed for main outcomes
Selective reporting (re-
porting bias)
Low risk Trials registry entry May 2011, study start date November 2009, completion
November 2011, so partially retrospective. However, entry appears to reflect
reported outcomes.
Attention Low risk Capsules, appears similar
Compliance Low risk Monitored every 4 weeks, mean rate of compliance reported as > 96% in each
group
Other bias Low risk None noted
ORL 2013  (Continued)
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Methods RCT, parallel, (EPA + DHA fish oil vs omega 6 sunola oil), 12 months
Summary risk of bias: low
Participants Patients with rheumatoid arthritis < 12 months' duration, DMARD-naive
N: 87 intervention, 53 control. (analysed, intervention: 75 control: 47)
Level of risk for CVD: low
Men: 29% intervention, 25% control
Mean age in years (SD): 56.1 (15.9) intervention, 55.5 (14.1) control
Age range: unclear
Smokers: 65.1% intervention, 54.7% control (includes current and previous smokers)
Hypertension: not reported
Medications taken by at least 50% of those in the control group: triple DMARD therapy (SSZ 0.5 g/d,
HCQ 200 mg twice/day and MTX 10 mg once per week)
Medications taken by 20%-49% of those in the control group: NSAIDS
Medications taken by some, but less than 20% of the control group: oral or parenteral steroids
Location: Australia
Ethnicity: not reported
Interventions Type: supplement (fish oil)
Comparison: high EPA + DHA vs omega 6 (low EPA + DHA with sunola oil)
Intervention: 10 mL/d fish oil concentrate (BLT Incromega TG3525) providing 5.5 g/day (3.2 EPA + 2.3
DHA). Dose: 5.5 g/d EPA + DHA
Control: 10 mL/d sunola oil:capelin oil (2:1) providing 0.21 g EPA + 0.19 g DHA/d as TAG (0.40 g/day EPA
+ DHA).
Compliance: consumption checked at each visit. 100% compliance would be consumption of 3650 mL
oil at 12 months. The fish oil group was less compliant than the control group with median intakes of
2482 mL and 3248 mL, respectively (P = 0.015, Mann-Whitney U test). This provided an average daily in-
take of EPA + DHA of 3.7 g and 0.36 g in the fish oil and control groups, respectively.
Duration of intervention: 12 months
Outcomes Main study outcome: disease-modifying anti-rheumatic drugs (DMARD) failure and remission
Dropouts: 11 intervention, 6 control
Available outcomes: mortality (nil death), adverse events including CVD, DAS score, diabetes, authors
supplied methodology data plus BMI change
Response to contact: yes
Notes DAS scores are reported as median and IQR in Proudman 2012 abstract
Study funding: National Health Medical Research Council of Australia and Royal Adelaide Hospital Re-
search Committee. Melrose Health provided support for ongoing studies. The oil was made by the Roy-
al Adelaide Hospital Pharmacy
Proudman 2015 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The randomisation schedule was prepared using an online random
number generator and involved randomly permuted blocks of size six."
Allocation concealment
(selection bias)
Low risk Quote: "Randomisation was performed by the RAH pharmacy, which also pre-
pared and provided the study oils in 500 mL identical dark brown bottles la-
belled with consecutive study numbers"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Both participants and investigators/assessors were blinded to the
group allocation. Although the control oil was paler in colour than the fish oil,
this was not evident in the brown bottles. The 'fishy' odour of each oil was sim-
ilar."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Both participants and investigators/assessors were blinded to the group al-
location. Quote: "Investigators and subjects remained blinded for all with-
drawals."
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk The flow of all study participants shown in FIGURE 2
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported in trial register matched with the outcomes reported in
publications. However, the study was retrospectively registered – registered in
2013, recruitment began in 2001
Attention Low risk No difference between groups
Compliance High risk Consumption checked at each visit. 100% compliance would be consumption
of 3650 mL oil at 12 months. The fish oil group was less compliant than the
control group with median intakes of 2482 mL (68%) and 3248 mL (89%), re-
spectively (P = 0.015, Mann-Whitney U test). This provided an average daily in-
take of EPA + DHA of 3.7 g and 0.36 g in the fish oil and control groups, respec-
tively
Other bias Low risk None noted
Proudman 2015  (Continued)
 
 
Methods RCT, parallel (ethyl-EPA vs paraffin), 2 arm, 12 months
Summary risk of bias: low
Participants People with Huntington's Disease
N: 67 intervention, 68 control (analysed, intervention: 39 control: 44)
Level of risk for CVD: low
Men: 57% intervention, 44% control
Mean age in years (SD): 50 (9.3) intervention, 49 (9.0) control
Age range: not reported
Smokers: not reported
Puri 2005 
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Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: antidepressants
Medications taken by some, but < 20%: neuroleptics
Location: UK, USA, Canada, Australia
Ethnicity: intervention: 94% white, 4% black, 1% Asian; control: 97%, 3%, 0%, respectively
Interventions Type: supplement (ethyl-EPA)
Comparison: EPA vs paraffin (non-fat)
Intervention: 2 × 2 × 500 mg capsules/d, total dose of 2 g/day ethyl-EPA (code name LAX-101, purity
95%). Dose: 1.9 g/d EPA
Control: 2 × 2 × 500 mg capsules/d liquid paraffin
Compliance: 38 were excluded for protocol violations, 4 intervention and 16 control were non-compli-
ant with capsules
Duration of intervention: 12 months
Outcomes Main study outcome: functional status in Huntington's Disease
Dropouts: 7 intervention, 7 control
Available outcomes: measures of functional capacity, CV events, cancers (nil deaths)
Response to contact: yes (no additional data provided)
Notes Study funding: Amarin Neuroscience Ltd. (formerly known as Laxdale Ltd.), provided organisation,
funding and salaries
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "After screening and acceptance... patients were assigned to treatment
by receiving a numbered pack supplied by a clinical trials packaging organiza-
tion ... independent of all other aspects of the trial. Randomization was strati-
fied in a block size of four, with the appropriate number of blocks allocated to
each center. PCI Clinical Services held the randomization code until the data-
base had been closed and all patients had been assigned"
Allocation concealment
(selection bias)
Low risk As above
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "[p]lacebo and ethyl-EPA capsules were of identical appear-
ance" (though taste and smell not reported).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Randomisation described as "double-blind", "neither the patients nor the par-
ticipating medical staC had access to this code during the course of the study"
Incomplete outcome data
(attrition bias) 
High risk Clearly reported and complete, however > 20% attrition
Puri 2005  (Continued)
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All outcomes
Selective reporting (re-
porting bias)
Unclear risk No protocol or trials registry entry identified
Attention Low risk Unlikely
Compliance Unclear risk 38 were excluded for protocol violations, 4 intervention and 16 control were
non-compliant with capsules
Other bias Low risk None noted
Puri 2005  (Continued)
 
 
Methods RCT, parallel, (fish oil or olive oil), 24 months
Summary risk of bias: moderate or high
Participants People with implantable cardioverter defibrillators and recent sustained ventricular tachycardia or
ventricular fibrillation (VT/VF)
N: 100 intervention, 100 control
Level of risk for CVD: high
Men: 86% intervention, 86% control
Mean age in years (SD): 63 (13) intervention, 62 (13) control
Age range: not reported but 18-75 inclusion criteria
Smokers: not reported
Hypertension: 46% intervention, 55% control
Medications taken by at least 50% of those in the control group: diuretic, beta blockers, ACE inhibitors
Medications taken by 20%-49% of those in the control group: digoxin, statins
Medications taken by some, but less than 20% of the control group: calcium channel blocker
Location: USA
Ethnicity: 94% white in intervention group, 97% in control group
Interventions Type: supplement (fish oil capsules vs olive oil capsules)
Comparison: EPA + DHA vs MUFA
Intervention: 1.8 g/d fish oil capsules (Hoffman LaRoche, including ethyl esters of EPA and DHA, 0.76 g/
d EPA, 0.54 g/d DHA). Dose: 1.3 g/d EPA + DHA
Control: 1.8 g/d olive oil capsules (Hoffman LaRoche, 73% oleic acid)
Compliance: while control group plasma and platelet DHA and EPA did not change, there were increas-
es of 2%-8.3% in the intervention group
Duration of intervention: 24 months (median 718 days)
Outcomes Main study outcome: time to first episode of VT/VF
Raitt 2005 
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Dropouts: 17 intervention, 26 control
Available outcomes: deaths, CV death, MI, angina, revascularisation, arrhythmias, sudden cardiac
death, cancer
Response to contact: yes but no data provided
Notes Study funding: NIH and Hoffman LaRoche
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "computer generated block randomisation scheme"
Allocation concealment
(selection bias)
Unclear risk Not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Participant blinding unclear
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk ICD traces were viewed by researchers blinded to allocation, "double blind
placebo-controlled"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Almost all participants were included in outcome assessment, well described
Selective reporting (re-
porting bias)
High risk NCT registered in February 2000, study carried out from February 1999 to Jan-
uary 2004. Most outcomes stated in registry entry reported, but quality of life
missing
Attention Low risk Capsules were the only different interventions between arms, little opportuni-
ty for attention bias
Compliance Low risk While control group plasma and platelet DHA and EPA did not change, there
were increases of 2%-8.3% in the intervention group
Other bias Low risk None noted
Raitt 2005  (Continued)
 
 
Methods RCT, parallel, (fish oil vs sunflower oil), 12 months
Summary risk of bias: moderate or high
Participants People with relapsing remitting multiple sclerosis
N: 25 intervention, 25 control. (analysed, intervention: 20 control: 19)
Level of risk for CVD: low
Men: 83% intervention, 82% control (but these appear unlikely)
Ramirez-Ramirez 2013 
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Mean age (SD) years: 35.1 (7.6) intervention, 34.9 (7.8) control
Age range: not reported but 18-55 years were inclusion criteria
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: 100% treated with interferon beta1b
for at least 1 year before the trial began
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Mexico
Ethnicity: not reported
Interventions Type: supplement
Comparison: DHA + EPA vs sunflower oil
Intervention: 4 g/d omega Rx capsules (Dr Sears zone diet, with excipient of glycerin, water, tocopherol,
sunflower oil, titanium dioxide, includes 0.8 g/d EPA plus 1.6 g/d DHA). Dose: 2.4 g/d EPA + DHA
Control: excipient only (Perfect Source Natural Products, glycerin, water, tocopherol, sunflower oil, ti-
tanium dioxide)
Compliance: consumption diary plus pills returned at each visit, adherence calculated (correct formu-
la?? pills consumed × 100/pills returned), optimal adherence was considered to be > 80%, 1 interven-
tion and 3 control were excluded due to compliance < 80%. Blood DHA and EPA were significantly dif-
ferent at 12 months.
Duration of intervention: 12 months
Outcomes Main study outcome: TNF-alpha
Dropouts: 5 of 25 intervention, 6 of 25 control
Available outcomes: TNF-alpha, IL-6, IL-1 beta, nitric oxide catabolites, MS relapse, disability EDSS, liv-
er and renal function tests, haemoglobin, leucocytes, platelets, oxidative outcomes (glucose and lipids
data collected but not reported, for BMI and BP paper reports "no difference through study")
Response to contact: not yet attempted
Notes Study funding: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation sequence (blocks of 4)
Allocation concealment
(selection bias)
Unclear risk Not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "capsules were identical in appearance, packaging and labelling",
"physicians and patients were blind to the intervention", and there was a rose-
mary flavour to mask.
Ramirez-Ramirez 2013  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "an independent physician evaluated the EDSS score and collected
samples at each clinic visit"
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Loss of 11/50 over 1 year, 22% loss
Selective reporting (re-
porting bias)
High risk Paper reports analysis of glucose and lipids but these are not reported
Attention Low risk Appeared similar, reviewed every 3 months
Compliance Low risk Blood DHA and EPA were significantly different at 12 months
Other bias Low risk None noted
Ramirez-Ramirez 2013  (Continued)
 
 
Methods RCT, parallel, 3 arms (fish oil or borage oil), 18 months
Summary risk of bias: low
Participants Adults with rheumatoid arthritis
N: 53 intervention, 52 control (28 intervention, 24 control analysed)
Level of risk for CVD: low
Men: 13.2% intervention, 23.1% control
Mean age in years (SD): 57.3 (12.3) intervention, 60.3 (9.2) control
Age range: not reported but 18-85 inclusion criteria
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: methotrexate, DMARDs, and TNF
blockers
Medications taken by 20%-49% of those in the control group: corticosteroids and TNF blockers
Medications taken by some, but less than 20% of the control group: not reported
Location: USA
Ethnicity: black/African-American: intervention (fish oil): 7.8% control (borage oil): 7.8%
Interventions Type: supplement (fish oil vs borage oil)
Comparison: EPA + DHA vs Omega 6
Intervention: 7 fish oil (2.1 gm EPA:1.4 gm DHA) capsules and 6 sunflower seed oil capsules daily = 13
capsules divided doses. Dose: 3.5 g/d EPA + DHA
Control: 6 borage seed oil (1.8 g GLA) capsules plus 7 sunflower seed oil capsules daily
Reed 2014 
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Compliance: assessed by capsule counts and patient report. Patient report, indicates that 45% of pa-
tients reported ever missing a dose (borage: 42%, fish 48%). Median total capsules missed (excluding
those with 0) were 182 (borage: 164, fish 169)
Duration of intervention: 18 months
Outcomes Main study outcome: RA modified disease activity score
Dropouts: 25 intervention, 28 control
Available outcomes: mortality (nil death), CVD events (nil), DAS score, CDAI score. Authors suggested
that LDL and total cholesterol were reduced in the intervention group at 18 months, and HDL was in-
creased in both intervention and control at 18 months, while diastolic BP was reduced in the interven-
tion group at 18 months, but no numbers provided. CRP and ESR data were provided combined for the
intervention and control arms in the author response, so not useable
Response to contact: yes, authors supplied details of methodology but no usable outcome data
Notes A third arm (45 participants) were given a combination of both oils but not discussed here.
Study funding: National Institutes of Health Grant RO1-AT000309 from the National Center for Comple-
mentary and Alternative Medicine
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Author stated "stratified random block, stratified by site using random blocks
of 3 & 6"
Allocation concealment
(selection bias)
Low risk No methodology provided in the paper, but the author suggested conceal-
ment
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Double-blind, all capsules were identical in appearance and colour, they were
shipped in opaque plastic bottles to the University of Massachusetts University
Hospital pharmacy, from where they were distributed to participating centres.
However no information provided as to their smell and taste.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Author confirmed outcome assessors were blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Authors mention intention-to-treat analysis but shows completers analysis.
Numbers of participants are not provided for all outcomes measured. Provide
results for the overall group (69 participants table 3a) while the flow diagram
states there are 74 completers. 51% dropped out.
Selective reporting (re-
porting bias)
Low risk Study prospectively registered in 2003, estimated study completion Novem-
ber 2008, published in 2014. Both outcomes reported in registry are reported
in the publication.
Attention Low risk All patients were evaluated at 3-month intervals, by the same examiner.
Compliance Unclear risk Assessed by capsule counts and patient report. Patient report, indicates that
45% of patients reported ever missing a dose (borage: 42%, fish 48%). Median
total capsules missed (excluding those with 0) were 182 (borage: 164, fish 169)
Other bias Low risk None noted
Reed 2014  (Continued)
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Methods RCT, parallel, (n-3 vs olive oil), 60 months
Summary risk of bias: moderate or high
Participants Patients with multiple cardiovascular risk factors
N: 6244 intervention, 6269 control (analysed, intervention: 6239 control: 6266)
Level of risk for CVD: high
Men: 62.3% intervention, 60.6% control
Mean age in years (SD): 63.9 (9.3) intervention, 64.0 (9.6) control
Age range: not reported
Smokers: 22.1% intervention, 21.4% control.
Hypertension: 84.6% intervention, 84.5% control
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: ACE inhibitor; ARB; diuretic agent; calci-
um-channel blocker; beta-blocker; oral hypoglycaemic drug; statin; antiplatelet agent
Medications taken by some, but less than 20% of the control group: insulin
Location: Italy
Ethnicity: not reported
Interventions Type: supplement (n-3 capsules)
Comparison: EPA + DHA vs MUFA
Intervention: 1 g/d n-3 capsules polyunsaturated fatty acid ethyl esters (EPA and DHA content 850-882
mg with an average ratio of 1.0 to 1.2). Dose: ˜0.87 g/d EPA + DHA
Control: 1 g/d olive oil capsules
Compliance: measured by self-report during follow-up visits but no results reported
Duration of intervention: 60 months
Outcomes Main study outcome: composite of time to death from cardiovascular causes or hospital admission for
cardiovascular causes
Dropouts: intervention: 5 withdrew consent before baseline, 43 lost to follow-up, 1115 stopped treat-
ment. 6239 analysed.
Control: 3 (withdrew consent before baseline), 39 lost to follow-up, 1218 stopped treatment. 6266
analysed
Available outcomes: mortality, CV mortality, CV events, coronary related events and mortality, MI, AF,
heart failure, side effects, stroke, cancer diagnosis, cancer death. Authors provided data on diabetes di-
agnosis, glucose and HbA1c.
Response to contact: yes
Notes All continuous outcomes change data are reported as least squares mean hence not used.
Risk & Prevention 2013 
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Study funding, quote: "The steering committee had the full and sole responsibility for planning and co-
ordinating the study, analyzing and interpreting the data, and preparing the manuscript and submit-
ting it for publication. Società Prodotti Antibiotici, Pfizer, and Sigma Tau funded the trial but had no
role in the study design, planning, conduct, or analysis or in the interpretation or reporting of the re-
sults"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Treatment was centrally assigned by means of telephone on the basis
of a concealed, computer-generated randomization list, stratified according to
general practitioner."
Allocation concealment
(selection bias)
Low risk As above
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Quote: "Patients, general practitioners, coordination and statistical staC, and
outcome assessors were unaware of the study assignments until the final
analyses were completed." However, there was no mention of placebo ap-
pearance or other methods of blinding, so unclear.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Patients, general practitioners, coordination and statistical staC, and
outcome assessors were unaware of the study assignments until the final
analyses were completed."
Quote: "All events included in the primary efficacy end point were documented
with the use of a narrative summary and supporting documentation and were
adjudicated on the basis of prespecified criteria by an ad hoc committee con-
sisting of a cardiologist, an internist, and a neurologist who were unaware of
the study assignments"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "Analyses were performed in the intention-to-treat population, ex-
cept for a prespecified per protocol analysis of the primary end point in pa-
tients with no major protocol violations who did not permanently stop treat-
ment." Figures differ in Visentin 2008: (p. i73)"At the end of March 2006, 12 521
patients have been Randomized"; "After 1-year of follow-up, 2.5% of the pa-
tients withdrawn from the trial and 5% of the patients discontinued treatment.
The reasons for drug discontinuation were 1.7% for side effects (mainly gas-
trointestinal) and 3.3% others (clinical or patient's refusal)… After 1-year of
follow-up, 1.0% had CV death and 3.4% hospitalisation for CV events (primary
end point)"
Selective reporting (re-
porting bias)
High risk Primary endpoint was amended part way through study. Differences in group-
ings of cardiovascular events in tables 2; S4 and S5. For hospital admissions
notes each patient could have more than one cardiovascular cause
Attention Unclear risk Does not state attention differs or is the same between groups- regularly see
GP for follow-up and blinding not clear
Compliance Unclear risk No results
Other bias Low risk None noted
Risk & Prevention 2013  (Continued)
 
 
Methods RCT, parallel, (fish oil vs olive oil), 12 months
Rossing 1996 
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Summary risk of bias: moderate or high
Participants Adults with insulin-dependant diabetes mellitus, diabetic nephropathy and normal BP
N: 18 intervention, 18 control (analysed, 17 intervention, 15 control)
Level of risk for CVD: moderate
Men: 64% intervention, 67% control
Mean age (SD) years: 32 (7) intervention, 34 (10) control
Age range: 18-55 years
Smokers: 50% intervention, 47% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: insulin
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Denmark
Ethnicity: not reported
Interventions Type: supplement
Comparison: EPA + DHA vs MUFA
Intervention: cod-liver oil emulsion (Pharma-Vinci A/S Denmark). EPA 2 g, DHA 2.6 g, total PUFA 4.6 g/
day. Dose: 4.6 g/d EPA + DHA
Control: olive oil emulsion (Pharma-Vinci A/S Denmark)
Compliance: assessed through omega 3 incorporation in platelets, and the paper reports significantly
higher omega 3 levels in platelets at 12 months
Duration of intervention: 12 months
Outcomes Main study outcome: diabetic nephropathy
Dropouts: 1 intervention, 3 control (though 3 further intervention participants are not included in all
data)
Available outcomes: mortality (nil), breast cancer, total and LDL cholesterol, sBP (TGs reported as me-
dians so not used, albuminurea, fractional albumin clearance, transcapillary escape rate of albumin,
prothrombin fragment reported as geometric means or medians, HbA1c, HDL and diastolic BP too dif-
ferent at baseline to include, GFR, PAI1, TPA, fibrinogen, etc. not relevant)
Response to contact: yes
Notes Study funding: the Danish Heart Association. Eskisol Fish oil and placebo oil emulsions were provided
by Pharma-Vinci A/S, Frederiksvaerk, Denmark
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Patients were randomised using concealed randomisation to receive either
fish oil or olive oil in blocks of 4 according to their glomerular filtration rate."
Rossing 1996  (Continued)
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Allocation concealment
(selection bias)
Unclear risk No further details
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk "Active and placebo (olive oil) were given as emulsions with orange flavour. At
the end patients were allowed to guess about treatment and ˜50% were right"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No details
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Dropouts similar between groups although relatively high for small sample
size. 3 dropouts from fish oil and 1 from control due to side effects. Inten-
tion-to-treat analysis appears to have been given for albuminuria only
Selective reporting (re-
porting bias)
Unclear risk No trials registry entry or protocol found
Attention Low risk Time and attention appear to be the same. All patients were given dietary ad-
vice.
Compliance Low risk Reports significantly higher omega 3 levels in platelets at 12 months for the in-
tervention group
Other bias Low risk None noted
Rossing 1996  (Continued)
 
 
Methods RCT, parallel 5 arms (combined groups 4 and 5 omega-3-acid ethyl esters (Lovaza) n-3 ± raloxifene vs
control groups 1 and 3 ± raloxifene), 24 months
Summary risk of bias: moderate or high
Participants Healthy postmenopausal women (50% normal weight, 30% overweight, 20% obese) with high breast
density detected on their routine screening mammograms
N: 54 + 53 intervention, 53 + 53 control
Level of risk for CVD: low
Men: 0% intervention, 0% control
Mean age in years (SD): 56.56 (6.9) + 57.85 (5.1) intervention, 57.11 (5.9) + 57.68 (5.1) control
Age range: not reported
Smokers: 0% intervention, 0% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: USA
Sandhu 2016 
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Ethnicity: not reported
Interventions Type: supplement (n-3 capsules)
Comparison: EPA + DHA vs nil
Intervention: group 4, Lovaza 4 g per day. Lovaza is the FDA-approved n-3 FA formulation containing
465 mg of EPA + 375 mg of DHA per gram, total dose; 1860 mg/d EPA, 1500 mg/d DHA. Group 5 as group
4 plus 30 mg raloxifene/d. Dose: 3.36 g/d EPA + DHA
Control: group 1, no treatment; group 3, 30 mg raloxifene/d
Compliance: measured by pill count, recorded at follow-up visits and further verified by serum fatty
acids monitoring. Compliance was 94% (SE 2%) at 6 months and 97% (SE 2%) at 12 months. Only 2 par-
ticipants had a compliance < 85% (84% and 81%).
Duration of intervention: 24 months
Outcomes Main study outcome: change in breast density
Dropouts: 5 intervention, 6 control
Available outcomes: cardiovascular events, breast cancer, lipids, dietary intake, plasma FAs, adverse
events (including one incidence of hyperglycaemia)
Response to contact: yes
Notes The study had 5 arms: group 1, no treatment, control; group 2, raloxifene 60 mg orally daily; group 3,
raloxifene 30 mg orally daily; group 4, Lovaza 4 g orally daily; and group 5, Lovaza 4 g/d plus raloxifene
30 mg orally daily. Data here is combined for groups 4 and 5 vs 1 and 3 for binary outcomes and group 1
vs 4 used for continuous outcomes
Study funding: GlaxoSmith Kline and Eli Lilly provided Lovaza and raloxifene, respectively. Funded by
Susan G Komen for the Cure, KG081632 (A Manni) and pilot funds from the Penn State Hershey Cancer
Institute (K El-Bayoumy)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Sandhu 2016 pg 276: "each study participant was randomly assigned with
equal probability to one of the following five groups. A block randomization
scheme was used to ensure balance treatment allocation during the course of
enrolment."
Allocation concealment
(selection bias)
Unclear risk No description of concealment of allocation
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Open label
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk < 20% lost over 2 years, detailed reasons provided, no suggestion these are un-
balanced
Sandhu 2016  (Continued)
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Selective reporting (re-
porting bias)
High risk Biomarkers of oxidative stress (Urinary 8-(isoprostane) F-2α and 8OHdG, Lym-
phocyte 8-OHdG, DNA etheno adducts), Urinary 2-OHE1, 4-OHE1, and 16α-
OHE1, Serum level of C-reactive protein and IL-6, Serum level of IGF-I and IGF-
BP-3, complete blood count mentioned in trial registry but not reported in
Sandhu 2016. (More outcomes reported than in registry – diet, physical activity
levels, adverse events)
Attention Low risk Participants assessed at baseline, 1-year and 2-year follow-up
Compliance Unclear risk Measured by pill count, recorded at follow-up visits and further verified by
serum fatty acids monitoring. Compliance was 94% (SE 2%) at 6 months and
97% (SE 2%) at 12 months. Only 2 participants had a compliance < 85% (84%
and 81%)
Other bias Low risk None noted
Sandhu 2016  (Continued)
 
 
Methods Study on prevention of Coronary atherosclerosis with Marine Omega 3 fatty acids (SCIMO)
RCT, parallel (omega 3 vs average European fats), 2 years
Summary risk of bias: low
Participants People with angiographically proven coronary artery disease
N: 112 intervention, 111 control (analysed 82 intervention, 80 control)
Level of risk for CVD: high
Men: 82% intervention, 78.6% control
Mean age in years (SD): 57.8 (9.7) intervention, 58.9 (8.1) control
Age range: unclear (18-75 inclusion criteria)
Smokers: 16.2% intervention, 22.3% control
Hypertension: 53.1% intervention, 45.5% control (history of high blood pressure)
Medications taken by at least 50% of those in the control group: platelet inhibitors, beta-blockers
Medications taken by 20%-49% of those in the control group: long-term nitrate therapy, lipid-lowering
agents, ACE inhibitors, diuretics, calcium antagonists, other antihypertensive agents and digitalis.
Medications taken by some, but less than 20% of the control group: nitrates only on demand
Location: Germany
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs SFA + MUFA (average European fat composition)
Intervention: concentrated fish oil capsules, 6x 1 g capsules/d for first 3 months, 3 × 1 g/d for rest of
study (4 g/d EPA +DHA + DPA + ALA for first 3 months, then 2 g/d). Dose: ˜2 g/d LCn3
Control: capsules containing fat which replicated the fat composition of the average European diet, 6/
d for first 3 months, 3/d for rest of study, opaque soW gelatin capsules identical to fish capsules in iden-
tical screw-top containers
SCIMO 1999 
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Compliance: capsule count, overall 2284 (SD 313) capsules taken of 2460 prescribed for each person,
erythrocyte phospholipids rose from 4.6% to 11.8% at 24 months in intervention, and didn't alter from
baseline in controls
Length of intervention: 24 months
Outcomes Main study outcome: changes in stenosis on angiography
Dropouts: unclear
Available outcomes: mortality, MI, CV events, revascularisation, angina, stroke, cancer diagnosis,
weight, lipids, BP, side effects
Response to contact: yes
Notes Asked participants to guess treatment allocation, of those in intervention 63/90 were unsure, 5/90
guessed placebo and 22/90 guessed fish oil; of those in control 66/85 were unsure, 9/85 guessed place-
bo and 10/85 guessed fish oil
Study funding: Pronova provided capsules and funds for study monitoring but it was stated that the
funders played no part in analysis or publication
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Stratified, and for the resulting 9 strata "a random sequence of study group as-
signments was computer generated by the trial monitor"
Allocation concealment
(selection bias)
Low risk Sealed, sequential numbered envelopes used (opaque not stated, but provid-
ed only a random number which linked to a specific container of capsules).
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Placebo and fish oil capsules "looked identical and were made of soW opaque
gelatin and each contained 1 g of a fatty acid mixture". These were provided
in identical containers with identical labels with a randomisation number. Pa-
tients were told that capsules differed in composition but not in taste.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Blinding is described and is very strong for angiographic outcomes, but there
is no description of how cardiovascular events were assessed or recorded.
However outcomes assessors were probably the same assessors and so blind-
ed
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Unclear for how many participants clinical events were assessed (though de-
scribed in detail for angiographic outcomes), so trial flow unclear
Selective reporting (re-
porting bias)
Unclear risk No study trials register entry or protocol was found
Attention Low risk As study personnel were unaware of assignments bias in attention was not
possible
Compliance Low risk Capsule count, overall 2284 (SD 313) capsules taken of 2460 prescribed for
each person, erythrocyte phospholipids rose from 4.6% to 11.8% at 24 months
in intervention and didn't alter from baseline in controls
Other bias Low risk No further bias noted
SCIMO 1999  (Continued)
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Methods RCT, parallel (fish oil capsule vs soybean oil capsule), 12 months
Summary risk of bias: moderate to high
Participants Patients aged 55 or more with probable Alzheimer dementia diagnosis
N: 13 intervention, 13 control
Level of risk for CVD: low
Men: 61% intervention 46% control
Mean age in years (SD): 75.9 (8.1) intervention, 75.2 (10.8) control
Age range: 55+ (inclusion criteria)
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: anti-cholinesterases or memantine
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Lipid-lowering medications and many other drugs were not allowed
Location: USA
Ethnicity: 100% white
Interventions Type: fish oil capsules
Comparison: EPA + DHA vs n-6
Intervention: 3 × 1 g capsules/day of fish oils (975 mg EPA, 675 mg DHA per day). Dose: 1.65 g/d EPA +
DHA
Control: 3 × 1 g capsules/day soybean oil (which contains 5% fish oil)
Both groups had a placebo lipoic acid tablet and lemon-flavoured capsules
Compliance: assessed by pill counts and FA in red blood cell membranes. Results showed increased
EPA + DHA levels in the intervention group.
Length of intervention: 12 months
Outcomes Main study outcome: F2-isoprostane levels (oxidative stress measure)
Dropouts: 2 intervention, 2 control
Available outcomes: mortality, CVD events, adverse events, serum fatty acids, measures of cognition
(ADAS Cog and MMSE), ADL, IADL (also F2 isoprostane)
Response to contact: not attempted
Notes Study funding: National Institutes of Health/National Institute of Aging (NIH/NIA) and NIH General Clini-
cal Research
Risk of bias
Bias Authors' judgement Support for judgement
Shinto 2014 
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Random sequence genera-
tion (selection bias)
Low risk Participants were randomised by a computer-generated scheme that was
stratified by smoking status
Allocation concealment
(selection bias)
Unclear risk No details
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Capsules matched for taste and flavour. Blinding assessed at the end and ma-
jority of staC and participants were unaware of treatment
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk As above
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 15% dropouts explained and included
Selective reporting (re-
porting bias)
Low risk NCT00090402 first received: 25 August 2004, study start date April 2004. More
secondary outcomes reported than included in the trial register entry
Attention Low risk Both arms seem to have had the same contact
Compliance Low risk Compliance measured and FAs levels reported. Results showed increased EPA
+ DHA levels in the intervention group
Other bias Low risk None noted
Shinto 2014  (Continued)
 
 
Methods SHunt Occlusion Trial (SHOT)
RCT, parallel (omega 3 vs nil), 4 arms, 1 year
Summary risk of bias: moderate or high
Participants People admitted for coronary bypass grafting
N: 317 intervention, 293 control
Level of risk for CVD: high
Men: 86% intervention, 88% control
Mean age in years (SD): 59.9 (8.7) intervention, 59.4 (8.8) control
Age range: unclear
Smokers: 19% intervention, 20% control
Hypertension: 20% intervention, 25% control
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: antihypertensives
Medications taken by some, but less than 20% of the control group: not reported
Location: Norway
SHOT 1996 
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Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs nil
Intervention: 4 fish-oil concentrate soW gelatin capsules/d (Omacor; Pronova AS, Oslo,Norway) contain-
ing 51% EPA and 32% DHA ethyl esters and 3.7 mg
vitamin E as an antioxidant. Dose: 3.3 g/d EPA + DHA
Control: no treatment
Compliance: capsule count, 88% taken, serum EPA + DHA rose in the intervention group (176 to 257
mg/L at 9 months) and fell in the control group (170 to 169 mg/L at 9 months)
Length of intervention: 12 months
Outcomes Main study outcome: CABG graW patency
Dropouts: 15 intervention, 14 control
Available outcomes: deaths, CV deaths, MI, stroke, repeat CABG, combined CV events, lipids, side ef-
fects
Response to contact: yes
Notes The study had 4 arms; aspirin; warfarin; fish oil + aspirin; and warfarin + fish oil. The first 2 groups are
combined as the control and the last two combined as intervention.
Dietary assessment suggested total diet plus supplement intakes as follows: 2.7 g/d EPA + DHA at base-
line, 5.5 g/d at 9 months intervention, 2.5 g/d at baseline, 2.2 g/d at 9 months control group
Study funding: in part by Pronova and Nycomed Pharma
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random numbers were provided in consecutively sealed envelopes generated
centrally
Allocation concealment
(selection bias)
Unclear risk Envelopes not reported as opaque
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open trial, no blinding apart from outcome assessors so participants and
study personnel were aware of assignments. However, author suggested in
personal communication that participants were not aware of their assign-
ments.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome assessors (radiologists) reported as blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reasons for attrition and exclusions stated, numbers clear, dropouts < 20% per
year
Selective reporting (re-
porting bias)
Unclear risk No study protocol or trials register entry was found
Attention Low risk Appeared equivalent between arms
SHOT 1996  (Continued)
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Compliance Low risk Capsule count, 88% taken, serum EPA + DHA rose in the intervention group
(176 to 257 mg/L at 9 months) and fell in the control group (170 to 169 mg/L at
9 months)
Other bias Low risk No further bias noted
SHOT 1996  (Continued)
 
 
Methods RCT, parallel, (fish oil vs placebo), 12 months
Summary risk of bias: moderate or high
Participants Patients with hypertension and paroxysmal or persistent atrial fibrillation (AF)
N: 268 intervention, 60 control
Level of risk for CVD: moderate
Men: not reported
Mean age (SD) years: 62 (6), not reported by arm
Age range: not reported
Smokers: not reported
Hypertension: 100%
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Greece
Ethnicity: not reported
Interventions Type: supplement
Comparison: fish oil vs unclear placebo
Intervention: omega-3 fatty acids with no further details. Dose: 4 g/d omega
Control: placebo, no further details
Compliance: no details
Duration of intervention: 12 months
Outcomes Main study outcome: AF recurrence and BP
Dropouts: no details
Available outcomes: new AF episodes, BP (not in a usable format)
Response to contact: no
Notes Study funding: unclear
The study's only publication was a conference abstract.
Sianni 2013 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details, probably randomised but unclear
Allocation concealment
(selection bias)
Unclear risk No details
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk No details
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No details
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No details
Selective reporting (re-
porting bias)
Unclear risk No protocol or trial register record found
Attention Unclear risk No details
Compliance Unclear risk No details
Other bias Unclear risk No details
Sianni 2013  (Continued)
 
 
Methods SMART trial (from the Smart Foods Centre)
RCT, 3-arm parallel, (Fish + S: hypocaloric diet plus fish plus fish oil capsules vs Fish: hypocaloric diet
plus fish plus olive oil capsules vs control: hypocaloric diet plus olive oil capsules), 12 months
Summary risk of bias: moderate or high
Participants Overweight adults
N: fish + S intervention 41, fish 43, control 42. (analysed, fish + S intervention 21, fish 25, control 18)
Level of risk for CVD: low
Men: 27% fish + S intervention, 23% fish intervention, 28% control
Mean age (SD) years: unclear by arm, overall 45.1 (8.4)
Age range: not reported but 18-60 years eligible
Smokers: not reported but 5.9% overall
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
SMART 2013 
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Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Australia
Ethnicity: not reported
Interventions Type: supplement and food
Comparison: EPA + DHA vs MUFA (Fish plus fish oil supplements vs Fish plus olive oil supplements vs
olive oil supplements)
Intervention, Fish + S: hypocaloric diet aiming at 30% E from fat, 25% E from protein, 45% E from CHO,
plus 180 g fish/week plus capsules including 420 mg/d EPA + 210 mg/d DHA (Blackmores Promega
Heart). Dose: 0.63 g/d EPA + DHA
Intervention, fish: hypocaloric diet aiming at 30% E from fat, 25% E from protein, 45% E from CHO, plus
180 g fish/week plus capsules including 1 g olive oil/d
Control: hypocaloric diet aiming at 30% E from fat, 25% E from protein, 45% E from CHO, plus capsules
including 1 g olive oil/d
Compliance: assessed through diet histories (fish) and erythrocyte fatty acid supplements (capsules),
but results not reported
Duration of intervention: 12 months
Outcomes Main study outcome: total % body fat
Dropouts: fish + supplement intervention 20, fish intervention 18, control 24
Available outcomes: weight, BMI, lipids, BP, fasting glucose, fasting insulin, % body fat (leptin also re-
ported), no deaths or cardiovascular events occurred (authors report)
Response to contact: authors provided data on CVD events (none) and mean/SD data for TGs and fast-
ing insulin
Notes To assess effects of omega 3 fats the best comparison in this study is fish + S vs fish, so numerical data
reflect this comparison.
Study funding: Australian National Health and Medical Research Council, fish and olive oil capsules
were provided free by Blackmores Australia
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "A researcher independent of the subject interface undertook the ran-
domisation of participants into diet groups (stratified by sex and block ran-
domised...)"
Allocation concealment
(selection bias)
Low risk Quote: "Randomisation was performed centrally, oC-site and the holder of the
allocation schedule provided the codes to a single researcher who was inde-
pendent to the subject interface. The placebo and active ingredient capsules
were coded oC-site . The codes were kept from the researchers collecting di-
etary data and delivering treatment. Allocation concealment was maintained
as the persons responsible for screening eligible participants for inclusion in
the trial was unaware to which supplement group the subject would be allo-
cated. Different dietitians collected the dietary data and provided dietary ad-
vice"
SMART 2013  (Continued)
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
190
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk As above, but impossible to blind participants to the fish advice
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk As above
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Very high levels of attrition, though intention-to-treat analyses carried out
Selective reporting (re-
porting bias)
High risk We were unable to find data on 24 hour energy expenditure, oxidation or heart
rate which were stated as primary and secondary outcomes in the trials reg-
istry.
Attention Unclear risk While dietary education was for 1 hour then 6 further half hour follow-ups plus
written materials and monthly newsletters plus dietary interviews it is not
clear whether this was in all arms or only some of them.
Compliance High risk Quote: "Of the 12 months completers, 57% were judged to be compliant, 39%
(n = 7) for the control group who reported < 180 g fish/week, 48% (n = 12) for
the Fish group who reported ≥180 g fish/week, and 85% (n = 17) for the Fish
+ S group who reported ≥180 g fish/week or ≥90% supplements". However,
erythrocyte (EPA + DHA)/total fatty acids × 100 was significantly different for
the fish oil supplemented group compared to the two others – but it was only
measured in around half of the participants as the others dropped out, so pre-
sumably were non-compliant.
Other bias Low risk None noted
SMART 2013  (Continued)
 
 
Methods Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA)
2 arm, parallel RCT (n-3 EPA + DHA vs MUFA), 12 months
Summary risk of bias: low
Participants People with previous ventricular arrhythmias and implantable cardioverter defibrillators
N: 273 intervention, 273 control (273 intervention, 273 control analysed)
Level of risk for CVD: high
Men: 84% intervention, 85 % control
Mean age in years (SD): 60.5 (12.8) intervention, 62.4 (11.4) control
Age range: unclear (18 years and older)
Smokers: 16% intervention, 8% control
Hypertension: 53% intervention, 49% control
Medications taken by at least 50% of those in the control group: beta-blockers
SOFA 2006 
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Medications taken by 20%-49% of those in the control group: lipid lowering, antiarrythmic medications
(combined)
Medications taken by some, but less than 20% of the control group: amiodarone, sotalol
Location: 8 countries in Europe
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs MUFA + omega 6
Intervention: 2 g/d (4 capsules) purified fish oil. 961 mg n-3 PUFAS (464 mg EPA + 335 mg DHA and 162
mg other n-3 PUFAs) daily. 3000 ppm vitamin E (Loders Croklann, Wormeveer). Dose: 0.8 g/d EPA + DHA
Control: 2 g/d high-oleic acid sunflower oil. 3000 ppm vitamin E (Loders Croklann, Wormeveer)
Compliance: daily diary, checked by research nurses every 4 months. Judging by capsule count, 207 pa-
tients in the fish oil group and 218 in the placebo took more than 80% of their capsules. N-3 fatty acid
composition in serum cholesterol levels was measured at baseline and the end of the trial. The EPA
concentration in serum cholesterol esters increased in the expected range. No data provided
Length of intervention: 12 months
Outcomes Main study outcome: spontaneous ventricular tachyarrhythmias and all-cause mortality
Dropouts: 33 intervention (23 partial follow-up), 33 control (14 partial follow-up)
Available outcomes: deaths, MI, new angina, new heart failure, no fatal arrhythmias, cancer, cardiovas-
cular events, side effects
Response to contact: yes but no data provided
Notes Study funding: Wageningen Centre for Food Sciences (alliance of major Dutch food industries and oth-
ers)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Patients using beta-blockers were separately randomised in blocks of 2. A
computer randomisation programme randomly took the first treatment of a
block. The second patient in a block of 2 always received the opposite treat-
ment.
Allocation concealment
(selection bias)
Low risk Treatments (blinded medication numbers) were centrally assigned by a tele-
phone allocation service.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Double blinding. Bottles containing capsules labelled with medication num-
bers that are unidentifiable for patients as well as investigators. Fish oil and
placebo capsules have identical appearance. Difference can't be tasted if swal-
lowed with water (as suggested)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "blinded endpoint adjudication committee"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis. Did a partial follow-up on some patients who dropped out due to
non-compliance.
SOFA 2006  (Continued)
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Selective reporting (re-
porting bias)
Low risk NCT00110838, trial registered in May 2005, end of trial January 2005, trial re-
sults published in 2006. However, rationale and design paper (stating out-
comes) published in 2003. Outcomes in the 2006 paper appear to be the same
as in Rationale paper.
Attention Low risk Unlikely as intervention blinded to investigators and only intervention was
capsules
Compliance Unclear risk Daily diary, checked by research nurses every 4 months. Judging by capsule
count, 207 patients in the fish oil group and 218 in the placebo took more than
80% of their capsules. N-3 fatty acid composition in serum cholesterol levels
was measured at baseline and the end of the trial. The EPA concentration in
serum cholesterol esters increased in the expected range. No data provided
Other bias Low risk No further bias noted
SOFA 2006  (Continued)
 
 
Methods 2-arm, parallel RCT (enriched olive oil vs olive oil), 12 months
Summary risk of bias: moderate or high
Participants Non-alcoholic fatty liver disease patients
N: 6 intervention, 5 control
Level of risk for CVD: low
Men: 66.7% intervention, 100% control
Median age: 55 intervention, 54 control
Age range: 30-41 intervention, 42-70 control
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Italy
Ethnicity: not reported
Interventions Type: supplement (oil)
Comparison: EPA + DHA vs MUFA
Intervention: 6.5 mL/d olive oil enriched with n-3 (t-Omega 3, tFarma srl, Italy) containing 0.47 g EPA,
0.24 g DHA plus dietary recommendations. Dose: 0.83 g/d EPA + DHA
Control: 6.5 mL/d olive oil plus dietary recommendations
Compliance: was verified by counting the empty boxes on return but no data reported
Length of intervention: 12 months
Outcomes Main study outcome: fatty liver status
Sofi 2010 
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Dropouts: unclear
Available outcomes: lipids, glucose, insulin, HOMA, (BMI not in usable format, also LFTs, oxidative
markers, adiponectin, fatty liver and steatosis outcomes)
Response to contact: not yet attempted
Notes Study funding: oil supplied by tFarma and funding not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "The patients were randomized into two groups"
Allocation concealment
(selection bias)
Unclear risk No details
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk No details
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No details
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Numbers analysed for liver health are for those randomised. Numbers
analysed for other outcomes not stated. No mention of dropouts
Selective reporting (re-
porting bias)
Unclear risk No protocol or trial registration
Attention Low risk Both groups received same contact
Compliance Unclear risk Measured but no results reported
Other bias Low risk None noted
Sofi 2010  (Continued)
 
 
Methods Supplementation en Folates et Omega 3 (SU.FOL.OM3)
RCT, 2 × 2 factorial (LCn3 omega 3 vs placebo, also B vitamin comparison), 4 years
Summary risk of bias: low
Participants People with a history of MI, unstable angina or ischemic stroke
N: control: 1248, intervention: 1253
Level of risk for CVD: high
Men: 80.85% intervention, 78.25% control
Mean age in years (SD): 61.1 (8.8) intervention, 60.8 (8.7) control
Age range: 53-68 years intervention, 54-68 years control
SU.FOL.OM3 2010 
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Smokers: 11.1% intervention, 10.4% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: beta-blockers, aspirin or antiplatelets,
lipid lowering, ACE inhibitors
Medications taken by 20%-49%: not reported
Medications taken by some, but < 20%: calcium channel blocker, angiotensin II receptor blockers
Location: France
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs non fat placebo
Intervention: 2 gelatin capsules Pierre Fabre omega 3 (400 mg/d EPA and 200 mg/d DHA)
Control: 2 gelatin capsules/d placebo (liquid paraffin with fish flavour)                   
Compliance: tested by questionnaire, response rate was on average 96%. Out of this, 86% complied
Duration of intervention: 4 years
Outcomes Main study outcome: composite of myocardial infarction, cerebral vascular ischemic accident or car-
diovascular deaths
Dropouts: control: 145 (66 withdrew, 11 lost to follow-up, 68 deaths), intervention: 134 (61 withdrew, 7
lost to follow-up, 66 deaths)
Available outcomes: deaths, cardiovascular death, non fatal MI, stroke, CV events, coronary events,
cancer events, Geriatric Depression Scale score, authors provided additional information on outcomes
and methodology
Response to contact: yes (data provided)
Notes The other factorial intervention was B-vitamins (560 µg methyl-terahydrofolate, 3 mg B-6, 20 µg B12) vs
placebo
Study funding: French Ministry of Research, Ministry of Health, Sodexo, Candia, Unilever, Danone,
Roche, Merck
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Used computerized block randomisation with stratification by sex,
age, prior CVD, and city of residence". "Permuted block randomisation (with a
block size randomly selected as 8) was used".
Allocation concealment
(selection bias)
Low risk Allocation of participants was programmed by the statistical coordinating cen-
tre, who sent participants sufficient treatment capsules for 1 year in an appro-
priately labelled package
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "All subjects and investigators were blinded to treatment allocation",
and placebo capsules looked and tasted "identical to the active supplementa-
tion". Fish oil flavour was used in placebos.
SU.FOL.OM3 2010  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome investigators were blinded to allocation
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Attritions and exclusions were well described. Only 10% loss over 4 years, well
balanced
Selective reporting (re-
porting bias)
Low risk ISRCTN41926726 registered 2005, 2003 publication on background and ratio-
nale, recruitment started April 2003, 2008 protocol, recruitment ended June
2009, 2010 results published. Outcomes in registry entry appear to have been
published.
Attention Low risk Not likely as capsules used
Compliance Low risk Quote: "Allocation to omega 3 fatty acids increased plasma concentrations
of omega 3 fatty acids by 37% compared with placebo" (appears statistically
significantly different, though not explicitly stated) … "The overall response
rate for return of completed questionnaires was 99%, 96%, 94%, and 95% at
6, 12, and 24 months and at the end of the trial, respectively. About 86% of
those who returned a questionnaire reported that they were compliant with
the study treatment and compliance was similar in all four groups"
Other bias Low risk No further bias noted
SU.FOL.OM3 2010  (Continued)
 
 
Methods 2 arm, parallel RCT (calanus (marine) oil vs olive oil), 12 months
Summary risk of bias: moderate to high
Participants Healthy male and female volunteers with BMI 25-35 kg/m2
N: 64 intervention, 63 control (50 intervention, 50 control analysed)
Level of risk for CVD: low
Men: 42% intervention, 43 % control
Mean age in years (SD): 50.7 (7.7) intervention, 49 (9.4) control
Age range: unclear (18 years and older)
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Norway
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs MUFA
Intervention: 2 × 500 mg Calanus oil capsules twice daily to provide a daily dose of 2 g. Supplements
were provided by Ayanda AS (Norway) as blister packs of 60 capsules each. The Calanus oil contained
approximately 85% wax ester with a sum of neutral lipids > 90%. Dose: 2 g/d EPA + DHA
Tande 2016 
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Control: identical capsules of olive oil. Compositional analysis indicated that the fatty acid content of
the olive oil was primarily oleic acid (76.9%), palmitic acid (10.2%), and linoleic acid (7.7%).
Compliance: assessed through the return of unused capsules. Compliance rate reported for both inter-
vention and placebo groups was good (86-88%)
Length of intervention: 12 months
Outcomes Main study outcome: safety of Calanus oil consumption
Dropouts: 14 intervention, 13 control
Available outcomes: BMI, waist-hip ratio, BP, pulse, HbA1c, ESR, CRP, lipids, glucose tolerance, insulin,
clinical chemistry parameters, adverse events (no CVD events, deaths or other major health outcomes
occurred according to author reply)
Response to contact: author replied with methodological and event information
Notes Study funding: Calanus AS
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomization of the study subjects into the intervention group or
the placebo group was performed by the University Hospital of North Norway
clinical research unit and was stratified by gender." Author reply stated that
"[r]andomization was performed by competent people at the drugstore affili-
ated to the University Hospital, with no interconnection, formally or material-
ly with the research department from where the study was managed. Random-
ization was performed prior to recruiting subjects."
Allocation concealment
(selection bias)
Unclear risk As above, unclear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Participants in the placebo group received identical capsules at similar daily
doses as the intervention group. However, no information provided as to their
smell and taste. Also unclear if investigators were blinded. Author reply stat-
ed "Each study subject was given a randomization number, which carried the
name of the person, date of birth and treatment information (intervention or
control). The randomization number was the only information made available
to the study personnel, and the code was managed by personnel outside the
research department. This code was broken after the completion of all analy-
sis with all primary data processed." Blinding of participants only possible for
fish plus supplementation vs fish plus placebo.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk As above
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All dropouts (˜20%) are explained
Selective reporting (re-
porting bias)
Unclear risk No trials registry entry or protocol found
Attention Low risk Appear to be similar in both groups
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Compliance Unclear risk Quote: "levels of DHA and EPA in the blood were generally higher in the
Calanus oil group over baseline values relative to the placebo controls" but no
data provided
Other bias Low risk None noted
Tande 2016  (Continued)
 
 
Methods The Heart Institute of Spokane Diet Study (THIS-DIET)
RCT- parallel, 24 months
Summary risk of bias: moderate or high
Participants Recent survivors of first myocardial infarction (within < 6 weeks)
N: 51 intervention, 50 control
Level of CVD risk: high
Men: 80% intervention, 68% control
Mean age in years (SD): 58 (10) intervention, 58 (9) control
Age range: unclear
Smokers: 25% intervention, 30% control
Hypertension: 43% intervention, 50% control (uncontrolled or secondary hypertension excluded)
Medications taken by at least 50% of those in the control group: aspirin, statins, beta-blockers, and ACE
inhibitors or angiotensin receptor blockers.
Medications taken by 20%-49%: not reported
Medications taken by some, but < 20%: not reported
Location: USA
Ethnicity: intervention 98% white; control 94% white
Interventions Type: dietary advice (to follow a Mediterranean style diet high in n-3)
Comparison: EPA + DHA vs MUFA (biggest dietary change)
Intervention: Mediterranean style diet high in n-3. Dietary counselling group sessions; two in first
month then at months 3, 6, 12 and 24. Sessions focused on behaviour modification and practical as-
pects of assigned diet including recipes, shopping and dining out. Aim to increase omega 3 fat intake to
> 0.75% kcal. Dose: ˜1.5 g/d omega 3 fat, or 0.31% E by intake assessment.
Control: dietary advice (to follow the American Heart Association Step II diet). Same number of group
sessions as intervention.
The 2 diets were low in saturated fat (< 7% kcal) and cholesterol (< 200 mg/day); the Mediter-
ranean-style diet was distinguished by greater omega-3 fat intake (> 0.75% kcal).
Compliance: participants were required to attend six sessions and only invited but not required to at-
tend extra sessions. 3-day food diaries were reviewed with dietitians. Compliance results not stated.
Dietary achievements:
Total fat intake, % E (at 24 months): control 29.7 (SD 9.3), intervention 29.1 (SD 8.6)
THIS DIET 2008 
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Saturated fat intake, % E (at 24 months): control 8.0 (SD 2.9), intervention 7.9 (SD 3.2)
PUFA intake, % E (at 24 months): control 5.7 (SD 3.1), intervention 5.7 (SD 2.4)
PUFA n-3 intake, % E: control 0.46 (SD 0.38), intervention 0.67 (SD 0.35) g/week
PUFA n-6 intake: not reported
MUFA intake, % E (at 24 months): control 10.3 (SD 5.1), intervention 9.7 (SD 3.6)
CHO intake, % E (at 24 months): control 54 (SD 11), intervention 54 (SD 10)
Protein intake, % E (at 24 months): control 17 (SD 2), intervention 18 (SD 3)
Trans fat intake: not reported
Length of intervention: 24 months
Outcomes Main study outcome: a composite of endpoints including all-cause and cardiac death, MI, hospital ad-
missions for heart failure, unstable angina, or stroke
Dropouts: none for primary outcomes
Available outcomes: total and CVD deaths (nil deaths), CV events, stroke, MI, diagnosis of diabetes mel-
litus, BMI and weight (different at baseline hence not used), waist circum, lipids, blood pressure, albu-
minuria, CRP, creatinine and dietary intake (authors supplied further data on newly diagnosed DM, glu-
cose and insulin data, cancers, depression, atrial fibrillation)
Response to contact: yes further data supplied as above
Notes The study compared the 2 intervention groups to a non-randomised usual care control group (not re-
ported here)
Study funding: no funding details is provided but some reported conflict of interests for an author.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Sealed envelopes concealing the allocation sequence were prepared by a re-
search coordinator. Assignment was stratified by diabetes mellitus status us-
ing 10-envelope blocks. Envelopes were selected in the prepared order from a
locked drawer by a study dietitian to assign interventions
Allocation concealment
(selection bias)
Unclear risk As above but opacity of envelopes is not stated.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Neither the intervention team nor participants could be blinded to dietary as-
signment.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The PI was blinded for the purpose of adjudicating clinical end points and ad-
verse events by the removal of identifiers from records used for review.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Primary outcomes data provided for all randomised
Selective reporting (re-
porting bias)
High risk NCT00269425. Trial was registered in 2005, data collection started in October
2000, January 2008 (final data collection date for primary outcome measure),
THIS DIET 2008  (Continued)
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publication 2008. A number of the outcomes from the registration were not re-
ported e.g. cardiovascular revascularisation, peripheral revascularisation or
amputation, doubling of serum creatinine, dialysis, or kidney transplant, new
hypertension. Also numerous secondary measures were reported that were
not in the original registration.
Attention Low risk Both arms had the same contact and attention
Compliance Unclear risk No details
Other bias Low risk None noted
THIS DIET 2008  (Continued)
 
 
Methods The Walnut and Healthy Aging Study (WAHA)
2-arm, parallel RCT (usual diet plus walnuts vs usual diet), 2 years
Summary risk of bias: moderate to high
Participants Middle-aged healthy adults
N: 362 intervention, 346 control (only preliminary data on 312 participants from one of the two centres
is available)
Level of risk for CVD: low
Men: 32.6% intervention, 31.5% control
Mean age in years (SD): 69.4 (3.8) intervention, 68.9 (3.5) control
Age range: 63-79 (inclusion criteria)
Smokers: 4.4% intervention, 1.2% control
Hypertension: 52.8% intervention, 52.9% control
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Spain and USA
Ethnicity: not reported
Interventions Type: supplement (food)
Comparison: ALA vs unclear
Intervention: 15% of daily energy intake as walnuts. The estimated amount of walnuts ranged from
about 30–60 g/day (1-2 ounces). Sachets for daily consumption containing 30 g, 45 g, or 60 g of raw,
pieced walnuts were provided as 8-week allotments to be eaten daily, preferably as the raw product,
either as a snack or by incorporating them into shakes, yogurts, cereals, or salads. To improve partic-
ipants' compliance, 1-kg extra walnut allowances were provided every 2 months to take into account
family needs. Dose: ˜5 g/d ALA
Control: usual diet without walnut
WAHA 2016 
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Compliance: assessed by dietitians through FFQs, recount of empty packages, and changes in FAs con-
centrations. 95% consumed at least 30 g/d. The proportion of α-linolenic acid in red blood cells in-
creased in the walnut group by 0.16% (95% CI 0.14 to 0.18) and in the control group by 0.02% (95% CI
−0.01 to 0.04; P < 0.001). No data on dietary intake provided.
Length of intervention: 2 years (only 1 year results have partly been published)
Outcomes Main study outcome: change in cognitive decline (results not yet published)
Dropouts: 36 intervention, 21 control (after 1 year)
Available outcomes: lipids (for TG and HDL only data states "no between diet differences were ob-
served"), weight (waist circumference was provided but without variance, abstract stated that "there
were no significant changes in body fat and waist-to-hip ratio over time and between the two groups").
Authors provided data on mortality, CVD events, cancer deaths and diagnoses, IBD diagnosis (no CVD
deaths). Cognitive, ophthalmological, inflammatory markers, glycaemic status and other outcomes are
not yet available.
Response to contact: authors provided additional outcome and methodology data.
Notes Study funding: Calfornia Walnut Commission
The 2-year results as well the full 1-year results are yet to be published. Outcome data reported are for
only for participants from one centre (USA)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomized to either the control or walnut group using a computer-
ized random number table with stratification by center, sex, and age range.
Couples entering the study were treated as one number and were randomized
into the same group".
Allocation concealment
(selection bias)
Low risk Author reply states, "Baseline subject data was collected before randomiza-
tion. Randomization was done by the clinician, pressing the key on the com-
puter. Since this was a dual center (Barcelona and Loma Linda) trial, a single
computer software randomized participants for both the centers."
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Single blind. "An unavoidable limitation of the study is not being able to blind
participants to the intervention since it consists of a whole food" Rajaram
2017.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Author reply states "Study personnel not in contact with the subjects were
blind to the treatment assignment. So (lab technicians, ophthalmology tech-
nician, neuro cognitive testers) were not aware of the treatment assignment.
Of course clinicians who were visited by subjects every two months, knew the
treatment assignment". This suggests that allocation was known by physi-
cians, so high risk for event data
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 38/362 dropouts in intervention group = 10.5%. 34/346 dropouts in control
group = 9.8%. Similar dropout in groups over 2 years.
Selective reporting (re-
porting bias)
Unclear risk Although prospectively registered, no full results paper published – results
from conference abstracts only report some secondary outcomes
Attention Unclear risk Not enough details
WAHA 2016  (Continued)
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Compliance Low risk ALA levels were significantly higher in the intervention group
Other bias Low risk None noted
WAHA 2016  (Continued)
 
 
Methods RCT, parallel, (low fat diet (15% fat) with n-3 fish oils vs AHA Step I diet (fat ≤ 30%) with olive oil supple-
ments), 12 months
Summary risk of bias: moderate or high
Participants Population: adults with multiple sclerosis
N: 15 intervention, 16 control (analysed, intervention: 13, control: 14)
Level of risk for CVD: low
Men: 15.4% intervention, 14.3% control
Mean age in years (SD): 39.9 (10.0) intervention, 45.1 (7.7) control
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: all patients received 400 units of vita-
min E, one multivitamin tablet (not containing any PUFA) and at least 500 mg calcium per day
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: USA
Ethnicity: not reported
Interventions Type: dietary advice plus supplement
Comparison: EPA + DHA vs MUFA (low fat diet (15% fat) with n-3 fish oils vs AHA Step I diet (fat ≤ 30%)
with olive oil supplements)
Intervention: 1.98 g/d EPA, 1.32 g/d DHA supplements (EPAX 5500 EE, Tishcon Corp) + low fat diet (<
15% total calories). Dose: 3.3 g/d EPA + DHA
Control: one 1 g olive oil placebo capsules 6 times daily, moderate fat diet (< 30% total calories) (Ameri-
can Heart Association Step 1 diet)
Compliance: assessed by individual food records; intervention 69.2% control 66.7% compliance; also at
12 months there was a significant difference between the fatty acid status of the intervention and con-
trol groups in terms of EPA (P = 0.027), as described in table 3 of the main paper
Duration of intervention: 12 months
Outcomes Main study outcome: physical component scale (PCS)
Dropouts: 3 intervention, 7 control
Weinstock-Guttman 2005 
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Available outcomes: Mental Health Inventory, Modified Fatigue Impact Scale, weight change, HDL and
LDL cholesterol, adverse events (MS relapse, TNF-alpha, ICAM-1, VCAM-1 and other inflammatory mark-
ers, SF-36 not used)
Response to contact: no
Notes Study funding: National Multiple Sclerosis Society (PP0620T), Mellen Center Foundation and ''The Jog
for the Jake'' grant
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk States "randomly assigned", no further details
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "Patients knew the percentage of dietary fat but did not know the as-
signment of capsules oil supplementation."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not reported
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Discrepancy in numbers of participants discontinued and numbers analysed.
Per protocol analysis
Selective reporting (re-
porting bias)
Unclear risk No protocol or trials register entry found
Attention Low risk Treated equally
Compliance Low risk Assessed by individual food records; intervention 69.2% control 66.7% compli-
ance. At 12 months there was a significant difference between the EPA status
of the intervention and control groups (P = 0.027).
Other bias Low risk None noted
Weinstock-Guttman 2005  (Continued)
 
 
Methods Wessex Evaluation of Fatty Liver and Cardiovascular Markers in NAFLD with Omacor Therapy (WEL-
COME)
RCT, parallel, (Omacor or placebo), 15-18 months
Summary risk of bias: low
Participants Patients with NAFLD
N: 51 intervention, 52 control (analysed, 47 intervention, 48 control)
Level of risk for CVD: moderate
WELCOME 2015 
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Men: 49% intervention, 67% control
Mean age in years (SD): 48.6 (11.1) intervention, 54 (9.6) control
Age range: not reported (18-75 years inclusion criteria)
Smokers: 14.3% intervention, 11.8% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: lipid lowering drugs
Medications taken by 20%-49% of those in the control group: antihypertensives, metformin (data not
provided by group)
Medications taken by some, but less than 20% of the control group: none reported
Location: UK
Ethnicity: not reported
Interventions Type: supplement (Omacor capsules)
Comparison: DHA + EPA vs MUFA
Intervention: 4 g OMACOR per day (providing 1.84 g EPA, 1.52 g DHA as ethyl esters)]. Dose: 3.36 g/d EPA
+ DHA
Control: 4 g olive oil capsules/ day (providing; ALA1%, oleic acid 67%, palmitic acid 15%, stearic acid
2%, n-6 fat: 15%)
Compliance: was assessed by recording the returned unused capsules and quantification of erthrocyte
EPA + DHA enrichment (a prespecified threshold of 2% for DHA & threshold of 0.7% for EPA enrichment)
Duration of intervention: 15-18 months
Outcomes Main study outcome: changes in mean liver fat %, changes in 2 liver fibrosis scores, change in serum
biomarkers
Dropouts: 4 intervention, 4 control
Available outcomes: weight, BMI, lipids, blood pressure, glucose, insulin sensitivity, body fat measures,
liver enzymes, HbA1c, serum n-3 FAs, authors provided details of diabetes diagnoses, % body fat, BP
and carotid intima media thickness
Response to contact: yes
Notes Study funding: National Institute for Health Research (NIHR) Southampton Biomedical Research Unit
grant and by a Diabetes UK allied health research training fellowship awarded to KGM (Diabetes UK.
BDA 09/ 0003937). CDB, PCC and ES are supported in part by the NIHR Southampton Biomedical Re-
search Centre. Omacor and placebo were provided by Pronova Biopharma through Abbott Laborato-
ries, Southampton, UK
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were block randomised by an independent clinical trials phar-
macist to treatment with identical capsules by mouth of either n-3 fatty acid
ethyl esters (4 g/d Omacor; Pronova, Sandefjord, Norway) or placebo (4 g/
d olive oil) for a minimum of 15 months and a maximum of 18 months (Mc-
Cormick-2015, p2).
WELCOME 2015  (Continued)
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Patients were randomised according to standardised procedures (comput-
erised block randomisation) by a research pharmacist at University Hospital
Southampton NHS Foundation Trust. Simple randomisation in blocks of 4, ei-
ther to trial medication or placebo was used. (Scorletti-2014, p 2)
Allocation concealment
(selection bias)
Low risk Participants were block randomised by an independent clinical trials phar-
macist to treatment with identical capsules by mouth of either n-3 fatty acid
ethyl esters (4 g/d Omacor; Pronova, Sandefjord, Norway) or placebo (4 g/
d olive oil) for a minimum of 15 months and a maximum of 18 months (Mc-
Cormick-2015, p2). Only the clinical trials pharmacist was unblinded, and ran-
domisation group allocation was concealed from all study members through-
out the trial. (McCormick-2015, p 2).
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Paper states that only the clinical trials pharmacist was unblinded, and ran-
domisation group allocation was concealed from all study members through-
out the trial. However, the trial register record states "single blind (investi-
gator)". Although the capsules were identical, no information provided as to
their smell and taste
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk As above
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk The ITT analysis included all patients randomised who had complete data
(baseline and end-of-study measurements), regardless of whether they were
later found to be ineligible, a protocol violator, given the wrong treatment al-
location, or never treated) (Scorletti 2014, p 4)
Selective reporting (re-
porting bias)
Unclear risk Prospectively registered September 2008, study start September 2009, end
February 2017. Outcome data for cardiac function not yet published, though
other cardiovascular measures reported – take as ongoing as recent end date
Attention Low risk Both groups had the same attention
Compliance Low risk Assessed by recording the returned unused capsules and quantification of
erthrocyte EPA + DHA enrichment (a prespecified threshold of 2% for DHA and
threshold of 0.7% for EPA enrichment). Quote: "Enrichment was highly vari-
able in the DHA+EPA group and 5 and 6 participants in the DHA+EPA group did
not reach the prespecified threshold for EPA and DHA enrichment, respective-
ly. In the placebo group, we expected no enrichment between baseline and
end of study in all participants in this group, but 3 and 4 participants reached
the thresholds set for the DHA+EPA group, for EPA and DHA, respectively. One
participant in the placebo group admitted to taking cod liver oil during the
study and another markedly increased consumption of fish." 10 of 95 non-
compliant
Other bias Low risk None noted
WELCOME 2015  (Continued)
 
 
Methods RCT, parallel, (n-3 DHA vs n-6 LA), 12 months
Summary risk of bias: moderate to high
Participants Otherwise healthy elderly people with mild cognitive impairment.
N: 120 intervention, 120 control (analysed, intervention: 110 control: 109)
Zhang 2017 
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Level of risk for CVD: low
Men: 35.8% intervention, 34.2% control
Mean age in years (SD): 74.5 (2.65) intervention, 74.6 (3.31) control
Age range: eligibility criteria were age 65-85 years at trial start
Smokers: 59.17% intervention, 61.67% control
Hypertension: 9.17% intervention, 7.50% control
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: China
Ethnicity: assumed Chinese
Interventions Type: supplement (capsule)
Comparison: DHA vs corn oil (n-6)
Intervention: 1 capsule twice a day, with meals, including 2 g algal DHA (45-55% DHA by weight). Martek
Biosciences, Columbia, MD. Dose: ˜1 g/d DHA
Control: corn oil, orange-flavoured and orange colour to protect the study blind
Compliance: participants were asked to return any remaining tablets. Compliance was defined as a ra-
tio (actually taken/should have taken). Achieved 97% for intervention, 95% for control. Serum levels of
DHA also measured, DHA at 6 months barely higher in intervention than in controls
Duration of intervention: 12 months
Outcomes Main study outcome: cognitive function and hippocampal volume
Dropouts: 10 intervention, 11 control
Available outcomes: mortality, cognitive outcomes and cerebral volume measurements
Response to contact: no reply to date
Notes Study funding: Chinese Nutrition Society (CNS) Nutrition Research Foundation- DSM Research Fund
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated, also statistics analyst ignorant to this study used ran-
dom number table
Allocation concealment
(selection bias)
Unclear risk Insufficient information
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Placebo capsules … identical in appearance. All capsules were or-
ange-flavoured and orange colour to protect the study blind . Packaged into
identical pots, each containing 180 capsules, and labelled by staC who were
not involved in the study. A blinding key linked each participant to his or her
assigned treatment. This key was kept by an investigator not involved in any
Zhang 2017  (Continued)
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data collection or analyses, in a secure electronic file. The code was revealed
at the completion of the trial following analyses of the main study aims.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk All project staC were unaware of group assignments until the completion of
the trial and after data analysis
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk They did not describe how they imputed missing data (lost contact with pa-
tients, but called this an ITT analysis). Overall well matched and not high attri-
tion.
Selective reporting (re-
porting bias)
Low risk Registered trial prospectively. Outcomes match protocol
Attention Low risk "Adherence was encouraged and monitored throughout the trial by telephone
assessment at 15 time points, and by blood assay at baseline" 6 months and
12 months. This and assessments were described as same for both arms.
Compliance Unclear risk Quote: "participants were requested to return any remaining tablets in order
to measure compliance, together with the replenishment of capsules for the
following month." Compliance … defined "as a ratio = actually taken/should
have taken". "Adherence was encouraged and monitored throughout the trial
by telephone assessment at 15 time points, and by blood assay at baseline" 6
months and 12 months
On compliance tree, leads to "No, because no P values were supplied" there-
fore risk of compliance bias unclear
Other bias Unclear risk Although the register says single blind, the publication very clearly describes a
double-blind RCT
Zhang 2017  (Continued)
 
 
Methods RCT, parallel, (n-3 fish oil + amiodarone vs amiodarone), 12 months
Summary risk of bias: moderate or high
Participants Patients with persistent atrial fibrillation (AF) referred to cardioversion
N: 23 intervention, 24 control
Level of risk for CVD: high
Men: 47.8% intervention, 37.5% control
Mean age in years (SD): 62 (12) intervention, 61 (11) control
Age range: 37-81
Smokers: not reported
Hypertension: 56.5% intervention, 50% control
Medications taken by at least 50% of those in the control group: all patients received amiodarone (an
antiarrhythmic medication)
Medications taken by 20%-49% of those in the control group: beta-blockers, statins, ACE inhibitors and
ARBs
Medications taken by some, but less than 20% of the control group: calcium antagonists
Özaydin 2011 
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
207
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Location: Turkey
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: LCn3 vs nil
Intervention: 2 g/d n-3 PUFA (Marincap, Kocak, Turkey). 4 × 500 mg capsules providing EPA 18% (360
mg/d); DHA 12% (240 mg/d). Dose: 0.6 g/d EPA + DHA
Control: no placebo. Amiodarone was given to both groups.
Compliance: no details
Duration of intervention: 12 months or AF recurrence
Outcomes Main study outcome: AF recurrence(endpoint)
Dropouts: no details
Available outcomes: all cause mortality (nil death), stroke, TIA, AF recurrence (hyperthyroidism diagno-
sis, hospitalisation)
Response to contact: not yet attempted
Notes Study funding: unclear
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details
Allocation concealment
(selection bias)
Unclear risk Quote: "randomised"; no further details
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No placebo
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No details
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All were accounted for
Selective reporting (re-
porting bias)
Unclear risk No trial registry entry or protocol found
Attention Low risk Both groups seem to have the same care
Compliance Unclear risk No information
Other bias Low risk None noted
Özaydin 2011  (Continued)
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ACE: angiotensin-converting enzyme; ADAS: Alzheimer's Disease Assessment Scale; ADL: activities of daily living; AF: atrial fibrillation;
AHA: American Heart Association; BMI: body mass index; ALT: alanine transaminase; ARB: angiotensin-receptor blocker; BMD: bone min-
eral density; BMI: body mass index; BP: blood pressure; CABG: coronary artery bypass grafting; CDAI: Clinical Disease Activity Index; CHD:
coronary heart disease; CHO: carbohydrate; CV: cardiovascular;CRP: C-reactive protein; CVD: cardiovascular disease; DAS: Disease Activ-
ity Score; DBP: diastolic blood pressure; DHA: docosahexaenoic acid; DM: diabetes mellitus; DMARD: disease-modifying antirheumatic
drugs; DPA: docosapentaenoic acid; E: dietary energy; ECG: electrocardiogram; EDSS: Expanded Disability Status Scale; EPA: eicosapen-
taenoic acid; ESR: erythrocyte sedimentation rate; FA: fatty acid; FFQ: food frequency questionnaire; FH: family history; FMD: flow-medi-
ated dilation; GFR: glomular filtration rate; GLA: gamma linolenic acid; HbA1c: glycated haemoglobin; HCQ: hydroxychloroquine; HDL:
high-density lipoprotein; H/O: personal history of; HOMA-IR: homeostatic model assessment of insulin resistance; HRT: hormone replace-
ment therapy; HT: hypertension; IBD: inflammatory bowel disease; IADL: instrumental activities of daily living; ICAM-1: intercellular ad-
hesion molecule 1; IL: interleukin;IMT: immune-mediated thrombocytopenia; IQR: interquartile range; LCn3: long-chain omega-3 fatty
acids; LDL: low-density lipoprotein; MD: mean difference; MDA: malondialdehyde; MI: myocardial infarction; MMSE: Mini–Mental State
Examination; MS: multiple sclerosis; MUFA: mono-unsaturated fatty acids; MXT: methotrexate;n-3: omega-3; NASH: non-alcoholic steato-
hepatitis; NSAID: non-steroidal anti-inflammatory drug; PAI1: plasminogen activator inhibitor-1; PI: principal investigator;PUFA: poly-un-
saturated fatty acids; PTCA: percutaneous transluminal coronary angioplasty; P/S: poly-unsaturated/saturated fat ratio; QoL: quality of
life; QUICKI: quantitative insulin sensitivity check index; RA: rheumatoid arthritis; RCT: randomised controlled trial; SBP: systolic blood
pressure; SD: standard deviation;SE: standard error; RCT: randomised controlled trial; SFA: saturated fatty acids; SSZ: sulfasalazine; TAG:
triacylglycerol; TG: serum triglycerides; TIA: transient ischaemic attack; TNF: tumour necrosis factor; VCAM-1: vascular cell adhesion mol-
ecule 1; WHO: World Health Organization.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Alekseeva 2000 Study not randomised
Baleztena 2015 No relevant outcomes measured
Belch 1988 No relevant outcomes measured
Belluzzi 1996 Authors confirmed no relevant outcomes measured
Berthoux 1992 Participants not adult humans, or participants unwell at baseline
Borchgrevink 1966 Mean duration of intervention 10 months (range 3 to 16 months)
Busnach 1998 Participants not adult humans, or participants unwell at baseline
CANN 2015 Intervention is multifactorial (FA/flavanoid blend)
Cappelli 1997 Participants not adult humans, or participants unwell at baseline
CARES 2015 Multisupplement intervention
Cheng 1990a No appropriate control group
Cheng 1990b No appropriate control group
Clark 1993 No relevant outcomes measured
Clark 1994 Participants not adult humans, or participants unwell at baseline
Clark 2001 Participants not adult humans, or participants unwell at baseline
Clausen 1989 Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, be-
havioural or drug interventions)
Diskin 1990 No omega-3 supplementation or dietary advice
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Study Reason for exclusion
Donadio 1994 Participants not adult humans, or participants unwell at baseline
Doyle 2001 Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, be-
havioural or drug interventions)
Dry 1991 No relevant outcomes measured
Ezaki 1999 Study not randomised
Feher 2005 Intervention is multifactorial (omega 3 given with coenzyme Q and other compounds vs placebo)
FISH 2012 No clinical outcomes collected (confirmed by corresponding author, 30 November 2016)
Fonolla 2009 Intervention was milk enriched with EPA and DHA but also other vitamins and minerals - multifac-
torial dietary intervention
Fonolla-Joya 2016 Intervention was milk enriched with EPA and DHA but also other vitamins and minerals - multifac-
torial dietary intervention
Franzen 1989 Study not randomised
Galarraga 2008 9-month intervention period
Gapparova 2000 Study not randomised
Gazso 1992 No omega-3 supplementation or dietary advice
Geusens 1994 No relevant outcomes measured
Gogos 1998 Participants not adult humans, or participants unwell at baseline
Greatrex 2000 Study not randomised
Griffin 1999 Study not randomised
Hamazaki 1984 Participants not adult humans, or participants unwell at baseline
Hansen 1996 Multi-factorial intervention (cannot separate effects of omega-3 fats from those of other dietary,
behavioural or drug interventions)
Harris 1991 No appropriate control group
Hashimoto 2012 No relevant outcomes measured
Hashimoto 2016 No relevant outcomes measured
Hawthorne 1992 Authors confirmed no relevant outcomes measured
HEARTS 2015 Intervention included intensive behavioural changes including exercise and nutrition counselling
geared towards weight loss
Hogg 1995 Participants not adult humans, or participants unwell at baseline
HOPE epilepsy 2012 Trial recruitment was suspended due to lack of funding
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Study Reason for exclusion
Huang 1996 No relevant outcomes measured
Huang 2008 Intervention was 9 months and no relevant outcomes
ISRCTN38354847 The proposed one-year study was never conducted
Junker 1990 Follow-up not at least a year
Kachorovskii 1977 No omega-3 supplementation or dietary advice
Kanorskii 2007 LCn3 compared to sotalol (group 1), sotalol & perindopril (group 2), sotalol, perindopril & rosuvas-
tatin (group 3), so no useful control group
Karlsson 1998 Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, be-
havioural or drug interventions)
Kaul 1992 Intervention duration 6 months
Khan 2003 Intervention was 8 months
Konya 2000 Study not randomised
Kremer 1995 < 1 year duration
Kruger 1998 No relevant outcomes measured
Kurabayashi 2000 < 1 year duration
Lau 1993 Authors confirmed no relevant outcomes
Leaf 1995 Study not randomised
Lee 2010 Authors confirmed no relevant outcomes measured
Leng 1998 Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, be-
havioural or drug interventions)
LipiDiDiet 2016 Multifactorial dietary intervention that included omega 3 fats but many other nutrition compo-
nents
Loeschke 1996 No relevant outcomes measured
LUTEGA 2013 Multisupplement intervention
Lyon Diet Heart 1994 Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary in-
terventions)
Maachi 1995 Participants not adult humans, or participants unwell at baseline
Macsai 2008 No relevant outcomes measured
Mansel 1990 Not an omega-3 intervention
Mantzaris 1996 No relevant outcomes measured
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Study Reason for exclusion
Mate-Jimenez 1991 Authors confirmed no relevant outcomes
Matsuyama 2005 Publication retracted (fraudulent)
Middleton 2002 Unbalanced intervention as the intervention arm contains additional GLA
MoodFOOD 2016 Multisupplement intervention
NAYAB 2017 No planned relevant outcomes. Follow-up < 12 months
NCT01235533 48 weeks intervention planned in trials register entry
NU-AGE 2014 Multifactorial dietary intervention
NutriMEMO 2014 Mutlisupplement intervention
OFAMS 2012 No relevant outcomes measured
Okuda 1996 No appropriate control group
OLIVE 1998 Study was not funded and did not achieve full recruitment (info provided by co-author)
Oslo DIET HEART 1970 Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, be-
havioural or drug interventions)
Pogozheva 1997 Study not randomised
Pogozheva 2000 Study not randomised
Puri 2008 Authors confirmed no relevant outcomes
Quazi 1994 Study not randomised, < 1 year intervention
Sacks 1994 < 1 year intervention
Saynor 1988 Study not randomised
Saynor 1992 No appropriate control group
Selvais 1995 Intervention was < 1 year
Shimizu 1995 Authors confirmed no relevant outcomes
Singh 1992 Expressions of concern issued by the BMJ and The Lancet regarding research by this first author
(BMJ 2005; Horton 2005)
Singh 1997a Expressions of concern issued by theBMJ and The Lancet regarding research by this first author
(BMJ 2005; Horton 2005)
Singh 1997b Expressions of concern issued by the BMJ and The Lancet regarding research by this first author
(BMJ 2005; Horton 2005)
Singh 2002 Expressions of concern issued by the BMJ and The Lancet regarding research by this first author
(BMJ 2005; Horton 2005)
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Study Reason for exclusion
Tariq 1989 Participants not adult humans, or participants unwell at baseline and intervention is < 1 year
Terano 1999 Authors confirmed no relevant outcomes during trial
Tomer 2001 No relevant outcomes. Measured lipids but unclear baseline and endpoint is probably 4 weeks
Torjesen 1997 Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, be-
havioural or drug interventions)
VSDR 2015 The supplement (Nutrof Omega) contained DHA, Vit C, E, B1, B2, B3, B6, B9, B12, Zn, Mn, Se, Cu,
lutein and zeaxanthin (multifactorial dietary intervention)
Wheaton 2010 Participants were not a minimum of 18 years old
Yasui 2001 No appropriate control group
Zinger 1987 Study not randomised
DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; FA: fatty acid; GLA: gamma linolenic acid.
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Aboriginal Cardiovascular Omega-3 randomised controlled trial (AC Omega3)
Methods RCT
Participants Indigenous Australian adults with stable coronary artery disease
Interventions Each for 12 months:
Arm 1: omega-3 (1800 mg/d AlaskOmega: 3 capsules/d: 400 mg EPA and 200 mg DHA)
Arm 2: placebo mixed oil capsules (1000 mg/d: 3 capsules/d containing palm oil, gelatin, glycerol,
sunflower oil, rapeseed oil, mixed tocopherols, and a "small amount" of fish oil (for taste to aid
blinding)
Outcomes Primary: serum non-HDL-C
Secondary: triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, lipid functionality by
cholesterol efflux and CETP, heart rate variability, platelet function and thrombosis markers, in-
flammation markers, cumulative combined rate of major adverse cardiac events (including death,
non-fatal MI, unstable angina, non-fatal stroke, revascularisation and cardiac related hospital ad-
missions)
Starting date Registered on trials registry: 10 July 2014
Study start date: 1 October 2014
Estimated study completion date: unclear
Contact information Alex Brown (PI), Wardliparingga Aboriginal Unit, Adelaide, Australia, alex.brown@sahmri.com
Notes ACTRN12614000732684
Alex Brown contacted in 2016: confirmed study is actively recruiting
AC Omega3 2014 
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Trial name or title Atorvastatin in Factorial with Omega-3 fatty acid Risk Reduction in Diabetes (AFORRD)
Methods RCT
Participants Patients with type 2 diabetes with no known CVD and not taking lipid-lowering therapy, adults (>
18 years)
N: intervention 397, control 403 (analysed intervention 371, control 361)
Interventions Each for 12 months:
Arm 1: atorvastatin (Lipitor 20 mg/d) and olive oil placebo (2 g/d)
Arm 2: omega-3 (Omacor 2 g/d: 46% EPA, 38% DHA) and placebo tablets for atorvastatin
Arm 3: atorvastatin (Lipitor 20 mg/d) and Omega-3 (Omacor 2 g/d: 46% EPA, 38% DHA)
Arm 4: placebo tablets for atorvastatin and olive oil placebo (2 g/d)
Outcomes Primary: lipid profiles
Secondary: phytosterol changes, HbA1c, estimated CVD risk using the UK Prospective Diabetes
Study risk engine
Starting date Registered on trials registry: 4 April 2004
Study start date: 1 November 2004
Estimated study completion date: 31 July 2006
Contact information Rury Holman, Oxford Centre for Diabetes
Notes ISRCTN76737502
Rury Holman contacted in 2016: confirmed results are not yet published, but planned
AFORRD 2010 
 
 
Trial name or title A Study of Cardiovascular Events iN Diabetes (ASCEND)
Methods RCT
Participants Patients with diabetes, without vascular disease
Interventions Each for 7 years:
Arm 1: omega-3 (1 g/d: 0.41 g EPA, 0.34 g DHA) and placebo tablets for aspirin
Arm 2: aspirin (100 mg/d) and olive oil placebo capsule
Arm 3: omega-3 (1 g/d) and aspirin (100 mg/d)
Arm 4: olive oil placebo and placebo tablets for aspirin
Outcomes Primary: cardiovascular events
Secondary: mortality, hospitalisations, cancer
ASCEND 2012 
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Starting date Registered on trials registry: 24 August 2005
Study start date: March 2005
Estimated study completion date: September 2017
Contact information Jane Armitage (PI), University of Oxford Clinical Trial Service Unit
Notes NCT00135226
Trial website: ascend.medsci.ox.ac.uk; rum.ctsu.ox.ac.uk/ascend
ASCEND 2012  (Continued)
 
 
Trial name or title Clinical efficacy of fish oil as adjunct therapy for patients with chronic periodontitis
Methods RCT
Participants Patients (25-80 years, non-smokers) with newly diagnosed severe but non-aggressive periodontitis
Interventions Each for 13 months:
Arm 1: fish oil rich in EPA (6 × 500 mg capsules/d: 277 mg EPA; 27 mg DHA) and standard periodon-
tal treatment (scaling and debridement)
Arm 2: fish oil rich in DHA (6 × 500 mg capsules/d: 66 mg EPA; 258 mg DHA) and standard periodon-
tal treatment
Arm 3: soya oil placebo (6 × 500 mg capsules/d) and standard periodontal treatment
Outcomes Primary: probing pocket depth, clinical attachment level (CAL)
Secondary: inflammatory biomarkers in gingival crevicular fluid, erythrocyte omega-3, C-reactive
protein
Starting date Registered on trials registry: 23 July 2010
Study start date: July 2010
Estimated study completion date: unclear
Contact information Mark Bartold, University of Adelaide, mark.bartold@adelaide.edu.au
Notes ACTRN12610000594022
PhD, Boram Park, available giving 4 month outcome data for pilot study N = 33 participants
Mark Bartold written to in 2016. Confirmed preparing full publications for submission
Bartold 2010 
 
 
Trial name or title Beyond Ageing Project phase 2: a selective prevention trial using novel pharmacotherapies in an
older age cohort at risk for depression
Methods RCT
Beyond Aging Project 2015 
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Participants Older adults (60+ years) at risk of depression (K-10 score ranging from 16-29) who initially partici-
pated in the first Beyond Ageing Project
Interventions Each for 12 months:
Arm 1: omega-3 (4 capsules, total 2 g/d: 1200 mg EPA and 800 mg DHA) and placebo microcrys-
talline cellulose (1 capsule)
Arm 2: paraffin oil placebo (4 capsules) and sertraline hydrochloride (1 capsule, 50 mg)
Arm 3: paraffin oil placebo (4 capsules) and placebo microcrystalline cellulose (1 capsule)
Outcomes Primary: depressive symptoms (PHQ-9, patient health questionnaire 9)
Secondary: cognitive decline, MMSE, brain metabolism, hippocampal volume, anxiety (assessed
using GAD-7), disability (WHODAS-II), sleeping problems (PSQI, Pittsburgh Sleep Quality Index), ex-
ercise (Active Australian Survey)
Starting date Registered on trials registry: 12 January 2010
Study start date: June 2011
Estimated study completion date: main results expected in 2017
Contact information Ian Hickie (PI), Brain and Mind Centre, University of Sydney, ian.hickie@sydney.adu.au
Notes ACTRN12610000032055
Beyond Aging Project 2015  (Continued)
 
 
Trial name or title Long-term effects of a reduced fat diet intervention in pre-diabetes
Methods RCT
Participants Participants with pre-diabetes, impaired fasting glucose (IFG) or impaired glucose tolerance (IGT),
201 participants discussed in one abstract, 134 in a later abstract
Interventions Each for 3 years:
Arm 1: reduced fat diet (fat content at or below 20% total energy, ratio of PUFA/SFA 0.8 to 1.0)
Arm 2: normal/control diet
Outcomes Incidence of diabetes, BMI, lipids, insulin, plasma glucose, HbA1c, blood pressure, nutritional in-
take
Starting date Registered on trials registry: no registration found
Study start date: not stated
Estimated study completion date: not stated
Contact information Chandrakala Galla, chandrakala.galla@gmail.com; Arpana Gaddam, dr.arpanag@gmail.com
Notes Authors written to in 2016: Dr Gaddam confirmed work submitted as a PhD but not published in
full. Requested copy of PhD thesis, but no reply to date.
Funding: DiabetOmics India
Chandrakala 2010 
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Trial name or title Influence of different sources of n-3 fatty acid on plasma lipid in moderately hypercholestero-
laemic subjects
Methods RCT
Participants Adults (40-65 years) with mild to moderate hypercholesterolaemia
Interventions Arm 1: EPA/DHA 1.8 g/d
Arm 2: EPA/DHA 3.6 g/d
Arm 3: ALA 4 g/d
Arm 4: placebo
Outcomes Fatty acids, lipids, cytokines (IL-6, IL-1a)
Starting date Registered on trials registry: 13 March 2012
Study start date: unclear
Estimated study completion date: unclear
Contact information Su Yixiang, Sun-Yat Sen University, China, suyx@mail.sysu.edu.cn; Zhou Quan, Guangzhou Medical
University, joan_zq@126.com
Notes ChiCTR-TRC−12002014
Su Yixiang and Zhou Quan contacted in 2016: no response
ChiCTR-TRC-12002014 
 
 
Trial name or title Vitamin D3- omega3- home exercise- healthy ageing and longevity trial (DO-HEALTH)
Methods RCT
Participants Community dwelling adults 70 years and older, 50% of seniors enrolled based on a fall in the year
before enrolment
Interventions Each for 3 years:
Arm 1: omega-3 (1 g/d, ratio EPA:DHA = 1:2) and vitamin D3 (2000 IU/d) capsules and strength home
exercise (3 × 30 min/week)
Arm 2: omega-3 (1 g/d, ratio EPA:DHA = 1:2) and vitamin D3 (2000 IU/d) capsules and flexibility
home exercise (3 × 30 min/week)
Arm 3: omega-3 (1 g/d, ratio EPA:DHA = 1:2) and placebo capsules and strength home exercise (3 ×
30 min/week)
Arm 4: omega-3 (1 g/d, ratio EPA:DHA = 1:2) and placebo capsules and flexibility home exercise (3 ×
30 min/week)
Arm 5: placebo and vitamin D3 (2000 IU/d) capsules and strength home exercise (3 × 30 min/week)
Arm 6: placebo and vitamin D3 (2000 IU/d) capsules and flexibility home exercise (3 × 30 min/week)
DO HEALTH 
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Arm 7: placebo and placebo capsules and strength home exercise (3 × 30 min/week)
Arm 8: placebo and placebo capsules and flexibility home exercise (3 × 30 min/week)
Outcomes Primary: non-vertebral fractures, functional decline, blood pressure, cognitive decline, rate of any
infection
Secondary: other fractures, falls, pain in knee osteoarthritis, musculoskeletal changes, gastro-in-
testinal symptoms, mental and oral health, quality of life, life-expectancy, cardiovascular events,
cancer, glucose measures, cost-benefit. All endpoints supported by a DO-HEALTH biomarker study
Starting date Registered on trials registry: 6 December 2012
Study start date: December 2012
Estimated study completion date: November 2017
Contact information Heike BischoC-Ferrari (PI), Centre on Aging and Mobility, University of Zurich
Notes NCT01745263
EudraCT: 2012−001249-41
www.do-health.eu
DO HEALTH  (Continued)
 
 
Trial name or title DRy Eye Assessment and Management study (DREAM)
Methods RCT
Participants Adults with dry eye
Interventions Each for 2 years
Arm 1: omega-3 supplements (2000 mg EPA + 1000 mgDHA/d as 5 gel caps)
Arm 2: olive oil supplements (5 gel caps)
Outcomes Primary: OSDI score (ocular surface disease index)
Secondary: other eye health measures, SF-36, healthcare utilisation costs, cost-effectiveness
Starting date Registered on Trials Registry 28 April 2014
Study start date: November 2014
Estimated study completion date: July 2017
Contact information Penny Asbell, Mount Sinai Icahn School of Medicine (Study Chair), Maureen Maguire, University of
Pennsylvania (PI)
Notes NCT02128763
DREAM 2014 
 
 
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
218
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Trial name or title ENabling Reduction of low-Grade Inflammation in SEniors (ENRGISE)
Methods RCT
Participants People aged 70+ years with self-reported walking or stair-climbing difficulty
Interventions Each for 1 year
Arm 1: omega-3 fish oil (1.4 g/d for 6 months, possibly increasing to 2.8 g/d)
Arm 2: losartan 25 mg/d
Arm 3: placebo corn oil (for omega-3) plus placebo cellulose (for losartan)
Arm 4: omega-3 plus losartan
Arm 5: placebo corn oil (for omega-3)
Arm 6: placebo cellulose (for losartan)
Outcomes Primary: IL-6, 400 meter walk test
Secondary: short physical performance battery, frailty, hand grip strength, knee dynamometry,
SF-36
Starting date Registered on Trials Registry 3 February 2016
Study start date: February 2016
Estimated study completion date: March 2018
Contact information Jane Lu janelu@ufl.edu
Michael Stancil mstancil@ufl.edu
Notes NCT02676466
ENRGISE 2016 
 
 
Trial name or title Intervention of testosterone and fish oil for the prevention of Alzheimer's Disease: InTrePad
Methods RCT
Participants PiB-PET (Pittsburgh compound B) positive men aged 60 years and over with subjective memory
complaints
Interventions Each for 56 weeks:
Arm 1: DHA capsules (1720 mg/d) and testosterone undecanoate (intramuscular injection 1000
mg/4 mL every 8 weeks)
Arm 2: placebo DHA and testosterone undecanoate (intramuscular injection 1000 mg/4 mL every 8
weeks)
Arm 3: placebo DHA and placebo testosterone
Outcomes Primary: PiB score
InTrePad 2013 
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
219
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Secondary: neuropsychological, mood and daily functioning questionnaires, beta amyloid levels,
fluorodeoxyglucose to assess brain glucose metabolism, inflammatory and oxidative biomarkers,
hippocampal volume, quality of life, safety and tolerability of treatment
Starting date Registered on trials registry: 14 January 2013
Study start date: 28 February 2013
Estimated study completion date: not stated
Contact information Ralph Martins (PI), Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Medical Cen-
tre, Nedlands, Australia, r.martins@ecu.edu.au
Notes ACTRN12613000034730
Ralph Martins written to in 2016- no response
InTrePad 2013  (Continued)
 
 
Trial name or title Long-term effects of interventional strategies to prevent cognitive decline in elderly (MAPT PLUS)
Methods RCT – extension of MAPT trial
Participants Participants of MAPT trial
Interventions Follow-up 2 year extension of patients in MAPT, after completion of MAPT interventions
Outcomes Primary: cognitive and functional status (Grober and Buschke test)
Secondary: markers of cerebral atrophy, cost-effectiveness
Starting date Registered on trials registry: 30 December 2011
Study start date: December 2011
Estimated study completion date: November 2016
Contact information Bruno Vellas (PI), University Hospital, Toulouse, vellas.b@chu-toulouse.fr
Notes NCT01513252
Bruno Vellas written to in 2016- no response
MAPT PLUS 
 
 
Trial name or title Omega 3 fatty acids in bipolar disorder prophylaxis
Methods RCT
Participants People aged 18 to 65 with bipolar disorder
Interventions Each for 12 months:
Arm 1: omega-3
NCT00010868 
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Arm 2: placebo
Outcomes Prophylactic efficacy
Starting date Trial Registration entry: 2 February 2001
Trial start date: July 2000
Estimated study completion: July 2004
Contact information Andrew Stoll, Mclean Hospital
Notes NCT00010868
The PI, Andrew Stoll, appears to have been struck oC the medical register in Massachusetts in 2011
(Commonwealth of Massachusetts Board of Registration in Medicine, Adjudicatory Case number
2011−026) so it has not been possible to contact him and no publication of results has been found
NCT00010868  (Continued)
 
 
Trial name or title Studies of serum PSA (prostate specific antigen) to help resolve the current implication of al-
pha-linolenic acid and prostate cancer
Methods RCT
Participants Adults 18-77 years
Interventions Arm 1: ALA rich diet
Arm 2: control (not detailed)
Outcomes Prostate specific antigen, atrial fibrillation
Starting date Registered on trials registry: 29 March 2006
Study start date: unclear
Estimated study completion date: unclear
Contact information David Jenkins, University of Toronnto, nutritionproject@smh.toronto.on.ca
Notes NCT00309439
David Jenkins written to in 2016: confirmed not published in full and data incomplete
NCT00309439 
 
 
Trial name or title Arrhythmia prevention with an alpha-linolenic enriched diet
Methods RCT, parallel, 2 arm, 12 months
Participants 98 people with successful atrial fibrillation electrical cardioversion
Interventions Canola margarine and oil, rich in ALA, versus a conventional diet (control), for 1 year
NCT00410020 
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Outcomes Length of time to first recurrence of AF
Starting date June 1999, expected finish date June 2003, registered December 2006 so appears to have been car-
ried out
Contact information Principal Investigator: Jean-Paul Broustet, MD, PhD, Universitary Hospital Haut-Lévêque Bordeaux
France
Notes NCT00410020, registered December 2006, no publication found
NCT00410020  (Continued)
 
 
Trial name or title Dietary energy restriction and omega-3 fatty acids on mammary tissue
Methods RCT
Participants Overweight women (30-55 years) with increased breast cancer risk
Interventions For 1 year:
Arm 1: lovaza (omega-3-acid ethyl esters)
Arm 2: lovaza and dietary energy restriction
Arm 3: placebo
Arm 4: placebo and dietary energy restriction
Outcomes Ki67 expression at 1 year
Starting date Registered on trials registry: 31 January 2013
Study start date: March 2013
Estimated study completion date: March 2018
Contact information Andrea Manni, Hershey Medical Centre, amanni@hmc.psu.edu (PI) or Cynthia DuBrock,
cdubrock@hmc.psu.edu
Notes NCT01784042. Trials register states "Withdrawn (no funding)"
NCT01784042 
 
 
Trial name or title Investigating a phosphatidylserine based dietary approach for the management of mild cognitive
impairment
Methods RCT
Participants People with mild cognitive impairment (MCI) aged 65-85 years
Interventions Each for 24 months:
Arm 1: phosphatidylserine omega-3 (DHA enriched)
Arm 2: placebo cellulose capsules
NCT02211560 
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Outcomes Primary: selective reminding test (SRT)
Secondary: mini mental state examination (MMSE), neurological battery test (NBT), dementia
(DSM-4 criteria), mini sleep questionnaire (MSQ), Hamilton Anxiety rating scale (HAM-A), safety and
adverse events
Starting date Registered on trials registry: 6 August 2014
Study start date: September 2014
Estimated study completion date: September 2019
Contact information Nadia Niemerzyanski, nadiaN@enzymotec.com; Yael Richter, yaelr@enzymotec.com
Notes NCT02211560
NCT02211560  (Continued)
 
 
Trial name or title Omega 3 fatty acids and ERPR(-)HER2(±) breast cancer prevention
Methods RCT
Participants Women at risk for recurrent breast cancer- with prior diagnosis of stage 0 to III breast cancer and
completion of surgery, chemotherapy or trastuzumab or radiation therapy
Interventions Each for 12 months:
Arm 1: omega-3 high dose capsules (5 g/d EPA + DHA)
Arm 2: omega-3 low dose capsules (0.9 g/d EPA + DHA)
Outcomes Primary: breast adipose tissue metabolites
Secondary: cytomorphology or cell proliferation of mammary epithelial cells, DNA promoter
methylation and pro-inflammatory gene expression in mammary epithelial and adipose tissue
Starting date Registered on trials registry: 14 October 2014
Study start date: August 2014
Estimated study completion date: January 2019
Contact information Anitra Sumbry, anitra.sumbry@osumc.edu; Lisa Yee (PI), Ohio State University
Notes NCT02295059
NCT02295059 
 
 
Trial name or title Impact of icosapent ethyl on Alzheimer's disease (AD) biomarkers in preclinical adults
Methods RCT
Participants Cognitively healthy adults aged 50 to 70 years whose parents had AD
Interventions Each for 18 months:
NCT02719327 
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Arm 1: Icosapent ethyl EPA (Vascepa) 4 g/d gel cap
Arm 2: matching gel cap placebo
Outcomes Primary: cerebral blood flow by MRI (magnetic resonance imaging)
Secondary: CSF biomarkers of AD, cognitive performance (preclinical Alzheimer's cognitive com-
posite, PACC)
Starting date Registered on trials registry: 21 March 2016
Study start date: December 2016
Estimated study completion date: November 2021
Contact information Cynthia Carlsson, cynthia.carlsson@va.gov; Elena Beckman, elena.beckman@va.gov
Notes NCT02719327
NCT02719327  (Continued)
 
 
Trial name or title OMega-3 fatty acids in Elderly patients with Myocardial Infarction study (OMEMI)
Methods RCT
Participants Elderly patients (70-82 years) with acute MI
Interventions Each for 24 months:
Arm 1: omega-3 capsules, 3/d (Pikasol, total of 1.8 g/d EPA + DHA) and standard therapy
Arm 2: corn oil placebo, 3/d and standard therapy
Outcomes Primary: composite of total mortality, first non-fatal recurring AMI, stroke and revascularisation
Secondary: new onset atrial fibrillation, adipose tissue, serum fatty acids, makers of endothelial
function, inflammation, coagulation and fibrinolytic activity, genes associated with atherothrom-
bosis
Starting date Registered on trials registry: 16 April 2013
Study start date: November 2012
Estimated study completion date: November 2019
Contact information Svein Solheim, Center for Clinical Heart Research, Oslo University Hospital, arnljot.tveit@vestre-
viken.no
Notes NCT01841944
OMEMI 2014 
 
 
Trial name or title Reduction of cardiovascular events with EPA-intervention trial (REDUCE-IT)
Methods RCT
REDUCE-IT 2011 
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Participants Patients (45 years or over) with hypertriglyceridaemia, with cardiovascular disease or at high risk
for cardiovascular disease, and on statin
Interventions Each for 4-6 years:
Arm 1: EPA ethyl ester (AMR101 4 g/d)
Arm 2: placebo
Outcomes Primary: composite of cardiovascular death, MI, stroke, coronary revascularisation and hospitalisa-
tion for unstable angina
Secondary: incidence of additional cardiovascular events, lipid and lipoprotein levels
Starting date Registered on trials registry: 13 December 2011
Study start date: November 2011
Estimated study completion date: December 2017
Contact information Deepak Bhatt (PI), Brigham and Women's Hospital
Notes NCT01492361
REDUCE-IT 2011  (Continued)
 
 
Trial name or title The seAFOod (systematic evaluation of Aspirin and Fish Oil) Polyp Prevention Trial
Methods RCT
Participants NHS Bowel Cancer Screening Programme patients (55-73 years) identified as "high risk" (5 or more
small adenomas; or 3 or more adenomas with at least one being 10 mm or more in diameter) after
their 1st screening colonoscopy
Interventions Each for 12 months:
Arm 1: EPA (ALFA capsules: 2 × 500 mg twice daily = 2 g/d) and aspirin placebo (1/d)
Arm 2: EPA placebo (capric and capryllic acid triglycerides: 2/d) and aspirin (1/d = 300 mg/d)
Arm 3: EPA (ALFA capsules: 2 × 500 mg twice daily = 2 g/d) and aspirin (1/d = 300 mg/d)
Arm 4: EPA placebo (cparic and capryllic acid triglycerides: 2/d) and aspirin placebo (1/d)
Outcomes Primary: number of patients with one or more adenomas at 12 months
Secondary: adverse events, number of "advanced" adenomas per patients, number of "high risk"
patients re-classified as "intermediate risk", number patients with one or more advanced adeno-
mas, adenoma region in the colorectum, total number of adenomas per patient, number of pa-
tients with colorectal cancer, levels of bioactive lipid mediators e.g. omega-3
Starting date Trial Registration entry: 6 May 2011
Trial start date: 30 May 2011
Estimated study completion: 31 July 2017
Contact information Mark Hull, Leeds Institute of Molecular Medicine, m.a.hull@leeds.ac.uk
seAFOOD 2013 
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
225
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Notes ISRCTN05926847
EudraCT 2010−020943−10
www.seafood-trial.co.uk
seAFOOD 2013  (Continued)
 
 
Trial name or title N-3 PUFA for vascular cognitive aging
Methods RCT
Participants Older adults (80 years and older) at high risk for cognitive decline and dementia of Alzheimer's type
Interventions Each for 3 years:
Arm 1: omega-3 fish oil (1.65 g/d EPA + DHA)
Arm 2: soybean oil placebo (1.65 g/d)
Outcomes Primary: total cerebral white matter volume
Secondary: biomarkers of endothelial health, total brain atrophy, medial temporal lobe atrophy,
ventricular expansion, trail making test part B, digit symbol WAIS-R, cerebral blood flow, fractional
anisotropy within frontal gyri
Starting date Registered on trials registry: 24 September 2013
Study start date: May 2014
Estimated study completion date: March 2019
Contact information Alena Borgatti, borgatti@ohsu.edu; James Dursch, dursch@ohsu.edu; Gene Bowman and Lynne
Shinto (PIs), Oregon Health and Science University
Notes NCT01953705
Shinto 2015 
 
 
Trial name or title A long-term outcomes study to assess statin residual risk reduction with EpaNova in high cardio-
vascular risk patients with hypertriglyceridemia (STRENGTH)
Methods RCT
Participants Adult patients with hypertriglyceridaemia and low HDL and high risk for CVD
Interventions Each for 3-5 years:
Arm 1: omega-3 carboxylic acid capsule (Epanova, not less than 800 mg/g) and statin (once daily)
Arm 2: corn oil placebo capsule and statin (once daily)
Outcomes Primary: time to first occurrence of any component of the composite MACE (cardiovascular death,
nonfatal MI, nonfatal stroke, emergent/elective coronary revascularisation, hospitalisation for un-
stable angina)
STRENGTH 2015 
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
226
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Secondary: composite measure of cardiovascular events that include the first occurrence of car-
diovascular death, nonfatal MI and non-fatal stroke; composite measure of coronary events that
include the first occurrence of cardiac death; first occurrence of individual components of MACE;
time to cardiovascular death. Other measures include: all cause mortality, new atrial fibrillation,
thrombotic events, heart failure events
Starting date Trial Registration entry: 2 April 2014
Trial start date: October 2014
Estimated study completion: November 2019
Contact information AstraZeneca Clinical Study Information Centre, information.center@astrazeneca.com. PIs Steven
Nissen (Cleveland Clinic), Michael Lincoff (Cleveland Clinic) Stephen Nicholls (Adelaide Clinical Re-
search)
Notes NCT02104817
EudraCT: 2014−001069−28
STRENGTH 2015  (Continued)
 
 
Trial name or title Improving the results of heart bypass surgery using new approaches to surgery and medication
(SUPERIORSVG)
Methods RCT
Participants Adults having coronary artery bypass graW (CABG) using saphenous vein graW (SVG)
Interventions Each for 12 months:
Arm 1: fish oil supplements (2 × 1 g/d Ocean Nutrition capsules: 55% fish oils EPA:DHA 33%:22%)
and SVG conventionally harvested
Arm 2: placebo and SVG conventionally harvested
Arm 3: fish oil supplements (2 × 1 g/d Ocean Nutrition capsules: 55% fish oils EPA:DHA 33%:22%)
and SVG no-touch harvest
Arm 4: placebo and SVG no-touch harvest
Outcomes Primary: proportion of graWs occluded
Secondary: significant stenosis, adverse SVG harvesting events, composite outcome of all-cause
mortality, non-fatal MI and repeat revascularisation
Starting date Registered on trials registry: 12 January 2010
Study start date: July 2011
Estimated study completion date: December 2016
Contact information Stephen Fremes, Sunnybrook Health Sciences Centre (PI)
Notes NCT01047449
SUPERIORSVG 2010 
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Trial name or title Effect of PUFA on vascular healing process in hypercholesterolemic patients with ACS
Methods RCT
Participants Hypercholesterolemic patients (20-80 years) with acute coronary syndrome who have received suc-
cessful OCT-guided PCI (optical coherence tomography-guided percutaneous coronary interven-
tion)
Interventions Each for 12 months:
Arm 1: intensive lipid lowering therapy with both statin and EPA + DHA
Arm 2: intensive lipid lowering therapy with both statin and EPA
Arm 3: standard lipid lowering therapy with statins
Outcomes Primary: changes in OCT parameter
Secondary: lipids, serum plasma profile, inflammatory parameters, adverse cardiovascular events
Starting date Registered on trials registry: 1 February 2014
Study start date: 1 February 2014
Estimated study completion date: 30 June 2019
Contact information Shiro Uemura (PI), Nara Medical University, Japan, suemura@naramed-u.ac.jp
Notes UMIN000012825
UMIN000012825 
 
 
Trial name or title VITamin D and omegA-3 triaL (VITAL)
Methods RCT
Participants Multi-ethnic population of > 25,000 apparently healthy adults (men 50 years plus, women 55 years
plus) without cancer or CVD at baseline
Interventions Each for mean 5 years:
Arm 1: omega-3 (Omacor fish oil, EPA + DHA 1 g/d: 465 mg EPA; 375 mg DHA) and placebo
Arm 2: placebo and vitamin D3 (1/d, 2,000IU)
Arm 3: omega-3 (Omacor fish oil, EPA + DHA 1 g/d: 465 mg EPA; 375 mg DHA) and vitamin D3 (1/d,
2000 IU)
Arm 4: placebo and placebo
Outcomes Primary: reduction in risk for total cancer and CVD events (a composite of MI, stroke, and cardiovas-
cular mortality)
Secondary: lowered risk for expanded composite cardiovascular endpoint (MI, stroke, cardiovascu-
lar mortality, coronary revascularisation), the individual components of the primary endpoint, site
specific cancers, mortality, diabetes, hypertension, cognitive decline, autoimmune conditions, in-
fections, chronic respiratory disease, depression, bone health, fractures, chronic knee pain, body
composition, physical disability, falls, plasma biomarker measures
VITAL 2018 
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Starting date Registered on trials registry: 13 January 2010
Study start date: July 2010
Estimated study completion date: December 2017
Contact information JoAnn Manson or Julie Buring (PIs), Brigham and Women's Hospital, Boston and Harvard School of
Public Health, Boston, vitalstudy@rics.bwh.harvard.edu
Notes NCT01169259
www.vitalstudy.org
VITAL 2018  (Continued)
ACS: acute coronary syndrome; AD: Alzheimer's disease; AF: atrial fibrillation; BMI: body mass index; BMI: body mass index; CABG: coro-
nary artery bypass graW; CETP: cholesteryl ester transfer protein; CHD: coronary heart disease; CVD: cardiovascular disease; DHA: do-
cosahexaenoic acid; EPA: eicosapentaenoic acid; GAD-7: generalised anxiety disorder 7; HbA1c: glycated haemoglobin; HDL: high-densi-
ty lipoprotein; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; IL: interleukin; LDL: low-density lipoprotein; MACE: major
adverse coronary event; MI: myocardial infarction; MRI: magentic resonance imaging; OCT: optical coherence tomography; OSDI: ocular
surface disease index; PCI: percutaneous coronary intervention; PHQ-9: patient health questionnaire 9; PI: principal investigator; PSA:
prostate specific antigen; PSQI: Pittsburgh Sleep Quality Index; PUFA: poly-unsaturated fatty acids; RCT: randomised controlled trial; RCT:
randomised controlled trial; SFA: saturated fatty acids; SVG: saphenous vein graW.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   High vs low LCn3 omega-3 fats (primary outcomes)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 All-cause mortality (overall)
- LCn3
39 92653 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.93, 1.03]
2 All-cause mortality - LCn3 -
sensitivity analysis (SA) fixed-
effect
39 90244 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.93, 1.01]
3 All-cause mortality - LCn3 -
SA by summary risk of bias
39 92653 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.93, 1.03]
3.1 Low risk of bias 15 33146 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.94, 1.08]
3.2 Moderate/high risk of bias 24 59507 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.86, 1.03]
4 All-cause mortality - LCn3 -
SA by compliance and study
size
38   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 SA - low risk of compliance
bias
18 15654 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.86, 1.14]
4.2 SA - 100+ randomised 35 92397 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.93, 1.03]
5 All-cause mortality - LCn3 -
subgroup by dose
39 92653 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.93, 1.03]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
5.1 LCn3 ≤150 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 LCn3 > 150 ≤ 250 mg/d 1 407 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.27, 2.18]
5.3 LCn3 > 250 ≤400 mg/d 1 2033 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.56, 0.92]
5.4 LCn3 > 400 ≤ 2400 mg/d 28 87445 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.93, 1.05]
5.5 LCn3 > 2.4 ≤ 4.4 g/d 7 2486 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.67, 1.70]
5.6 LCn3 > 4.4 g/d 2 282 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.03, 3.08]
6 All-cause mortality - LCn3 -
subgroup by replacement
39   Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 LCn3 replacing SFA 5 3279 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.56, 0.92]
6.2 LCn3 replacing MUFA 15 46176 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.90, 1.02]
6.3 LCn3 replacing N-6 9 2806 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.51, 1.09]
6.4 LCn3 replacing CHO 1 281 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.05, 5.65]
6.5 LCn3 replacing nil/low n-3
placebo
10 39601 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.86, 1.14]
6.6 LCn3 replacement unclear 3 3593 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.46, 1.79]
7 All-cause mortality - LCn3 -
subgroup by intervention type
39 92653 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.93, 1.03]
7.1 Dietary advice 3 5554 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.60, 1.35]
7.2 Supplemental foods 2 5039 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.84, 1.24]
7.3 Supplements (capsule) 33 81855 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.92, 1.01]
7.4 Any combination 1 205 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.11, 3.79]
8 All-cause mortality - LCn3 -
subgroup by duration
39 92653 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.93, 1.03]
8.1 Medium duration 1 to < 2
years in study
18 9737 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.82, 1.30]
8.2 Medium-long duration: 2 to
< 4 years in study
14 29234 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.86, 0.96]
8.3 Long duration: ≥ 4 years in
study
7 53682 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.98, 1.09]
9 All-cause mortality - LCn3 -
subgroup by primary or sec-
ondary prevention
39 92653 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.93, 1.03]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
9.1 Primary CVD prevention 17 41202 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.94, 1.08]
9.2 Secondary CVD prevention 22 51451 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.88, 1.04]
10 All-cause mortality - LCn3 -
subgroup by statin use
39 90244 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.92, 1.03]
10.1 LCn3 - ≥50% of control
group on statins
8 40500 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.93, 1.11]
10.2 LCn3 - < 50% of control
group on statins
26 46604 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.88, 1.03]
10.3 LCn3 - use of statins un-
clear
5 3140 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.58, 1.63]
11 Cardiovascular mortality
(overall) - LCn3
25 67772 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.03]
12 CVD mortality - LCn3 - SA
fixed-effect
25 67772 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.89, 1.00]
13 CVD mortality - LCn3 - SA by
summary risk of bias
25 67772 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.03]
13.1 Low risk of bias 9 29133 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.90, 1.09]
13.2 Moderate/high risk of bias 16 38639 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.80, 1.05]
14 CVD mortality - LCn3 - SA by
compliance and study size
24   Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 SA - low risk of compli-
ance bias
12 13244 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.23]
14.2 SA - 100+ randomised 21 67516 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.04]
15 CVD mortality - LCn3 - sub-
group by dose
26 67873 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.03]
15.1 LCn3 ≤ 150 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 LCn3 > 150 ≤ 250 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15.3 LCn3 > 250 ≤ 400 mg/d 1 2033 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.53, 0.91]
15.4 LCn3 > 400 ≤ 2400 mg/d 19 64126 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.89, 1.06]
15.5 LCn3 > 2.4 ≤ 4.4 g/d 4 1432 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.58, 1.77]
15.6 LCn3 > 4.4 g/d 2 282 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.03, 3.08]
16 CVD mortality - LCn3 - sub-
group by replacement
26   Risk Ratio (M-H, Random, 95% CI) Subtotals only
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
16.1 N-3 replacing SFA 3 2537 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.53, 0.90]
16.2 N-3 replacing MUFA 12 44242 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.86, 1.04]
16.3 N-3 replacing N-6 4 1435 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.41, 1.19]
16.4 N-3 replacing carbohy-
drates/sugars
1 281 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.12, 4.07]
16.5 N-3 replacing nil/low n-3
placebo
8 19275 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.73, 0.96]
16.6 Replacement unclear 2 3186 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.05, 5.77]
17 CVD mortality - LCn3 - sub-
group by intervention type
25 67772 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.03]
17.1 Dietary advice 2 5147 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.52, 1.71]
17.2 Supplemental foods 2 5039 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.72, 1.32]
17.3 Supplements (capsule) 21 57586 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.88, 0.99]
17.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18 CVD mortality - LCn3 - sub-
group by duration
25 67772 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.03]
18.1 Medium duration 1 to < 2
years in study
10 6177 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.57, 1.36]
18.2 Medium-long duration: 2
to < 4 years in study
10 26736 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.82, 0.95]
18.3 Long duration: ≥ 4 years in
study
5 34859 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.93, 1.18]
19 CVD mortality - LCn3 - sub-
group by primary or secondary
prevention
25 67772 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.03]
19.1 Primary prevention 7 17931 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.88, 1.09]
19.2 Secondary prevention 18 49841 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.83, 1.06]
20 CVD mortality - LCn3 - sub-
group by statin uses
25 67772 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.03]
20.1 LCn3 - ≥ 50% of control
group on statins
6 23994 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.90, 1.10]
20.2 LCn3 - < 50% of control
group on statins
17 43425 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.82, 1.04]
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20.3 LCn3- Use of statins un-
clear
2 353 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.06, 2.30]
21 Cardiovascular events
(overall) - LCn3
38 90378 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.04]
22 CVD events - LCn3 - SA
fixed-effect
38 90378 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.95, 1.00]
23 CVD events - LCn3 - SA by
summary risk of bias
38 90378 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.04]
23.1 Low risk of bias 14 31649 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.96, 1.05]
23.2 Moderate/high risk of bias 24 58729 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.03]
24 CVD events - LCn3 - SA by
compliance and study size
37   Risk Ratio (M-H, Random, 95% CI) Subtotals only
24.1 SA - low risk of compli-
ance bias
16 13649 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.84, 1.14]
24.2 SA - 100+ randomised 33 90058 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.04]
25 CVD events - LCn3 - sub-
group by dose
38 90453 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.04]
25.1 LCn3 ≤ 150 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
25.2 LCn3 > 150 ≤ 250 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
25.3 LCn3 > 250 ≤ 400 mg/d 1 2033 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.88, 1.05]
25.4 LCn3 > 400 ≤ 2400 mg/d 28 85818 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.93, 1.05]
25.5 LCn3 > 2.4 ≤ 4.4 g/d 7 2180 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.75, 1.28]
25.6 LCn3 > 4.4 g/d 3 422 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.65, 1.81]
26 CVD events - LCn3 - sub-
group by replacement
38   Risk Ratio (M-H, Random, 95% CI) Subtotals only
26.1 N-3 replacing SFA 4 2888 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.04]
26.2 N-3 replacing MUFA 16 45065 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.94, 1.02]
26.3 N-3 replacing n-6 6 1891 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.90, 1.35]
26.4 N-3 replacing carbohy-
drates/sugars
1 258 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.12, 3.98]
26.5 N-3 replacing nil/low n-3
placebo
12 39907 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.85, 1.07]
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26.6 Replacement unclear 3 3429 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.16, 2.07]
27 CVD events - LCn3 - sub-
group by intervention type
38 90378 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.04]
27.1 Dietary advice 3 5248 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.86, 1.49]
27.2 Supplemental foods 2 5039 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.89, 1.17]
27.3 Supplements (capsule) 33 80091 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.91, 1.02]
27.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
28 CVD events - LCn3 - sub-
group by duration
38 90378 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.04]
28.1 Medium duration 1 to < 2
years in study
18 8107 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.68, 1.16]
28.2 Medium-long duration: 2
to < 4 years in study
14 28767 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.93, 1.01]
28.3 Long duration: ≥ 4 years in
study
6 53504 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.91, 1.08]
29 CVD events - LCn3 - sub-
group by primary or secondary
prevention
38 90378 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.04]
29.1 Primary prevention of
CVD
16 39751 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.89, 1.05]
29.2 Secondary prevention 22 50627 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.93, 1.07]
30 CVD events - LCn3 - sub-
group by statin use
38 90378 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.04]
30.1 LCn3 - ≥ 50% of control
group on statins
8 42389 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.89, 1.08]
30.2 LCn3 - < 50% of control
group on statins
24 45160 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.91, 1.04]
30.3 LCn3 - use of statins un-
clear
6 2829 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.53, 1.63]
31 Coronary heart disease
mortality (overall) - LCn3
21 73491 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.09]
32 CHD mortality - LCn3 - SA
fixed-effect
21 73491 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.85, 1.03]
33 CHD mortality - LCn3 - SA by
summary risk of bias
21 73491 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.09]
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33.1 Low risk of bias 7 16372 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.72, 1.37]
33.2 Moderate/high risk of bias 14 57119 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.75, 1.10]
34 CHD mortality - LCn3 - SA by
compliance and study size
21   Risk Ratio (M-H, Random, 95% CI) Subtotals only
34.1 SA - low risk of compli-
ance bias
9 12938 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.83, 1.32]
34.2 SA - 100+ randomised 20 73411 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.09]
35 CHD mortality - LCn3 - SA
omitting cardiac death
16 65325 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.74, 0.94]
35.1 Low risk of bias 5 12022 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.69, 1.30]
35.2 Moderate/high risk of bias 11 53303 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.72, 0.94]
36 CHD mortality - LCn3 - sub-
group by dose
21 73491 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.09]
36.1 LCn3 ≤ 150 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
36.2 LCn3 > 150 ≤ 250 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
36.3 LCn3 > 250 ≤ 400 mg/d 2 5147 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.50, 1.74]
36.4 LCn3 > 400 ≤ 2400 mg/d 15 67442 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.80, 1.07]
36.5 LCn3 > 2.4 ≤ 4.4 g/d 3 822 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.49, 1.78]
36.6 LCn3 > 4.4 g/d 1 80 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.01, 7.57]
37 CHD mortality - LCn3 - sub-
group by replacement
21   Risk Ratio (M-H, Random, 95% CI) Subtotals only
37.1 N-3 replacing SFA 3 2514 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.51, 0.88]
37.2 N-3 replacing MUFA 10 31605 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.72, 1.10]
37.3 N-3 replacing n-6 3 1409 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.33, 1.24]
37.4 N-3 replacing carbohy-
drates/sugars
1 258 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.23]
37.5 N-3 replacing nil/low n-3
placebo
7 37651 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.70, 0.97]
37.6 Replacement unclear 1 3114 Risk Ratio (M-H, Random, 95% CI) 1.27 [1.03, 1.57]
38 CHD mortality - LCn3 - sub-
group by intervention type
21 73491 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.09]
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38.1 Dietary advice 2 5147 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.50, 1.74]
38.2 Supplemental foods 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.69, 1.33]
38.3 Supplements (capsule) 18 63507 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.79, 1.02]
38.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39 CHD mortality - LCn3 - sub-
group by duration
21 73491 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.09]
39.1 Medium duration 1 to < 2
years in study
7 5978 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.62, 1.50]
39.2 Medium-long duration: 2
to < 4 years in study
9 26545 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.69, 0.90]
39.3 Long duration: ≥ 4 years in
study
5 40968 Risk Ratio (M-H, Random, 95% CI) 1.18 [1.00, 1.39]
40 CHD mortality - LCn3 - sub-
group by primary or secondary
prevention
21 73491 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.09]
40.1 Primary prevention of
CVD
5 23789 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.46, 1.61]
40.2 Secondary prevention of
CVD
16 49702 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.11]
41 CHD mortality - LCn3 - sub-
group by statin use
21 73491 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.79, 1.09]
41.1 LCn3 - ≥ 50% of control
group on statins
5 30025 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.84, 1.30]
41.2 LCn3 - < 50% of control
group on statins
15 43208 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.72, 1.10]
41.3 LCn3 - use of statins un-
clear
1 258 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.23]
42 CHD mortality - LCn3 - sub-
group by CAD history
21 73491 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.80, 1.09]
42.1 Previous CAD 11 29074 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.77, 1.20]
42.2 No previous CAD 10 44417 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.74, 1.16]
43 Coronary heart disease
events (overall) - LCn3
28 84301 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.88, 0.97]
44 CHD events - LCn3 - SA
fixed-effect
28 84301 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.88, 0.97]
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45 CHD events - LCn3 - SA by
summary risk of bias
28 84301 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.88, 0.97]
45.1 Low risk of bias 12 30227 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.90, 1.05]
45.2 Moderate/high risk of bias 16 54074 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.84, 0.95]
46 CHD events - LCn3 - SA by
compliance and study size
27   Risk Ratio (M-H, Random, 95% CI) Subtotals only
46.1 SA - low risk of compli-
ance bias
12 13447 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.86, 1.02]
46.2 SA - 100+ randomised 25 84084 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.88, 0.98]
47 CHD events - LCn3 - sub-
group by dose
28 84376 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.89, 0.98]
47.1 LCn3 ≤ 150 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
47.2 LCn3 > 150 ≤ 250 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
47.3 LCn3 > 250 ≤ 400 mg/d 1 2033 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.82, 1.04]
47.4 LCn3 > 400 ≤ 2400 mg/d 21 80730 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.88, 0.98]
47.5 LCn3 > 2.4 ≤ 4.4 g/d 4 1191 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.53, 1.53]
47.6 LCn3 > 4.4 g/d 3 422 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.54, 1.85]
48 CHD events - LCn3 - sub-
group by replacement
28   Risk Ratio (M-H, Random, 95% CI) Subtotals only
48.1 N-3 replacing SFA 3 2514 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.16, 1.75]
48.2 N-3 replacing MUFA 15 44954 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.90, 1.01]
48.3 N-3 replacing n-6 4 1549 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.88, 1.39]
48.4 N-3 replacing carbohy-
drates/sugars
1 258 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.01, 2.07]
48.5 N-3 replacing nil/low n-3
placebo
8 37843 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.78, 0.94]
48.6 Replacement unclear 1 243 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.08, 9.70]
49 CHD events - LCn3 - sub-
group by intervention type
28 84301 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.89, 0.98]
49.1 Dietary advice 2 2134 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.67, 1.52]
49.2 Supplemental foods 2 5039 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.75, 1.18]
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49.3 Supplements (capsule) 24 77128 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.88, 0.98]
49.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
50 CHD events - LCn3 - sub-
group by duration
28 84301 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.89, 0.98]
50.1 Medium duration 1 to < 2
years in study
11 7009 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.86, 1.03]
50.2 Medium-long duration: 2
to < 4 years in study
12 26902 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.84, 0.98]
50.3 Long duration: ≥ 4 years in
study
5 50390 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
51 CHD events - LCn3 - sub-
group by primary or secondary
prevention
28 84301 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.89, 0.98]
51.1 Primary prevention of
CVD
11 37365 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.81, 1.10]
51.2 Secondary prevention of
CVD
17 46936 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.88, 0.98]
52 CHD events - LCn3 - sub-
group by statin use
28 84301 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.89, 0.98]
52.1 LCn3 - ≥ 50% of control
group on statins
8 42735 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.85, 1.05]
52.2 LCn3 - < 50% of control
group on statins
17 40674 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.86, 0.98]
52.3 LCn3 - use of statins un-
clear
3 892 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.11, 3.83]
53 CHD events - LCn3 sub-
group by CAD history
28 84301 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.88, 0.97]
53.1 Previous CAD 12 26124 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.87, 0.98]
53.2 No previous CAD 16 58177 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.86, 1.01]
54 Stroke (overall) - LCn3 28 89358 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.96, 1.16]
55 Stroke - LCn3 - SA fixed-ef-
fect
28 89358 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.97, 1.16]
56 Stroke - LCn3 - SA by sum-
mary risk of bias
28 89358 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.96, 1.16]
56.1 Low risk of bias 12 32039 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.86, 1.12]
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56.2 Moderate/high risk of bias 16 57319 Risk Ratio (M-H, Random, 95% CI) 1.13 [1.00, 1.29]
57 Stroke - LCn3 - SA by com-
pliance and study size
27   Risk Ratio (M-H, Random, 95% CI) Subtotals only
57.1 SA - low risk of compli-
ance bias
12 14451 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.86, 1.65]
57.2 SA - 100+ randomised 26 89231 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.97, 1.18]
58 Stroke - LCn3 - subgroup by
stroke type
13   Risk Ratio (M-H, Random, 95% CI) Subtotals only
58.1 Ischaemic stroke - LCn3 8 35040 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.89, 1.33]
58.2 Haemorrhagic stroke -
LCn3
8 36645 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.85, 1.69]
58.3 Transient ischaemic at-
tack (TIA)
5 5032 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.39, 1.39]
59 Stroke - LCn3 - subgroup by
dose
28   Risk Ratio (M-H, Random, 95% CI) Subtotals only
59.1 LCn3 ≤ 150 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
59.2 LCn3 > 150 ≤ 250 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
59.3 LCn3 > 250 ≤ 400 mg/d 1 2033 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.14, 1.44]
59.4 LCn3 > 400 ≤ 2400 mg/d 24 86335 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.97, 1.16]
59.5 LCn3 > 2.4 ≤ 4.4 g/d 1 610 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.16, 3.07]
59.6 LCn3 > 4.4 g/d 2 380 Risk Ratio (M-H, Random, 95% CI) 6.58 [0.78, 55.16]
60 Stroke - LCn3 - subgroup by
replacement
28   Risk Ratio (M-H, Random, 95% CI) Subtotals only
60.1 N-3 replacing SFA 3 2514 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.19, 1.50]
60.2 N-3 replacing MUFA 14 45252 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.94, 1.31]
60.3 N-3 replacing n-6 3 1179 Risk Ratio (M-H, Random, 95% CI) 2.08 [0.18, 24.31]
60.4 N-3 replacing carbohy-
drates/sugars
1 258 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.23]
60.5 N-3 replacing nil/low n-3
placebo
9 39555 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.92, 1.24]
60.6 Replacement unclear 1 3114 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.55, 2.29]
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61 Stroke - LCn3 - subgroup by
intervention type
28 89358 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.96, 1.16]
61.1 Dietary advice 3 5248 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.42, 2.05]
61.2 Supplemental foods 1 4837 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.47, 2.62]
61.3 Supplements (capsule) 24 79273 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.97, 1.18]
61.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
62 Stroke - LCn3 - subgroup by
duration
28 89358 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.96, 1.16]
62.1 Medium duration 1 to < 2
years in study
11 7467 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.86, 2.12]
62.2 Medium-long duration: 2
to < 4 years in study
11 28387 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.93, 1.41]
62.3 Long duration: ≥ 4 years in
study
6 53504 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.91, 1.13]
63 Stroke - LCn3 - subgroup by
primary or secondary preven-
tion
28 89358 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.96, 1.16]
63.1 Primary prevention of
CVD
9 39332 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.86, 1.09]
63.2 Secondary prevention of
CVD
19 50026 Risk Ratio (M-H, Random, 95% CI) 1.21 [1.05, 1.40]
64 Stroke - LCn3 - subgroup by
statin use
28 89358 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.96, 1.16]
64.1 LCn3 - ≥ 50% of control
group on statins
8 42962 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.86, 1.23]
64.2 LCn3 - < 50% of control
group on statins
17 44999 Risk Ratio (M-H, Random, 95% CI) 1.18 [1.02, 1.37]
64.3 LCn3 - use of statins un-
clear
3 1397 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.38, 2.34]
65 Arrythmia (overall) - LCn3 27 53796 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.90, 1.05]
66 Arrhythmia- LCn3 - SA fixed-
effect
27 53796 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.96, 1.07]
67 Arrhythmia- LCn3 - SA by
summary risk of bias
27 53796 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.90, 1.05]
67.1 Low risk of bias 10 25801 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.98, 1.23]
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partici-
pants
Statistical method Effect size
67.2 Moderate/high risk of bias 17 27995 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.84, 1.02]
68 Arrhythmia- LCn3 - SA by
compliance and study size
26   Risk Ratio (M-H, Random, 95% CI) Subtotals only
68.1 SA - low risk of compli-
ance bias
10 12914 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.86, 1.09]
68.2 SA - 100+ randomised 26 53749 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.89, 1.05]
69 Arrhythmia - LCn3 - sub-
group by new or recurrent
27   Risk Ratio (M-H, Random, 95% CI) Subtotals only
69.1 New arrhythmia 16 50175 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.99, 1.16]
69.2 Recurrent arrhythmia 12 4425 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.84, 1.03]
70 Arrhythmia - LCn3 - sub-
group by fatality
17   Risk Ratio (M-H, Random, 95% CI) Subtotals only
70.1 Fatal arrhythmias - LCn3 2 12938 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.95, 1.31]
70.2 Non-fatal arrhythmias -
LCn3
8 2079 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.57, 0.96]
70.3 Fatal and non-fatal ar-
rhythmias combined - LCn3
10 36007 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.97, 1.17]
71 Arrhythmia - LCn3 - sub-
group by dose
27 53796 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.89, 1.04]
71.1 LCn3 ≤ 150 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
71.2 LCn3 > 150 ≤ 250 mg/d 1 407 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.90, 1.12]
71.3 LCn3 > 250 ≤ 400 mg/d 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
71.4 LCn3 > 400 ≤ 2400 mg/d 19 51535 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.88, 1.08]
71.5 LCn3 > 2.4 ≤ 4.4 g/d 3 1076 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.55, 0.94]
71.6 LCn3 > 4.4 g/d 2 342 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.32, 3.83]
71.7 Unclear LCn3 dose 2 436 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.76, 1.28]
72 Arrhythmia - LCn3 - sub-
group by replacement
27   Risk Ratio (M-H, Random, 95% CI) Subtotals only
72.1 N-3 replacing SFA 2 632 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.10, 5.67]
72.2 N-3 replacing MUFA 12 42246 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.88, 1.11]
72.3 N-3 replacing n-6 4 1302 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.86, 1.16]
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72.4 N-3 replacing carbohy-
drates/sugars
1 258 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.04, 3.21]
72.5 N-3 replacing nil/low n-3
placebo
6 8983 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.69, 0.91]
72.6 Replacement unclear 4 1179 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.91, 1.08]
73 Arrhythmia - LCn3 - sub-
group by intervention type
27 53796 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.90, 1.05]
73.1 Dietary advice 2 508 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.44, 1.72]
73.2 Supplemental foods 2 5039 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.67, 1.26]
73.3 Supplements (capsule) 23 48249 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.88, 1.06]
73.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
74 Arrhythmia - LCn3 - sub-
group by duration
27 53796 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.89, 1.04]
74.1 Medium duration 1 to < 2
years in study
17 8553 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.84, 1.04]
74.2 Medium-long duration: 2
to < 4 years in study
7 17701 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.84, 1.10]
74.3 Long duration: ≥ 4 years in
study
3 27542 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.99, 1.29]
75 Arrhythmia - LCn3 - sub-
group by primary or secondary
prevention3
27   Risk Ratio (M-H, Random, 95% CI) Subtotals only
75.1 Primary prevention 8 14565 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.97, 1.28]
75.2 Secondary prevention 19 39231 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.86, 1.03]
76 Arrhythmia - LCn3 - sub-
group by statin use
27   Risk Ratio (M-H, Random, 95% CI) Subtotals only
76.1 LCn3 - ≥ 50% of control
group on statins
5 23779 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.95, 1.22]
76.2 LCn3 - < 50% of control
group on statins
18 28932 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.85, 1.04]
76.3 LCn3 - use of statins un-
clear
4 1085 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.80, 1.18]
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Analysis 1.1.   Comparison 1 High vs low LCn3 omega-3 fats
(primary outcomes), Outcome 1 All-cause mortality (overall) - LCn3.
Study or subgroup Favours high-
er omega 3
Lower
omega 3 fats
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
ADCS 2010 11/238 4/164 0.22% 1.89[0.61,5.85]
AFFORD 2013 0/153 1/163 0.03% 0.35[0.01,8.65]
AlphaOmega - EPA+DHA 2010 186/2404 184/2433 5.97% 1.02[0.84,1.24]
AREDS2 2014 200/2147 168/2056 5.96% 1.14[0.94,1.39]
Bates 1989 1/155 0/157 0.03% 3.04[0.12,74.02]
Berson 2004 0/105 1/103 0.03% 0.33[0.01,7.94]
Brox 2001 0/80 1/40 0.03% 0.17[0.01,4.05]
DART 1989 94/1015 131/1018 3.96% 0.72[0.56,0.92]
DART2 2003 283/1571 242/1543 8.39% 1.15[0.98,1.34]
Derosa 2016 1/138 2/143 0.05% 0.52[0.05,5.65]
DIPP 2015 2/104 3/101 0.09% 0.65[0.11,3.79]
DISAF 2003 6/201 8/206 0.26% 0.77[0.27,2.18]
DO IT 2010 14/282 24/281 0.69% 0.58[0.31,1.1]
Doi 2014 2/119 9/119 0.12% 0.22[0.05,1.01]
EPIC-1 2008 1/183 0/180 0.03% 2.95[0.12,71.97]
EPIC-2 2008 0/189 1/190 0.03% 0.34[0.01,8.17]
FAAT 2005 13/200 12/202 0.49% 1.09[0.51,2.34]
FORWARD 2013 4/289 5/297 0.17% 0.82[0.22,3.03]
FOSTAR 2016 0/101 1/101 0.03% 0.33[0.01,8.09]
GISSI-HF 2008 955/3494 1014/3481 18.85% 0.94[0.87,1.01]
GISSI-P 1999 472/5666 545/5658 12.22% 0.86[0.77,0.97]
HARP 1995 0/41 1/39 0.03% 0.32[0.01,7.57]
JELIS 2007 286/9326 265/9319 7.8% 1.08[0.91,1.27]
Kumar 2013 1/39 1/39 0.04% 1[0.06,15.43]
MAPT 2017 18/840 16/840 0.63% 1.13[0.58,2.19]
NAT2 2013 3/150 6/150 0.15% 0.5[0.13,1.96]
Nutristroke 2009 0/38 4/34 0.03% 0.1[0.01,1.79]
OFAMI 2001 11/150 11/150 0.44% 1[0.45,2.24]
OMEGA 2009 88/1919 70/1885 2.75% 1.23[0.91,1.68]
OPAL 2010 9/434 8/433 0.32% 1.12[0.44,2.88]
ORIGIN 2012 951/6281 964/6225 17.48% 0.98[0.9,1.06]
Raitt 2005 4/100 10/100 0.22% 0.4[0.13,1.23]
Risk & Prevention 2013 348/6239 337/6266 9.29% 1.04[0.9,1.2]
SCIMO 1999 1/112 2/111 0.05% 0.5[0.05,5.39]
Shinto 2014 1/13 1/13 0.04% 1[0.07,14.34]
SHOT 1996 8/317 6/293 0.26% 1.23[0.43,3.51]
SOFA 2006 8/273 14/273 0.39% 0.57[0.24,1.34]
SU.FOL.OM3 2010 66/1253 68/1248 2.42% 0.97[0.7,1.34]
Zhang 2017 0/120 1/120 0.03% 0.33[0.01,8.1]
   
Total (95% CI) 46479 46174 100% 0.98[0.93,1.03]
Total events: 4048 (Favours higher omega 3), 4141 (Lower omega 3 fats)  
Heterogeneity: Tau2=0; Chi2=43.01, df=38(P=0.27); I2=11.64%  
Test for overall effect: Z=0.87(P=0.39)  
Favours higher omega 3 200.05 50.2 1 Favours lower omega 3
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Analysis 1.2.   Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes),
Outcome 2 All-cause mortality - LCn3 - sensitivity analysis (SA) fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
ADCS 2010 11/238 4/164 0.12% 1.89[0.61,5.85]
AFFORD 2013 0/153 1/163 0.04% 0.35[0.01,8.65]
AlphaOmega - EPA+DHA 2010 95/1192 93/1236 2.25% 1.06[0.8,1.39]
AREDS2 2014 200/2147 168/2056 4.23% 1.14[0.94,1.39]
Bates 1989 1/155 0/157 0.01% 3.04[0.12,74.02]
Berson 2004 0/105 1/103 0.04% 0.33[0.01,7.94]
Brox 2001 0/80 1/40 0.05% 0.17[0.01,4.05]
DART 1989 94/1015 131/1018 3.22% 0.72[0.56,0.92]
DART2 2003 283/1571 242/1543 6.02% 1.15[0.98,1.34]
Derosa 2016 1/138 2/143 0.05% 0.52[0.05,5.65]
DIPP 2015 2/104 3/101 0.08% 0.65[0.11,3.79]
DISAF 2003 6/201 8/206 0.19% 0.77[0.27,2.18]
DO IT 2010 14/282 24/281 0.59% 0.58[0.31,1.1]
Doi 2014 2/119 9/119 0.22% 0.22[0.05,1.01]
EPIC-1 2008 1/183 0/180 0.01% 2.95[0.12,71.97]
EPIC-2 2008 0/189 1/190 0.04% 0.34[0.01,8.17]
FAAT 2005 13/200 12/202 0.29% 1.09[0.51,2.34]
FORWARD 2013 4/289 5/297 0.12% 0.82[0.22,3.03]
FOSTAR 2016 0/101 1/101 0.04% 0.33[0.01,8.09]
GISSI-HF 2008 955/3494 1014/3481 25.03% 0.94[0.87,1.01]
GISSI-P 1999 472/5666 545/5658 13.44% 0.86[0.77,0.97]
HARP 1995 0/41 1/39 0.04% 0.32[0.01,7.57]
JELIS 2007 286/9326 265/9319 6.53% 1.08[0.91,1.27]
Kumar 2013 1/39 1/39 0.02% 1[0.06,15.43]
MAPT 2017 18/840 16/840 0.39% 1.13[0.58,2.19]
NAT2 2013 3/150 6/150 0.15% 0.5[0.13,1.96]
Nutristroke 2009 0/38 4/34 0.12% 0.1[0.01,1.79]
OFAMI 2001 11/150 11/150 0.27% 1[0.45,2.24]
OMEGA 2009 88/1919 70/1885 1.74% 1.23[0.91,1.68]
OPAL 2010 9/434 8/433 0.2% 1.12[0.44,2.88]
ORIGIN 2012 951/6281 964/6225 23.86% 0.98[0.9,1.06]
Raitt 2005 4/100 10/100 0.25% 0.4[0.13,1.23]
Risk & Prevention 2013 348/6239 337/6266 8.29% 1.04[0.9,1.2]
SCIMO 1999 1/112 2/111 0.05% 0.5[0.05,5.39]
Shinto 2014 1/13 1/13 0.02% 1[0.07,14.34]
SHOT 1996 8/317 6/293 0.15% 1.23[0.43,3.51]
SOFA 2006 8/273 14/273 0.34% 0.57[0.24,1.34]
SU.FOL.OM3 2010 58/1253 59/1248 1.46% 0.98[0.69,1.39]
Zhang 2017 0/120 1/120 0.04% 0.33[0.01,8.1]
   
Total (95% CI) 45267 44977 100% 0.97[0.93,1.01]
Total events: 3949 (Higher omega 3), 4041 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=43.12, df=38(P=0.26); I2=11.87%  
Test for overall effect: Z=1.43(P=0.15)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Analysis 1.3.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 3 All-cause mortality - LCn3 - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 Low risk of bias  
ADCS 2010 11/238 4/164 0.22% 1.89[0.61,5.85]
AlphaOmega - EPA+DHA 2010 186/2404 184/2433 5.97% 1.02[0.84,1.24]
AREDS2 2014 200/2147 168/2056 5.96% 1.14[0.94,1.39]
Berson 2004 0/105 1/103 0.03% 0.33[0.01,7.94]
Derosa 2016 1/138 2/143 0.05% 0.52[0.05,5.65]
FORWARD 2013 4/289 5/297 0.17% 0.82[0.22,3.03]
FOSTAR 2016 0/101 1/101 0.03% 0.33[0.01,8.09]
MAPT 2017 18/840 16/840 0.63% 1.13[0.58,2.19]
NAT2 2013 3/150 6/150 0.15% 0.5[0.13,1.96]
OMEGA 2009 88/1919 70/1885 2.75% 1.23[0.91,1.68]
OPAL 2010 9/434 8/433 0.32% 1.12[0.44,2.88]
ORIGIN 2012 951/6281 964/6225 17.48% 0.98[0.9,1.06]
SCIMO 1999 1/112 2/111 0.05% 0.5[0.05,5.39]
SOFA 2006 8/273 14/273 0.39% 0.57[0.24,1.34]
SU.FOL.OM3 2010 66/1253 68/1248 2.42% 0.97[0.7,1.34]
Subtotal (95% CI) 16684 16462 36.61% 1.01[0.94,1.08]
Total events: 1546 (Higher omega 3), 1513 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=9.55, df=14(P=0.79); I2=0%  
Test for overall effect: Z=0.23(P=0.81)  
   
1.3.2 Moderate/high risk of bias  
AFFORD 2013 0/153 1/163 0.03% 0.35[0.01,8.65]
Bates 1989 1/155 0/157 0.03% 3.04[0.12,74.02]
Brox 2001 0/80 1/40 0.03% 0.17[0.01,4.05]
DART 1989 94/1015 131/1018 3.96% 0.72[0.56,0.92]
DART2 2003 283/1571 242/1543 8.39% 1.15[0.98,1.34]
DIPP 2015 2/104 3/101 0.09% 0.65[0.11,3.79]
DISAF 2003 6/201 8/206 0.26% 0.77[0.27,2.18]
DO IT 2010 14/282 24/281 0.69% 0.58[0.31,1.1]
Doi 2014 2/119 9/119 0.12% 0.22[0.05,1.01]
EPIC-1 2008 1/183 0/180 0.03% 2.95[0.12,71.97]
EPIC-2 2008 0/189 1/190 0.03% 0.34[0.01,8.17]
FAAT 2005 13/200 12/202 0.49% 1.09[0.51,2.34]
GISSI-HF 2008 955/3494 1014/3481 18.85% 0.94[0.87,1.01]
GISSI-P 1999 472/5666 545/5658 12.22% 0.86[0.77,0.97]
HARP 1995 0/41 1/39 0.03% 0.32[0.01,7.57]
JELIS 2007 286/9326 265/9319 7.8% 1.08[0.91,1.27]
Kumar 2013 1/39 1/39 0.04% 1[0.06,15.43]
Nutristroke 2009 0/38 4/34 0.03% 0.1[0.01,1.79]
OFAMI 2001 11/150 11/150 0.44% 1[0.45,2.24]
Raitt 2005 4/100 10/100 0.22% 0.4[0.13,1.23]
Risk & Prevention 2013 348/6239 337/6266 9.29% 1.04[0.9,1.2]
Shinto 2014 1/13 1/13 0.04% 1[0.07,14.34]
SHOT 1996 8/317 6/293 0.26% 1.23[0.43,3.51]
Zhang 2017 0/120 1/120 0.03% 0.33[0.01,8.1]
Subtotal (95% CI) 29795 29712 63.39% 0.94[0.86,1.03]
Total events: 2502 (Higher omega 3), 2628 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=31.55, df=23(P=0.11); I2=27.1%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=1.29(P=0.2)  
   
Total (95% CI) 46479 46174 100% 0.98[0.93,1.03]
Total events: 4048 (Higher omega 3), 4141 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=43.01, df=38(P=0.27); I2=11.64%  
Test for overall effect: Z=0.87(P=0.39)  
Test for subgroup differences: Chi2=1.36, df=1 (P=0.24), I2=26.63%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 1.4.   Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes),
Outcome 4 All-cause mortality - LCn3 - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.4.1 SA - low risk of compliance bias  
AFFORD 2013 0/153 1/163 0.18% 0.35[0.01,8.65]
AlphaOmega - EPA+DHA 2010 186/2404 184/2433 48.6% 1.02[0.84,1.24]
Bates 1989 1/155 0/157 0.18% 3.04[0.12,74.02]
Berson 2004 0/105 1/103 0.18% 0.33[0.01,7.94]
Brox 2001 0/80 1/40 0.18% 0.17[0.01,4.05]
DISAF 2003 6/201 8/206 1.72% 0.77[0.27,2.18]
DO IT 2010 14/282 24/281 4.58% 0.58[0.31,1.1]
FOSTAR 2016 0/101 1/101 0.18% 0.33[0.01,8.09]
HARP 1995 0/41 1/39 0.19% 0.32[0.01,7.57]
Kumar 2013 1/39 1/39 0.25% 1[0.06,15.43]
NAT2 2013 3/150 6/150 1% 0.5[0.13,1.96]
OMEGA 2009 88/1919 70/1885 19.73% 1.23[0.91,1.68]
OPAL 2010 9/434 8/433 2.1% 1.12[0.44,2.88]
Raitt 2005 4/100 10/100 1.47% 0.4[0.13,1.23]
SCIMO 1999 1/112 2/111 0.33% 0.5[0.05,5.39]
Shinto 2014 1/13 1/13 0.26% 1[0.07,14.34]
SHOT 1996 8/317 6/293 1.7% 1.23[0.43,3.51]
SU.FOL.OM3 2010 66/1253 68/1248 17.17% 0.97[0.7,1.34]
Subtotal (95% CI) 7859 7795 100% 0.99[0.86,1.14]
Total events: 388 (Higher omega 3), 393 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=12.5, df=17(P=0.77); I2=0%  
Test for overall effect: Z=0.12(P=0.9)  
   
1.4.2 SA - 100+ randomised  
ADCS 2010 11/238 4/164 0.24% 1.89[0.61,5.85]
AFFORD 2013 0/153 1/163 0.03% 0.35[0.01,8.65]
AlphaOmega - EPA+DHA 2010 186/2404 184/2433 6.2% 1.02[0.84,1.24]
AREDS2 2014 200/2147 168/2056 6.19% 1.14[0.94,1.39]
Bates 1989 1/155 0/157 0.03% 3.04[0.12,74.02]
Berson 2004 0/105 1/103 0.03% 0.33[0.01,7.94]
Brox 2001 0/80 1/40 0.03% 0.17[0.01,4.05]
DART 1989 94/1015 131/1018 4.18% 0.72[0.56,0.92]
DART2 2003 283/1571 242/1543 8.56% 1.15[0.98,1.34]
Derosa 2016 1/138 2/143 0.05% 0.52[0.05,5.65]
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
246
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
DIPP 2015 2/104 3/101 0.1% 0.65[0.11,3.79]
DISAF 2003 6/201 8/206 0.28% 0.77[0.27,2.18]
DO IT 2010 14/282 24/281 0.74% 0.58[0.31,1.1]
Doi 2014 2/119 9/119 0.14% 0.22[0.05,1.01]
EPIC-1 2008 1/183 0/180 0.03% 2.95[0.12,71.97]
EPIC-2 2008 0/189 1/190 0.03% 0.34[0.01,8.17]
FAAT 2005 13/200 12/202 0.53% 1.09[0.51,2.34]
FORWARD 2013 4/289 5/297 0.18% 0.82[0.22,3.03]
FOSTAR 2016 0/101 1/101 0.03% 0.33[0.01,8.09]
GISSI-HF 2008 955/3494 1014/3481 17.89% 0.94[0.87,1.01]
GISSI-P 1999 472/5666 545/5658 12.14% 0.86[0.77,0.97]
JELIS 2007 286/9326 265/9319 7.99% 1.08[0.91,1.27]
MAPT 2017 18/840 16/840 0.68% 1.13[0.58,2.19]
NAT2 2013 3/150 6/150 0.17% 0.5[0.13,1.96]
OFAMI 2001 11/150 11/150 0.47% 1[0.45,2.24]
OMEGA 2009 88/1919 70/1885 2.92% 1.23[0.91,1.68]
OPAL 2010 9/434 8/433 0.34% 1.12[0.44,2.88]
ORIGIN 2012 951/6281 964/6225 16.75% 0.98[0.9,1.06]
Raitt 2005 4/100 10/100 0.24% 0.4[0.13,1.23]
Risk & Prevention 2013 348/6239 337/6266 9.42% 1.04[0.9,1.2]
SCIMO 1999 1/112 2/111 0.05% 0.5[0.05,5.39]
SHOT 1996 8/317 6/293 0.28% 1.23[0.43,3.51]
SOFA 2006 8/273 14/273 0.42% 0.57[0.24,1.34]
SU.FOL.OM3 2010 66/1253 68/1248 2.58% 0.97[0.7,1.34]
Zhang 2017 0/120 1/120 0.03% 0.33[0.01,8.1]
Subtotal (95% CI) 46348 46049 100% 0.98[0.93,1.03]
Total events: 4046 (Higher omega 3), 4134 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=40.14, df=34(P=0.22); I2=15.29%  
Test for overall effect: Z=0.78(P=0.44)  
Test for subgroup differences: Chi2=0.03, df=1 (P=0.86), I2=0%  
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Analysis 1.5.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 5 All-cause mortality - LCn3 - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.5.1 LCn3 ≤150 mg/d  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.5.2 LCn3 > 150 ≤ 250 mg/d  
DISAF 2003 6/201 8/206 0.26% 0.77[0.27,2.18]
Subtotal (95% CI) 201 206 0.26% 0.77[0.27,2.18]
Total events: 6 (Higher omega 3), 8 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.5(P=0.62)  
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
1.5.3 LCn3 > 250 ≤400 mg/d  
DART 1989 94/1015 131/1018 3.98% 0.72[0.56,0.92]
Subtotal (95% CI) 1015 1018 3.98% 0.72[0.56,0.92]
Total events: 94 (Higher omega 3), 131 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.58(P=0.01)  
   
1.5.4 LCn3 > 400 ≤ 2400 mg/d  
ADCS 2010 11/238 4/164 0.22% 1.89[0.61,5.85]
AFFORD 2013 0/153 1/163 0.03% 0.35[0.01,8.65]
AlphaOmega - EPA+DHA 2010 186/2404 184/2433 5.99% 1.02[0.84,1.24]
AREDS2 2014 200/2147 168/2056 5.98% 1.14[0.94,1.39]
Berson 2004 0/105 1/103 0.03% 0.33[0.01,7.94]
DART2 2003 283/1571 242/1543 8.42% 1.15[0.98,1.34]
Derosa 2016 1/138 2/143 0.05% 0.52[0.05,5.65]
DIPP 2015 2/104 3/101 0.09% 0.65[0.11,3.79]
DO IT 2010 14/282 24/281 0.69% 0.58[0.31,1.1]
Doi 2014 2/119 9/119 0.13% 0.22[0.05,1.01]
FORWARD 2013 4/289 5/297 0.17% 0.82[0.22,3.03]
GISSI-HF 2008 955/3494 1014/3481 18.89% 0.94[0.87,1.01]
GISSI-P 1999 472/5666 545/5658 12.26% 0.86[0.77,0.97]
JELIS 2007 286/9326 265/9319 7.82% 1.08[0.91,1.27]
Kumar 2013 1/39 1/39 0.04% 1[0.06,15.43]
MAPT 2017 18/840 16/840 0.63% 1.13[0.58,2.19]
NAT2 2013 3/150 6/150 0.15% 0.5[0.13,1.96]
Nutristroke 2009 0/38 4/34 0.03% 0.1[0.01,1.79]
OMEGA 2009 88/1919 70/1885 2.76% 1.23[0.91,1.68]
OPAL 2010 9/434 8/433 0.32% 1.12[0.44,2.88]
ORIGIN 2012 951/6281 964/6225 17.52% 0.98[0.9,1.06]
Raitt 2005 4/100 10/100 0.22% 0.4[0.13,1.23]
Risk & Prevention 2013 348/6239 337/6266 9.32% 1.04[0.9,1.2]
SCIMO 1999 1/112 2/111 0.05% 0.5[0.05,5.39]
Shinto 2014 1/13 1/13 0.04% 1[0.07,14.34]
SOFA 2006 8/273 14/273 0.39% 0.57[0.24,1.34]
SU.FOL.OM3 2010 58/1253 59/1248 2.13% 0.98[0.69,1.39]
Zhang 2017 0/120 1/120 0.03% 0.33[0.01,8.1]
Subtotal (95% CI) 43847 43598 94.41% 0.99[0.93,1.05]
Total events: 3906 (Higher omega 3), 3960 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=33.41, df=27(P=0.18); I2=19.19%  
Test for overall effect: Z=0.29(P=0.77)  
   
1.5.5 LCn3 > 2.4 ≤ 4.4 g/d  
Bates 1989 1/155 0/157 0.03% 3.04[0.12,74.02]
Brox 2001 0/80 1/40 0.03% 0.17[0.01,4.05]
EPIC-1 2008 1/183 0/180 0.03% 2.95[0.12,71.97]
EPIC-2 2008 0/189 1/190 0.03% 0.34[0.01,8.17]
FAAT 2005 13/200 12/202 0.49% 1.09[0.51,2.34]
OFAMI 2001 11/150 11/150 0.44% 1[0.45,2.24]
SHOT 1996 8/317 6/293 0.26% 1.23[0.43,3.51]
Subtotal (95% CI) 1274 1212 1.3% 1.06[0.67,1.7]
Total events: 34 (Higher omega 3), 31 (Lower omega 3)  
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=2.7, df=6(P=0.85); I2=0%  
Test for overall effect: Z=0.25(P=0.8)  
   
1.5.6 LCn3 > 4.4 g/d  
FOSTAR 2016 0/101 1/101 0.03% 0.33[0.01,8.09]
HARP 1995 0/41 1/39 0.03% 0.32[0.01,7.57]
Subtotal (95% CI) 142 140 0.06% 0.33[0.03,3.08]
Total events: 0 (Higher omega 3), 2 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.98); I2=0%  
Test for overall effect: Z=0.98(P=0.33)  
   
Total (95% CI) 46479 46174 100% 0.98[0.93,1.03]
Total events: 4040 (Higher omega 3), 4132 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=43.01, df=38(P=0.27); I2=11.64%  
Test for overall effect: Z=0.85(P=0.39)  
Test for subgroup differences: Chi2=7.21, df=1 (P=0.13), I2=44.5%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 1.6.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 6 All-cause mortality - LCn3 - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.6.1 LCn3 replacing SFA  
DART 1989 94/1015 131/1018 96.69% 0.72[0.56,0.92]
Derosa 2016 1/138 2/143 1.06% 0.52[0.05,5.65]
EPIC-1 2008 1/183 0/180 0.59% 2.95[0.12,71.97]
EPIC-2 2008 0/189 1/190 0.59% 0.34[0.01,8.17]
SCIMO 1999 1/112 2/111 1.06% 0.5[0.05,5.39]
Subtotal (95% CI) 1637 1642 100% 0.72[0.56,0.92]
Total events: 97 (Higher omega 3), 136 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.14, df=4(P=0.89); I2=0%  
Test for overall effect: Z=2.65(P=0.01)  
   
1.6.2 LCn3 replacing MUFA  
AlphaOmega - EPA+DHA 2010 186/2404 184/2433 8.93% 1.02[0.84,1.24]
Bates 1989 1/155 0/157 0.04% 3.04[0.12,74.02]
DART 1989 94/1015 131/1018 5.78% 0.72[0.56,0.92]
FAAT 2005 13/200 12/202 0.68% 1.09[0.51,2.34]
FORWARD 2013 4/289 5/297 0.23% 0.82[0.22,3.03]
GISSI-HF 2008 955/3494 1014/3481 33.67% 0.94[0.87,1.01]
HARP 1995 0/41 1/39 0.04% 0.32[0.01,7.57]
NAT2 2013 3/150 6/150 0.21% 0.5[0.13,1.96]
OMEGA 2009 88/1919 70/1885 3.95% 1.23[0.91,1.68]
OPAL 2010 9/434 8/433 0.44% 1.12[0.44,2.88]
ORIGIN 2012 951/6281 964/6225 30.59% 0.98[0.9,1.06]
Raitt 2005 4/100 10/100 0.31% 0.4[0.13,1.23]
Risk & Prevention 2013 348/6239 337/6266 14.51% 1.04[0.9,1.2]
SCIMO 1999 1/112 2/111 0.07% 0.5[0.05,5.39]
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  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
SOFA 2006 8/273 14/273 0.54% 0.57[0.24,1.34]
Subtotal (95% CI) 23106 23070 100% 0.96[0.9,1.02]
Total events: 2665 (Higher omega 3), 2758 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=15.86, df=14(P=0.32); I2=11.75%  
Test for overall effect: Z=1.21(P=0.23)  
   
1.6.3 LCn3 replacing N-6  
ADCS 2010 11/238 4/164 11.38% 1.89[0.61,5.85]
AFFORD 2013 0/153 1/163 1.42% 0.35[0.01,8.65]
Berson 2004 0/105 1/103 1.42% 0.33[0.01,7.94]
DIPP 2015 2/104 3/101 4.62% 0.65[0.11,3.79]
DO IT 2010 14/282 24/281 35.49% 0.58[0.31,1.1]
OFAMI 2001 11/150 11/150 22.33% 1[0.45,2.24]
Shinto 2014 1/13 1/13 2.04% 1[0.07,14.34]
SOFA 2006 8/273 14/273 19.89% 0.57[0.24,1.34]
Zhang 2017 0/120 1/120 1.42% 0.33[0.01,8.1]
Subtotal (95% CI) 1438 1368 100% 0.74[0.51,1.09]
Total events: 47 (Higher omega 3), 60 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=4.88, df=8(P=0.77); I2=0%  
Test for overall effect: Z=1.53(P=0.13)  
   
1.6.4 LCn3 replacing CHO  
Derosa 2016 1/138 2/143 100% 0.52[0.05,5.65]
Subtotal (95% CI) 138 143 100% 0.52[0.05,5.65]
Total events: 1 (Higher omega 3), 2 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.54(P=0.59)  
   
1.6.5 LCn3 replacing nil/low n-3 placebo  
AREDS2 2014 200/2147 168/2056 22.61% 1.14[0.94,1.39]
Brox 2001 0/80 1/40 0.19% 0.17[0.01,4.05]
Doi 2014 2/119 9/119 0.81% 0.22[0.05,1.01]
FOSTAR 2016 0/101 1/101 0.19% 0.33[0.01,8.09]
GISSI-P 1999 472/5666 545/5658 31.98% 0.86[0.77,0.97]
JELIS 2007 286/9326 265/9319 26.13% 1.08[0.91,1.27]
Kumar 2013 1/39 1/39 0.25% 1[0.06,15.43]
MAPT 2017 18/840 16/840 3.87% 1.13[0.58,2.19]
SHOT 1996 8/317 6/293 1.66% 1.23[0.43,3.51]
SU.FOL.OM3 2010 66/1253 68/1248 12.31% 0.97[0.7,1.34]
Subtotal (95% CI) 19888 19713 100% 0.99[0.86,1.14]
Total events: 1053 (Higher omega 3), 1080 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=13.49, df=9(P=0.14); I2=33.28%  
Test for overall effect: Z=0.15(P=0.88)  
   
1.6.6 LCn3 replacement unclear  
DART2 2003 283/1571 242/1543 68.48% 1.15[0.98,1.34]
DISAF 2003 6/201 8/206 26.44% 0.77[0.27,2.18]
Nutristroke 2009 0/38 4/34 5.08% 0.1[0.01,1.79]
Subtotal (95% CI) 1810 1783 100% 0.91[0.46,1.79]
Total events: 289 (Higher omega 3), 254 (Lower omega 3)  
Heterogeneity: Tau2=0.17; Chi2=3.31, df=2(P=0.19); I2=39.55%  
Test for overall effect: Z=0.27(P=0.79)  
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  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for subgroup differences: Chi2=7.35, df=1 (P=0.2), I2=31.98%  
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Analysis 1.7.   Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes),
Outcome 7 All-cause mortality - LCn3 - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.7.1 Dietary advice  
DART 1989 94/1015 131/1018 3.96% 0.72[0.56,0.92]
DART2 2003 283/1571 242/1543 8.39% 1.15[0.98,1.34]
DISAF 2003 6/201 8/206 0.26% 0.77[0.27,2.18]
Subtotal (95% CI) 2787 2767 12.61% 0.9[0.6,1.35]
Total events: 383 (Higher omega 3), 381 (Lower omega 3)  
Heterogeneity: Tau2=0.08; Chi2=9.9, df=2(P=0.01); I2=79.81%  
Test for overall effect: Z=0.51(P=0.61)  
   
1.7.2 Supplemental foods  
AlphaOmega - EPA+DHA 2010 186/2404 184/2433 5.97% 1.02[0.84,1.24]
FOSTAR 2016 0/101 1/101 0.03% 0.33[0.01,8.09]
Subtotal (95% CI) 2505 2534 6% 1.02[0.84,1.24]
Total events: 186 (Higher omega 3), 185 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.47, df=1(P=0.49); I2=0%  
Test for overall effect: Z=0.19(P=0.85)  
   
1.7.3 Supplements (capsule)  
ADCS 2010 11/238 4/164 0.22% 1.89[0.61,5.85]
AFFORD 2013 0/153 1/163 0.03% 0.35[0.01,8.65]
AREDS2 2014 200/2147 168/2056 5.96% 1.14[0.94,1.39]
Bates 1989 1/155 0/157 0.03% 3.04[0.12,74.02]
Berson 2004 0/105 1/103 0.03% 0.33[0.01,7.94]
Brox 2001 0/80 1/40 0.03% 0.17[0.01,4.05]
Derosa 2016 1/138 2/143 0.05% 0.52[0.05,5.65]
DO IT 2010 14/282 24/281 0.69% 0.58[0.31,1.1]
Doi 2014 2/119 9/119 0.12% 0.22[0.05,1.01]
EPIC-1 2008 1/183 0/180 0.03% 2.95[0.12,71.97]
EPIC-2 2008 0/189 1/190 0.03% 0.34[0.01,8.17]
FAAT 2005 13/200 12/202 0.49% 1.09[0.51,2.34]
FORWARD 2013 4/289 5/297 0.17% 0.82[0.22,3.03]
GISSI-HF 2008 955/3494 1014/3481 18.85% 0.94[0.87,1.01]
GISSI-P 1999 472/5666 545/5658 12.22% 0.86[0.77,0.97]
HARP 1995 0/41 1/39 0.03% 0.32[0.01,7.57]
JELIS 2007 286/9326 265/9319 7.8% 1.08[0.91,1.27]
Kumar 2013 1/39 1/39 0.04% 1[0.06,15.43]
MAPT 2017 18/840 16/840 0.63% 1.13[0.58,2.19]
NAT2 2013 3/150 6/150 0.15% 0.5[0.13,1.96]
Nutristroke 2009 0/38 4/34 0.03% 0.1[0.01,1.79]
OFAMI 2001 11/150 11/150 0.44% 1[0.45,2.24]
OMEGA 2009 88/1919 70/1885 2.75% 1.23[0.91,1.68]
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
251
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
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  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
OPAL 2010 9/434 8/433 0.32% 1.12[0.44,2.88]
ORIGIN 2012 951/6281 964/6225 17.48% 0.98[0.9,1.06]
Raitt 2005 4/100 10/100 0.22% 0.4[0.13,1.23]
Risk & Prevention 2013 348/6239 337/6266 9.29% 1.04[0.9,1.2]
SCIMO 1999 1/112 2/111 0.05% 0.5[0.05,5.39]
Shinto 2014 1/13 1/13 0.04% 1[0.07,14.34]
SHOT 1996 8/317 6/293 0.26% 1.23[0.43,3.51]
SOFA 2006 8/273 14/273 0.39% 0.57[0.24,1.34]
SU.FOL.OM3 2010 66/1253 68/1248 2.42% 0.97[0.7,1.34]
Zhang 2017 0/120 1/120 0.03% 0.33[0.01,8.1]
Subtotal (95% CI) 41083 40772 81.3% 0.97[0.92,1.01]
Total events: 3477 (Higher omega 3), 3572 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=31.92, df=32(P=0.47); I2=0%  
Test for overall effect: Z=1.6(P=0.11)  
   
1.7.4 Any combination  
DIPP 2015 2/104 3/101 0.09% 0.65[0.11,3.79]
Subtotal (95% CI) 104 101 0.09% 0.65[0.11,3.79]
Total events: 2 (Higher omega 3), 3 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.48(P=0.63)  
   
Total (95% CI) 46479 46174 100% 0.98[0.93,1.03]
Total events: 4048 (Higher omega 3), 4141 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=43.01, df=38(P=0.27); I2=11.64%  
Test for overall effect: Z=0.87(P=0.39)  
Test for subgroup differences: Chi2=0.59, df=1 (P=0.9), I2=0%  
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Analysis 1.8.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 8 All-cause mortality - LCn3 - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.8.1 Medium duration 1 to < 2 years in study  
ADCS 2010 11/238 4/164 0.22% 1.89[0.61,5.85]
AFFORD 2013 0/153 1/163 0.03% 0.35[0.01,8.65]
Brox 2001 0/80 1/40 0.03% 0.17[0.01,4.05]
Derosa 2016 1/138 2/143 0.05% 0.52[0.05,5.65]
DISAF 2003 6/201 8/206 0.26% 0.77[0.27,2.18]
Doi 2014 2/119 9/119 0.13% 0.22[0.05,1.01]
EPIC-1 2008 1/183 0/180 0.03% 2.95[0.12,71.97]
EPIC-2 2008 0/189 1/190 0.03% 0.34[0.01,8.17]
FAAT 2005 13/200 12/202 0.49% 1.09[0.51,2.34]
FORWARD 2013 4/289 5/297 0.17% 0.82[0.22,3.03]
Kumar 2013 1/39 1/39 0.04% 1[0.06,15.43]
Nutristroke 2009 0/38 4/34 0.03% 0.1[0.01,1.79]
OMEGA 2009 88/1919 70/1885 2.76% 1.23[0.91,1.68]
OPAL 2010 9/434 8/433 0.32% 1.12[0.44,2.88]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Shinto 2014 1/13 1/13 0.04% 1[0.07,14.34]
SHOT 1996 8/317 6/293 0.26% 1.23[0.43,3.51]
SOFA 2006 8/273 14/273 0.39% 0.57[0.24,1.34]
Zhang 2017 0/120 1/120 0.03% 0.33[0.01,8.1]
Subtotal (95% CI) 4943 4794 5.3% 1.03[0.82,1.3]
Total events: 153 (Higher omega 3), 148 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=14.81, df=17(P=0.61); I2=0%  
Test for overall effect: Z=0.29(P=0.77)  
   
1.8.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - EPA+DHA 2010 186/2404 184/2433 5.99% 1.02[0.84,1.24]
Bates 1989 1/155 0/157 0.03% 3.04[0.12,74.02]
DART 1989 94/1015 131/1018 3.98% 0.72[0.56,0.92]
DIPP 2015 2/104 3/101 0.09% 0.65[0.11,3.79]
DO IT 2010 14/282 24/281 0.69% 0.58[0.31,1.1]
FOSTAR 2016 0/101 1/101 0.03% 0.33[0.01,8.09]
GISSI-HF 2008 955/3494 1014/3481 18.89% 0.94[0.87,1.01]
GISSI-P 1999 472/5666 545/5658 12.26% 0.86[0.77,0.97]
HARP 1995 0/41 1/39 0.03% 0.32[0.01,7.57]
MAPT 2017 18/840 16/840 0.63% 1.13[0.58,2.19]
NAT2 2013 3/150 6/150 0.15% 0.5[0.13,1.96]
OFAMI 2001 11/150 11/150 0.44% 1[0.45,2.24]
Raitt 2005 4/100 10/100 0.22% 0.4[0.13,1.23]
SCIMO 1999 1/112 2/111 0.05% 0.5[0.05,5.39]
Subtotal (95% CI) 14614 14620 43.47% 0.91[0.86,0.96]
Total events: 1761 (Higher omega 3), 1948 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=13.01, df=13(P=0.45); I2=0.06%  
Test for overall effect: Z=3.28(P=0)  
   
1.8.3 Long duration: ≥ 4 years in study  
AREDS2 2014 200/2147 168/2056 5.98% 1.14[0.94,1.39]
Berson 2004 0/105 1/103 0.03% 0.33[0.01,7.94]
DART2 2003 283/1571 242/1543 8.42% 1.15[0.98,1.34]
JELIS 2007 286/9326 265/9319 7.82% 1.08[0.91,1.27]
ORIGIN 2012 951/6281 964/6225 17.52% 0.98[0.9,1.06]
Risk & Prevention 2013 348/6239 337/6266 9.32% 1.04[0.9,1.2]
SU.FOL.OM3 2010 58/1253 59/1248 2.13% 0.98[0.69,1.39]
Subtotal (95% CI) 26922 26760 51.22% 1.03[0.98,1.09]
Total events: 2126 (Higher omega 3), 2036 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=5.3, df=6(P=0.51); I2=0%  
Test for overall effect: Z=1.12(P=0.26)  
   
Total (95% CI) 46479 46174 100% 0.98[0.93,1.03]
Total events: 4040 (Higher omega 3), 4132 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=43.01, df=38(P=0.27); I2=11.64%  
Test for overall effect: Z=0.85(P=0.39)  
Test for subgroup differences: Chi2=10.01, df=1 (P=0.01), I2=80.01%  
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Analysis 1.9.   Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes),
Outcome 9 All-cause mortality - LCn3 - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.9.1 Primary CVD prevention  
ADCS 2010 11/238 4/164 0.22% 1.89[0.61,5.85]
AREDS2 2014 200/2147 168/2056 5.98% 1.14[0.94,1.39]
Bates 1989 1/155 0/157 0.03% 3.04[0.12,74.02]
Berson 2004 0/105 1/103 0.03% 0.33[0.01,7.94]
Brox 2001 0/80 1/40 0.03% 0.17[0.01,4.05]
Derosa 2016 1/138 2/143 0.05% 0.52[0.05,5.65]
DIPP 2015 2/104 3/101 0.09% 0.65[0.11,3.79]
DO IT 2010 14/282 24/281 0.69% 0.58[0.31,1.1]
EPIC-1 2008 1/183 0/180 0.03% 2.95[0.12,71.97]
EPIC-2 2008 0/189 1/190 0.03% 0.34[0.01,8.17]
FOSTAR 2016 0/101 1/101 0.03% 0.33[0.01,8.09]
JELIS 2007 286/9326 265/9319 7.82% 1.08[0.91,1.27]
MAPT 2017 18/840 16/840 0.63% 1.13[0.58,2.19]
OPAL 2010 9/434 8/433 0.32% 1.12[0.44,2.88]
ORIGIN 2012 951/6281 964/6225 17.52% 0.98[0.9,1.06]
Shinto 2014 1/13 1/13 0.04% 1[0.07,14.34]
Zhang 2017 0/120 1/120 0.03% 0.33[0.01,8.1]
Subtotal (95% CI) 20736 20466 33.57% 1.01[0.94,1.08]
Total events: 1495 (Higher omega 3), 1460 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=11.42, df=16(P=0.78); I2=0%  
Test for overall effect: Z=0.24(P=0.81)  
   
1.9.2 Secondary CVD prevention  
AFFORD 2013 0/153 1/163 0.03% 0.35[0.01,8.65]
AlphaOmega - EPA+DHA 2010 186/2404 184/2433 5.99% 1.02[0.84,1.24]
DART 1989 94/1015 131/1018 3.98% 0.72[0.56,0.92]
DART2 2003 283/1571 242/1543 8.42% 1.15[0.98,1.34]
DISAF 2003 6/201 8/206 0.26% 0.77[0.27,2.18]
Doi 2014 2/119 9/119 0.13% 0.22[0.05,1.01]
FAAT 2005 13/200 12/202 0.49% 1.09[0.51,2.34]
FORWARD 2013 4/289 5/297 0.17% 0.82[0.22,3.03]
GISSI-HF 2008 955/3494 1014/3481 18.89% 0.94[0.87,1.01]
GISSI-P 1999 472/5666 545/5658 12.26% 0.86[0.77,0.97]
HARP 1995 0/41 1/39 0.03% 0.32[0.01,7.57]
Kumar 2013 1/39 1/39 0.04% 1[0.06,15.43]
NAT2 2013 3/150 6/150 0.15% 0.5[0.13,1.96]
Nutristroke 2009 0/38 4/34 0.03% 0.1[0.01,1.79]
OFAMI 2001 11/150 11/150 0.44% 1[0.45,2.24]
OMEGA 2009 88/1919 70/1885 2.76% 1.23[0.91,1.68]
Raitt 2005 4/100 10/100 0.22% 0.4[0.13,1.23]
Risk & Prevention 2013 348/6239 337/6266 9.32% 1.04[0.9,1.2]
SCIMO 1999 1/112 2/111 0.05% 0.5[0.05,5.39]
SHOT 1996 8/317 6/293 0.26% 1.23[0.43,3.51]
SOFA 2006 8/273 14/273 0.39% 0.57[0.24,1.34]
SU.FOL.OM3 2010 58/1253 59/1248 2.13% 0.98[0.69,1.39]
Subtotal (95% CI) 25743 25708 66.43% 0.95[0.88,1.04]
Total events: 2545 (Higher omega 3), 2672 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=29.78, df=21(P=0.1); I2=29.48%  
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=1.11(P=0.27)  
   
Total (95% CI) 46479 46174 100% 0.98[0.93,1.03]
Total events: 4040 (Higher omega 3), 4132 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=43.01, df=38(P=0.27); I2=11.64%  
Test for overall effect: Z=0.85(P=0.39)  
Test for subgroup differences: Chi2=1.03, df=1 (P=0.31), I2=2.54%  
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Analysis 1.10.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 10 All-cause mortality - LCn3 - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.10.1 LCn3 - ≥50% of control group on statins  
AlphaOmega - EPA+DHA 2010 95/1192 93/1236 3.52% 1.06[0.8,1.39]
Doi 2014 2/119 9/119 0.13% 0.22[0.05,1.01]
JELIS 2007 286/9326 265/9319 8.08% 1.08[0.91,1.27]
Kumar 2013 1/39 1/39 0.04% 1[0.06,15.43]
NAT2 2013 3/150 6/150 0.16% 0.5[0.13,1.96]
OMEGA 2009 88/1919 70/1885 2.87% 1.23[0.91,1.68]
ORIGIN 2012 951/6281 964/6225 17.8% 0.98[0.9,1.06]
SU.FOL.OM3 2010 58/1253 59/1248 2.22% 0.98[0.69,1.39]
Subtotal (95% CI) 20279 20221 34.83% 1.02[0.93,1.11]
Total events: 1484 (Higher omega 3), 1467 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=7.85, df=7(P=0.35); I2=10.86%  
Test for overall effect: Z=0.38(P=0.7)  
   
1.10.2 LCn3 - < 50% of control group on statins  
ADCS 2010 11/238 4/164 0.23% 1.89[0.61,5.85]
AFFORD 2013 0/153 1/163 0.03% 0.35[0.01,8.65]
AREDS2 2014 200/2147 168/2056 6.2% 1.14[0.94,1.39]
Bates 1989 1/155 0/157 0.03% 3.04[0.12,74.02]
Berson 2004 0/105 1/103 0.03% 0.33[0.01,7.94]
Brox 2001 0/80 1/40 0.03% 0.17[0.01,4.05]
DART 1989 94/1015 131/1018 4.13% 0.72[0.56,0.92]
DART2 2003 283/1571 242/1543 8.69% 1.15[0.98,1.34]
DIPP 2015 2/104 3/101 0.1% 0.65[0.11,3.79]
DISAF 2003 6/201 8/206 0.28% 0.77[0.27,2.18]
DO IT 2010 14/282 24/281 0.72% 0.58[0.31,1.1]
EPIC-1 2008 1/183 0/180 0.03% 2.95[0.12,71.97]
EPIC-2 2008 0/189 1/190 0.03% 0.34[0.01,8.17]
FAAT 2005 13/200 12/202 0.51% 1.09[0.51,2.34]
FORWARD 2013 4/289 5/297 0.18% 0.82[0.22,3.03]
FOSTAR 2016 0/101 1/101 0.03% 0.33[0.01,8.09]
GISSI-HF 2008 955/3494 1014/3481 19.15% 0.94[0.87,1.01]
GISSI-P 1999 472/5666 545/5658 12.57% 0.86[0.77,0.97]
HARP 1995 0/41 1/39 0.03% 0.32[0.01,7.57]
OFAMI 2001 11/150 11/150 0.46% 1[0.45,2.24]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Raitt 2005 4/100 10/100 0.24% 0.4[0.13,1.23]
Risk & Prevention 2013 348/6239 337/6266 9.6% 1.04[0.9,1.2]
SCIMO 1999 1/112 2/111 0.05% 0.5[0.05,5.39]
Shinto 2014 1/13 1/13 0.04% 1[0.07,14.34]
SHOT 1996 8/317 6/293 0.27% 1.23[0.43,3.51]
SOFA 2006 8/273 14/273 0.41% 0.57[0.24,1.34]
Subtotal (95% CI) 23418 23186 64.06% 0.95[0.88,1.03]
Total events: 2437 (Higher omega 3), 2543 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=30.26, df=25(P=0.21); I2=17.39%  
Test for overall effect: Z=1.19(P=0.23)  
   
1.10.3 LCn3 - use of statins unclear  
Derosa 2016 1/138 2/143 0.05% 0.52[0.05,5.65]
MAPT 2017 18/840 16/840 0.66% 1.13[0.58,2.19]
Nutristroke 2009 0/38 4/34 0.04% 0.1[0.01,1.79]
OPAL 2010 9/434 8/433 0.33% 1.12[0.44,2.88]
Zhang 2017 0/120 1/120 0.03% 0.33[0.01,8.1]
Subtotal (95% CI) 1570 1570 1.11% 0.97[0.58,1.63]
Total events: 28 (Higher omega 3), 31 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.45, df=4(P=0.49); I2=0%  
Test for overall effect: Z=0.11(P=0.92)  
   
Total (95% CI) 45267 44977 100% 0.98[0.92,1.03]
Total events: 3949 (Higher omega 3), 4041 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=43.12, df=38(P=0.26); I2=11.87%  
Test for overall effect: Z=0.83(P=0.41)  
Test for subgroup differences: Chi2=1.16, df=1 (P=0.56), I2=0%  
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Analysis 1.11.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 11 Cardiovascular mortality (overall) - LCn3.
Study or subgroup Favours high-
er omega 3
Lower
omega 3 fats
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 6.29% 0.99[0.73,1.34]
AREDS2 2014 14/2147 13/2056 1.28% 1.03[0.49,2.19]
Brox 2001 0/80 1/40 0.08% 0.17[0.01,4.05]
DART 1989 84/1015 121/1018 7.67% 0.7[0.53,0.91]
DART2 2003 180/1571 139/1543 10.35% 1.27[1.03,1.57]
Derosa 2016 2/138 3/143 0.24% 0.69[0.12,4.07]
DO IT 2010 7/282 11/281 0.85% 0.63[0.25,1.61]
Doi 2014 1/119 5/119 0.17% 0.2[0.02,1.69]
FAAT 2005 9/200 9/202 0.9% 1.01[0.41,2.49]
FOSTAR 2016 0/101 1/101 0.07% 0.33[0.01,8.09]
GISSI-HF 2008 712/3494 765/3481 20.11% 0.93[0.85,1.02]
GISSI-P 1999 291/5665 348/5658 14.51% 0.84[0.72,0.97]
HARP 1995 0/41 1/39 0.08% 0.32[0.01,7.57]
Kumar 2013 1/39 1/39 0.1% 1[0.06,15.43]
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Study or subgroup Favours high-
er omega 3
Lower
omega 3 fats
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Nutristroke 2009 0/38 4/34 0.09% 0.1[0.01,1.79]
OFAMI 2001 8/150 8/150 0.81% 1[0.39,2.59]
OMEGA 2009 67/1919 51/1885 4.83% 1.29[0.9,1.85]
ORIGIN 2012 574/6281 581/6255 18.25% 0.98[0.88,1.1]
Raitt 2005 2/100 5/100 0.29% 0.4[0.08,2.01]
Risk & Prevention 2013 142/6239 137/6266 9.14% 1.04[0.83,1.31]
SCIMO 1999 0/112 1/111 0.07% 0.33[0.01,8.02]
Shinto 2014 1/13 0/13 0.08% 3[0.13,67.51]
SHOT 1996 7/317 5/293 0.58% 1.29[0.42,4.03]
SOFA 2006 6/273 13/273 0.82% 0.46[0.18,1.2]
SU.FOL.OM3 2010 23/1253 28/1248 2.33% 0.82[0.47,1.41]
   
Total (95% CI) 33991 33781 100% 0.95[0.87,1.03]
Total events: 2211 (Favours higher omega 3), 2333 (Lower omega 3 fats)  
Heterogeneity: Tau2=0.01; Chi2=31.76, df=24(P=0.13); I2=24.44%  
Test for overall effect: Z=1.26(P=0.21)  
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Analysis 1.12.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 12 CVD mortality - LCn3 - SA fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 3.48% 0.99[0.73,1.34]
AREDS2 2014 14/2147 13/2056 0.57% 1.03[0.49,2.19]
Brox 2001 0/80 1/40 0.09% 0.17[0.01,4.05]
DART 1989 84/1015 121/1018 5.16% 0.7[0.53,0.91]
DART2 2003 180/1571 139/1543 5.99% 1.27[1.03,1.57]
Derosa 2016 2/138 3/143 0.13% 0.69[0.12,4.07]
DO IT 2010 7/282 11/281 0.47% 0.63[0.25,1.61]
Doi 2014 1/119 5/119 0.21% 0.2[0.02,1.69]
FAAT 2005 9/200 9/202 0.38% 1.01[0.41,2.49]
FOSTAR 2016 0/101 1/101 0.06% 0.33[0.01,8.09]
GISSI-HF 2008 712/3494 765/3481 32.74% 0.93[0.85,1.02]
GISSI-P 1999 291/5665 348/5658 14.88% 0.84[0.72,0.97]
HARP 1995 0/41 1/39 0.07% 0.32[0.01,7.57]
Kumar 2013 1/39 1/39 0.04% 1[0.06,15.43]
Nutristroke 2009 0/38 4/34 0.2% 0.1[0.01,1.79]
OFAMI 2001 8/150 8/150 0.34% 1[0.39,2.59]
OMEGA 2009 67/1919 51/1885 2.2% 1.29[0.9,1.85]
ORIGIN 2012 574/6281 581/6255 24.87% 0.98[0.88,1.1]
Raitt 2005 2/100 5/100 0.21% 0.4[0.08,2.01]
Risk & Prevention 2013 142/6239 137/6266 5.84% 1.04[0.83,1.31]
SCIMO 1999 0/112 1/111 0.06% 0.33[0.01,8.02]
Shinto 2014 1/13 0/13 0.02% 3[0.13,67.51]
SHOT 1996 7/317 5/293 0.22% 1.29[0.42,4.03]
SOFA 2006 6/273 13/273 0.56% 0.46[0.18,1.2]
SU.FOL.OM3 2010 23/1253 28/1248 1.2% 0.82[0.47,1.41]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
   
Total (95% CI) 33991 33781 100% 0.94[0.89,1]
Total events: 2211 (Higher omega 3), 2333 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=31.76, df=24(P=0.13); I2=24.44%  
Test for overall effect: Z=2.07(P=0.04)  
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Analysis 1.13.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 13 CVD mortality - LCn3 - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.13.1 Low risk of bias  
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 6.29% 0.99[0.73,1.34]
AREDS2 2014 14/2147 13/2056 1.28% 1.03[0.49,2.19]
Derosa 2016 2/138 3/143 0.24% 0.69[0.12,4.07]
FOSTAR 2016 0/101 1/101 0.07% 0.33[0.01,8.09]
OMEGA 2009 67/1919 51/1885 4.83% 1.29[0.9,1.85]
ORIGIN 2012 574/6281 581/6255 18.25% 0.98[0.88,1.1]
SCIMO 1999 0/112 1/111 0.07% 0.33[0.01,8.02]
SOFA 2006 6/273 13/273 0.82% 0.46[0.18,1.2]
SU.FOL.OM3 2010 23/1253 28/1248 2.33% 0.82[0.47,1.41]
Subtotal (95% CI) 14628 14505 34.19% 0.99[0.9,1.09]
Total events: 766 (Higher omega 3), 773 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=6.11, df=8(P=0.63); I2=0%  
Test for overall effect: Z=0.25(P=0.81)  
   
1.13.2 Moderate/high risk of bias  
Brox 2001 0/80 1/40 0.08% 0.17[0.01,4.05]
DART 1989 84/1015 121/1018 7.67% 0.7[0.53,0.91]
DART2 2003 180/1571 139/1543 10.35% 1.27[1.03,1.57]
DO IT 2010 7/282 11/281 0.85% 0.63[0.25,1.61]
Doi 2014 1/119 5/119 0.17% 0.2[0.02,1.69]
FAAT 2005 9/200 9/202 0.9% 1.01[0.41,2.49]
GISSI-HF 2008 712/3494 765/3481 20.11% 0.93[0.85,1.02]
GISSI-P 1999 291/5665 348/5658 14.51% 0.84[0.72,0.97]
HARP 1995 0/41 1/39 0.08% 0.32[0.01,7.57]
Kumar 2013 1/39 1/39 0.1% 1[0.06,15.43]
Nutristroke 2009 0/38 4/34 0.09% 0.1[0.01,1.79]
OFAMI 2001 8/150 8/150 0.81% 1[0.39,2.59]
Raitt 2005 2/100 5/100 0.29% 0.4[0.08,2.01]
Risk & Prevention 2013 142/6239 137/6266 9.14% 1.04[0.83,1.31]
Shinto 2014 1/13 0/13 0.08% 3[0.13,67.51]
SHOT 1996 7/317 5/293 0.58% 1.29[0.42,4.03]
Subtotal (95% CI) 19363 19276 65.81% 0.92[0.8,1.05]
Total events: 1445 (Higher omega 3), 1560 (Lower omega 3)  
Heterogeneity: Tau2=0.02; Chi2=24.46, df=15(P=0.06); I2=38.67%  
Test for overall effect: Z=1.23(P=0.22)  
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total (95% CI) 33991 33781 100% 0.95[0.87,1.03]
Total events: 2211 (Higher omega 3), 2333 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=31.76, df=24(P=0.13); I2=24.44%  
Test for overall effect: Z=1.26(P=0.21)  
Test for subgroup differences: Chi2=0.73, df=1 (P=0.39), I2=0%  
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Analysis 1.14.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 14 CVD mortality - LCn3 - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.14.1 SA - low risk of compliance bias  
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 43.67% 0.99[0.73,1.34]
Brox 2001 0/80 1/40 0.4% 0.17[0.01,4.05]
DO IT 2010 7/282 11/281 4.6% 0.63[0.25,1.61]
FOSTAR 2016 0/101 1/101 0.39% 0.33[0.01,8.09]
HARP 1995 0/41 1/39 0.4% 0.32[0.01,7.57]
Kumar 2013 1/39 1/39 0.53% 1[0.06,15.43]
OMEGA 2009 67/1919 51/1885 31.13% 1.29[0.9,1.85]
Raitt 2005 2/100 5/100 1.53% 0.4[0.08,2.01]
SCIMO 1999 0/112 1/111 0.39% 0.33[0.01,8.02]
Shinto 2014 1/13 0/13 0.41% 3[0.13,67.51]
SHOT 1996 7/317 5/293 3.1% 1.29[0.42,4.03]
SU.FOL.OM3 2010 23/1253 28/1248 13.43% 0.82[0.47,1.41]
Subtotal (95% CI) 6661 6583 100% 1[0.82,1.23]
Total events: 188 (Higher omega 3), 187 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=7.92, df=11(P=0.72); I2=0%  
Test for overall effect: Z=0.04(P=0.97)  
   
1.14.2 SA - 100+ randomised  
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 6.45% 0.99[0.73,1.34]
AREDS2 2014 14/2147 13/2056 1.34% 1.03[0.49,2.19]
Brox 2001 0/80 1/40 0.08% 0.17[0.01,4.05]
DART 1989 84/1015 121/1018 7.82% 0.7[0.53,0.91]
DART2 2003 180/1571 139/1543 10.47% 1.27[1.03,1.57]
Derosa 2016 2/138 3/143 0.25% 0.69[0.12,4.07]
DO IT 2010 7/282 11/281 0.89% 0.63[0.25,1.61]
Doi 2014 1/119 5/119 0.18% 0.2[0.02,1.69]
FAAT 2005 9/200 9/202 0.94% 1.01[0.41,2.49]
FOSTAR 2016 0/101 1/101 0.08% 0.33[0.01,8.09]
GISSI-HF 2008 712/3494 765/3481 19.69% 0.93[0.85,1.02]
GISSI-P 1999 291/5665 348/5658 14.47% 0.84[0.72,0.97]
OFAMI 2001 8/150 8/150 0.85% 1[0.39,2.59]
OMEGA 2009 67/1919 51/1885 4.97% 1.29[0.9,1.85]
ORIGIN 2012 574/6281 581/6255 17.98% 0.98[0.88,1.1]
Raitt 2005 2/100 5/100 0.3% 0.4[0.08,2.01]
Risk & Prevention 2013 142/6239 137/6266 9.28% 1.04[0.83,1.31]
SCIMO 1999 0/112 1/111 0.08% 0.33[0.01,8.02]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
SHOT 1996 7/317 5/293 0.6% 1.29[0.42,4.03]
SOFA 2006 6/273 13/273 0.85% 0.46[0.18,1.2]
SU.FOL.OM3 2010 23/1253 28/1248 2.42% 0.82[0.47,1.41]
Subtotal (95% CI) 33860 33656 100% 0.95[0.87,1.04]
Total events: 2209 (Higher omega 3), 2327 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=28.44, df=20(P=0.1); I2=29.68%  
Test for overall effect: Z=1.19(P=0.23)  
Test for subgroup differences: Chi2=0.27, df=1 (P=0.6), I2=0%  
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Analysis 1.15.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 15 CVD mortality - LCn3 - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.15.1 LCn3 ≤ 150 mg/d  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.15.2 LCn3 > 150 ≤ 250 mg/d  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.15.3 LCn3 > 250 ≤ 400 mg/d  
DART 1989 84/1015 121/1018 7.67% 0.7[0.53,0.91]
Subtotal (95% CI) 1015 1018 7.67% 0.7[0.53,0.91]
Total events: 84 (Higher omega 3), 121 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.68(P=0.01)  
   
1.15.4 LCn3 > 400 ≤ 2400 mg/d  
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 6.29% 0.99[0.73,1.34]
AREDS2 2014 14/2147 13/2056 1.28% 1.03[0.49,2.19]
DART2 2003 180/1571 139/1543 10.35% 1.27[1.03,1.57]
Derosa 2016 2/138 3/143 0.24% 0.69[0.12,4.07]
DO IT 2010 7/282 11/281 0.85% 0.63[0.25,1.61]
Doi 2014 1/119 5/119 0.17% 0.2[0.02,1.69]
GISSI-HF 2008 712/3494 765/3481 20.11% 0.93[0.85,1.02]
GISSI-P 1999 291/5665 348/5658 14.51% 0.84[0.72,0.97]
Kumar 2013 1/39 1/39 0.1% 1[0.06,15.43]
Nutristroke 2009 0/38 4/34 0.09% 0.1[0.01,1.79]
OMEGA 2009 67/1919 51/1885 4.83% 1.29[0.9,1.85]
ORIGIN 2012 574/6281 581/6255 18.25% 0.98[0.88,1.1]
Raitt 2005 2/100 5/100 0.29% 0.4[0.08,2.01]
Risk & Prevention 2013 142/6239 137/6266 9.14% 1.04[0.83,1.31]
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  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
SCIMO 1999 0/112 1/111 0.07% 0.33[0.01,8.02]
Shinto 2014 1/13 0/13 0.08% 3[0.13,67.51]
SOFA 2006 6/273 13/273 0.82% 0.46[0.18,1.2]
SU.FOL.OM3 2010 23/1253 28/1248 2.33% 0.82[0.47,1.41]
THIS DIET 2008 0/51 0/50   Not estimable
Subtotal (95% CI) 32138 31988 89.81% 0.97[0.89,1.06]
Total events: 2103 (Higher omega 3), 2187 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=24.07, df=17(P=0.12); I2=29.37%  
Test for overall effect: Z=0.64(P=0.52)  
   
1.15.5 LCn3 > 2.4 ≤ 4.4 g/d  
Brox 2001 0/80 1/40 0.08% 0.17[0.01,4.05]
FAAT 2005 9/200 9/202 0.9% 1.01[0.41,2.49]
OFAMI 2001 8/150 8/150 0.81% 1[0.39,2.59]
SHOT 1996 7/317 5/293 0.58% 1.29[0.42,4.03]
Subtotal (95% CI) 747 685 2.37% 1.01[0.58,1.77]
Total events: 24 (Higher omega 3), 23 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.4, df=3(P=0.7); I2=0%  
Test for overall effect: Z=0.04(P=0.97)  
   
1.15.6 LCn3 > 4.4 g/d  
FOSTAR 2016 0/101 1/101 0.07% 0.33[0.01,8.09]
HARP 1995 0/41 1/39 0.08% 0.32[0.01,7.57]
Subtotal (95% CI) 142 140 0.15% 0.33[0.03,3.08]
Total events: 0 (Higher omega 3), 2 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.98); I2=0%  
Test for overall effect: Z=0.98(P=0.33)  
   
Total (95% CI) 34042 33831 100% 0.95[0.87,1.03]
Total events: 2211 (Higher omega 3), 2333 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=31.76, df=24(P=0.13); I2=24.44%  
Test for overall effect: Z=1.26(P=0.21)  
Test for subgroup differences: Chi2=6.32, df=1 (P=0.1), I2=52.54%  
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Analysis 1.16.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 16 CVD mortality - LCn3 - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.16.1 N-3 replacing SFA  
DART 1989 84/1015 121/1018 97.17% 0.7[0.53,0.91]
Derosa 2016 2/138 3/143 2.16% 0.69[0.12,4.07]
SCIMO 1999 0/112 1/111 0.67% 0.33[0.01,8.02]
Subtotal (95% CI) 1265 1272 100% 0.69[0.53,0.9]
Total events: 86 (Higher omega 3), 125 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.21, df=2(P=0.9); I2=0%  
Test for overall effect: Z=2.76(P=0.01)  
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  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.16.2 N-3 replacing MUFA  
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 8.27% 0.99[0.73,1.34]
DART 1989 84/1015 121/1018 10.25% 0.7[0.53,0.91]
FAAT 2005 9/200 9/202 1.11% 1.01[0.41,2.49]
GISSI-HF 2008 712/3494 765/3481 31.94% 0.93[0.85,1.02]
HARP 1995 0/41 1/39 0.09% 0.32[0.01,7.57]
OMEGA 2009 67/1919 51/1885 6.23% 1.29[0.9,1.85]
ORIGIN 2012 574/6281 581/6255 28.2% 0.98[0.88,1.1]
Raitt 2005 2/100 5/100 0.35% 0.4[0.08,2.01]
Risk & Prevention 2013 142/6239 137/6266 12.45% 1.04[0.83,1.31]
SCIMO 1999 0/112 1/111 0.09% 0.33[0.01,8.02]
SOFA 2006 6/273 13/273 1% 0.46[0.18,1.2]
THIS DIET 2008 0/51 0/50   Not estimable
Subtotal (95% CI) 22129 22113 100% 0.94[0.86,1.04]
Total events: 1676 (Higher omega 3), 1766 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=13.61, df=10(P=0.19); I2=26.54%  
Test for overall effect: Z=1.2(P=0.23)  
   
1.16.3 N-3 replacing N-6  
DO IT 2010 7/282 11/281 33.26% 0.63[0.25,1.61]
OFAMI 2001 8/150 8/150 31.85% 1[0.39,2.59]
Shinto 2014 1/13 0/13 2.99% 3[0.13,67.51]
SOFA 2006 6/273 13/273 31.91% 0.46[0.18,1.2]
Subtotal (95% CI) 718 717 100% 0.69[0.41,1.19]
Total events: 22 (Higher omega 3), 32 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.15, df=3(P=0.54); I2=0%  
Test for overall effect: Z=1.33(P=0.18)  
   
1.16.4 N-3 replacing carbohydrates/sugars  
Derosa 2016 2/138 3/143 100% 0.69[0.12,4.07]
Subtotal (95% CI) 138 143 100% 0.69[0.12,4.07]
Total events: 2 (Higher omega 3), 3 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.41(P=0.68)  
   
1.16.5 N-3 replacing nil/low n-3 placebo  
AREDS2 2014 14/2147 13/2056 3.52% 1.03[0.49,2.19]
Brox 2001 0/80 1/40 0.2% 0.17[0.01,4.05]
Doi 2014 1/119 5/119 0.44% 0.2[0.02,1.69]
FOSTAR 2016 0/101 1/101 0.2% 0.33[0.01,8.09]
GISSI-P 1999 291/5665 348/5658 87.15% 0.84[0.72,0.97]
Kumar 2013 1/39 1/39 0.27% 1[0.06,15.43]
SHOT 1996 7/317 5/293 1.54% 1.29[0.42,4.03]
SU.FOL.OM3 2010 23/1253 28/1248 6.69% 0.82[0.47,1.41]
Subtotal (95% CI) 9721 9554 100% 0.84[0.73,0.96]
Total events: 337 (Higher omega 3), 402 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.91, df=7(P=0.79); I2=0%  
Test for overall effect: Z=2.47(P=0.01)  
   
1.16.6 Replacement unclear  
DART2 2003 180/1571 139/1543 66.49% 1.27[1.03,1.57]
Nutristroke 2009 0/38 4/34 33.51% 0.1[0.01,1.79]
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  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 1609 1577 100% 0.54[0.05,5.77]
Total events: 180 (Higher omega 3), 143 (Lower omega 3)  
Heterogeneity: Tau2=2.18; Chi2=3, df=1(P=0.08); I2=66.67%  
Test for overall effect: Z=0.51(P=0.61)  
Test for subgroup differences: Chi2=6.66, df=1 (P=0.25), I2=24.92%  
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Analysis 1.17.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 17 CVD mortality - LCn3 - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.17.1 Dietary advice  
DART 1989 84/1015 121/1018 7.67% 0.7[0.53,0.91]
DART2 2003 180/1571 139/1543 10.35% 1.27[1.03,1.57]
Subtotal (95% CI) 2586 2561 18.02% 0.95[0.52,1.71]
Total events: 264 (Higher omega 3), 260 (Lower omega 3)  
Heterogeneity: Tau2=0.17; Chi2=12.24, df=1(P=0); I2=91.83%  
Test for overall effect: Z=0.18(P=0.85)  
   
1.17.2 Supplemental foods  
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 6.29% 0.99[0.73,1.34]
FOSTAR 2016 0/101 1/101 0.07% 0.33[0.01,8.09]
Subtotal (95% CI) 2505 2534 6.37% 0.98[0.72,1.32]
Total events: 80 (Higher omega 3), 83 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.44, df=1(P=0.51); I2=0%  
Test for overall effect: Z=0.15(P=0.88)  
   
1.17.3 Supplements (capsule)  
AREDS2 2014 14/2147 13/2056 1.28% 1.03[0.49,2.19]
Brox 2001 0/80 1/40 0.08% 0.17[0.01,4.05]
Derosa 2016 2/138 3/143 0.24% 0.69[0.12,4.07]
DO IT 2010 7/282 11/281 0.85% 0.63[0.25,1.61]
Doi 2014 1/119 5/119 0.17% 0.2[0.02,1.69]
FAAT 2005 9/200 9/202 0.9% 1.01[0.41,2.49]
GISSI-HF 2008 712/3494 765/3481 20.11% 0.93[0.85,1.02]
GISSI-P 1999 291/5665 348/5658 14.51% 0.84[0.72,0.97]
HARP 1995 0/41 1/39 0.08% 0.32[0.01,7.57]
Kumar 2013 1/39 1/39 0.1% 1[0.06,15.43]
Nutristroke 2009 0/38 4/34 0.09% 0.1[0.01,1.79]
OFAMI 2001 8/150 8/150 0.81% 1[0.39,2.59]
OMEGA 2009 67/1919 51/1885 4.83% 1.29[0.9,1.85]
ORIGIN 2012 574/6281 581/6255 18.25% 0.98[0.88,1.1]
Raitt 2005 2/100 5/100 0.29% 0.4[0.08,2.01]
Risk & Prevention 2013 142/6239 137/6266 9.14% 1.04[0.83,1.31]
SCIMO 1999 0/112 1/111 0.07% 0.33[0.01,8.02]
Shinto 2014 1/13 0/13 0.08% 3[0.13,67.51]
SHOT 1996 7/317 5/293 0.58% 1.29[0.42,4.03]
SOFA 2006 6/273 13/273 0.82% 0.46[0.18,1.2]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
SU.FOL.OM3 2010 23/1253 28/1248 2.33% 0.82[0.47,1.41]
Subtotal (95% CI) 28900 28686 75.61% 0.94[0.88,0.99]
Total events: 1867 (Higher omega 3), 1990 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=18.36, df=20(P=0.56); I2=0%  
Test for overall effect: Z=2.18(P=0.03)  
   
1.17.4 Any combination  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 33991 33781 100% 0.95[0.87,1.03]
Total events: 2211 (Higher omega 3), 2333 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=31.76, df=24(P=0.13); I2=24.44%  
Test for overall effect: Z=1.26(P=0.21)  
Test for subgroup differences: Chi2=0.08, df=1 (P=0.96), I2=0%  
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Analysis 1.18.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 18 CVD mortality - LCn3 - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.18.1 Medium duration 1 to < 2 years in study  
Brox 2001 0/80 1/40 0.08% 0.17[0.01,4.05]
Derosa 2016 2/138 3/143 0.24% 0.69[0.12,4.07]
Doi 2014 1/119 5/119 0.17% 0.2[0.02,1.69]
FAAT 2005 9/200 9/202 0.9% 1.01[0.41,2.49]
Kumar 2013 1/39 1/39 0.1% 1[0.06,15.43]
Nutristroke 2009 0/38 4/34 0.09% 0.1[0.01,1.79]
OMEGA 2009 67/1919 51/1885 4.83% 1.29[0.9,1.85]
Shinto 2014 1/13 0/13 0.08% 3[0.13,67.51]
SHOT 1996 7/317 5/293 0.58% 1.29[0.42,4.03]
SOFA 2006 6/273 13/273 0.82% 0.46[0.18,1.2]
Subtotal (95% CI) 3136 3041 7.88% 0.88[0.57,1.36]
Total events: 94 (Higher omega 3), 92 (Lower omega 3)  
Heterogeneity: Tau2=0.09; Chi2=11.17, df=9(P=0.26); I2=19.45%  
Test for overall effect: Z=0.57(P=0.57)  
   
1.18.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 6.29% 0.99[0.73,1.34]
DART 1989 84/1015 121/1018 7.67% 0.7[0.53,0.91]
DO IT 2010 7/282 11/281 0.85% 0.63[0.25,1.61]
FOSTAR 2016 0/101 1/101 0.07% 0.33[0.01,8.09]
GISSI-HF 2008 712/3494 765/3481 20.11% 0.93[0.85,1.02]
GISSI-P 1999 291/5665 348/5658 14.51% 0.84[0.72,0.97]
HARP 1995 0/41 1/39 0.08% 0.32[0.01,7.57]
OFAMI 2001 8/150 8/150 0.81% 1[0.39,2.59]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Raitt 2005 2/100 5/100 0.29% 0.4[0.08,2.01]
SCIMO 1999 0/112 1/111 0.07% 0.33[0.01,8.02]
Subtotal (95% CI) 13364 13372 50.76% 0.89[0.82,0.95]
Total events: 1184 (Higher omega 3), 1343 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=7.88, df=9(P=0.55); I2=0%  
Test for overall effect: Z=3.32(P=0)  
   
1.18.3 Long duration: ≥ 4 years in study  
AREDS2 2014 14/2147 13/2056 1.28% 1.03[0.49,2.19]
DART2 2003 180/1571 139/1543 10.35% 1.27[1.03,1.57]
ORIGIN 2012 574/6281 581/6255 18.25% 0.98[0.88,1.1]
Risk & Prevention 2013 142/6239 137/6266 9.14% 1.04[0.83,1.31]
SU.FOL.OM3 2010 23/1253 28/1248 2.33% 0.82[0.47,1.41]
Subtotal (95% CI) 17491 17368 41.36% 1.05[0.93,1.18]
Total events: 933 (Higher omega 3), 898 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=5.24, df=4(P=0.26); I2=23.59%  
Test for overall effect: Z=0.79(P=0.43)  
   
Total (95% CI) 33991 33781 100% 0.95[0.87,1.03]
Total events: 2211 (Higher omega 3), 2333 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=31.76, df=24(P=0.13); I2=24.44%  
Test for overall effect: Z=1.26(P=0.21)  
Test for subgroup differences: Chi2=5.68, df=1 (P=0.06), I2=64.81%  
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Analysis 1.19.   Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes),
Outcome 19 CVD mortality - LCn3 - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.19.1 Primary prevention  
AREDS2 2014 14/2147 13/2056 1.28% 1.03[0.49,2.19]
Brox 2001 0/80 1/40 0.08% 0.17[0.01,4.05]
Derosa 2016 2/138 3/143 0.24% 0.69[0.12,4.07]
DO IT 2010 7/282 11/281 0.85% 0.63[0.25,1.61]
FOSTAR 2016 0/101 1/101 0.07% 0.33[0.01,8.09]
ORIGIN 2012 574/6281 581/6255 18.25% 0.98[0.88,1.1]
Shinto 2014 1/13 0/13 0.08% 3[0.13,67.51]
Subtotal (95% CI) 9042 8889 20.86% 0.98[0.88,1.09]
Total events: 598 (Higher omega 3), 610 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.11, df=6(P=0.79); I2=0%  
Test for overall effect: Z=0.44(P=0.66)  
   
1.19.2 Secondary prevention  
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 6.29% 0.99[0.73,1.34]
DART 1989 84/1015 121/1018 7.67% 0.7[0.53,0.91]
DART2 2003 180/1571 139/1543 10.35% 1.27[1.03,1.57]
Doi 2014 1/119 5/119 0.17% 0.2[0.02,1.69]
FAAT 2005 9/200 9/202 0.9% 1.01[0.41,2.49]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
GISSI-HF 2008 712/3494 765/3481 20.11% 0.93[0.85,1.02]
GISSI-P 1999 291/5665 348/5658 14.51% 0.84[0.72,0.97]
HARP 1995 0/41 1/39 0.08% 0.32[0.01,7.57]
Kumar 2013 1/39 1/39 0.1% 1[0.06,15.43]
Nutristroke 2009 0/38 4/34 0.09% 0.1[0.01,1.79]
OFAMI 2001 8/150 8/150 0.81% 1[0.39,2.59]
OMEGA 2009 67/1919 51/1885 4.83% 1.29[0.9,1.85]
Raitt 2005 2/100 5/100 0.29% 0.4[0.08,2.01]
Risk & Prevention 2013 142/6239 137/6266 9.14% 1.04[0.83,1.31]
SCIMO 1999 0/112 1/111 0.07% 0.33[0.01,8.02]
SHOT 1996 7/317 5/293 0.58% 1.29[0.42,4.03]
SOFA 2006 6/273 13/273 0.82% 0.46[0.18,1.2]
SU.FOL.OM3 2010 23/1253 28/1248 2.33% 0.82[0.47,1.41]
Subtotal (95% CI) 24949 24892 79.14% 0.94[0.83,1.06]
Total events: 1613 (Higher omega 3), 1723 (Lower omega 3)  
Heterogeneity: Tau2=0.02; Chi2=28.2, df=17(P=0.04); I2=39.71%  
Test for overall effect: Z=1.02(P=0.31)  
   
Total (95% CI) 33991 33781 100% 0.95[0.87,1.03]
Total events: 2211 (Higher omega 3), 2333 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=31.76, df=24(P=0.13); I2=24.44%  
Test for overall effect: Z=1.26(P=0.21)  
Test for subgroup differences: Chi2=0.21, df=1 (P=0.64), I2=0%  
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Analysis 1.20.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 20 CVD mortality - LCn3 - subgroup by statin uses.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.20.1 LCn3 - ≥ 50% of control group on statins  
AlphaOmega - EPA+DHA 2010 80/2404 82/2433 6.29% 0.99[0.73,1.34]
Doi 2014 1/119 5/119 0.17% 0.2[0.02,1.69]
Kumar 2013 1/39 1/39 0.1% 1[0.06,15.43]
OMEGA 2009 67/1919 51/1885 4.83% 1.29[0.9,1.85]
ORIGIN 2012 574/6281 581/6255 18.25% 0.98[0.88,1.1]
SU.FOL.OM3 2010 23/1253 28/1248 2.33% 0.82[0.47,1.41]
Subtotal (95% CI) 12015 11979 31.97% 0.99[0.9,1.1]
Total events: 746 (Higher omega 3), 748 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=4.73, df=5(P=0.45); I2=0%  
Test for overall effect: Z=0.1(P=0.92)  
   
1.20.2 LCn3 - < 50% of control group on statins  
AREDS2 2014 14/2147 13/2056 1.28% 1.03[0.49,2.19]
Brox 2001 0/80 1/40 0.08% 0.17[0.01,4.05]
DART 1989 84/1015 121/1018 7.67% 0.7[0.53,0.91]
DART2 2003 180/1571 139/1543 10.35% 1.27[1.03,1.57]
DO IT 2010 7/282 11/281 0.85% 0.63[0.25,1.61]
FAAT 2005 9/200 9/202 0.9% 1.01[0.41,2.49]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
FOSTAR 2016 0/101 1/101 0.07% 0.33[0.01,8.09]
GISSI-HF 2008 712/3494 765/3481 20.11% 0.93[0.85,1.02]
GISSI-P 1999 291/5665 348/5658 14.51% 0.84[0.72,0.97]
HARP 1995 0/41 1/39 0.08% 0.32[0.01,7.57]
OFAMI 2001 8/150 8/150 0.81% 1[0.39,2.59]
Raitt 2005 2/100 5/100 0.29% 0.4[0.08,2.01]
Risk & Prevention 2013 142/6239 137/6266 9.14% 1.04[0.83,1.31]
SCIMO 1999 0/112 1/111 0.07% 0.33[0.01,8.02]
Shinto 2014 1/13 0/13 0.08% 3[0.13,67.51]
SHOT 1996 7/317 5/293 0.58% 1.29[0.42,4.03]
SOFA 2006 6/273 13/273 0.82% 0.46[0.18,1.2]
Subtotal (95% CI) 21800 21625 67.69% 0.92[0.82,1.04]
Total events: 1463 (Higher omega 3), 1578 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=23.1, df=16(P=0.11); I2=30.73%  
Test for overall effect: Z=1.36(P=0.17)  
   
1.20.3 LCn3- Use of statins unclear  
Derosa 2016 2/138 3/143 0.24% 0.69[0.12,4.07]
Nutristroke 2009 0/38 4/34 0.09% 0.1[0.01,1.79]
Subtotal (95% CI) 176 177 0.33% 0.36[0.06,2.3]
Total events: 2 (Higher omega 3), 7 (Lower omega 3)  
Heterogeneity: Tau2=0.5; Chi2=1.34, df=1(P=0.25); I2=25.11%  
Test for overall effect: Z=1.08(P=0.28)  
   
Total (95% CI) 33991 33781 100% 0.95[0.87,1.03]
Total events: 2211 (Higher omega 3), 2333 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=31.76, df=24(P=0.13); I2=24.44%  
Test for overall effect: Z=1.26(P=0.21)  
Test for subgroup differences: Chi2=2.06, df=1 (P=0.36), I2=2.85%  
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Analysis 1.21.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 21 Cardiovascular events (overall) - LCn3.
Study or subgroup Favours high-
er omega 3
Lower
omega 3 fats
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AFFORD 2013 20/153 11/163 0.51% 1.94[0.96,3.91]
AlphaOmega - EPA+DHA 2010 336/2404 335/2433 6.72% 1.02[0.88,1.17]
AREDS2 2014 183/2147 187/2056 4.57% 0.94[0.77,1.14]
Baldassarre 2006 1/32 0/32 0.03% 3[0.13,71]
Brox 2001 0/80 1/40 0.03% 0.17[0.01,4.05]
DART 1989 467/1015 487/1018 9.45% 0.96[0.88,1.05]
DART2 2003 206/1571 155/1543 4.52% 1.31[1.07,1.59]
Derosa 2016 2/128 3/130 0.08% 0.68[0.12,3.98]
DO IT 2010 32/282 36/281 1.19% 0.89[0.57,1.38]
Doi 2014 11/119 24/119 0.56% 0.46[0.24,0.89]
EPE-A 2014 5/168 6/75 0.19% 0.37[0.12,1.18]
EPIC-1 2008 1/188 0/186 0.03% 2.97[0.12,72.4]
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Study or subgroup Favours high-
er omega 3
Lower
omega 3 fats
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
EPOCH 2014 8/195 5/196 0.21% 1.61[0.54,4.83]
FAAT 2005 31/200 39/202 1.28% 0.8[0.52,1.23]
FORWARD 2013 4/289 4/297 0.14% 1.03[0.26,4.07]
FOSTAR 2016 18/101 16/101 0.65% 1.13[0.61,2.08]
GISSI-HF 2008 1635/3494 1687/3481 12.17% 0.97[0.92,1.01]
GISSI-P 1999 547/5666 608/5658 8.4% 0.9[0.81,1]
HARP 1995 7/41 7/39 0.28% 0.95[0.37,2.46]
JELIS 2007 262/9326 324/9319 5.82% 0.81[0.69,0.95]
Kumar 2013 1/39 1/39 0.03% 1[0.06,15.43]
MAPT 2017 192/820 164/832 4.9% 1.19[0.99,1.43]
Nodari 2011 HF 10/67 26/66 0.6% 0.38[0.2,0.72]
Nutristroke 2009 0/38 4/34 0.03% 0.1[0.01,1.79]
OFAMI 2001 42/150 36/150 1.57% 1.17[0.8,1.71]
OMEGA 2009 182/1752 149/1701 4.23% 1.19[0.97,1.46]
ORIGIN 2012 2055/6281 2087/6255 12.14% 0.98[0.93,1.03]
Proudman 2015 1/87 0/53 0.03% 1.84[0.08,44.38]
Puri 2005 1/60 0/61 0.03% 3.05[0.13,73.4]
Raitt 2005 2/100 5/100 0.1% 0.4[0.08,2.01]
Risk & Prevention 2013 620/6239 630/6266 8.66% 0.99[0.89,1.1]
Sandhu 2016 2/107 1/106 0.05% 1.98[0.18,21.52]
SCIMO 1999 17/112 26/111 0.8% 0.65[0.37,1.13]
Shinto 2014 1/13 0/13 0.03% 3[0.13,67.51]
SHOT 1996 15/317 12/293 0.46% 1.16[0.55,2.43]
SOFA 2006 65/273 62/273 2.32% 1.05[0.77,1.42]
SU.FOL.OM3 2010 303/1253 290/1248 6.71% 1.04[0.9,1.2]
THIS DIET 2008 14/51 10/50 0.49% 1.37[0.67,2.8]
   
Total (95% CI) 45358 45020 100% 0.99[0.94,1.04]
Total events: 7299 (Favours higher omega 3), 7438 (Lower omega 3 fats)  
Heterogeneity: Tau2=0; Chi2=58.47, df=37(P=0.01); I2=36.72%  
Test for overall effect: Z=0.54(P=0.59)  
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Analysis 1.22.   Comparison 1 High vs low LCn3 omega-3 fats
(primary outcomes), Outcome 22 CVD events - LCn3 - SA fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
AFFORD 2013 20/153 11/163 0.14% 1.94[0.96,3.91]
AlphaOmega - EPA+DHA 2010 336/2404 335/2433 4.47% 1.02[0.88,1.17]
AREDS2 2014 183/2147 187/2056 2.56% 0.94[0.77,1.14]
Baldassarre 2006 1/32 0/32 0.01% 3[0.13,71]
Brox 2001 0/80 1/40 0.03% 0.17[0.01,4.05]
DART 1989 467/1015 487/1018 6.52% 0.96[0.88,1.05]
DART2 2003 206/1571 155/1543 2.1% 1.31[1.07,1.59]
Derosa 2016 2/128 3/130 0.04% 0.68[0.12,3.98]
DO IT 2010 32/282 36/281 0.48% 0.89[0.57,1.38]
Doi 2014 11/119 24/119 0.32% 0.46[0.24,0.89]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
EPE-A 2014 5/168 6/75 0.11% 0.37[0.12,1.18]
EPIC-1 2008 1/188 0/186 0.01% 2.97[0.12,72.4]
EPOCH 2014 8/195 5/196 0.07% 1.61[0.54,4.83]
FAAT 2005 31/200 39/202 0.52% 0.8[0.52,1.23]
FORWARD 2013 4/289 4/297 0.05% 1.03[0.26,4.07]
FOSTAR 2016 18/101 16/101 0.21% 1.13[0.61,2.08]
GISSI-HF 2008 1635/3494 1687/3481 22.67% 0.97[0.92,1.01]
GISSI-P 1999 547/5666 608/5658 8.16% 0.9[0.81,1]
HARP 1995 7/41 7/39 0.1% 0.95[0.37,2.46]
JELIS 2007 262/9326 324/9319 4.35% 0.81[0.69,0.95]
Kumar 2013 1/39 1/39 0.01% 1[0.06,15.43]
MAPT 2017 192/820 164/832 2.18% 1.19[0.99,1.43]
Nodari 2011 HF 10/67 26/66 0.35% 0.38[0.2,0.72]
Nutristroke 2009 0/38 4/34 0.06% 0.1[0.01,1.79]
OFAMI 2001 42/150 36/150 0.48% 1.17[0.8,1.71]
OMEGA 2009 182/1752 149/1701 2.03% 1.19[0.97,1.46]
ORIGIN 2012 2055/6281 2087/6255 28.05% 0.98[0.93,1.03]
Proudman 2015 1/87 0/53 0.01% 1.84[0.08,44.38]
Puri 2005 1/60 0/61 0.01% 3.05[0.13,73.4]
Raitt 2005 2/100 5/100 0.07% 0.4[0.08,2.01]
Risk & Prevention 2013 620/6239 630/6266 8.43% 0.99[0.89,1.1]
Sandhu 2016 2/107 1/106 0.01% 1.98[0.18,21.52]
SCIMO 1999 17/112 26/111 0.35% 0.65[0.37,1.13]
Shinto 2014 1/13 0/13 0.01% 3[0.13,67.51]
SHOT 1996 15/317 12/293 0.17% 1.16[0.55,2.43]
SOFA 2006 65/273 62/273 0.83% 1.05[0.77,1.42]
SU.FOL.OM3 2010 303/1253 290/1248 3.9% 1.04[0.9,1.2]
THIS DIET 2008 14/51 10/50 0.14% 1.37[0.67,2.8]
   
Total (95% CI) 45358 45020 100% 0.98[0.95,1]
Total events: 7299 (Higher omega 3), 7438 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=58.47, df=37(P=0.01); I2=36.72%  
Test for overall effect: Z=1.63(P=0.1)  
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Analysis 1.23.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 23 CVD events - LCn3 - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.23.1 Low risk of bias  
AlphaOmega - EPA+DHA 2010 336/2404 335/2433 6.72% 1.02[0.88,1.17]
AREDS2 2014 183/2147 187/2056 4.57% 0.94[0.77,1.14]
Derosa 2016 2/128 3/130 0.08% 0.68[0.12,3.98]
EPOCH 2014 8/195 5/196 0.21% 1.61[0.54,4.83]
FORWARD 2013 4/289 4/297 0.14% 1.03[0.26,4.07]
FOSTAR 2016 18/101 16/101 0.65% 1.13[0.61,2.08]
MAPT 2017 192/820 164/832 4.9% 1.19[0.99,1.43]
OMEGA 2009 182/1752 149/1701 4.23% 1.19[0.97,1.46]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
ORIGIN 2012 2055/6281 2087/6255 12.14% 0.98[0.93,1.03]
Proudman 2015 1/87 0/53 0.03% 1.84[0.08,44.38]
Puri 2005 1/60 0/61 0.03% 3.05[0.13,73.4]
SCIMO 1999 17/112 26/111 0.8% 0.65[0.37,1.13]
SOFA 2006 65/273 62/273 2.32% 1.05[0.77,1.42]
SU.FOL.OM3 2010 303/1253 290/1248 6.71% 1.04[0.9,1.2]
Subtotal (95% CI) 15902 15747 43.53% 1[0.96,1.05]
Total events: 3367 (Higher omega 3), 3328 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=11.46, df=13(P=0.57); I2=0%  
Test for overall effect: Z=0.17(P=0.87)  
   
1.23.2 Moderate/high risk of bias  
AFFORD 2013 20/153 11/163 0.51% 1.94[0.96,3.91]
Baldassarre 2006 1/32 0/32 0.03% 3[0.13,71]
Brox 2001 0/80 1/40 0.03% 0.17[0.01,4.05]
DART 1989 467/1015 487/1018 9.45% 0.96[0.88,1.05]
DART2 2003 206/1571 155/1543 4.52% 1.31[1.07,1.59]
DO IT 2010 32/282 36/281 1.19% 0.89[0.57,1.38]
Doi 2014 11/119 24/119 0.56% 0.46[0.24,0.89]
EPE-A 2014 5/168 6/75 0.19% 0.37[0.12,1.18]
EPIC-1 2008 1/188 0/186 0.03% 2.97[0.12,72.4]
FAAT 2005 31/200 39/202 1.28% 0.8[0.52,1.23]
GISSI-HF 2008 1635/3494 1687/3481 12.17% 0.97[0.92,1.01]
GISSI-P 1999 547/5666 608/5658 8.4% 0.9[0.81,1]
HARP 1995 7/41 7/39 0.28% 0.95[0.37,2.46]
JELIS 2007 262/9326 324/9319 5.82% 0.81[0.69,0.95]
Kumar 2013 1/39 1/39 0.03% 1[0.06,15.43]
Nodari 2011 HF 10/67 26/66 0.6% 0.38[0.2,0.72]
Nutristroke 2009 0/38 4/34 0.03% 0.1[0.01,1.79]
OFAMI 2001 42/150 36/150 1.57% 1.17[0.8,1.71]
Raitt 2005 2/100 5/100 0.1% 0.4[0.08,2.01]
Risk & Prevention 2013 620/6239 630/6266 8.66% 0.99[0.89,1.1]
Sandhu 2016 2/107 1/106 0.05% 1.98[0.18,21.52]
Shinto 2014 1/13 0/13 0.03% 3[0.13,67.51]
SHOT 1996 15/317 12/293 0.46% 1.16[0.55,2.43]
THIS DIET 2008 14/51 10/50 0.49% 1.37[0.67,2.8]
Subtotal (95% CI) 29456 29273 56.47% 0.95[0.87,1.03]
Total events: 3932 (Higher omega 3), 4110 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=44.28, df=23(P=0); I2=48.06%  
Test for overall effect: Z=1.21(P=0.22)  
   
Total (95% CI) 45358 45020 100% 0.99[0.94,1.04]
Total events: 7299 (Higher omega 3), 7438 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=58.47, df=37(P=0.01); I2=36.72%  
Test for overall effect: Z=0.54(P=0.59)  
Test for subgroup differences: Chi2=1.36, df=1 (P=0.24), I2=26.34%  
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Analysis 1.24.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 24 CVD events - LCn3 - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.24.1 SA - low risk of compliance bias  
AFFORD 2013 20/153 11/163 4.03% 1.94[0.96,3.91]
AlphaOmega - EPA+DHA 2010 336/2404 335/2433 22.19% 1.02[0.88,1.17]
Baldassarre 2006 1/32 0/32 0.23% 3[0.13,71]
Brox 2001 0/80 1/40 0.23% 0.17[0.01,4.05]
DO IT 2010 32/282 36/281 8.18% 0.89[0.57,1.38]
EPE-A 2014 5/168 6/75 1.64% 0.37[0.12,1.18]
FOSTAR 2016 18/101 16/101 5.03% 1.13[0.61,2.08]
HARP 1995 7/41 7/39 2.35% 0.95[0.37,2.46]
Kumar 2013 1/39 1/39 0.31% 1[0.06,15.43]
Nodari 2011 HF 10/67 26/66 4.64% 0.38[0.2,0.72]
OMEGA 2009 182/1752 149/1701 18.24% 1.19[0.97,1.46]
Raitt 2005 2/100 5/100 0.86% 0.4[0.08,2.01]
SCIMO 1999 17/112 26/111 5.97% 0.65[0.37,1.13]
Shinto 2014 1/13 0/13 0.24% 3[0.13,67.51]
SHOT 1996 15/317 12/293 3.66% 1.16[0.55,2.43]
SU.FOL.OM3 2010 303/1253 290/1248 22.18% 1.04[0.9,1.2]
Subtotal (95% CI) 6914 6735 100% 0.98[0.84,1.14]
Total events: 950 (Higher omega 3), 921 (Lower omega 3)  
Heterogeneity: Tau2=0.02; Chi2=23.95, df=15(P=0.07); I2=37.37%  
Test for overall effect: Z=0.31(P=0.76)  
   
1.24.2 SA - 100+ randomised  
AFFORD 2013 20/153 11/163 0.53% 1.94[0.96,3.91]
AlphaOmega - EPA+DHA 2010 336/2404 335/2433 6.78% 1.02[0.88,1.17]
AREDS2 2014 183/2147 187/2056 4.66% 0.94[0.77,1.14]
Brox 2001 0/80 1/40 0.03% 0.17[0.01,4.05]
DART 1989 467/1015 487/1018 9.39% 0.96[0.88,1.05]
DART2 2003 206/1571 155/1543 4.61% 1.31[1.07,1.59]
Derosa 2016 2/128 3/130 0.09% 0.68[0.12,3.98]
DO IT 2010 32/282 36/281 1.24% 0.89[0.57,1.38]
Doi 2014 11/119 24/119 0.58% 0.46[0.24,0.89]
EPE-A 2014 5/168 6/75 0.2% 0.37[0.12,1.18]
EPIC-1 2008 1/188 0/186 0.03% 2.97[0.12,72.4]
EPOCH 2014 8/195 5/196 0.22% 1.61[0.54,4.83]
FAAT 2005 31/200 39/202 1.33% 0.8[0.52,1.23]
FORWARD 2013 4/289 4/297 0.14% 1.03[0.26,4.07]
FOSTAR 2016 18/101 16/101 0.68% 1.13[0.61,2.08]
GISSI-HF 2008 1635/3494 1687/3481 11.92% 0.97[0.92,1.01]
GISSI-P 1999 547/5666 608/5658 8.4% 0.9[0.81,1]
JELIS 2007 262/9326 324/9319 5.9% 0.81[0.69,0.95]
MAPT 2017 192/820 164/832 4.98% 1.19[0.99,1.43]
Nodari 2011 HF 10/67 26/66 0.62% 0.38[0.2,0.72]
OFAMI 2001 42/150 36/150 1.62% 1.17[0.8,1.71]
OMEGA 2009 182/1752 149/1701 4.32% 1.19[0.97,1.46]
ORIGIN 2012 2055/6281 2087/6255 11.89% 0.98[0.93,1.03]
Proudman 2015 1/87 0/53 0.03% 1.84[0.08,44.38]
Puri 2005 1/60 0/61 0.03% 3.05[0.13,73.4]
Raitt 2005 2/100 5/100 0.1% 0.4[0.08,2.01]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Risk & Prevention 2013 620/6239 630/6266 8.64% 0.99[0.89,1.1]
Sandhu 2016 2/107 1/106 0.05% 1.98[0.18,21.52]
SCIMO 1999 17/112 26/111 0.84% 0.65[0.37,1.13]
SHOT 1996 15/317 12/293 0.48% 1.16[0.55,2.43]
SOFA 2006 65/273 62/273 2.4% 1.05[0.77,1.42]
SU.FOL.OM3 2010 303/1253 290/1248 6.77% 1.04[0.9,1.2]
THIS DIET 2008 14/51 10/50 0.52% 1.37[0.67,2.8]
Subtotal (95% CI) 45195 44863 100% 0.99[0.94,1.04]
Total events: 7289 (Higher omega 3), 7426 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=55.08, df=32(P=0.01); I2=41.91%  
Test for overall effect: Z=0.52(P=0.6)  
Test for subgroup differences: Chi2=0.02, df=1 (P=0.9), I2=0%  
Favours higher omega 3 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 1.25.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 25 CVD events - LCn3 - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.25.1 LCn3 ≤ 150 mg/d  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.25.2 LCn3 > 150 ≤ 250 mg/d  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.25.3 LCn3 > 250 ≤ 400 mg/d  
DART 1989 467/1015 487/1018 9.46% 0.96[0.88,1.05]
Subtotal (95% CI) 1015 1018 9.46% 0.96[0.88,1.05]
Total events: 467 (Higher omega 3), 487 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.83(P=0.41)  
   
1.25.4 LCn3 > 400 ≤ 2400 mg/d  
AFFORD 2013 20/153 11/163 0.51% 1.94[0.96,3.91]
AlphaOmega - EPA+DHA 2010 336/2404 335/2433 6.71% 1.02[0.88,1.17]
AREDS2 2014 183/2147 187/2056 4.56% 0.94[0.77,1.14]
Baldassarre 2006 1/32 0/32 0.03% 3[0.13,71]
DART2 2003 206/1571 155/1543 4.51% 1.31[1.07,1.59]
Derosa 2016 2/128 3/130 0.08% 0.68[0.12,3.98]
DO IT 2010 32/282 36/281 1.18% 0.89[0.57,1.38]
Doi 2014 11/119 24/119 0.56% 0.46[0.24,0.89]
EPE-A 2014 3/82 6/75 0.14% 0.46[0.12,1.76]
EPOCH 2014 8/195 5/196 0.21% 1.61[0.54,4.83]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
FORWARD 2013 4/289 4/297 0.13% 1.03[0.26,4.07]
GISSI-HF 2008 1635/3494 1687/3481 12.2% 0.97[0.92,1.01]
GISSI-P 1999 547/5666 608/5658 8.41% 0.9[0.81,1]
JELIS 2007 262/9326 324/9319 5.81% 0.81[0.69,0.95]
Kumar 2013 1/39 1/39 0.03% 1[0.06,15.43]
MAPT 2017 192/820 164/832 4.88% 1.19[0.99,1.43]
Nodari 2011 HF 10/67 26/66 0.59% 0.38[0.2,0.72]
Nutristroke 2009 0/38 4/34 0.03% 0.1[0.01,1.79]
OMEGA 2009 182/1752 149/1701 4.22% 1.19[0.97,1.46]
ORIGIN 2012 2055/6281 2087/6255 12.17% 0.98[0.93,1.03]
Puri 2005 1/60 0/61 0.03% 3.05[0.13,73.4]
Raitt 2005 2/100 5/100 0.1% 0.4[0.08,2.01]
Risk & Prevention 2013 620/6239 630/6266 8.66% 0.99[0.89,1.1]
SCIMO 1999 17/112 26/111 0.8% 0.65[0.37,1.13]
Shinto 2014 1/13 0/13 0.03% 3[0.13,67.51]
SOFA 2006 65/273 62/273 2.31% 1.05[0.77,1.42]
SU.FOL.OM3 2010 303/1253 290/1248 6.7% 1.04[0.9,1.2]
THIS DIET 2008 14/51 10/50 0.49% 1.37[0.67,2.8]
Subtotal (95% CI) 42986 42832 86.1% 0.99[0.93,1.05]
Total events: 6713 (Higher omega 3), 6839 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=52.73, df=27(P=0); I2=48.79%  
Test for overall effect: Z=0.4(P=0.69)  
   
1.25.5 LCn3 > 2.4 ≤ 4.4 g/d  
Brox 2001 0/80 1/40 0.03% 0.17[0.01,4.05]
EPE-A 2014 2/86 6/75 0.1% 0.29[0.06,1.4]
EPIC-1 2008 1/188 0/186 0.03% 2.97[0.12,72.4]
FAAT 2005 31/200 39/202 1.27% 0.8[0.52,1.23]
OFAMI 2001 42/150 36/150 1.56% 1.17[0.8,1.71]
Sandhu 2016 2/107 1/106 0.05% 1.98[0.18,21.52]
SHOT 1996 15/317 12/293 0.45% 1.16[0.55,2.43]
Subtotal (95% CI) 1128 1052 3.48% 0.98[0.75,1.28]
Total events: 93 (Higher omega 3), 95 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=6.11, df=6(P=0.41); I2=1.78%  
Test for overall effect: Z=0.18(P=0.86)  
   
1.25.6 LCn3 > 4.4 g/d  
FOSTAR 2016 18/101 16/101 0.65% 1.13[0.61,2.08]
HARP 1995 7/41 7/39 0.28% 0.95[0.37,2.46]
Proudman 2015 1/87 0/53 0.03% 1.84[0.08,44.38]
Subtotal (95% CI) 229 193 0.96% 1.09[0.65,1.81]
Total events: 26 (Higher omega 3), 23 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.19, df=2(P=0.91); I2=0%  
Test for overall effect: Z=0.32(P=0.75)  
   
Total (95% CI) 45358 45095 100% 0.99[0.94,1.04]
Total events: 7299 (Higher omega 3), 7444 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=59.29, df=38(P=0.02); I2=35.91%  
Test for overall effect: Z=0.57(P=0.57)  
Test for subgroup differences: Chi2=0.38, df=1 (P=0.94), I2=0%  
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Analysis 1.26.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 26 CVD events - LCn3 - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.26.1 N-3 replacing SFA  
DART 1989 467/1015 487/1018 96.93% 0.96[0.88,1.05]
Derosa 2016 2/128 3/130 0.26% 0.68[0.12,3.98]
EPIC-1 2008 1/188 0/186 0.08% 2.97[0.12,72.4]
SCIMO 1999 17/112 26/111 2.72% 0.65[0.37,1.13]
Subtotal (95% CI) 1443 1445 100% 0.95[0.87,1.04]
Total events: 487 (Higher omega 3), 516 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.55, df=3(P=0.47); I2=0%  
Test for overall effect: Z=1.07(P=0.28)  
   
1.26.2 N-3 replacing MUFA  
AlphaOmega - EPA+DHA 2010 336/2404 335/2433 8.12% 1.02[0.88,1.17]
Baldassarre 2006 1/32 0/32 0.02% 3[0.13,71]
DART 1989 467/1015 487/1018 14.92% 0.96[0.88,1.05]
EPOCH 2014 8/195 5/196 0.16% 1.61[0.54,4.83]
FAAT 2005 31/200 39/202 1.05% 0.8[0.52,1.23]
FORWARD 2013 4/289 4/297 0.1% 1.03[0.26,4.07]
GISSI-HF 2008 1635/3494 1687/3481 27.61% 0.97[0.92,1.01]
HARP 1995 7/41 7/39 0.22% 0.95[0.37,2.46]
Nodari 2011 HF 10/67 26/66 0.47% 0.38[0.2,0.72]
OMEGA 2009 182/1752 149/1701 4.22% 1.19[0.97,1.46]
ORIGIN 2012 2055/6281 2087/6255 27.38% 0.98[0.93,1.03]
Raitt 2005 2/100 5/100 0.08% 0.4[0.08,2.01]
Risk & Prevention 2013 620/6239 630/6266 12.56% 0.99[0.89,1.1]
SCIMO 1999 17/112 26/111 0.64% 0.65[0.37,1.13]
SOFA 2006 65/273 62/273 2.04% 1.05[0.77,1.42]
THIS DIET 2008 14/51 10/50 0.39% 1.37[0.67,2.8]
Subtotal (95% CI) 22545 22520 100% 0.98[0.94,1.02]
Total events: 5454 (Higher omega 3), 5559 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=18.85, df=15(P=0.22); I2=20.44%  
Test for overall effect: Z=0.93(P=0.35)  
   
1.26.3 N-3 replacing n-6  
AFFORD 2013 20/153 11/163 8.18% 1.94[0.96,3.91]
DO IT 2010 32/282 36/281 20.21% 0.89[0.57,1.38]
OFAMI 2001 42/150 36/150 27.43% 1.17[0.8,1.71]
Proudman 2015 1/87 0/53 0.4% 1.84[0.08,44.38]
Shinto 2014 1/13 0/13 0.42% 3[0.13,67.51]
SOFA 2006 65/273 62/273 43.37% 1.05[0.77,1.42]
Subtotal (95% CI) 958 933 100% 1.1[0.9,1.35]
Total events: 161 (Higher omega 3), 145 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=4.09, df=5(P=0.54); I2=0%  
Test for overall effect: Z=0.97(P=0.33)  
   
1.26.4 N-3 replacing carbohydrates/sugars  
Derosa 2016 2/128 3/130 100% 0.68[0.12,3.98]
Subtotal (95% CI) 128 130 100% 0.68[0.12,3.98]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 2 (Higher omega 3), 3 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.43(P=0.67)  
   
1.26.5 N-3 replacing nil/low n-3 placebo  
AREDS2 2014 183/2147 187/2056 15.41% 0.94[0.77,1.14]
Brox 2001 0/80 1/40 0.13% 0.17[0.01,4.05]
Doi 2014 11/119 24/119 2.64% 0.46[0.24,0.89]
FOSTAR 2016 18/101 16/101 3.05% 1.13[0.61,2.08]
GISSI-P 1999 547/5666 608/5658 22.28% 0.9[0.81,1]
JELIS 2007 262/9326 324/9319 18.03% 0.81[0.69,0.95]
Kumar 2013 1/39 1/39 0.17% 1[0.06,15.43]
MAPT 2017 192/820 164/832 16.13% 1.19[0.99,1.43]
Puri 2005 1/60 0/61 0.13% 3.05[0.13,73.4]
Sandhu 2016 2/107 1/106 0.23% 1.98[0.18,21.52]
SHOT 1996 15/317 12/293 2.17% 1.16[0.55,2.43]
SU.FOL.OM3 2010 303/1253 290/1248 19.64% 1.04[0.9,1.2]
Subtotal (95% CI) 20035 19872 100% 0.95[0.85,1.07]
Total events: 1535 (Higher omega 3), 1628 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=19.4, df=11(P=0.05); I2=43.3%  
Test for overall effect: Z=0.86(P=0.39)  
   
1.26.6 Replacement unclear  
DART2 2003 206/1571 155/1543 50.15% 1.31[1.07,1.59]
EPE-A 2014 5/168 6/75 35.79% 0.37[0.12,1.18]
Nutristroke 2009 0/38 4/34 14.06% 0.1[0.01,1.79]
Subtotal (95% CI) 1777 1652 100% 0.58[0.16,2.07]
Total events: 211 (Higher omega 3), 165 (Lower omega 3)  
Heterogeneity: Tau2=0.83; Chi2=7.39, df=2(P=0.02); I2=72.94%  
Test for overall effect: Z=0.84(P=0.4)  
Test for subgroup differences: Chi2=2.77, df=1 (P=0.74), I2=0%  
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Analysis 1.27.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 27 CVD events - LCn3 - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.27.1 Dietary advice  
DART 1989 467/1015 487/1018 9.45% 0.96[0.88,1.05]
DART2 2003 206/1571 155/1543 4.52% 1.31[1.07,1.59]
THIS DIET 2008 14/51 10/50 0.49% 1.37[0.67,2.8]
Subtotal (95% CI) 2637 2611 14.47% 1.13[0.86,1.49]
Total events: 687 (Higher omega 3), 652 (Lower omega 3)  
Heterogeneity: Tau2=0.04; Chi2=8.74, df=2(P=0.01); I2=77.13%  
Test for overall effect: Z=0.9(P=0.37)  
   
1.27.2 Supplemental foods  
AlphaOmega - EPA+DHA 2010 336/2404 335/2433 6.72% 1.02[0.88,1.17]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
FOSTAR 2016 18/101 16/101 0.65% 1.13[0.61,2.08]
Subtotal (95% CI) 2505 2534 7.38% 1.02[0.89,1.17]
Total events: 354 (Higher omega 3), 351 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%  
Test for overall effect: Z=0.29(P=0.77)  
   
1.27.3 Supplements (capsule)  
AFFORD 2013 20/153 11/163 0.51% 1.94[0.96,3.91]
AREDS2 2014 183/2147 187/2056 4.57% 0.94[0.77,1.14]
Baldassarre 2006 1/32 0/32 0.03% 3[0.13,71]
Brox 2001 0/80 1/40 0.03% 0.17[0.01,4.05]
Derosa 2016 2/128 3/130 0.08% 0.68[0.12,3.98]
DO IT 2010 32/282 36/281 1.19% 0.89[0.57,1.38]
Doi 2014 11/119 24/119 0.56% 0.46[0.24,0.89]
EPE-A 2014 5/168 6/75 0.19% 0.37[0.12,1.18]
EPIC-1 2008 1/188 0/186 0.03% 2.97[0.12,72.4]
EPOCH 2014 8/195 5/196 0.21% 1.61[0.54,4.83]
FAAT 2005 31/200 39/202 1.28% 0.8[0.52,1.23]
FORWARD 2013 4/289 4/297 0.14% 1.03[0.26,4.07]
GISSI-HF 2008 1635/3494 1687/3481 12.17% 0.97[0.92,1.01]
GISSI-P 1999 547/5666 608/5658 8.4% 0.9[0.81,1]
HARP 1995 7/41 7/39 0.28% 0.95[0.37,2.46]
JELIS 2007 262/9326 324/9319 5.82% 0.81[0.69,0.95]
Kumar 2013 1/39 1/39 0.03% 1[0.06,15.43]
MAPT 2017 192/820 164/832 4.9% 1.19[0.99,1.43]
Nodari 2011 HF 10/67 26/66 0.6% 0.38[0.2,0.72]
Nutristroke 2009 0/38 4/34 0.03% 0.1[0.01,1.79]
OFAMI 2001 42/150 36/150 1.57% 1.17[0.8,1.71]
OMEGA 2009 182/1752 149/1701 4.23% 1.19[0.97,1.46]
ORIGIN 2012 2055/6281 2087/6255 12.14% 0.98[0.93,1.03]
Proudman 2015 1/87 0/53 0.03% 1.84[0.08,44.38]
Puri 2005 1/60 0/61 0.03% 3.05[0.13,73.4]
Raitt 2005 2/100 5/100 0.1% 0.4[0.08,2.01]
Risk & Prevention 2013 620/6239 630/6266 8.66% 0.99[0.89,1.1]
Sandhu 2016 2/107 1/106 0.05% 1.98[0.18,21.52]
SCIMO 1999 17/112 26/111 0.8% 0.65[0.37,1.13]
Shinto 2014 1/13 0/13 0.03% 3[0.13,67.51]
SHOT 1996 15/317 12/293 0.46% 1.16[0.55,2.43]
SOFA 2006 65/273 62/273 2.32% 1.05[0.77,1.42]
SU.FOL.OM3 2010 303/1253 290/1248 6.71% 1.04[0.9,1.2]
Subtotal (95% CI) 40216 39875 78.15% 0.97[0.91,1.02]
Total events: 6258 (Higher omega 3), 6435 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=48.44, df=32(P=0.03); I2=33.94%  
Test for overall effect: Z=1.14(P=0.26)  
   
1.27.4 Any combination  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 45358 45020 100% 0.99[0.94,1.04]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 7299 (Higher omega 3), 7438 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=58.47, df=37(P=0.01); I2=36.72%  
Test for overall effect: Z=0.54(P=0.59)  
Test for subgroup differences: Chi2=1.61, df=1 (P=0.45), I2=0%  
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Analysis 1.28.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 28 CVD events - LCn3 - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.28.1 Medium duration 1 to < 2 years in study  
AFFORD 2013 20/153 11/163 0.51% 1.94[0.96,3.91]
Brox 2001 0/80 1/40 0.03% 0.17[0.01,4.05]
Derosa 2016 2/128 3/130 0.08% 0.68[0.12,3.98]
Doi 2014 11/119 24/119 0.56% 0.46[0.24,0.89]
EPE-A 2014 5/168 6/75 0.19% 0.37[0.12,1.18]
EPIC-1 2008 1/188 0/186 0.03% 2.97[0.12,72.4]
EPOCH 2014 8/195 5/196 0.21% 1.61[0.54,4.83]
FAAT 2005 31/200 39/202 1.28% 0.8[0.52,1.23]
FORWARD 2013 4/289 4/297 0.14% 1.03[0.26,4.07]
Kumar 2013 1/39 1/39 0.03% 1[0.06,15.43]
Nodari 2011 HF 10/67 26/66 0.6% 0.38[0.2,0.72]
Nutristroke 2009 0/38 4/34 0.03% 0.1[0.01,1.79]
OMEGA 2009 182/1752 149/1701 4.23% 1.19[0.97,1.46]
Proudman 2015 1/87 0/53 0.03% 1.84[0.08,44.38]
Puri 2005 1/60 0/61 0.03% 3.05[0.13,73.4]
Shinto 2014 1/13 0/13 0.03% 3[0.13,67.51]
SHOT 1996 15/317 12/293 0.46% 1.16[0.55,2.43]
SOFA 2006 65/273 62/273 2.32% 1.05[0.77,1.42]
Subtotal (95% CI) 4166 3941 10.77% 0.89[0.68,1.16]
Total events: 358 (Higher omega 3), 347 (Lower omega 3)  
Heterogeneity: Tau2=0.09; Chi2=30.14, df=17(P=0.03); I2=43.6%  
Test for overall effect: Z=0.84(P=0.4)  
   
1.28.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - EPA+DHA 2010 336/2404 335/2433 6.72% 1.02[0.88,1.17]
Baldassarre 2006 1/32 0/32 0.03% 3[0.13,71]
DART 1989 467/1015 487/1018 9.45% 0.96[0.88,1.05]
DO IT 2010 32/282 36/281 1.19% 0.89[0.57,1.38]
FOSTAR 2016 18/101 16/101 0.65% 1.13[0.61,2.08]
GISSI-HF 2008 1635/3494 1687/3481 12.17% 0.97[0.92,1.01]
GISSI-P 1999 547/5666 608/5658 8.4% 0.9[0.81,1]
HARP 1995 7/41 7/39 0.28% 0.95[0.37,2.46]
MAPT 2017 192/820 164/832 4.9% 1.19[0.99,1.43]
OFAMI 2001 42/150 36/150 1.57% 1.17[0.8,1.71]
Raitt 2005 2/100 5/100 0.1% 0.4[0.08,2.01]
Sandhu 2016 2/107 1/106 0.05% 1.98[0.18,21.52]
SCIMO 1999 17/112 26/111 0.8% 0.65[0.37,1.13]
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  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
THIS DIET 2008 14/51 10/50 0.49% 1.37[0.67,2.8]
Subtotal (95% CI) 14375 14392 46.8% 0.97[0.93,1.01]
Total events: 3312 (Higher omega 3), 3418 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=13.2, df=13(P=0.43); I2=1.51%  
Test for overall effect: Z=1.52(P=0.13)  
   
1.28.3 Long duration: ≥ 4 years in study  
AREDS2 2014 183/2147 187/2056 4.57% 0.94[0.77,1.14]
DART2 2003 206/1571 155/1543 4.52% 1.31[1.07,1.59]
JELIS 2007 262/9326 324/9319 5.82% 0.81[0.69,0.95]
ORIGIN 2012 2055/6281 2087/6255 12.14% 0.98[0.93,1.03]
Risk & Prevention 2013 620/6239 630/6266 8.66% 0.99[0.89,1.1]
SU.FOL.OM3 2010 303/1253 290/1248 6.71% 1.04[0.9,1.2]
Subtotal (95% CI) 26817 26687 42.43% 0.99[0.91,1.08]
Total events: 3629 (Higher omega 3), 3673 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=14.65, df=5(P=0.01); I2=65.88%  
Test for overall effect: Z=0.19(P=0.85)  
   
Total (95% CI) 45358 45020 100% 0.99[0.94,1.04]
Total events: 7299 (Higher omega 3), 7438 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=58.47, df=37(P=0.01); I2=36.72%  
Test for overall effect: Z=0.54(P=0.59)  
Test for subgroup differences: Chi2=0.61, df=1 (P=0.74), I2=0%  
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Analysis 1.29.   Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes),
Outcome 29 CVD events - LCn3 - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.29.1 Primary prevention of CVD  
AREDS2 2014 183/2147 187/2056 4.57% 0.94[0.77,1.14]
Baldassarre 2006 1/32 0/32 0.03% 3[0.13,71]
Brox 2001 0/80 1/40 0.03% 0.17[0.01,4.05]
Derosa 2016 2/128 3/130 0.08% 0.68[0.12,3.98]
DO IT 2010 32/282 36/281 1.19% 0.89[0.57,1.38]
EPE-A 2014 5/168 6/75 0.19% 0.37[0.12,1.18]
EPIC-1 2008 1/188 0/186 0.03% 2.97[0.12,72.4]
EPOCH 2014 8/195 5/196 0.21% 1.61[0.54,4.83]
FOSTAR 2016 18/101 16/101 0.65% 1.13[0.61,2.08]
JELIS 2007 262/9326 324/9319 5.82% 0.81[0.69,0.95]
MAPT 2017 192/820 164/832 4.9% 1.19[0.99,1.43]
ORIGIN 2012 2055/6281 2087/6255 12.14% 0.98[0.93,1.03]
Proudman 2015 1/87 0/53 0.03% 1.84[0.08,44.38]
Puri 2005 1/60 0/61 0.03% 3.05[0.13,73.4]
Sandhu 2016 2/107 1/106 0.05% 1.98[0.18,21.52]
Shinto 2014 1/13 0/13 0.03% 3[0.13,67.51]
Subtotal (95% CI) 20015 19736 29.96% 0.97[0.89,1.05]
Total events: 2764 (Higher omega 3), 2830 (Lower omega 3)  
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  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=17.54, df=15(P=0.29); I2=14.48%  
Test for overall effect: Z=0.76(P=0.45)  
   
1.29.2 Secondary prevention  
AFFORD 2013 20/153 11/163 0.51% 1.94[0.96,3.91]
AlphaOmega - EPA+DHA 2010 336/2404 335/2433 6.72% 1.02[0.88,1.17]
DART 1989 467/1015 487/1018 9.45% 0.96[0.88,1.05]
DART2 2003 206/1571 155/1543 4.52% 1.31[1.07,1.59]
Doi 2014 11/119 24/119 0.56% 0.46[0.24,0.89]
FAAT 2005 31/200 39/202 1.28% 0.8[0.52,1.23]
FORWARD 2013 4/289 4/297 0.14% 1.03[0.26,4.07]
GISSI-HF 2008 1635/3494 1687/3481 12.17% 0.97[0.92,1.01]
GISSI-P 1999 547/5666 608/5658 8.4% 0.9[0.81,1]
HARP 1995 7/41 7/39 0.28% 0.95[0.37,2.46]
Kumar 2013 1/39 1/39 0.03% 1[0.06,15.43]
Nodari 2011 HF 10/67 26/66 0.6% 0.38[0.2,0.72]
Nutristroke 2009 0/38 4/34 0.03% 0.1[0.01,1.79]
OFAMI 2001 42/150 36/150 1.57% 1.17[0.8,1.71]
OMEGA 2009 182/1752 149/1701 4.23% 1.19[0.97,1.46]
Raitt 2005 2/100 5/100 0.1% 0.4[0.08,2.01]
Risk & Prevention 2013 620/6239 630/6266 8.66% 0.99[0.89,1.1]
SCIMO 1999 17/112 26/111 0.8% 0.65[0.37,1.13]
SHOT 1996 15/317 12/293 0.46% 1.16[0.55,2.43]
SOFA 2006 65/273 62/273 2.32% 1.05[0.77,1.42]
SU.FOL.OM3 2010 303/1253 290/1248 6.71% 1.04[0.9,1.2]
THIS DIET 2008 14/51 10/50 0.49% 1.37[0.67,2.8]
Subtotal (95% CI) 25343 25284 70.04% 1[0.93,1.07]
Total events: 4535 (Higher omega 3), 4608 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=40.98, df=21(P=0.01); I2=48.75%  
Test for overall effect: Z=0.14(P=0.89)  
   
Total (95% CI) 45358 45020 100% 0.99[0.94,1.04]
Total events: 7299 (Higher omega 3), 7438 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=58.47, df=37(P=0.01); I2=36.72%  
Test for overall effect: Z=0.54(P=0.59)  
Test for subgroup differences: Chi2=0.25, df=1 (P=0.61), I2=0%  
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Analysis 1.30.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 30 CVD events - LCn3 - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.30.1 LCn3 - ≥ 50% of control group on statins  
AlphaOmega - EPA+DHA 2010 336/2404 335/2433 6.72% 1.02[0.88,1.17]
Doi 2014 11/119 24/119 0.56% 0.46[0.24,0.89]
JELIS 2007 262/9326 324/9319 5.82% 0.81[0.69,0.95]
Kumar 2013 1/39 1/39 0.03% 1[0.06,15.43]
OMEGA 2009 182/1752 149/1701 4.23% 1.19[0.97,1.46]
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  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
ORIGIN 2012 2055/6281 2087/6255 12.14% 0.98[0.93,1.03]
SU.FOL.OM3 2010 303/1253 290/1248 6.71% 1.04[0.9,1.2]
THIS DIET 2008 14/51 10/50 0.49% 1.37[0.67,2.8]
Subtotal (95% CI) 21225 21164 36.71% 0.98[0.89,1.08]
Total events: 3164 (Higher omega 3), 3220 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=15.66, df=7(P=0.03); I2=55.29%  
Test for overall effect: Z=0.38(P=0.7)  
   
1.30.2 LCn3 - < 50% of control group on statins  
AFFORD 2013 20/153 11/163 0.51% 1.94[0.96,3.91]
AREDS2 2014 183/2147 187/2056 4.57% 0.94[0.77,1.14]
Baldassarre 2006 1/32 0/32 0.03% 3[0.13,71]
Brox 2001 0/80 1/40 0.03% 0.17[0.01,4.05]
DART 1989 467/1015 487/1018 9.45% 0.96[0.88,1.05]
DART2 2003 206/1571 155/1543 4.52% 1.31[1.07,1.59]
DO IT 2010 32/282 36/281 1.19% 0.89[0.57,1.38]
EPIC-1 2008 1/188 0/186 0.03% 2.97[0.12,72.4]
FAAT 2005 31/200 39/202 1.28% 0.8[0.52,1.23]
FORWARD 2013 4/289 4/297 0.14% 1.03[0.26,4.07]
FOSTAR 2016 18/101 16/101 0.65% 1.13[0.61,2.08]
GISSI-HF 2008 1635/3494 1687/3481 12.17% 0.97[0.92,1.01]
GISSI-P 1999 547/5666 608/5658 8.4% 0.9[0.81,1]
HARP 1995 7/41 7/39 0.28% 0.95[0.37,2.46]
Nodari 2011 HF 10/67 26/66 0.6% 0.38[0.2,0.72]
OFAMI 2001 42/150 36/150 1.57% 1.17[0.8,1.71]
Proudman 2015 1/87 0/53 0.03% 1.84[0.08,44.38]
Puri 2005 1/60 0/61 0.03% 3.05[0.13,73.4]
Raitt 2005 2/100 5/100 0.1% 0.4[0.08,2.01]
Risk & Prevention 2013 620/6239 630/6266 8.66% 0.99[0.89,1.1]
SCIMO 1999 17/112 26/111 0.8% 0.65[0.37,1.13]
Shinto 2014 1/13 0/13 0.03% 3[0.13,67.51]
SHOT 1996 15/317 12/293 0.46% 1.16[0.55,2.43]
SOFA 2006 65/273 62/273 2.32% 1.05[0.77,1.42]
Subtotal (95% CI) 22677 22483 57.83% 0.98[0.91,1.04]
Total events: 3926 (Higher omega 3), 4035 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=31.84, df=23(P=0.1); I2=27.77%  
Test for overall effect: Z=0.77(P=0.44)  
   
1.30.3 LCn3 - use of statins unclear  
Derosa 2016 2/128 3/130 0.08% 0.68[0.12,3.98]
EPE-A 2014 5/168 6/75 0.19% 0.37[0.12,1.18]
EPOCH 2014 8/195 5/196 0.21% 1.61[0.54,4.83]
MAPT 2017 192/820 164/832 4.9% 1.19[0.99,1.43]
Nutristroke 2009 0/38 4/34 0.03% 0.1[0.01,1.79]
Sandhu 2016 2/107 1/106 0.05% 1.98[0.18,21.52]
Subtotal (95% CI) 1456 1373 5.46% 0.93[0.53,1.63]
Total events: 209 (Higher omega 3), 183 (Lower omega 3)  
Heterogeneity: Tau2=0.15; Chi2=7.48, df=5(P=0.19); I2=33.15%  
Test for overall effect: Z=0.25(P=0.8)  
   
Total (95% CI) 45358 45020 100% 0.99[0.94,1.04]
Total events: 7299 (Higher omega 3), 7438 (Lower omega 3)  
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  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=58.47, df=37(P=0.01); I2=36.72%  
Test for overall effect: Z=0.54(P=0.59)  
Test for subgroup differences: Chi2=0.04, df=1 (P=0.98), I2=0%  
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Analysis 1.31.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 31 Coronary heart disease mortality (overall) - LCn3.
Study or subgroup Favours high-
er omega 3
Lower
omega 3 fats
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.79% 0.96[0.69,1.33]
AREDS2 2014 3/2147 0/2056 0.28% 6.7[0.35,129.7]
Brox 2001 0/80 1/40 0.24% 0.17[0.01,4.05]
DART 1989 78/1015 116/1018 12.62% 0.67[0.51,0.89]
DART2 2003 180/1571 139/1543 14.95% 1.27[1.03,1.57]
Derosa 2016 0/128 1/130 0.24% 0.34[0.01,8.23]
DO IT 2010 0/282 2/281 0.27% 0.2[0.01,4.13]
Doi 2014 0/119 2/119 0.27% 0.2[0.01,4.12]
FAAT 2005 9/200 9/202 2.66% 1.01[0.41,2.49]
GISSI-HF 2008 20/3494 25/3481 5.35% 0.8[0.44,1.43]
GISSI-P 1999 214/5666 265/5668 16.2% 0.81[0.68,0.96]
HARP 1995 0/41 1/39 0.25% 0.32[0.01,7.57]
JELIS 2007 29/9326 31/9319 6.59% 0.93[0.56,1.55]
OFAMI 2001 8/150 8/150 2.42% 1[0.39,2.59]
OMEGA 2009 67/1919 51/1885 9.92% 1.29[0.9,1.85]
Raitt 2005 2/100 5/100 0.91% 0.4[0.08,2.01]
Risk & Prevention 2013 82/6239 76/6266 11.39% 1.08[0.79,1.48]
SCIMO 1999 0/112 1/111 0.24% 0.33[0.01,8.02]
SHOT 1996 7/317 4/293 1.55% 1.62[0.48,5.47]
SOFA 2006 6/273 13/273 2.42% 0.46[0.18,1.2]
SU.FOL.OM3 2010 1/1253 2/1248 0.42% 0.5[0.05,5.49]
   
Total (95% CI) 36836 36655 100% 0.93[0.79,1.09]
Total events: 773 (Favours higher omega 3), 823 (Lower omega 3 fats)  
Heterogeneity: Tau2=0.03; Chi2=30.96, df=20(P=0.06); I2=35.41%  
Test for overall effect: Z=0.91(P=0.36)  
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Analysis 1.32.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 32 CHD mortality - LCn3 - SA fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 8.52% 0.96[0.69,1.33]
AREDS2 2014 3/2147 0/2056 0.06% 6.7[0.35,129.7]
Brox 2001 0/80 1/40 0.24% 0.17[0.01,4.05]
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  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
DART 1989 78/1015 116/1018 13.99% 0.67[0.51,0.89]
DART2 2003 180/1571 139/1543 16.94% 1.27[1.03,1.57]
Derosa 2016 0/128 1/130 0.18% 0.34[0.01,8.23]
DO IT 2010 0/282 2/281 0.3% 0.2[0.01,4.13]
Doi 2014 0/119 2/119 0.3% 0.2[0.01,4.12]
FAAT 2005 9/200 9/202 1.08% 1.01[0.41,2.49]
GISSI-HF 2008 20/3494 25/3481 3.02% 0.8[0.44,1.43]
GISSI-P 1999 214/5666 265/5668 31.99% 0.81[0.68,0.96]
HARP 1995 0/41 1/39 0.19% 0.32[0.01,7.57]
JELIS 2007 29/9326 31/9319 3.74% 0.93[0.56,1.55]
OFAMI 2001 8/150 8/150 0.97% 1[0.39,2.59]
OMEGA 2009 67/1919 51/1885 6.21% 1.29[0.9,1.85]
Raitt 2005 2/100 5/100 0.6% 0.4[0.08,2.01]
Risk & Prevention 2013 82/6239 76/6266 9.16% 1.08[0.79,1.48]
SCIMO 1999 0/112 1/111 0.18% 0.33[0.01,8.02]
SHOT 1996 7/317 4/293 0.5% 1.62[0.48,5.47]
SOFA 2006 6/273 13/273 1.57% 0.46[0.18,1.2]
SU.FOL.OM3 2010 1/1253 2/1248 0.24% 0.5[0.05,5.49]
   
Total (95% CI) 36836 36655 100% 0.94[0.85,1.03]
Total events: 773 (Higher omega 3), 823 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=30.96, df=20(P=0.06); I2=35.41%  
Test for overall effect: Z=1.38(P=0.17)  
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Analysis 1.33.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 33 CHD mortality - LCn3 - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.33.1 Low risk of bias  
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.79% 0.96[0.69,1.33]
AREDS2 2014 3/2147 0/2056 0.28% 6.7[0.35,129.7]
Derosa 2016 0/128 1/130 0.24% 0.34[0.01,8.23]
OMEGA 2009 67/1919 51/1885 9.92% 1.29[0.9,1.85]
SCIMO 1999 0/112 1/111 0.24% 0.33[0.01,8.02]
SOFA 2006 6/273 13/273 2.42% 0.46[0.18,1.2]
SU.FOL.OM3 2010 1/1253 2/1248 0.42% 0.5[0.05,5.49]
Subtotal (95% CI) 8236 8136 24.33% 1[0.72,1.37]
Total events: 144 (Higher omega 3), 139 (Lower omega 3)  
Heterogeneity: Tau2=0.03; Chi2=7.29, df=6(P=0.29); I2=17.71%  
Test for overall effect: Z=0.03(P=0.98)  
   
1.33.2 Moderate/high risk of bias  
Brox 2001 0/80 1/40 0.24% 0.17[0.01,4.05]
DART 1989 78/1015 116/1018 12.62% 0.67[0.51,0.89]
DART2 2003 180/1571 139/1543 14.95% 1.27[1.03,1.57]
DO IT 2010 0/282 2/281 0.27% 0.2[0.01,4.13]
Doi 2014 0/119 2/119 0.27% 0.2[0.01,4.12]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
FAAT 2005 9/200 9/202 2.66% 1.01[0.41,2.49]
GISSI-HF 2008 20/3494 25/3481 5.35% 0.8[0.44,1.43]
GISSI-P 1999 214/5666 265/5668 16.2% 0.81[0.68,0.96]
HARP 1995 0/41 1/39 0.25% 0.32[0.01,7.57]
JELIS 2007 29/9326 31/9319 6.59% 0.93[0.56,1.55]
OFAMI 2001 8/150 8/150 2.42% 1[0.39,2.59]
Raitt 2005 2/100 5/100 0.91% 0.4[0.08,2.01]
Risk & Prevention 2013 82/6239 76/6266 11.39% 1.08[0.79,1.48]
SHOT 1996 7/317 4/293 1.55% 1.62[0.48,5.47]
Subtotal (95% CI) 28600 28519 75.67% 0.91[0.75,1.1]
Total events: 629 (Higher omega 3), 684 (Lower omega 3)  
Heterogeneity: Tau2=0.04; Chi2=22.9, df=13(P=0.04); I2=43.23%  
Test for overall effect: Z=1(P=0.32)  
   
Total (95% CI) 36836 36655 100% 0.93[0.79,1.09]
Total events: 773 (Higher omega 3), 823 (Lower omega 3)  
Heterogeneity: Tau2=0.03; Chi2=30.96, df=20(P=0.06); I2=35.41%  
Test for overall effect: Z=0.91(P=0.36)  
Test for subgroup differences: Chi2=0.24, df=1 (P=0.62), I2=0%  
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Analysis 1.34.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 34 CHD mortality - LCn3 - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.34.1 SA - low risk of compliance bias  
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 49.53% 0.96[0.69,1.33]
Brox 2001 0/80 1/40 0.53% 0.17[0.01,4.05]
DO IT 2010 0/282 2/281 0.58% 0.2[0.01,4.13]
HARP 1995 0/41 1/39 0.53% 0.32[0.01,7.57]
OMEGA 2009 67/1919 51/1885 41.69% 1.29[0.9,1.85]
Raitt 2005 2/100 5/100 2.05% 0.4[0.08,2.01]
SCIMO 1999 0/112 1/111 0.53% 0.33[0.01,8.02]
SHOT 1996 7/317 4/293 3.61% 1.62[0.48,5.47]
SU.FOL.OM3 2010 1/1253 2/1248 0.93% 0.5[0.05,5.49]
Subtotal (95% CI) 6508 6430 100% 1.05[0.83,1.32]
Total events: 144 (Higher omega 3), 138 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=7.3, df=8(P=0.5); I2=0%  
Test for overall effect: Z=0.38(P=0.7)  
   
1.34.2 SA - 100+ randomised  
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.82% 0.96[0.69,1.33]
AREDS2 2014 3/2147 0/2056 0.29% 6.7[0.35,129.7]
Brox 2001 0/80 1/40 0.25% 0.17[0.01,4.05]
DART 1989 78/1015 116/1018 12.6% 0.67[0.51,0.89]
DART2 2003 180/1571 139/1543 14.83% 1.27[1.03,1.57]
Derosa 2016 0/128 1/130 0.25% 0.34[0.01,8.23]
DO IT 2010 0/282 2/281 0.28% 0.2[0.01,4.13]
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
283
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
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  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Doi 2014 0/119 2/119 0.28% 0.2[0.01,4.12]
FAAT 2005 9/200 9/202 2.72% 1.01[0.41,2.49]
GISSI-HF 2008 20/3494 25/3481 5.44% 0.8[0.44,1.43]
GISSI-P 1999 214/5666 265/5668 16.03% 0.81[0.68,0.96]
JELIS 2007 29/9326 31/9319 6.68% 0.93[0.56,1.55]
OFAMI 2001 8/150 8/150 2.48% 1[0.39,2.59]
OMEGA 2009 67/1919 51/1885 9.97% 1.29[0.9,1.85]
Raitt 2005 2/100 5/100 0.94% 0.4[0.08,2.01]
Risk & Prevention 2013 82/6239 76/6266 11.4% 1.08[0.79,1.48]
SCIMO 1999 0/112 1/111 0.25% 0.33[0.01,8.02]
SHOT 1996 7/317 4/293 1.59% 1.62[0.48,5.47]
SOFA 2006 6/273 13/273 2.48% 0.46[0.18,1.2]
SU.FOL.OM3 2010 1/1253 2/1248 0.44% 0.5[0.05,5.49]
Subtotal (95% CI) 36795 36616 100% 0.93[0.79,1.09]
Total events: 773 (Higher omega 3), 822 (Lower omega 3)  
Heterogeneity: Tau2=0.03; Chi2=30.51, df=19(P=0.05); I2=37.73%  
Test for overall effect: Z=0.88(P=0.38)  
Test for subgroup differences: Chi2=0.66, df=1 (P=0.42), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 1.35.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 35 CHD mortality - LCn3 - SA omitting cardiac death.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.35.1 Low risk of bias  
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 12.49% 0.96[0.69,1.33]
AREDS2 2014 3/2147 0/2056 0.15% 6.7[0.35,129.7]
Derosa 2016 0/128 1/130 0.13% 0.34[0.01,8.23]
SCIMO 1999 0/112 1/111 0.13% 0.33[0.01,8.02]
SU.FOL.OM3 2010 1/1253 2/1248 0.23% 0.5[0.05,5.49]
Subtotal (95% CI) 6044 5978 13.15% 0.95[0.69,1.3]
Total events: 71 (Higher omega 3), 75 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.78, df=4(P=0.6); I2=0%  
Test for overall effect: Z=0.34(P=0.73)  
   
1.35.2 Moderate/high risk of bias  
Brox 2001 0/80 1/40 0.13% 0.17[0.01,4.05]
DART 1989 78/1015 116/1018 18.08% 0.67[0.51,0.89]
DO IT 2010 0/282 2/281 0.15% 0.2[0.01,4.13]
Doi 2014 0/119 2/119 0.15% 0.2[0.01,4.12]
GISSI-HF 2008 20/3494 25/3481 3.94% 0.8[0.44,1.43]
GISSI-P 1999 214/5666 265/5668 43.49% 0.81[0.68,0.96]
HARP 1995 0/41 1/39 0.13% 0.32[0.01,7.57]
JELIS 2007 29/9326 31/9319 5.29% 0.93[0.56,1.55]
Raitt 2005 2/100 5/100 0.52% 0.4[0.08,2.01]
Risk & Prevention 2013 82/6239 76/6266 14.06% 1.08[0.79,1.48]
SHOT 1996 7/317 4/293 0.91% 1.62[0.48,5.47]
Subtotal (95% CI) 26679 26624 86.85% 0.82[0.72,0.94]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 432 (Higher omega 3), 528 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=10.28, df=10(P=0.42); I2=2.71%  
Test for overall effect: Z=2.94(P=0)  
   
Total (95% CI) 32723 32602 100% 0.83[0.74,0.94]
Total events: 503 (Higher omega 3), 603 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=13.73, df=15(P=0.55); I2=0%  
Test for overall effect: Z=3.06(P=0)  
Test for subgroup differences: Chi2=0.65, df=1 (P=0.42), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 1.36.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 36 CHD mortality - LCn3 - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.36.1 LCn3 ≤ 150 mg/d  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.36.2 LCn3 > 150 ≤ 250 mg/d  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.36.3 LCn3 > 250 ≤ 400 mg/d  
DART 1989 78/1015 116/1018 12.62% 0.67[0.51,0.89]
DART2 2003 180/1571 139/1543 14.95% 1.27[1.03,1.57]
Subtotal (95% CI) 2586 2561 27.57% 0.93[0.5,1.74]
Total events: 258 (Higher omega 3), 255 (Lower omega 3)  
Heterogeneity: Tau2=0.19; Chi2=13.01, df=1(P=0); I2=92.31%  
Test for overall effect: Z=0.22(P=0.82)  
   
1.36.4 LCn3 > 400 ≤ 2400 mg/d  
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.79% 0.96[0.69,1.33]
AREDS2 2014 3/2147 0/2056 0.28% 6.7[0.35,129.7]
Derosa 2016 0/128 1/130 0.24% 0.34[0.01,8.23]
DO IT 2010 0/282 2/281 0.27% 0.2[0.01,4.13]
Doi 2014 0/119 2/119 0.27% 0.2[0.01,4.12]
GISSI-HF 2008 20/3494 25/3481 5.35% 0.8[0.44,1.43]
GISSI-P 1999 214/5666 265/5668 16.2% 0.81[0.68,0.96]
JELIS 2007 29/9326 31/9319 6.59% 0.93[0.56,1.55]
OMEGA 2009 67/1919 51/1885 9.92% 1.29[0.9,1.85]
Raitt 2005 2/100 5/100 0.91% 0.4[0.08,2.01]
Risk & Prevention 2013 82/6239 76/6266 11.39% 1.08[0.79,1.48]
SCIMO 1999 0/112 1/111 0.24% 0.33[0.01,8.02]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
SHOT 1996 7/317 4/293 1.55% 1.62[0.48,5.47]
SOFA 2006 6/273 13/273 2.42% 0.46[0.18,1.2]
SU.FOL.OM3 2010 1/1253 2/1248 0.42% 0.5[0.05,5.49]
Subtotal (95% CI) 33779 33663 66.87% 0.92[0.8,1.07]
Total events: 498 (Higher omega 3), 549 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=15.37, df=14(P=0.35); I2=8.94%  
Test for overall effect: Z=1.1(P=0.27)  
   
1.36.5 LCn3 > 2.4 ≤ 4.4 g/d  
Brox 2001 0/80 1/40 0.24% 0.17[0.01,4.05]
FAAT 2005 9/200 9/202 2.66% 1.01[0.41,2.49]
OFAMI 2001 8/150 8/150 2.42% 1[0.39,2.59]
Subtotal (95% CI) 430 392 5.32% 0.93[0.49,1.78]
Total events: 17 (Higher omega 3), 18 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.17, df=2(P=0.56); I2=0%  
Test for overall effect: Z=0.21(P=0.84)  
   
1.36.6 LCn3 > 4.4 g/d  
HARP 1995 0/41 1/39 0.25% 0.32[0.01,7.57]
Subtotal (95% CI) 41 39 0.25% 0.32[0.01,7.57]
Total events: 0 (Higher omega 3), 1 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.48)  
   
Total (95% CI) 36836 36655 100% 0.93[0.79,1.09]
Total events: 773 (Higher omega 3), 823 (Lower omega 3)  
Heterogeneity: Tau2=0.03; Chi2=30.96, df=20(P=0.06); I2=35.41%  
Test for overall effect: Z=0.91(P=0.36)  
Test for subgroup differences: Chi2=0.44, df=1 (P=0.93), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 1.37.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 37 CHD mortality - LCn3 - subgroup by replacement.
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.37.1 N-3 replacing SFA  
DART 1989 78/1015 116/1018 98.55% 0.67[0.51,0.89]
Derosa 2016 0/128 1/130 0.72% 0.34[0.01,8.23]
SCIMO 1999 0/112 1/111 0.72% 0.33[0.01,8.02]
Subtotal (95% CI) 1255 1259 100% 0.67[0.51,0.88]
Total events: 78 (High omega 3), 118 (Control)  
Heterogeneity: Tau2=0; Chi2=0.37, df=2(P=0.83); I2=0%  
Test for overall effect: Z=2.92(P=0)  
   
1.37.2 N-3 replacing MUFA  
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 19.09% 0.96[0.69,1.33]
DART 1989 78/1015 116/1018 22.33% 0.67[0.51,0.89]
FAAT 2005 9/200 9/202 4.69% 1.01[0.41,2.49]
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Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
GISSI-HF 2008 20/3494 25/3481 9.45% 0.8[0.44,1.43]
HARP 1995 0/41 1/39 0.43% 0.32[0.01,7.57]
OMEGA 2009 67/1919 51/1885 17.54% 1.29[0.9,1.85]
Raitt 2005 2/100 5/100 1.61% 0.4[0.08,2.01]
Risk & Prevention 2013 82/6239 76/6266 20.15% 1.08[0.79,1.48]
SCIMO 1999 0/112 1/111 0.43% 0.33[0.01,8.02]
SOFA 2006 6/273 13/273 4.27% 0.46[0.18,1.2]
Subtotal (95% CI) 15797 15808 100% 0.89[0.72,1.1]
Total events: 331 (High omega 3), 368 (Control)  
Heterogeneity: Tau2=0.03; Chi2=13.53, df=9(P=0.14); I2=33.5%  
Test for overall effect: Z=1.07(P=0.29)  
   
1.37.3 N-3 replacing n-6  
DO IT 2010 0/282 2/281 4.71% 0.2[0.01,4.13]
OFAMI 2001 8/150 8/150 47.61% 1[0.39,2.59]
SOFA 2006 6/273 13/273 47.69% 0.46[0.18,1.2]
Subtotal (95% CI) 705 704 100% 0.64[0.33,1.24]
Total events: 14 (High omega 3), 23 (Control)  
Heterogeneity: Tau2=0; Chi2=1.88, df=2(P=0.39); I2=0%  
Test for overall effect: Z=1.32(P=0.19)  
   
1.37.4 N-3 replacing carbohydrates/sugars  
Derosa 2016 0/128 1/130 100% 0.34[0.01,8.23]
Subtotal (95% CI) 128 130 100% 0.34[0.01,8.23]
Total events: 0 (High omega 3), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.67(P=0.51)  
   
1.37.5 N-3 replacing nil/low n-3 placebo  
AREDS2 2014 3/2147 0/2056 0.31% 6.7[0.35,129.7]
Brox 2001 0/80 1/40 0.27% 0.17[0.01,4.05]
Doi 2014 0/119 2/119 0.29% 0.2[0.01,4.12]
GISSI-P 1999 214/5666 265/5668 86.35% 0.81[0.68,0.96]
JELIS 2007 29/9326 31/9319 10.51% 0.93[0.56,1.55]
SHOT 1996 7/317 4/293 1.81% 1.62[0.48,5.47]
SU.FOL.OM3 2010 1/1253 2/1248 0.47% 0.5[0.05,5.49]
Subtotal (95% CI) 18908 18743 100% 0.83[0.7,0.97]
Total events: 254 (High omega 3), 305 (Control)  
Heterogeneity: Tau2=0; Chi2=5.35, df=6(P=0.5); I2=0%  
Test for overall effect: Z=2.27(P=0.02)  
   
1.37.6 Replacement unclear  
DART2 2003 180/1571 139/1543 100% 1.27[1.03,1.57]
Subtotal (95% CI) 1571 1543 100% 1.27[1.03,1.57]
Total events: 180 (High omega 3), 139 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.25(P=0.02)  
Test for subgroup differences: Chi2=17.48, df=1 (P=0), I2=71.4%  
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Analysis 1.38.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 38 CHD mortality - LCn3 - subgroup by intervention type.
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.38.1 Dietary advice  
DART 1989 78/1015 116/1018 12.62% 0.67[0.51,0.89]
DART2 2003 180/1571 139/1543 14.95% 1.27[1.03,1.57]
Subtotal (95% CI) 2586 2561 27.57% 0.93[0.5,1.74]
Total events: 258 (High omega 3), 255 (Control)  
Heterogeneity: Tau2=0.19; Chi2=13.01, df=1(P=0); I2=92.31%  
Test for overall effect: Z=0.22(P=0.82)  
   
1.38.2 Supplemental foods  
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.79% 0.96[0.69,1.33]
Subtotal (95% CI) 2404 2433 10.79% 0.96[0.69,1.33]
Total events: 67 (High omega 3), 71 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.27(P=0.78)  
   
1.38.3 Supplements (capsule)  
AREDS2 2014 3/2147 0/2056 0.28% 6.7[0.35,129.7]
Brox 2001 0/80 1/40 0.24% 0.17[0.01,4.05]
Derosa 2016 0/128 1/130 0.24% 0.34[0.01,8.23]
DO IT 2010 0/282 2/281 0.27% 0.2[0.01,4.13]
Doi 2014 0/119 2/119 0.27% 0.2[0.01,4.12]
FAAT 2005 9/200 9/202 2.66% 1.01[0.41,2.49]
GISSI-HF 2008 20/3494 25/3481 5.35% 0.8[0.44,1.43]
GISSI-P 1999 214/5666 265/5668 16.2% 0.81[0.68,0.96]
HARP 1995 0/41 1/39 0.25% 0.32[0.01,7.57]
JELIS 2007 29/9326 31/9319 6.59% 0.93[0.56,1.55]
OFAMI 2001 8/150 8/150 2.42% 1[0.39,2.59]
OMEGA 2009 67/1919 51/1885 9.92% 1.29[0.9,1.85]
Raitt 2005 2/100 5/100 0.91% 0.4[0.08,2.01]
Risk & Prevention 2013 82/6239 76/6266 11.39% 1.08[0.79,1.48]
SCIMO 1999 0/112 1/111 0.24% 0.33[0.01,8.02]
SHOT 1996 7/317 4/293 1.55% 1.62[0.48,5.47]
SOFA 2006 6/273 13/273 2.42% 0.46[0.18,1.2]
SU.FOL.OM3 2010 1/1253 2/1248 0.42% 0.5[0.05,5.49]
Subtotal (95% CI) 31846 31661 61.64% 0.9[0.79,1.02]
Total events: 448 (High omega 3), 497 (Control)  
Heterogeneity: Tau2=0; Chi2=16.86, df=17(P=0.46); I2=0%  
Test for overall effect: Z=1.64(P=0.1)  
   
1.38.4 Any combination  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (High omega 3), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 36836 36655 100% 0.93[0.79,1.09]
Total events: 773 (High omega 3), 823 (Control)  
Heterogeneity: Tau2=0.03; Chi2=30.96, df=20(P=0.06); I2=35.41%  
Test for overall effect: Z=0.91(P=0.36)  
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Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for subgroup differences: Chi2=0.12, df=1 (P=0.94), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 1.39.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 39 CHD mortality - LCn3 - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.39.1 Medium duration 1 to < 2 years in study  
Brox 2001 0/80 1/40 0.24% 0.17[0.01,4.05]
Derosa 2016 0/128 1/130 0.24% 0.34[0.01,8.23]
Doi 2014 0/119 2/119 0.27% 0.2[0.01,4.12]
FAAT 2005 9/200 9/202 2.66% 1.01[0.41,2.49]
OMEGA 2009 67/1919 51/1885 9.92% 1.29[0.9,1.85]
SHOT 1996 7/317 4/293 1.55% 1.62[0.48,5.47]
SOFA 2006 6/273 13/273 2.42% 0.46[0.18,1.2]
Subtotal (95% CI) 3036 2942 17.31% 0.96[0.62,1.5]
Total events: 89 (Higher omega 3), 81 (Lower omega 3)  
Heterogeneity: Tau2=0.07; Chi2=7.47, df=6(P=0.28); I2=19.71%  
Test for overall effect: Z=0.16(P=0.87)  
   
1.39.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.79% 0.96[0.69,1.33]
DART 1989 78/1015 116/1018 12.62% 0.67[0.51,0.89]
DO IT 2010 0/282 2/281 0.27% 0.2[0.01,4.13]
GISSI-HF 2008 20/3494 25/3481 5.35% 0.8[0.44,1.43]
GISSI-P 1999 214/5666 265/5668 16.2% 0.81[0.68,0.96]
HARP 1995 0/41 1/39 0.25% 0.32[0.01,7.57]
OFAMI 2001 8/150 8/150 2.42% 1[0.39,2.59]
Raitt 2005 2/100 5/100 0.91% 0.4[0.08,2.01]
SCIMO 1999 0/112 1/111 0.24% 0.33[0.01,8.02]
Subtotal (95% CI) 13264 13281 49.05% 0.79[0.69,0.9]
Total events: 389 (Higher omega 3), 494 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=4.94, df=8(P=0.76); I2=0%  
Test for overall effect: Z=3.55(P=0)  
   
1.39.3 Long duration: ≥ 4 years in study  
AREDS2 2014 3/2147 0/2056 0.28% 6.7[0.35,129.7]
DART2 2003 180/1571 139/1543 14.95% 1.27[1.03,1.57]
JELIS 2007 29/9326 31/9319 6.59% 0.93[0.56,1.55]
Risk & Prevention 2013 82/6239 76/6266 11.39% 1.08[0.79,1.48]
SU.FOL.OM3 2010 1/1253 2/1248 0.42% 0.5[0.05,5.49]
Subtotal (95% CI) 20536 20432 33.64% 1.18[1,1.39]
Total events: 295 (Higher omega 3), 248 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.41, df=4(P=0.49); I2=0%  
Test for overall effect: Z=1.97(P=0.05)  
   
Total (95% CI) 36836 36655 100% 0.93[0.79,1.09]
Total events: 773 (Higher omega 3), 823 (Lower omega 3)  
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0.03; Chi2=30.96, df=20(P=0.06); I2=35.41%  
Test for overall effect: Z=0.91(P=0.36)  
Test for subgroup differences: Chi2=14.06, df=1 (P=0), I2=85.78%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 1.40.   Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes),
Outcome 40 CHD mortality - LCn3 - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.40.1 Primary prevention of CVD  
AREDS2 2014 3/2147 0/2056 0.28% 6.7[0.35,129.7]
Brox 2001 0/80 1/40 0.24% 0.17[0.01,4.05]
Derosa 2016 0/128 1/130 0.24% 0.34[0.01,8.23]
DO IT 2010 0/282 2/281 0.27% 0.2[0.01,4.13]
JELIS 2007 29/9326 31/9319 6.59% 0.93[0.56,1.55]
Subtotal (95% CI) 11963 11826 7.63% 0.86[0.46,1.61]
Total events: 32 (Higher omega 3), 35 (Lower omega 3)  
Heterogeneity: Tau2=0.05; Chi2=4.16, df=4(P=0.38); I2=3.9%  
Test for overall effect: Z=0.47(P=0.64)  
   
1.40.2 Secondary prevention of CVD  
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.79% 0.96[0.69,1.33]
DART 1989 78/1015 116/1018 12.62% 0.67[0.51,0.89]
DART2 2003 180/1571 139/1543 14.95% 1.27[1.03,1.57]
Doi 2014 0/119 2/119 0.27% 0.2[0.01,4.12]
FAAT 2005 9/200 9/202 2.66% 1.01[0.41,2.49]
GISSI-HF 2008 20/3494 25/3481 5.35% 0.8[0.44,1.43]
GISSI-P 1999 214/5666 265/5668 16.2% 0.81[0.68,0.96]
HARP 1995 0/41 1/39 0.25% 0.32[0.01,7.57]
OFAMI 2001 8/150 8/150 2.42% 1[0.39,2.59]
OMEGA 2009 67/1919 51/1885 9.92% 1.29[0.9,1.85]
Raitt 2005 2/100 5/100 0.91% 0.4[0.08,2.01]
Risk & Prevention 2013 82/6239 76/6266 11.39% 1.08[0.79,1.48]
SCIMO 1999 0/112 1/111 0.24% 0.33[0.01,8.02]
SHOT 1996 7/317 4/293 1.55% 1.62[0.48,5.47]
SOFA 2006 6/273 13/273 2.42% 0.46[0.18,1.2]
SU.FOL.OM3 2010 1/1253 2/1248 0.42% 0.5[0.05,5.49]
Subtotal (95% CI) 24873 24829 92.37% 0.93[0.79,1.11]
Total events: 741 (Higher omega 3), 788 (Lower omega 3)  
Heterogeneity: Tau2=0.04; Chi2=26.75, df=15(P=0.03); I2=43.94%  
Test for overall effect: Z=0.81(P=0.42)  
   
Total (95% CI) 36836 36655 100% 0.93[0.79,1.09]
Total events: 773 (Higher omega 3), 823 (Lower omega 3)  
Heterogeneity: Tau2=0.03; Chi2=30.96, df=20(P=0.06); I2=35.41%  
Test for overall effect: Z=0.91(P=0.36)  
Test for subgroup differences: Chi2=0.06, df=1 (P=0.81), I2=0%  
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Analysis 1.41.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 41 CHD mortality - LCn3 - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.41.1 LCn3 - ≥ 50% of control group on statins  
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.79% 0.96[0.69,1.33]
Doi 2014 0/119 2/119 0.27% 0.2[0.01,4.12]
JELIS 2007 29/9326 31/9319 6.59% 0.93[0.56,1.55]
OMEGA 2009 67/1919 51/1885 9.92% 1.29[0.9,1.85]
SU.FOL.OM3 2010 1/1253 2/1248 0.42% 0.5[0.05,5.49]
Subtotal (95% CI) 15021 15004 28% 1.05[0.84,1.3]
Total events: 164 (Higher omega 3), 157 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.32, df=4(P=0.51); I2=0%  
Test for overall effect: Z=0.42(P=0.67)  
   
1.41.2 LCn3 - < 50% of control group on statins  
AREDS2 2014 3/2147 0/2056 0.28% 6.7[0.35,129.7]
Brox 2001 0/80 1/40 0.24% 0.17[0.01,4.05]
DART 1989 78/1015 116/1018 12.62% 0.67[0.51,0.89]
DART2 2003 180/1571 139/1543 14.95% 1.27[1.03,1.57]
DO IT 2010 0/282 2/281 0.27% 0.2[0.01,4.13]
FAAT 2005 9/200 9/202 2.66% 1.01[0.41,2.49]
GISSI-HF 2008 20/3494 25/3481 5.35% 0.8[0.44,1.43]
GISSI-P 1999 214/5666 265/5668 16.2% 0.81[0.68,0.96]
HARP 1995 0/41 1/39 0.25% 0.32[0.01,7.57]
OFAMI 2001 8/150 8/150 2.42% 1[0.39,2.59]
Raitt 2005 2/100 5/100 0.91% 0.4[0.08,2.01]
Risk & Prevention 2013 82/6239 76/6266 11.39% 1.08[0.79,1.48]
SCIMO 1999 0/112 1/111 0.24% 0.33[0.01,8.02]
SHOT 1996 7/317 4/293 1.55% 1.62[0.48,5.47]
SOFA 2006 6/273 13/273 2.42% 0.46[0.18,1.2]
Subtotal (95% CI) 21687 21521 71.76% 0.89[0.72,1.1]
Total events: 609 (Higher omega 3), 665 (Lower omega 3)  
Heterogeneity: Tau2=0.05; Chi2=26.04, df=14(P=0.03); I2=46.24%  
Test for overall effect: Z=1.11(P=0.27)  
   
1.41.3 LCn3 - use of statins unclear  
Derosa 2016 0/128 1/130 0.24% 0.34[0.01,8.23]
Subtotal (95% CI) 128 130 0.24% 0.34[0.01,8.23]
Total events: 0 (Higher omega 3), 1 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.67(P=0.51)  
   
Total (95% CI) 36836 36655 100% 0.93[0.79,1.09]
Total events: 773 (Higher omega 3), 823 (Lower omega 3)  
Heterogeneity: Tau2=0.03; Chi2=30.96, df=20(P=0.06); I2=35.41%  
Test for overall effect: Z=0.91(P=0.36)  
Test for subgroup differences: Chi2=1.57, df=1 (P=0.46), I2=0%  
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Analysis 1.42.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 42 CHD mortality - LCn3 - subgroup by CAD history.
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.42.1 Previous CAD  
AlphaOmega - EPA+DHA 2010 67/2404 71/2433 10.82% 0.96[0.69,1.33]
DART 1989 78/1015 116/1018 12.65% 0.67[0.51,0.89]
DART2 2003 180/1571 139/1543 14.98% 1.27[1.03,1.57]
Doi 2014 0/119 0/119   Not estimable
GISSI-P 1999 214/5666 265/5668 16.24% 0.81[0.68,0.96]
HARP 1995 0/41 1/39 0.25% 0.32[0.01,7.57]
OFAMI 2001 8/150 8/150 2.43% 1[0.39,2.59]
OMEGA 2009 67/1919 51/1885 9.95% 1.29[0.9,1.85]
SCIMO 1999 0/112 1/111 0.24% 0.33[0.01,8.02]
SHOT 1996 7/317 4/293 1.56% 1.62[0.48,5.47]
SU.FOL.OM3 2010 1/1253 2/1248 0.43% 0.5[0.05,5.49]
Subtotal (95% CI) 14567 14507 69.55% 0.96[0.77,1.2]
Total events: 622 (High omega 3), 658 (Control)  
Heterogeneity: Tau2=0.05; Chi2=21.39, df=9(P=0.01); I2=57.93%  
Test for overall effect: Z=0.36(P=0.72)  
   
1.42.2 No previous CAD  
AREDS2 2014 3/2147 0/2056 0.28% 6.7[0.35,129.7]
Brox 2001 0/80 1/40 0.24% 0.17[0.01,4.05]
Derosa 2016 0/128 1/130 0.24% 0.34[0.01,8.23]
DO IT 2010 0/282 2/281 0.27% 0.2[0.01,4.13]
FAAT 2005 9/200 9/202 2.67% 1.01[0.41,2.49]
GISSI-HF 2008 20/3494 25/3481 5.37% 0.8[0.44,1.43]
JELIS 2007 29/9326 31/9319 6.61% 0.93[0.56,1.55]
Raitt 2005 2/100 5/100 0.92% 0.4[0.08,2.01]
Risk & Prevention 2013 82/6239 76/6266 11.42% 1.08[0.79,1.48]
SOFA 2006 6/273 13/273 2.43% 0.46[0.18,1.2]
Subtotal (95% CI) 22269 22148 30.45% 0.93[0.74,1.16]
Total events: 151 (High omega 3), 163 (Control)  
Heterogeneity: Tau2=0; Chi2=8.55, df=9(P=0.48); I2=0%  
Test for overall effect: Z=0.66(P=0.51)  
   
Total (95% CI) 36836 36655 100% 0.93[0.8,1.09]
Total events: 773 (High omega 3), 821 (Control)  
Heterogeneity: Tau2=0.03; Chi2=29.96, df=19(P=0.05); I2=36.58%  
Test for overall effect: Z=0.86(P=0.39)  
Test for subgroup differences: Chi2=0.05, df=1 (P=0.82), I2=0%  
Favours high LCn3 1000.01 100.1 1 Favours low LCn3
 
 
Analysis 1.43.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 43 Coronary heart disease events (overall) - LCn3.
Study or subgroup Favours high-
er omega 3
Lower
omega 3 fats
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.11% 0.94[0.74,1.19]
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Study or subgroup Favours high-
er omega 3
Lower
omega 3 fats
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AREDS2 2014 28/2147 30/2056 0.9% 0.89[0.54,1.49]
Baldassarre 2006 1/32 0/32 0.02% 3[0.13,71]
Brox 2001 0/80 1/40 0.02% 0.17[0.01,4.05]
DART 1989 337/1015 366/1018 16.46% 0.92[0.82,1.04]
Derosa 2016 0/128 4/130 0.03% 0.11[0.01,2.07]
DO IT 2010 11/282 9/281 0.32% 1.22[0.51,2.89]
Doi 2014 1/119 0/119 0.02% 3[0.12,72.91]
EPE-A 2014 2/168 1/75 0.04% 0.89[0.08,9.7]
EPOCH 2014 1/195 0/196 0.02% 3.02[0.12,73.57]
FORWARD 2013 1/289 1/297 0.03% 1.03[0.06,16.35]
FOSTAR 2016 10/101 10/101 0.34% 1[0.44,2.3]
GISSI-HF 2008 107/3494 129/3481 3.72% 0.83[0.64,1.06]
GISSI-P 1999 424/5666 485/5658 15.11% 0.87[0.77,0.99]
HARP 1995 7/41 7/39 0.26% 0.95[0.37,2.46]
JELIS 2007 262/9326 324/9319 9.19% 0.81[0.69,0.95]
Nye 1990 5/36 11/37 0.26% 0.47[0.18,1.21]
OFAMI 2001 42/150 36/150 1.61% 1.17[0.8,1.71]
OMEGA 2009 547/1919 568/1885 24.22% 0.95[0.86,1.04]
ORIGIN 2012 344/6281 316/6255 10.68% 1.08[0.93,1.26]
Proudman 2015 1/87 0/53 0.02% 1.84[0.08,44.38]
Raitt 2005 1/100 3/100 0.05% 0.33[0.04,3.15]
Risk & Prevention 2013 310/6239 324/6266 10.25% 0.96[0.83,1.12]
SCIMO 1999 1/112 4/111 0.05% 0.25[0.03,2.18]
SHOT 1996 7/317 12/293 0.28% 0.54[0.22,1.35]
SOFA 2006 1/273 3/273 0.05% 0.33[0.03,3.18]
SU.FOL.OM3 2010 51/1253 53/1248 1.67% 0.96[0.66,1.4]
THIS DIET 2008 10/51 6/50 0.27% 1.63[0.64,4.16]
   
Total (95% CI) 42305 41996 100% 0.93[0.88,0.97]
Total events: 2634 (Favours higher omega 3), 2835 (Lower omega 3 fats)  
Heterogeneity: Tau2=0; Chi2=23.63, df=27(P=0.65); I2=0%  
Test for overall effect: Z=3.02(P=0)  
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Analysis 1.44.   Comparison 1 High vs low LCn3 omega-3 fats
(primary outcomes), Outcome 44 CHD events - LCn3 - SA fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.52% 0.94[0.74,1.19]
AREDS2 2014 28/2147 30/2056 1.06% 0.89[0.54,1.49]
Baldassarre 2006 1/32 0/32 0.02% 3[0.13,71]
Brox 2001 0/80 1/40 0.07% 0.17[0.01,4.05]
DART 1989 337/1015 366/1018 12.59% 0.92[0.82,1.04]
Derosa 2016 0/128 4/130 0.15% 0.11[0.01,2.07]
DO IT 2010 11/282 9/281 0.31% 1.22[0.51,2.89]
Doi 2014 1/119 0/119 0.02% 3[0.12,72.91]
EPE-A 2014 2/168 1/75 0.05% 0.89[0.08,9.7]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
EPOCH 2014 1/195 0/196 0.02% 3.02[0.12,73.57]
FORWARD 2013 1/289 1/297 0.03% 1.03[0.06,16.35]
FOSTAR 2016 10/101 10/101 0.34% 1[0.44,2.3]
GISSI-HF 2008 107/3494 129/3481 4.45% 0.83[0.64,1.06]
GISSI-P 1999 424/5666 485/5658 16.71% 0.87[0.77,0.99]
HARP 1995 7/41 7/39 0.25% 0.95[0.37,2.46]
JELIS 2007 262/9326 324/9319 11.16% 0.81[0.69,0.95]
Nye 1990 5/36 11/37 0.37% 0.47[0.18,1.21]
OFAMI 2001 42/150 36/150 1.24% 1.17[0.8,1.71]
OMEGA 2009 547/1919 568/1885 19.74% 0.95[0.86,1.04]
ORIGIN 2012 344/6281 316/6255 10.91% 1.08[0.93,1.26]
Proudman 2015 1/87 0/53 0.02% 1.84[0.08,44.38]
Raitt 2005 1/100 3/100 0.1% 0.33[0.04,3.15]
Risk & Prevention 2013 310/6239 324/6266 11.13% 0.96[0.83,1.12]
SCIMO 1999 1/112 4/111 0.14% 0.25[0.03,2.18]
SHOT 1996 7/317 12/293 0.43% 0.54[0.22,1.35]
SOFA 2006 65/273 62/273 2.14% 1.05[0.77,1.42]
SU.FOL.OM3 2010 51/1253 53/1248 1.83% 0.96[0.66,1.4]
THIS DIET 2008 10/51 6/50 0.21% 1.63[0.64,4.16]
   
Total (95% CI) 42305 41996 100% 0.93[0.88,0.97]
Total events: 2698 (Higher omega 3), 2894 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=23.44, df=27(P=0.66); I2=0%  
Test for overall effect: Z=3.03(P=0)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 1.45.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 45 CHD events - LCn3 - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.45.1 Low risk of bias  
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.11% 0.94[0.74,1.19]
AREDS2 2014 28/2147 30/2056 0.9% 0.89[0.54,1.49]
Derosa 2016 0/128 4/130 0.03% 0.11[0.01,2.07]
EPOCH 2014 1/195 0/196 0.02% 3.02[0.12,73.57]
FORWARD 2013 1/289 1/297 0.03% 1.03[0.06,16.35]
FOSTAR 2016 10/101 10/101 0.34% 1[0.44,2.3]
OMEGA 2009 547/1919 568/1885 24.22% 0.95[0.86,1.04]
ORIGIN 2012 344/6281 316/6255 10.68% 1.08[0.93,1.26]
Proudman 2015 1/87 0/53 0.02% 1.84[0.08,44.38]
SCIMO 1999 1/112 4/111 0.05% 0.25[0.03,2.18]
SOFA 2006 1/273 3/273 0.05% 0.33[0.03,3.18]
SU.FOL.OM3 2010 51/1253 53/1248 1.67% 0.96[0.66,1.4]
Subtotal (95% CI) 15189 15038 42.12% 0.97[0.9,1.05]
Total events: 1107 (Higher omega 3), 1121 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=7.69, df=11(P=0.74); I2=0%  
Test for overall effect: Z=0.67(P=0.51)  
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.45.2 Moderate/high risk of bias  
Baldassarre 2006 1/32 0/32 0.02% 3[0.13,71]
Brox 2001 0/80 1/40 0.02% 0.17[0.01,4.05]
DART 1989 337/1015 366/1018 16.46% 0.92[0.82,1.04]
DO IT 2010 11/282 9/281 0.32% 1.22[0.51,2.89]
Doi 2014 1/119 0/119 0.02% 3[0.12,72.91]
EPE-A 2014 2/168 1/75 0.04% 0.89[0.08,9.7]
GISSI-HF 2008 107/3494 129/3481 3.72% 0.83[0.64,1.06]
GISSI-P 1999 424/5666 485/5658 15.11% 0.87[0.77,0.99]
HARP 1995 7/41 7/39 0.26% 0.95[0.37,2.46]
JELIS 2007 262/9326 324/9319 9.19% 0.81[0.69,0.95]
Nye 1990 5/36 11/37 0.26% 0.47[0.18,1.21]
OFAMI 2001 42/150 36/150 1.61% 1.17[0.8,1.71]
Raitt 2005 1/100 3/100 0.05% 0.33[0.04,3.15]
Risk & Prevention 2013 310/6239 324/6266 10.25% 0.96[0.83,1.12]
SHOT 1996 7/317 12/293 0.28% 0.54[0.22,1.35]
THIS DIET 2008 10/51 6/50 0.27% 1.63[0.64,4.16]
Subtotal (95% CI) 27116 26958 57.88% 0.89[0.84,0.95]
Total events: 1527 (Higher omega 3), 1714 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=13.04, df=15(P=0.6); I2=0%  
Test for overall effect: Z=3.41(P=0)  
   
Total (95% CI) 42305 41996 100% 0.93[0.88,0.97]
Total events: 2634 (Higher omega 3), 2835 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=23.63, df=27(P=0.65); I2=0%  
Test for overall effect: Z=3.02(P=0)  
Test for subgroup differences: Chi2=2.91, df=1 (P=0.09), I2=65.62%  
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Analysis 1.46.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 46 CHD events - LCn3 - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.46.1 SA - low risk of compliance bias  
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 13.1% 0.94[0.74,1.19]
Baldassarre 2006 1/32 0/32 0.08% 3[0.13,71]
Brox 2001 0/80 1/40 0.07% 0.17[0.01,4.05]
DO IT 2010 11/282 9/281 1% 1.22[0.51,2.89]
EPE-A 2014 2/168 1/75 0.13% 0.89[0.08,9.7]
FOSTAR 2016 10/101 10/101 1.09% 1[0.44,2.3]
HARP 1995 7/41 7/39 0.83% 0.95[0.37,2.46]
OMEGA 2009 547/1919 568/1885 77.18% 0.95[0.86,1.04]
Raitt 2005 1/100 3/100 0.15% 0.33[0.04,3.15]
SCIMO 1999 1/112 4/111 0.16% 0.25[0.03,2.18]
SHOT 1996 7/317 12/293 0.89% 0.54[0.22,1.35]
SU.FOL.OM3 2010 51/1253 53/1248 5.31% 0.96[0.66,1.4]
Subtotal (95% CI) 6809 6638 100% 0.94[0.86,1.02]
Total events: 760 (Higher omega 3), 800 (Lower omega 3)  
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=5.71, df=11(P=0.89); I2=0%  
Test for overall effect: Z=1.41(P=0.16)  
   
1.46.2 SA - 100+ randomised  
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.13% 0.94[0.74,1.19]
AREDS2 2014 28/2147 30/2056 0.91% 0.89[0.54,1.49]
Brox 2001 0/80 1/40 0.02% 0.17[0.01,4.05]
DART 1989 337/1015 366/1018 16.55% 0.92[0.82,1.04]
Derosa 2016 0/128 4/130 0.03% 0.11[0.01,2.07]
DO IT 2010 11/282 9/281 0.32% 1.22[0.51,2.89]
Doi 2014 1/119 0/119 0.02% 3[0.12,72.91]
EPE-A 2014 2/168 1/75 0.04% 0.89[0.08,9.7]
EPOCH 2014 1/195 0/196 0.02% 3.02[0.12,73.57]
FORWARD 2013 1/289 1/297 0.03% 1.03[0.06,16.35]
FOSTAR 2016 10/101 10/101 0.34% 1[0.44,2.3]
GISSI-HF 2008 107/3494 129/3481 3.74% 0.83[0.64,1.06]
GISSI-P 1999 424/5666 485/5658 15.19% 0.87[0.77,0.99]
JELIS 2007 262/9326 324/9319 9.24% 0.81[0.69,0.95]
OFAMI 2001 42/150 36/150 1.61% 1.17[0.8,1.71]
OMEGA 2009 547/1919 568/1885 24.35% 0.95[0.86,1.04]
ORIGIN 2012 344/6281 316/6255 10.74% 1.08[0.93,1.26]
Proudman 2015 1/87 0/53 0.02% 1.84[0.08,44.38]
Raitt 2005 1/100 3/100 0.05% 0.33[0.04,3.15]
Risk & Prevention 2013 310/6239 324/6266 10.31% 0.96[0.83,1.12]
SCIMO 1999 1/112 4/111 0.05% 0.25[0.03,2.18]
SHOT 1996 7/317 12/293 0.28% 0.54[0.22,1.35]
SOFA 2006 1/273 3/273 0.05% 0.33[0.03,3.18]
SU.FOL.OM3 2010 51/1253 53/1248 1.68% 0.96[0.66,1.4]
THIS DIET 2008 10/51 6/50 0.27% 1.63[0.64,4.16]
Subtotal (95% CI) 42196 41888 100% 0.93[0.88,0.98]
Total events: 2621 (Higher omega 3), 2817 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=21.1, df=24(P=0.63); I2=0%  
Test for overall effect: Z=2.96(P=0)  
Test for subgroup differences: Chi2=0.05, df=1 (P=0.83), I2=0%  
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Analysis 1.47.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 47 CHD events - LCn3 - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.47.1 LCn3 ≤ 150 mg/d  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.47.2 LCn3 > 150 ≤ 250 mg/d  
Subtotal (95% CI) 0 0 Not estimable
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.47.3 LCn3 > 250 ≤ 400 mg/d  
DART 1989 337/1015 366/1018 16.06% 0.92[0.82,1.04]
Subtotal (95% CI) 1015 1018 16.06% 0.92[0.82,1.04]
Total events: 337 (Higher omega 3), 366 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.3(P=0.19)  
   
1.47.4 LCn3 > 400 ≤ 2400 mg/d  
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.01% 0.94[0.74,1.19]
AREDS2 2014 28/2147 30/2056 0.88% 0.89[0.54,1.49]
Baldassarre 2006 1/32 0/32 0.02% 3[0.13,71]
Derosa 2016 0/128 4/130 0.03% 0.11[0.01,2.07]
DO IT 2010 11/282 9/281 0.31% 1.22[0.51,2.89]
Doi 2014 1/119 0/119 0.02% 3[0.12,72.91]
EPE-A 2014 1/82 0/75 0.02% 2.75[0.11,66.42]
EPOCH 2014 1/195 0/196 0.02% 3.02[0.12,73.57]
FORWARD 2013 1/289 1/297 0.03% 1.03[0.06,16.35]
GISSI-HF 2008 107/3494 129/3481 3.63% 0.83[0.64,1.06]
GISSI-P 1999 424/5666 485/5658 14.74% 0.87[0.77,0.99]
JELIS 2007 262/9326 324/9319 8.96% 0.81[0.69,0.95]
Nye 1990 5/36 11/37 0.25% 0.47[0.18,1.21]
OMEGA 2009 547/1919 568/1885 23.63% 0.95[0.86,1.04]
ORIGIN 2012 344/6281 316/6255 10.42% 1.08[0.93,1.26]
Raitt 2005 1/100 3/100 0.05% 0.33[0.04,3.15]
Risk & Prevention 2013 310/6239 324/6266 10% 0.96[0.83,1.12]
SCIMO 1999 1/112 4/111 0.05% 0.25[0.03,2.18]
SOFA 2006 65/273 62/273 2.48% 1.05[0.77,1.42]
SU.FOL.OM3 2010 51/1253 53/1248 1.63% 0.96[0.66,1.4]
THIS DIET 2008 10/51 6/50 0.26% 1.63[0.64,4.16]
Subtotal (95% CI) 40428 40302 81.44% 0.93[0.88,0.98]
Total events: 2293 (Higher omega 3), 2461 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=19.85, df=20(P=0.47); I2=0%  
Test for overall effect: Z=2.66(P=0.01)  
   
1.47.5 LCn3 > 2.4 ≤ 4.4 g/d  
Brox 2001 0/80 1/40 0.02% 0.17[0.01,4.05]
EPE-A 2014 1/86 1/75 0.03% 0.87[0.06,13.7]
OFAMI 2001 42/150 36/150 1.57% 1.17[0.8,1.71]
SHOT 1996 7/317 12/293 0.27% 0.54[0.22,1.35]
Subtotal (95% CI) 633 558 1.89% 0.9[0.53,1.53]
Total events: 50 (Higher omega 3), 50 (Lower omega 3)  
Heterogeneity: Tau2=0.07; Chi2=3.63, df=3(P=0.3); I2=17.35%  
Test for overall effect: Z=0.38(P=0.7)  
   
1.47.6 LCn3 > 4.4 g/d  
FOSTAR 2016 10/101 10/101 0.33% 1[0.44,2.3]
HARP 1995 7/41 7/39 0.25% 0.95[0.37,2.46]
Proudman 2015 1/87 0/53 0.02% 1.84[0.08,44.38]
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
297
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 229 193 0.61% 1[0.54,1.85]
Total events: 18 (Higher omega 3), 17 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.15, df=2(P=0.93); I2=0%  
Test for overall effect: Z=0.01(P=1)  
   
Total (95% CI) 42305 42071 100% 0.93[0.89,0.98]
Total events: 2698 (Higher omega 3), 2894 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=23.88, df=28(P=0.69); I2=0%  
Test for overall effect: Z=2.91(P=0)  
Test for subgroup differences: Chi2=0.08, df=1 (P=0.99), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 1.48.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 48 CHD events - LCn3 - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.48.1 N-3 replacing SFA  
DART 1989 337/1015 366/1018 65.71% 0.92[0.82,1.04]
Derosa 2016 0/128 4/130 13.49% 0.11[0.01,2.07]
SCIMO 1999 1/112 4/111 20.8% 0.25[0.03,2.18]
Subtotal (95% CI) 1255 1259 100% 0.53[0.16,1.75]
Total events: 338 (Higher omega 3), 374 (Lower omega 3)  
Heterogeneity: Tau2=0.57; Chi2=3.43, df=2(P=0.18); I2=41.61%  
Test for overall effect: Z=1.04(P=0.3)  
   
1.48.2 N-3 replacing MUFA  
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 5.64% 0.94[0.74,1.19]
Baldassarre 2006 1/32 0/32 0.03% 3[0.13,71]
DART 1989 337/1015 366/1018 22.57% 0.92[0.82,1.04]
EPOCH 2014 1/195 0/196 0.03% 3.02[0.12,73.57]
FORWARD 2013 1/289 1/297 0.04% 1.03[0.06,16.35]
GISSI-HF 2008 107/3494 129/3481 5.1% 0.83[0.64,1.06]
HARP 1995 7/41 7/39 0.36% 0.95[0.37,2.46]
Nye 1990 5/36 11/37 0.36% 0.47[0.18,1.21]
OMEGA 2009 547/1919 568/1885 33.2% 0.95[0.86,1.04]
ORIGIN 2012 344/6281 316/6255 14.64% 1.08[0.93,1.26]
Raitt 2005 1/100 3/100 0.06% 0.33[0.04,3.15]
Risk & Prevention 2013 310/6239 324/6266 14.06% 0.96[0.83,1.12]
SCIMO 1999 1/112 4/111 0.07% 0.25[0.03,2.18]
SOFA 2006 65/273 62/273 3.48% 1.05[0.77,1.42]
THIS DIET 2008 10/51 6/50 0.37% 1.63[0.64,4.16]
Subtotal (95% CI) 22481 22473 100% 0.96[0.9,1.01]
Total events: 1859 (Higher omega 3), 1929 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=11.56, df=14(P=0.64); I2=0%  
Test for overall effect: Z=1.52(P=0.13)  
   
1.48.3 N-3 replacing n-6  
DO IT 2010 11/282 9/281 7.03% 1.22[0.51,2.89]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
OFAMI 2001 42/150 36/150 35.81% 1.17[0.8,1.71]
Proudman 2015 1/87 0/53 0.52% 1.84[0.08,44.38]
SOFA 2006 65/273 62/273 56.64% 1.05[0.77,1.42]
Subtotal (95% CI) 792 757 100% 1.1[0.88,1.39]
Total events: 119 (Higher omega 3), 107 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.34, df=3(P=0.95); I2=0%  
Test for overall effect: Z=0.85(P=0.4)  
   
1.48.4 N-3 replacing carbohydrates/sugars  
Derosa 2016 0/128 4/130 100% 0.11[0.01,2.07]
Subtotal (95% CI) 128 130 100% 0.11[0.01,2.07]
Total events: 0 (Higher omega 3), 4 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.47(P=0.14)  
   
1.48.5 N-3 replacing nil/low n-3 placebo  
AREDS2 2014 28/2147 30/2056 3.28% 0.89[0.54,1.49]
Brox 2001 0/80 1/40 0.08% 0.17[0.01,4.05]
Doi 2014 1/119 0/119 0.08% 3[0.12,72.91]
FOSTAR 2016 10/101 10/101 1.24% 1[0.44,2.3]
GISSI-P 1999 424/5666 485/5658 54.88% 0.87[0.77,0.99]
JELIS 2007 262/9326 324/9319 33.37% 0.81[0.69,0.95]
SHOT 1996 7/317 12/293 1.02% 0.54[0.22,1.35]
SU.FOL.OM3 2010 51/1253 53/1248 6.05% 0.96[0.66,1.4]
Subtotal (95% CI) 19009 18834 100% 0.85[0.78,0.94]
Total events: 783 (Higher omega 3), 915 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.67, df=7(P=0.82); I2=0%  
Test for overall effect: Z=3.36(P=0)  
   
1.48.6 Replacement unclear  
EPE-A 2014 2/168 1/75 100% 0.89[0.08,9.7]
Subtotal (95% CI) 168 75 100% 0.89[0.08,9.7]
Total events: 2 (Higher omega 3), 1 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.09(P=0.93)  
Test for subgroup differences: Chi2=9.3, df=1 (P=0.1), I2=46.22%  
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Analysis 1.49.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 49 CHD events - LCn3 - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.49.1 Dietary advice  
DART 1989 337/1015 366/1018 16.06% 0.92[0.82,1.04]
THIS DIET 2008 10/51 6/50 0.26% 1.63[0.64,4.16]
Subtotal (95% CI) 1066 1068 16.33% 1.01[0.67,1.52]
Total events: 347 (Higher omega 3), 372 (Lower omega 3)  
Heterogeneity: Tau2=0.05; Chi2=1.41, df=1(P=0.23); I2=29.26%  
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.05(P=0.96)  
   
1.49.2 Supplemental foods  
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.01% 0.94[0.74,1.19]
FOSTAR 2016 10/101 10/101 0.33% 1[0.44,2.3]
Subtotal (95% CI) 2505 2534 4.34% 0.94[0.75,1.18]
Total events: 132 (Higher omega 3), 142 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.88); I2=0%  
Test for overall effect: Z=0.52(P=0.6)  
   
1.49.3 Supplements (capsule)  
AREDS2 2014 28/2147 30/2056 0.88% 0.89[0.54,1.49]
Baldassarre 2006 1/32 0/32 0.02% 3[0.13,71]
Brox 2001 0/80 1/40 0.02% 0.17[0.01,4.05]
Derosa 2016 0/128 4/130 0.03% 0.11[0.01,2.07]
DO IT 2010 11/282 9/281 0.31% 1.22[0.51,2.89]
Doi 2014 1/119 0/119 0.02% 3[0.12,72.91]
EPE-A 2014 2/168 1/75 0.04% 0.89[0.08,9.7]
EPOCH 2014 1/195 0/196 0.02% 3.02[0.12,73.57]
FORWARD 2013 1/289 1/297 0.03% 1.03[0.06,16.35]
GISSI-HF 2008 107/3494 129/3481 3.63% 0.83[0.64,1.06]
GISSI-P 1999 424/5666 485/5658 14.74% 0.87[0.77,0.99]
HARP 1995 7/41 7/39 0.25% 0.95[0.37,2.46]
JELIS 2007 262/9326 324/9319 8.96% 0.81[0.69,0.95]
Nye 1990 5/36 11/37 0.25% 0.47[0.18,1.21]
OFAMI 2001 42/150 36/150 1.57% 1.17[0.8,1.71]
OMEGA 2009 547/1919 568/1885 23.63% 0.95[0.86,1.04]
ORIGIN 2012 344/6281 316/6255 10.42% 1.08[0.93,1.26]
Proudman 2015 1/87 0/53 0.02% 1.84[0.08,44.38]
Raitt 2005 1/100 3/100 0.05% 0.33[0.04,3.15]
Risk & Prevention 2013 310/6239 324/6266 10% 0.96[0.83,1.12]
SCIMO 1999 1/112 4/111 0.05% 0.25[0.03,2.18]
SHOT 1996 7/317 12/293 0.27% 0.54[0.22,1.35]
SOFA 2006 65/273 62/273 2.48% 1.05[0.77,1.42]
SU.FOL.OM3 2010 51/1253 53/1248 1.63% 0.96[0.66,1.4]
Subtotal (95% CI) 38734 38394 79.33% 0.93[0.88,0.98]
Total events: 2219 (Higher omega 3), 2380 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=22.01, df=23(P=0.52); I2=0%  
Test for overall effect: Z=2.63(P=0.01)  
   
1.49.4 Any combination  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 42305 41996 100% 0.93[0.89,0.98]
Total events: 2698 (Higher omega 3), 2894 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=23.44, df=27(P=0.66); I2=0%  
Test for overall effect: Z=2.92(P=0)  
Test for subgroup differences: Chi2=0.16, df=1 (P=0.92), I2=0%  
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Analysis 1.50.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 50 CHD events - LCn3 - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.50.1 Medium duration 1 to < 2 years in study  
Brox 2001 0/80 1/40 0.02% 0.17[0.01,4.05]
Derosa 2016 0/128 4/130 0.03% 0.11[0.01,2.07]
Doi 2014 1/119 0/119 0.02% 3[0.12,72.91]
EPE-A 2014 2/168 1/75 0.04% 0.89[0.08,9.7]
EPOCH 2014 1/195 0/196 0.02% 3.02[0.12,73.57]
FORWARD 2013 1/289 1/297 0.03% 1.03[0.06,16.35]
Nye 1990 5/36 11/37 0.25% 0.47[0.18,1.21]
OMEGA 2009 547/1919 568/1885 23.63% 0.95[0.86,1.04]
Proudman 2015 1/87 0/53 0.02% 1.84[0.08,44.38]
SHOT 1996 7/317 12/293 0.27% 0.54[0.22,1.35]
SOFA 2006 65/273 62/273 2.48% 1.05[0.77,1.42]
Subtotal (95% CI) 3611 3398 26.82% 0.94[0.86,1.03]
Total events: 630 (Higher omega 3), 660 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=8.36, df=10(P=0.59); I2=0%  
Test for overall effect: Z=1.26(P=0.21)  
   
1.50.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.01% 0.94[0.74,1.19]
Baldassarre 2006 1/32 0/32 0.02% 3[0.13,71]
DART 1989 337/1015 366/1018 16.06% 0.92[0.82,1.04]
DO IT 2010 11/282 9/281 0.31% 1.22[0.51,2.89]
FOSTAR 2016 10/101 10/101 0.33% 1[0.44,2.3]
GISSI-HF 2008 107/3494 129/3481 3.63% 0.83[0.64,1.06]
GISSI-P 1999 424/5666 485/5658 14.74% 0.87[0.77,0.99]
HARP 1995 7/41 7/39 0.25% 0.95[0.37,2.46]
OFAMI 2001 42/150 36/150 1.57% 1.17[0.8,1.71]
Raitt 2005 1/100 3/100 0.05% 0.33[0.04,3.15]
SCIMO 1999 1/112 4/111 0.05% 0.25[0.03,2.18]
THIS DIET 2008 10/51 6/50 0.26% 1.63[0.64,4.16]
Subtotal (95% CI) 13448 13454 41.28% 0.91[0.84,0.98]
Total events: 1073 (Higher omega 3), 1187 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=7.42, df=11(P=0.76); I2=0%  
Test for overall effect: Z=2.49(P=0.01)  
   
1.50.3 Long duration: ≥ 4 years in study  
AREDS2 2014 28/2147 30/2056 0.88% 0.89[0.54,1.49]
JELIS 2007 262/9326 324/9319 8.96% 0.81[0.69,0.95]
ORIGIN 2012 344/6281 316/6255 10.42% 1.08[0.93,1.26]
Risk & Prevention 2013 310/6239 324/6266 10% 0.96[0.83,1.12]
SU.FOL.OM3 2010 51/1253 53/1248 1.63% 0.96[0.66,1.4]
Subtotal (95% CI) 25246 25144 31.89% 0.95[0.83,1.07]
Total events: 995 (Higher omega 3), 1047 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=7.03, df=4(P=0.13); I2=43.08%  
Test for overall effect: Z=0.88(P=0.38)  
   
Total (95% CI) 42305 41996 100% 0.93[0.89,0.98]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 2698 (Higher omega 3), 2894 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=23.44, df=27(P=0.66); I2=0%  
Test for overall effect: Z=2.92(P=0)  
Test for subgroup differences: Chi2=0.46, df=1 (P=0.79), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 1.51.   Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes),
Outcome 51 CHD events - LCn3 - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.51.1 Primary prevention of CVD  
AREDS2 2014 28/2147 30/2056 0.88% 0.89[0.54,1.49]
Baldassarre 2006 1/32 0/32 0.02% 3[0.13,71]
Brox 2001 0/80 1/40 0.02% 0.17[0.01,4.05]
Derosa 2016 0/128 4/130 0.03% 0.11[0.01,2.07]
DO IT 2010 11/282 9/281 0.31% 1.22[0.51,2.89]
EPE-A 2014 2/168 1/75 0.04% 0.89[0.08,9.7]
EPOCH 2014 1/195 0/196 0.02% 3.02[0.12,73.57]
FOSTAR 2016 10/101 10/101 0.33% 1[0.44,2.3]
JELIS 2007 262/9326 324/9319 8.96% 0.81[0.69,0.95]
ORIGIN 2012 344/6281 316/6255 10.42% 1.08[0.93,1.26]
Proudman 2015 1/87 0/53 0.02% 1.84[0.08,44.38]
Subtotal (95% CI) 18827 18538 21.06% 0.94[0.81,1.1]
Total events: 660 (Higher omega 3), 695 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=11.71, df=10(P=0.31); I2=14.59%  
Test for overall effect: Z=0.75(P=0.45)  
   
1.51.2 Secondary prevention of CVD  
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.01% 0.94[0.74,1.19]
DART 1989 337/1015 366/1018 16.06% 0.92[0.82,1.04]
Doi 2014 1/119 0/119 0.02% 3[0.12,72.91]
FORWARD 2013 1/289 1/297 0.03% 1.03[0.06,16.35]
GISSI-HF 2008 107/3494 129/3481 3.63% 0.83[0.64,1.06]
GISSI-P 1999 424/5666 485/5658 14.74% 0.87[0.77,0.99]
HARP 1995 7/41 7/39 0.25% 0.95[0.37,2.46]
Nye 1990 5/36 11/37 0.25% 0.47[0.18,1.21]
OFAMI 2001 42/150 36/150 1.57% 1.17[0.8,1.71]
OMEGA 2009 547/1919 568/1885 23.63% 0.95[0.86,1.04]
Raitt 2005 1/100 3/100 0.05% 0.33[0.04,3.15]
Risk & Prevention 2013 310/6239 324/6266 10% 0.96[0.83,1.12]
SCIMO 1999 1/112 4/111 0.05% 0.25[0.03,2.18]
SHOT 1996 7/317 12/293 0.27% 0.54[0.22,1.35]
SOFA 2006 65/273 62/273 2.48% 1.05[0.77,1.42]
SU.FOL.OM3 2010 51/1253 53/1248 1.63% 0.96[0.66,1.4]
THIS DIET 2008 10/51 6/50 0.26% 1.63[0.64,4.16]
Subtotal (95% CI) 23478 23458 78.94% 0.93[0.88,0.98]
Total events: 2038 (Higher omega 3), 2199 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=11.61, df=16(P=0.77); I2=0%  
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=2.76(P=0.01)  
   
Total (95% CI) 42305 41996 100% 0.93[0.89,0.98]
Total events: 2698 (Higher omega 3), 2894 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=23.44, df=27(P=0.66); I2=0%  
Test for overall effect: Z=2.92(P=0)  
Test for subgroup differences: Chi2=0.04, df=1 (P=0.84), I2=0%  
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Analysis 1.52.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 52 CHD events - LCn3 - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.52.1 LCn3 - ≥ 50% of control group on statins  
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.01% 0.94[0.74,1.19]
Doi 2014 1/119 0/119 0.02% 3[0.12,72.91]
JELIS 2007 262/9326 324/9319 8.96% 0.81[0.69,0.95]
Nye 1990 5/36 11/37 0.25% 0.47[0.18,1.21]
OMEGA 2009 547/1919 568/1885 23.63% 0.95[0.86,1.04]
ORIGIN 2012 344/6281 316/6255 10.42% 1.08[0.93,1.26]
SU.FOL.OM3 2010 51/1253 53/1248 1.63% 0.96[0.66,1.4]
THIS DIET 2008 10/51 6/50 0.26% 1.63[0.64,4.16]
Subtotal (95% CI) 21389 21346 49.19% 0.94[0.85,1.05]
Total events: 1342 (Higher omega 3), 1410 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=10.88, df=7(P=0.14); I2=35.68%  
Test for overall effect: Z=1.08(P=0.28)  
   
1.52.2 LCn3 - < 50% of control group on statins  
AREDS2 2014 28/2147 30/2056 0.88% 0.89[0.54,1.49]
Baldassarre 2006 1/32 0/32 0.02% 3[0.13,71]
Brox 2001 0/80 1/40 0.02% 0.17[0.01,4.05]
DART 1989 337/1015 366/1018 16.06% 0.92[0.82,1.04]
DO IT 2010 11/282 9/281 0.31% 1.22[0.51,2.89]
FORWARD 2013 1/289 1/297 0.03% 1.03[0.06,16.35]
FOSTAR 2016 10/101 10/101 0.33% 1[0.44,2.3]
GISSI-HF 2008 107/3494 129/3481 3.63% 0.83[0.64,1.06]
GISSI-P 1999 424/5666 485/5658 14.74% 0.87[0.77,0.99]
HARP 1995 7/41 7/39 0.25% 0.95[0.37,2.46]
OFAMI 2001 42/150 36/150 1.57% 1.17[0.8,1.71]
Proudman 2015 1/87 0/53 0.02% 1.84[0.08,44.38]
Raitt 2005 1/100 3/100 0.05% 0.33[0.04,3.15]
Risk & Prevention 2013 310/6239 324/6266 10% 0.96[0.83,1.12]
SCIMO 1999 1/112 4/111 0.05% 0.25[0.03,2.18]
SHOT 1996 7/317 12/293 0.27% 0.54[0.22,1.35]
SOFA 2006 65/273 62/273 2.48% 1.05[0.77,1.42]
Subtotal (95% CI) 20425 20249 50.72% 0.92[0.86,0.98]
Total events: 1353 (Higher omega 3), 1479 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=9.65, df=16(P=0.88); I2=0%  
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=2.5(P=0.01)  
   
1.52.3 LCn3 - use of statins unclear  
Derosa 2016 0/128 4/130 0.03% 0.11[0.01,2.07]
EPE-A 2014 2/168 1/75 0.04% 0.89[0.08,9.7]
EPOCH 2014 1/195 0/196 0.02% 3.02[0.12,73.57]
Subtotal (95% CI) 491 401 0.09% 0.65[0.11,3.83]
Total events: 3 (Higher omega 3), 5 (Lower omega 3)  
Heterogeneity: Tau2=0.44; Chi2=2.43, df=2(P=0.3); I2=17.71%  
Test for overall effect: Z=0.48(P=0.63)  
   
Total (95% CI) 42305 41996 100% 0.93[0.89,0.98]
Total events: 2698 (Higher omega 3), 2894 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=23.44, df=27(P=0.66); I2=0%  
Test for overall effect: Z=2.92(P=0)  
Test for subgroup differences: Chi2=0.32, df=1 (P=0.85), I2=0%  
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Analysis 1.53.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 53 CHD events - LCn3 subgroup by CAD history.
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.53.1 Previous CAD  
AlphaOmega - EPA+DHA 2010 122/2404 132/2433 4.11% 0.94[0.74,1.19]
DART 1989 337/1015 366/1018 16.46% 0.92[0.82,1.04]
Doi 2014 1/119 0/119 0.02% 3[0.12,72.91]
GISSI-P 1999 424/5666 485/5658 15.11% 0.87[0.77,0.99]
HARP 1995 7/41 7/39 0.26% 0.95[0.37,2.46]
Nye 1990 5/36 11/37 0.26% 0.47[0.18,1.21]
OFAMI 2001 42/150 36/150 1.61% 1.17[0.8,1.71]
OMEGA 2009 547/1919 568/1885 24.22% 0.95[0.86,1.04]
SCIMO 1999 1/112 4/111 0.05% 0.25[0.03,2.18]
SHOT 1996 7/317 12/293 0.28% 0.54[0.22,1.35]
SU.FOL.OM3 2010 51/1253 53/1248 1.67% 0.96[0.66,1.4]
THIS DIET 2008 10/51 6/50 0.27% 1.63[0.64,4.16]
Subtotal (95% CI) 13083 13041 64.32% 0.92[0.87,0.98]
Total events: 1554 (High omega 3), 1680 (Control)  
Heterogeneity: Tau2=0; Chi2=9.15, df=11(P=0.61); I2=0%  
Test for overall effect: Z=2.57(P=0.01)  
   
1.53.2 No previous CAD  
AREDS2 2014 28/2147 30/2056 0.9% 0.89[0.54,1.49]
Baldassarre 2006 1/32 0/32 0.02% 3[0.13,71]
Brox 2001 0/80 1/40 0.02% 0.17[0.01,4.05]
Derosa 2016 0/128 4/130 0.03% 0.11[0.01,2.07]
DO IT 2010 11/282 9/281 0.32% 1.22[0.51,2.89]
EPE-A 2014 2/168 1/75 0.04% 0.89[0.08,9.7]
EPOCH 2014 1/195 0/196 0.02% 3.02[0.12,73.57]
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Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
FORWARD 2013 1/289 1/297 0.03% 1.03[0.06,16.35]
FOSTAR 2016 10/101 10/101 0.34% 1[0.44,2.3]
GISSI-HF 2008 107/3494 129/3481 3.72% 0.83[0.64,1.06]
JELIS 2007 262/9326 324/9319 9.19% 0.81[0.69,0.95]
ORIGIN 2012 344/6281 316/6255 10.68% 1.08[0.93,1.26]
Proudman 2015 1/87 0/53 0.02% 1.84[0.08,44.38]
Raitt 2005 1/100 3/100 0.05% 0.33[0.04,3.15]
Risk & Prevention 2013 310/6239 324/6266 10.25% 0.96[0.83,1.12]
SOFA 2006 1/273 3/273 0.05% 0.33[0.03,3.18]
Subtotal (95% CI) 29222 28955 35.68% 0.94[0.86,1.01]
Total events: 1080 (High omega 3), 1155 (Control)  
Heterogeneity: Tau2=0; Chi2=14.43, df=15(P=0.49); I2=0%  
Test for overall effect: Z=1.62(P=0.11)  
   
Total (95% CI) 42305 41996 100% 0.93[0.88,0.97]
Total events: 2634 (High omega 3), 2835 (Control)  
Heterogeneity: Tau2=0; Chi2=23.63, df=27(P=0.65); I2=0%  
Test for overall effect: Z=3.02(P=0)  
Test for subgroup differences: Chi2=0.06, df=1 (P=0.81), I2=0%  
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Analysis 1.54.   Comparison 1 High vs low LCn3 omega-3 fats
(primary outcomes), Outcome 54 Stroke (overall) - LCn3.
Study or subgroup Favours high-
er omega 3
Lower
omega 3 fats
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AFFORD 2013 1/153 0/163 0.08% 3.19[0.13,77.83]
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.13% 1.11[0.47,2.62]
AREDS2 2014 48/2147 41/2056 4.86% 1.12[0.74,1.69]
DART 1989 4/1015 9/1018 0.6% 0.45[0.14,1.44]
DART2 2003 16/1571 14/1543 1.62% 1.12[0.55,2.29]
Derosa 2016 0/128 1/130 0.08% 0.34[0.01,8.23]
DO IT 2010 0/282 2/281 0.09% 0.2[0.01,4.13]
Doi 2014 0/119 4/119 0.1% 0.11[0.01,2.04]
EPOCH 2014 2/195 0/196 0.09% 5.03[0.24,104.01]
FORWARD 2013 3/289 3/297 0.33% 1.03[0.21,5.05]
GISSI-HF 2008 122/3494 103/3481 12.42% 1.18[0.91,1.53]
GISSI-P 1999 92/5665 77/5658 9.16% 1.19[0.88,1.61]
HARP 1995 1/41 0/39 0.08% 2.86[0.12,68.1]
JELIS 2007 166/9326 162/9319 17.96% 1.02[0.83,1.27]
MAPT 2017 1/820 4/832 0.17% 0.25[0.03,2.26]
NAT2 2013 0/150 1/150 0.08% 0.33[0.01,8.12]
Nodari 2011 HF 0/67 1/66 0.08% 0.33[0.01,7.92]
OFAMI 2001 6/150 0/150 0.1% 13[0.74,228.73]
OMEGA 2009 27/1919 13/1885 1.91% 2.04[1.06,3.94]
OPAL 2010 7/376 8/372 0.82% 0.87[0.32,2.36]
ORIGIN 2012 314/6281 336/6255 36.84% 0.93[0.8,1.08]
ORL 2013 2/171 0/165 0.09% 4.83[0.23,99.76]
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Study or subgroup Favours high-
er omega 3
Lower
omega 3 fats
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Risk & Prevention 2013 80/6239 60/6266 7.46% 1.34[0.96,1.87]
SCIMO 1999 1/112 0/111 0.08% 2.97[0.12,72.21]
SHOT 1996 3/317 4/293 0.37% 0.69[0.16,3.07]
SU.FOL.OM3 2010 29/1253 28/1248 3.14% 1.03[0.62,1.72]
THIS DIET 2008 3/51 1/50 0.17% 2.94[0.32,27.33]
Özaydin 2011 1/23 0/24 0.08% 3.13[0.13,73.01]
   
Total (95% CI) 44758 44600 100% 1.06[0.96,1.16]
Total events: 940 (Favours higher omega 3), 882 (Lower omega 3 fats)  
Heterogeneity: Tau2=0; Chi2=26.66, df=27(P=0.48); I2=0%  
Test for overall effect: Z=1.17(P=0.24)  
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Analysis 1.55.   Comparison 1 High vs low LCn3 omega-3 fats
(primary outcomes), Outcome 55 Stroke - LCn3 - SA fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
AFFORD 2013 1/153 0/163 0.05% 3.19[0.13,77.83]
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.12% 1.11[0.47,2.62]
AREDS2 2014 48/2147 41/2056 4.71% 1.12[0.74,1.69]
DART 1989 4/1015 9/1018 1.01% 0.45[0.14,1.44]
DART2 2003 16/1571 14/1543 1.59% 1.12[0.55,2.29]
Derosa 2016 0/128 1/130 0.17% 0.34[0.01,8.23]
DO IT 2010 0/282 2/281 0.28% 0.2[0.01,4.13]
Doi 2014 0/119 4/119 0.51% 0.11[0.01,2.04]
EPOCH 2014 2/195 0/196 0.06% 5.03[0.24,104.01]
FORWARD 2013 3/289 3/297 0.33% 1.03[0.21,5.05]
GISSI-HF 2008 122/3494 103/3481 11.59% 1.18[0.91,1.53]
GISSI-P 1999 92/5665 77/5658 8.66% 1.19[0.88,1.61]
HARP 1995 1/41 0/39 0.06% 2.86[0.12,68.1]
JELIS 2007 166/9326 162/9319 18.21% 1.02[0.83,1.27]
MAPT 2017 1/820 4/832 0.45% 0.25[0.03,2.26]
NAT2 2013 0/150 1/150 0.17% 0.33[0.01,8.12]
Nodari 2011 HF 0/67 1/66 0.17% 0.33[0.01,7.92]
OFAMI 2001 6/150 0/150 0.06% 13[0.74,228.73]
OMEGA 2009 27/1919 13/1885 1.47% 2.04[1.06,3.94]
OPAL 2010 7/376 8/372 0.9% 0.87[0.32,2.36]
ORIGIN 2012 314/6281 336/6255 37.83% 0.93[0.8,1.08]
ORL 2013 2/171 0/165 0.06% 4.83[0.23,99.76]
Risk & Prevention 2013 80/6239 60/6266 6.73% 1.34[0.96,1.87]
SCIMO 1999 1/112 0/111 0.06% 2.97[0.12,72.21]
SHOT 1996 3/317 4/293 0.47% 0.69[0.16,3.07]
SU.FOL.OM3 2010 29/1253 28/1248 3.15% 1.03[0.62,1.72]
THIS DIET 2008 3/51 1/50 0.11% 2.94[0.32,27.33]
Özaydin 2011 1/23 0/24 0.06% 3.13[0.13,73.01]
   
Total (95% CI) 44758 44600 100% 1.06[0.97,1.16]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total events: 940 (Higher omega 3), 882 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=26.66, df=27(P=0.48); I2=0%  
Test for overall effect: Z=1.27(P=0.2)  
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Analysis 1.56.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 56 Stroke - LCn3 - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.56.1 Low risk of bias  
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.13% 1.11[0.47,2.62]
AREDS2 2014 48/2147 41/2056 4.86% 1.12[0.74,1.69]
Derosa 2016 0/128 1/130 0.08% 0.34[0.01,8.23]
EPOCH 2014 2/195 0/196 0.09% 5.03[0.24,104.01]
FORWARD 2013 3/289 3/297 0.33% 1.03[0.21,5.05]
MAPT 2017 1/820 4/832 0.17% 0.25[0.03,2.26]
NAT2 2013 0/150 1/150 0.08% 0.33[0.01,8.12]
OMEGA 2009 27/1919 13/1885 1.91% 2.04[1.06,3.94]
OPAL 2010 7/376 8/372 0.82% 0.87[0.32,2.36]
ORIGIN 2012 314/6281 336/6255 36.84% 0.93[0.8,1.08]
SCIMO 1999 1/112 0/111 0.08% 2.97[0.12,72.21]
SU.FOL.OM3 2010 29/1253 28/1248 3.14% 1.03[0.62,1.72]
Subtotal (95% CI) 16074 15965 49.53% 0.98[0.86,1.12]
Total events: 443 (Higher omega 3), 445 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=9.72, df=11(P=0.56); I2=0%  
Test for overall effect: Z=0.25(P=0.81)  
   
1.56.2 Moderate/high risk of bias  
AFFORD 2013 1/153 0/163 0.08% 3.19[0.13,77.83]
DART 1989 4/1015 9/1018 0.6% 0.45[0.14,1.44]
DART2 2003 16/1571 14/1543 1.62% 1.12[0.55,2.29]
DO IT 2010 0/282 2/281 0.09% 0.2[0.01,4.13]
Doi 2014 0/119 4/119 0.1% 0.11[0.01,2.04]
GISSI-HF 2008 122/3494 103/3481 12.42% 1.18[0.91,1.53]
GISSI-P 1999 92/5665 77/5658 9.16% 1.19[0.88,1.61]
HARP 1995 1/41 0/39 0.08% 2.86[0.12,68.1]
JELIS 2007 166/9326 162/9319 17.96% 1.02[0.83,1.27]
Nodari 2011 HF 0/67 1/66 0.08% 0.33[0.01,7.92]
OFAMI 2001 6/150 0/150 0.1% 13[0.74,228.73]
ORL 2013 2/171 0/165 0.09% 4.83[0.23,99.76]
Risk & Prevention 2013 80/6239 60/6266 7.46% 1.34[0.96,1.87]
SHOT 1996 3/317 4/293 0.37% 0.69[0.16,3.07]
THIS DIET 2008 3/51 1/50 0.17% 2.94[0.32,27.33]
Özaydin 2011 1/23 0/24 0.08% 3.13[0.13,73.01]
Subtotal (95% CI) 28684 28635 50.47% 1.13[1,1.29]
Total events: 497 (Higher omega 3), 437 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=14.66, df=15(P=0.48); I2=0%  
Test for overall effect: Z=1.9(P=0.06)  
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
Total (95% CI) 44758 44600 100% 1.06[0.96,1.16]
Total events: 940 (Higher omega 3), 882 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=26.66, df=27(P=0.48); I2=0%  
Test for overall effect: Z=1.17(P=0.24)  
Test for subgroup differences: Chi2=2.28, df=1 (P=0.13), I2=56.09%  
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Analysis 1.57.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 57 Stroke - LCn3 - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.57.1 SA - low risk of compliance bias  
AFFORD 2013 1/153 0/163 1.02% 3.19[0.13,77.83]
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 14.23% 1.11[0.47,2.62]
DO IT 2010 0/282 2/281 1.13% 0.2[0.01,4.13]
HARP 1995 1/41 0/39 1.03% 2.86[0.12,68.1]
NAT2 2013 0/150 1/150 1.02% 0.33[0.01,8.12]
Nodari 2011 HF 0/67 1/66 1.03% 0.33[0.01,7.92]
OMEGA 2009 27/1919 13/1885 23.96% 2.04[1.06,3.94]
OPAL 2010 7/376 8/372 10.3% 0.87[0.32,2.36]
ORL 2013 2/171 0/165 1.13% 4.83[0.23,99.76]
SCIMO 1999 1/112 0/111 1.02% 2.97[0.12,72.21]
SHOT 1996 3/317 4/293 4.69% 0.69[0.16,3.07]
SU.FOL.OM3 2010 29/1253 28/1248 39.43% 1.03[0.62,1.72]
Subtotal (95% CI) 7245 7206 100% 1.19[0.86,1.65]
Total events: 82 (Higher omega 3), 67 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=8.16, df=11(P=0.7); I2=0%  
Test for overall effect: Z=1.08(P=0.28)  
   
1.57.2 SA - 100+ randomised  
AFFORD 2013 1/153 0/163 0.1% 3.19[0.13,77.83]
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.34% 1.11[0.47,2.62]
AREDS2 2014 48/2147 41/2056 5.53% 1.12[0.74,1.69]
DART 1989 4/1015 9/1018 0.71% 0.45[0.14,1.44]
DART2 2003 16/1571 14/1543 1.91% 1.12[0.55,2.29]
Derosa 2016 0/128 1/130 0.1% 0.34[0.01,8.23]
DO IT 2010 0/282 2/281 0.11% 0.2[0.01,4.13]
Doi 2014 0/119 4/119 0.12% 0.11[0.01,2.04]
EPOCH 2014 2/195 0/196 0.11% 5.03[0.24,104.01]
FORWARD 2013 3/289 3/297 0.39% 1.03[0.21,5.05]
GISSI-HF 2008 122/3494 103/3481 13.15% 1.18[0.91,1.53]
GISSI-P 1999 92/5665 77/5658 10% 1.19[0.88,1.61]
JELIS 2007 166/9326 162/9319 18.1% 1.02[0.83,1.27]
MAPT 2017 1/820 4/832 0.21% 0.25[0.03,2.26]
NAT2 2013 0/150 1/150 0.1% 0.33[0.01,8.12]
Nodari 2011 HF 0/67 1/66 0.1% 0.33[0.01,7.92]
OFAMI 2001 6/150 0/150 0.12% 13[0.74,228.73]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
OMEGA 2009 27/1919 13/1885 2.23% 2.04[1.06,3.94]
OPAL 2010 7/376 8/372 0.97% 0.87[0.32,2.36]
ORIGIN 2012 314/6281 336/6255 31.86% 0.93[0.8,1.08]
ORL 2013 2/171 0/165 0.11% 4.83[0.23,99.76]
Risk & Prevention 2013 80/6239 60/6266 8.28% 1.34[0.96,1.87]
SCIMO 1999 1/112 0/111 0.1% 2.97[0.12,72.21]
SHOT 1996 3/317 4/293 0.44% 0.69[0.16,3.07]
SU.FOL.OM3 2010 29/1253 28/1248 3.63% 1.03[0.62,1.72]
THIS DIET 2008 3/51 1/50 0.2% 2.94[0.32,27.33]
Subtotal (95% CI) 44694 44537 100% 1.07[0.97,1.18]
Total events: 938 (Higher omega 3), 882 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=25.83, df=25(P=0.42); I2=3.2%  
Test for overall effect: Z=1.26(P=0.21)  
Test for subgroup differences: Chi2=0.43, df=1 (P=0.51), I2=0%  
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Analysis 1.58.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 58 Stroke - LCn3 - subgroup by stroke type.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.58.1 Ischaemic stroke - LCn3  
AREDS2 2014 40/2147 31/2056 15.54% 1.24[0.78,1.97]
DART 1989 2/1015 6/1018 1.55% 0.33[0.07,1.65]
GISSI-HF 2008 97/3494 79/3481 31.22% 1.22[0.91,1.64]
JELIS 2007 115/9326 123/9319 37.7% 0.93[0.73,1.2]
OFAMI 2001 6/150 0/150 0.49% 13[0.74,228.73]
ORL 2013 1/171 0/165 0.39% 2.9[0.12,70.57]
SU.FOL.OM3 2010 29/1253 26/1248 12.71% 1.11[0.66,1.88]
Özaydin 2011 1/23 0/24 0.4% 3.13[0.13,73.01]
Subtotal (95% CI) 17579 17461 100% 1.09[0.89,1.33]
Total events: 291 (Higher omega 3), 265 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=8.07, df=7(P=0.33); I2=13.25%  
Test for overall effect: Z=0.86(P=0.39)  
   
1.58.2 Haemorrhagic stroke - LCn3  
AREDS2 2014 3/2147 1/2056 2.34% 2.87[0.3,27.6]
DART 1989 2/1015 3/1018 3.75% 0.67[0.11,3.99]
GISSI-HF 2008 13/3494 10/3481 17.68% 1.3[0.57,2.95]
JELIS 2007 49/9326 39/9319 68.04% 1.26[0.83,1.91]
MAPT 2017 1/820 2/832 2.08% 0.51[0.05,5.58]
NAT2 2013 0/150 1/150 1.18% 0.33[0.01,8.12]
ORL 2013 1/171 0/165 1.17% 2.9[0.12,70.57]
SU.FOL.OM3 2010 2/1253 3/1248 3.75% 0.66[0.11,3.97]
Subtotal (95% CI) 18376 18269 100% 1.2[0.85,1.69]
Total events: 71 (Higher omega 3), 59 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.89, df=7(P=0.9); I2=0%  
Test for overall effect: Z=1.02(P=0.31)  
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.58.3 Transient ischaemic attack (TIA)  
AFFORD 2013 0/153 2/163 4.32% 0.21[0.01,4.4]
AREDS2 2014 15/2147 17/2056 82.81% 0.84[0.42,1.69]
EPE-A 2014 2/168 0/75 4.33% 2.25[0.11,46.27]
SCIMO 1999 0/112 3/111 4.55% 0.14[0.01,2.71]
Özaydin 2011 0/23 1/24 3.99% 0.35[0.01,8.11]
Subtotal (95% CI) 2603 2429 100% 0.74[0.39,1.39]
Total events: 17 (Higher omega 3), 23 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.77, df=4(P=0.6); I2=0%  
Test for overall effect: Z=0.94(P=0.35)  
Test for subgroup differences: Chi2=1.74, df=1 (P=0.42), I2=0%  
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Analysis 1.59.   Comparison 1 High vs low LCn3 omega-3 fats
(primary outcomes), Outcome 59 Stroke - LCn3 - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.59.1 LCn3 ≤ 150 mg/d  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.59.2 LCn3 > 150 ≤ 250 mg/d  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.59.3 LCn3 > 250 ≤ 400 mg/d  
DART 1989 4/1015 9/1018 100% 0.45[0.14,1.44]
Subtotal (95% CI) 1015 1018 100% 0.45[0.14,1.44]
Total events: 4 (Higher omega 3), 9 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.35(P=0.18)  
   
1.59.4 LCn3 > 400 ≤ 2400 mg/d  
AFFORD 2013 1/153 0/163 0.08% 3.19[0.13,77.83]
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.15% 1.11[0.47,2.62]
AREDS2 2014 48/2147 41/2056 4.92% 1.12[0.74,1.69]
DART2 2003 16/1571 14/1543 1.64% 1.12[0.55,2.29]
Derosa 2016 0/128 1/130 0.08% 0.34[0.01,8.23]
DO IT 2010 0/282 2/281 0.09% 0.2[0.01,4.13]
Doi 2014 0/119 4/119 0.1% 0.11[0.01,2.04]
EPOCH 2014 2/195 0/196 0.09% 5.03[0.24,104.01]
FORWARD 2013 3/289 3/297 0.33% 1.03[0.21,5.05]
GISSI-HF 2008 122/3494 103/3481 12.56% 1.18[0.91,1.53]
GISSI-P 1999 92/5665 77/5658 9.26% 1.19[0.88,1.61]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
JELIS 2007 166/9326 162/9319 18.17% 1.02[0.83,1.27]
MAPT 2017 1/820 4/832 0.17% 0.25[0.03,2.26]
NAT2 2013 0/150 1/150 0.08% 0.33[0.01,8.12]
Nodari 2011 HF 0/67 1/66 0.08% 0.33[0.01,7.92]
OMEGA 2009 27/1919 13/1885 1.93% 2.04[1.06,3.94]
OPAL 2010 7/376 8/372 0.83% 0.87[0.32,2.36]
ORIGIN 2012 314/6281 336/6255 37.27% 0.93[0.8,1.08]
ORL 2013 2/171 0/165 0.09% 4.83[0.23,99.76]
Risk & Prevention 2013 80/6239 60/6266 7.55% 1.34[0.96,1.87]
SCIMO 1999 1/112 0/111 0.08% 2.97[0.12,72.21]
SU.FOL.OM3 2010 29/1253 28/1248 3.17% 1.03[0.62,1.72]
THIS DIET 2008 3/51 1/50 0.17% 2.94[0.32,27.33]
Özaydin 2011 1/23 0/24 0.08% 3.13[0.13,73.01]
Subtotal (95% CI) 43235 43100 100% 1.06[0.97,1.16]
Total events: 926 (Higher omega 3), 869 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=20.95, df=23(P=0.58); I2=0%  
Test for overall effect: Z=1.24(P=0.21)  
   
1.59.5 LCn3 > 2.4 ≤ 4.4 g/d  
SHOT 1996 3/317 4/293 100% 0.69[0.16,3.07]
Subtotal (95% CI) 317 293 100% 0.69[0.16,3.07]
Total events: 3 (Higher omega 3), 4 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.48(P=0.63)  
   
1.59.6 LCn3 > 4.4 g/d  
HARP 1995 1/41 0/39 44.99% 2.86[0.12,68.1]
OFAMI 2001 6/150 0/150 55.01% 13[0.74,228.73]
Subtotal (95% CI) 191 189 100% 6.58[0.78,55.16]
Total events: 7 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.51, df=1(P=0.48); I2=0%  
Test for overall effect: Z=1.74(P=0.08)  
Test for subgroup differences: Chi2=5.22, df=1 (P=0.16), I2=42.57%  
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Analysis 1.60.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 60 Stroke - LCn3 - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.60.1 N-3 replacing SFA  
DART 1989 4/1015 9/1018 78.68% 0.45[0.14,1.44]
Derosa 2016 0/128 1/130 10.66% 0.34[0.01,8.23]
SCIMO 1999 1/112 0/111 10.67% 2.97[0.12,72.21]
Subtotal (95% CI) 1255 1259 100% 0.53[0.19,1.5]
Total events: 5 (Higher omega 3), 10 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.29, df=2(P=0.53); I2=0%  
Test for overall effect: Z=1.19(P=0.23)  
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.60.2 N-3 replacing MUFA  
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 3.61% 1.11[0.47,2.62]
DART 1989 4/1015 9/1018 1.97% 0.45[0.14,1.44]
EPOCH 2014 2/195 0/196 0.3% 5.03[0.24,104.01]
FORWARD 2013 3/289 3/297 1.09% 1.03[0.21,5.05]
GISSI-HF 2008 122/3494 103/3481 24.7% 1.18[0.91,1.53]
HARP 1995 1/41 0/39 0.28% 2.86[0.12,68.1]
NAT2 2013 0/150 1/150 0.27% 0.33[0.01,8.12]
Nodari 2011 HF 0/67 1/66 0.28% 0.33[0.01,7.92]
OMEGA 2009 27/1919 13/1885 5.84% 2.04[1.06,3.94]
OPAL 2010 7/376 8/372 2.66% 0.87[0.32,2.36]
ORIGIN 2012 314/6281 336/6255 40.39% 0.93[0.8,1.08]
Risk & Prevention 2013 80/6239 60/6266 17.78% 1.34[0.96,1.87]
SCIMO 1999 1/112 0/111 0.27% 2.97[0.12,72.21]
THIS DIET 2008 3/51 1/50 0.56% 2.94[0.32,27.33]
Subtotal (95% CI) 22633 22619 100% 1.11[0.94,1.31]
Total events: 575 (Higher omega 3), 545 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=15.09, df=13(P=0.3); I2=13.86%  
Test for overall effect: Z=1.18(P=0.24)  
   
1.60.3 N-3 replacing n-6  
AFFORD 2013 1/153 0/163 31.55% 3.19[0.13,77.83]
DO IT 2010 0/282 2/281 33.29% 0.2[0.01,4.13]
OFAMI 2001 6/150 0/150 35.16% 13[0.74,228.73]
Subtotal (95% CI) 585 594 100% 2.08[0.18,24.31]
Total events: 7 (Higher omega 3), 2 (Lower omega 3)  
Heterogeneity: Tau2=2.34; Chi2=3.96, df=2(P=0.14); I2=49.48%  
Test for overall effect: Z=0.58(P=0.56)  
   
1.60.4 N-3 replacing carbohydrates/sugars  
Derosa 2016 0/128 1/130 100% 0.34[0.01,8.23]
Subtotal (95% CI) 128 130 100% 0.34[0.01,8.23]
Total events: 0 (Higher omega 3), 1 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.67(P=0.51)  
   
1.60.5 N-3 replacing nil/low n-3 placebo  
AREDS2 2014 48/2147 41/2056 13.53% 1.12[0.74,1.69]
Doi 2014 0/119 4/119 0.27% 0.11[0.01,2.04]
GISSI-P 1999 92/5665 77/5658 25.48% 1.19[0.88,1.61]
JELIS 2007 166/9326 162/9319 49.98% 1.02[0.83,1.27]
MAPT 2017 1/820 4/832 0.48% 0.25[0.03,2.26]
ORL 2013 2/171 0/165 0.25% 4.83[0.23,99.76]
SHOT 1996 3/317 4/293 1.04% 0.69[0.16,3.07]
SU.FOL.OM3 2010 29/1253 28/1248 8.73% 1.03[0.62,1.72]
Özaydin 2011 1/23 0/24 0.23% 3.13[0.13,73.01]
Subtotal (95% CI) 19841 19714 100% 1.07[0.92,1.24]
Total events: 342 (Higher omega 3), 320 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=6.45, df=8(P=0.6); I2=0%  
Test for overall effect: Z=0.84(P=0.4)  
   
1.60.6 Replacement unclear  
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
DART2 2003 16/1571 14/1543 100% 1.12[0.55,2.29]
Subtotal (95% CI) 1571 1543 100% 1.12[0.55,2.29]
Total events: 16 (Higher omega 3), 14 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.32(P=0.75)  
Test for subgroup differences: Chi2=2.68, df=1 (P=0.75), I2=0%  
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Analysis 1.61.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 61 Stroke - LCn3 - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.61.1 Dietary advice  
DART 1989 4/1015 9/1018 0.6% 0.45[0.14,1.44]
DART2 2003 16/1571 14/1543 1.62% 1.12[0.55,2.29]
THIS DIET 2008 3/51 1/50 0.17% 2.94[0.32,27.33]
Subtotal (95% CI) 2637 2611 2.39% 0.93[0.42,2.05]
Total events: 23 (Higher omega 3), 24 (Lower omega 3)  
Heterogeneity: Tau2=0.15; Chi2=2.79, df=2(P=0.25); I2=28.36%  
Test for overall effect: Z=0.17(P=0.86)  
   
1.61.2 Supplemental foods  
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.13% 1.11[0.47,2.62]
Subtotal (95% CI) 2404 2433 1.13% 1.11[0.47,2.62]
Total events: 11 (Higher omega 3), 10 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.25(P=0.81)  
   
1.61.3 Supplements (capsule)  
AFFORD 2013 1/153 0/163 0.08% 3.19[0.13,77.83]
AREDS2 2014 48/2147 41/2056 4.86% 1.12[0.74,1.69]
Derosa 2016 0/128 1/130 0.08% 0.34[0.01,8.23]
DO IT 2010 0/282 2/281 0.09% 0.2[0.01,4.13]
Doi 2014 0/119 4/119 0.1% 0.11[0.01,2.04]
EPOCH 2014 2/195 0/196 0.09% 5.03[0.24,104.01]
FORWARD 2013 3/289 3/297 0.33% 1.03[0.21,5.05]
GISSI-HF 2008 122/3494 103/3481 12.42% 1.18[0.91,1.53]
GISSI-P 1999 92/5665 77/5658 9.16% 1.19[0.88,1.61]
HARP 1995 1/41 0/39 0.08% 2.86[0.12,68.1]
JELIS 2007 166/9326 162/9319 17.96% 1.02[0.83,1.27]
MAPT 2017 1/820 4/832 0.17% 0.25[0.03,2.26]
NAT2 2013 0/150 1/150 0.08% 0.33[0.01,8.12]
Nodari 2011 HF 0/67 1/66 0.08% 0.33[0.01,7.92]
OFAMI 2001 6/150 0/150 0.1% 13[0.74,228.73]
OMEGA 2009 27/1919 13/1885 1.91% 2.04[1.06,3.94]
OPAL 2010 7/376 8/372 0.82% 0.87[0.32,2.36]
ORIGIN 2012 314/6281 336/6255 36.84% 0.93[0.8,1.08]
ORL 2013 2/171 0/165 0.09% 4.83[0.23,99.76]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Risk & Prevention 2013 80/6239 60/6266 7.46% 1.34[0.96,1.87]
SCIMO 1999 1/112 0/111 0.08% 2.97[0.12,72.21]
SHOT 1996 3/317 4/293 0.37% 0.69[0.16,3.07]
SU.FOL.OM3 2010 29/1253 28/1248 3.14% 1.03[0.62,1.72]
Özaydin 2011 1/23 0/24 0.08% 3.13[0.13,73.01]
Subtotal (95% CI) 39717 39556 96.48% 1.07[0.97,1.18]
Total events: 906 (Higher omega 3), 848 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=23.74, df=23(P=0.42); I2=3.11%  
Test for overall effect: Z=1.32(P=0.19)  
   
1.61.4 Any combination  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 44758 44600 100% 1.06[0.96,1.16]
Total events: 940 (Higher omega 3), 882 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=26.66, df=27(P=0.48); I2=0%  
Test for overall effect: Z=1.17(P=0.24)  
Test for subgroup differences: Chi2=0.12, df=1 (P=0.94), I2=0%  
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Analysis 1.62.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 62 Stroke - LCn3 - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.62.1 Medium duration 1 to < 2 years in study  
AFFORD 2013 1/153 0/163 0.08% 3.19[0.13,77.83]
Derosa 2016 0/128 1/130 0.08% 0.34[0.01,8.23]
Doi 2014 0/119 4/119 0.1% 0.11[0.01,2.04]
EPOCH 2014 2/195 0/196 0.09% 5.03[0.24,104.01]
FORWARD 2013 3/289 3/297 0.33% 1.03[0.21,5.05]
Nodari 2011 HF 0/67 1/66 0.08% 0.33[0.01,7.92]
OMEGA 2009 27/1919 13/1885 1.91% 2.04[1.06,3.94]
OPAL 2010 7/376 8/372 0.82% 0.87[0.32,2.36]
ORL 2013 2/171 0/165 0.09% 4.83[0.23,99.76]
SHOT 1996 3/317 4/293 0.37% 0.69[0.16,3.07]
Özaydin 2011 1/23 0/24 0.08% 3.13[0.13,73.01]
Subtotal (95% CI) 3757 3710 4.03% 1.35[0.86,2.12]
Total events: 46 (Higher omega 3), 34 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=9.43, df=10(P=0.49); I2=0%  
Test for overall effect: Z=1.28(P=0.2)  
   
1.62.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.13% 1.11[0.47,2.62]
DART 1989 4/1015 9/1018 0.6% 0.45[0.14,1.44]
DO IT 2010 0/282 2/281 0.09% 0.2[0.01,4.13]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
GISSI-HF 2008 122/3494 103/3481 12.42% 1.18[0.91,1.53]
GISSI-P 1999 92/5665 77/5658 9.16% 1.19[0.88,1.61]
HARP 1995 1/41 0/39 0.08% 2.86[0.12,68.1]
MAPT 2017 1/820 4/832 0.17% 0.25[0.03,2.26]
NAT2 2013 0/150 1/150 0.08% 0.33[0.01,8.12]
OFAMI 2001 6/150 0/150 0.1% 13[0.74,228.73]
SCIMO 1999 1/112 0/111 0.08% 2.97[0.12,72.21]
THIS DIET 2008 3/51 1/50 0.17% 2.94[0.32,27.33]
Subtotal (95% CI) 14184 14203 24.08% 1.15[0.93,1.41]
Total events: 241 (Higher omega 3), 207 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=10.38, df=10(P=0.41); I2=3.7%  
Test for overall effect: Z=1.29(P=0.2)  
   
1.62.3 Long duration: ≥ 4 years in study  
AREDS2 2014 48/2147 41/2056 4.86% 1.12[0.74,1.69]
DART2 2003 16/1571 14/1543 1.62% 1.12[0.55,2.29]
JELIS 2007 166/9326 162/9319 17.96% 1.02[0.83,1.27]
ORIGIN 2012 314/6281 336/6255 36.84% 0.93[0.8,1.08]
Risk & Prevention 2013 80/6239 60/6266 7.46% 1.34[0.96,1.87]
SU.FOL.OM3 2010 29/1253 28/1248 3.14% 1.03[0.62,1.72]
Subtotal (95% CI) 26817 26687 71.89% 1.01[0.91,1.13]
Total events: 653 (Higher omega 3), 641 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=4.26, df=5(P=0.51); I2=0%  
Test for overall effect: Z=0.2(P=0.84)  
   
Total (95% CI) 44758 44600 100% 1.06[0.96,1.16]
Total events: 940 (Higher omega 3), 882 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=26.66, df=27(P=0.48); I2=0%  
Test for overall effect: Z=1.17(P=0.24)  
Test for subgroup differences: Chi2=2.32, df=1 (P=0.31), I2=13.73%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 1.63.   Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes),
Outcome 63 Stroke - LCn3 - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.63.1 Primary prevention of CVD  
AREDS2 2014 48/2147 41/2056 4.86% 1.12[0.74,1.69]
Derosa 2016 0/128 1/130 0.08% 0.34[0.01,8.23]
DO IT 2010 0/282 2/281 0.09% 0.2[0.01,4.13]
EPOCH 2014 2/195 0/196 0.09% 5.03[0.24,104.01]
JELIS 2007 166/9326 162/9319 17.96% 1.02[0.83,1.27]
MAPT 2017 1/820 4/832 0.17% 0.25[0.03,2.26]
OPAL 2010 7/376 8/372 0.82% 0.87[0.32,2.36]
ORIGIN 2012 314/6281 336/6255 36.84% 0.93[0.8,1.08]
ORL 2013 2/171 0/165 0.09% 4.83[0.23,99.76]
Subtotal (95% CI) 19726 19606 61.01% 0.97[0.86,1.09]
Total events: 540 (Higher omega 3), 554 (Lower omega 3)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=6.18, df=8(P=0.63); I2=0%  
Test for overall effect: Z=0.54(P=0.59)  
   
1.63.2 Secondary prevention of CVD  
AFFORD 2013 1/153 0/163 0.08% 3.19[0.13,77.83]
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.13% 1.11[0.47,2.62]
DART 1989 4/1015 9/1018 0.6% 0.45[0.14,1.44]
DART2 2003 16/1571 14/1543 1.62% 1.12[0.55,2.29]
Doi 2014 0/119 4/119 0.1% 0.11[0.01,2.04]
FORWARD 2013 3/289 3/297 0.33% 1.03[0.21,5.05]
GISSI-HF 2008 122/3494 103/3481 12.42% 1.18[0.91,1.53]
GISSI-P 1999 92/5665 77/5658 9.16% 1.19[0.88,1.61]
HARP 1995 1/41 0/39 0.08% 2.86[0.12,68.1]
NAT2 2013 0/150 1/150 0.08% 0.33[0.01,8.12]
Nodari 2011 HF 0/67 1/66 0.08% 0.33[0.01,7.92]
OFAMI 2001 6/150 0/150 0.1% 13[0.74,228.73]
OMEGA 2009 27/1919 13/1885 1.91% 2.04[1.06,3.94]
Risk & Prevention 2013 80/6239 60/6266 7.46% 1.34[0.96,1.87]
SCIMO 1999 1/112 0/111 0.08% 2.97[0.12,72.21]
SHOT 1996 3/317 4/293 0.37% 0.69[0.16,3.07]
SU.FOL.OM3 2010 29/1253 28/1248 3.14% 1.03[0.62,1.72]
THIS DIET 2008 3/51 1/50 0.17% 2.94[0.32,27.33]
Özaydin 2011 1/23 0/24 0.08% 3.13[0.13,73.01]
Subtotal (95% CI) 25032 24994 38.99% 1.21[1.05,1.4]
Total events: 400 (Higher omega 3), 328 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=15.02, df=18(P=0.66); I2=0%  
Test for overall effect: Z=2.56(P=0.01)  
   
Total (95% CI) 44758 44600 100% 1.06[0.96,1.16]
Total events: 940 (Higher omega 3), 882 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=26.66, df=27(P=0.48); I2=0%  
Test for overall effect: Z=1.17(P=0.24)  
Test for subgroup differences: Chi2=5.47, df=1 (P=0.02), I2=81.71%  
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Analysis 1.64.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 64 Stroke - LCn3 - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.64.1 LCn3 - ≥ 50% of control group on statins  
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 1.13% 1.11[0.47,2.62]
Doi 2014 0/119 4/119 0.1% 0.11[0.01,2.04]
JELIS 2007 166/9326 162/9319 17.96% 1.02[0.83,1.27]
NAT2 2013 0/150 1/150 0.08% 0.33[0.01,8.12]
OMEGA 2009 27/1919 13/1885 1.91% 2.04[1.06,3.94]
ORIGIN 2012 314/6281 336/6255 36.84% 0.93[0.8,1.08]
SU.FOL.OM3 2010 29/1253 28/1248 3.14% 1.03[0.62,1.72]
THIS DIET 2008 3/51 1/50 0.17% 2.94[0.32,27.33]
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 21503 21459 61.33% 1.03[0.86,1.23]
Total events: 550 (Higher omega 3), 555 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=9.01, df=7(P=0.25); I2=22.28%  
Test for overall effect: Z=0.28(P=0.78)  
   
1.64.2 LCn3 - < 50% of control group on statins  
AFFORD 2013 1/153 0/163 0.08% 3.19[0.13,77.83]
AREDS2 2014 48/2147 41/2056 4.86% 1.12[0.74,1.69]
DART 1989 4/1015 9/1018 0.6% 0.45[0.14,1.44]
DART2 2003 16/1571 14/1543 1.62% 1.12[0.55,2.29]
DO IT 2010 0/282 2/281 0.09% 0.2[0.01,4.13]
FORWARD 2013 3/289 3/297 0.33% 1.03[0.21,5.05]
GISSI-HF 2008 122/3494 103/3481 12.42% 1.18[0.91,1.53]
GISSI-P 1999 92/5665 77/5658 9.16% 1.19[0.88,1.61]
HARP 1995 1/41 0/39 0.08% 2.86[0.12,68.1]
MAPT 2017 1/820 4/832 0.17% 0.25[0.03,2.26]
Nodari 2011 HF 0/67 1/66 0.08% 0.33[0.01,7.92]
OFAMI 2001 6/150 0/150 0.1% 13[0.74,228.73]
ORL 2013 2/171 0/165 0.09% 4.83[0.23,99.76]
Risk & Prevention 2013 80/6239 60/6266 7.46% 1.34[0.96,1.87]
SCIMO 1999 1/112 0/111 0.08% 2.97[0.12,72.21]
SHOT 1996 3/317 4/293 0.37% 0.69[0.16,3.07]
Özaydin 2011 1/23 0/24 0.08% 3.13[0.13,73.01]
Subtotal (95% CI) 22556 22443 37.68% 1.18[1.02,1.37]
Total events: 381 (Higher omega 3), 318 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=12.52, df=16(P=0.71); I2=0%  
Test for overall effect: Z=2.2(P=0.03)  
   
1.64.3 LCn3 - use of statins unclear  
Derosa 2016 0/128 1/130 0.08% 0.34[0.01,8.23]
EPOCH 2014 2/195 0/196 0.09% 5.03[0.24,104.01]
OPAL 2010 7/376 8/372 0.82% 0.87[0.32,2.36]
Subtotal (95% CI) 699 698 0.99% 0.94[0.38,2.34]
Total events: 9 (Higher omega 3), 9 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.61, df=2(P=0.45); I2=0%  
Test for overall effect: Z=0.13(P=0.9)  
   
Total (95% CI) 44758 44600 100% 1.06[0.96,1.16]
Total events: 940 (Higher omega 3), 882 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=26.66, df=27(P=0.48); I2=0%  
Test for overall effect: Z=1.17(P=0.24)  
Test for subgroup differences: Chi2=1.55, df=1 (P=0.46), I2=0%  
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Analysis 1.65.   Comparison 1 High vs low LCn3 omega-3 fats
(primary outcomes), Outcome 65 Arrythmia (overall) - LCn3.
Study or subgroup Favours high-
er omega 3
Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AFFORD 2013 98/153 103/163 7.52% 1.01[0.86,1.2]
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 3.81% 0.92[0.66,1.27]
Derosa 2016 1/128 3/130 0.12% 0.34[0.04,3.21]
DISAF 2003 154/201 157/206 9.41% 1.01[0.9,1.12]
EPIC-1 2008 1/188 0/186 0.06% 2.97[0.12,72.4]
EPOCH 2014 2/195 1/196 0.1% 2.01[0.18,21.99]
Erdogan 2007 41/54 46/54 6.91% 0.89[0.74,1.07]
FAAT 2005 60/200 79/202 4.76% 0.77[0.58,1.01]
FORWARD 2013 68/289 56/297 3.99% 1.25[0.91,1.71]
FOSTAR 2016 4/101 4/101 0.32% 1[0.26,3.89]
GISSI-HF 2008 76/278 98/284 5.25% 0.79[0.62,1.02]
GISSI-HF 2008 444/2921 408/2914 8.89% 1.09[0.96,1.23]
GISSI-P 1999 40/2836 46/2828 2.63% 0.87[0.57,1.32]
Kumar 2012 61/91 78/87 7.71% 0.75[0.64,0.88]
Nodari 2011 AF 37/100 56/99 4.09% 0.65[0.48,0.89]
Nodari 2011 HF 1/67 4/66 0.13% 0.25[0.03,2.15]
OFAMI 2001 8/150 15/150 0.82% 0.53[0.23,1.22]
OMEGA 2009 99/1919 84/1885 4.54% 1.16[0.87,1.54]
ORIGIN 2012 288/6281 259/6255 7.6% 1.11[0.94,1.3]
ORL 2013 0/171 1/165 0.06% 0.32[0.01,7.84]
Proudman 2015 1/87 0/53 0.06% 1.84[0.08,44.38]
Raitt 2005 65/100 59/100 6.05% 1.1[0.89,1.37]
Risk & Prevention 2013 113/6239 92/6266 4.75% 1.23[0.94,1.62]
Sianni 2013 147/268 29/60 4.55% 1.13[0.85,1.51]
SOFA 2006 36/273 34/273 2.47% 1.06[0.68,1.64]
SU.FOL.OM3 2010 33/1253 32/1248 2.13% 1.03[0.64,1.66]
THIS DIET 2008 2/51 5/50 0.23% 0.39[0.08,1.93]
Özaydin 2011 9/23 9/24 1.04% 1.04[0.51,2.16]
   
Total (95% CI) 27021 26775 100% 0.97[0.9,1.05]
Total events: 1956 (Favours higher omega 3), 1832 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=47.34, df=27(P=0.01); I2=42.97%  
Test for overall effect: Z=0.83(P=0.41)  
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Analysis 1.66.   Comparison 1 High vs low LCn3 omega-3 fats
(primary outcomes), Outcome 66 Arrhythmia- LCn3 - SA fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
AFFORD 2013 98/153 103/163 5.4% 1.01[0.86,1.2]
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 3.98% 0.92[0.66,1.27]
Derosa 2016 1/128 3/130 0.16% 0.34[0.04,3.21]
DISAF 2003 154/201 157/206 8.4% 1.01[0.9,1.12]
EPIC-1 2008 1/188 0/186 0.03% 2.97[0.12,72.4]
EPOCH 2014 2/195 1/196 0.05% 2.01[0.18,21.99]
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Erdogan 2007 41/54 46/54 2.49% 0.89[0.74,1.07]
FAAT 2005 57/200 78/202 4.2% 0.74[0.56,0.98]
FORWARD 2013 68/289 56/297 2.99% 1.25[0.91,1.71]
FOSTAR 2016 4/101 4/101 0.22% 1[0.26,3.89]
GISSI-HF 2008 76/278 98/284 5.25% 0.79[0.62,1.02]
GISSI-HF 2008 444/2921 408/2914 22.12% 1.09[0.96,1.23]
GISSI-P 1999 40/2836 46/2828 2.49% 0.87[0.57,1.32]
Kumar 2012 61/91 78/87 4.32% 0.75[0.64,0.88]
Nodari 2011 AF 37/100 56/99 3.05% 0.65[0.48,0.89]
Nodari 2011 HF 1/67 4/66 0.22% 0.25[0.03,2.15]
OFAMI 2001 8/150 15/150 0.81% 0.53[0.23,1.22]
OMEGA 2009 99/1919 84/1885 4.59% 1.16[0.87,1.54]
ORIGIN 2012 288/6281 259/6255 14.05% 1.11[0.94,1.3]
ORL 2013 0/171 1/165 0.08% 0.32[0.01,7.84]
Proudman 2015 1/87 0/53 0.03% 1.84[0.08,44.38]
Raitt 2005 65/100 59/100 3.19% 1.1[0.89,1.37]
Risk & Prevention 2013 113/6239 92/6266 4.97% 1.23[0.94,1.62]
Sianni 2013 147/268 29/60 2.57% 1.13[0.85,1.51]
SOFA 2006 36/273 34/273 1.84% 1.06[0.68,1.64]
SU.FOL.OM3 2010 33/1253 32/1248 1.74% 1.03[0.64,1.66]
THIS DIET 2008 2/51 5/50 0.27% 0.39[0.08,1.93]
Özaydin 2011 9/23 9/24 0.48% 1.04[0.51,2.16]
   
Total (95% CI) 27021 26775 100% 1.01[0.96,1.07]
Total events: 1953 (Higher omega 3), 1831 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=48.15, df=27(P=0.01); I2=43.92%  
Test for overall effect: Z=0.35(P=0.73)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 1.67.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 67 Arrhythmia- LCn3 - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.67.1 Low risk of bias  
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 3.81% 0.92[0.66,1.27]
Derosa 2016 1/128 3/130 0.12% 0.34[0.04,3.21]
EPOCH 2014 2/195 1/196 0.1% 2.01[0.18,21.99]
FORWARD 2013 68/289 56/297 3.99% 1.25[0.91,1.71]
FOSTAR 2016 4/101 4/101 0.32% 1[0.26,3.89]
OMEGA 2009 99/1919 84/1885 4.54% 1.16[0.87,1.54]
ORIGIN 2012 288/6281 259/6255 7.6% 1.11[0.94,1.3]
Proudman 2015 1/87 0/53 0.06% 1.84[0.08,44.38]
SOFA 2006 36/273 34/273 2.47% 1.06[0.68,1.64]
SU.FOL.OM3 2010 33/1253 32/1248 2.13% 1.03[0.64,1.66]
Subtotal (95% CI) 12930 12871 25.15% 1.1[0.98,1.23]
Total events: 599 (Higher omega 3), 547 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.49, df=9(P=0.94); I2=0%  
Test for overall effect: Z=1.63(P=0.1)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
1.67.2 Moderate/high risk of bias  
AFFORD 2013 98/153 103/163 7.52% 1.01[0.86,1.2]
DISAF 2003 154/201 157/206 9.41% 1.01[0.9,1.12]
EPIC-1 2008 1/188 0/186 0.06% 2.97[0.12,72.4]
Erdogan 2007 41/54 46/54 6.91% 0.89[0.74,1.07]
FAAT 2005 60/200 79/202 4.76% 0.77[0.58,1.01]
GISSI-HF 2008 444/2921 408/2914 8.89% 1.09[0.96,1.23]
GISSI-HF 2008 76/278 98/284 5.25% 0.79[0.62,1.02]
GISSI-P 1999 40/2836 46/2828 2.63% 0.87[0.57,1.32]
Kumar 2012 61/91 78/87 7.71% 0.75[0.64,0.88]
Nodari 2011 AF 37/100 56/99 4.09% 0.65[0.48,0.89]
Nodari 2011 HF 1/67 4/66 0.13% 0.25[0.03,2.15]
OFAMI 2001 8/150 15/150 0.82% 0.53[0.23,1.22]
ORL 2013 0/171 1/165 0.06% 0.32[0.01,7.84]
Raitt 2005 65/100 59/100 6.05% 1.1[0.89,1.37]
Risk & Prevention 2013 113/6239 92/6266 4.75% 1.23[0.94,1.62]
Sianni 2013 147/268 29/60 4.55% 1.13[0.85,1.51]
THIS DIET 2008 2/51 5/50 0.23% 0.39[0.08,1.93]
Özaydin 2011 9/23 9/24 1.04% 1.04[0.51,2.16]
Subtotal (95% CI) 14091 13904 74.85% 0.93[0.84,1.02]
Total events: 1357 (Higher omega 3), 1285 (Lower omega 3)  
Heterogeneity: Tau2=0.02; Chi2=38.14, df=17(P=0); I2=55.43%  
Test for overall effect: Z=1.54(P=0.12)  
   
Total (95% CI) 27021 26775 100% 0.97[0.9,1.05]
Total events: 1956 (Higher omega 3), 1832 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=47.34, df=27(P=0.01); I2=42.97%  
Test for overall effect: Z=0.83(P=0.41)  
Test for subgroup differences: Chi2=4.99, df=1 (P=0.03), I2=79.97%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 1.68.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 68 Arrhythmia- LCn3 - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.68.1 SA - low risk of compliance bias  
AFFORD 2013 98/153 103/163 18.21% 1.01[0.86,1.2]
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 8.81% 0.92[0.66,1.27]
DISAF 2003 154/201 157/206 23.35% 1.01[0.9,1.12]
FOSTAR 2016 4/101 4/101 0.71% 1[0.26,3.89]
Kumar 2012 61/91 78/87 18.71% 0.75[0.64,0.88]
Nodari 2011 HF 1/67 4/66 0.28% 0.25[0.03,2.15]
OMEGA 2009 99/1919 84/1885 10.6% 1.16[0.87,1.54]
ORL 2013 0/171 1/165 0.13% 0.32[0.01,7.84]
Raitt 2005 65/100 59/100 14.37% 1.1[0.89,1.37]
SU.FOL.OM3 2010 33/1253 32/1248 4.84% 1.03[0.64,1.66]
Subtotal (95% CI) 6460 6454 100% 0.97[0.86,1.09]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 582 (Higher omega 3), 596 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=16.13, df=9(P=0.06); I2=44.19%  
Test for overall effect: Z=0.56(P=0.57)  
   
1.68.2 SA - 100+ randomised  
AFFORD 2013 98/153 103/163 7.55% 1.01[0.86,1.2]
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 3.89% 0.92[0.66,1.27]
Derosa 2016 1/128 3/130 0.12% 0.34[0.04,3.21]
DISAF 2003 154/201 157/206 9.37% 1.01[0.9,1.12]
EPIC-1 2008 1/188 0/186 0.06% 2.97[0.12,72.4]
EPOCH 2014 2/195 1/196 0.11% 2.01[0.18,21.99]
Erdogan 2007 41/54 46/54 6.95% 0.89[0.74,1.07]
FAAT 2005 60/200 79/202 4.84% 0.77[0.58,1.01]
FORWARD 2013 68/289 56/297 4.07% 1.25[0.91,1.71]
FOSTAR 2016 4/101 4/101 0.33% 1[0.26,3.89]
GISSI-HF 2008 76/278 98/284 5.33% 0.79[0.62,1.02]
GISSI-HF 2008 444/2921 408/2914 8.87% 1.09[0.96,1.23]
GISSI-P 1999 40/2836 46/2828 2.7% 0.87[0.57,1.32]
Kumar 2012 61/91 78/87 7.73% 0.75[0.64,0.88]
Nodari 2011 AF 37/100 56/99 4.17% 0.65[0.48,0.89]
Nodari 2011 HF 1/67 4/66 0.13% 0.25[0.03,2.15]
OFAMI 2001 8/150 15/150 0.85% 0.53[0.23,1.22]
OMEGA 2009 99/1919 84/1885 4.62% 1.16[0.87,1.54]
ORIGIN 2012 288/6281 259/6255 7.63% 1.11[0.94,1.3]
ORL 2013 0/171 1/165 0.06% 0.32[0.01,7.84]
Proudman 2015 1/87 0/53 0.06% 1.84[0.08,44.38]
Raitt 2005 65/100 59/100 6.11% 1.1[0.89,1.37]
Risk & Prevention 2013 113/6239 92/6266 4.83% 1.23[0.94,1.62]
Sianni 2013 147/268 29/60 4.63% 1.13[0.85,1.51]
SOFA 2006 36/273 34/273 2.54% 1.06[0.68,1.64]
SU.FOL.OM3 2010 33/1253 32/1248 2.2% 1.03[0.64,1.66]
THIS DIET 2008 2/51 5/50 0.24% 0.39[0.08,1.93]
Subtotal (95% CI) 26998 26751 100% 0.97[0.89,1.05]
Total events: 1947 (Higher omega 3), 1823 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=47.32, df=26(P=0.01); I2=45.05%  
Test for overall effect: Z=0.84(P=0.4)  
Test for subgroup differences: Chi2=0, df=1 (P=0.99), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 1.69.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 69 Arrhythmia - LCn3 - subgroup by new or recurrent.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.69.1 New arrhythmia  
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 6.26% 0.92[0.66,1.27]
Derosa 2016 1/128 3/130 0.13% 0.34[0.04,3.21]
Derosa 2016 1/128 3/130 0.13% 0.34[0.04,3.21]
EPIC-1 2008 1/188 0/186 0.07% 2.97[0.12,72.4]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
EPOCH 2014 2/195 1/196 0.12% 2.01[0.18,21.99]
FOSTAR 2016 4/101 4/101 0.36% 1[0.26,3.89]
GISSI-HF 2008 444/2921 408/2914 43.01% 1.09[0.96,1.23]
GISSI-P 1999 40/2836 46/2828 3.75% 0.87[0.57,1.32]
Nodari 2011 HF 1/67 4/66 0.14% 0.25[0.03,2.15]
OFAMI 2001 8/150 15/150 0.97% 0.53[0.23,1.22]
OMEGA 2009 99/1919 84/1885 8.25% 1.16[0.87,1.54]
ORIGIN 2012 288/6281 259/6255 24.64% 1.11[0.94,1.3]
ORL 2013 0/171 1/165 0.07% 0.32[0.01,7.84]
Proudman 2015 1/87 0/53 0.07% 1.84[0.08,44.38]
Risk & Prevention 2013 113/6239 92/6266 8.91% 1.23[0.94,1.62]
SU.FOL.OM3 2010 33/1253 32/1248 2.88% 1.03[0.64,1.66]
THIS DIET 2008 2/51 5/50 0.26% 0.39[0.08,1.93]
Subtotal (95% CI) 25119 25056 100% 1.07[0.99,1.16]
Total events: 1105 (Higher omega 3), 1031 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=12.77, df=16(P=0.69); I2=0%  
Test for overall effect: Z=1.66(P=0.1)  
   
1.69.2 Recurrent arrhythmia  
AFFORD 2013 98/153 103/163 11.06% 1.01[0.86,1.2]
DISAF 2003 154/201 157/206 13.38% 1.01[0.9,1.12]
Erdogan 2007 41/54 46/54 10.28% 0.89[0.74,1.07]
FAAT 2005 57/200 78/202 7.18% 0.74[0.56,0.98]
FORWARD 2013 68/289 56/297 6.28% 1.25[0.91,1.71]
GISSI-HF 2008 76/278 98/284 8.07% 0.79[0.62,1.02]
Kumar 2012 61/91 78/87 11.3% 0.75[0.64,0.88]
Nodari 2011 AF 37/100 56/99 6.43% 0.65[0.48,0.89]
Raitt 2005 65/100 59/100 9.15% 1.1[0.89,1.37]
Sianni 2013 147/268 29/60 7.09% 1.13[0.85,1.51]
SOFA 2006 36/273 34/273 4.02% 1.06[0.68,1.64]
SOFA 2006 36/273 34/273 4.02% 1.06[0.68,1.64]
Özaydin 2011 9/23 9/24 1.75% 1.04[0.51,2.16]
Subtotal (95% CI) 2303 2122 100% 0.93[0.84,1.03]
Total events: 885 (Higher omega 3), 837 (Lower omega 3)  
Heterogeneity: Tau2=0.02; Chi2=27.83, df=12(P=0.01); I2=56.88%  
Test for overall effect: Z=1.41(P=0.16)  
Test for subgroup differences: Chi2=4.58, df=1 (P=0.03), I2=78.17%  
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Analysis 1.70.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 70 Arrhythmia - LCn3 - subgroup by fatality.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.70.1 Fatal arrhythmias - LCn3  
FAAT 2005 3/200 1/202 0.53% 3.03[0.32,28.88]
ORIGIN 2012 288/6281 259/6255 99.47% 1.11[0.94,1.3]
Subtotal (95% CI) 6481 6457 100% 1.11[0.95,1.31]
Total events: 291 (Higher omega 3), 260 (Lower omega 3)  
Favours higher omega 3 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=0.76, df=1(P=0.38); I2=0%  
Test for overall effect: Z=1.28(P=0.2)  
   
1.70.2 Non-fatal arrhythmias - LCn3  
EPIC-1 2008 1/188 0/186 0.68% 2.97[0.12,72.4]
EPOCH 2014 2/195 1/196 1.22% 2.01[0.18,21.99]
FAAT 2005 57/200 78/202 88.73% 0.74[0.56,0.98]
FOSTAR 2016 4/101 4/101 3.77% 1[0.26,3.89]
Nodari 2011 HF 1/67 4/66 1.48% 0.25[0.03,2.15]
ORL 2013 0/171 1/165 0.68% 0.32[0.01,7.84]
Proudman 2015 1/87 0/53 0.69% 1.84[0.08,44.38]
THIS DIET 2008 2/51 5/50 2.74% 0.39[0.08,1.93]
Subtotal (95% CI) 1060 1019 100% 0.74[0.57,0.96]
Total events: 68 (Higher omega 3), 93 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.77, df=7(P=0.81); I2=0%  
Test for overall effect: Z=2.26(P=0.02)  
   
1.70.3 Fatal and non-fatal arrhythmias combined - LCn3  
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 8.37% 0.92[0.66,1.27]
Derosa 2016 1/128 3/130 0.18% 0.34[0.04,3.21]
FOSTAR 2016 4/101 4/101 0.48% 1[0.26,3.89]
GISSI-HF 2008 444/2921 408/2914 57.52% 1.09[0.96,1.23]
GISSI-P 1999 40/2836 46/2828 5.02% 0.87[0.57,1.32]
OFAMI 2001 8/150 15/150 1.3% 0.53[0.23,1.22]
OMEGA 2009 99/1919 84/1885 11.03% 1.16[0.87,1.54]
Risk & Prevention 2013 113/6239 92/6266 11.91% 1.23[0.94,1.62]
SU.FOL.OM3 2010 33/1253 32/1248 3.85% 1.03[0.64,1.66]
THIS DIET 2008 2/51 5/50 0.35% 0.39[0.08,1.93]
Subtotal (95% CI) 18002 18005 100% 1.06[0.97,1.17]
Total events: 811 (Higher omega 3), 763 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=8.5, df=9(P=0.48); I2=0%  
Test for overall effect: Z=1.28(P=0.2)  
Test for subgroup differences: Chi2=7.37, df=1 (P=0.03), I2=72.86%  
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Analysis 1.71.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 71 Arrhythmia - LCn3 - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.71.1 LCn3 ≤ 150 mg/d  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.71.2 LCn3 > 150 ≤ 250 mg/d  
DISAF 2003 154/201 157/206 9.32% 1.01[0.9,1.12]
Subtotal (95% CI) 201 206 9.32% 1.01[0.9,1.12]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 154 (Higher omega 3), 157 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.1(P=0.92)  
   
1.71.3 LCn3 > 250 ≤ 400 mg/d  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.71.4 LCn3 > 400 ≤ 2400 mg/d  
AFFORD 2013 98/153 103/163 7.49% 1.01[0.86,1.2]
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 3.84% 0.92[0.66,1.27]
Derosa 2016 1/128 3/130 0.12% 0.34[0.04,3.21]
EPOCH 2014 2/195 1/196 0.11% 2.01[0.18,21.99]
FORWARD 2013 68/289 56/297 4.02% 1.25[0.91,1.71]
GISSI-HF 2008 76/278 98/284 5.28% 0.79[0.62,1.02]
GISSI-HF 2008 444/2921 408/2914 8.81% 1.09[0.96,1.23]
GISSI-P 1999 40/2836 46/2828 2.67% 0.87[0.57,1.32]
Kumar 2012 61/91 78/87 7.67% 0.75[0.64,0.88]
Nodari 2011 AF 37/100 56/99 4.12% 0.65[0.48,0.89]
Nodari 2011 HF 1/67 4/66 0.13% 0.25[0.03,2.15]
OMEGA 2009 99/1919 84/1885 4.57% 1.16[0.87,1.54]
ORIGIN 2012 288/6281 259/6255 7.57% 1.11[0.94,1.3]
ORL 2013 0/171 1/165 0.06% 0.32[0.01,7.84]
Raitt 2005 65/100 59/100 6.05% 1.1[0.89,1.37]
Risk & Prevention 2013 113/6239 92/6266 4.78% 1.23[0.94,1.62]
SOFA 2006 36/273 34/273 2.51% 1.06[0.68,1.64]
SU.FOL.OM3 2010 33/1253 32/1248 2.17% 1.03[0.64,1.66]
THIS DIET 2008 2/51 5/50 0.24% 0.39[0.08,1.93]
Özaydin 2011 9/23 9/24 1.06% 1.04[0.51,2.16]
Subtotal (95% CI) 25772 25763 73.28% 0.98[0.88,1.08]
Total events: 1540 (Higher omega 3), 1502 (Lower omega 3)  
Heterogeneity: Tau2=0.02; Chi2=39.22, df=19(P=0); I2=51.56%  
Test for overall effect: Z=0.42(P=0.67)  
   
1.71.5 LCn3 > 2.4 ≤ 4.4 g/d  
EPIC-1 2008 1/188 0/186 0.06% 2.97[0.12,72.4]
FAAT 2005 57/200 78/202 4.64% 0.74[0.56,0.98]
OFAMI 2001 8/150 15/150 0.83% 0.53[0.23,1.22]
Subtotal (95% CI) 538 538 5.54% 0.72[0.55,0.94]
Total events: 66 (Higher omega 3), 93 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.29, df=2(P=0.52); I2=0%  
Test for overall effect: Z=2.43(P=0.02)  
   
1.71.6 LCn3 > 4.4 g/d  
FOSTAR 2016 4/101 4/101 0.33% 1[0.26,3.89]
Proudman 2015 1/87 0/53 0.06% 1.84[0.08,44.38]
Subtotal (95% CI) 188 154 0.39% 1.1[0.32,3.83]
Total events: 5 (Higher omega 3), 4 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.12, df=1(P=0.73); I2=0%  
Test for overall effect: Z=0.15(P=0.88)  
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
1.71.7 Unclear LCn3 dose  
Erdogan 2007 41/54 46/54 6.9% 0.89[0.74,1.07]
Sianni 2013 147/268 29/60 4.58% 1.13[0.85,1.51]
Subtotal (95% CI) 322 114 11.48% 0.99[0.76,1.28]
Total events: 188 (Higher omega 3), 75 (Lower omega 3)  
Heterogeneity: Tau2=0.02; Chi2=2.45, df=1(P=0.12); I2=59.21%  
Test for overall effect: Z=0.1(P=0.92)  
   
Total (95% CI) 27021 26775 100% 0.97[0.89,1.04]
Total events: 1953 (Higher omega 3), 1831 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=48.15, df=27(P=0.01); I2=43.92%  
Test for overall effect: Z=0.86(P=0.39)  
Test for subgroup differences: Chi2=5.35, df=1 (P=0.25), I2=25.19%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 1.72.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 72 Arrhythmia - LCn3 - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.72.1 N-3 replacing SFA  
Derosa 2016 1/128 3/130 64.18% 0.34[0.04,3.21]
EPIC-1 2008 1/188 0/186 35.82% 2.97[0.12,72.4]
Subtotal (95% CI) 316 316 100% 0.74[0.1,5.67]
Total events: 2 (Higher omega 3), 3 (Lower omega 3)  
Heterogeneity: Tau2=0.37; Chi2=1.19, df=1(P=0.28); I2=15.78%  
Test for overall effect: Z=0.29(P=0.77)  
   
1.72.2 N-3 replacing MUFA  
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 7.26% 0.92[0.66,1.27]
FAAT 2005 57/200 78/202 8.49% 0.74[0.56,0.98]
FORWARD 2013 68/289 56/297 7.54% 1.25[0.91,1.71]
GISSI-HF 2008 76/278 98/284 9.41% 0.79[0.62,1.02]
GISSI-HF 2008 444/2921 408/2914 13.83% 1.09[0.96,1.23]
Nodari 2011 AF 37/100 56/99 7.69% 0.65[0.48,0.89]
Nodari 2011 HF 1/67 4/66 0.29% 0.25[0.03,2.15]
OMEGA 2009 99/1919 84/1885 8.38% 1.16[0.87,1.54]
ORIGIN 2012 288/6281 259/6255 12.4% 1.11[0.94,1.3]
Raitt 2005 65/100 59/100 10.48% 1.1[0.89,1.37]
Risk & Prevention 2013 113/6239 92/6266 8.69% 1.23[0.94,1.62]
SOFA 2006 36/273 34/273 5.01% 1.06[0.68,1.64]
THIS DIET 2008 2/51 5/50 0.53% 0.39[0.08,1.93]
Subtotal (95% CI) 21122 21124 100% 0.99[0.88,1.11]
Total events: 1353 (Higher omega 3), 1307 (Lower omega 3)  
Heterogeneity: Tau2=0.02; Chi2=27.26, df=12(P=0.01); I2=55.98%  
Test for overall effect: Z=0.19(P=0.85)  
   
1.72.3 N-3 replacing n-6  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AFFORD 2013 98/153 103/163 84.13% 1.01[0.86,1.2]
OFAMI 2001 8/150 15/150 3.42% 0.53[0.23,1.22]
Proudman 2015 1/87 0/53 0.23% 1.84[0.08,44.38]
SOFA 2006 36/273 34/273 12.22% 1.06[0.68,1.64]
Subtotal (95% CI) 663 639 100% 1[0.86,1.16]
Total events: 143 (Higher omega 3), 152 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.51, df=3(P=0.47); I2=0%  
Test for overall effect: Z=0.02(P=0.98)  
   
1.72.4 N-3 replacing carbohydrates/sugars  
Derosa 2016 1/128 3/130 100% 0.34[0.04,3.21]
Subtotal (95% CI) 128 130 100% 0.34[0.04,3.21]
Total events: 1 (Higher omega 3), 3 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.94(P=0.35)  
   
1.72.5 N-3 replacing nil/low n-3 placebo  
EPOCH 2014 2/195 1/196 0.34% 2.01[0.18,21.99]
FOSTAR 2016 4/101 4/101 1.06% 1[0.26,3.89]
GISSI-P 1999 40/2836 46/2828 11.03% 0.87[0.57,1.32]
Kumar 2012 61/91 78/87 75.41% 0.75[0.64,0.88]
SU.FOL.OM3 2010 33/1253 32/1248 8.47% 1.03[0.64,1.66]
Özaydin 2011 9/23 9/24 3.7% 1.04[0.51,2.16]
Subtotal (95% CI) 4499 4484 100% 0.8[0.69,0.91]
Total events: 149 (Higher omega 3), 170 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=4.25, df=5(P=0.51); I2=0%  
Test for overall effect: Z=3.21(P=0)  
   
1.72.6 Replacement unclear  
DISAF 2003 154/201 157/206 67.57% 1.01[0.9,1.12]
Erdogan 2007 41/54 46/54 22.54% 0.89[0.74,1.07]
ORL 2013 0/171 1/165 0.08% 0.32[0.01,7.84]
Sianni 2013 147/268 29/60 9.81% 1.13[0.85,1.51]
Subtotal (95% CI) 694 485 100% 0.99[0.91,1.08]
Total events: 342 (Higher omega 3), 233 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.78, df=3(P=0.43); I2=0%  
Test for overall effect: Z=0.24(P=0.81)  
Test for subgroup differences: Chi2=8.71, df=1 (P=0.12), I2=42.59%  
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Analysis 1.73.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 73 Arrhythmia - LCn3 - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.73.1 Dietary advice  
DISAF 2003 154/201 157/206 9.41% 1.01[0.9,1.12]
THIS DIET 2008 2/51 5/50 0.23% 0.39[0.08,1.93]
Subtotal (95% CI) 252 256 9.65% 0.87[0.44,1.72]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 156 (Higher omega 3), 162 (Lower omega 3)  
Heterogeneity: Tau2=0.14; Chi2=1.41, df=1(P=0.23); I2=29.15%  
Test for overall effect: Z=0.39(P=0.7)  
   
1.73.2 Supplemental foods  
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 3.81% 0.92[0.66,1.27]
FOSTAR 2016 4/101 4/101 0.32% 1[0.26,3.89]
Subtotal (95% CI) 2505 2534 4.13% 0.92[0.67,1.26]
Total events: 71 (Higher omega 3), 78 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.9); I2=0%  
Test for overall effect: Z=0.51(P=0.61)  
   
1.73.3 Supplements (capsule)  
AFFORD 2013 98/153 103/163 7.52% 1.01[0.86,1.2]
Derosa 2016 1/128 3/130 0.12% 0.34[0.04,3.21]
EPIC-1 2008 1/188 0/186 0.06% 2.97[0.12,72.4]
EPOCH 2014 2/195 1/196 0.1% 2.01[0.18,21.99]
Erdogan 2007 41/54 46/54 6.91% 0.89[0.74,1.07]
FAAT 2005 60/200 79/202 4.76% 0.77[0.58,1.01]
FORWARD 2013 68/289 56/297 3.99% 1.25[0.91,1.71]
GISSI-HF 2008 76/278 98/284 5.25% 0.79[0.62,1.02]
GISSI-HF 2008 444/2921 408/2914 8.89% 1.09[0.96,1.23]
GISSI-P 1999 40/2836 46/2828 2.63% 0.87[0.57,1.32]
Kumar 2012 61/91 78/87 7.71% 0.75[0.64,0.88]
Nodari 2011 AF 37/100 56/99 4.09% 0.65[0.48,0.89]
Nodari 2011 HF 1/67 4/66 0.13% 0.25[0.03,2.15]
OFAMI 2001 8/150 15/150 0.82% 0.53[0.23,1.22]
OMEGA 2009 99/1919 84/1885 4.54% 1.16[0.87,1.54]
ORIGIN 2012 288/6281 259/6255 7.6% 1.11[0.94,1.3]
ORL 2013 0/171 1/165 0.06% 0.32[0.01,7.84]
Proudman 2015 1/87 0/53 0.06% 1.84[0.08,44.38]
Raitt 2005 65/100 59/100 6.05% 1.1[0.89,1.37]
Risk & Prevention 2013 113/6239 92/6266 4.75% 1.23[0.94,1.62]
Sianni 2013 147/268 29/60 4.55% 1.13[0.85,1.51]
SOFA 2006 36/273 34/273 2.47% 1.06[0.68,1.64]
SU.FOL.OM3 2010 33/1253 32/1248 2.13% 1.03[0.64,1.66]
Özaydin 2011 9/23 9/24 1.04% 1.04[0.51,2.16]
Subtotal (95% CI) 24264 23985 86.23% 0.97[0.88,1.06]
Total events: 1729 (Higher omega 3), 1592 (Lower omega 3)  
Heterogeneity: Tau2=0.02; Chi2=46.27, df=23(P=0); I2=50.29%  
Test for overall effect: Z=0.72(P=0.47)  
   
1.73.4 Any combination  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 27021 26775 100% 0.97[0.9,1.05]
Total events: 1956 (Higher omega 3), 1832 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=47.34, df=27(P=0.01); I2=42.97%  
Test for overall effect: Z=0.83(P=0.41)  
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Test for subgroup differences: Chi2=0.16, df=1 (P=0.92), I2=0%  
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Analysis 1.74.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 74 Arrhythmia - LCn3 - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.74.1 Medium duration 1 to < 2 years in study  
AFFORD 2013 98/153 103/163 7.49% 1.01[0.86,1.2]
Derosa 2016 1/128 3/130 0.12% 0.34[0.04,3.21]
DISAF 2003 154/201 157/206 9.32% 1.01[0.9,1.12]
EPIC-1 2008 1/188 0/186 0.06% 2.97[0.12,72.4]
EPOCH 2014 2/195 1/196 0.11% 2.01[0.18,21.99]
Erdogan 2007 41/54 46/54 6.9% 0.89[0.74,1.07]
FAAT 2005 57/200 78/202 4.64% 0.74[0.56,0.98]
FORWARD 2013 68/289 56/297 4.02% 1.25[0.91,1.71]
Kumar 2012 61/91 78/87 7.67% 0.75[0.64,0.88]
Nodari 2011 AF 37/100 56/99 4.12% 0.65[0.48,0.89]
Nodari 2011 HF 1/67 4/66 0.13% 0.25[0.03,2.15]
OMEGA 2009 99/1919 84/1885 4.57% 1.16[0.87,1.54]
ORL 2013 0/171 1/165 0.06% 0.32[0.01,7.84]
Proudman 2015 1/87 0/53 0.06% 1.84[0.08,44.38]
Sianni 2013 147/268 29/60 4.58% 1.13[0.85,1.51]
SOFA 2006 36/273 34/273 2.51% 1.06[0.68,1.64]
Özaydin 2011 9/23 9/24 1.06% 1.04[0.51,2.16]
Subtotal (95% CI) 4407 4146 57.42% 0.93[0.84,1.04]
Total events: 813 (Higher omega 3), 739 (Lower omega 3)  
Heterogeneity: Tau2=0.02; Chi2=30.04, df=16(P=0.02); I2=46.73%  
Test for overall effect: Z=1.21(P=0.23)  
   
1.74.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 3.84% 0.92[0.66,1.27]
FOSTAR 2016 4/101 4/101 0.33% 1[0.26,3.89]
GISSI-HF 2008 76/278 98/284 5.28% 0.79[0.62,1.02]
GISSI-HF 2008 444/2921 408/2914 8.81% 1.09[0.96,1.23]
GISSI-P 1999 40/2836 46/2828 2.67% 0.87[0.57,1.32]
OFAMI 2001 8/150 15/150 0.83% 0.53[0.23,1.22]
Raitt 2005 65/100 59/100 6.05% 1.1[0.89,1.37]
THIS DIET 2008 2/51 5/50 0.24% 0.39[0.08,1.93]
Subtotal (95% CI) 8841 8860 28.06% 0.96[0.84,1.1]
Total events: 706 (Higher omega 3), 709 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=10.05, df=7(P=0.19); I2=30.38%  
Test for overall effect: Z=0.58(P=0.56)  
   
1.74.3 Long duration: ≥ 4 years in study  
ORIGIN 2012 288/6281 259/6255 7.57% 1.11[0.94,1.3]
Risk & Prevention 2013 113/6239 92/6266 4.78% 1.23[0.94,1.62]
SU.FOL.OM3 2010 33/1253 32/1248 2.17% 1.03[0.64,1.66]
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  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 13773 13769 14.52% 1.13[0.99,1.29]
Total events: 434 (Higher omega 3), 383 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.61, df=2(P=0.74); I2=0%  
Test for overall effect: Z=1.78(P=0.08)  
   
Total (95% CI) 27021 26775 100% 0.97[0.89,1.04]
Total events: 1953 (Higher omega 3), 1831 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=48.15, df=27(P=0.01); I2=43.92%  
Test for overall effect: Z=0.86(P=0.39)  
Test for subgroup differences: Chi2=4.93, df=1 (P=0.08), I2=59.44%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 1.75.   Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes),
Outcome 75 Arrhythmia - LCn3 - subgroup by primary or secondary prevention3.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.75.1 Primary prevention  
Derosa 2016 1/128 3/130 0.39% 0.34[0.04,3.21]
EPIC-1 2008 1/188 0/186 0.19% 2.97[0.12,72.4]
EPOCH 2014 2/195 1/196 0.34% 2.01[0.18,21.99]
FOSTAR 2016 4/101 4/101 1.07% 1[0.26,3.89]
ORIGIN 2012 288/6281 259/6255 73.08% 1.11[0.94,1.3]
ORL 2013 0/171 1/165 0.19% 0.32[0.01,7.84]
Proudman 2015 1/87 0/53 0.19% 1.84[0.08,44.38]
Sianni 2013 147/268 29/60 24.54% 1.13[0.85,1.51]
Subtotal (95% CI) 7419 7146 100% 1.11[0.97,1.28]
Total events: 444 (Higher omega 3), 297 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.4, df=7(P=0.93); I2=0%  
Test for overall effect: Z=1.46(P=0.14)  
   
1.75.2 Secondary prevention  
AFFORD 2013 98/153 103/163 8.34% 1.01[0.86,1.2]
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 4.6% 0.92[0.66,1.27]
DISAF 2003 154/201 157/206 10.03% 1.01[0.9,1.12]
Erdogan 2007 41/54 46/54 7.77% 0.89[0.74,1.07]
FAAT 2005 57/200 78/202 5.46% 0.74[0.56,0.98]
FORWARD 2013 68/289 56/297 4.8% 1.25[0.91,1.71]
GISSI-HF 2008 76/278 98/284 6.13% 0.79[0.62,1.02]
GISSI-HF 2008 444/2921 408/2914 9.58% 1.09[0.96,1.23]
GISSI-P 1999 40/2836 46/2828 3.27% 0.87[0.57,1.32]
Kumar 2012 61/91 78/87 8.52% 0.75[0.64,0.88]
Nodari 2011 AF 37/100 56/99 4.9% 0.65[0.48,0.89]
Nodari 2011 HF 1/67 4/66 0.17% 0.25[0.03,2.15]
OFAMI 2001 8/150 15/150 1.06% 0.53[0.23,1.22]
OMEGA 2009 99/1919 84/1885 5.39% 1.16[0.87,1.54]
Raitt 2005 65/100 59/100 6.93% 1.1[0.89,1.37]
Risk & Prevention 2013 113/6239 92/6266 5.61% 1.23[0.94,1.62]
SOFA 2006 36/273 34/273 3.08% 1.06[0.68,1.64]
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  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
SU.FOL.OM3 2010 33/1253 32/1248 2.68% 1.03[0.64,1.66]
THIS DIET 2008 2/51 5/50 0.31% 0.39[0.08,1.93]
Özaydin 2011 9/23 9/24 1.35% 1.04[0.51,2.16]
Subtotal (95% CI) 19602 19629 100% 0.95[0.86,1.03]
Total events: 1509 (Higher omega 3), 1534 (Lower omega 3)  
Heterogeneity: Tau2=0.02; Chi2=41.83, df=19(P=0); I2=54.57%  
Test for overall effect: Z=1.24(P=0.22)  
Test for subgroup differences: Chi2=3.61, df=1 (P=0.06), I2=72.27%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 1.76.   Comparison 1 High vs low LCn3 omega-3 fats (primary
outcomes), Outcome 76 Arrhythmia - LCn3 - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.76.1 LCn3 - ≥ 50% of control group on statins  
AlphaOmega - EPA+DHA 2010 67/2404 74/2433 14.8% 0.92[0.66,1.27]
OMEGA 2009 99/1919 84/1885 19.5% 1.16[0.87,1.54]
ORIGIN 2012 288/6281 259/6255 58.26% 1.11[0.94,1.3]
SU.FOL.OM3 2010 33/1253 32/1248 6.82% 1.03[0.64,1.66]
THIS DIET 2008 2/51 5/50 0.62% 0.39[0.08,1.93]
Subtotal (95% CI) 11908 11871 100% 1.07[0.95,1.22]
Total events: 489 (Higher omega 3), 454 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.89, df=4(P=0.58); I2=0%  
Test for overall effect: Z=1.11(P=0.27)  
   
1.76.2 LCn3 - < 50% of control group on statins  
AFFORD 2013 98/153 103/163 10.31% 1.01[0.86,1.2]
DISAF 2003 154/201 157/206 12.22% 1.01[0.9,1.12]
EPIC-1 2008 1/188 0/186 0.1% 2.97[0.12,72.4]
FAAT 2005 57/200 78/202 6.92% 0.74[0.56,0.98]
FORWARD 2013 68/289 56/297 6.11% 1.25[0.91,1.71]
FOSTAR 2016 4/101 4/101 0.56% 1[0.26,3.89]
GISSI-HF 2008 444/2921 408/2914 11.71% 1.09[0.96,1.23]
GISSI-HF 2008 76/278 98/284 7.73% 0.79[0.62,1.02]
GISSI-P 1999 40/2836 46/2828 4.22% 0.87[0.57,1.32]
Kumar 2012 61/91 78/87 10.51% 0.75[0.64,0.88]
Nodari 2011 AF 37/100 56/99 6.24% 0.65[0.48,0.89]
Nodari 2011 HF 1/67 4/66 0.22% 0.25[0.03,2.15]
OFAMI 2001 8/150 15/150 1.4% 0.53[0.23,1.22]
ORL 2013 0/171 1/165 0.1% 0.32[0.01,7.84]
Proudman 2015 1/87 0/53 0.1% 1.84[0.08,44.38]
Raitt 2005 65/100 59/100 8.67% 1.1[0.89,1.37]
Risk & Prevention 2013 113/6239 92/6266 7.1% 1.23[0.94,1.62]
SOFA 2006 36/273 34/273 3.99% 1.06[0.68,1.64]
Özaydin 2011 9/23 9/24 1.77% 1.04[0.51,2.16]
Subtotal (95% CI) 14468 14464 100% 0.94[0.85,1.04]
Total events: 1273 (Higher omega 3), 1298 (Lower omega 3)  
Heterogeneity: Tau2=0.02; Chi2=38.89, df=18(P=0); I2=53.72%  
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  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=1.18(P=0.24)  
   
1.76.3 LCn3 - use of statins unclear  
Derosa 2016 1/128 3/130 0.77% 0.34[0.04,3.21]
EPOCH 2014 2/195 1/196 0.68% 2.01[0.18,21.99]
Erdogan 2007 41/54 46/54 62.3% 0.89[0.74,1.07]
Sianni 2013 147/268 29/60 36.24% 1.13[0.85,1.51]
Subtotal (95% CI) 645 440 100% 0.97[0.8,1.18]
Total events: 191 (Higher omega 3), 79 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=3.5, df=3(P=0.32); I2=14.38%  
Test for overall effect: Z=0.29(P=0.77)  
Test for subgroup differences: Chi2=2.62, df=1 (P=0.27), I2=23.53%  
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Comparison 2.   High vs low LCn3 omega-3 fats (secondary outcomes)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 MACCEs - LCn3 5 34730 Risk Ratio (M-H, Random,
95% CI)
1.03 [0.97, 1.09]
2 Myocardial infarction (overall) - LCn3 23 72159 Risk Ratio (M-H, Random,
95% CI)
0.95 [0.88, 1.03]
3 Total MI - sensitivity analysis (SA) by summa-
ry risk of bias
23 72159 Risk Ratio (M-H, Random,
95% CI)
0.95 [0.88, 1.03]
3.1 Low summary risk of bias 11 30025 Risk Ratio (M-H, Random,
95% CI)
1.03 [0.92, 1.15]
3.2 Moderate to high risk of bias 12 42134 Risk Ratio (M-H, Random,
95% CI)
0.88 [0.79, 0.99]
4 Total MI - LCn3 - SA by compliance and study
size
23   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
4.1 SA - low risk of compliance bias 10 13002 Risk Ratio (M-H, Random,
95% CI)
0.94 [0.79, 1.13]
4.2 SA - 100+ randomised 21 72015 Risk Ratio (M-H, Random,
95% CI)
0.95 [0.88, 1.03]
5 Total MI - LCn3 - subgroup by fatality 23   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
5.1 Fatal MI 15 60471 Risk Ratio (M-H, Random,
95% CI)
0.76 [0.53, 1.10]
5.2 Non-fatal MI 21 70407 Risk Ratio (M-H, Random,
95% CI)
0.96 [0.87, 1.06]
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studies
No. of
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pants
Statistical method Effect size
6 Sudden cardiac death (overall) - LCn3 14 65004 Risk Ratio (M-H, Random,
95% CI)
0.97 [0.80, 1.18]
7 Angina - LCn3 11 39907 Risk Ratio (M-H, Random,
95% CI)
0.99 [0.91, 1.06]
8 Heart failure - LCn3 15 49644 Risk Ratio (M-H, Random,
95% CI)
0.93 [0.85, 1.03]
8.1 Low summary risk of bias 6 24176 Risk Ratio (M-H, Random,
95% CI)
0.97 [0.89, 1.06]
8.2 Moderate to high risk of bias 9 25468 Risk Ratio (M-H, Random,
95% CI)
0.78 [0.57, 1.08]
9 Revascularisation - LCn3 15   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
9.1 CABG - LCn3 5 1535 Risk Ratio (M-H, Random,
95% CI)
0.56 [0.15, 2.14]
9.2 Angioplasty - LCn3 4 3195 Risk Ratio (M-H, Random,
95% CI)
0.96 [0.74, 1.24]
9.3 Any revascularisation - LCn3 12 66095 Risk Ratio (M-H, Random,
95% CI)
0.98 [0.94, 1.03]
10 Peripheral arterial disease - LCn3 6 49035 Risk Ratio (M-H, Random,
95% CI)
0.93 [0.74, 1.18]
11 PAD - LCn3 - SA by summary risk of bias 6   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
11.1 Low summary risk of bias 2 12738 Risk Ratio (M-H, Random,
95% CI)
1.10 [0.75, 1.62]
11.2 Moderate to high summary risk of bias 4 36297 Risk Ratio (M-H, Random,
95% CI)
0.85 [0.64, 1.14]
12 PAD - LCn3 - SA compliance and study size 6   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
12.1 SA compliance 1 202 Risk Ratio (M-H, Random,
95% CI)
1.0 [0.06, 15.77]
12.2 SA study size 100+ 6 49035 Risk Ratio (M-H, Random,
95% CI)
0.93 [0.74, 1.18]
13 Acute coronary syndrome - LCn3 2   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
13.1 LCn3 2 2703 Risk Ratio (M-H, Random,
95% CI)
1.19 [0.71, 2.00]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
14 Body weight, kg - LCn3 12 15812 Mean Difference (IV, Random,
95% CI)
-0.01 [-0.84, 0.82]
15 Weight, kg - LCn3 - SA by summary risk of
bias
12 15812 Mean Difference (IV, Random,
95% CI)
-0.01 [-0.84, 0.82]
15.1 Low risk of bias 7 15458 Mean Difference (IV, Random,
95% CI)
-0.01 [-0.91, 0.90]
15.2 Moderate/high risk of bias 5 354 Mean Difference (IV, Random,
95% CI)
-0.28 [-3.12, 2.55]
16 Weight, kg - LCn3 - SA by compliance and
study size
10   Mean Difference (IV, Random,
95% CI)
Subtotals only
16.1 SA - low risk of compliance bias 7 828 Mean Difference (IV, Random,
95% CI)
0.58 [-0.52, 1.69]
16.2 SA - 100+ randomised 7 15545 Mean Difference (IV, Random,
95% CI)
0.07 [-0.84, 0.97]
17 Weight, kg - LCn3 - subgroup by dose 12   Mean Difference (IV, Random,
95% CI)
Subtotals only
17.1 LCn3 ≤ 150 mg/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
17.2 LCn3 > 150 ≤ 250 mg/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
17.3 LCn3 > 250 ≤ 400 mg/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
17.4 LCn3 > 400 ≤ 2400 mg/d 8 15420 Mean Difference (IV, Random,
95% CI)
-0.29 [-1.16, 0.58]
17.5 LCn3 > 2.4 ≤ 4.4 g/d 3 241 Mean Difference (IV, Random,
95% CI)
0.07 [-6.38, 6.51]
17.6 LCn3 > 4.4 g/d 2 261 Mean Difference (IV, Random,
95% CI)
1.51 [0.28, 2.75]
18 Weight, kg - LCn3 - subgroup by replace-
ment
12   Mean Difference (IV, Random,
95% CI)
Subtotals only
18.1 N-3 replacing SFA 2 433 Mean Difference (IV, Random,
95% CI)
-2.51 [-4.30, -0.72]
18.2 N-3 replacing MUFA 7 15088 Mean Difference (IV, Random,
95% CI)
0.23 [-0.28, 0.75]
18.3 N-3 replacing n-6 1 41 Mean Difference (IV, Random,
95% CI)
-1.3 [-3.83, 1.23]
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No. of
partici-
pants
Statistical method Effect size
18.4 N-3 replacing carbs/sugars 1 258 Mean Difference (IV, Random,
95% CI)
-2.70 [-4.75, -0.65]
18.5 N-3 replacing nil/low n-3 placebo 1 202 Mean Difference (IV, Random,
95% CI)
1.5 [0.25, 2.75]
18.6 Replacement unclear 2 223 Mean Difference (IV, Random,
95% CI)
0.60 [-4.93, 6.13]
19 Weight, kg - LCn3 - subgroup by intervention
type
12 15812 Mean Difference (IV, Random,
95% CI)
-0.01 [-0.84, 0.82]
19.1 Dietary advice 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
19.2 Supplemental foods 1 202 Mean Difference (IV, Random,
95% CI)
1.5 [0.25, 2.75]
19.3 Supplement (capsule) 9 15538 Mean Difference (IV, Random,
95% CI)
-0.23 [-1.08, 0.63]
19.4 Any combination 2 72 Mean Difference (IV, Random,
95% CI)
-0.43 [-6.47, 5.61]
20 Weight, kg - LCn3 - subgroup by duration 12   Mean Difference (IV, Random,
95% CI)
Subtotals only
20.1 Medium duration 1 to < 2 years in study 8 840 Mean Difference (IV, Random,
95% CI)
-0.54 [-2.21, 1.12]
20.2 Medium-long duration: 2 to < 4 years in
study
3 436 Mean Difference (IV, Random,
95% CI)
0.67 [-1.58, 2.91]
20.3 Long duration ≥ 4 years in study 1 14536 Mean Difference (IV, Random,
95% CI)
0.10 [-0.48, 0.68]
21 Weight, kg - LCn3 - subgroup by primary or
secondary prevention
12   Mean Difference (IV, Random,
95% CI)
Subtotals only
21.1 Primary CVD prevention 10 15578 Mean Difference (IV, Random,
95% CI)
0.05 [-0.83, 0.92]
21.2 Secondary CVD prevention 2 234 Mean Difference (IV, Random,
95% CI)
-1.13 [-4.43, 2.16]
22 Weight, kg - LCn3 - subgroup by statin use 12   Mean Difference (IV, Random,
95% CI)
Subtotals only
22.1 LCn3 - ≥ 50% of control group on statins 2 14631 Mean Difference (IV, Random,
95% CI)
0.64 [-1.88, 3.17]
22.2 LCn3 - < 50% of control group on statins 5 614 Mean Difference (IV, Random,
95% CI)
0.47 [-0.66, 1.60]
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pants
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22.3 LCn3 - use of statins unclear 5 567 Mean Difference (IV, Random,
95% CI)
-1.51 [-3.30, 0.27]
23 Body mass index, kg/m2 - LCn3 14 15234 Mean Difference (IV, Random,
95% CI)
0.04 [-0.16, 0.24]
24 BMI, kg/m2- LCn3 - SA by summary risk of
bias
14 15234 Mean Difference (IV, Random,
95% CI)
0.04 [-0.16, 0.24]
24.1 Low risk of bias 5 14190 Mean Difference (IV, Random,
95% CI)
-0.01 [-0.36, 0.33]
24.2 Moderate/high risk of bias 9 1044 Mean Difference (IV, Random,
95% CI)
0.04 [-0.13, 0.20]
25 BMI, kg/m2- LCn3 - SA by compliance and
study size
10   Mean Difference (IV, Random,
95% CI)
Subtotals only
25.1 SA - low risk of compliance bias 5 1848 Mean Difference (IV, Random,
95% CI)
0.09 [-0.21, 0.38]
25.2 SA - 100+ randomised 9 14982 Mean Difference (IV, Random,
95% CI)
0.01 [-0.12, 0.14]
26 BMI, kg/m2 - LCn3 - subgroup by dose 14   Mean Difference (IV, Random,
95% CI)
Subtotals only
26.1 LCn3 > 150 ≤ 250 mg/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
26.2 LCn3 ≤ 150 mg/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
26.3 LCn3 > 250 ≤ 400 mg/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
26.4 LCn3 > 400 ≤ 2400 mg/d 11 14789 Mean Difference (IV, Random,
95% CI)
0.01 [-0.11, 0.13]
26.5 LCn3 > 2.4 ≤ 4.4 g/d 3 445 Mean Difference (IV, Random,
95% CI)
1.42 [-0.51, 3.35]
26.6 LCn3 > 4.4 g/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
27 BMI, kg/m2 - LCn3 - subgroup by replace-
ment
14   Mean Difference (IV, Random,
95% CI)
Subtotals only
27.1 N-3 replacing SFA 1 258 Mean Difference (IV, Random,
95% CI)
-0.60 [-1.14, -0.06]
27.2 N-3 replacing MUFA 7 14180 Mean Difference (IV, Random,
95% CI)
0.08 [-0.12, 0.28]
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27.3 N-3 replacing n-6 3 513 Mean Difference (IV, Random,
95% CI)
0.18 [-0.46, 0.81]
27.4 N-3 replacing carbs/sugars 1 258 Mean Difference (IV, Random,
95% CI)
-0.60 [-1.14, -0.06]
27.5 N-3 replacing nil/low n-3 placebo 1 60 Mean Difference (IV, Random,
95% CI)
1.0 [-1.18, 3.18]
27.6 Replacement unclear 2 223 Mean Difference (IV, Random,
95% CI)
0.58 [-1.17, 2.33]
28 BMI, kg/m2 - LCn3 - subgroup by interven-
tion type
14 15234 Mean Difference (IV, Random,
95% CI)
0.04 [-0.16, 0.24]
28.1 Dietary advice 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
28.2 Supplemental foods 1 1260 Mean Difference (IV, Random,
95% CI)
0.1 [-0.10, 0.30]
28.3 Supplement (capsule) 12 13929 Mean Difference (IV, Random,
95% CI)
0.01 [-0.25, 0.27]
28.4 Any combination 1 45 Mean Difference (IV, Random,
95% CI)
1.60 [-0.43, 3.63]
29 BMI, kg/m2 - LCn3 - subgroup by duration 14   Mean Difference (IV, Random,
95% CI)
Subtotals only
29.1 Medium duration 1 to < 2 years in study 9 906 Mean Difference (IV, Random,
95% CI)
0.24 [-0.40, 0.88]
29.2 Medium-long duration: 2 to < 4 years in
study
4 1792 Mean Difference (IV, Random,
95% CI)
0.12 [-0.07, 0.31]
29.3 Long duration ≥ 4 years in study 1 12536 Mean Difference (IV, Random,
95% CI)
0.0 [-0.20, 0.20]
30 BMI, kg/m2 - LCn3 - subgroup by primary or
secondary prevention
14   Mean Difference (IV, Random,
95% CI)
Subtotals only
30.1 Primary CVD prevention 11 13610 Mean Difference (IV, Random,
95% CI)
0.15 [-0.36, 0.66]
30.2 Secondary CVD prevention 3 1624 Mean Difference (IV, Random,
95% CI)
0.05 [-0.08, 0.18]
31 BMI, kg/m2 - LCn3 - subgroup by statin use 14   Mean Difference (IV, Random,
95% CI)
Subtotals only
31.1 LCn3 - ≥ 50% of control group on statins 3 13891 Mean Difference (IV, Random,
95% CI)
0.13 [-0.22, 0.48]
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31.2 LCn3 - < 50% of control group on statins 4 665 Mean Difference (IV, Random,
95% CI)
0.02 [-0.15, 0.19]
31.3 LCn3 - use of statins unclear 7 678 Mean Difference (IV, Random,
95% CI)
0.06 [-0.86, 0.97]
32 Other measures of adiposity - LCn3 6   Mean Difference (IV, Random,
95% CI)
Subtotals only
32.1 Percentage body fat 2 127 Mean Difference (IV, Random,
95% CI)
0.85 [-6.87, 8.57]
32.2 Percentage visceral fat 1 95 Mean Difference (IV, Random,
95% CI)
-1.80 [-15.03, 11.43]
32.3 Waist circumference, cm 3 676 Mean Difference (IV, Random,
95% CI)
0.66 [-0.09, 1.42]
32.4 Waist-hip ratio 1 100 Mean Difference (IV, Random,
95% CI)
0.0 [-0.01, 0.01]
32.5 Abdominal circumference, cm 1 256 Mean Difference (IV, Random,
95% CI)
-0.70 [-8.78, 7.38]
32.6 Hip circumference, cm 1 258 Mean Difference (IV, Random,
95% CI)
-2.40 [-9.80, 5.00]
33 Total cholesterol, serum, mmoL/L - LCn3 28 37281 Mean Difference (IV, Random,
95% CI)
-0.01 [-0.05, 0.04]
34 TC, mmoL/L - LCn3 - SA by summary risk of
bias
28 37281 Mean Difference (IV, Random,
95% CI)
-0.01 [-0.05, 0.03]
34.1 Low risk of bias 9 14930 Mean Difference (IV, Random,
95% CI)
0.01 [-0.05, 0.06]
34.2 Moderate/high risk of bias 19 22351 Mean Difference (IV, Random,
95% CI)
-0.03 [-0.09, 0.03]
35 TC, mmoL/L - LCn3 - SA by compliance and
study size
20   Mean Difference (IV, Random,
95% CI)
Subtotals only
35.1 SA - low risk of compliance bias 14 3341 Mean Difference (IV, Random,
95% CI)
0.02 [-0.05, 0.09]
35.2 SA - 100+ randomised 15 36622 Mean Difference (IV, Random,
95% CI)
0.00 [-0.05, 0.06]
36 TC, mmoL/L - LCn3 - subgroup by dose 28   Mean Difference (IV, Random,
95% CI)
Subtotals only
36.1 LCn3 ≤ 150 mg/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
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36.2 LCn3 > 150 ≤ 250 mg/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
36.3 LCn3 > 250 ≤ 400 mg/d 1 1715 Mean Difference (IV, Random,
95% CI)
0.10 [-0.01, 0.21]
36.4 LCn3 > 400 ≤ 2400 mg/d 18 34262 Mean Difference (IV, Random,
95% CI)
-0.03 [-0.06, 0.00]
36.5 LCn3 > 2.4 ≤ 4.4 g/d 7 1216 Mean Difference (IV, Random,
95% CI)
-0.14 [-0.28, -0.01]
36.6 LCn3 > 4.4 g/d 2 88 Mean Difference (IV, Random,
95% CI)
0.08 [-0.28, 0.45]
37 TC, mmoL/L - LCn3 - subgroup by replace-
ment
28   Mean Difference (IV, Random,
95% CI)
Subtotals only
37.1 N-3 replacing SFA 3 2148 Mean Difference (IV, Random,
95% CI)
0.10 [-0.01, 0.20]
37.2 N-3 replacing MUFA 15 16504 Mean Difference (IV, Random,
95% CI)
0.01 [-0.04, 0.06]
37.3 N-3 replacing n-6 5 895 Mean Difference (IV, Random,
95% CI)
0.02 [-0.22, 0.26]
37.4 N-3 replacing carbs/sugars 1 258 Mean Difference (IV, Random,
95% CI)
-0.20 [-1.03, 0.63]
37.5 N-3 replacing nil/low n-3 placebo 5 19431 Mean Difference (IV, Random,
95% CI)
-0.05 [-0.07, -0.03]
37.6 Replacement unclear 2 193 Mean Difference (IV, Random,
95% CI)
-0.15 [-0.47, 0.17]
38 TC, mmoL/L - LCn3 - subgroup by interven-
tion type
28   Mean Difference (IV, Random,
95% CI)
Subtotals only
38.1 Dietary advice 1 1715 Mean Difference (IV, Random,
95% CI)
0.10 [-0.01, 0.21]
38.2 Supplemental foods 1 1210 Mean Difference (IV, Random,
95% CI)
0.02 [-0.09, 0.13]
38.3 Supplement (capsule) 24 34145 Mean Difference (IV, Random,
95% CI)
-0.05 [-0.07, -0.03]
38.4 Any combination 2 211 Mean Difference (IV, Random,
95% CI)
0.13 [-0.10, 0.37]
39 TC, mmoL/L - LCn3 - subgroup by duration 28   Mean Difference (IV, Random,
95% CI)
Subtotals only
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39.1 Medium duration 1 to < 2 years in study 15 1661 Mean Difference (IV, Random,
95% CI)
-0.06 [-0.16, 0.04]
39.2 Medium-long duration: 2 to < 4 years in
study
10 4231 Mean Difference (IV, Random,
95% CI)
0.02 [-0.05, 0.10]
39.3 Long duration ≥ 4 years in study 3 31389 Mean Difference (IV, Random,
95% CI)
0.00 [-0.09, 0.09]
40 TC, mmoL/L - LCn3 - subgroup by primary or
secondary prevention
28   Mean Difference (IV, Random,
95% CI)
Subtotals only
40.1 Primary prevention 17 32796 Mean Difference (IV, Random,
95% CI)
-0.04 [-0.07, -0.02]
40.2 Secondary prevention 11 4485 Mean Difference (IV, Random,
95% CI)
-0.01 [-0.09, 0.08]
41 TC, mmoL/L - LCn3 - subgroup by statin use 28   Mean Difference (IV, Random,
95% CI)
Subtotals only
41.1 LCn3 - ≥ 50% of control group on statins 6 32823 Mean Difference (IV, Random,
95% CI)
-0.05 [-0.07, -0.02]
41.2 LCn3 - < 50% of control group on statins 15 3871 Mean Difference (IV, Random,
95% CI)
0.01 [-0.08, 0.10]
41.3 LCn3 - use of statins unclear 7 587 Mean Difference (IV, Random,
95% CI)
-0.03 [-0.27, 0.22]
42 Triglycerides, fasting, serum, mmoL/L - LCn3 25 35579 Mean Difference (IV, Random,
95% CI)
-0.24 [-0.31, -0.16]
43 TG, fasting, mmoL/L - LCn3 - SA by summary
risk of bias
25 35579 Mean Difference (IV, Random,
95% CI)
-0.23 [-0.30, -0.16]
43.1 Low risk of bias 8 14654 Mean Difference (IV, Random,
95% CI)
-0.17 [-0.25, -0.09]
43.2 Moderate/high risk of bias 17 20925 Mean Difference (IV, Random,
95% CI)
-0.25 [-0.35, -0.15]
44 TG, fasting, mmoL/L - LCn3 - SA by compli-
ance and study size
19   Mean Difference (IV, Random,
95% CI)
Subtotals only
44.1 SA - low risk of compliance bias 12 3306 Mean Difference (IV, Random,
95% CI)
-0.26 [-0.36, -0.16]
44.2 SA - 100+ randomised 18 35197 Mean Difference (IV, Random,
95% CI)
-0.24 [-0.32, -0.16]
45 TG, fasting, mmoL/L - LCn3 - subgroup by
dose
25   Mean Difference (IV, Random,
95% CI)
Subtotals only
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45.1 LCn3 ≤ 150 mg/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
45.2 LCn3 > 150 ≤ 250 mg/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
45.3 LCn3 > 250 ≤ 400 mg/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
45.4 LCn3 > 400 ≤ 2400 mg/d 18 34388 Mean Difference (IV, Random,
95% CI)
-0.18 [-0.25, -0.11]
45.5 LCn3 > 2.4 ≤ 4.4 g/d 5 1107 Mean Difference (IV, Random,
95% CI)
-0.36 [-0.53, -0.20]
45.6 LCn3 > 4.4 g/d 2 84 Mean Difference (IV, Random,
95% CI)
-0.41 [-0.68, -0.14]
46 TG, fasting, mmoL/L - LCn3 - subgroup by re-
placement
25   Mean Difference (IV, Random,
95% CI)
Subtotals only
46.1 N-3 replacing SFA 2 429 Mean Difference (IV, Random,
95% CI)
-0.27 [-0.59, 0.04]
46.2 N-3 replacing MUFA 13 14634 Mean Difference (IV, Random,
95% CI)
-0.18 [-0.25, -0.10]
46.3 N-3 replacing n-6 5 876 Mean Difference (IV, Random,
95% CI)
-0.27 [-0.45, -0.08]
46.4 N-3 replacing carbs/sugars 1 258 Mean Difference (IV, Random,
95% CI)
-0.5 [-1.49, 0.49]
46.5 N-3 replacing nil/low n-3 placebo 4 19357 Mean Difference (IV, Random,
95% CI)
-0.18 [-0.51, 0.14]
46.6 Replacement unclear 2 454 Mean Difference (IV, Random,
95% CI)
-0.38 [-0.57, -0.19]
47 TG, fasting, mmoL/L - LCn3 - subgroup by in-
tervention type
25   Mean Difference (IV, Random,
95% CI)
Subtotals only
47.1 Dietary advice 1 71 Mean Difference (IV, Random,
95% CI)
0.02 [-0.36, 0.40]
47.2 Supplemental foods 1 1210 Mean Difference (IV, Random,
95% CI)
-0.03 [-0.15, 0.09]
47.3 Supplement (capsule) 22 34137 Mean Difference (IV, Random,
95% CI)
-0.19 [-0.38, -0.00]
47.4 Any combination 1 161 Mean Difference (IV, Random,
95% CI)
0.01 [-0.28, 0.30]
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48 TG, fasting, mmoL/L - LCn3 - subgroup by
duration
25   Mean Difference (IV, Random,
95% CI)
Subtotals only
48.1 Medium duration 1 to < 2 years in study 13 1880 Mean Difference (IV, Random,
95% CI)
-0.27 [-0.36, -0.19]
48.2 Medium-long duration: 2 to < 4 years in
study
9 2310 Mean Difference (IV, Random,
95% CI)
-0.16 [-0.31, -0.02]
48.3 Long duration ≥ 4 years in study 3 31389 Mean Difference (IV, Random,
95% CI)
-0.20 [-0.32, -0.07]
49 TG, fasting, mmoL/L - LCn3 - subgroup by
primary or secondary prevention
25   Mean Difference (IV, Random,
95% CI)
Subtotals only
49.1 Primary prevention 17 33114 Mean Difference (IV, Random,
95% CI)
-0.20 [-0.26, -0.14]
49.2 Secondary prevention 8 2465 Mean Difference (IV, Random,
95% CI)
-0.27 [-0.44, -0.10]
50 TG, fasting, mmoL/L - LCn3 - subgroup by
statin use
25   Mean Difference (IV, Random,
95% CI)
Subtotals only
50.1 LCn3 - ≥ 50% of control group on statins 5 32557 Mean Difference (IV, Random,
95% CI)
-0.11 [-0.21, -0.01]
50.2 LCn3 - < 50% of control group on statins 14 2414 Mean Difference (IV, Random,
95% CI)
-0.27 [-0.36, -0.18]
50.3 LCn3 - use of statins unclear 6 608 Mean Difference (IV, Random,
95% CI)
-0.23 [-0.38, -0.08]
51 High-density lipoprotein, serum, mmoL/L -
LCn3
27 37237 Mean Difference (IV, Random,
95% CI)
0.02 [0.00, 0.04]
52 HDL, mmoL/L - LCn3 - SA by summary risk of
bias
27 37237 Mean Difference (IV, Random,
95% CI)
0.03 [0.01, 0.05]
52.1 Low risk of bias 8 14892 Mean Difference (IV, Random,
95% CI)
0.03 [-0.01, 0.07]
52.2 Moderate/high risk of bias 19 22345 Mean Difference (IV, Random,
95% CI)
0.03 [0.00, 0.06]
53 HDL, mmoL/L - LCn3 - SA by compliance and
study size
20   Mean Difference (IV, Random,
95% CI)
Subtotals only
53.1 SA - low risk of compliance bias 13 3202 Mean Difference (IV, Random,
95% CI)
0.05 [0.01, 0.10]
53.2 SA - 100+ randomised 15 36573 Mean Difference (IV, Random,
95% CI)
0.03 [0.00, 0.05]
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54 HDL, mmoL/L - LCn3 - subgroup by dose 27   Mean Difference (IV, Random,
95% CI)
Subtotals only
54.1 LCn3 ≤ 150 mg/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
54.2 LCn3 > 150 ≤ 250 mg/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
54.3 LCn3 > 250 ≤ 400 mg/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
54.4 LCn3 > 400 ≤ 2400 mg/d 19 35972 Mean Difference (IV, Random,
95% CI)
0.02 [-0.00, 0.04]
54.5 LCn3 > 2.4 ≤ 4.4 g/d 7 1206 Mean Difference (IV, Random,
95% CI)
0.06 [0.00, 0.12]
54.6 LCn3 > 4.4 g/d 1 59 Mean Difference (IV, Random,
95% CI)
0.0 [-0.16, 0.16]
55 HDL, mmoL/L - LCn3 - subgroup by replace-
ment
27   Mean Difference (IV, Random,
95% CI)
Subtotals only
55.1 N-3 replacing SFA 3 2143 Mean Difference (IV, Random,
95% CI)
-0.02 [-0.10, 0.07]
55.2 N-3 replacing MUFA 15 16505 Mean Difference (IV, Random,
95% CI)
0.02 [-0.01, 0.06]
55.3 N-3 replacing n-6 4 850 Mean Difference (IV, Random,
95% CI)
0.04 [-0.01, 0.09]
55.4 N-3 replacing carbs/sugars 1 258 Mean Difference (IV, Random,
95% CI)
0.10 [-0.17, 0.37]
55.5 N-3 replacing nil/low n-3 placebo 5 19431 Mean Difference (IV, Random,
95% CI)
0.04 [-0.03, 0.11]
55.6 Replacement unclear 2 193 Mean Difference (IV, Random,
95% CI)
0.05 [-0.10, 0.20]
56 HDL, mmoL/L - LCn3 - subgroup by interven-
tion type
27   Mean Difference (IV, Random,
95% CI)
Subtotals only
56.1 Dietary advice 2 1785 Mean Difference (IV, Random,
95% CI)
0.01 [-0.02, 0.04]
56.2 Supplemental foods 1 1210 Mean Difference (IV, Random,
95% CI)
0.03 [0.00, 0.06]
56.3 Supplement (capsule) 21 34008 Mean Difference (IV, Random,
95% CI)
0.03 [0.00, 0.06]
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56.4 Any combination 3 234 Mean Difference (IV, Random,
95% CI)
0.10 [-0.10, 0.31]
57 HDL, mmoL/L - LCn3 - subgroup by duration 27   Mean Difference (IV, Random,
95% CI)
Subtotals only
57.1 Medium duration 1 to < 2 years in study 13 1562 Mean Difference (IV, Random,
95% CI)
0.08 [0.01, 0.14]
57.2 Medium-long duration: 2 to < 4 years in
study
11 4286 Mean Difference (IV, Random,
95% CI)
0.02 [-0.01, 0.04]
57.3 Long duration ≥ 4 years in study 3 31389 Mean Difference (IV, Random,
95% CI)
0.00 [-0.01, 0.01]
58 HDL, mmoL/L - LCn3 - subgroup by primary
or secondary prevention
26   Mean Difference (IV, Random,
95% CI)
Subtotals only
58.1 Primary prevention 17 32856 Mean Difference (IV, Random,
95% CI)
0.03 [-0.00, 0.05]
58.2 Secondary prevention 9 4307 Mean Difference (IV, Random,
95% CI)
0.03 [-0.01, 0.07]
59 HDL, mmoL/L - LCn3 - subgroup by statin
use
27   Mean Difference (IV, Random,
95% CI)
Subtotals only
59.1 LCn3 - ≥ 50% of control group on statins 7 32894 Mean Difference (IV, Random,
95% CI)
0.01 [-0.01, 0.03]
59.2 LCn3 - < 50% of control group on statins 13 3690 Mean Difference (IV, Random,
95% CI)
0.04 [-0.00, 0.08]
59.3 LCn3 - use of statins unclear 7 653 Mean Difference (IV, Random,
95% CI)
0.07 [-0.07, 0.21]
60 Low-density lipoprotein, serum, mmoL/L -
LCn3
23 35035 Mean Difference (IV, Random,
95% CI)
0.01 [-0.01, 0.03]
61 LDL, mmoL/L - LCn3 - SA by summary risk of
bias
23 35035 Mean Difference (IV, Random,
95% CI)
0.01 [-0.01, 0.03]
61.1 Low risk of bias 9 14840 Mean Difference (IV, Random,
95% CI)
0.02 [-0.03, 0.07]
61.2 Moderate/high risk of bias 14 20195 Mean Difference (IV, Random,
95% CI)
0.00 [-0.02, 0.03]
62 LDL, mmoL/L - LCn3 - SA by compliance and
study size
17 37718 Mean Difference (IV, Random,
95% CI)
0.02 [-0.01, 0.05]
62.1 SA - low risk of compliance bias 13 3165 Mean Difference (IV, Random,
95% CI)
0.05 [-0.02, 0.11]
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62.2 SA - 100+ randomised 14 34553 Mean Difference (IV, Random,
95% CI)
0.01 [-0.02, 0.04]
63 LDL, mmoL/L - LCn3 - subgroup by dose 23   Mean Difference (IV, Random,
95% CI)
Subtotals only
63.1 LCn3 ≤ 150 mg/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
63.2 LCn3 > 150 ≤ 250 mg/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
63.3 LCn3 > 250 ≤ 400 mg/d 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
63.4 LCn3 > 400 ≤ 2400 mg/d 16 34054 Mean Difference (IV, Random,
95% CI)
0.01 [-0.01, 0.02]
63.5 LCn3 > 2.4 ≤ 4.4 g/d 5 893 Mean Difference (IV, Random,
95% CI)
0.01 [-0.14, 0.15]
63.6 LCn3 > 4.4 g/d 2 88 Mean Difference (IV, Random,
95% CI)
0.22 [-0.09, 0.54]
64 LDL, mmoL/L - LCn3 - subgroup by replace-
ment
23   Mean Difference (IV, Random,
95% CI)
Subtotals only
64.1 N-3 replacing SFA 2 429 Mean Difference (IV, Random,
95% CI)
0.17 [-0.14, 0.47]
64.2 N-3 replacing MUFA 14 14710 Mean Difference (IV, Random,
95% CI)
0.01 [-0.03, 0.05]
64.3 N-3 replacing n-6 2 242 Mean Difference (IV, Random,
95% CI)
0.14 [-0.26, 0.55]
64.4 N-3 replacing carbs/sugars 1 258 Mean Difference (IV, Random,
95% CI)
0.20 [-0.51, 0.91]
64.5 N-3 replacing nil/low n-3 placebo 3 19297 Mean Difference (IV, Random,
95% CI)
0.00 [-0.02, 0.02]
64.6 Replacement unclear 3 528 Mean Difference (IV, Random,
95% CI)
0.10 [-0.03, 0.23]
65 LDL, mmoL/L - LCn3 - subgroup by interven-
tion type
23   Mean Difference (IV, Random,
95% CI)
Subtotals only
65.1 Dietary advice 1 71 Mean Difference (IV, Random,
95% CI)
0.08 [-0.22, 0.38]
65.2 Supplemental foods 1 1124 Mean Difference (IV, Random,
95% CI)
-0.02 [-0.10, 0.06]
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65.3 Supplement (capsule) 19 33768 Mean Difference (IV, Random,
95% CI)
0.01 [-0.01, 0.03]
65.4 Any combination 2 72 Mean Difference (IV, Random,
95% CI)
0.08 [-0.44, 0.61]
66 LDL, mmoL/L - LCn3 - subgroup by duration 23   Mean Difference (IV, Random,
95% CI)
Subtotals only
66.1 Medium duration 1 to < 2 years in study 14 1862 Mean Difference (IV, Random,
95% CI)
0.06 [-0.03, 0.14]
66.2 Medium-long duration: 2 to < 4 years in
study
6 1784 Mean Difference (IV, Random,
95% CI)
-0.01 [-0.08, 0.06]
66.3 Long duration ≥ 4 years in study 3 31389 Mean Difference (IV, Random,
95% CI)
0.03 [-0.04, 0.10]
67 LDL, mmoL/L - LCn3 - subgroup by primary
or secondary prevention
23   Mean Difference (IV, Random,
95% CI)
Subtotals only
67.1 Primary prevention 16 32717 Mean Difference (IV, Random,
95% CI)
0.01 [-0.01, 0.03]
67.2 Secondary prevention 7 2318 Mean Difference (IV, Random,
95% CI)
0.01 [-0.05, 0.08]
68 LDL, mmoL/L - LCn3 - subgroup by statin use 23   Mean Difference (IV, Random,
95% CI)
Subtotals only
68.1 LCn3 - ≥ 50% of control group on statins 7 32808 Mean Difference (IV, Random,
95% CI)
0.00 [-0.02, 0.02]
68.2 LCn3 - < 50% of control group on statins 9 1564 Mean Difference (IV, Random,
95% CI)
0.12 [0.03, 0.21]
68.3 LCn3 - use of statins unclear 7 663 Mean Difference (IV, Random,
95% CI)
-0.01 [-0.17, 0.14]
 
 
Analysis 2.1.   Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 1 MACCEs - LCn3.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AREDS2 2014 116/2147 113/2056 4.76% 0.98[0.76,1.26]
DART 1989 338/1015 332/1018 19.65% 1.02[0.9,1.16]
OMEGA 2009 182/1752 149/1701 7.12% 1.19[0.97,1.46]
ORIGIN 2012 1034/6281 1017/6255 48.23% 1.01[0.94,1.1]
Risk & Prevention 2013 484/6239 467/6266 20.24% 1.04[0.92,1.18]
   
Total (95% CI) 17434 17296 100% 1.03[0.97,1.09]
Favours higher omega 3 20.5 1.50.7 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 2154 (Higher omega 3), 2078 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.16, df=4(P=0.71); I2=0%  
Test for overall effect: Z=1.05(P=0.29)  
Favours higher omega 3 20.5 1.50.7 1 Favours lower omega 3
 
 
Analysis 2.2.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 2 Myocardial infarction (overall) - LCn3.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AlphaOmega - EPA+DHA 2010 89/2404 102/2433 8.37% 0.88[0.67,1.17]
AREDS2 2014 28/2147 30/2056 2.49% 0.89[0.54,1.49]
Baldassarre 2006 1/32 0/32 0.06% 3[0.13,71]
Brox 2001 0/80 1/40 0.06% 0.17[0.01,4.05]
DART 1989 207/1015 215/1018 22.52% 0.97[0.81,1.14]
Derosa 2016 0/128 3/130 0.07% 0.15[0.01,2.78]
DO IT 2010 11/282 9/281 0.87% 1.22[0.51,2.89]
Doi 2014 1/119 0/119 0.06% 3[0.12,72.91]
EPOCH 2014 1/195 0/196 0.06% 3.02[0.12,73.57]
FORWARD 2013 1/289 1/297 0.08% 1.03[0.06,16.35]
GISSI-HF 2008 107/3494 129/3481 10.24% 0.83[0.64,1.06]
HARP 1995 1/41 3/39 0.13% 0.32[0.03,2.92]
JELIS 2007 71/9326 93/9319 6.87% 0.76[0.56,1.04]
OMEGA 2009 87/1919 78/1885 7.27% 1.1[0.81,1.48]
ORIGIN 2012 344/6281 316/6255 29.42% 1.08[0.93,1.26]
Proudman 2015 1/87 0/53 0.06% 1.84[0.08,44.38]
Raitt 2005 1/100 3/100 0.13% 0.33[0.04,3.15]
Risk & Prevention 2013 80/6239 90/6266 7.27% 0.89[0.66,1.2]
SCIMO 1999 1/112 4/111 0.14% 0.25[0.03,2.18]
SHOT 1996 7/317 12/293 0.77% 0.54[0.22,1.35]
SOFA 2006 1/273 3/273 0.13% 0.33[0.03,3.18]
SU.FOL.OM3 2010 32/1253 32/1248 2.78% 1[0.61,1.62]
THIS DIET 2008 1/51 3/50 0.13% 0.33[0.04,3.04]
   
Total (95% CI) 36184 35975 100% 0.95[0.88,1.03]
Total events: 1073 (Higher omega 3), 1127 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=18.7, df=22(P=0.66); I2=0%  
Test for overall effect: Z=1.17(P=0.24)  
Favours higher omega 3 200.05 50.2 1 Favours lower omega 3
 
 
Analysis 2.3.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 3 Total MI - sensitivity analysis (SA) by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.3.1 Low summary risk of bias  
AlphaOmega - EPA+DHA 2010 89/2404 102/2433 8.37% 0.88[0.67,1.17]
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AREDS2 2014 28/2147 30/2056 2.49% 0.89[0.54,1.49]
Derosa 2016 0/128 3/130 0.07% 0.15[0.01,2.78]
EPOCH 2014 1/195 0/196 0.06% 3.02[0.12,73.57]
FORWARD 2013 1/289 1/297 0.08% 1.03[0.06,16.35]
OMEGA 2009 87/1919 78/1885 7.27% 1.1[0.81,1.48]
ORIGIN 2012 344/6281 316/6255 29.42% 1.08[0.93,1.26]
Proudman 2015 1/87 0/53 0.06% 1.84[0.08,44.38]
SCIMO 1999 1/112 4/111 0.14% 0.25[0.03,2.18]
SOFA 2006 1/273 3/273 0.13% 0.33[0.03,3.18]
SU.FOL.OM3 2010 32/1253 32/1248 2.78% 1[0.61,1.62]
Subtotal (95% CI) 15088 14937 50.88% 1.03[0.92,1.15]
Total events: 585 (Higher omega 3), 569 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=6.97, df=10(P=0.73); I2=0%  
Test for overall effect: Z=0.46(P=0.65)  
   
2.3.2 Moderate to high risk of bias  
Baldassarre 2006 1/32 0/32 0.06% 3[0.13,71]
Brox 2001 0/80 1/40 0.06% 0.17[0.01,4.05]
DART 1989 207/1015 215/1018 22.52% 0.97[0.81,1.14]
DO IT 2010 11/282 9/281 0.87% 1.22[0.51,2.89]
Doi 2014 1/119 0/119 0.06% 3[0.12,72.91]
GISSI-HF 2008 107/3494 129/3481 10.24% 0.83[0.64,1.06]
HARP 1995 1/41 3/39 0.13% 0.32[0.03,2.92]
JELIS 2007 71/9326 93/9319 6.87% 0.76[0.56,1.04]
Raitt 2005 1/100 3/100 0.13% 0.33[0.04,3.15]
Risk & Prevention 2013 80/6239 90/6266 7.27% 0.89[0.66,1.2]
SHOT 1996 7/317 12/293 0.77% 0.54[0.22,1.35]
THIS DIET 2008 1/51 3/50 0.13% 0.33[0.04,3.04]
Subtotal (95% CI) 21096 21038 49.12% 0.88[0.79,0.99]
Total events: 488 (Higher omega 3), 558 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=8.36, df=11(P=0.68); I2=0%  
Test for overall effect: Z=2.13(P=0.03)  
   
Total (95% CI) 36184 35975 100% 0.95[0.88,1.03]
Total events: 1073 (Higher omega 3), 1127 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=18.7, df=22(P=0.66); I2=0%  
Test for overall effect: Z=1.17(P=0.24)  
Test for subgroup differences: Chi2=3.39, df=1 (P=0.07), I2=70.49%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 2.4.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 4 Total MI - LCn3 - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.4.1 SA - low risk of compliance bias  
AlphaOmega - EPA+DHA 2010 89/2404 102/2433 40.66% 0.88[0.67,1.17]
Baldassarre 2006 1/32 0/32 0.32% 3[0.13,71]
Brox 2001 0/80 1/40 0.31% 0.17[0.01,4.05]
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
DO IT 2010 11/282 9/281 4.22% 1.22[0.51,2.89]
HARP 1995 1/41 3/39 0.64% 0.32[0.03,2.92]
OMEGA 2009 87/1919 78/1885 35.33% 1.1[0.81,1.48]
Raitt 2005 1/100 3/100 0.63% 0.33[0.04,3.15]
SCIMO 1999 1/112 4/111 0.67% 0.25[0.03,2.18]
SHOT 1996 7/317 12/293 3.74% 0.54[0.22,1.35]
SU.FOL.OM3 2010 32/1253 32/1248 13.49% 1[0.61,1.62]
Subtotal (95% CI) 6540 6462 100% 0.94[0.79,1.13]
Total events: 230 (Higher omega 3), 244 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=7.84, df=9(P=0.55); I2=0%  
Test for overall effect: Z=0.65(P=0.51)  
   
2.4.2 SA - 100+ randomised  
AlphaOmega - EPA+DHA 2010 89/2404 102/2433 8.39% 0.88[0.67,1.17]
AREDS2 2014 28/2147 30/2056 2.49% 0.89[0.54,1.49]
Brox 2001 0/80 1/40 0.06% 0.17[0.01,4.05]
DART 1989 207/1015 215/1018 22.56% 0.97[0.81,1.14]
Derosa 2016 0/128 3/130 0.07% 0.15[0.01,2.78]
DO IT 2010 11/282 9/281 0.87% 1.22[0.51,2.89]
Doi 2014 1/119 0/119 0.06% 3[0.12,72.91]
EPOCH 2014 1/195 0/196 0.06% 3.02[0.12,73.57]
FORWARD 2013 1/289 1/297 0.09% 1.03[0.06,16.35]
GISSI-HF 2008 107/3494 129/3481 10.26% 0.83[0.64,1.06]
JELIS 2007 71/9326 93/9319 6.89% 0.76[0.56,1.04]
OMEGA 2009 87/1919 78/1885 7.29% 1.1[0.81,1.48]
ORIGIN 2012 344/6281 316/6255 29.48% 1.08[0.93,1.26]
Proudman 2015 1/87 0/53 0.06% 1.84[0.08,44.38]
Raitt 2005 1/100 3/100 0.13% 0.33[0.04,3.15]
Risk & Prevention 2013 80/6239 90/6266 7.28% 0.89[0.66,1.2]
SCIMO 1999 1/112 4/111 0.14% 0.25[0.03,2.18]
SHOT 1996 7/317 12/293 0.77% 0.54[0.22,1.35]
SOFA 2006 1/273 3/273 0.13% 0.33[0.03,3.18]
SU.FOL.OM3 2010 32/1253 32/1248 2.78% 1[0.61,1.62]
THIS DIET 2008 1/51 3/50 0.13% 0.33[0.04,3.04]
Subtotal (95% CI) 36111 35904 100% 0.95[0.88,1.03]
Total events: 1071 (Higher omega 3), 1124 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=17.25, df=20(P=0.64); I2=0%  
Test for overall effect: Z=1.15(P=0.25)  
Test for subgroup differences: Chi2=0.01, df=1 (P=0.9), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 2.5.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 5 Total MI - LCn3 - subgroup by fatality.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.5.1 Fatal MI  
AlphaOmega - EPA+DHA 2010 36/2404 102/2433 14.39% 0.36[0.25,0.52]
AREDS2 2014 3/2147 0/2056 1.4% 6.7[0.35,129.7]
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Brox 2001 0/80 1/40 1.23% 0.17[0.01,4.05]
DART 1989 56/1015 84/1018 14.94% 0.67[0.48,0.93]
DART2 2003 102/1571 76/1543 15.35% 1.32[0.99,1.76]
Derosa 2016 0/128 1/130 1.22% 0.34[0.01,8.23]
DO IT 2010 0/282 2/281 1.34% 0.2[0.01,4.13]
GISSI-HF 2008 20/3494 25/3481 11.82% 0.8[0.44,1.43]
HARP 1995 0/41 1/39 1.23% 0.32[0.01,7.57]
JELIS 2007 11/9326 14/9319 9.48% 0.79[0.36,1.73]
OMEGA 2009 13/1919 11/1885 9.36% 1.16[0.52,2.58]
Risk & Prevention 2013 10/6239 13/6266 9.12% 0.77[0.34,1.76]
SCIMO 1999 0/112 1/111 1.22% 0.33[0.01,8.02]
SHOT 1996 7/317 4/293 5.88% 1.62[0.48,5.47]
SU.FOL.OM3 2010 1/1253 2/1248 2.04% 0.5[0.05,5.49]
Subtotal (95% CI) 30328 30143 100% 0.76[0.53,1.1]
Total events: 259 (Higher omega 3), 337 (Lower omega 3)  
Heterogeneity: Tau2=0.2; Chi2=37.23, df=14(P=0); I2=62.4%  
Test for overall effect: Z=1.44(P=0.15)  
   
2.5.2 Non-fatal MI  
AlphaOmega - EPA+DHA 2010 53/2404 57/2433 7.43% 0.94[0.65,1.36]
AREDS2 2014 25/2147 30/2433 3.65% 0.94[0.56,1.6]
Baldassarre 2006 1/32 0/32 0.1% 3[0.13,71]
DART 1989 49/1015 33/1018 5.42% 1.49[0.97,2.3]
Derosa 2016 0/128 2/130 0.11% 0.2[0.01,4.19]
DO IT 2010 11/282 7/281 1.17% 1.57[0.62,3.98]
Doi 2014 1/119 0/119 0.1% 3[0.12,72.91]
EPOCH 2014 1/195 0/196 0.1% 3.02[0.12,73.57]
GISSI-HF 2008 87/3494 104/3481 12.87% 0.83[0.63,1.1]
GISSI-P 1999 223/5665 233/5658 31.38% 0.96[0.8,1.14]
HARP 1995 1/41 2/39 0.18% 0.48[0.04,5.04]
JELIS 2007 62/9326 83/9319 9.45% 0.75[0.54,1.04]
OFAMI 2001 21/150 15/150 2.62% 1.4[0.75,2.61]
OMEGA 2009 74/1662 67/1631 9.71% 1.08[0.78,1.5]
OPAL 2010 5/376 9/372 0.86% 0.55[0.19,1.62]
Proudman 2015 1/86 0/53 0.1% 1.86[0.08,44.89]
Risk & Prevention 2013 70/6239 77/6266 9.81% 0.91[0.66,1.26]
SCIMO 1999 1/112 3/111 0.2% 0.33[0.03,3.13]
SHOT 1996 5/317 3/293 0.5% 1.54[0.37,6.39]
SU.FOL.OM3 2010 32/1253 28/1248 4.04% 1.14[0.69,1.88]
THIS DIET 2008 1/51 3/50 0.2% 0.33[0.04,3.04]
Subtotal (95% CI) 35094 35313 100% 0.96[0.87,1.06]
Total events: 724 (Higher omega 3), 756 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=16.96, df=20(P=0.66); I2=0%  
Test for overall effect: Z=0.75(P=0.45)  
Test for subgroup differences: Chi2=1.41, df=1 (P=0.23), I2=29.28%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Analysis 2.6.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 6 Sudden cardiac death (overall) - LCn3.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AREDS2 2014 7/2147 9/2056 3.39% 0.74[0.28,2]
Brox 2001 0/80 0/40   Not estimable
DART2 2003 73/1571 47/1543 14.55% 1.53[1.06,2.19]
DO IT 2010 3/282 5/281 1.73% 0.6[0.14,2.48]
Doi 2014 0/119 2/119 0.4% 0.2[0.01,4.12]
FOSTAR 2016 0/101 1/101 0.36% 0.33[0.01,8.09]
GISSI-HF 2008 307/3494 325/3481 25.08% 0.94[0.81,1.09]
GISSI-P 1999 122/5666 164/5658 20.69% 0.74[0.59,0.94]
JELIS 2007 18/9326 17/9319 6.58% 1.06[0.55,2.05]
OMEGA 2009 28/1919 29/1885 9.49% 0.95[0.57,1.59]
Raitt 2005 2/100 0/100 0.4% 5[0.24,102.85]
Risk & Prevention 2013 49/6239 40/6266 12.42% 1.23[0.81,1.87]
SHOT 1996 7/317 4/293 2.31% 1.62[0.48,5.47]
SU.FOL.OM3 2010 4/1253 11/1248 2.6% 0.36[0.12,1.13]
   
Total (95% CI) 32614 32390 100% 0.97[0.8,1.18]
Total events: 620 (Higher omega 3), 654 (Lower omega 3)  
Heterogeneity: Tau2=0.03; Chi2=19.29, df=12(P=0.08); I2=37.79%  
Test for overall effect: Z=0.29(P=0.77)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 2.7.   Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 7 Angina - LCn3.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AREDS2 2014 26/2147 25/2056 1.93% 1[0.58,1.72]
EPE-A 2014 2/168 1/75 0.1% 0.89[0.08,9.7]
FAAT 2005 0/200 4/202 0.07% 0.11[0.01,2.07]
GISSI-P 1999 254/2836 249/2828 20.67% 1.02[0.86,1.2]
Nye 1990 5/36 11/37 0.63% 0.47[0.18,1.21]
OMEGA 2009 21/1661 25/1651 1.73% 0.83[0.47,1.49]
ORIGIN 2012 724/6281 725/6255 61.36% 0.99[0.9,1.1]
Raitt 2005 10/100 7/100 0.67% 1.43[0.57,3.6]
Risk & Prevention 2013 143/6239 148/6266 11.16% 0.97[0.77,1.22]
SCIMO 1999 9/112 11/111 0.81% 0.81[0.35,1.88]
SOFA 2006 10/273 12/273 0.85% 0.83[0.37,1.9]
   
Total (95% CI) 20053 19854 100% 0.99[0.91,1.06]
Total events: 1204 (Higher omega 3), 1218 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=6, df=10(P=0.82); I2=0%  
Test for overall effect: Z=0.35(P=0.72)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Analysis 2.8.   Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 8 Heart failure - LCn3.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.8.1 Low summary risk of bias  
AREDS2 2014 55/2147 49/2056 5.8% 1.07[0.73,1.57]
FORWARD 2013 5/289 6/297 0.71% 0.86[0.26,2.78]
OMEGA 2009 467/1919 492/1885 24.45% 0.93[0.84,1.04]
ORIGIN 2012 331/6281 320/6255 19.53% 1.03[0.89,1.2]
SOFA 2006 22/273 19/273 2.67% 1.16[0.64,2.09]
SU.FOL.OM3 2010 21/1253 22/1248 2.65% 0.95[0.53,1.72]
Subtotal (95% CI) 12162 12014 55.8% 0.97[0.89,1.06]
Total events: 901 (Higher omega 3), 908 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.81, df=5(P=0.87); I2=0%  
Test for overall effect: Z=0.63(P=0.53)  
   
2.8.2 Moderate to high risk of bias  
DART 1989 5/1015 4/1018 0.58% 1.25[0.34,4.66]
DART2 2003 1/1571 2/1543 0.17% 0.49[0.04,5.41]
FAAT 2005 6/200 8/202 0.91% 0.76[0.27,2.14]
GISSI-HF 2008 978/3494 995/3481 28.96% 0.98[0.91,1.06]
HARP 1995 0/41 1/39 0.1% 0.32[0.01,7.57]
Nodari 2011 HF 4/67 20/66 0.94% 0.2[0.07,0.55]
Raitt 2005 14/100 12/100 1.84% 1.17[0.57,2.4]
Risk & Prevention 2013 96/6239 142/6266 10.6% 0.68[0.53,0.88]
Shinto 2014 1/13 0/13 0.1% 3[0.13,67.51]
Subtotal (95% CI) 12740 12728 44.2% 0.78[0.57,1.08]
Total events: 1105 (Higher omega 3), 1184 (Lower omega 3)  
Heterogeneity: Tau2=0.07; Chi2=18.5, df=8(P=0.02); I2=56.75%  
Test for overall effect: Z=1.51(P=0.13)  
   
Total (95% CI) 24902 24742 100% 0.93[0.85,1.03]
Total events: 2006 (Higher omega 3), 2092 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=20.4, df=14(P=0.12); I2=31.36%  
Test for overall effect: Z=1.32(P=0.19)  
Test for subgroup differences: Chi2=1.68, df=1 (P=0.19), I2=40.52%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 2.9.   Comparison 2 High vs low LCn3 omega-3 fats
(secondary outcomes), Outcome 9 Revascularisation - LCn3.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.9.1 CABG - LCn3  
Doi 2014 1/119 1/119 23.4% 1[0.06,15.8]
EPOCH 2014 0/195 1/196 17.47% 0.34[0.01,8.17]
Nye 1990 1/36 1/37 23.86% 1.03[0.07,15.82]
SCIMO 1999 1/112 3/111 35.28% 0.33[0.03,3.13]
SHOT 1996 0/317 0/293   Not estimable
Subtotal (95% CI) 779 756 100% 0.56[0.15,2.14]
Total events: 3 (Higher omega 3), 6 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.67, df=3(P=0.88); I2=0%  
Favours higher omega 3 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.84(P=0.4)  
   
2.9.2 Angioplasty - LCn3  
EPOCH 2014 2/195 1/196 1.14% 2.01[0.18,21.99]
HARP 1995 3/41 3/39 2.76% 0.95[0.2,4.43]
SCIMO 1999 25/112 19/111 22.79% 1.3[0.76,2.23]
SU.FOL.OM3 2010 75/1253 87/1248 73.3% 0.86[0.64,1.16]
Subtotal (95% CI) 1601 1594 100% 0.96[0.74,1.24]
Total events: 105 (Higher omega 3), 110 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.16, df=3(P=0.54); I2=0%  
Test for overall effect: Z=0.34(P=0.73)  
   
2.9.3 Any revascularisation - LCn3  
AREDS2 2014 60/2147 53/2056 1.47% 1.08[0.75,1.56]
Doi 2014 9/119 15/119 0.32% 0.6[0.27,1.32]
GISSI-P 1999 1104/5666 1053/5658 33.83% 1.05[0.97,1.13]
HARP 1995 3/41 3/39 0.08% 0.95[0.2,4.43]
JELIS 2007 191/9326 222/9319 5.33% 0.86[0.71,1.04]
OFAMI 2001 43/150 49/150 1.68% 0.88[0.62,1.23]
OMEGA 2009 466/1686 482/1654 16.81% 0.95[0.85,1.06]
ORIGIN 2012 866/6281 896/6255 26.04% 0.96[0.88,1.05]
Raitt 2005 2/100 4/100 0.07% 0.5[0.09,2.67]
Risk & Prevention 2013 334/6239 347/6266 9.15% 0.97[0.84,1.12]
SCIMO 1999 26/112 22/111 0.77% 1.17[0.71,1.94]
SU.FOL.OM3 2010 152/1253 156/1248 4.46% 0.97[0.79,1.2]
Subtotal (95% CI) 33120 32975 100% 0.98[0.94,1.03]
Total events: 3256 (Higher omega 3), 3302 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=8.56, df=11(P=0.66); I2=0%  
Test for overall effect: Z=0.79(P=0.43)  
Favours higher omega 3 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 2.10.   Comparison 2 High vs low LCn3 omega-3 fats
(secondary outcomes), Outcome 10 Peripheral arterial disease - LCn3.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
JELIS 2007 21/9326 29/9319 17.26% 0.72[0.41,1.27]
ORIGIN 2012 52/6281 47/6255 35.17% 1.1[0.74,1.63]
Risk & Prevention 2013 62/6239 68/6266 46.32% 0.92[0.65,1.29]
FOSTAR 2016 1/101 1/101 0.71% 1[0.06,15.77]
DART 1989 0/1015 1/1018 0.53% 0.33[0.01,8.2]
DART2 2003 0/1571 0/1543   Not estimable
   
Total (95% CI) 24533 24502 100% 0.93[0.74,1.18]
Total events: 136 (Higher omega 3), 146 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.89, df=4(P=0.76); I2=0%  
Test for overall effect: Z=0.57(P=0.57)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Analysis 2.11.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 11 PAD - LCn3 - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.11.1 Low summary risk of bias  
ORIGIN 2012 52/6281 47/6255 98.01% 1.1[0.74,1.63]
FOSTAR 2016 1/101 1/101 1.99% 1[0.06,15.77]
Subtotal (95% CI) 6382 6356 100% 1.1[0.75,1.62]
Total events: 53 (Higher omega 3), 48 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%  
Test for overall effect: Z=0.48(P=0.63)  
   
2.11.2 Moderate to high summary risk of bias  
JELIS 2007 21/9326 29/9319 26.92% 0.72[0.41,1.27]
Risk & Prevention 2013 62/6239 68/6266 72.25% 0.92[0.65,1.29]
DART 1989 0/1015 1/1018 0.83% 0.33[0.01,8.2]
DART2 2003 0/1571 0/1543   Not estimable
Subtotal (95% CI) 18151 18146 100% 0.85[0.64,1.14]
Total events: 83 (Higher omega 3), 98 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.82, df=2(P=0.66); I2=0%  
Test for overall effect: Z=1.08(P=0.28)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 2.12.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 12 PAD - LCn3 - SA compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.12.1 SA compliance  
FOSTAR 2016 1/101 1/101 100% 1[0.06,15.77]
Subtotal (95% CI) 101 101 100% 1[0.06,15.77]
Total events: 1 (Higher omega 3), 1 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.12.2 SA study size 100+  
JELIS 2007 21/9326 29/9319 17.26% 0.72[0.41,1.27]
ORIGIN 2012 52/6281 47/6255 35.17% 1.1[0.74,1.63]
Risk & Prevention 2013 62/6239 68/6266 46.32% 0.92[0.65,1.29]
FOSTAR 2016 1/101 1/101 0.71% 1[0.06,15.77]
DART 1989 0/1015 1/1018 0.53% 0.33[0.01,8.2]
DART2 2003 0/1571 0/1543   Not estimable
Subtotal (95% CI) 24533 24502 100% 0.93[0.74,1.18]
Total events: 136 (Higher omega 3), 146 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.89, df=4(P=0.76); I2=0%  
Test for overall effect: Z=0.57(P=0.57)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Analysis 2.13.   Comparison 2 High vs low LCn3 omega-3 fats
(secondary outcomes), Outcome 13 Acute coronary syndrome - LCn3.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.13.1 LCn3  
FOSTAR 2016 10/101 10/101 38.97% 1[0.44,2.3]
SU.FOL.OM3 2010 20/1253 15/1248 61.03% 1.33[0.68,2.58]
Subtotal (95% CI) 1354 1349 100% 1.19[0.71,2]
Total events: 30 (Higher omega 3), 25 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.27, df=1(P=0.6); I2=0%  
Test for overall effect: Z=0.65(P=0.51)  
Favours high LCn3 1000.01 100.1 1 Favours low LCn3
 
 
Analysis 2.14.   Comparison 2 High vs low LCn3 omega-3 fats
(secondary outcomes), Outcome 14 Body weight, kg - LCn3.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Caldwell 2011 20 -1.5 (4.5) 21 -0.2 (3.7) 7.89% -1.3[-3.83,1.23]
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 10.51% -2.7[-4.75,-0.65]
EPE-A 2014 64 0 (0) 55 -1 (0)   Not estimable
FOSTAR 2016 101 1.8 (5) 101 0.3 (4) 17.6% 1.5[0.25,2.75]
HARP 1995 31 82 (14) 28 80 (15) 1.2% 2[-5.43,9.43]
MARINA 2011 80 0.2 (1.8) 71 -0.3 (2.5) 24.22% 0.5[-0.21,1.21]
Norouzi 2014 54 71.4 (14.4) 50 70.8 (14.4) 2.09% 0.6[-4.93,6.13]
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 25.7% 0.1[-0.48,0.68]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 4.35% -1.9[-5.57,1.77]
SMART 2013 20 84.3 (11.7) 25 80.9 (12.7) 1.29% 3.4[-3.75,10.55]
Weinstock-Guttman 2005 13 -2.7 (6.2) 14 0.2 (5.1) 3.31% -2.91[-7.21,1.39]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 1.84% 3.7[-2.22,9.62]
   
Total *** 8928   6884   100% -0.01[-0.84,0.82]
Heterogeneity: Tau2=0.61; Chi2=19.57, df=10(P=0.03); I2=48.89%  
Test for overall effect: Z=0.01(P=0.99)  
Favours higher omega 3 52.5-5 -2.5 0 Favours lower omega 3
 
 
Analysis 2.15.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 15 Weight, kg - LCn3 - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.15.1 Low risk of bias  
Caldwell 2011 20 -1.5 (4.5) 21 -0.2 (3.7) 7.89% -1.3[-3.83,1.23]
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 10.51% -2.7[-4.75,-0.65]
FOSTAR 2016 101 1.8 (5) 101 0.3 (4) 17.6% 1.5[0.25,2.75]
MARINA 2011 80 0.2 (1.8) 71 -0.3 (2.5) 24.22% 0.5[-0.21,1.21]
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 25.7% 0.1[-0.48,0.68]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 4.35% -1.9[-5.57,1.77]
Favours higher omega 3 52.5-5 -2.5 0 Favours lower omega 3
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
354
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 1.84% 3.7[-2.22,9.62]
Subtotal *** 8746   6712   92.11% -0.01[-0.91,0.9]
Heterogeneity: Tau2=0.7; Chi2=16.53, df=6(P=0.01); I2=63.7%  
Test for overall effect: Z=0.02(P=0.98)  
   
2.15.2 Moderate/high risk of bias  
EPE-A 2014 64 0 (0) 55 -1 (0)   Not estimable
HARP 1995 31 82 (14) 28 80 (15) 1.2% 2[-5.43,9.43]
Norouzi 2014 54 71.4 (14.4) 50 70.8 (14.4) 2.09% 0.6[-4.93,6.13]
SMART 2013 20 84.3 (11.7) 25 80.9 (12.7) 1.29% 3.4[-3.75,10.55]
Weinstock-Guttman 2005 13 -2.7 (6.2) 14 0.2 (5.1) 3.31% -2.91[-7.21,1.39]
Subtotal *** 182   172   7.89% -0.28[-3.12,2.55]
Heterogeneity: Tau2=0; Chi2=2.92, df=3(P=0.4); I2=0%  
Test for overall effect: Z=0.19(P=0.85)  
   
Total *** 8928   6884   100% -0.01[-0.84,0.82]
Heterogeneity: Tau2=0.61; Chi2=19.57, df=10(P=0.03); I2=48.89%  
Test for overall effect: Z=0.01(P=0.99)  
Test for subgroup differences: Chi2=0.03, df=1 (P=0.86), I2=0%  
Favours higher omega 3 52.5-5 -2.5 0 Favours lower omega 3
 
 
Analysis 2.16.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 16 Weight, kg - LCn3 - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.16.1 SA - low risk of compliance bias  
EPE-A 2014 64 0 (0) 55 -1 (0)   Not estimable
FOSTAR 2016 101 1.8 (5) 101 0.3 (4) 33.45% 1.5[0.25,2.75]
HARP 1995 31 82 (14) 28 80 (15) 2.13% 2[-5.43,9.43]
MARINA 2011 80 0.2 (1.8) 71 -0.3 (2.5) 47.38% 0.5[-0.21,1.21]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 7.83% -1.9[-5.57,1.77]
Weinstock-Guttman 2005 13 -2.7 (6.2) 14 0.2 (5.1) 5.93% -2.91[-7.21,1.39]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 3.28% 3.7[-2.22,9.62]
Subtotal *** 425   403   100% 0.58[-0.52,1.69]
Heterogeneity: Tau2=0.54; Chi2=7.57, df=5(P=0.18); I2=33.92%  
Test for overall effect: Z=1.03(P=0.3)  
   
2.16.2 SA - 100+ randomised  
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 12.5% -2.7[-4.75,-0.65]
EPE-A 2014 64 0 (0) 55 -1 (0)   Not estimable
FOSTAR 2016 101 1.8 (5) 101 0.3 (4) 20.85% 1.5[0.25,2.75]
MARINA 2011 80 0.2 (1.8) 71 -0.3 (2.5) 28.61% 0.5[-0.21,1.21]
Norouzi 2014 54 71.4 (14.4) 50 70.8 (14.4) 2.5% 0.6[-4.93,6.13]
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 30.35% 0.1[-0.48,0.68]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 5.19% -1.9[-5.57,1.77]
Subtotal *** 8797   6748   100% 0.07[-0.84,0.97]
Heterogeneity: Tau2=0.62; Chi2=13.81, df=5(P=0.02); I2=63.81%  
Test for overall effect: Z=0.14(P=0.89)  
Favours higher omega 3 52.5-5 -2.5 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for subgroup differences: Chi2=0.5, df=1 (P=0.48), I2=0%  
Favours higher omega 3 52.5-5 -2.5 0 Favours lower omega 3
 
 
Analysis 2.17.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 17 Weight, kg - LCn3 - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.17.1 LCn3 ≤ 150 mg/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.17.2 LCn3 > 150 ≤ 250 mg/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.17.3 LCn3 > 250 ≤ 400 mg/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.17.4 LCn3 > 400 ≤ 2400 mg/d  
Caldwell 2011 20 -1.5 (4.5) 21 -0.2 (3.7) 9.27% -1.3[-3.83,1.23]
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 12.65% -2.7[-4.75,-0.65]
EPE-A 2014 55 0.5 (0) 55 -1 (0)   Not estimable
MARINA 2011 80 0.2 (1.8) 71 -0.3 (2.5) 33.38% 0.5[-0.21,1.21]
Norouzi 2014 54 71.4 (14.4) 50 70.8 (14.4) 2.33% 0.6[-4.93,6.13]
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 35.99% 0.1[-0.48,0.68]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 4.95% -1.9[-5.57,1.77]
SMART 2013 20 84.3 (11.7) 25 80.9 (12.7) 1.43% 3.4[-3.75,10.55]
Subtotal *** 8727   6693   100% -0.29[-1.16,0.58]
Heterogeneity: Tau2=0.46; Chi2=11.52, df=6(P=0.07); I2=47.92%  
Test for overall effect: Z=0.65(P=0.51)  
   
2.17.5 LCn3 > 2.4 ≤ 4.4 g/d  
EPE-A 2014 64 0 (0) 55 -1 (0)   Not estimable
Weinstock-Guttman 2005 13 -2.7 (6.2) 14 0.2 (5.1) 54.95% -2.91[-7.21,1.39]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 45.05% 3.7[-2.22,9.62]
Subtotal *** 124   117   100% 0.07[-6.38,6.51]
Heterogeneity: Tau2=14.88; Chi2=3.13, df=1(P=0.08); I2=68.09%  
Test for overall effect: Z=0.02(P=0.98)  
   
2.17.6 LCn3 > 4.4 g/d  
FOSTAR 2016 101 1.8 (5) 101 0.3 (4) 97.23% 1.5[0.25,2.75]
HARP 1995 31 82 (14) 28 80 (15) 2.77% 2[-5.43,9.43]
Subtotal *** 132   129   100% 1.51[0.28,2.75]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.9); I2=0%  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=2.4(P=0.02)  
Test for subgroup differences: Chi2=5.48, df=1 (P=0.06), I2=63.49%  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
 
 
Analysis 2.18.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 18 Weight, kg - LCn3 - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.18.1 N-3 replacing SFA  
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 76.22% -2.7[-4.75,-0.65]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 23.78% -1.9[-5.57,1.77]
Subtotal *** 217   216   100% -2.51[-4.3,-0.72]
Heterogeneity: Tau2=0; Chi2=0.14, df=1(P=0.71); I2=0%  
Test for overall effect: Z=2.74(P=0.01)  
   
2.18.2 N-3 replacing MUFA  
HARP 1995 31 82 (14) 28 80 (15) 0.47% 2[-5.43,9.43]
MARINA 2011 80 0.2 (1.8) 71 -0.3 (2.5) 40.53% 0.5[-0.21,1.21]
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 54.42% 0.1[-0.48,0.68]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 1.92% -1.9[-5.57,1.77]
SMART 2013 20 84.3 (11.7) 25 80.9 (12.7) 0.51% 3.4[-3.75,10.55]
Weinstock-Guttman 2005 13 -2.7 (6.2) 14 0.2 (5.1) 1.4% -2.91[-7.21,1.39]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 0.74% 3.7[-2.22,9.62]
Subtotal *** 8561   6527   100% 0.23[-0.28,0.75]
Heterogeneity: Tau2=0.04; Chi2=6.38, df=6(P=0.38); I2=6.01%  
Test for overall effect: Z=0.9(P=0.37)  
   
2.18.3 N-3 replacing n-6  
Caldwell 2011 20 -1.5 (4.5) 21 -0.2 (3.7) 100% -1.3[-3.83,1.23]
Subtotal *** 20   21   100% -1.3[-3.83,1.23]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.01(P=0.31)  
   
2.18.4 N-3 replacing carbs/sugars  
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 100% -2.7[-4.75,-0.65]
Subtotal *** 128   130   100% -2.7[-4.75,-0.65]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.58(P=0.01)  
   
2.18.5 N-3 replacing nil/low n-3 placebo  
FOSTAR 2016 101 1.8 (5) 101 0.3 (4) 100% 1.5[0.25,2.75]
Subtotal *** 101   101   100% 1.5[0.25,2.75]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.34(P=0.02)  
   
2.18.6 Replacement unclear  
EPE-A 2014 64 0 (0) 55 -1 (0)   Not estimable
Norouzi 2014 54 71.4 (14.4) 50 70.8 (14.4) 100% 0.6[-4.93,6.13]
Favours higher omega 3 42-4 -2 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Subtotal *** 118   105   100% 0.6[-4.93,6.13]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.21(P=0.83)  
Test for subgroup differences: Chi2=21.5, df=1 (P=0), I2=76.74%  
Favours higher omega 3 42-4 -2 0 Favours lower omega 3
 
 
Analysis 2.19.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 19 Weight, kg - LCn3 - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.19.1 Dietary advice  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.19.2 Supplemental foods  
FOSTAR 2016 101 1.8 (5) 101 0.3 (4) 17.6% 1.5[0.25,2.75]
Subtotal *** 101   101   17.6% 1.5[0.25,2.75]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.34(P=0.02)  
   
2.19.3 Supplement (capsule)  
Caldwell 2011 20 -1.5 (4.5) 21 -0.2 (3.7) 7.89% -1.3[-3.83,1.23]
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 10.51% -2.7[-4.75,-0.65]
EPE-A 2014 64 0 (0) 55 -1 (0)   Not estimable
HARP 1995 31 82 (14) 28 80 (15) 1.2% 2[-5.43,9.43]
MARINA 2011 80 0.2 (1.8) 71 -0.3 (2.5) 24.22% 0.5[-0.21,1.21]
Norouzi 2014 54 71.4 (14.4) 50 70.8 (14.4) 2.09% 0.6[-4.93,6.13]
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 25.7% 0.1[-0.48,0.68]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 4.35% -1.9[-5.57,1.77]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 1.84% 3.7[-2.22,9.62]
Subtotal *** 8794   6744   77.8% -0.23[-1.08,0.63]
Heterogeneity: Tau2=0.44; Chi2=12.39, df=7(P=0.09); I2=43.48%  
Test for overall effect: Z=0.52(P=0.6)  
   
2.19.4 Any combination  
SMART 2013 20 84.3 (11.7) 25 80.9 (12.7) 1.29% 3.4[-3.75,10.55]
Weinstock-Guttman 2005 13 -2.7 (6.2) 14 0.2 (5.1) 3.31% -2.91[-7.21,1.39]
Subtotal *** 33   39   4.6% -0.43[-6.47,5.61]
Heterogeneity: Tau2=10.86; Chi2=2.2, df=1(P=0.14); I2=54.53%  
Test for overall effect: Z=0.14(P=0.89)  
   
Total *** 8928   6884   100% -0.01[-0.84,0.82]
Heterogeneity: Tau2=0.61; Chi2=19.57, df=10(P=0.03); I2=48.89%  
Test for overall effect: Z=0.01(P=0.99)  
Test for subgroup differences: Chi2=5.04, df=1 (P=0.08), I2=60.3%  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
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Analysis 2.20.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 20 Weight, kg - LCn3 - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.20.1 Medium duration 1 to < 2 years in study  
Caldwell 2011 20 -1.5 (4.5) 21 -0.2 (3.7) 18.68% -1.3[-3.83,1.23]
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 21.9% -2.7[-4.75,-0.65]
EPE-A 2014 64 0 (0) 55 -1 (0)   Not estimable
MARINA 2011 80 0.2 (1.8) 71 -0.3 (2.5) 31% 0.5[-0.21,1.21]
Norouzi 2014 54 71.4 (14.4) 50 70.8 (14.4) 7.1% 0.6[-4.93,6.13]
SMART 2013 20 84.3 (11.7) 25 80.9 (12.7) 4.66% 3.4[-3.75,10.55]
Weinstock-Guttman 2005 13 -2.7 (6.2) 14 0.2 (5.1) 10.3% -2.91[-7.21,1.39]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 6.37% 3.7[-2.22,9.62]
Subtotal *** 426   414   100% -0.54[-2.21,1.12]
Heterogeneity: Tau2=2.2; Chi2=13.7, df=6(P=0.03); I2=56.19%  
Test for overall effect: Z=0.64(P=0.52)  
   
2.20.2 Medium-long duration: 2 to < 4 years in study  
FOSTAR 2016 101 1.8 (5) 101 0.3 (4) 66.05% 1.5[0.25,2.75]
HARP 1995 31 82 (14) 28 80 (15) 8.22% 2[-5.43,9.43]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 25.74% -1.9[-5.57,1.77]
Subtotal *** 221   215   100% 0.67[-1.58,2.91]
Heterogeneity: Tau2=1.57; Chi2=3, df=2(P=0.22); I2=33.23%  
Test for overall effect: Z=0.58(P=0.56)  
   
2.20.3 Long duration ≥ 4 years in study  
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 100% 0.1[-0.48,0.68]
Subtotal *** 8281   6255   100% 0.1[-0.48,0.68]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.34(P=0.74)  
Test for subgroup differences: Chi2=0.8, df=1 (P=0.67), I2=0%  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
 
 
Analysis 2.21.   Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes),
Outcome 21 Weight, kg - LCn3 - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.21.1 Primary CVD prevention  
Caldwell 2011 20 -1.5 (4.5) 21 -0.2 (3.7) 8.6% -1.3[-3.83,1.23]
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 11.37% -2.7[-4.75,-0.65]
EPE-A 2014 64 0 (0) 55 -1 (0)   Not estimable
FOSTAR 2016 101 1.8 (5) 101 0.3 (4) 18.67% 1.5[0.25,2.75]
MARINA 2011 80 0.2 (1.8) 71 -0.3 (2.5) 25.24% 0.5[-0.21,1.21]
Norouzi 2014 54 71.4 (14.4) 50 70.8 (14.4) 2.32% 0.6[-4.93,6.13]
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 26.68% 0.1[-0.48,0.68]
SMART 2013 20 84.3 (11.7) 25 80.9 (12.7) 1.43% 3.4[-3.75,10.55]
Weinstock-Guttman 2005 13 -2.7 (6.2) 14 0.2 (5.1) 3.66% -2.91[-7.21,1.39]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 2.04% 3.7[-2.22,9.62]
Subtotal *** 8808   6770   100% 0.05[-0.83,0.92]
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Tau2=0.66; Chi2=18.06, df=8(P=0.02); I2=55.71%  
Test for overall effect: Z=0.1(P=0.92)  
   
2.21.2 Secondary CVD prevention  
HARP 1995 31 82 (14) 28 80 (15) 19.67% 2[-5.43,9.43]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 80.33% -1.9[-5.57,1.77]
Subtotal *** 120   114   100% -1.13[-4.43,2.16]
Heterogeneity: Tau2=0; Chi2=0.85, df=1(P=0.36); I2=0%  
Test for overall effect: Z=0.67(P=0.5)  
Test for subgroup differences: Chi2=0.46, df=1 (P=0.5), I2=0%  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
 
 
Analysis 2.22.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 22 Weight, kg - LCn3 - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.22.1 LCn3 - ≥ 50% of control group on statins  
ORIGIN 2012 8281 83.9 (17.8) 6255 83.8 (17.6) 84.89% 0.1[-0.48,0.68]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 15.11% 3.7[-2.22,9.62]
Subtotal *** 8328   6303   100% 0.64[-1.88,3.17]
Heterogeneity: Tau2=1.87; Chi2=1.41, df=1(P=0.24); I2=28.87%  
Test for overall effect: Z=0.5(P=0.62)  
   
2.22.2 LCn3 - < 50% of control group on statins  
FOSTAR 2016 101 1.8 (5) 101 0.3 (4) 34.62% 1.5[0.25,2.75]
HARP 1995 31 82 (14) 28 80 (15) 2.23% 2[-5.43,9.43]
MARINA 2011 80 0.2 (1.8) 71 -0.3 (2.5) 48.77% 0.5[-0.21,1.21]
SCIMO 1999 89 79.1 (12.5) 86 81 (12.3) 8.18% -1.9[-5.57,1.77]
Weinstock-Guttman 2005 13 -2.7 (6.2) 14 0.2 (5.1) 6.2% -2.91[-7.21,1.39]
Subtotal *** 314   300   100% 0.47[-0.66,1.6]
Heterogeneity: Tau2=0.55; Chi2=6.53, df=4(P=0.16); I2=38.74%  
Test for overall effect: Z=0.82(P=0.41)  
   
2.22.3 LCn3 - use of statins unclear  
Caldwell 2011 20 -1.5 (4.5) 21 -0.2 (3.7) 36.23% -1.3[-3.83,1.23]
Derosa 2016 128 78.7 (7.9) 130 81.4 (8.9) 48.17% -2.7[-4.75,-0.65]
EPE-A 2014 64 0 (0) 55 -1 (0)   Not estimable
Norouzi 2014 54 71.4 (14.4) 50 70.8 (14.4) 9.65% 0.6[-4.93,6.13]
SMART 2013 20 84.3 (11.7) 25 80.9 (12.7) 5.96% 3.4[-3.75,10.55]
Subtotal *** 286   281   100% -1.51[-3.3,0.27]
Heterogeneity: Tau2=0.62; Chi2=3.63, df=3(P=0.3); I2=17.31%  
Test for overall effect: Z=1.66(P=0.1)  
Test for subgroup differences: Chi2=3.67, df=1 (P=0.16), I2=45.53%  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
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Analysis 2.23.   Comparison 2 High vs low LCn3 omega-3 fats
(secondary outcomes), Outcome 23 Body mass index, kg/m2 - LCn3.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
AlphaOmega - EPA+DHA 2010 630 0 (1.8) 630 -0.1 (1.8) 25.26% 0.1[-0.1,0.3]
Caldwell 2011 20 -0.5 (4.5) 21 -0.2 (3.7) 0.6% -0.3[-2.83,2.23]
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 9.65% -0.6[-1.14,-0.06]
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 3.92% -0.2[-1.14,0.74]
EPE-A 2014 64 0 (0) 55 -0.3 (0)   Not estimable
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 0.8% 1[-1.18,3.18]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 26.9% 0[-0.17,0.17]
Norouzi 2014 54 24.8 (4.9) 50 24.2 (4.2) 1.22% 0.58[-1.17,2.33]
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 4.04% 0.6[-0.32,1.52]
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 25.44% 0[-0.2,0.2]
SMART 2013 20 29.8 (3.5) 25 28.2 (3.4) 0.92% 1.6[-0.43,3.63]
Sofi 2010 6 -0.6 (0) 5 -0.1 (0)   Not estimable
Tande 2016 50 0.6 (9.7) 50 -0.4 (12.1) 0.21% 1[-3.3,5.3]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.05% 2.6[0.71,4.49]
   
Total *** 7636   7598   100% 0.04[-0.16,0.24]
Heterogeneity: Tau2=0.03; Chi2=18.44, df=11(P=0.07); I2=40.34%  
Test for overall effect: Z=0.41(P=0.68)  
Favours higher omega 3 52.5-5 -2.5 0 Favours lower omega 3
 
 
Analysis 2.24.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 24 BMI, kg/m2- LCn3 - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.24.1 Low risk of bias  
AlphaOmega - EPA+DHA 2010 630 0 (1.8) 630 -0.1 (1.8) 25.26% 0.1[-0.1,0.3]
Caldwell 2011 20 -0.5 (4.5) 21 -0.2 (3.7) 0.6% -0.3[-2.83,2.23]
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 9.65% -0.6[-1.14,-0.06]
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 25.44% 0[-0.2,0.2]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.05% 2.6[0.71,4.49]
Subtotal *** 7106   7084   61.99% -0.01[-0.36,0.33]
Heterogeneity: Tau2=0.08; Chi2=12.98, df=4(P=0.01); I2=69.17%  
Test for overall effect: Z=0.07(P=0.94)  
   
2.24.2 Moderate/high risk of bias  
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 3.92% -0.2[-1.14,0.74]
EPE-A 2014 64 0 (0) 55 -0.3 (0)   Not estimable
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 0.8% 1[-1.18,3.18]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 26.9% 0[-0.17,0.17]
Norouzi 2014 54 24.8 (4.9) 50 24.2 (4.2) 1.22% 0.58[-1.17,2.33]
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 4.04% 0.6[-0.32,1.52]
SMART 2013 20 29.8 (3.5) 25 28.2 (3.4) 0.92% 1.6[-0.43,3.63]
Sofi 2010 6 -0.6 (0) 5 -0.1 (0)   Not estimable
Tande 2016 50 0.6 (9.7) 50 -0.4 (12.1) 0.21% 1[-3.3,5.3]
Subtotal *** 530   514   38.01% 0.04[-0.13,0.2]
Heterogeneity: Tau2=0; Chi2=5.44, df=6(P=0.49); I2=0%  
Favours higher omega 3 42-4 -2 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=0.43(P=0.67)  
   
Total *** 7636   7598   100% 0.04[-0.16,0.24]
Heterogeneity: Tau2=0.03; Chi2=18.44, df=11(P=0.07); I2=40.34%  
Test for overall effect: Z=0.41(P=0.68)  
Test for subgroup differences: Chi2=0.06, df=1 (P=0.8), I2=0%  
Favours higher omega 3 42-4 -2 0 Favours lower omega 3
 
 
Analysis 2.25.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 25 BMI, kg/m2- LCn3 - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.25.1 SA - low risk of compliance bias  
AlphaOmega - EPA+DHA 2010 630 0 (1.8) 630 -0.1 (1.8) 43.64% 0.1[-0.1,0.3]
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 8.24% -0.2[-1.14,0.74]
EPE-A 2014 64 0 (0) 55 -0.3 (0)   Not estimable
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 45.84% 0[-0.17,0.17]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 2.28% 2.6[0.71,4.49]
Subtotal *** 932   916   100% 0.09[-0.21,0.38]
Heterogeneity: Tau2=0.04; Chi2=7.81, df=3(P=0.05); I2=61.57%  
Test for overall effect: Z=0.58(P=0.56)  
   
2.25.2 SA - 100+ randomised  
AlphaOmega - EPA+DHA 2010 630 0 (1.8) 630 -0.1 (1.8) 28.14% 0.1[-0.1,0.3]
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 5.27% -0.6[-1.14,-0.06]
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 1.8% -0.2[-1.14,0.74]
EPE-A 2014 64 0 (0) 55 -0.3 (0)   Not estimable
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 33.64% 0[-0.17,0.17]
Norouzi 2014 54 24.8 (4.9) 50 24.2 (4.2) 0.52% 0.58[-1.17,2.33]
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 1.87% 0.6[-0.32,1.52]
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 28.68% 0[-0.2,0.2]
Tande 2016 50 0.6 (9.7) 50 -0.4 (12.1) 0.09% 1[-3.3,5.3]
Subtotal *** 7513   7469   100% 0.01[-0.12,0.14]
Heterogeneity: Tau2=0; Chi2=8.14, df=7(P=0.32); I2=14%  
Test for overall effect: Z=0.12(P=0.9)  
Test for subgroup differences: Chi2=0.23, df=1 (P=0.63), I2=0%  
Favours higher omega 3 42-4 -2 0 Favours lower omega 3
 
 
Analysis 2.26.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 26 BMI, kg/m2 - LCn3 - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.26.1 LCn3 > 150 ≤ 250 mg/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Not applicable  
   
2.26.2 LCn3 ≤ 150 mg/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.26.3 LCn3 > 250 ≤ 400 mg/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.26.4 LCn3 > 400 ≤ 2400 mg/d  
AlphaOmega - EPA+DHA 2010 630 0 (1.8) 630 -0.1 (1.8) 28.38% 0.1[-0.1,0.3]
Caldwell 2011 20 -0.5 (4.5) 21 -0.2 (3.7) 0.23% -0.3[-2.83,2.23]
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 4.87% -0.6[-1.14,-0.06]
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 1.65% -0.2[-1.14,0.74]
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 0.31% 1[-1.18,3.18]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 34.68% 0[-0.17,0.17]
Norouzi 2014 54 24.8 (4.9) 50 24.2 (4.2) 0.48% 0.58[-1.17,2.33]
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 28.98% 0[-0.2,0.2]
SMART 2013 20 29.8 (3.5) 25 28.2 (3.4) 0.35% 1.6[-0.43,3.63]
Sofi 2010 6 -0.6 (0) 5 -0.1 (0)   Not estimable
Tande 2016 50 0.6 (9.7) 50 -0.4 (12.1) 0.08% 1[-3.3,5.3]
Subtotal *** 7410   7379   100% 0.01[-0.11,0.13]
Heterogeneity: Tau2=0; Chi2=9.77, df=9(P=0.37); I2=7.85%  
Test for overall effect: Z=0.12(P=0.9)  
   
2.26.5 LCn3 > 2.4 ≤ 4.4 g/d  
EPE-A 2014 64 0 (0) 55 -0.3 (0)   Not estimable
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 58.9% 0.6[-0.32,1.52]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 41.1% 2.6[0.71,4.49]
Subtotal *** 226   219   100% 1.42[-0.51,3.35]
Heterogeneity: Tau2=1.42; Chi2=3.47, df=1(P=0.06); I2=71.17%  
Test for overall effect: Z=1.45(P=0.15)  
   
2.26.6 LCn3 > 4.4 g/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=2.06, df=1 (P=0.15), I2=51.41%  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
 
 
Analysis 2.27.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 27 BMI, kg/m2 - LCn3 - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.27.1 N-3 replacing SFA  
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 100% -0.6[-1.14,-0.06]
Subtotal *** 128   130   100% -0.6[-1.14,-0.06]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.19(P=0.03)  
   
2.27.2 N-3 replacing MUFA  
AlphaOmega - EPA+DHA 2010 630 0 (1.8) 630 -0.1 (1.8) 31.65% 0.1[-0.1,0.3]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 34.09% 0[-0.17,0.17]
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 31.92% 0[-0.2,0.2]
SMART 2013 20 29.8 (3.5) 25 28.2 (3.4) 0.98% 1.6[-0.43,3.63]
Sofi 2010 6 -0.6 (0) 5 -0.1 (0)   Not estimable
Tande 2016 50 0.6 (9.7) 50 -0.4 (12.1) 0.22% 1[-3.3,5.3]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.13% 2.6[0.71,4.49]
Subtotal *** 7101   7079   100% 0.08[-0.12,0.28]
Heterogeneity: Tau2=0.02; Chi2=10.19, df=5(P=0.07); I2=50.94%  
Test for overall effect: Z=0.76(P=0.45)  
   
2.27.3 N-3 replacing n-6  
Caldwell 2011 20 -0.5 (4.5) 21 -0.2 (3.7) 6.32% -0.3[-2.83,2.23]
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 45.98% -0.2[-1.14,0.74]
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 47.7% 0.6[-0.32,1.52]
Subtotal *** 259   254   100% 0.18[-0.46,0.81]
Heterogeneity: Tau2=0; Chi2=1.57, df=2(P=0.46); I2=0%  
Test for overall effect: Z=0.54(P=0.59)  
   
2.27.4 N-3 replacing carbs/sugars  
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 100% -0.6[-1.14,-0.06]
Subtotal *** 128   130   100% -0.6[-1.14,-0.06]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.19(P=0.03)  
   
2.27.5 N-3 replacing nil/low n-3 placebo  
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 100% 1[-1.18,3.18]
Subtotal *** 30   30   100% 1[-1.18,3.18]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.9(P=0.37)  
   
2.27.6 Replacement unclear  
EPE-A 2014 64 0 (0) 55 -0.3 (0)   Not estimable
Norouzi 2014 54 24.8 (4.9) 50 24.2 (4.2) 100% 0.58[-1.17,2.33]
Subtotal *** 118   105   100% 0.58[-1.17,2.33]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.65(P=0.52)  
Test for subgroup differences: Chi2=11.45, df=1 (P=0.04), I2=56.34%  
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Analysis 2.28.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 28 BMI, kg/m2 - LCn3 - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.28.1 Dietary advice  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.28.2 Supplemental foods  
AlphaOmega - EPA+DHA 2010 630 0 (1.8) 630 -0.1 (1.8) 25.26% 0.1[-0.1,0.3]
Subtotal *** 630   630   25.26% 0.1[-0.1,0.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.99(P=0.32)  
   
2.28.3 Supplement (capsule)  
Caldwell 2011 20 -0.5 (4.5) 21 -0.2 (3.7) 0.6% -0.3[-2.83,2.23]
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 9.65% -0.6[-1.14,-0.06]
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 3.92% -0.2[-1.14,0.74]
EPE-A 2014 64 0 (0) 55 -0.3 (0)   Not estimable
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 0.8% 1[-1.18,3.18]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 26.9% 0[-0.17,0.17]
Norouzi 2014 54 24.8 (4.9) 50 24.2 (4.2) 1.22% 0.58[-1.17,2.33]
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 4.04% 0.6[-0.32,1.52]
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 25.44% 0[-0.2,0.2]
Sofi 2010 6 -0.6 (0) 5 -0.1 (0)   Not estimable
Tande 2016 50 0.6 (9.7) 50 -0.4 (12.1) 0.21% 1[-3.3,5.3]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.05% 2.6[0.71,4.49]
Subtotal *** 6986   6943   73.82% 0.01[-0.25,0.27]
Heterogeneity: Tau2=0.04; Chi2=15.32, df=9(P=0.08); I2=41.27%  
Test for overall effect: Z=0.08(P=0.94)  
   
2.28.4 Any combination  
SMART 2013 20 29.8 (3.5) 25 28.2 (3.4) 0.92% 1.6[-0.43,3.63]
Subtotal *** 20   25   0.92% 1.6[-0.43,3.63]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.54(P=0.12)  
   
Total *** 7636   7598   100% 0.04[-0.16,0.24]
Heterogeneity: Tau2=0.03; Chi2=18.44, df=11(P=0.07); I2=40.34%  
Test for overall effect: Z=0.41(P=0.68)  
Test for subgroup differences: Chi2=2.47, df=1 (P=0.29), I2=19.04%  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
 
 
Analysis 2.29.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 29 BMI, kg/m2 - LCn3 - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.29.1 Medium duration 1 to < 2 years in study  
Caldwell 2011 20 -0.5 (4.5) 21 -0.2 (3.7) 5.5% -0.3[-2.83,2.23]
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 29.57% -0.6[-1.14,-0.06]
EPE-A 2014 64 0 (0) 55 -0.3 (0)   Not estimable
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 36.29% 0[-0.17,0.17]
Norouzi 2014 54 24.8 (4.9) 50 24.2 (4.2) 9.87% 0.58[-1.17,2.33]
SMART 2013 20 29.8 (3.5) 25 28.2 (3.4) 7.88% 1.6[-0.43,3.63]
Sofi 2010 6 -0.6 (0) 5 -0.1 (0)   Not estimable
Tande 2016 50 0.6 (9.7) 50 -0.4 (12.1) 2.1% 1[-3.3,5.3]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 8.79% 2.6[0.71,4.49]
Subtotal *** 456   450   100% 0.24[-0.4,0.88]
Heterogeneity: Tau2=0.29; Chi2=15.04, df=6(P=0.02); I2=60.11%  
Test for overall effect: Z=0.73(P=0.47)  
   
2.29.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - EPA+DHA 2010 630 0 (1.8) 630 -0.1 (1.8) 90.92% 0.1[-0.1,0.3]
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 4.09% -0.2[-1.14,0.74]
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 0.76% 1[-1.18,3.18]
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 4.24% 0.6[-0.32,1.52]
Subtotal *** 899   893   100% 0.12[-0.07,0.31]
Heterogeneity: Tau2=0; Chi2=2.16, df=3(P=0.54); I2=0%  
Test for overall effect: Z=1.2(P=0.23)  
   
2.29.3 Long duration ≥ 4 years in study  
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 100% 0[-0.2,0.2]
Subtotal *** 6281   6255   100% 0[-0.2,0.2]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=0.98, df=1 (P=0.61), I2=0%  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
 
 
Analysis 2.30.   Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes),
Outcome 30 BMI, kg/m2 - LCn3 - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.30.1 Primary CVD prevention  
Caldwell 2011 20 -0.5 (4.5) 21 -0.2 (3.7) 3.65% -0.3[-2.83,2.23]
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 24.45% -0.6[-1.14,-0.06]
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 15.77% -0.2[-1.14,0.74]
EPE-A 2014 64 0 (0) 55 -0.3 (0)   Not estimable
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 4.74% 1[-1.18,3.18]
Norouzi 2014 54 24.8 (4.9) 50 24.2 (4.2) 6.8% 0.58[-1.17,2.33]
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 31.9% 0[-0.2,0.2]
SMART 2013 20 29.8 (3.5) 25 28.2 (3.4) 5.33% 1.6[-0.43,3.63]
Sofi 2010 6 -0.6 (0) 5 -0.1 (0)   Not estimable
Tande 2016 50 0.6 (9.7) 50 -0.4 (12.1) 1.36% 1[-3.3,5.3]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 6% 2.6[0.71,4.49]
Subtotal *** 6824   6786   100% 0.15[-0.36,0.66]
Heterogeneity: Tau2=0.2; Chi2=16.01, df=8(P=0.04); I2=50.04%  
Test for overall effect: Z=0.58(P=0.56)  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
   
2.30.2 Secondary CVD prevention  
AlphaOmega - EPA+DHA 2010 630 0 (1.8) 630 -0.1 (1.8) 42.41% 0.1[-0.1,0.3]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 55.62% 0[-0.17,0.17]
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 1.98% 0.6[-0.32,1.52]
Subtotal *** 812   812   100% 0.05[-0.08,0.18]
Heterogeneity: Tau2=0; Chi2=1.93, df=2(P=0.38); I2=0%  
Test for overall effect: Z=0.82(P=0.41)  
Test for subgroup differences: Chi2=0.13, df=1 (P=0.72), I2=0%  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
 
 
Analysis 2.31.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 31 BMI, kg/m2 - LCn3 - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.31.1 LCn3 - ≥ 50% of control group on statins  
AlphaOmega - EPA+DHA 2010 630 0 (1.8) 630 -0.1 (1.8) 48.32% 0.1[-0.1,0.3]
ORIGIN 2012 6281 30.3 (5.6) 6255 30.3 (5.6) 48.53% 0[-0.2,0.2]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 3.16% 2.6[0.71,4.49]
Subtotal *** 6958   6933   100% 0.13[-0.22,0.48]
Heterogeneity: Tau2=0.05; Chi2=7.43, df=2(P=0.02); I2=73.08%  
Test for overall effect: Z=0.74(P=0.46)  
   
2.31.2 LCn3 - < 50% of control group on statins  
DO IT 2010 124 26.8 (3.5) 117 27 (3.9) 3.19% -0.2[-1.14,0.74]
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 0.59% 1[-1.18,3.18]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 92.92% 0[-0.17,0.17]
OFAMI 2001 115 26.6 (3.9) 116 26 (3.2) 3.3% 0.6[-0.32,1.52]
Subtotal *** 336   329   100% 0.02[-0.15,0.19]
Heterogeneity: Tau2=0; Chi2=2.56, df=3(P=0.46); I2=0%  
Test for overall effect: Z=0.23(P=0.82)  
   
2.31.3 LCn3 - use of statins unclear  
Caldwell 2011 20 -0.5 (4.5) 21 -0.2 (3.7) 10.74% -0.3[-2.83,2.23]
Derosa 2016 128 28.6 (2.1) 130 29.2 (2.3) 51.05% -0.6[-1.14,-0.06]
EPE-A 2014 64 0 (0) 55 -0.3 (0)   Not estimable
Norouzi 2014 54 24.8 (4.9) 50 24.2 (4.2) 18.84% 0.58[-1.17,2.33]
SMART 2013 20 29.8 (3.5) 25 28.2 (3.4) 15.19% 1.6[-0.43,3.63]
Sofi 2010 6 -0.6 (0) 5 -0.1 (0)   Not estimable
Tande 2016 50 0.6 (9.7) 50 -0.4 (12.1) 4.18% 1[-3.3,5.3]
Subtotal *** 342   336   100% 0.06[-0.86,0.97]
Heterogeneity: Tau2=0.35; Chi2=5.83, df=4(P=0.21); I2=31.4%  
Test for overall effect: Z=0.12(P=0.9)  
Test for subgroup differences: Chi2=0.32, df=1 (P=0.85), I2=0%  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
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Analysis 2.32.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 32 Other measures of adiposity - LCn3.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.32.1 Percentage body fat  
SMART 2013 16 34 (10.2) 16 37.4 (8.1) 46.25% -3.4[-9.78,2.98]
WELCOME 2015 47 33.5 (9.6) 48 29 (13.8) 53.75% 4.5[-0.27,9.27]
Subtotal *** 63   64   100% 0.85[-6.87,8.57]
Heterogeneity: Tau2=22.94; Chi2=3.78, df=1(P=0.05); I2=73.51%  
Test for overall effect: Z=0.21(P=0.83)  
   
2.32.2 Percentage visceral fat  
WELCOME 2015 47 15.9 (46) 48 17.7 (5.1) 100% -1.8[-15.03,11.43]
Subtotal *** 47   48   100% -1.8[-15.03,11.43]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.27(P=0.79)  
   
2.32.3 Waist circumference, cm  
Derosa 2016 128 89.5 (27.2) 130 91.7 (38.8) 0.85% -2.2[-10.36,5.96]
ORL 2013 168 0.1 (2.9) 165 -0.6 (4.1) 97.36% 0.7[-0.06,1.46]
THIS DIET 2008 37 102.7 (12.8) 48 102.6 (13.6) 1.79% 0.1[-5.54,5.74]
Subtotal *** 333   343   100% 0.66[-0.09,1.42]
Heterogeneity: Tau2=0; Chi2=0.52, df=2(P=0.77); I2=0%  
Test for overall effect: Z=1.73(P=0.08)  
   
2.32.4 Waist-hip ratio  
Tande 2016 50 0 (0) 50 0 (0) 100% 0[-0.01,0.01]
Subtotal *** 50   50   100% 0[-0.01,0.01]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.32.5 Abdominal circumference, cm  
Derosa 2016 128 93.2 (29.4) 128 93.9 (36.2) 100% -0.7[-8.78,7.38]
Subtotal *** 128   128   100% -0.7[-8.78,7.38]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.17(P=0.87)  
   
2.32.6 Hip circumference, cm  
Derosa 2016 130 98.5 (22.8) 128 100.9 (36.2) 100% -2.4[-9.8,5]
Subtotal *** 130   128   100% -2.4[-9.8,5]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.64(P=0.52)  
Favours higher omega 3 52.5-5 -2.5 0 Favours lower omega 3
 
 
Analysis 2.33.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 33 Total cholesterol, serum, mmoL/L - LCn3.
Study or subgroup Favours high-
er omega 3
Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Ahn 2016 38 3.6 (0.7) 36 3.8 (0.7) 1.78% -0.15[-0.47,0.17]
Favours higher omega 3 0.40.2-0.4 -0.2 0 Favours lower omega 3
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Study or subgroup Favours high-
er omega 3
Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
AlphaOmega - EPA+DHA 2010 605 -0.3 (1) 605 -0.3 (1) 10.45% 0.02[-0.09,0.13]
Berson 2004 105 5.2 (0.8) 103 4.9 (0.9) 3.15% 0.3[0.06,0.54]
Brox 2001 37 7.8 (0.9) 37 7.9 (0.8) 1.24% -0.1[-0.49,0.29]
Caldwell 2011 17 5 (1.2) 17 5.1 (1) 0.37% -0.13[-0.86,0.6]
DART 1989 868 6.5 (1.1) 847 6.4 (1.1) 10.95% 0.1[-0.01,0.21]
Derosa 2016 128 4.9 (3.4) 130 5.1 (3.4) 0.28% -0.2[-1.03,0.63]
Deslypere 1992 14 5.5 (0.9) 14 5.9 (1) 0.38% -0.41[-1.12,0.3]
DIPP 2015 91 5.5 (0.9) 75 5.4 (0.8) 2.68% 0.12[-0.14,0.38]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 1.83% 0[-0.32,0.32]
EPE-A 2014 64 0.1 (0) 55 0.2 (0)   Not estimable
Franzen 1993 15 5.8 (1) 15 6.3 (1.1) 0.34% -0.49[-1.24,0.26]
HARP 1995 31 5 (1) 28 5 (0.6) 1.12% 0.03[-0.38,0.44]
JELIS 2007 9326 5.8 (0.8) 9319 5.9 (0.8) 27.95% -0.05[-0.07,-0.03]
MARINA 2011 80 0.2 (0.9) 71 0.1 (0.6) 2.92% 0.1[-0.15,0.35]
Mita 2007 30 5.2 (0.8) 30 5.3 (1) 0.88% -0.12[-0.58,0.34]
NAT2 2013 134 5.7 (1.2) 129 5.6 (1) 2.56% 0.06[-0.2,0.32]
Nodari 2011 HF 67 4.8 (0.6) 66 4.9 (0.6) 3.83% -0.1[-0.31,0.11]
Nye 1990 12 6.8 (1) 12 6.2 (1.3) 0.22% 0.63[-0.3,1.56]
OFAMI 2001 123 5.3 (1.1) 123 5.6 (1.2) 2.24% -0.32[-0.6,-0.04]
ORIGIN 2012 6281 -0.4 (2.1) 6255 -0.4 (2.1) 16.71% -0.03[-0.1,0.04]
Rossing 1996 14 5.5 (1.1) 15 5.2 (1.2) 0.28% 0.31[-0.52,1.14]
Sandhu 2016 49 5.2 (0.9) 47 5.4 (0.9) 1.38% -0.19[-0.56,0.18]
SCIMO 1999 89 6.2 (1.6) 86 6.1 (1.6) 0.85% 0.15[-0.32,0.62]
SHOT 1996 289 7 (1.3) 267 7 (1.3) 3.68% -0.02[-0.24,0.2]
SMART 2013 21 5.4 (0.9) 24 5.2 (1) 0.62% 0.2[-0.36,0.76]
Sofi 2010 6 -0 (1) 5 -0.1 (0.5) 0.26% 0.1[-0.77,0.97]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 1.05% -0.1[-0.52,0.32]
   
Total *** 18705   18576   100% -0.01[-0.05,0.04]
Heterogeneity: Tau2=0; Chi2=32.2, df=26(P=0.19); I2=19.24%  
Test for overall effect: Z=0.34(P=0.73)  
Favours higher omega 3 0.40.2-0.4 -0.2 0 Favours lower omega 3
 
 
Analysis 2.34.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 34 TC, mmoL/L - LCn3 - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.34.1 Low risk of bias  
AlphaOmega - EPA+DHA 2010 605 -0.3 (1) 605 -0.3 (1) 10.12% 0.02[-0.09,0.13]
Berson 2004 105 5.2 (0.8) 103 4.9 (0.9) 2.91% 0.3[0.06,0.54]
Caldwell 2011 17 5 (1.2) 17 5.1 (1) 0.33% -0.13[-0.86,0.6]
Derosa 2016 128 4.9 (3.4) 130 5.1 (3.4) 0.25% -0.2[-1.03,0.63]
MARINA 2011 80 5.6 (0.9) 71 5.6 (0.4) 3.29% 0[-0.22,0.22]
NAT2 2013 134 5.7 (1.2) 129 5.6 (1) 2.36% 0.06[-0.2,0.32]
ORIGIN 2012 6281 -0.4 (2.1) 6255 -0.4 (2.1) 16.87% -0.03[-0.1,0.04]
SCIMO 1999 89 6.2 (1.6) 86 6.1 (1.6) 0.77% 0.15[-0.32,0.62]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 0.96% -0.1[-0.52,0.32]
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Subtotal *** 7486   7444   37.87% 0.01[-0.05,0.06]
Heterogeneity: Tau2=0; Chi2=8.03, df=8(P=0.43); I2=0.4%  
Test for overall effect: Z=0.24(P=0.81)  
   
2.34.2 Moderate/high risk of bias  
Ahn 2016 38 3.6 (0.7) 36 3.8 (0.7) 1.63% -0.15[-0.47,0.17]
Brox 2001 37 7.8 (0.9) 37 7.9 (0.8) 1.13% -0.1[-0.49,0.29]
DART 1989 868 6.5 (1.1) 847 6.4 (1.1) 10.64% 0.1[-0.01,0.21]
Deslypere 1992 14 5.5 (0.9) 14 5.9 (1) 0.34% -0.41[-1.12,0.3]
DIPP 2015 91 5.5 (0.9) 75 5.4 (0.8) 2.48% 0.12[-0.14,0.38]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 1.68% 0[-0.32,0.32]
EPE-A 2014 64 0.1 (0) 55 0.2 (0)   Not estimable
Franzen 1993 15 5.8 (1) 15 6.3 (1.1) 0.31% -0.49[-1.24,0.26]
HARP 1995 31 5 (1) 28 5 (0.6) 1.03% 0.03[-0.38,0.44]
JELIS 2007 9326 5.8 (0.8) 9319 5.9 (0.8) 30.52% -0.05[-0.07,-0.03]
Mita 2007 30 5.2 (0.8) 30 5.3 (1) 0.81% -0.12[-0.58,0.34]
Nodari 2011 HF 67 4.8 (0.6) 66 4.9 (0.6) 3.56% -0.1[-0.31,0.11]
Nye 1990 12 6.8 (1) 12 6.2 (1.3) 0.2% 0.63[-0.3,1.56]
OFAMI 2001 123 5.3 (1.1) 123 5.6 (1.2) 2.06% -0.32[-0.6,-0.04]
Rossing 1996 14 5.5 (1.1) 15 5.2 (1.2) 0.25% 0.31[-0.52,1.14]
Sandhu 2016 49 5.2 (0.9) 47 5.4 (0.9) 1.27% -0.19[-0.56,0.18]
SHOT 1996 289 7 (1.3) 267 7 (1.3) 3.41% -0.02[-0.24,0.2]
SMART 2013 21 5.4 (0.9) 24 5.2 (1) 0.56% 0.2[-0.36,0.76]
Sofi 2010 6 -0 (1) 5 -0.1 (0.5) 0.23% 0.1[-0.77,0.97]
Subtotal *** 11219   11132   62.13% -0.03[-0.09,0.03]
Heterogeneity: Tau2=0; Chi2=20.13, df=17(P=0.27); I2=15.54%  
Test for overall effect: Z=0.98(P=0.33)  
   
Total *** 18705   18576   100% -0.01[-0.05,0.03]
Heterogeneity: Tau2=0; Chi2=31.1, df=26(P=0.22); I2=16.4%  
Test for overall effect: Z=0.56(P=0.58)  
Test for subgroup differences: Chi2=0.78, df=1 (P=0.38), I2=0%  
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Analysis 2.35.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 35 TC, mmoL/L - LCn3 - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.35.1 SA - low risk of compliance bias  
AlphaOmega - EPA+DHA 2010 605 -0.3 (1) 605 -0.3 (1) 38.11% 0.02[-0.09,0.13]
Berson 2004 105 5.2 (0.8) 103 4.9 (0.9) 8.38% 0.3[0.06,0.54]
Brox 2001 37 7.8 (0.9) 37 7.9 (0.8) 3.09% -0.1[-0.49,0.29]
Deslypere 1992 14 5.5 (0.9) 14 5.9 (1) 0.91% -0.41[-1.12,0.3]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 4.64% 0[-0.32,0.32]
EPE-A 2014 64 0.1 (0) 55 0.2 (0)   Not estimable
HARP 1995 31 5 (1) 28 5 (0.6) 2.78% 0.03[-0.38,0.44]
MARINA 2011 80 5.6 (0.9) 71 5.6 (0.4) 9.6% 0[-0.22,0.22]
NAT2 2013 134 5.7 (1.2) 129 5.6 (1) 6.67% 0.06[-0.2,0.32]
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Nodari 2011 HF 67 4.8 (0.6) 66 4.9 (0.6) 10.47% -0.1[-0.31,0.11]
Rossing 1996 14 5.5 (1.1) 15 5.2 (1.2) 0.67% 0.31[-0.52,1.14]
SCIMO 1999 89 6.2 (1.6) 86 6.1 (1.6) 2.08% 0.15[-0.32,0.62]
SHOT 1996 289 7 (1.3) 267 7 (1.3) 10% -0.02[-0.24,0.2]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 2.6% -0.1[-0.52,0.32]
Subtotal *** 1700   1641   100% 0.02[-0.05,0.09]
Heterogeneity: Tau2=0; Chi2=9.78, df=12(P=0.64); I2=0%  
Test for overall effect: Z=0.6(P=0.55)  
   
2.35.2 SA - 100+ randomised  
AlphaOmega - EPA+DHA 2010 605 -0.3 (1) 605 -0.3 (1) 12.2% 0.02[-0.09,0.13]
Berson 2004 105 5.2 (0.8) 103 4.9 (0.9) 4.38% 0.3[0.06,0.54]
DART 1989 868 6.5 (1.1) 847 6.4 (1.1) 12.65% 0.1[-0.01,0.21]
Derosa 2016 128 4.9 (3.4) 130 5.1 (3.4) 0.42% -0.2[-1.03,0.63]
DIPP 2015 91 5.5 (0.9) 75 5.4 (0.8) 3.78% 0.12[-0.14,0.38]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 2.64% 0[-0.32,0.32]
EPE-A 2014 64 0.1 (0) 55 0.2 (0)   Not estimable
JELIS 2007 9326 5.8 (0.8) 9319 5.9 (0.8) 23.54% -0.05[-0.07,-0.03]
MARINA 2011 80 5.6 (0.9) 71 5.6 (0.4) 4.89% 0[-0.22,0.22]
NAT2 2013 134 5.7 (1.2) 129 5.6 (1) 3.62% 0.06[-0.2,0.32]
Nodari 2011 HF 67 4.8 (0.6) 66 4.9 (0.6) 5.24% -0.1[-0.31,0.11]
OFAMI 2001 123 5.3 (1.1) 123 5.6 (1.2) 3.19% -0.32[-0.6,-0.04]
ORIGIN 2012 6281 -0.4 (2.1) 6255 -0.4 (2.1) 17.15% -0.03[-0.1,0.04]
SCIMO 1999 89 6.2 (1.6) 86 6.1 (1.6) 1.25% 0.15[-0.32,0.62]
SHOT 1996 289 7 (1.3) 267 7 (1.3) 5.05% -0.02[-0.24,0.2]
Subtotal *** 18374   18248   100% 0[-0.05,0.06]
Heterogeneity: Tau2=0; Chi2=23.61, df=13(P=0.03); I2=44.94%  
Test for overall effect: Z=0.11(P=0.92)  
Test for subgroup differences: Chi2=0.16, df=1 (P=0.69), I2=0%  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
 
 
Analysis 2.36.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 36 TC, mmoL/L - LCn3 - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.36.1 LCn3 ≤ 150 mg/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.36.2 LCn3 > 150 ≤ 250 mg/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.36.3 LCn3 > 250 ≤ 400 mg/d  
DART 1989 868 6.5 (1.1) 847 6.4 (1.1) 100% 0.1[-0.01,0.21]
Subtotal *** 868   847   100% 0.1[-0.01,0.21]
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.84(P=0.07)  
   
2.36.4 LCn3 > 400 ≤ 2400 mg/d  
Ahn 2016 38 3.6 (0.7) 36 3.8 (0.7) 0.95% -0.15[-0.47,0.17]
AlphaOmega - EPA+DHA 2010 605 -0.3 (1) 605 -0.3 (1) 7.47% 0.02[-0.09,0.13]
Berson 2004 105 5.2 (0.8) 103 4.9 (0.9) 1.75% 0.3[0.06,0.54]
Caldwell 2011 17 5 (1.2) 17 5.1 (1) 0.19% -0.13[-0.86,0.6]
Derosa 2016 128 4.9 (3.4) 130 5.1 (3.4) 0.14% -0.2[-1.03,0.63]
Deslypere 1992 14 5.5 (0.9) 14 5.9 (1) 0.19% -0.41[-1.12,0.3]
DIPP 2015 91 5.5 (0.9) 75 5.4 (0.8) 1.47% 0.12[-0.14,0.38]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 0.98% 0[-0.32,0.32]
JELIS 2007 9326 5.8 (0.8) 9319 5.9 (0.8) 63.98% -0.05[-0.07,-0.03]
MARINA 2011 80 5.6 (0.9) 71 5.6 (0.4) 2% 0[-0.22,0.22]
Mita 2007 30 5.2 (0.8) 30 5.3 (1) 0.46% -0.12[-0.58,0.34]
NAT2 2013 134 5.7 (1.2) 129 5.6 (1) 1.4% 0.06[-0.2,0.32]
Nodari 2011 HF 67 4.8 (0.6) 66 4.9 (0.6) 2.17% -0.1[-0.31,0.11]
Nye 1990 12 6.8 (1) 12 6.2 (1.3) 0.11% 0.63[-0.3,1.56]
ORIGIN 2012 6281 -0.4 (2.1) 6255 -0.4 (2.1) 15.85% -0.03[-0.1,0.04]
SCIMO 1999 89 6.2 (1.6) 86 6.1 (1.6) 0.44% 0.15[-0.32,0.62]
SMART 2013 21 5.4 (0.9) 24 5.2 (1) 0.32% 0.2[-0.36,0.76]
Sofi 2010 6 -0 (1) 5 -0.1 (0.5) 0.13% 0.1[-0.77,0.97]
Subtotal *** 17168   17094   100% -0.03[-0.06,0]
Heterogeneity: Tau2=0; Chi2=17.74, df=17(P=0.41); I2=4.18%  
Test for overall effect: Z=1.9(P=0.06)  
   
2.36.5 LCn3 > 2.4 ≤ 4.4 g/d  
Brox 2001 37 7.8 (0.9) 37 7.9 (0.8) 12% -0.1[-0.49,0.29]
EPE-A 2014 64 0.1 (0) 55 0.2 (0)   Not estimable
Franzen 1993 15 5.8 (1) 15 6.3 (1.1) 3.19% -0.49[-1.24,0.26]
OFAMI 2001 123 5.3 (1.1) 123 5.6 (1.2) 22.42% -0.32[-0.6,-0.04]
Sandhu 2016 49 5.2 (0.9) 47 5.4 (0.9) 13.45% -0.19[-0.56,0.18]
SHOT 1996 289 7 (1.3) 267 7 (1.3) 38.84% -0.02[-0.24,0.2]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 10.1% -0.1[-0.52,0.32]
Subtotal *** 624   592   100% -0.14[-0.28,-0.01]
Heterogeneity: Tau2=0; Chi2=3.71, df=5(P=0.59); I2=0%  
Test for overall effect: Z=2.08(P=0.04)  
   
2.36.6 LCn3 > 4.4 g/d  
HARP 1995 31 5 (1) 28 5 (0.6) 80.49% 0.03[-0.38,0.44]
Rossing 1996 14 5.5 (1.1) 15 5.2 (1.2) 19.51% 0.31[-0.52,1.14]
Subtotal *** 45   43   100% 0.08[-0.28,0.45]
Heterogeneity: Tau2=0; Chi2=0.35, df=1(P=0.55); I2=0%  
Test for overall effect: Z=0.45(P=0.65)  
Test for subgroup differences: Chi2=8.7, df=1 (P=0.03), I2=65.52%  
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Analysis 2.37.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 37 TC, mmoL/L - LCn3 - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.37.1 N-3 replacing SFA  
DART 1989 868 6.5 (1.1) 847 6.4 (1.1) 93.71% 0.1[-0.01,0.21]
Derosa 2016 128 4.9 (3.4) 130 5.1 (3.4) 1.54% -0.2[-1.03,0.63]
SCIMO 1999 89 6.2 (1.6) 86 6.1 (1.6) 4.75% 0.15[-0.32,0.62]
Subtotal *** 1085   1063   100% 0.1[-0.01,0.2]
Heterogeneity: Tau2=0; Chi2=0.54, df=2(P=0.76); I2=0%  
Test for overall effect: Z=1.86(P=0.06)  
   
2.37.2 N-3 replacing MUFA  
AlphaOmega - EPA+DHA 2010 605 -0.3 (1) 605 -0.3 (1) 18.35% 0.02[-0.09,0.13]
DART 1989 868 6.5 (1.1) 847 6.4 (1.1) 19.73% 0.1[-0.01,0.21]
Deslypere 1992 14 5.5 (0.9) 14 5.9 (1) 0.44% -0.41[-1.12,0.3]
Franzen 1993 15 5.8 (1) 15 6.3 (1.1) 0.4% -0.49[-1.24,0.26]
HARP 1995 31 5 (1) 28 5 (0.6) 1.34% 0.03[-0.38,0.44]
MARINA 2011 80 5.6 (0.9) 71 5.6 (0.4) 4.62% 0[-0.22,0.22]
NAT2 2013 134 5.7 (1.2) 129 5.6 (1) 3.21% 0.06[-0.2,0.32]
Nodari 2011 HF 67 4.8 (0.6) 66 4.9 (0.6) 5.04% -0.1[-0.31,0.11]
Nye 1990 12 6.8 (1) 12 6.2 (1.3) 0.26% 0.63[-0.3,1.56]
ORIGIN 2012 6281 -0.4 (2.1) 6255 -0.4 (2.1) 43.02% -0.03[-0.1,0.04]
Rossing 1996 14 5.5 (1.1) 15 5.2 (1.2) 0.32% 0.31[-0.52,1.14]
SCIMO 1999 89 6.2 (1.6) 86 6.1 (1.6) 1% 0.15[-0.32,0.62]
SMART 2013 21 5.4 (0.9) 24 5.2 (1) 0.73% 0.2[-0.36,0.76]
Sofi 2010 6 -0 (1) 5 -0.1 (0.5) 0.3% 0.1[-0.77,0.97]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 1.25% -0.1[-0.52,0.32]
Subtotal *** 8284   8220   100% 0.01[-0.04,0.06]
Heterogeneity: Tau2=0; Chi2=11.36, df=14(P=0.66); I2=0%  
Test for overall effect: Z=0.4(P=0.69)  
   
2.37.3 N-3 replacing n-6  
Berson 2004 105 5.2 (0.8) 103 4.9 (0.9) 24.89% 0.3[0.06,0.54]
Caldwell 2011 17 5 (1.2) 17 5.1 (1) 8.11% -0.13[-0.86,0.6]
DIPP 2015 91 5.5 (0.9) 75 5.4 (0.8) 23.77% 0.12[-0.14,0.38]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 20.81% 0[-0.32,0.32]
OFAMI 2001 123 5.3 (1.1) 123 5.6 (1.2) 22.42% -0.32[-0.6,-0.04]
Subtotal *** 460   435   100% 0.02[-0.22,0.26]
Heterogeneity: Tau2=0.04; Chi2=11.47, df=4(P=0.02); I2=65.12%  
Test for overall effect: Z=0.17(P=0.86)  
   
2.37.4 N-3 replacing carbs/sugars  
Derosa 2016 128 4.9 (3.4) 130 5.1 (3.4) 100% -0.2[-1.03,0.63]
Subtotal *** 128   130   100% -0.2[-1.03,0.63]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.47(P=0.64)  
   
2.37.5 N-3 replacing nil/low n-3 placebo  
Brox 2001 37 7.8 (0.9) 37 7.9 (0.8) 0.33% -0.1[-0.49,0.29]
JELIS 2007 9326 5.8 (0.8) 9319 5.9 (0.8) 97.97% -0.05[-0.07,-0.03]
Mita 2007 30 5.2 (0.8) 30 5.3 (1) 0.24% -0.12[-0.58,0.34]
Sandhu 2016 49 5.2 (0.9) 47 5.4 (0.9) 0.38% -0.19[-0.56,0.18]
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
373
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
SHOT 1996 289 7 (1.3) 267 7 (1.3) 1.08% -0.02[-0.24,0.2]
Subtotal *** 9731   9700   100% -0.05[-0.07,-0.03]
Heterogeneity: Tau2=0; Chi2=0.78, df=4(P=0.94); I2=0%  
Test for overall effect: Z=4.41(P<0.0001)  
   
2.37.6 Replacement unclear  
Ahn 2016 38 3.6 (0.7) 36 3.8 (0.7) 100% -0.15[-0.47,0.17]
EPE-A 2014 64 0.1 (0) 55 0.2 (0)   Not estimable
Subtotal *** 102   91   100% -0.15[-0.47,0.17]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.91(P=0.36)  
Test for subgroup differences: Chi2=12.47, df=1 (P=0.03), I2=59.89%  
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Analysis 2.38.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 38 TC, mmoL/L - LCn3 - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.38.1 Dietary advice  
DART 1989 868 6.5 (1.1) 847 6.4 (1.1) 100% 0.1[-0.01,0.21]
Subtotal *** 868   847   100% 0.1[-0.01,0.21]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.84(P=0.07)  
   
2.38.2 Supplemental foods  
AlphaOmega - EPA+DHA 2010 605 -0.3 (1) 605 -0.3 (1) 100% 0.02[-0.09,0.13]
Subtotal *** 605   605   100% 0.02[-0.09,0.13]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.35(P=0.72)  
   
2.38.3 Supplement (capsule)  
Ahn 2016 38 3.6 (0.7) 36 3.8 (0.7) 0.42% -0.15[-0.47,0.17]
Berson 2004 105 5.2 (0.8) 103 4.9 (0.9) 0.78% 0.3[0.06,0.54]
Brox 2001 37 7.8 (0.9) 37 7.9 (0.8) 0.29% -0.1[-0.49,0.29]
Caldwell 2011 17 5 (1.2) 17 5.1 (1) 0.08% -0.13[-0.86,0.6]
Derosa 2016 128 4.9 (3.4) 130 5.1 (3.4) 0.06% -0.2[-1.03,0.63]
Deslypere 1992 14 5.5 (0.9) 14 5.9 (1) 0.09% -0.41[-1.12,0.3]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 0.43% 0[-0.32,0.32]
EPE-A 2014 64 0.1 (0) 55 0.2 (0)   Not estimable
Franzen 1993 15 5.8 (1) 15 6.3 (1.1) 0.08% -0.49[-1.24,0.26]
HARP 1995 31 5 (1) 28 5 (0.6) 0.26% 0.03[-0.38,0.44]
JELIS 2007 9326 5.8 (0.8) 9319 5.9 (0.8) 84.11% -0.05[-0.07,-0.03]
MARINA 2011 80 5.6 (0.9) 71 5.6 (0.4) 0.89% 0[-0.22,0.22]
Mita 2007 30 5.2 (0.8) 30 5.3 (1) 0.2% -0.12[-0.58,0.34]
NAT2 2013 134 5.7 (1.2) 129 5.6 (1) 0.62% 0.06[-0.2,0.32]
Nodari 2011 HF 67 4.8 (0.6) 66 4.9 (0.6) 0.97% -0.1[-0.31,0.11]
Nye 1990 12 6.8 (1) 12 6.2 (1.3) 0.05% 0.63[-0.3,1.56]
OFAMI 2001 123 5.3 (1.1) 123 5.6 (1.2) 0.54% -0.32[-0.6,-0.04]
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
ORIGIN 2012 6281 -0.4 (2.1) 6255 -0.4 (2.1) 8.32% -0.03[-0.1,0.04]
Rossing 1996 14 5.5 (1.1) 15 5.2 (1.2) 0.06% 0.31[-0.52,1.14]
Sandhu 2016 49 5.2 (0.9) 47 5.4 (0.9) 0.32% -0.19[-0.56,0.18]
SCIMO 1999 89 6.2 (1.6) 86 6.1 (1.6) 0.19% 0.15[-0.32,0.62]
SHOT 1996 289 7 (1.3) 267 7 (1.3) 0.93% -0.02[-0.24,0.2]
Sofi 2010 6 -0 (1) 5 -0.1 (0.5) 0.06% 0.1[-0.77,0.97]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 0.24% -0.1[-0.52,0.32]
Subtotal *** 17120   17025   100% -0.05[-0.07,-0.03]
Heterogeneity: Tau2=0; Chi2=20.78, df=22(P=0.53); I2=0%  
Test for overall effect: Z=4.39(P<0.0001)  
   
2.38.4 Any combination  
DIPP 2015 91 5.5 (0.9) 75 5.4 (0.8) 82.33% 0.12[-0.14,0.38]
SMART 2013 21 5.4 (0.9) 24 5.2 (1) 17.67% 0.2[-0.36,0.76]
Subtotal *** 112   99   100% 0.13[-0.1,0.37]
Heterogeneity: Tau2=0; Chi2=0.07, df=1(P=0.8); I2=0%  
Test for overall effect: Z=1.13(P=0.26)  
Test for subgroup differences: Chi2=10.26, df=1 (P=0.02), I2=70.75%  
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Analysis 2.39.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 39 TC, mmoL/L - LCn3 - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.39.1 Medium duration 1 to < 2 years in study  
Ahn 2016 38 3.6 (0.7) 36 3.8 (0.7) 9.6% -0.15[-0.47,0.17]
Brox 2001 37 7.8 (0.9) 37 7.9 (0.8) 6.59% -0.1[-0.49,0.29]
Caldwell 2011 17 5 (1.2) 17 5.1 (1) 1.88% -0.13[-0.86,0.6]
Derosa 2016 128 4.9 (3.4) 130 5.1 (3.4) 1.44% -0.2[-1.03,0.63]
Deslypere 1992 14 5.5 (0.9) 14 5.9 (1) 1.95% -0.41[-1.12,0.3]
EPE-A 2014 64 0.1 (0) 55 0.2 (0)   Not estimable
Franzen 1993 15 5.8 (1) 15 6.3 (1.1) 1.75% -0.49[-1.24,0.26]
MARINA 2011 80 5.6 (0.9) 71 5.6 (0.4) 20.47% 0[-0.22,0.22]
Nodari 2011 HF 67 4.8 (0.6) 66 4.9 (0.6) 22.33% -0.1[-0.31,0.11]
Nye 1990 12 6.8 (1) 12 6.2 (1.3) 1.14% 0.63[-0.3,1.56]
Rossing 1996 14 5.5 (1.1) 15 5.2 (1.2) 1.44% 0.31[-0.52,1.14]
SHOT 1996 289 7 (1.3) 267 7 (1.3) 21.32% -0.02[-0.24,0.2]
SMART 2013 21 5.4 (0.9) 24 5.2 (1) 3.22% 0.2[-0.36,0.76]
Sofi 2010 6 -0 (1) 5 -0.1 (0.5) 1.32% 0.1[-0.77,0.97]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 5.54% -0.1[-0.52,0.32]
Subtotal *** 849   812   100% -0.06[-0.16,0.04]
Heterogeneity: Tau2=0; Chi2=7.09, df=13(P=0.9); I2=0%  
Test for overall effect: Z=1.09(P=0.27)  
   
2.39.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - EPA+DHA 2010 605 -0.3 (1) 605 -0.3 (1) 30.06% 0.02[-0.09,0.13]
DART 1989 868 6.5 (1.1) 847 6.4 (1.1) 31.53% 0.1[-0.01,0.21]
DIPP 2015 91 5.5 (0.9) 75 5.4 (0.8) 7.62% 0.12[-0.14,0.38]
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 5.18% 0[-0.32,0.32]
HARP 1995 31 5 (1) 28 5 (0.6) 3.18% 0.03[-0.38,0.44]
Mita 2007 30 5.2 (0.8) 30 5.3 (1) 2.5% -0.12[-0.58,0.34]
NAT2 2013 134 5.7 (1.2) 129 5.6 (1) 7.26% 0.06[-0.2,0.32]
OFAMI 2001 123 5.3 (1.1) 123 5.6 (1.2) 6.35% -0.32[-0.6,-0.04]
Sandhu 2016 49 5.2 (0.9) 47 5.4 (0.9) 3.92% -0.19[-0.56,0.18]
SCIMO 1999 89 6.2 (1.6) 86 6.1 (1.6) 2.39% 0.15[-0.32,0.62]
Subtotal *** 2144   2087   100% 0.02[-0.05,0.1]
Heterogeneity: Tau2=0; Chi2=10.11, df=9(P=0.34); I2=11.01%  
Test for overall effect: Z=0.66(P=0.51)  
   
2.39.3 Long duration ≥ 4 years in study  
Berson 2004 105 5.2 (0.8) 103 4.9 (0.9) 12.04% 0.3[0.06,0.54]
JELIS 2007 9326 5.8 (0.8) 9319 5.9 (0.8) 49.08% -0.05[-0.07,-0.03]
ORIGIN 2012 6281 -0.4 (2.1) 6255 -0.4 (2.1) 38.88% -0.03[-0.1,0.04]
Subtotal *** 15712   15677   100% 0[-0.09,0.09]
Heterogeneity: Tau2=0; Chi2=8.64, df=2(P=0.01); I2=76.85%  
Test for overall effect: Z=0.01(P=0.99)  
Test for subgroup differences: Chi2=1.62, df=1 (P=0.45), I2=0%  
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Analysis 2.40.   Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes),
Outcome 40 TC, mmoL/L - LCn3 - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.40.1 Primary prevention  
Berson 2004 105 5.2 (0.8) 103 4.9 (0.9) 0.81% 0.3[0.06,0.54]
Brox 2001 37 7.8 (0.9) 37 7.9 (0.8) 0.3% -0.1[-0.49,0.29]
Caldwell 2011 17 5 (1.2) 17 5.1 (1) 0.08% -0.13[-0.86,0.6]
Derosa 2016 128 4.9 (3.4) 130 5.1 (3.4) 0.06% -0.2[-1.03,0.63]
Deslypere 1992 14 5.5 (0.9) 14 5.9 (1) 0.09% -0.41[-1.12,0.3]
DIPP 2015 91 5.5 (0.9) 75 5.4 (0.8) 0.68% 0.12[-0.14,0.38]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 0.45% 0[-0.32,0.32]
EPE-A 2014 64 0.1 (0) 55 0.2 (0)   Not estimable
JELIS 2007 9326 5.8 (0.8) 9319 5.9 (0.8) 86.95% -0.05[-0.07,-0.03]
MARINA 2011 80 5.6 (0.9) 71 5.6 (0.4) 0.92% 0[-0.22,0.22]
Mita 2007 30 5.2 (0.8) 30 5.3 (1) 0.21% -0.12[-0.58,0.34]
ORIGIN 2012 6281 -0.4 (2.1) 6255 -0.4 (2.1) 8.6% -0.03[-0.1,0.04]
Rossing 1996 14 5.5 (1.1) 15 5.2 (1.2) 0.06% 0.31[-0.52,1.14]
Sandhu 2016 49 5.2 (0.9) 47 5.4 (0.9) 0.33% -0.19[-0.56,0.18]
SMART 2013 21 5.4 (0.9) 24 5.2 (1) 0.15% 0.2[-0.36,0.76]
Sofi 2010 6 -0 (1) 5 -0.1 (0.5) 0.06% 0.1[-0.77,0.97]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 0.25% -0.1[-0.52,0.32]
Subtotal *** 16434   16362   100% -0.04[-0.07,-0.02]
Heterogeneity: Tau2=0; Chi2=14.05, df=15(P=0.52); I2=0%  
Test for overall effect: Z=4.09(P<0.0001)  
   
2.40.2 Secondary prevention  
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Ahn 2016 38 3.6 (0.7) 36 3.8 (0.7) 5.94% -0.15[-0.47,0.17]
AlphaOmega - EPA+DHA 2010 605 -0.3 (1) 605 -0.3 (1) 23.21% 0.02[-0.09,0.13]
DART 1989 868 6.5 (1.1) 847 6.4 (1.1) 23.87% 0.1[-0.01,0.21]
Franzen 1993 15 5.8 (1) 15 6.3 (1.1) 1.24% -0.49[-1.24,0.26]
HARP 1995 31 5 (1) 28 5 (0.6) 3.91% 0.03[-0.38,0.44]
NAT2 2013 134 5.7 (1.2) 129 5.6 (1) 8.19% 0.06[-0.2,0.32]
Nodari 2011 HF 67 4.8 (0.6) 66 4.9 (0.6) 11.45% -0.1[-0.31,0.11]
Nye 1990 12 6.8 (1) 12 6.2 (1.3) 0.82% 0.63[-0.3,1.56]
OFAMI 2001 123 5.3 (1.1) 123 5.6 (1.2) 7.29% -0.32[-0.6,-0.04]
SCIMO 1999 89 6.2 (1.6) 86 6.1 (1.6) 2.99% 0.15[-0.32,0.62]
SHOT 1996 289 7 (1.3) 267 7 (1.3) 11.08% -0.02[-0.24,0.2]
Subtotal *** 2271   2214   100% -0.01[-0.09,0.08]
Heterogeneity: Tau2=0; Chi2=13.89, df=10(P=0.18); I2=28.03%  
Test for overall effect: Z=0.18(P=0.86)  
Test for subgroup differences: Chi2=0.66, df=1 (P=0.42), I2=0%  
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Analysis 2.41.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 41 TC, mmoL/L - LCn3 - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.41.1 LCn3 - ≥ 50% of control group on statins  
Ahn 2016 38 3.6 (0.7) 36 3.8 (0.7) 0.43% -0.15[-0.47,0.17]
AlphaOmega - EPA+DHA 2010 605 -0.3 (1) 605 -0.3 (1) 3.65% 0.02[-0.09,0.13]
JELIS 2007 9326 5.8 (0.8) 9319 5.9 (0.8) 86.48% -0.05[-0.07,-0.03]
NAT2 2013 134 5.7 (1.2) 129 5.6 (1) 0.64% 0.06[-0.2,0.32]
ORIGIN 2012 6281 -0.4 (2.1) 6255 -0.4 (2.1) 8.55% -0.03[-0.1,0.04]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 0.25% -0.1[-0.52,0.32]
Subtotal *** 16431   16392   100% -0.05[-0.07,-0.02]
Heterogeneity: Tau2=0; Chi2=2.81, df=5(P=0.73); I2=0%  
Test for overall effect: Z=4.22(P<0.0001)  
   
2.41.2 LCn3 - < 50% of control group on statins  
Berson 2004 105 5.2 (0.8) 103 4.9 (0.9) 9.29% 0.3[0.06,0.54]
Brox 2001 37 7.8 (0.9) 37 7.9 (0.8) 4.37% -0.1[-0.49,0.29]
DART 1989 868 6.5 (1.1) 847 6.4 (1.1) 19.42% 0.1[-0.01,0.21]
Deslypere 1992 14 5.5 (0.9) 14 5.9 (1) 1.46% -0.41[-1.12,0.3]
DIPP 2015 91 5.5 (0.9) 75 5.4 (0.8) 8.25% 0.12[-0.14,0.38]
DO IT 2010 124 6.3 (1.2) 117 6.3 (1.3) 6.08% 0[-0.32,0.32]
Franzen 1993 15 5.8 (1) 15 6.3 (1.1) 1.32% -0.49[-1.24,0.26]
HARP 1995 31 5 (1) 28 5 (0.6) 4.01% 0.03[-0.38,0.44]
MARINA 2011 80 5.6 (0.9) 71 5.6 (0.4) 10.13% 0[-0.22,0.22]
Mita 2007 30 5.2 (0.8) 30 5.3 (1) 3.24% -0.12[-0.58,0.34]
Nodari 2011 HF 67 4.8 (0.6) 66 4.9 (0.6) 10.69% -0.1[-0.31,0.11]
OFAMI 2001 123 5.3 (1.1) 123 5.6 (1.2) 7.16% -0.32[-0.6,-0.04]
Rossing 1996 14 5.5 (1.1) 15 5.2 (1.2) 1.09% 0.31[-0.52,1.14]
SCIMO 1999 89 6.2 (1.6) 86 6.1 (1.6) 3.11% 0.15[-0.32,0.62]
SHOT 1996 289 7 (1.3) 267 7 (1.3) 10.39% -0.02[-0.24,0.2]
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Subtotal *** 1977   1894   100% 0.01[-0.08,0.1]
Heterogeneity: Tau2=0.01; Chi2=19.6, df=14(P=0.14); I2=28.57%  
Test for overall effect: Z=0.22(P=0.82)  
   
2.41.3 LCn3 - use of statins unclear  
Caldwell 2011 17 5 (1.2) 17 5.1 (1) 11.48% -0.13[-0.86,0.6]
Derosa 2016 128 4.9 (3.4) 130 5.1 (3.4) 8.79% -0.2[-1.03,0.63]
EPE-A 2014 64 0.1 (0) 55 0.2 (0)   Not estimable
Nye 1990 12 6.8 (1) 12 6.2 (1.3) 6.96% 0.63[-0.3,1.56]
Sandhu 2016 49 5.2 (0.9) 47 5.4 (0.9) 45.06% -0.19[-0.56,0.18]
SMART 2013 21 5.4 (0.9) 24 5.2 (1) 19.64% 0.2[-0.36,0.76]
Sofi 2010 6 -0 (1) 5 -0.1 (0.5) 8.08% 0.1[-0.77,0.97]
Subtotal *** 297   290   100% -0.03[-0.27,0.22]
Heterogeneity: Tau2=0; Chi2=3.64, df=5(P=0.6); I2=0%  
Test for overall effect: Z=0.21(P=0.83)  
Test for subgroup differences: Chi2=1.44, df=1 (P=0.49), I2=0%  
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Analysis 2.42.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 42 Triglycerides, fasting, serum, mmoL/L - LCn3.
Study or subgroup Favours high-
er omega 3
Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
AlphaOmega - EPA+DHA 2010 605 -0.1 (1.2) 605 -0 (1) 8.47% -0.03[-0.15,0.09]
Berson 2004 105 1.1 (0.7) 103 1.4 (1.2) 4.43% -0.33[-0.6,-0.06]
Derosa 2016 128 1.4 (3.4) 130 1.9 (4.6) 0.54% -0.5[-1.49,0.49]
Deslypere 1992 14 0.8 (0.4) 14 1.2 (0.8) 2.16% -0.43[-0.88,0.02]
DIPP 2015 90 1.5 (1.1) 71 1.4 (0.8) 4.16% 0.01[-0.28,0.3]
DO IT 2010 124 1.4 (0.8) 117 1.6 (0.9) 5.72% -0.16[-0.38,0.06]
EPE-A 2014 64 -0.1 (0) 55 0.1 (0)   Not estimable
HARP 1995 31 1.1 (0.6) 28 1.6 (0.8) 3.28% -0.47[-0.81,-0.13]
JELIS 2007 2303 1.6 (0) 2262 1.7 (0)   Not estimable
JELIS 2007 7023 1.4 (0) 7057 1.5 (0)   Not estimable
Lorenz-Meyer 1996 13 -0.4 (0.7) 12 -0.1 (0.5) 2.3% -0.32[-0.76,0.12]
MARINA 2011 80 -0.2 (0.5) 71 0.1 (0.6) 6.8% -0.3[-0.48,-0.12]
Mita 2007 30 1.8 (1.1) 30 1.5 (0.9) 1.83% 0.26[-0.24,0.76]
Nodari 2011 HF 67 1.6 (0.5) 66 1.8 (0.8) 5.5% -0.14[-0.36,0.08]
Nye 1990 12 1.4 (0.6) 12 1.8 (0.6) 2.16% -0.4[-0.85,0.05]
OFAMI 2001 120 1.3 (0.6) 121 1.8 (1.1) 5.72% -0.51[-0.73,-0.29]
ORIGIN 2012 6281 -0.3 (2.7) 6255 -0.1 (2.7) 9.39% -0.16[-0.26,-0.07]
ORL 2013 170 -0.8 (0.9) 165 -0.4 (0.9) 6.43% -0.38[-0.57,-0.19]
Sandhu 2016 49 1.1 (0.6) 47 1.2 (0.5) 5.81% -0.16[-0.37,0.05]
SCIMO 1999 87 -0.2 (1) 84 0.1 (1.2) 3.51% -0.25[-0.58,0.08]
SHOT 1996 289 1.6 (1) 267 2.1 (1.2) 6.46% -0.45[-0.64,-0.26]
SMART 2013 21 1.1 (0.6) 24 1.2 (0.5) 3.85% -0.07[-0.38,0.24]
Sofi 2010 6 -0.4 (0.8) 5 0.2 (0.2) 1.2% -0.59[-1.23,0.05]
Tande 2016 50 -0 (0.7) 50 0.2 (0.7) 4.59% -0.21[-0.47,0.05]
THIS DIET 2008 37 1.5 (0.8) 34 1.4 (0.9) 2.88% 0.02[-0.36,0.4]
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Study or subgroup Favours high-
er omega 3
Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 2.8% -0.3[-0.68,0.08]
   
Total *** 17846   17733   100% -0.24[-0.31,-0.16]
Heterogeneity: Tau2=0.01; Chi2=42.25, df=22(P=0.01); I2=47.93%  
Test for overall effect: Z=6.24(P<0.0001)  
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Analysis 2.43.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 43 TG, fasting, mmoL/L - LCn3 - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.43.1 Low risk of bias  
AlphaOmega - EPA+DHA 2010 605 -0.1 (1.2) 605 -0 (1) 8.57% -0.03[-0.15,0.09]
Berson 2004 105 1.1 (0.7) 103 1.4 (1.2) 4.35% -0.33[-0.6,-0.06]
Derosa 2016 128 1.4 (3.4) 130 1.9 (4.6) 0.52% -0.5[-1.49,0.49]
Lorenz-Meyer 1996 13 -0.4 (0.7) 12 -0.1 (0.5) 2.23% -0.32[-0.76,0.12]
MARINA 2011 80 1 (0.4) 71 1.2 (0.5) 7.74% -0.23[-0.38,-0.08]
ORIGIN 2012 6281 -0.3 (2.7) 6255 -0.1 (2.7) 9.56% -0.16[-0.26,-0.07]
SCIMO 1999 87 -0.2 (1) 84 0.1 (1.2) 3.43% -0.25[-0.58,0.08]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 2.73% -0.3[-0.68,0.08]
Subtotal *** 7346   7308   39.12% -0.17[-0.25,-0.09]
Heterogeneity: Tau2=0; Chi2=8.4, df=7(P=0.3); I2=16.66%  
Test for overall effect: Z=4.39(P<0.0001)  
   
2.43.2 Moderate/high risk of bias  
Deslypere 1992 14 0.8 (0.4) 14 1.2 (0.8) 2.09% -0.43[-0.88,0.02]
DIPP 2015 90 1.5 (1.1) 71 1.4 (0.8) 4.08% 0.01[-0.28,0.3]
DO IT 2010 124 1.4 (0.8) 117 1.6 (0.9) 5.68% -0.16[-0.38,0.06]
EPE-A 2014 64 -0.1 (0) 55 0.1 (0)   Not estimable
HARP 1995 31 1.1 (0.6) 28 1.6 (0.8) 3.2% -0.47[-0.81,-0.13]
JELIS 2007 2303 1.6 (0) 2262 1.7 (0)   Not estimable
JELIS 2007 7023 1.4 (0) 7057 1.5 (0)   Not estimable
Mita 2007 30 1.8 (1.1) 30 1.5 (0.9) 1.77% 0.26[-0.24,0.76]
Nodari 2011 HF 67 1.6 (0.5) 66 1.8 (0.8) 5.45% -0.14[-0.36,0.08]
Nye 1990 12 1.4 (0.6) 12 1.8 (0.6) 2.09% -0.4[-0.85,0.05]
OFAMI 2001 120 1.3 (0.6) 121 1.8 (1.1) 5.67% -0.51[-0.73,-0.29]
ORL 2013 170 -0.8 (0.9) 165 -0.4 (0.9) 6.4% -0.38[-0.57,-0.19]
Sandhu 2016 49 1.1 (0.6) 47 1.2 (0.5) 5.76% -0.16[-0.37,0.05]
SHOT 1996 289 1.6 (1) 267 2.1 (1.2) 6.44% -0.45[-0.64,-0.26]
SMART 2013 21 1.1 (0.6) 24 1.2 (0.5) 3.77% -0.07[-0.38,0.24]
Sofi 2010 6 -0.4 (0.8) 5 0.2 (0.2) 1.16% -0.59[-1.23,0.05]
Tande 2016 50 -0 (0.7) 50 0.2 (0.7) 4.52% -0.21[-0.47,0.05]
THIS DIET 2008 37 1.5 (0.8) 34 1.4 (0.9) 2.8% 0.02[-0.36,0.4]
Subtotal *** 10500   10425   60.88% -0.25[-0.35,-0.15]
Heterogeneity: Tau2=0.02; Chi2=28.02, df=14(P=0.01); I2=50.04%  
Test for overall effect: Z=4.72(P<0.0001)  
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Total *** 17846   17733   100% -0.23[-0.3,-0.16]
Heterogeneity: Tau2=0.01; Chi2=41.33, df=22(P=0.01); I2=46.77%  
Test for overall effect: Z=6.25(P<0.0001)  
Test for subgroup differences: Chi2=1.45, df=1 (P=0.23), I2=31.05%  
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Analysis 2.44.   Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes),
Outcome 44 TG, fasting, mmoL/L - LCn3 - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.44.1 SA - low risk of compliance bias  
AlphaOmega - EPA+DHA 2010 605 -0.1 (1.2) 605 -0 (1) 14.6% -0.03[-0.15,0.09]
Berson 2004 105 1.1 (0.7) 103 1.4 (1.2) 7.97% -0.33[-0.6,-0.06]
Deslypere 1992 14 0.8 (0.4) 14 1.2 (0.8) 3.98% -0.43[-0.88,0.02]
DO IT 2010 124 1.4 (0.8) 117 1.6 (0.9) 10.15% -0.16[-0.38,0.06]
EPE-A 2014 64 -0.1 (0) 55 0.1 (0)   Not estimable
HARP 1995 31 1.1 (0.6) 28 1.6 (0.8) 5.97% -0.47[-0.81,-0.13]
MARINA 2011 80 1 (0.4) 71 1.2 (0.5) 13.37% -0.23[-0.38,-0.08]
Nodari 2011 HF 67 1.6 (0.5) 66 1.8 (0.8) 9.78% -0.14[-0.36,0.08]
ORL 2013 170 -0.8 (0.9) 165 -0.4 (0.9) 11.31% -0.38[-0.57,-0.19]
SCIMO 1999 87 -0.2 (1) 84 0.1 (1.2) 6.37% -0.25[-0.58,0.08]
SHOT 1996 289 1.6 (1) 267 2.1 (1.2) 11.37% -0.45[-0.64,-0.26]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 5.13% -0.3[-0.68,0.08]
Subtotal *** 1683   1623   100% -0.26[-0.36,-0.16]
Heterogeneity: Tau2=0.01; Chi2=22.03, df=10(P=0.01); I2=54.6%  
Test for overall effect: Z=5.04(P<0.0001)  
   
2.44.2 SA - 100+ randomised  
AlphaOmega - EPA+DHA 2010 605 -0.1 (1.2) 605 -0 (1) 10.25% -0.03[-0.15,0.09]
Berson 2004 105 1.1 (0.7) 103 1.4 (1.2) 5.44% -0.33[-0.6,-0.06]
Derosa 2016 128 1.4 (3.4) 130 1.9 (4.6) 0.67% -0.5[-1.49,0.49]
Deslypere 1992 14 0.8 (0.4) 14 1.2 (0.8) 2.68% -0.43[-0.88,0.02]
DIPP 2015 90 1.5 (1.1) 71 1.4 (0.8) 5.12% 0.01[-0.28,0.3]
DO IT 2010 124 1.4 (0.8) 117 1.6 (0.9) 7% -0.16[-0.38,0.06]
EPE-A 2014 64 -0.1 (0) 55 0.1 (0)   Not estimable
HARP 1995 31 1.1 (0.6) 28 1.6 (0.8) 4.05% -0.47[-0.81,-0.13]
JELIS 2007 2303 1.6 (0) 2262 1.7 (0)   Not estimable
JELIS 2007 7023 1.4 (0) 7057 1.5 (0)   Not estimable
MARINA 2011 80 1 (0.4) 71 1.2 (0.5) 9.34% -0.23[-0.38,-0.08]
Nodari 2011 HF 67 1.6 (0.5) 66 1.8 (0.8) 6.73% -0.14[-0.36,0.08]
OFAMI 2001 120 1.3 (0.6) 121 1.8 (1.1) 6.99% -0.51[-0.73,-0.29]
ORIGIN 2012 6281 -0.3 (2.7) 6255 -0.1 (2.7) 11.33% -0.16[-0.26,-0.07]
ORL 2013 170 -0.8 (0.9) 165 -0.4 (0.9) 7.83% -0.38[-0.57,-0.19]
SCIMO 1999 87 -0.2 (1) 84 0.1 (1.2) 4.32% -0.25[-0.58,0.08]
SHOT 1996 289 1.6 (1) 267 2.1 (1.2) 7.88% -0.45[-0.64,-0.26]
SMART 2013 21 1.1 (0.6) 24 1.2 (0.5) 4.74% -0.07[-0.38,0.24]
Tande 2016 50 -0 (0.7) 50 0.2 (0.7) 5.64% -0.21[-0.47,0.05]
Subtotal *** 17652   17545   100% -0.24[-0.32,-0.16]
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Tau2=0.01; Chi2=33.8, df=15(P=0); I2=55.61%  
Test for overall effect: Z=5.72(P<0.0001)  
Test for subgroup differences: Chi2=0.09, df=1 (P=0.76), I2=0%  
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
 
 
Analysis 2.45.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 45 TG, fasting, mmoL/L - LCn3 - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.45.1 LCn3 ≤ 150 mg/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.45.2 LCn3 > 150 ≤ 250 mg/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.45.3 LCn3 > 250 ≤ 400 mg/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.45.4 LCn3 > 400 ≤ 2400 mg/d  
AlphaOmega - EPA+DHA 2010 605 -0.1 (1.2) 605 -0 (1) 14.01% -0.03[-0.15,0.09]
Berson 2004 105 1.1 (0.7) 103 1.4 (1.2) 5.14% -0.33[-0.6,-0.06]
Derosa 2016 128 1.4 (3.4) 130 1.9 (4.6) 0.48% -0.5[-1.49,0.49]
Deslypere 1992 14 0.8 (0.4) 14 1.2 (0.8) 2.14% -0.43[-0.88,0.02]
DIPP 2015 90 1.5 (1.1) 71 1.4 (0.8) 4.73% 0.01[-0.28,0.3]
DO IT 2010 124 1.4 (0.8) 117 1.6 (0.9) 7.34% -0.16[-0.38,0.06]
JELIS 2007 7023 1.4 (0) 7057 1.5 (0)   Not estimable
JELIS 2007 2303 1.6 (0) 2262 1.7 (0)   Not estimable
MARINA 2011 80 1 (0.4) 71 1.2 (0.5) 11.77% -0.23[-0.38,-0.08]
Mita 2007 30 1.8 (1.1) 30 1.5 (0.9) 1.78% 0.26[-0.24,0.76]
Nodari 2011 HF 67 1.6 (0.5) 66 1.8 (0.8) 6.92% -0.14[-0.36,0.08]
Nye 1990 12 1.4 (0.6) 12 1.8 (0.6) 2.15% -0.4[-0.85,0.05]
ORIGIN 2012 6281 -0.3 (2.7) 6255 -0.1 (2.7) 17.21% -0.16[-0.26,-0.07]
ORL 2013 170 -0.8 (0.9) 165 -0.4 (0.9) 8.74% -0.38[-0.57,-0.19]
SCIMO 1999 87 -0.2 (1) 84 0.1 (1.2) 3.8% -0.25[-0.58,0.08]
SMART 2013 21 1.1 (0.6) 24 1.2 (0.5) 4.27% -0.07[-0.38,0.24]
Sofi 2010 6 -0.4 (0.8) 5 0.2 (0.2) 1.12% -0.59[-1.23,0.05]
Tande 2016 50 -0 (0.7) 50 0.2 (0.7) 5.39% -0.21[-0.47,0.05]
THIS DIET 2008 37 1.5 (0.8) 34 1.4 (0.9) 2.99% 0.02[-0.36,0.4]
Subtotal *** 17233   17155   100% -0.18[-0.25,-0.11]
Heterogeneity: Tau2=0; Chi2=22.1, df=16(P=0.14); I2=27.59%  
Test for overall effect: Z=4.98(P<0.0001)  
   
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.45.5 LCn3 > 2.4 ≤ 4.4 g/d  
EPE-A 2014 64 -0.1 (0) 55 0.1 (0)   Not estimable
OFAMI 2001 120 1.3 (0.6) 121 1.8 (1.1) 27.44% -0.51[-0.73,-0.29]
Sandhu 2016 49 1.1 (0.6) 47 1.2 (0.5) 27.85% -0.16[-0.37,0.05]
SHOT 1996 289 1.6 (1) 267 2.1 (1.2) 30.73% -0.45[-0.64,-0.26]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 13.98% -0.3[-0.68,0.08]
Subtotal *** 569   538   100% -0.36[-0.53,-0.2]
Heterogeneity: Tau2=0.01; Chi2=6.2, df=3(P=0.1); I2=51.64%  
Test for overall effect: Z=4.24(P<0.0001)  
   
2.45.6 LCn3 > 4.4 g/d  
HARP 1995 31 1.1 (0.6) 28 1.6 (0.8) 61.63% -0.47[-0.81,-0.13]
Lorenz-Meyer 1996 13 -0.4 (0.7) 12 -0.1 (0.5) 38.37% -0.32[-0.76,0.12]
Subtotal *** 44   40   100% -0.41[-0.68,-0.14]
Heterogeneity: Tau2=0; Chi2=0.28, df=1(P=0.6); I2=0%  
Test for overall effect: Z=3(P=0)  
Test for subgroup differences: Chi2=6.29, df=1 (P=0.04), I2=68.22%  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
 
 
Analysis 2.46.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 46 TG, fasting, mmoL/L - LCn3 - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.46.1 N-3 replacing SFA  
Derosa 2016 128 1.4 (3.4) 130 1.9 (4.6) 9.93% -0.5[-1.49,0.49]
SCIMO 1999 87 -0.2 (1) 84 0.1 (1.2) 90.07% -0.25[-0.58,0.08]
Subtotal *** 215   214   100% -0.27[-0.59,0.04]
Heterogeneity: Tau2=0; Chi2=0.22, df=1(P=0.64); I2=0%  
Test for overall effect: Z=1.73(P=0.08)  
   
2.46.2 N-3 replacing MUFA  
AlphaOmega - EPA+DHA 2010 605 -0.1 (1.2) 605 -0 (1) 19.34% -0.03[-0.15,0.09]
Deslypere 1992 14 0.8 (0.4) 14 1.2 (0.8) 2.31% -0.43[-0.88,0.02]
HARP 1995 31 1.1 (0.6) 28 1.6 (0.8) 3.87% -0.47[-0.81,-0.13]
MARINA 2011 80 1 (0.4) 71 1.2 (0.5) 15.43% -0.23[-0.38,-0.08]
Nodari 2011 HF 67 1.6 (0.5) 66 1.8 (0.8) 8.19% -0.14[-0.36,0.08]
Nye 1990 12 1.4 (0.6) 12 1.8 (0.6) 2.32% -0.4[-0.85,0.05]
ORIGIN 2012 6281 -0.3 (2.7) 6255 -0.1 (2.7) 25.7% -0.16[-0.26,-0.07]
SCIMO 1999 87 -0.2 (1) 84 0.1 (1.2) 4.23% -0.25[-0.58,0.08]
SMART 2013 21 1.1 (0.6) 24 1.2 (0.5) 4.8% -0.07[-0.38,0.24]
Sofi 2010 6 -0.4 (0.8) 5 0.2 (0.2) 1.19% -0.59[-1.23,0.05]
Tande 2016 50 -0 (0.7) 50 0.2 (0.7) 6.18% -0.21[-0.47,0.05]
THIS DIET 2008 37 1.5 (0.8) 34 1.4 (0.9) 3.27% 0.02[-0.36,0.4]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 3.17% -0.3[-0.68,0.08]
Subtotal *** 7338   7296   100% -0.18[-0.25,-0.1]
Heterogeneity: Tau2=0; Chi2=14.61, df=12(P=0.26); I2=17.89%  
Test for overall effect: Z=4.86(P<0.0001)  
   
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.46.3 N-3 replacing n-6  
Berson 2004 105 1.1 (0.7) 103 1.4 (1.2) 20.24% -0.33[-0.6,-0.06]
DIPP 2015 90 1.5 (1.1) 71 1.4 (0.8) 19.34% 0.01[-0.28,0.3]
DO IT 2010 124 1.4 (0.8) 117 1.6 (0.9) 24.13% -0.16[-0.38,0.06]
Lorenz-Meyer 1996 13 -0.4 (0.7) 12 -0.1 (0.5) 12.18% -0.32[-0.76,0.12]
OFAMI 2001 120 1.3 (0.6) 121 1.8 (1.1) 24.11% -0.51[-0.73,-0.29]
Subtotal *** 452   424   100% -0.27[-0.45,-0.08]
Heterogeneity: Tau2=0.03; Chi2=9.63, df=4(P=0.05); I2=58.46%  
Test for overall effect: Z=2.77(P=0.01)  
   
2.46.4 N-3 replacing carbs/sugars  
Derosa 2016 128 1.4 (3.4) 130 1.9 (4.6) 100% -0.5[-1.49,0.49]
Subtotal *** 128   130   100% -0.5[-1.49,0.49]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.99(P=0.32)  
   
2.46.5 N-3 replacing nil/low n-3 placebo  
JELIS 2007 7023 1.4 (0) 7057 1.5 (0)   Not estimable
JELIS 2007 2303 1.6 (0) 2262 1.7 (0)   Not estimable
Mita 2007 30 1.8 (1.1) 30 1.5 (0.9) 21.8% 0.26[-0.24,0.76]
Sandhu 2016 49 1.1 (0.6) 47 1.2 (0.5) 38.39% -0.16[-0.37,0.05]
SHOT 1996 289 1.6 (1) 267 2.1 (1.2) 39.81% -0.45[-0.64,-0.26]
Subtotal *** 9694   9663   100% -0.18[-0.51,0.14]
Heterogeneity: Tau2=0.06; Chi2=8.84, df=2(P=0.01); I2=77.37%  
Test for overall effect: Z=1.12(P=0.26)  
   
2.46.6 Replacement unclear  
EPE-A 2014 64 -0.1 (0) 55 0.1 (0)   Not estimable
ORL 2013 170 -0.8 (0.9) 165 -0.4 (0.9) 100% -0.38[-0.57,-0.19]
Subtotal *** 234   220   100% -0.38[-0.57,-0.19]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.93(P<0.0001)  
Test for subgroup differences: Chi2=4.89, df=1 (P=0.43), I2=0%  
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
 
 
Analysis 2.47.   Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes),
Outcome 47 TG, fasting, mmoL/L - LCn3 - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.47.1 Dietary advice  
THIS DIET 2008 37 1.5 (0.8) 34 1.4 (0.9) 100% 0.02[-0.36,0.4]
Subtotal *** 37   34   100% 0.02[-0.36,0.4]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.1(P=0.92)  
   
2.47.2 Supplemental foods  
AlphaOmega - EPA+DHA 2010 605 -0.1 (1.2) 605 -0 (1) 100% -0.03[-0.15,0.09]
Subtotal *** 605   605   100% -0.03[-0.15,0.09]
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
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  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.48(P=0.63)  
   
2.47.3 Supplement (capsule)  
Berson 2004 105 1.1 (0.7) 103 1.4 (1.2) 5.35% -0.33[-0.6,-0.06]
Derosa 2016 128 1.4 (3.4) 130 1.9 (4.6) 2.32% -0.5[-1.49,0.49]
Deslypere 1992 14 0.8 (0.4) 14 1.2 (0.8) 4.5% -0.43[-0.88,0.02]
DO IT 2010 124 1.4 (0.8) 117 1.6 (0.9) 5.58% -0.16[-0.38,0.06]
EPE-A 2014 64 -0.1 (0) 55 0.1 (0)   Not estimable
HARP 1995 31 1.1 (0.6) 28 1.6 (0.8) 5.03% -0.47[-0.81,-0.13]
JELIS 2007 7023 1.4 (0) 7057 1.5 (0)   Not estimable
JELIS 2007 2303 1.6 (0) 2262 1.7 (0)   Not estimable
Lorenz-Meyer 1996 13 -0.4 (0.7) 12 -0.1 (0.5) 4.58% -0.32[-0.76,0.12]
MARINA 2011 80 1 (0.4) 71 1.2 (0.5) 5.79% -0.23[-0.38,-0.08]
Mita 2007 30 1.8 (1.1) 30 1.5 (0.9) 4.26% 0.26[-0.24,0.76]
Nodari 2011 HF 67 1.6 (0.5) 66 1.8 (0.8) 5.54% -0.14[-0.36,0.08]
Nye 1990 12 1.4 (0.6) 12 1.8 (0.6) 4.5% -0.4[-0.85,0.05]
OFAMI 2001 120 1.3 (0.6) 121 1.8 (1.1) 5.58% -0.51[-0.73,-0.29]
ORIGIN 2012 6281 -0.3 (2.7) 6255 -0.1 (2.7) 5.91% -0.16[-0.26,-0.07]
ORL 2013 170 0.8 (0.9) 165 -0.4 (0.9) 5.67% 1.18[0.99,1.37]
Sandhu 2016 49 1.1 (0.6) 47 1.2 (0.5) 5.59% -0.16[-0.37,0.05]
SCIMO 1999 87 -0.2 (1) 84 0.1 (1.2) 5.11% -0.25[-0.58,0.08]
SHOT 1996 289 1.6 (1) 267 2.1 (1.2) 5.67% -0.45[-0.64,-0.26]
SMART 2013 21 1.1 (0.6) 24 1.2 (0.5) 5.21% -0.07[-0.38,0.24]
Sofi 2010 6 -0.4 (0.8) 5 0.2 (0.2) 3.6% -0.59[-1.23,0.05]
Tande 2016 50 -0 (0.7) 50 0.2 (0.7) 5.38% -0.21[-0.47,0.05]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 4.84% -0.3[-0.68,0.08]
Subtotal *** 17114   17023   100% -0.19[-0.38,-0]
Heterogeneity: Tau2=0.16; Chi2=225.13, df=19(P<0.0001); I2=91.56%  
Test for overall effect: Z=1.97(P=0.05)  
   
2.47.4 Any combination  
DIPP 2015 90 1.5 (1.1) 71 1.4 (0.8) 100% 0.01[-0.28,0.3]
Subtotal *** 90   71   100% 0.01[-0.28,0.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.07(P=0.95)  
Test for subgroup differences: Chi2=2.47, df=1 (P=0.48), I2=0%  
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
 
 
Analysis 2.48.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 48 TG, fasting, mmoL/L - LCn3 - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.48.1 Medium duration 1 to < 2 years in study  
Derosa 2016 128 1.4 (3.4) 130 1.9 (4.6) 0.71% -0.5[-1.49,0.49]
Deslypere 1992 14 0.8 (0.4) 14 1.2 (0.8) 3.38% -0.43[-0.88,0.02]
EPE-A 2014 64 -0.1 (0) 55 0.1 (0)   Not estimable
Lorenz-Meyer 1996 13 -0.4 (0.7) 12 -0.1 (0.5) 3.65% -0.32[-0.76,0.12]
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
MARINA 2011 80 1 (0.4) 71 1.2 (0.5) 31.83% -0.23[-0.38,-0.08]
Nodari 2011 HF 67 1.6 (0.5) 66 1.8 (0.8) 13.76% -0.14[-0.36,0.08]
Nye 1990 12 1.4 (0.6) 12 1.8 (0.6) 3.39% -0.4[-0.85,0.05]
ORL 2013 170 -0.3 (0) 165 -0.2 (0)   Not estimable
SHOT 1996 289 1.6 (1) 267 2.1 (1.2) 19.56% -0.45[-0.64,-0.26]
SMART 2013 21 1.1 (0.6) 24 1.2 (0.5) 7.42% -0.07[-0.38,0.24]
Sofi 2010 6 -0.4 (0.8) 5 0.2 (0.2) 1.7% -0.59[-1.23,0.05]
Tande 2016 50 -0 (0.7) 50 0.2 (0.7) 9.88% -0.21[-0.47,0.05]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 4.73% -0.3[-0.68,0.08]
Subtotal *** 961   919   100% -0.27[-0.36,-0.19]
Heterogeneity: Tau2=0; Chi2=8.97, df=10(P=0.54); I2=0%  
Test for overall effect: Z=6.45(P<0.0001)  
   
2.48.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - EPA+DHA 2010 605 -0.1 (1.2) 605 -0 (1) 16.7% -0.03[-0.15,0.09]
DIPP 2015 90 1.5 (1.1) 71 1.4 (0.8) 10.77% 0.01[-0.28,0.3]
DO IT 2010 124 1.4 (0.8) 117 1.6 (0.9) 13.3% -0.16[-0.38,0.06]
HARP 1995 31 1.1 (0.6) 28 1.6 (0.8) 9.06% -0.47[-0.81,-0.13]
Mita 2007 30 1.8 (1.1) 30 1.5 (0.9) 5.71% 0.26[-0.24,0.76]
OFAMI 2001 120 1.3 (0.6) 121 1.8 (1.1) 13.29% -0.51[-0.73,-0.29]
Sandhu 2016 49 1.1 (0.6) 47 1.2 (0.5) 13.43% -0.16[-0.37,0.05]
SCIMO 1999 87 -0.2 (1) 84 0.1 (1.2) 9.53% -0.25[-0.58,0.08]
THIS DIET 2008 37 1.5 (0.8) 34 1.4 (0.9) 8.21% 0.02[-0.36,0.4]
Subtotal *** 1173   1137   100% -0.16[-0.31,-0.02]
Heterogeneity: Tau2=0.03; Chi2=22.58, df=8(P=0); I2=64.56%  
Test for overall effect: Z=2.26(P=0.02)  
   
2.48.3 Long duration ≥ 4 years in study  
Berson 2004 105 1.1 (0.7) 103 1.4 (1.2) 19.01% -0.33[-0.6,-0.06]
JELIS 2007 7023 1.4 (0) 7057 1.5 (0)   Not estimable
JELIS 2007 2303 1.6 (0) 2262 1.7 (0)   Not estimable
ORIGIN 2012 6281 -0.3 (2.7) 6255 -0.1 (2.7) 80.99% -0.16[-0.26,-0.07]
Subtotal *** 15712   15677   100% -0.2[-0.32,-0.07]
Heterogeneity: Tau2=0; Chi2=1.27, df=1(P=0.26); I2=21.26%  
Test for overall effect: Z=3(P=0)  
Test for subgroup differences: Chi2=2.14, df=1 (P=0.34), I2=6.72%  
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
 
 
Analysis 2.49.   Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes),
Outcome 49 TG, fasting, mmoL/L - LCn3 - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.49.1 Primary prevention  
Berson 2004 105 1.1 (0.7) 103 1.4 (1.2) 4.84% -0.33[-0.6,-0.06]
Derosa 2016 128 1.4 (3.4) 130 1.9 (4.6) 0.38% -0.5[-1.49,0.49]
Deslypere 1992 14 0.8 (0.4) 14 1.2 (0.8) 1.8% -0.43[-0.88,0.02]
DIPP 2015 90 1.5 (1.1) 71 1.4 (0.8) 4.38% 0.01[-0.28,0.3]
DO IT 2010 124 1.4 (0.8) 117 1.6 (0.9) 7.6% -0.16[-0.38,0.06]
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
EPE-A 2014 64 -0.1 (0) 55 0.1 (0)   Not estimable
JELIS 2007 7023 1.4 (0) 7057 1.5 (0)   Not estimable
JELIS 2007 2303 1.6 (0) 2262 1.7 (0)   Not estimable
Lorenz-Meyer 1996 13 -0.4 (0.7) 12 -0.1 (0.5) 1.94% -0.32[-0.76,0.12]
MARINA 2011 80 1 (0.4) 71 1.2 (0.5) 15.28% -0.23[-0.38,-0.08]
Mita 2007 30 1.8 (1.1) 30 1.5 (0.9) 1.47% 0.26[-0.24,0.76]
ORIGIN 2012 6281 -0.3 (2.7) 6255 -0.1 (2.7) 32.39% -0.16[-0.26,-0.07]
ORL 2013 170 -0.8 (0.9) 165 -0.4 (0.9) 9.67% -0.38[-0.57,-0.19]
Sandhu 2016 49 1.1 (0.6) 47 1.2 (0.5) 7.83% -0.16[-0.37,0.05]
SMART 2013 21 1.1 (0.6) 24 1.2 (0.5) 3.89% -0.07[-0.38,0.24]
Sofi 2010 6 -0.4 (0.8) 5 0.2 (0.2) 0.91% -0.59[-1.23,0.05]
Tande 2016 50 -0 (0.7) 50 0.2 (0.7) 5.13% -0.21[-0.47,0.05]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 2.5% -0.3[-0.68,0.08]
Subtotal *** 16598   16516   100% -0.2[-0.26,-0.14]
Heterogeneity: Tau2=0; Chi2=14.66, df=14(P=0.4); I2=4.48%  
Test for overall effect: Z=6.53(P<0.0001)  
   
2.49.2 Secondary prevention  
AlphaOmega - EPA+DHA 2010 605 -0.1 (1.2) 605 -0 (1) 17.03% -0.03[-0.15,0.09]
HARP 1995 31 1.1 (0.6) 28 1.6 (0.8) 10.57% -0.47[-0.81,-0.13]
Nodari 2011 HF 67 1.6 (0.5) 66 1.8 (0.8) 14.09% -0.14[-0.36,0.08]
Nye 1990 12 1.4 (0.6) 12 1.8 (0.6) 8.01% -0.4[-0.85,0.05]
OFAMI 2001 120 1.3 (0.6) 121 1.8 (1.1) 14.36% -0.51[-0.73,-0.29]
SCIMO 1999 87 -0.2 (1) 84 0.1 (1.2) 11.01% -0.25[-0.58,0.08]
SHOT 1996 289 1.6 (1) 267 2.1 (1.2) 15.2% -0.45[-0.64,-0.26]
THIS DIET 2008 37 1.5 (0.8) 34 1.4 (0.9) 9.73% 0.02[-0.36,0.4]
Subtotal *** 1248   1217   100% -0.27[-0.44,-0.1]
Heterogeneity: Tau2=0.04; Chi2=26.5, df=7(P=0); I2=73.59%  
Test for overall effect: Z=3.17(P=0)  
Test for subgroup differences: Chi2=0.58, df=1 (P=0.44), I2=0%  
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
 
 
Analysis 2.50.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 50 TG, fasting, mmoL/L - LCn3 - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.50.1 LCn3 - ≥ 50% of control group on statins  
AlphaOmega - EPA+DHA 2010 605 -0.1 (1.2) 605 -0 (1) 37.68% -0.03[-0.15,0.09]
JELIS 2007 2303 1.6 (0) 2262 1.7 (0)   Not estimable
JELIS 2007 7023 1.4 (0) 7057 1.5 (0)   Not estimable
ORIGIN 2012 6281 -0.3 (2.7) 6255 -0.1 (2.7) 49.11% -0.16[-0.26,-0.07]
THIS DIET 2008 37 1.5 (0.8) 34 1.4 (0.9) 6.71% 0.02[-0.36,0.4]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 6.5% -0.3[-0.68,0.08]
Subtotal *** 16296   16261   100% -0.11[-0.21,-0.01]
Heterogeneity: Tau2=0; Chi2=4.25, df=3(P=0.24); I2=29.43%  
Test for overall effect: Z=2.12(P=0.03)  
   
2.50.2 LCn3 - < 50% of control group on statins  
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Berson 2004 105 1.1 (0.7) 103 1.4 (1.2) 7.04% -0.33[-0.6,-0.06]
Deslypere 1992 14 0.8 (0.4) 14 1.2 (0.8) 3.46% -0.43[-0.88,0.02]
DIPP 2015 90 1.5 (1.1) 71 1.4 (0.8) 6.62% 0.01[-0.28,0.3]
DO IT 2010 124 1.4 (0.8) 117 1.6 (0.9) 9.06% -0.16[-0.38,0.06]
HARP 1995 31 1.1 (0.6) 28 1.6 (0.8) 5.23% -0.47[-0.81,-0.13]
Lorenz-Meyer 1996 13 -0.4 (0.7) 12 -0.1 (0.5) 3.67% -0.32[-0.76,0.12]
MARINA 2011 80 1 (0.4) 71 1.2 (0.5) 12.13% -0.23[-0.38,-0.08]
Mita 2007 30 1.8 (1.1) 30 1.5 (0.9) 2.94% 0.26[-0.24,0.76]
Nodari 2011 HF 67 1.6 (0.5) 66 1.8 (0.8) 8.72% -0.14[-0.36,0.08]
OFAMI 2001 120 1.3 (0.6) 121 1.8 (1.1) 9.06% -0.51[-0.73,-0.29]
ORL 2013 170 -0.8 (0.9) 165 -0.4 (0.9) 10.16% -0.38[-0.57,-0.19]
SCIMO 1999 87 -0.2 (1) 84 0.1 (1.2) 5.59% -0.25[-0.58,0.08]
SHOT 1996 289 1.6 (1) 267 2.1 (1.2) 10.22% -0.45[-0.64,-0.26]
SMART 2013 21 1.1 (0.6) 24 1.2 (0.5) 6.12% -0.07[-0.38,0.24]
Subtotal *** 1241   1173   100% -0.27[-0.36,-0.18]
Heterogeneity: Tau2=0.01; Chi2=23.69, df=13(P=0.03); I2=45.13%  
Test for overall effect: Z=5.62(P<0.0001)  
   
2.50.3 LCn3 - use of statins unclear  
Derosa 2016 128 1.4 (3.4) 130 1.9 (4.6) 2.29% -0.5[-1.49,0.49]
EPE-A 2014 64 -0.1 (0) 55 0.1 (0)   Not estimable
Nye 1990 12 1.4 (0.6) 12 1.8 (0.6) 10.9% -0.4[-0.85,0.05]
Sandhu 2016 49 1.1 (0.6) 47 1.2 (0.5) 49.53% -0.16[-0.37,0.05]
Sofi 2010 6 -0.4 (0.8) 5 0.2 (0.2) 5.46% -0.59[-1.23,0.05]
Tande 2016 50 -0 (0.7) 50 0.2 (0.7) 31.81% -0.21[-0.47,0.05]
Subtotal *** 309   299   100% -0.23[-0.38,-0.08]
Heterogeneity: Tau2=0; Chi2=2.49, df=4(P=0.65); I2=0%  
Test for overall effect: Z=3.06(P=0)  
Test for subgroup differences: Chi2=5.31, df=1 (P=0.07), I2=62.36%  
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
 
 
Analysis 2.51.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 51 High-density lipoprotein, serum, mmoL/L - LCn3.
Study or subgroup Favours low-
er omega 3
Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Ahn 2016 38 1.2 (0.3) 36 1.1 (0.3) 1.66% 0.05[-0.1,0.2]
AlphaOmega - EPA+DHA 2010 605 0.2 (0.3) 605 0.2 (0.3) 11.88% 0.03[0,0.06]
Berson 2004 105 1.5 (0.4) 103 1.4 (0.4) 2.66% 0.08[-0.03,0.19]
Brox 2001 37 1.3 (0.4) 37 1.3 (0.4) 1.11% 0[-0.18,0.18]
DART 1989 867 1.1 (0.3) 847 1 (0.3) 12.11% 0.01[-0.02,0.04]
Derosa 2016 128 1.2 (1.1) 130 1.1 (1.1) 0.53% 0.1[-0.17,0.37]
Deslypere 1992 14 1.3 (0.2) 14 1.3 (0.4) 0.82% -0.03[-0.24,0.18]
DIPP 2015 89 1.4 (0.4) 73 1.5 (0.3) 2.87% -0.03[-0.14,0.08]
DO IT 2010 124 1.5 (0.4) 117 1.4 (0.4) 3.52% 0.06[-0.03,0.15]
EPE-A 2014 64 0 (0) 55 0 (0)   Not estimable
HARP 1995 31 1.1 (0.3) 28 1.1 (0.3) 1.41% 0[-0.16,0.16]
JELIS 2007 9326 1.5 (0.4) 9319 1.5 (0.4) 14.78% 0[-0.01,0.01]
Favours lower omega 3 0.50.25-0.5 -0.25 0 Favours higher omega 3
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Study or subgroup Favours low-
er omega 3
Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
MARINA 2011 80 0 (0.5) 71 0 (0.2) 2.71% 0[-0.11,0.11]
Mita 2007 30 1.5 (0.6) 30 1.4 (0.4) 0.61% 0.07[-0.18,0.32]
NAT2 2013 134 2 (0.6) 129 1.8 (0.5) 1.93% 0.15[0.02,0.28]
Nye 1990 12 1.4 (0.4) 12 1.5 (0.4) 0.37% -0.07[-0.39,0.25]
OFAMI 2001 119 1.3 (0.3) 120 1.2 (0.3) 4.16% 0.04[-0.04,0.12]
ORIGIN 2012 6281 -0 (0.6) 6255 -0 (0.6) 13.08% 0[-0.02,0.02]
Sandhu 2016 49 1.8 (0.5) 47 1.8 (0.5) 0.93% 0.01[-0.19,0.21]
SCIMO 1999 87 0 (0.3) 84 0.1 (0.3) 4.1% -0.09[-0.17,-0.01]
SHOT 1996 289 1.2 (0.3) 267 1.1 (0.3) 8.02% 0.1[0.05,0.15]
SMART 2013 21 1.5 (0.4) 24 1.4 (0.4) 0.69% 0.1[-0.13,0.33]
Sofi 2010 6 0.4 (0.3) 5 -0.7 (0.7) 0.09% 1.08[0.42,1.74]
Tande 2016 50 0 (0.2) 50 0 (0.2) 4.23% 0.01[-0.07,0.09]
THIS DIET 2008 37 1 (0.2) 34 1 (0.3) 2.21% 0[-0.12,0.12]
Weinstock-Guttman 2005 13 0.1 (0.2) 14 -0.3 (0.5) 0.47% 0.34[0.05,0.63]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 3.03% 0[-0.1,0.1]
   
Total *** 18683   18554   100% 0.02[0,0.04]
Heterogeneity: Tau2=0; Chi2=48.46, df=25(P=0); I2=48.41%  
Test for overall effect: Z=2.2(P=0.03)  
Favours lower omega 3 0.50.25-0.5 -0.25 0 Favours higher omega 3
 
 
Analysis 2.52.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 52 HDL, mmoL/L - LCn3 - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.52.1 Low risk of bias  
AlphaOmega - EPA+DHA 2010 605 0.2 (0.3) 605 0.2 (0.3) 11.26% 0.03[0,0.06]
Berson 2004 105 1.5 (0.4) 103 1.4 (0.4) 2.96% 0.08[-0.03,0.19]
Derosa 2016 128 1.2 (1.1) 130 1.1 (1.1) 0.62% 0.1[-0.17,0.37]
MARINA 2011 80 1.7 (0.5) 71 1.5 (0.4) 2.06% 0.2[0.06,0.34]
NAT2 2013 134 2 (0.6) 129 1.8 (0.5) 2.19% 0.15[0.02,0.28]
ORIGIN 2012 6281 -0 (0.6) 6255 -0 (0.6) 12.16% 0[-0.02,0.02]
SCIMO 1999 87 0 (0.3) 84 0.1 (0.3) 4.44% -0.09[-0.17,-0.01]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 3.36% 0[-0.1,0.1]
Subtotal *** 7467   7425   39.05% 0.03[-0.01,0.07]
Heterogeneity: Tau2=0; Chi2=20.83, df=7(P=0); I2=66.4%  
Test for overall effect: Z=1.43(P=0.15)  
   
2.52.2 Moderate/high risk of bias  
Ahn 2016 38 1.2 (0.3) 36 1.1 (0.3) 1.89% 0.05[-0.1,0.2]
Brox 2001 37 1.3 (0.4) 37 1.3 (0.4) 1.28% 0[-0.18,0.18]
DART 1989 867 1.1 (0.3) 847 1 (0.3) 11.44% 0.01[-0.02,0.04]
Deslypere 1992 14 1.3 (0.2) 14 1.3 (0.4) 0.95% -0.03[-0.24,0.18]
DIPP 2015 89 1.4 (0.4) 73 1.5 (0.3) 3.18% -0.03[-0.14,0.08]
DO IT 2010 124 1.5 (0.4) 117 1.4 (0.4) 3.86% 0.06[-0.03,0.15]
EPE-A 2014 64 0 (0) 55 0 (0)   Not estimable
HARP 1995 31 1.1 (0.3) 28 1.1 (0.3) 1.61% 0[-0.16,0.16]
Favours lower omega 3 0.20.1-0.2 -0.1 0 Favours higher omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
JELIS 2007 9326 1.5 (0.4) 9319 1.5 (0.4) 13.38% 0[-0.01,0.01]
Mita 2007 30 1.5 (0.6) 30 1.4 (0.4) 0.71% 0.07[-0.18,0.32]
Nye 1990 12 1.4 (0.4) 12 1.5 (0.4) 0.43% -0.07[-0.39,0.25]
OFAMI 2001 119 1.3 (0.3) 120 1.2 (0.3) 4.51% 0.04[-0.04,0.12]
Sandhu 2016 49 1.8 (0.5) 47 1.8 (0.5) 1.08% 0.01[-0.19,0.21]
SHOT 1996 289 1.2 (0.3) 267 1.1 (0.3) 8.11% 0.1[0.05,0.15]
SMART 2013 21 1.5 (0.4) 24 1.4 (0.4) 0.8% 0.1[-0.13,0.33]
Sofi 2010 6 0.4 (0.3) 5 -0.7 (0.7) 0.11% 1.08[0.42,1.74]
Tande 2016 50 0 (0.2) 50 0 (0.2) 4.58% 0.01[-0.07,0.09]
THIS DIET 2008 37 1 (0.2) 34 1 (0.3) 2.49% 0[-0.12,0.12]
Weinstock-Guttman 2005 13 0.1 (0.2) 14 -0.3 (0.5) 0.55% 0.34[0.05,0.63]
Subtotal *** 11216   11129   60.95% 0.03[0,0.06]
Heterogeneity: Tau2=0; Chi2=34.32, df=17(P=0.01); I2=50.47%  
Test for overall effect: Z=1.99(P=0.05)  
   
Total *** 18683   18554   100% 0.03[0.01,0.05]
Heterogeneity: Tau2=0; Chi2=55.68, df=25(P=0); I2=55.1%  
Test for overall effect: Z=2.51(P=0.01)  
Test for subgroup differences: Chi2=0, df=1 (P=0.97), I2=0%  
Favours lower omega 3 0.20.1-0.2 -0.1 0 Favours higher omega 3
 
 
Analysis 2.53.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 53 HDL, mmoL/L - LCn3 - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.53.1 SA - low risk of compliance bias  
AlphaOmega - EPA+DHA 2010 605 0.2 (0.3) 605 0.2 (0.3) 16.52% 0.03[0,0.06]
Berson 2004 105 1.5 (0.4) 103 1.4 (0.4) 8.6% 0.08[-0.03,0.19]
Brox 2001 37 1.3 (0.4) 37 1.3 (0.4) 4.63% 0[-0.18,0.18]
Deslypere 1992 14 1.3 (0.2) 14 1.3 (0.4) 3.63% -0.03[-0.24,0.18]
DO IT 2010 124 1.5 (0.4) 117 1.4 (0.4) 10.15% 0.06[-0.03,0.15]
EPE-A 2014 64 0 (0) 55 0 (0)   Not estimable
HARP 1995 31 1.1 (0.3) 28 1.1 (0.3) 5.58% 0[-0.16,0.16]
MARINA 2011 80 1.7 (0.5) 71 1.5 (0.4) 6.71% 0.2[0.06,0.34]
NAT2 2013 134 2 (0.6) 129 1.8 (0.5) 7% 0.15[0.02,0.28]
SCIMO 1999 87 0 (0.3) 84 0.1 (0.3) 10.99% -0.09[-0.17,-0.01]
SHOT 1996 289 1.2 (0.3) 267 1.1 (0.3) 14.65% 0.1[0.05,0.15]
Weinstock-Guttman 2005 13 0.1 (0.2) 14 -0.3 (0.5) 2.22% 0.34[0.05,0.63]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 9.32% 0[-0.1,0.1]
Subtotal *** 1630   1572   100% 0.05[0.01,0.1]
Heterogeneity: Tau2=0; Chi2=29.14, df=11(P=0); I2=62.26%  
Test for overall effect: Z=2.28(P=0.02)  
   
2.53.2 SA - 100+ randomised  
AlphaOmega - EPA+DHA 2010 605 0.2 (0.3) 605 0.2 (0.3) 13.52% 0.03[0,0.06]
Berson 2004 105 1.5 (0.4) 103 1.4 (0.4) 3.34% 0.08[-0.03,0.19]
DART 1989 867 1.1 (0.3) 847 1 (0.3) 13.76% 0.01[-0.02,0.04]
Derosa 2016 128 1.2 (1.1) 130 1.1 (1.1) 0.69% 0.1[-0.17,0.37]
Favours lower omega 3 0.20.1-0.2 -0.1 0 Favours higher omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
DIPP 2015 89 1.4 (0.4) 73 1.5 (0.3) 3.59% -0.03[-0.14,0.08]
DO IT 2010 124 1.5 (0.4) 117 1.4 (0.4) 4.38% 0.06[-0.03,0.15]
EPE-A 2014 64 0 (0) 55 0 (0)   Not estimable
JELIS 2007 9326 1.5 (0.4) 9319 1.5 (0.4) 16.34% 0[-0.01,0.01]
MARINA 2011 80 1.7 (0.5) 71 1.5 (0.4) 2.31% 0.2[0.06,0.34]
NAT2 2013 134 2 (0.6) 129 1.8 (0.5) 2.45% 0.15[0.02,0.28]
OFAMI 2001 119 1.3 (0.3) 120 1.2 (0.3) 5.14% 0.04[-0.04,0.12]
ORIGIN 2012 6281 -0 (0.6) 6255 -0 (0.6) 14.71% 0[-0.02,0.02]
SCIMO 1999 87 0 (0.3) 84 0.1 (0.3) 5.06% -0.09[-0.17,-0.01]
SHOT 1996 289 1.2 (0.3) 267 1.1 (0.3) 9.5% 0.1[0.05,0.15]
Tande 2016 50 0 (0.2) 50 0 (0.2) 5.22% 0.01[-0.07,0.09]
Subtotal *** 18348   18225   100% 0.03[0,0.05]
Heterogeneity: Tau2=0; Chi2=39.02, df=13(P=0); I2=66.68%  
Test for overall effect: Z=2.28(P=0.02)  
Test for subgroup differences: Chi2=1.05, df=1 (P=0.31), I2=4.46%  
Favours lower omega 3 0.20.1-0.2 -0.1 0 Favours higher omega 3
 
 
Analysis 2.54.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 54 HDL, mmoL/L - LCn3 - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.54.1 LCn3 ≤ 150 mg/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.54.2 LCn3 > 150 ≤ 250 mg/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.54.3 LCn3 > 250 ≤ 400 mg/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.54.4 LCn3 > 400 ≤ 2400 mg/d  
Ahn 2016 38 1.2 (0.3) 36 1.1 (0.3) 1.96% 0.05[-0.1,0.2]
AlphaOmega - EPA+DHA 2010 605 0.2 (0.3) 605 0.2 (0.3) 15.11% 0.03[0,0.06]
Berson 2004 105 1.5 (0.4) 103 1.4 (0.4) 3.15% 0.08[-0.03,0.19]
DART 1989 867 1.1 (0.3) 847 1 (0.3) 15.44% 0.01[-0.02,0.04]
Derosa 2016 128 1.2 (1.1) 130 1.1 (1.1) 0.62% 0.1[-0.17,0.37]
Deslypere 1992 14 1.3 (0.2) 14 1.3 (0.4) 0.96% -0.03[-0.24,0.18]
DIPP 2015 89 1.4 (0.4) 73 1.5 (0.3) 3.4% -0.03[-0.14,0.08]
DO IT 2010 124 1.5 (0.4) 117 1.4 (0.4) 4.2% 0.06[-0.03,0.15]
JELIS 2007 9326 1.5 (0.4) 9319 1.5 (0.4) 19.26% 0[-0.01,0.01]
MARINA 2011 80 1.7 (0.5) 71 1.5 (0.4) 2.15% 0.2[0.06,0.34]
Mita 2007 30 1.5 (0.6) 30 1.4 (0.4) 0.72% 0.07[-0.18,0.32]
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
NAT2 2013 134 2 (0.6) 129 1.8 (0.5) 2.28% 0.15[0.02,0.28]
Nye 1990 12 1.4 (0.4) 12 1.5 (0.4) 0.43% -0.07[-0.39,0.25]
ORIGIN 2012 6281 -0 (0.6) 6255 -0 (0.6) 16.8% 0[-0.02,0.02]
SCIMO 1999 87 0 (0.3) 84 0.1 (0.3) 4.91% -0.09[-0.17,-0.01]
SMART 2013 21 1.5 (0.4) 24 1.4 (0.4) 0.81% 0.1[-0.13,0.33]
Sofi 2010 6 0.4 (0.3) 5 -0.7 (0.7) 0.1% 1.08[0.42,1.74]
Tande 2016 50 0 (0.2) 50 0 (0.2) 5.08% 0.01[-0.07,0.09]
THIS DIET 2008 37 1 (0.2) 34 1 (0.3) 2.61% 0[-0.12,0.12]
Subtotal *** 18034   17938   100% 0.02[-0,0.04]
Heterogeneity: Tau2=0; Chi2=36.41, df=18(P=0.01); I2=50.57%  
Test for overall effect: Z=1.61(P=0.11)  
   
2.54.5 LCn3 > 2.4 ≤ 4.4 g/d  
Brox 2001 37 1.3 (0.4) 37 1.3 (0.4) 8.48% 0[-0.18,0.18]
EPE-A 2014 64 0 (0) 55 0 (0)   Not estimable
OFAMI 2001 119 1.3 (0.3) 120 1.2 (0.3) 24.45% 0.04[-0.04,0.12]
Sandhu 2016 49 1.8 (0.5) 47 1.8 (0.5) 7.25% 0.01[-0.19,0.21]
SHOT 1996 289 1.2 (0.3) 267 1.1 (0.3) 36.5% 0.1[0.05,0.15]
Weinstock-Guttman 2005 13 0.1 (0.2) 14 -0.3 (0.5) 3.83% 0.34[0.05,0.63]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 19.48% 0[-0.1,0.1]
Subtotal *** 618   588   100% 0.06[0,0.12]
Heterogeneity: Tau2=0; Chi2=8.03, df=5(P=0.15); I2=37.75%  
Test for overall effect: Z=2.02(P=0.04)  
   
2.54.6 LCn3 > 4.4 g/d  
HARP 1995 31 1.1 (0.3) 28 1.1 (0.3) 100% 0[-0.16,0.16]
Subtotal *** 31   28   100% 0[-0.16,0.16]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=1.86, df=1 (P=0.4), I2=0%  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
 
 
Analysis 2.55.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 55 HDL, mmoL/L - LCn3 - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.55.1 N-3 replacing SFA  
DART 1989 867 1.1 (0.3) 847 1 (0.3) 54.93% 0.01[-0.02,0.04]
Derosa 2016 128 1.2 (1.1) 130 1.1 (1.1) 8.41% 0.1[-0.17,0.37]
SCIMO 1999 87 0 (0.3) 84 0.1 (0.3) 36.66% -0.09[-0.17,-0.01]
Subtotal *** 1082   1061   100% -0.02[-0.1,0.07]
Heterogeneity: Tau2=0; Chi2=5.39, df=2(P=0.07); I2=62.92%  
Test for overall effect: Z=0.44(P=0.66)  
   
2.55.2 N-3 replacing MUFA  
AlphaOmega - EPA+DHA 2010 605 0.2 (0.3) 605 0.2 (0.3) 17.14% 0.03[0,0.06]
DART 1989 867 1.1 (0.3) 847 1 (0.3) 17.32% 0.01[-0.02,0.04]
Deslypere 1992 14 1.3 (0.2) 14 1.3 (0.4) 2.08% -0.03[-0.24,0.18]
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
HARP 1995 31 1.1 (0.3) 28 1.1 (0.3) 3.44% 0[-0.16,0.16]
MARINA 2011 80 1.7 (0.5) 71 1.5 (0.4) 4.31% 0.2[0.06,0.34]
NAT2 2013 134 2 (0.6) 129 1.8 (0.5) 4.55% 0.15[0.02,0.28]
Nye 1990 12 1.4 (0.4) 12 1.5 (0.4) 0.96% -0.07[-0.39,0.25]
ORIGIN 2012 6281 -0 (0.6) 6255 -0 (0.6) 18.03% 0[-0.02,0.02]
SCIMO 1999 87 0 (0.3) 84 0.1 (0.3) 8.47% -0.09[-0.17,-0.01]
SMART 2013 21 1.5 (0.4) 24 1.4 (0.4) 1.77% 0.1[-0.13,0.33]
Sofi 2010 6 0.4 (0.3) 5 -0.7 (0.7) 0.24% 1.08[0.42,1.74]
Tande 2016 50 0 (0.2) 50 0 (0.2) 8.69% 0.01[-0.07,0.09]
THIS DIET 2008 37 1 (0.2) 34 1 (0.3) 5.11% 0[-0.12,0.12]
Weinstock-Guttman 2005 13 0.1 (0.2) 14 -0.3 (0.5) 1.22% 0.34[0.05,0.63]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 6.67% 0[-0.1,0.1]
Subtotal *** 8285   8220   100% 0.02[-0.01,0.06]
Heterogeneity: Tau2=0; Chi2=35.1, df=14(P=0); I2=60.11%  
Test for overall effect: Z=1.39(P=0.16)  
   
2.55.3 N-3 replacing n-6  
Berson 2004 105 1.5 (0.4) 103 1.4 (0.4) 18.89% 0.08[-0.03,0.19]
DIPP 2015 89 1.4 (0.4) 73 1.5 (0.3) 20.72% -0.03[-0.14,0.08]
DO IT 2010 124 1.5 (0.4) 117 1.4 (0.4) 26.87% 0.06[-0.03,0.15]
OFAMI 2001 119 1.3 (0.3) 120 1.2 (0.3) 33.52% 0.04[-0.04,0.12]
Subtotal *** 437   413   100% 0.04[-0.01,0.09]
Heterogeneity: Tau2=0; Chi2=2.33, df=3(P=0.51); I2=0%  
Test for overall effect: Z=1.55(P=0.12)  
   
2.55.4 N-3 replacing carbs/sugars  
Derosa 2016 128 1.2 (1.1) 130 1.1 (1.1) 100% 0.1[-0.17,0.37]
Subtotal *** 128   130   100% 0.1[-0.17,0.37]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.73(P=0.47)  
   
2.55.5 N-3 replacing nil/low n-3 placebo  
Brox 2001 37 1.3 (0.4) 37 1.3 (0.4) 10.85% 0[-0.18,0.18]
JELIS 2007 9326 1.5 (0.4) 9319 1.5 (0.4) 39.58% 0[-0.01,0.01]
Mita 2007 30 1.5 (0.6) 30 1.4 (0.4) 6.64% 0.07[-0.18,0.32]
Sandhu 2016 49 1.8 (0.5) 47 1.8 (0.5) 9.44% 0.01[-0.19,0.21]
SHOT 1996 289 1.2 (0.3) 267 1.1 (0.3) 33.5% 0.1[0.05,0.15]
Subtotal *** 9731   9700   100% 0.04[-0.03,0.11]
Heterogeneity: Tau2=0; Chi2=15.38, df=4(P=0); I2=74%  
Test for overall effect: Z=1.09(P=0.28)  
   
2.55.6 Replacement unclear  
Ahn 2016 38 1.2 (0.3) 36 1.1 (0.3) 100% 0.05[-0.1,0.2]
EPE-A 2014 64 0 (0) 55 0 (0)   Not estimable
Subtotal *** 102   91   100% 0.05[-0.1,0.2]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.67(P=0.5)  
Test for subgroup differences: Chi2=1.91, df=1 (P=0.86), I2=0%  
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
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Analysis 2.56.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 56 HDL, mmoL/L - LCn3 - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.56.1 Dietary advice  
DART 1989 867 1.1 (0.3) 847 1 (0.3) 95.5% 0.01[-0.02,0.04]
THIS DIET 2008 37 1 (0.2) 34 1 (0.3) 4.5% 0[-0.12,0.12]
Subtotal *** 904   881   100% 0.01[-0.02,0.04]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.88); I2=0%  
Test for overall effect: Z=0.71(P=0.48)  
   
2.56.2 Supplemental foods  
AlphaOmega - EPA+DHA 2010 605 0.2 (0.3) 605 0.2 (0.3) 100% 0.03[0,0.06]
Subtotal *** 605   605   100% 0.03[0,0.06]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.09(P=0.04)  
   
2.56.3 Supplement (capsule)  
Ahn 2016 38 1.2 (0.3) 36 1.1 (0.3) 3.15% 0.05[-0.1,0.2]
Berson 2004 105 1.5 (0.4) 103 1.4 (0.4) 4.75% 0.08[-0.03,0.19]
Brox 2001 37 1.3 (0.4) 37 1.3 (0.4) 2.17% 0[-0.18,0.18]
Derosa 2016 128 1.2 (1.1) 130 1.1 (1.1) 1.08% 0.1[-0.17,0.37]
Deslypere 1992 14 1.3 (0.2) 14 1.3 (0.4) 1.64% -0.03[-0.24,0.18]
DO IT 2010 124 1.5 (0.4) 117 1.4 (0.4) 6% 0.06[-0.03,0.15]
EPE-A 2014 64 0 (0) 55 0 (0)   Not estimable
HARP 1995 31 1.1 (0.3) 28 1.1 (0.3) 2.71% 0[-0.16,0.16]
JELIS 2007 9326 1.5 (0.4) 9319 1.5 (0.4) 15.76% 0[-0.01,0.01]
MARINA 2011 80 1.7 (0.5) 71 1.5 (0.4) 3.41% 0.2[0.06,0.34]
Mita 2007 30 1.5 (0.6) 30 1.4 (0.4) 1.24% 0.07[-0.18,0.32]
NAT2 2013 134 2 (0.6) 129 1.8 (0.5) 3.6% 0.15[0.02,0.28]
Nye 1990 12 1.4 (0.4) 12 1.5 (0.4) 0.75% -0.07[-0.39,0.25]
OFAMI 2001 119 1.3 (0.3) 120 1.2 (0.3) 6.86% 0.04[-0.04,0.12]
ORIGIN 2012 6281 -0 (0.6) 6255 -0 (0.6) 14.78% 0[-0.02,0.02]
Sandhu 2016 49 1.8 (0.5) 47 1.8 (0.5) 1.85% 0.01[-0.19,0.21]
SCIMO 1999 87 0 (0.3) 84 0.1 (0.3) 6.77% -0.09[-0.17,-0.01]
SHOT 1996 289 1.2 (0.3) 267 1.1 (0.3) 11.03% 0.1[0.05,0.15]
Sofi 2010 6 0.4 (0.3) 5 -0.7 (0.7) 0.19% 1.08[0.42,1.74]
Tande 2016 50 0 (0.2) 50 0 (0.2) 6.95% 0.01[-0.07,0.09]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 5.31% 0[-0.1,0.1]
Subtotal *** 17051   16957   100% 0.03[0,0.06]
Heterogeneity: Tau2=0; Chi2=47.19, df=19(P=0); I2=59.73%  
Test for overall effect: Z=2.24(P=0.03)  
   
2.56.4 Any combination  
DIPP 2015 89 1.4 (0.4) 73 1.5 (0.3) 44.34% -0.03[-0.14,0.08]
SMART 2013 21 1.5 (0.4) 24 1.4 (0.4) 30.33% 0.1[-0.13,0.33]
Weinstock-Guttman 2005 13 0.1 (0.2) 14 -0.3 (0.5) 25.33% 0.34[0.05,0.63]
Subtotal *** 123   111   100% 0.1[-0.1,0.31]
Heterogeneity: Tau2=0.02; Chi2=6.06, df=2(P=0.05); I2=67.01%  
Test for overall effect: Z=0.99(P=0.32)  
Test for subgroup differences: Chi2=2.28, df=1 (P=0.52), I2=0%  
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
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Analysis 2.57.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 57 HDL, mmoL/L - LCn3 - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.57.1 Medium duration 1 to < 2 years in study  
Ahn 2016 38 1.2 (0.3) 36 1.1 (0.3) 9.97% 0.05[-0.1,0.2]
Brox 2001 37 1.3 (0.4) 37 1.3 (0.4) 7.72% 0[-0.18,0.18]
Derosa 2016 128 1.2 (1.1) 130 1.1 (1.1) 4.45% 0.1[-0.17,0.37]
Deslypere 1992 14 1.3 (0.2) 14 1.3 (0.4) 6.25% -0.03[-0.24,0.18]
EPE-A 2014 64 0 (0) 55 0 (0)   Not estimable
MARINA 2011 80 1.7 (0.5) 71 1.5 (0.4) 10.49% 0.2[0.06,0.34]
Nye 1990 12 1.4 (0.4) 12 1.5 (0.4) 3.27% -0.07[-0.39,0.25]
SHOT 1996 289 1.2 (0.3) 267 1.1 (0.3) 18.52% 0.1[0.05,0.15]
SMART 2013 21 1.5 (0.4) 24 1.4 (0.4) 5.48% 0.1[-0.13,0.33]
Sofi 2010 6 0.4 (0.3) 5 -0.7 (0.7) 0.89% 1.08[0.42,1.74]
Tande 2016 50 0 (0.2) 50 0 (0.2) 15.42% 0.01[-0.07,0.09]
Weinstock-Guttman 2005 13 0.1 (0.2) 14 -0.3 (0.5) 4.02% 0.34[0.05,0.63]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 13.52% 0[-0.1,0.1]
Subtotal *** 799   763   100% 0.08[0.01,0.14]
Heterogeneity: Tau2=0.01; Chi2=23.18, df=11(P=0.02); I2=52.54%  
Test for overall effect: Z=2.3(P=0.02)  
   
2.57.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - EPA+DHA 2010 605 0.2 (0.3) 605 0.2 (0.3) 29.88% 0.03[0,0.06]
DART 1989 867 1.1 (0.3) 847 1 (0.3) 30.8% 0.01[-0.02,0.04]
DIPP 2015 89 1.4 (0.4) 73 1.5 (0.3) 5.14% -0.03[-0.14,0.08]
DO IT 2010 124 1.5 (0.4) 117 1.4 (0.4) 6.46% 0.06[-0.03,0.15]
HARP 1995 31 1.1 (0.3) 28 1.1 (0.3) 2.42% 0[-0.16,0.16]
Mita 2007 30 1.5 (0.6) 30 1.4 (0.4) 1.03% 0.07[-0.18,0.32]
NAT2 2013 134 2 (0.6) 129 1.8 (0.5) 3.37% 0.15[0.02,0.28]
OFAMI 2001 119 1.3 (0.3) 120 1.2 (0.3) 7.79% 0.04[-0.04,0.12]
Sandhu 2016 49 1.8 (0.5) 47 1.8 (0.5) 1.58% 0.01[-0.19,0.21]
SCIMO 1999 87 0 (0.3) 84 0.1 (0.3) 7.65% -0.09[-0.17,-0.01]
THIS DIET 2008 37 1 (0.2) 34 1 (0.3) 3.89% 0[-0.12,0.12]
Subtotal *** 2172   2114   100% 0.02[-0.01,0.04]
Heterogeneity: Tau2=0; Chi2=13.14, df=10(P=0.22); I2=23.9%  
Test for overall effect: Z=1.27(P=0.2)  
   
2.57.3 Long duration ≥ 4 years in study  
Berson 2004 105 1.5 (0.4) 103 1.4 (0.4) 0.85% 0.08[-0.03,0.19]
JELIS 2007 9326 1.5 (0.4) 9319 1.5 (0.4) 77.57% 0[-0.01,0.01]
ORIGIN 2012 6281 -0 (0.6) 6255 -0 (0.6) 21.58% 0[-0.02,0.02]
Subtotal *** 15712   15677   100% 0[-0.01,0.01]
Heterogeneity: Tau2=0; Chi2=1.97, df=2(P=0.37); I2=0%  
Test for overall effect: Z=0.21(P=0.83)  
Test for subgroup differences: Chi2=5.95, df=1 (P=0.05), I2=66.4%  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
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Analysis 2.58.   Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes),
Outcome 58 HDL, mmoL/L - LCn3 - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.58.1 Primary prevention  
Berson 2004 105 1.5 (0.4) 103 1.4 (0.4) 5.59% 0.08[-0.03,0.19]
Brox 2001 37 1.3 (0.4) 37 1.3 (0.4) 2.39% 0[-0.18,0.18]
Derosa 2016 128 1.2 (1.1) 130 1.1 (1.1) 1.16% 0.1[-0.17,0.37]
Deslypere 1992 14 1.3 (0.2) 14 1.3 (0.4) 1.78% -0.03[-0.24,0.18]
DIPP 2015 89 1.4 (0.4) 73 1.5 (0.3) 6.01% -0.03[-0.14,0.08]
DO IT 2010 124 1.5 (0.4) 117 1.4 (0.4) 7.33% 0.06[-0.03,0.15]
EPE-A 2014 64 0 (0) 55 0 (0)   Not estimable
JELIS 2007 9326 1.5 (0.4) 9319 1.5 (0.4) 26.66% 0[-0.01,0.01]
MARINA 2011 80 1.7 (0.5) 71 1.5 (0.4) 3.88% 0.2[0.06,0.34]
Mita 2007 30 1.5 (0.6) 30 1.4 (0.4) 1.33% 0.07[-0.18,0.32]
ORIGIN 2012 6281 -0 (0.6) 6255 -0 (0.6) 24.07% 0[-0.02,0.02]
Sandhu 2016 49 1.8 (0.5) 47 1.8 (0.5) 2.01% 0.01[-0.19,0.21]
SMART 2013 21 1.5 (0.4) 24 1.4 (0.4) 1.5% 0.1[-0.13,0.33]
Sofi 2010 6 0.4 (0.3) 5 -0.7 (0.7) 0.2% 1.08[0.42,1.74]
Tande 2016 50 0 (0.2) 50 0 (0.2) 8.72% 0.01[-0.07,0.09]
Weinstock-Guttman 2005 13 0.1 (0.2) 14 -0.3 (0.5) 1.02% 0.34[0.05,0.63]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 6.35% 0[-0.1,0.1]
Subtotal *** 16464   16392   100% 0.03[-0,0.05]
Heterogeneity: Tau2=0; Chi2=28.63, df=15(P=0.02); I2=47.61%  
Test for overall effect: Z=1.66(P=0.1)  
   
2.58.2 Secondary prevention  
AlphaOmega - EPA+DHA 2010 605 0.2 (0.3) 605 0.2 (0.3) 21.6% 0.03[0,0.06]
DART 1989 867 1.1 (0.3) 847 1 (0.3) 21.83% 0.01[-0.02,0.04]
HARP 1995 31 1.1 (0.3) 28 1.1 (0.3) 4.36% 0[-0.16,0.16]
NAT2 2013 134 2 (0.6) 129 1.8 (0.5) 5.77% 0.15[0.02,0.28]
Nye 1990 12 1.4 (0.4) 12 1.5 (0.4) 1.22% -0.07[-0.39,0.25]
OFAMI 2001 119 1.3 (0.3) 120 1.2 (0.3) 10.85% 0.04[-0.04,0.12]
SCIMO 1999 87 0 (0.3) 84 0.1 (0.3) 10.72% -0.09[-0.17,-0.01]
SHOT 1996 289 1.2 (0.3) 267 1.1 (0.3) 17.18% 0.1[0.05,0.15]
THIS DIET 2008 37 1 (0.2) 34 1 (0.3) 6.47% 0[-0.12,0.12]
Subtotal *** 2181   2126   100% 0.03[-0.01,0.07]
Heterogeneity: Tau2=0; Chi2=21.38, df=8(P=0.01); I2=62.59%  
Test for overall effect: Z=1.51(P=0.13)  
Test for subgroup differences: Chi2=0.02, df=1 (P=0.89), I2=0%  
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
 
 
Analysis 2.59.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 59 HDL, mmoL/L - LCn3 - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.59.1 LCn3 - ≥ 50% of control group on statins  
Ahn 2016 38 1.2 (0.3) 36 1.1 (0.3) 1.25% 0.05[-0.1,0.2]
AlphaOmega - EPA+DHA 2010 605 0.2 (0.3) 605 0.2 (0.3) 21.31% 0.03[0,0.06]
JELIS 2007 9326 1.5 (0.4) 9319 1.5 (0.4) 43.75% 0[-0.01,0.01]
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
NAT2 2013 134 2 (0.6) 129 1.8 (0.5) 1.48% 0.15[0.02,0.28]
ORIGIN 2012 6281 -0 (0.6) 6255 -0 (0.6) 28.01% 0[-0.02,0.02]
THIS DIET 2008 37 1 (0.2) 34 1 (0.3) 1.72% 0[-0.12,0.12]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 2.48% 0[-0.1,0.1]
Subtotal *** 16468   16426   100% 0.01[-0.01,0.03]
Heterogeneity: Tau2=0; Chi2=8.67, df=6(P=0.19); I2=30.81%  
Test for overall effect: Z=1.16(P=0.25)  
   
2.59.2 LCn3 - < 50% of control group on statins  
Berson 2004 105 1.5 (0.4) 103 1.4 (0.4) 8.02% 0.08[-0.03,0.19]
Brox 2001 37 1.3 (0.4) 37 1.3 (0.4) 4.28% 0[-0.18,0.18]
DART 1989 867 1.1 (0.3) 847 1 (0.3) 15.82% 0.01[-0.02,0.04]
Deslypere 1992 14 1.3 (0.2) 14 1.3 (0.4) 3.34% -0.03[-0.24,0.18]
DIPP 2015 89 1.4 (0.4) 73 1.5 (0.3) 8.41% -0.03[-0.14,0.08]
DO IT 2010 124 1.5 (0.4) 117 1.4 (0.4) 9.5% 0.06[-0.03,0.15]
HARP 1995 31 1.1 (0.3) 28 1.1 (0.3) 5.16% 0[-0.16,0.16]
MARINA 2011 80 1.7 (0.5) 71 1.5 (0.4) 6.23% 0.2[0.06,0.34]
Mita 2007 30 1.5 (0.6) 30 1.4 (0.4) 2.59% 0.07[-0.18,0.32]
OFAMI 2001 119 1.3 (0.3) 120 1.2 (0.3) 10.4% 0.04[-0.04,0.12]
SCIMO 1999 87 0 (0.3) 84 0.1 (0.3) 10.31% -0.09[-0.17,-0.01]
SHOT 1996 289 1.2 (0.3) 267 1.1 (0.3) 13.89% 0.1[0.05,0.15]
Weinstock-Guttman 2005 13 0.1 (0.2) 14 -0.3 (0.5) 2.04% 0.34[0.05,0.63]
Subtotal *** 1885   1805   100% 0.04[-0,0.08]
Heterogeneity: Tau2=0; Chi2=31.01, df=12(P=0); I2=61.3%  
Test for overall effect: Z=1.8(P=0.07)  
   
2.59.3 LCn3 - use of statins unclear  
Derosa 2016 128 1.2 (1.1) 130 1.1 (1.1) 15.08% 0.1[-0.17,0.37]
EPE-A 2014 64 0 (0) 55 0 (0)   Not estimable
Nye 1990 12 1.4 (0.4) 12 1.5 (0.4) 11.91% -0.07[-0.39,0.25]
Sandhu 2016 49 1.8 (0.5) 47 1.8 (0.5) 20.26% 0.01[-0.19,0.21]
SMART 2013 21 1.5 (0.4) 24 1.4 (0.4) 17.48% 0.1[-0.13,0.33]
Sofi 2010 6 0.4 (0.3) 5 -0.7 (0.7) 3.84% 1.08[0.42,1.74]
Tande 2016 50 0 (0.2) 50 0 (0.2) 31.43% 0.01[-0.07,0.09]
Subtotal *** 330   323   100% 0.07[-0.07,0.21]
Heterogeneity: Tau2=0.01; Chi2=10.86, df=5(P=0.05); I2=53.96%  
Test for overall effect: Z=1.01(P=0.31)  
Test for subgroup differences: Chi2=2.28, df=1 (P=0.32), I2=12.34%  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
 
 
Analysis 2.60.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 60 Low-density lipoprotein, serum, mmoL/L - LCn3.
Study or subgroup Favours high-
er omega 3
Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Ahn 2016 38 2.2 (1.3) 36 2.1 (0.1) 0.2% 0.16[-0.26,0.58]
AlphaOmega - EPA+DHA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 5.15% -0.02[-0.1,0.06]
Berson 2004 105 3.2 (0.9) 103 2.9 (0.8) 0.64% 0.31[0.07,0.55]
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
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Study or subgroup Favours high-
er omega 3
Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Caldwell 2011 17 3.2 (0.9) 17 3.3 (0.1) 0.18% -0.11[-0.56,0.34]
Derosa 2016 128 3.3 (3.4) 130 3.1 (2.3) 0.07% 0.2[-0.51,0.91]
Deslypere 1992 14 3.9 (0.9) 14 4.1 (0.9) 0.08% -0.2[-0.85,0.45]
EPE-A 2014 64 0.2 (0) 55 0.1 (0)   Not estimable
HARP 1995 31 3.4 (0.8) 28 3.2 (0.6) 0.28% 0.25[-0.11,0.61]
JELIS 2007 9326 3.5 (0.8) 9319 3.5 (0.7) 76.45% 0[-0.02,0.02]
MARINA 2011 80 0.2 (0.9) 71 0.2 (0.4) 0.73% 0[-0.22,0.22]
NAT2 2013 134 3.7 (1.1) 129 3.7 (0.9) 0.64% -0.06[-0.3,0.18]
ORIGIN 2012 6281 -0.3 (1.7) 6255 -0.3 (1.7) 10.5% 0.02[-0.04,0.07]
ORL 2013 170 0.1 (0.7) 165 -0 (0.6) 1.88% 0.09[-0.04,0.23]
Rossing 1996 14 3.5 (0.9) 15 3.4 (1) 0.08% 0.12[-0.56,0.8]
Sandhu 2016 49 2.8 (0.8) 47 3 (0.8) 0.39% -0.13[-0.43,0.17]
SCIMO 1999 87 -0.2 (1.2) 84 -0.4 (1) 0.32% 0.16[-0.17,0.49]
SHOT 1996 289 5.1 (1.2) 267 5 (1.2) 0.89% 0.08[-0.12,0.28]
SMART 2013 21 3.4 (0.9) 24 3.2 (0.9) 0.13% 0.2[-0.33,0.73]
Sofi 2010 6 -0 (1) 5 -0.1 (0.4) 0.04% 0.1[-0.79,0.99]
Tande 2016 50 -0 (0.7) 50 -0 (0.5) 0.64% 0.01[-0.23,0.25]
THIS DIET 2008 37 2.6 (0.7) 34 2.5 (0.6) 0.4% 0.08[-0.22,0.38]
Weinstock-Guttman 2005 13 0.1 (0.6) 14 0.6 (2.4) 0.02% -0.53[-1.82,0.76]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 0.3% 0[-0.34,0.34]
   
Total *** 17563   17472   100% 0.01[-0.01,0.03]
Heterogeneity: Tau2=0; Chi2=15.99, df=21(P=0.77); I2=0%  
Test for overall effect: Z=0.64(P=0.52)  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
 
 
Analysis 2.61.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 61 LDL, mmoL/L - LCn3 - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.61.1 Low risk of bias  
AlphaOmega - EPA+DHA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 5.16% -0.02[-0.1,0.06]
Berson 2004 105 3.2 (0.9) 103 2.9 (0.8) 0.64% 0.31[0.07,0.55]
Caldwell 2011 17 3.2 (0.9) 17 3.3 (0.1) 0.18% -0.11[-0.56,0.34]
Derosa 2016 128 3.3 (3.4) 130 3.1 (2.3) 0.07% 0.2[-0.51,0.91]
MARINA 2011 80 3.4 (0.9) 71 3.4 (0.8) 0.46% 0[-0.28,0.28]
NAT2 2013 134 3.7 (1.1) 129 3.7 (0.9) 0.64% -0.06[-0.3,0.18]
ORIGIN 2012 6281 -0.3 (1.7) 6255 -0.3 (1.7) 10.53% 0.02[-0.04,0.07]
SCIMO 1999 87 -0.2 (1.2) 84 -0.4 (1) 0.32% 0.16[-0.17,0.49]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 0.3% 0[-0.34,0.34]
Subtotal *** 7441   7399   18.3% 0.02[-0.03,0.07]
Heterogeneity: Tau2=0; Chi2=8.4, df=8(P=0.4); I2=4.8%  
Test for overall effect: Z=0.65(P=0.52)  
   
2.61.2 Moderate/high risk of bias  
Ahn 2016 38 2.2 (1.3) 36 2.1 (0.1) 0.2% 0.16[-0.26,0.58]
Deslypere 1992 14 3.9 (0.9) 14 4.1 (0.9) 0.08% -0.2[-0.85,0.45]
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
397
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
EPE-A 2014 64 0.2 (0) 55 0.1 (0)   Not estimable
HARP 1995 31 3.4 (0.8) 28 3.2 (0.6) 0.28% 0.25[-0.11,0.61]
JELIS 2007 9326 3.5 (0.8) 9319 3.5 (0.7) 76.66% 0[-0.02,0.02]
ORL 2013 170 0.1 (0.7) 165 -0 (0.6) 1.89% 0.09[-0.04,0.23]
Rossing 1996 14 3.5 (0.9) 15 3.4 (1) 0.08% 0.12[-0.56,0.8]
Sandhu 2016 49 2.8 (0.8) 47 3 (0.8) 0.39% -0.13[-0.43,0.17]
SHOT 1996 289 5.1 (1.2) 267 5 (1.2) 0.89% 0.08[-0.12,0.28]
SMART 2013 21 3.4 (0.9) 24 3.2 (0.9) 0.13% 0.2[-0.33,0.73]
Sofi 2010 6 -0 (1) 5 -0.1 (0.4) 0.04% 0.1[-0.79,0.99]
Tande 2016 50 -0 (0.7) 50 -0 (0.5) 0.64% 0.01[-0.23,0.25]
THIS DIET 2008 37 2.6 (0.7) 34 2.5 (0.6) 0.4% 0.08[-0.22,0.38]
Weinstock-Guttman 2005 13 0.1 (0.6) 14 0.6 (2.4) 0.02% -0.53[-1.82,0.76]
Subtotal *** 10122   10073   81.7% 0[-0.02,0.03]
Heterogeneity: Tau2=0; Chi2=7.41, df=12(P=0.83); I2=0%  
Test for overall effect: Z=0.4(P=0.69)  
   
Total *** 17563   17472   100% 0.01[-0.01,0.03]
Heterogeneity: Tau2=0; Chi2=15.99, df=21(P=0.77); I2=0%  
Test for overall effect: Z=0.64(P=0.52)  
Test for subgroup differences: Chi2=0.19, df=1 (P=0.66), I2=0%  
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
 
 
Analysis 2.62.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 62 LDL, mmoL/L - LCn3 - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.62.1 SA - low risk of compliance bias  
AlphaOmega - EPA+DHA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 8.81% -0.02[-0.1,0.06]
Berson 2004 105 3.2 (0.9) 103 2.9 (0.8) 1.25% 0.31[0.07,0.55]
Deslypere 1992 14 3.9 (0.9) 14 4.1 (0.9) 0.17% -0.2[-0.85,0.45]
EPE-A 2014 64 0.2 (0) 55 0.1 (0)   Not estimable
HARP 1995 31 3.4 (0.8) 28 3.2 (0.6) 0.55% 0.25[-0.11,0.61]
MARINA 2011 80 3.4 (0.9) 71 3.4 (0.8) 0.9% 0[-0.28,0.28]
NAT2 2013 134 3.7 (1.1) 129 3.7 (0.9) 1.24% -0.06[-0.3,0.18]
ORL 2013 170 0.1 (0.7) 165 -0 (0.6) 3.54% 0.09[-0.04,0.23]
Rossing 1996 14 3.5 (0.9) 15 3.4 (1) 0.15% 0.12[-0.56,0.8]
SCIMO 1999 87 -0.2 (1.2) 84 -0.4 (1) 0.62% 0.16[-0.17,0.49]
SHOT 1996 289 5.1 (1.2) 267 5 (1.2) 1.72% 0.08[-0.12,0.28]
Weinstock-Guttman 2005 13 0.1 (0.6) 14 0.6 (2.4) 0.04% -0.53[-1.82,0.76]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 0.6% 0[-0.34,0.34]
Subtotal *** 1610   1555   19.58% 0.05[-0.02,0.11]
Heterogeneity: Tau2=0; Chi2=11.76, df=11(P=0.38); I2=6.45%  
Test for overall effect: Z=1.41(P=0.16)  
   
2.62.2 SA - 100+ randomised  
AlphaOmega - EPA+DHA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 8.81% -0.02[-0.1,0.06]
Berson 2004 105 3.2 (0.9) 103 2.9 (0.8) 1.25% 0.31[0.07,0.55]
Derosa 2016 128 3.3 (3.4) 130 3.1 (2.3) 0.14% 0.2[-0.51,0.91]
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
398
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Deslypere 1992 14 3.9 (0.9) 14 4.1 (0.9) 0.17% -0.2[-0.85,0.45]
EPE-A 2014 64 0.2 (0) 55 0.1 (0)   Not estimable
HARP 1995 31 3.4 (0.8) 28 3.2 (0.6) 0.55% 0.25[-0.11,0.61]
JELIS 2007 9326 3.5 (0.8) 9319 3.5 (0.7) 44.55% 0[-0.02,0.02]
MARINA 2011 80 3.4 (0.9) 71 3.4 (0.8) 0.9% 0[-0.28,0.28]
NAT2 2013 134 3.7 (1.1) 129 3.7 (0.9) 1.24% -0.06[-0.3,0.18]
ORIGIN 2012 6281 -0.3 (1.7) 6255 -0.3 (1.7) 15.7% 0.02[-0.04,0.07]
ORL 2013 170 0.1 (0.7) 165 -0 (0.6) 3.54% 0.09[-0.04,0.23]
SCIMO 1999 87 -0.2 (1.2) 84 -0.4 (1) 0.62% 0.16[-0.17,0.49]
SHOT 1996 289 5.1 (1.2) 267 5 (1.2) 1.72% 0.08[-0.12,0.28]
Tande 2016 50 -0 (0.7) 50 -0 (0.5) 1.24% 0.01[-0.23,0.25]
Subtotal *** 17321   17232   80.42% 0.01[-0.02,0.04]
Heterogeneity: Tau2=0; Chi2=12.87, df=12(P=0.38); I2=6.76%  
Test for overall effect: Z=0.86(P=0.39)  
   
Total *** 18931   18787   100% 0.02[-0.01,0.05]
Heterogeneity: Tau2=0; Chi2=25.69, df=24(P=0.37); I2=6.56%  
Test for overall effect: Z=1.41(P=0.16)  
Test for subgroup differences: Chi2=0.91, df=1 (P=0.34), I2=0%  
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
 
 
Analysis 2.63.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 63 LDL, mmoL/L - LCn3 - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.63.1 LCn3 ≤ 150 mg/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.63.2 LCn3 > 150 ≤ 250 mg/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.63.3 LCn3 > 250 ≤ 400 mg/d  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.63.4 LCn3 > 400 ≤ 2400 mg/d  
Ahn 2016 38 2.2 (1.3) 36 2.1 (0.1) 0.2% 0.16[-0.26,0.58]
AlphaOmega - EPA+DHA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 5.26% -0.02[-0.1,0.06]
Berson 2004 105 3.2 (0.9) 103 2.9 (0.8) 0.65% 0.31[0.07,0.55]
Caldwell 2011 17 3.2 (0.9) 17 3.3 (0.1) 0.18% -0.11[-0.56,0.34]
Derosa 2016 128 3.3 (3.4) 130 3.1 (2.3) 0.07% 0.2[-0.51,0.91]
Deslypere 1992 14 3.9 (0.9) 14 4.1 (0.9) 0.09% -0.2[-0.85,0.45]
JELIS 2007 9326 3.5 (0.8) 9319 3.5 (0.7) 78.2% 0[-0.02,0.02]
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
MARINA 2011 80 3.4 (0.9) 71 3.4 (0.8) 0.47% 0[-0.28,0.28]
NAT2 2013 134 3.7 (1.1) 129 3.7 (0.9) 0.65% -0.06[-0.3,0.18]
ORIGIN 2012 6281 -0.3 (1.7) 6255 -0.3 (1.7) 10.74% 0.02[-0.04,0.07]
ORL 2013 170 0.1 (0.7) 165 -0 (0.6) 1.93% 0.09[-0.04,0.23]
SCIMO 1999 87 -0.2 (1.2) 84 -0.4 (1) 0.32% 0.16[-0.17,0.49]
SMART 2013 21 3.4 (0.9) 24 3.2 (0.9) 0.13% 0.2[-0.33,0.73]
Sofi 2010 6 -0 (1) 5 -0.1 (0.4) 0.05% 0.1[-0.79,0.99]
Tande 2016 50 -0 (0.7) 50 -0 (0.5) 0.65% 0.01[-0.23,0.25]
THIS DIET 2008 37 2.6 (0.7) 34 2.5 (0.6) 0.41% 0.08[-0.22,0.38]
Subtotal *** 17056   16998   100% 0.01[-0.01,0.02]
Heterogeneity: Tau2=0; Chi2=12.12, df=15(P=0.67); I2=0%  
Test for overall effect: Z=0.56(P=0.58)  
   
2.63.5 LCn3 > 2.4 ≤ 4.4 g/d  
EPE-A 2014 64 0.2 (0) 55 0.1 (0)   Not estimable
Sandhu 2016 49 2.8 (0.8) 47 3 (0.8) 24.56% -0.13[-0.43,0.17]
SHOT 1996 289 5.1 (1.2) 267 5 (1.2) 55.28% 0.08[-0.12,0.28]
Weinstock-Guttman 2005 13 0.1 (0.6) 14 0.6 (2.4) 1.32% -0.53[-1.82,0.76]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 18.84% 0[-0.34,0.34]
Subtotal *** 462   431   100% 0.01[-0.14,0.15]
Heterogeneity: Tau2=0; Chi2=1.98, df=3(P=0.58); I2=0%  
Test for overall effect: Z=0.07(P=0.94)  
   
2.63.6 LCn3 > 4.4 g/d  
HARP 1995 31 3.4 (0.8) 28 3.2 (0.6) 78.33% 0.25[-0.11,0.61]
Rossing 1996 14 3.5 (0.9) 15 3.4 (1) 21.67% 0.12[-0.56,0.8]
Subtotal *** 45   43   100% 0.22[-0.09,0.54]
Heterogeneity: Tau2=0; Chi2=0.11, df=1(P=0.74); I2=0%  
Test for overall effect: Z=1.37(P=0.17)  
Test for subgroup differences: Chi2=1.79, df=1 (P=0.41), I2=0%  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
 
 
Analysis 2.64.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 64 LDL, mmoL/L - LCn3 - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.64.1 N-3 replacing SFA  
Derosa 2016 128 3.3 (3.4) 130 3.1 (2.3) 18.22% 0.2[-0.51,0.91]
SCIMO 1999 87 -0.2 (1.2) 84 -0.4 (1) 81.78% 0.16[-0.17,0.49]
Subtotal *** 215   214   100% 0.17[-0.14,0.47]
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.92); I2=0%  
Test for overall effect: Z=1.08(P=0.28)  
   
2.64.2 N-3 replacing MUFA  
AlphaOmega - EPA+DHA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 27.05% -0.02[-0.1,0.06]
Deslypere 1992 14 3.9 (0.9) 14 4.1 (0.9) 0.44% -0.2[-0.85,0.45]
HARP 1995 31 3.4 (0.8) 28 3.2 (0.6) 1.45% 0.25[-0.11,0.61]
MARINA 2011 80 3.4 (0.9) 71 3.4 (0.8) 2.41% 0[-0.28,0.28]
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
NAT2 2013 134 3.7 (1.1) 129 3.7 (0.9) 3.34% -0.06[-0.3,0.18]
ORIGIN 2012 6281 -0.3 (1.7) 6255 -0.3 (1.7) 55.19% 0.02[-0.04,0.07]
Rossing 1996 14 3.5 (0.9) 15 3.4 (1) 0.4% 0.12[-0.56,0.8]
SCIMO 1999 87 -0.2 (1.2) 84 -0.4 (1) 1.66% 0.16[-0.17,0.49]
SMART 2013 21 3.4 (0.9) 24 3.2 (0.9) 0.67% 0.2[-0.33,0.73]
Sofi 2010 6 -0 (1) 5 -0.1 (0.4) 0.23% 0.1[-0.79,0.99]
Tande 2016 50 -0 (0.7) 50 -0 (0.5) 3.34% 0.01[-0.23,0.25]
THIS DIET 2008 37 2.6 (0.7) 34 2.5 (0.6) 2.1% 0.08[-0.22,0.38]
Weinstock-Guttman 2005 13 0.1 (0.6) 14 0.6 (2.4) 0.11% -0.53[-1.82,0.76]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 1.59% 0[-0.34,0.34]
Subtotal *** 7377   7333   100% 0.01[-0.03,0.05]
Heterogeneity: Tau2=0; Chi2=5.31, df=13(P=0.97); I2=0%  
Test for overall effect: Z=0.47(P=0.64)  
   
2.64.3 N-3 replacing n-6  
Berson 2004 105 3.2 (0.9) 103 2.9 (0.8) 60.61% 0.31[0.07,0.55]
Caldwell 2011 17 3.2 (0.9) 17 3.3 (0.1) 39.39% -0.11[-0.56,0.34]
Subtotal *** 122   120   100% 0.14[-0.26,0.55]
Heterogeneity: Tau2=0.06; Chi2=2.66, df=1(P=0.1); I2=62.41%  
Test for overall effect: Z=0.7(P=0.48)  
   
2.64.4 N-3 replacing carbs/sugars  
Derosa 2016 128 3.3 (3.4) 130 3.1 (2.3) 100% 0.2[-0.51,0.91]
Subtotal *** 128   130   100% 0.2[-0.51,0.91]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.55(P=0.58)  
   
2.64.5 N-3 replacing nil/low n-3 placebo  
JELIS 2007 9326 3.5 (0.8) 9319 3.5 (0.7) 98.35% 0[-0.02,0.02]
Sandhu 2016 49 2.8 (0.8) 47 3 (0.8) 0.51% -0.13[-0.43,0.17]
SHOT 1996 289 5.1 (1.2) 267 5 (1.2) 1.14% 0.08[-0.12,0.28]
Subtotal *** 9664   9633   100% 0[-0.02,0.02]
Heterogeneity: Tau2=0; Chi2=1.33, df=2(P=0.51); I2=0%  
Test for overall effect: Z=0.02(P=0.98)  
   
2.64.6 Replacement unclear  
Ahn 2016 38 2.2 (1.3) 36 2.1 (0.1) 9.44% 0.16[-0.26,0.58]
EPE-A 2014 64 0.2 (0) 55 0.1 (0)   Not estimable
ORL 2013 170 0.1 (0.7) 165 -0 (0.6) 90.56% 0.09[-0.04,0.23]
Subtotal *** 272   256   100% 0.1[-0.03,0.23]
Heterogeneity: Tau2=0; Chi2=0.08, df=1(P=0.77); I2=0%  
Test for overall effect: Z=1.5(P=0.13)  
Test for subgroup differences: Chi2=4.15, df=1 (P=0.53), I2=0%  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
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Analysis 2.65.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 65 LDL, mmoL/L - LCn3 - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.65.1 Dietary advice  
THIS DIET 2008 37 2.6 (0.7) 34 2.5 (0.6) 100% 0.08[-0.22,0.38]
Subtotal *** 37   34   100% 0.08[-0.22,0.38]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.53(P=0.6)  
   
2.65.2 Supplemental foods  
AlphaOmega - EPA+DHA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 100% -0.02[-0.1,0.06]
Subtotal *** 562   562   100% -0.02[-0.1,0.06]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.47(P=0.64)  
   
2.65.3 Supplement (capsule)  
Ahn 2016 38 2.2 (1.3) 36 2.1 (0.1) 0.21% 0.16[-0.26,0.58]
Berson 2004 105 3.2 (0.9) 103 2.9 (0.8) 0.68% 0.31[0.07,0.55]
Caldwell 2011 17 3.2 (0.9) 17 3.3 (0.1) 0.19% -0.11[-0.56,0.34]
Derosa 2016 128 3.3 (3.4) 130 3.1 (2.3) 0.07% 0.2[-0.51,0.91]
Deslypere 1992 14 3.9 (0.9) 14 4.1 (0.9) 0.09% -0.2[-0.85,0.45]
EPE-A 2014 64 0.2 (0) 55 0.1 (0)   Not estimable
HARP 1995 31 3.4 (0.8) 28 3.2 (0.6) 0.29% 0.25[-0.11,0.61]
JELIS 2007 9326 3.5 (0.8) 9319 3.5 (0.7) 81.31% 0[-0.02,0.02]
MARINA 2011 80 3.4 (0.9) 71 3.4 (0.8) 0.49% 0[-0.28,0.28]
NAT2 2013 134 3.7 (1.1) 129 3.7 (0.9) 0.68% -0.06[-0.3,0.18]
ORIGIN 2012 6281 -0.3 (1.7) 6255 -0.3 (1.7) 11.17% 0.02[-0.04,0.07]
ORL 2013 170 0.1 (0.7) 165 -0 (0.6) 2% 0.09[-0.04,0.23]
Rossing 1996 14 3.5 (0.9) 15 3.4 (1) 0.08% 0.12[-0.56,0.8]
Sandhu 2016 49 2.8 (0.8) 47 3 (0.8) 0.42% -0.13[-0.43,0.17]
SCIMO 1999 87 -0.2 (1.2) 84 -0.4 (1) 0.34% 0.16[-0.17,0.49]
SHOT 1996 289 5.1 (1.2) 267 5 (1.2) 0.94% 0.08[-0.12,0.28]
Sofi 2010 6 -0 (1) 5 -0.1 (0.4) 0.05% 0.1[-0.79,0.99]
Tande 2016 50 -0 (0.7) 50 -0 (0.5) 0.68% 0.01[-0.23,0.25]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 0.32% 0[-0.34,0.34]
Subtotal *** 16930   16838   100% 0.01[-0.01,0.03]
Heterogeneity: Tau2=0; Chi2=14.18, df=17(P=0.65); I2=0%  
Test for overall effect: Z=0.72(P=0.47)  
   
2.65.4 Any combination  
SMART 2013 21 3.4 (0.9) 24 3.2 (0.9) 84.01% 0.2[-0.33,0.73]
Weinstock-Guttman 2005 13 0.1 (0.6) 14 0.6 (2.4) 15.99% -0.53[-1.82,0.76]
Subtotal *** 34   38   100% 0.08[-0.44,0.61]
Heterogeneity: Tau2=0.01; Chi2=1.05, df=1(P=0.31); I2=4.84%  
Test for overall effect: Z=0.31(P=0.76)  
Test for subgroup differences: Chi2=0.71, df=1 (P=0.87), I2=0%  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
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Analysis 2.66.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 66 LDL, mmoL/L - LCn3 - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.66.1 Medium duration 1 to < 2 years in study  
Ahn 2016 38 2.2 (1.3) 36 2.1 (0.1) 3.96% 0.16[-0.26,0.58]
Caldwell 2011 17 3.2 (0.9) 17 3.3 (0.1) 3.59% -0.11[-0.56,0.34]
Derosa 2016 128 3.3 (3.4) 130 3.1 (2.3) 1.42% 0.2[-0.51,0.91]
Deslypere 1992 14 3.9 (0.9) 14 4.1 (0.9) 1.68% -0.2[-0.85,0.45]
EPE-A 2014 64 0.2 (0) 55 0.1 (0)   Not estimable
MARINA 2011 80 3.4 (0.9) 71 3.4 (0.8) 9.23% 0[-0.28,0.28]
ORL 2013 170 0.1 (0.7) 165 -0 (0.6) 37.94% 0.09[-0.04,0.23]
Rossing 1996 14 3.5 (0.9) 15 3.4 (1) 1.54% 0.12[-0.56,0.8]
SHOT 1996 289 5.1 (1.2) 267 5 (1.2) 17.86% 0.08[-0.12,0.28]
SMART 2013 21 3.4 (0.9) 24 3.2 (0.9) 2.57% 0.2[-0.33,0.73]
Sofi 2010 6 -0 (1) 5 -0.1 (0.4) 0.89% 0.1[-0.79,0.99]
Tande 2016 50 -0 (0.7) 50 -0 (0.5) 12.81% 0.01[-0.23,0.25]
Weinstock-Guttman 2005 13 0.1 (0.6) 14 0.6 (2.4) 0.43% -0.53[-1.82,0.76]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 6.08% 0[-0.34,0.34]
Subtotal *** 951   911   100% 0.06[-0.03,0.14]
Heterogeneity: Tau2=0; Chi2=3.38, df=12(P=0.99); I2=0%  
Test for overall effect: Z=1.36(P=0.17)  
   
2.66.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - EPA+DHA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 71.79% -0.02[-0.1,0.06]
HARP 1995 31 3.4 (0.8) 28 3.2 (0.6) 3.86% 0.25[-0.11,0.61]
NAT2 2013 134 3.7 (1.1) 129 3.7 (0.9) 8.87% -0.06[-0.3,0.18]
Sandhu 2016 49 2.8 (0.8) 47 3 (0.8) 5.49% -0.13[-0.43,0.17]
SCIMO 1999 87 -0.2 (1.2) 84 -0.4 (1) 4.41% 0.16[-0.17,0.49]
THIS DIET 2008 37 2.6 (0.7) 34 2.5 (0.6) 5.57% 0.08[-0.22,0.38]
Subtotal *** 900   884   100% -0.01[-0.08,0.06]
Heterogeneity: Tau2=0; Chi2=4.19, df=5(P=0.52); I2=0%  
Test for overall effect: Z=0.16(P=0.88)  
   
2.66.3 Long duration ≥ 4 years in study  
Berson 2004 105 3.2 (0.9) 103 2.9 (0.8) 7.49% 0.31[0.07,0.55]
JELIS 2007 9326 3.5 (0.8) 9319 3.5 (0.7) 52.63% 0[-0.02,0.02]
ORIGIN 2012 6281 -0.3 (1.7) 6255 -0.3 (1.7) 39.88% 0.02[-0.04,0.07]
Subtotal *** 15712   15677   100% 0.03[-0.04,0.1]
Heterogeneity: Tau2=0; Chi2=6.78, df=2(P=0.03); I2=70.52%  
Test for overall effect: Z=0.84(P=0.4)  
Test for subgroup differences: Chi2=1.36, df=1 (P=0.51), I2=0%  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
 
 
Analysis 2.67.   Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes),
Outcome 67 LDL, mmoL/L - LCn3 - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.67.1 Primary prevention  
Berson 2004 105 3.2 (0.9) 103 2.9 (0.8) 0.7% 0.31[0.07,0.55]
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
403
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Caldwell 2011 17 3.2 (0.9) 17 3.3 (0.1) 0.19% -0.11[-0.56,0.34]
Derosa 2016 128 3.3 (3.4) 130 3.1 (2.3) 0.08% 0.2[-0.51,0.91]
Deslypere 1992 14 3.9 (0.9) 14 4.1 (0.9) 0.09% -0.2[-0.85,0.45]
EPE-A 2014 64 0.2 (0) 55 0.1 (0)   Not estimable
JELIS 2007 9326 3.5 (0.8) 9319 3.5 (0.7) 83.22% 0[-0.02,0.02]
MARINA 2011 80 3.4 (0.9) 71 3.4 (0.8) 0.5% 0[-0.28,0.28]
ORIGIN 2012 6281 -0.3 (1.7) 6255 -0.3 (1.7) 11.43% 0.02[-0.04,0.07]
ORL 2013 170 0.1 (0.7) 165 -0 (0.6) 2.05% 0.09[-0.04,0.23]
Rossing 1996 14 3.5 (0.9) 15 3.4 (1) 0.08% 0.12[-0.56,0.8]
Sandhu 2016 49 2.8 (0.8) 47 3 (0.8) 0.43% -0.13[-0.43,0.17]
SMART 2013 21 3.4 (0.9) 24 3.2 (0.9) 0.14% 0.2[-0.33,0.73]
Sofi 2010 6 -0 (1) 5 -0.1 (0.4) 0.05% 0.1[-0.79,0.99]
Tande 2016 50 -0 (0.7) 50 -0 (0.5) 0.69% 0.01[-0.23,0.25]
Weinstock-Guttman 2005 13 0.1 (0.6) 14 0.6 (2.4) 0.02% -0.53[-1.82,0.76]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 0.33% 0[-0.34,0.34]
Subtotal *** 16385   16332   100% 0.01[-0.01,0.03]
Heterogeneity: Tau2=0; Chi2=11.45, df=14(P=0.65); I2=0%  
Test for overall effect: Z=0.55(P=0.58)  
   
2.67.2 Secondary prevention  
Ahn 2016 38 2.2 (1.3) 36 2.1 (0.1) 2.5% 0.16[-0.26,0.58]
AlphaOmega - EPA+DHA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 65.5% -0.02[-0.1,0.06]
HARP 1995 31 3.4 (0.8) 28 3.2 (0.6) 3.52% 0.25[-0.11,0.61]
NAT2 2013 134 3.7 (1.1) 129 3.7 (0.9) 8.09% -0.06[-0.3,0.18]
SCIMO 1999 87 -0.2 (1.2) 84 -0.4 (1) 4.03% 0.16[-0.17,0.49]
SHOT 1996 289 5.1 (1.2) 267 5 (1.2) 11.28% 0.08[-0.12,0.28]
THIS DIET 2008 37 2.6 (0.7) 34 2.5 (0.6) 5.09% 0.08[-0.22,0.38]
Subtotal *** 1178   1140   100% 0.01[-0.05,0.08]
Heterogeneity: Tau2=0; Chi2=4.48, df=6(P=0.61); I2=0%  
Test for overall effect: Z=0.42(P=0.67)  
Test for subgroup differences: Chi2=0.06, df=1 (P=0.8), I2=0%  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
 
 
Analysis 2.68.   Comparison 2 High vs low LCn3 omega-3 fats (secondary
outcomes), Outcome 68 LDL, mmoL/L - LCn3 - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.68.1 LCn3 - ≥ 50% of control group on statins  
Ahn 2016 38 2.2 (1.3) 36 2.1 (0.1) 0.21% 0.16[-0.26,0.58]
AlphaOmega - EPA+DHA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 5.5% -0.02[-0.1,0.06]
JELIS 2007 9326 3.5 (0.8) 9319 3.5 (0.7) 81.65% 0[-0.02,0.02]
NAT2 2013 134 3.7 (1.1) 129 3.7 (0.9) 0.68% -0.06[-0.3,0.18]
ORIGIN 2012 6281 -0.3 (1.7) 6255 -0.3 (1.7) 11.21% 0.02[-0.04,0.07]
THIS DIET 2008 37 2.6 (0.7) 34 2.5 (0.6) 0.43% 0.08[-0.22,0.38]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 0.32% 0[-0.34,0.34]
Subtotal *** 16425   16383   100% 0[-0.02,0.02]
Heterogeneity: Tau2=0; Chi2=1.57, df=6(P=0.95); I2=0%  
Test for overall effect: Z=0.1(P=0.92)  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
   
2.68.2 LCn3 - < 50% of control group on statins  
Berson 2004 105 3.2 (0.9) 103 2.9 (0.8) 13.78% 0.31[0.07,0.55]
Deslypere 1992 14 3.9 (0.9) 14 4.1 (0.9) 1.8% -0.2[-0.85,0.45]
HARP 1995 31 3.4 (0.8) 28 3.2 (0.6) 5.96% 0.25[-0.11,0.61]
MARINA 2011 80 3.4 (0.9) 71 3.4 (0.8) 9.87% 0[-0.28,0.28]
ORL 2013 170 0.1 (0.7) 165 -0 (0.6) 40.57% 0.09[-0.04,0.23]
Rossing 1996 14 3.5 (0.9) 15 3.4 (1) 1.65% 0.12[-0.56,0.8]
SCIMO 1999 87 -0.2 (1.2) 84 -0.4 (1) 6.82% 0.16[-0.17,0.49]
SHOT 1996 289 5.1 (1.2) 267 5 (1.2) 19.1% 0.08[-0.12,0.28]
Weinstock-Guttman 2005 13 0.1 (0.6) 14 0.6 (2.4) 0.46% -0.53[-1.82,0.76]
Subtotal *** 803   761   100% 0.12[0.03,0.21]
Heterogeneity: Tau2=0; Chi2=5.96, df=8(P=0.65); I2=0%  
Test for overall effect: Z=2.64(P=0.01)  
   
2.68.3 LCn3 - use of statins unclear  
Caldwell 2011 17 3.2 (0.9) 17 3.3 (0.1) 12.27% -0.11[-0.56,0.34]
Derosa 2016 128 3.3 (3.4) 130 3.1 (2.3) 4.86% 0.2[-0.51,0.91]
EPE-A 2014 64 0.2 (0) 55 0.1 (0)   Not estimable
Sandhu 2016 49 2.8 (0.8) 47 3 (0.8) 27.15% -0.13[-0.43,0.17]
SMART 2013 21 3.4 (0.9) 24 3.2 (0.9) 8.8% 0.2[-0.33,0.73]
Sofi 2010 6 -0 (1) 5 -0.1 (0.4) 3.06% 0.1[-0.79,0.99]
Tande 2016 50 -0 (0.7) 50 -0 (0.5) 43.84% 0.01[-0.23,0.25]
Subtotal *** 335   328   100% -0.01[-0.17,0.14]
Heterogeneity: Tau2=0; Chi2=1.84, df=5(P=0.87); I2=0%  
Test for overall effect: Z=0.18(P=0.86)  
Test for subgroup differences: Chi2=6.62, df=1 (P=0.04), I2=69.77%  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
 
 
Comparison 3.   High vs low LCn3 omega-3 fats (tertiary outcomes)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Blood pressure, mmHg - LCn3 15   Mean Difference (IV, Random,
95% CI)
Subtotals only
1.1 Systolic BP - LCn3 15 34413 Mean Difference (IV, Random,
95% CI)
0.02 [-0.32, 0.35]
1.2 Diastolic BP - LCn3 14 35386 Mean Difference (IV, Random,
95% CI)
-0.02 [-0.22, 0.17]
2 Serious adverse events - LCn3 14   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.1 Any serious adverse events 1 402 Risk Ratio (M-H, Random, 95%
CI)
1.05 [0.78, 1.41]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2.2 Bleeding 8 45562 Risk Ratio (M-H, Random, 95%
CI)
1.06 [0.73, 1.52]
2.3 GI hospitalisation 1 200 Risk Ratio (M-H, Random, 95%
CI)
1.75 [0.53, 5.79]
2.4 Pulmonary embolus or DVT - LCn3 4 3011 Risk Ratio (M-H, Random, 95%
CI)
1.25 [0.41, 3.78]
2.5 Progression to advanced AMD (age-re-
lated macular degeneration)
1 4203 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.90, 1.02]
3 Side effects - LCn3 33   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
3.1 Dropouts due to side effects 23 16755 Risk Ratio (M-H, Random, 95%
CI)
1.16 [0.99, 1.36]
3.2 Abdominal pain or discomfort 7 14650 Risk Ratio (M-H, Random, 95%
CI)
1.10 [0.84, 1.45]
3.3 Diarrhoea 10 2428 Risk Ratio (M-H, Random, 95%
CI)
1.15 [0.92, 1.43]
3.4 Nausea 5 1234 Risk Ratio (M-H, Random, 95%
CI)
1.73 [1.23, 2.44]
3.5 Any gastrointestinal side effect - LCn3
fats
29 65185 Risk Ratio (M-H, Random, 95%
CI)
1.12 [0.94, 1.34]
3.6 Skin problems (itching, rashes) 8 36186 Risk Ratio (M-H, Random, 95%
CI)
1.04 [0.47, 2.30]
3.7 Headache or worsening migraine 3 991 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.48, 1.35]
3.8 Reflux 1 202 Risk Ratio (M-H, Random, 95%
CI)
1.42 [0.71, 2.81]
3.9 Pain (joint, lumbar, muscle pain) 1 18645 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.64, 0.99]
3.10 All side effects combined 13 38904 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.95, 1.08]
4 Dropouts - LCn3 30 31321 Risk Ratio (M-H, Random, 95%
CI)
1.02 [0.95, 1.09]
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Analysis 3.1.   Comparison 3 High vs low LCn3 omega-3 fats
(tertiary outcomes), Outcome 1 Blood pressure, mmHg - LCn3.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.1.1 Systolic BP - LCn3  
AlphaOmega - EPA+DHA 2010 632 -0.6 (20) 632 -2.3 (21.3) 2.15% 1.65[-0.63,3.93]
DART 1989 871 138.1 (21.9) 852 137.7 (21.2) 2.7% 0.33[-1.7,2.36]
Deslypere 1992 14 118 (21) 14 119 (18) 0.05% -1[-15.49,13.49]
DO IT 2010 124 143 (16) 117 143 (22) 0.47% 0[-4.88,4.88]
HARP 1995 31 129 (16) 28 137 (29) 0.08% -8[-20.13,4.13]
JELIS 2007 9326 133.3 (14) 9319 133.3 (13) 74.25% 0[-0.39,0.39]
MARINA 2011 80 118.3 (12.1) 71 122.1 (12.7) 0.71% -3.8[-7.77,0.17]
OFAMI 2001 127 132.2 (24.4) 130 136 (19.3) 0.38% -3.8[-9.19,1.59]
ORIGIN 2012 6281 -4.4 (22.5) 5255 -4.5 (22.5) 16.43% 0.14[-0.68,0.96]
Rossing 1996 14 142 (18.7) 15 144 (15.5) 0.07% -2[-14.55,10.55]
SCIMO 1999 87 8.3 (19.1) 84 8.3 (24.2) 0.26% 0[-6.55,6.55]
SMART 2013 20 120 (13) 23 128 (17) 0.14% -8[-16.98,0.98]
Tande 2016 50 2.7 (6.3) 50 2 (7.1) 1.61% 0.73[-1.9,3.36]
THIS DIET 2008 37 123 (16) 34 123 (12) 0.26% 0[-6.55,6.55]
WELCOME 2015 47 133.3 (13.7) 48 133.9 (11.3) 0.44% -0.6[-5.66,4.46]
Subtotal *** 17741   16672   100% 0.02[-0.32,0.35]
Heterogeneity: Tau2=0; Chi2=12.83, df=14(P=0.54); I2=0%  
Test for overall effect: Z=0.09(P=0.93)  
   
3.1.2 Diastolic BP - LCn3  
AlphaOmega - EPA+DHA 2010 632 -3.2 (10.5) 632 -2.7 (10.3) 2.89% -0.42[-1.57,0.73]
DART 1989 870 81.4 (12.5) 852 81.6 (11.9) 2.87% -0.18[-1.33,0.97]
Deslypere 1992 14 72 (13) 14 75 (11) 0.05% -3[-11.92,5.92]
DO IT 2010 124 79 (11) 117 79 (12) 0.45% 0[-2.91,2.91]
HARP 1995 31 77 (7) 28 77 (7) 0.3% 0[-3.58,3.58]
JELIS 2007 9326 78 (8) 9319 78 (8) 71.94% 0[-0.23,0.23]
MARINA 2011 80 71.2 (6.2) 71 72.9 (6.3) 0.95% -1.7[-3.7,0.3]
OFAMI 2001 127 80.8 (9.3) 130 81.1 (12.6) 0.52% -0.3[-3,2.4]
ORIGIN 2012 6281 -4.9 (12.8) 6255 -5 (13.1) 18.45% 0.03[-0.42,0.48]
SCIMO 1999 87 4.2 (11.5) 84 3.4 (14.6) 0.24% 0.8[-3.15,4.75]
SMART 2013 20 74 (9) 23 77 (10) 0.12% -3[-8.68,2.68]
Tande 2016 50 -0.9 (7.2) 50 -2.4 (6) 0.56% 1.48[-1.13,4.09]
THIS DIET 2008 37 74 (9) 37 72 (8) 0.25% 2[-1.88,5.88]
WELCOME 2015 47 81.7 (8.2) 48 82.9 (6.5) 0.43% -1.2[-4.18,1.78]
Subtotal *** 17726   17660   100% -0.02[-0.22,0.17]
Heterogeneity: Tau2=0; Chi2=7.93, df=13(P=0.85); I2=0%  
Test for overall effect: Z=0.24(P=0.81)  
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Analysis 3.2.   Comparison 3 High vs low LCn3 omega-3 fats
(tertiary outcomes), Outcome 2 Serious adverse events - LCn3.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.2.1 Any serious adverse events  
ADCS 2010 76/238 50/164 100% 1.05[0.78,1.41]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 238 164 100% 1.05[0.78,1.41]
Total events: 76 (Higher omega 3), 50 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.31(P=0.76)  
   
3.2.2 Bleeding  
AFFORD 2013 10/153 14/163 13.15% 0.76[0.35,1.66]
EPIC-1 2008 0/187 2/184 1.4% 0.2[0.01,4.07]
EPIC-2 2008 9/189 10/188 11.37% 0.9[0.37,2.15]
FOSTAR 2016 1/101 4/101 2.61% 0.25[0.03,2.2]
JELIS 2007 105/9326 60/9319 26.26% 1.75[1.28,2.4]
ORIGIN 2012 57/6281 65/6255 25.02% 0.87[0.61,1.24]
Risk & Prevention 2013 16/6239 12/6266 13.84% 1.34[0.63,2.83]
SHOT 1996 5/317 4/293 6.35% 1.16[0.31,4.26]
Subtotal (95% CI) 22793 22769 100% 1.06[0.73,1.52]
Total events: 203 (Higher omega 3), 171 (Lower omega 3)  
Heterogeneity: Tau2=0.11; Chi2=13.73, df=7(P=0.06); I2=49.03%  
Test for overall effect: Z=0.29(P=0.77)  
   
3.2.3 GI hospitalisation  
Raitt 2005 7/100 4/100 100% 1.75[0.53,5.79]
Subtotal (95% CI) 100 100 100% 1.75[0.53,5.79]
Total events: 7 (Higher omega 3), 4 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.92(P=0.36)  
   
3.2.4 Pulmonary embolus or DVT - LCn3  
ADCS 2010 8/214 2/164 41.69% 3.07[0.66,14.24]
DART 1989 2/1015 4/1018 35.5% 0.5[0.09,2.73]
NAT2 2013 1/150 0/150 11.41% 3[0.12,73.06]
OFAMI 2001 0/150 1/150 11.41% 0.33[0.01,8.12]
Subtotal (95% CI) 1529 1482 100% 1.25[0.41,3.78]
Total events: 11 (Higher omega 3), 7 (Lower omega 3)  
Heterogeneity: Tau2=0.15; Chi2=3.38, df=3(P=0.34); I2=11.16%  
Test for overall effect: Z=0.39(P=0.69)  
   
3.2.5 Progression to advanced AMD (age-related macular degenera-
tion)
 
AREDS2 2014 1025/2147 1024/2056 100% 0.96[0.9,1.02]
Subtotal (95% CI) 2147 2056 100% 0.96[0.9,1.02]
Total events: 1025 (Higher omega 3), 1024 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.34(P=0.18)  
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Analysis 3.3.   Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 3 Side e2ects - LCn3.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.3.1 Dropouts due to side effects  
ADCS 2010 14/238 10/167 4.03% 0.98[0.45,2.16]
AFFORD 2013 10/153 7/163 2.83% 1.52[0.59,3.9]
AlphaOmega - EPA+DHA 2010 32/1192 21/1236 8.36% 1.58[0.92,2.72]
EPE-A 2014 7/168 7/75 2.44% 0.45[0.16,1.23]
EPIC-1 2008 9/187 7/185 2.68% 1.27[0.48,3.34]
EPIC-2 2008 9/189 5/188 2.17% 1.79[0.61,5.24]
FORWARD 2013 6/289 8/297 2.29% 0.77[0.27,2.19]
FOSTAR 2016 17/101 6/101 3.16% 2.83[1.16,6.89]
GISSI-HF 2008 102/3494 104/3481 33.14% 0.98[0.75,1.28]
HARP 1995 3/41 0/39 0.29% 6.67[0.36,125.02]
HERO 2009 1/26 0/24 0.25% 2.78[0.12,65.08]
Kumar 2012 4/91 0/87 0.3% 8.61[0.47,157.57]
Kumar 2013 1/39 0/39 0.25% 3[0.13,71.46]
MAPT 2017 48/820 51/832 16.8% 0.95[0.65,1.4]
NAT2 2013 12/150 7/150 3.06% 1.71[0.69,4.23]
Nodari 2011 AF 2/100 3/99 0.8% 0.66[0.11,3.87]
OPAL 2010 17/434 18/433 5.9% 0.94[0.49,1.8]
ORL 2013 9/171 4/165 1.87% 2.17[0.68,6.91]
Puri 2005 3/67 1/68 0.5% 3.04[0.32,28.54]
Rossing 1996 3/18 1/18 0.53% 3[0.34,26.19]
Sandhu 2016 1/54 0/53 0.25% 2.95[0.12,70.72]
SCIMO 1999 4/112 3/111 1.15% 1.32[0.3,5.77]
SHOT 1996 27/317 16/293 6.96% 1.56[0.86,2.84]
Subtotal (95% CI) 8451 8304 100% 1.16[0.99,1.36]
Total events: 341 (Higher omega 3), 279 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=22.11, df=22(P=0.45); I2=0.51%  
Test for overall effect: Z=1.86(P=0.06)  
   
3.3.2 Abdominal pain or discomfort  
EPE-A 2014 3/68 0/75 0.84% 7.71[0.41,146.61]
EPIC-1 2008 45/187 41/184 29.42% 1.08[0.75,1.57]
EPIC-2 2008 65/189 62/188 38.15% 1.04[0.79,1.38]
Lorenz-Meyer 1996 0/70 2/63 0.8% 0.18[0.01,3.69]
OPAL 2010 11/434 17/433 11% 0.65[0.31,1.36]
ORIGIN 2012 32/6281 18/6255 16.56% 1.77[0.99,3.15]
SCIMO 1999 4/112 3/111 3.23% 1.32[0.3,5.77]
Subtotal (95% CI) 7341 7309 100% 1.1[0.84,1.45]
Total events: 160 (Higher omega 3), 143 (Lower omega 3)  
Heterogeneity: Tau2=0.03; Chi2=7.86, df=6(P=0.25); I2=23.68%  
Test for overall effect: Z=0.7(P=0.48)  
   
3.3.3 Diarrhoea  
ADCS 2010 18/238 10/167 8.45% 1.26[0.6,2.67]
EPE-A 2014 17/168 13/75 10.54% 0.58[0.3,1.14]
EPIC-1 2008 35/187 21/184 18.77% 1.64[0.99,2.71]
EPIC-2 2008 44/189 37/188 31.37% 1.18[0.8,1.74]
FOSTAR 2016 8/101 5/101 4.02% 1.6[0.54,4.72]
Lorenz-Meyer 1996 1/70 1/63 0.62% 0.9[0.06,14.09]
ORL 2013 9/171 8/165 5.48% 1.09[0.43,2.75]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Puri 2005 17/67 14/68 12.2% 1.23[0.66,2.29]
Raitt 2005 11/100 12/100 7.96% 0.92[0.42,1.98]
Shinto 2014 0/13 3/13 0.57% 0.14[0.01,2.52]
Subtotal (95% CI) 1304 1124 100% 1.15[0.92,1.43]
Total events: 160 (Higher omega 3), 124 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=8.77, df=9(P=0.46); I2=0%  
Test for overall effect: Z=1.25(P=0.21)  
   
3.3.4 Nausea  
EPE-A 2014 24/168 7/75 18.57% 1.53[0.69,3.4]
EPIC-1 2008 17/188 4/186 10.29% 4.2[1.44,12.26]
EPIC-2 2008 30/189 19/190 40.68% 1.59[0.93,2.72]
FOSTAR 2016 19/101 13/101 27.95% 1.46[0.76,2.8]
Rossing 1996 3/18 1/18 2.51% 3[0.34,26.19]
Subtotal (95% CI) 664 570 100% 1.73[1.23,2.44]
Total events: 93 (Higher omega 3), 44 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.39, df=4(P=0.5); I2=0%  
Test for overall effect: Z=3.13(P=0)  
   
3.3.5 Any gastrointestinal side effect - LCn3 fats  
ADCS 2010 18/238 10/167 3.18% 1.26[0.6,2.67]
AFFORD 2013 6/153 5/163 1.77% 1.28[0.4,4.1]
AlphaOmega - EPA+DHA 2010 18/1192 10/1236 3.08% 1.87[0.87,4.03]
AREDS2 2014 119/2147 145/2056 6.41% 0.79[0.62,0.99]
EPE-A 2014 67/168 40/75 6.11% 0.75[0.56,0.99]
EPIC-1 2008 45/187 41/184 5.49% 1.08[0.75,1.57]
EPIC-2 2008 65/189 62/188 6.1% 1.04[0.79,1.38]
FORWARD 2013 6/289 8/297 2.07% 0.77[0.27,2.19]
FOSTAR 2016 67/101 62/101 6.56% 1.08[0.88,1.33]
GISSI-HF 2008 96/3494 92/3481 6.11% 1.04[0.78,1.38]
JELIS 2007 352/9326 155/9319 6.68% 2.27[1.88,2.74]
Kumar 2012 4/91 0/87 0.36% 8.61[0.47,157.57]
Kumar 2013 14/39 0/39 0.39% 29[1.79,469.76]
Lorenz-Meyer 1996 10/70 2/63 1.21% 4.5[1.02,19.76]
MAPT 2017 175/820 164/832 6.66% 1.08[0.9,1.31]
OPAL 2010 0/434 4/433 0.36% 0.11[0.01,2.05]
ORIGIN 2012 14/6281 24/6255 3.64% 0.58[0.3,1.12]
ORL 2013 27/171 24/165 4.56% 1.09[0.65,1.8]
Proudman 2015 1/86 1/53 0.4% 0.62[0.04,9.65]
Puri 2005 17/67 14/68 3.84% 1.23[0.66,2.29]
Raitt 2005 11/100 12/100 3.08% 0.92[0.42,1.98]
Risk & Prevention 2013 200/6239 186/6266 6.63% 1.08[0.89,1.31]
Rossing 1996 3/18 1/18 0.62% 3[0.34,26.19]
Sandhu 2016 2/54 1/53 0.53% 1.96[0.18,21.01]
SCIMO 1999 4/112 3/111 1.22% 1.32[0.3,5.77]
Shinto 2014 0/13 3/13 0.37% 0.14[0.01,2.52]
SHOT 1996 40/317 20/293 4.52% 1.85[1.11,3.09]
SOFA 2006 17/273 12/273 3.32% 1.42[0.69,2.91]
Tande 2016 18/64 28/63 4.74% 0.63[0.39,1.02]
Subtotal (95% CI) 32733 32452 100% 1.12[0.94,1.34]
Total events: 1416 (Higher omega 3), 1129 (Lower omega 3)  
Heterogeneity: Tau2=0.12; Chi2=106.35, df=28(P<0.0001); I2=73.67%  
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=1.26(P=0.21)  
   
3.3.6 Skin problems (itching, rashes)  
AREDS2 2014 8/2147 7/2056 16.53% 1.09[0.4,3.01]
EPE-A 2014 4/168 3/75 12.74% 0.6[0.14,2.59]
JELIS 2007 160/9326 65/9319 21.92% 2.46[1.85,3.28]
Lorenz-Meyer 1996 2/70 4/63 11.38% 0.45[0.09,2.37]
Risk & Prevention 2013 8/6239 17/6266 18.04% 0.47[0.2,1.09]
Sandhu 2016 0/54 3/53 5.54% 0.14[0.01,2.65]
SCIMO 1999 1/112 0/111 4.89% 2.97[0.12,72.21]
Tande 2016 7/64 1/63 8.96% 6.89[0.87,54.4]
Subtotal (95% CI) 18180 18006 100% 1.04[0.47,2.3]
Total events: 190 (Higher omega 3), 100 (Lower omega 3)  
Heterogeneity: Tau2=0.73; Chi2=24.63, df=7(P=0); I2=71.57%  
Test for overall effect: Z=0.09(P=0.93)  
   
3.3.7 Headache or worsening migraine  
EPE-A 2014 1/168 0/75 2.64% 1.35[0.06,32.74]
EPIC-1 2008 12/187 10/184 40.47% 1.18[0.52,2.67]
EPIC-2 2008 12/189 20/188 56.9% 0.6[0.3,1.19]
Subtotal (95% CI) 544 447 100% 0.8[0.48,1.35]
Total events: 25 (Higher omega 3), 30 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.68, df=2(P=0.43); I2=0%  
Test for overall effect: Z=0.83(P=0.41)  
   
3.3.8 Reflux  
FOSTAR 2016 17/101 12/101 100% 1.42[0.71,2.81]
Subtotal (95% CI) 101 101 100% 1.42[0.71,2.81]
Total events: 17 (Higher omega 3), 12 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1(P=0.32)  
   
3.3.9 Pain (joint, lumbar, muscle pain)  
JELIS 2007 144/9326 180/9319 100% 0.8[0.64,0.99]
Subtotal (95% CI) 9326 9319 100% 0.8[0.64,0.99]
Total events: 144 (Higher omega 3), 180 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=2.02(P=0.04)  
   
3.3.10 All side effects combined  
ADCS 2010 214/238 144/167 11.64% 1.04[0.97,1.12]
AREDS2 2014 1024/2147 963/2056 12.08% 1.02[0.96,1.09]
EPE-A 2014 139/168 71/75 11.01% 0.87[0.8,0.95]
HARP 1995 3/41 0/39 0.05% 6.67[0.36,125.02]
JELIS 2007 2334/9326 2004/9319 12.54% 1.16[1.1,1.23]
Lorenz-Meyer 1996 17/70 15/63 1.11% 1.02[0.56,1.87]
MAPT 2017 702/820 712/832 12.98% 1[0.96,1.04]
NAT2 2013 125/134 115/129 11.57% 1.05[0.97,1.13]
ORL 2013 216/336 109/167 8.65% 0.98[0.86,1.13]
Proudman 2015 74/86 49/53 9.68% 0.93[0.83,1.04]
Risk & Prevention 2013 240/6239 218/6266 6.81% 1.11[0.92,1.32]
Sandhu 2016 16/54 16/53 1.2% 0.98[0.55,1.75]
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Shinto 2014 5/13 9/13 0.69% 0.56[0.26,1.21]
Subtotal (95% CI) 19672 19232 100% 1.01[0.95,1.08]
Total events: 5109 (Higher omega 3), 4425 (Lower omega 3)  
Heterogeneity: Tau2=0.01; Chi2=62.03, df=12(P<0.0001); I2=80.65%  
Test for overall effect: Z=0.36(P=0.72)  
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Analysis 3.4.   Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 4 Dropouts - LCn3.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
ADCS 2010 67/238 40/164 3.57% 1.15[0.82,1.62]
AFFORD 2013 21/165 19/172 1.28% 1.15[0.64,2.06]
AlphaOmega - EPA+DHA 2010 214/1192 191/1236 10.2% 1.16[0.97,1.39]
Bates 1989 10/155 10/157 0.62% 1.01[0.43,2.37]
Berson 2004 6/105 8/103 0.43% 0.74[0.26,2.05]
Brox 2001 13/80 3/40 0.31% 2.17[0.65,7.17]
DIPP 2015 3/104 5/101 0.23% 0.58[0.14,2.37]
DISAF 2003 26/201 31/206 1.83% 0.86[0.53,1.39]
EPE-A 2014 49/168 20/75 2.16% 1.09[0.7,1.7]
EPIC-1 2008 80/188 91/186 7.32% 0.87[0.7,1.09]
EPIC-2 2008 114/189 112/190 11.3% 1.02[0.87,1.21]
FAAT 2005 73/200 69/202 5.46% 1.07[0.82,1.39]
FORWARD 2013 20/289 25/297 1.36% 0.82[0.47,1.45]
FOSTAR 2016 18/101 16/101 1.16% 1.13[0.61,2.08]
HARP 1995 10/41 11/39 0.81% 0.86[0.41,1.8]
JELIS 2007 1766/9326 1582/9319 27.76% 1.12[1.05,1.19]
MARINA 2011 38/279 17/88 1.6% 0.71[0.42,1.19]
Mita 2007 10/40 11/41 0.81% 0.93[0.45,1.95]
NAT2 2013 29/150 34/150 2.18% 0.85[0.55,1.33]
Nodari 2011 AF 6/100 5/99 0.34% 1.19[0.37,3.77]
Norouzi 2014 1/55 5/55 0.1% 0.2[0.02,1.66]
OPAL 2010 67/434 78/433 4.45% 0.86[0.64,1.15]
ORL 2013 22/336 21/167 1.34% 0.52[0.29,0.92]
Raitt 2005 17/100 26/100 1.46% 0.65[0.38,1.13]
Rossing 1996 4/18 3/18 0.25% 1.33[0.35,5.13]
Sandhu 2016 5/54 6/53 0.35% 0.82[0.27,2.52]
Shinto 2014 2/13 2/13 0.14% 1[0.16,6.07]
SHOT 1996 41/317 25/293 1.92% 1.52[0.95,2.43]
SMART 2013 20/41 18/43 1.92% 1.17[0.73,1.87]
SU.FOL.OM3 2010 134/1253 145/1248 7.34% 0.92[0.74,1.15]
   
Total (95% CI) 15932 15389 100% 1.02[0.95,1.09]
Total events: 2886 (Higher omega 3), 2629 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=32.74, df=29(P=0.29); I2=11.41%  
Test for overall effect: Z=0.51(P=0.61)  
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Comparison 4.   High vs low ALA omega-3 fat (primary outcomes)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 All-cause mortality (overall)
- ALA
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.84, 1.20]
2 All-cause mortality - ALA -
sensitivity analysis (SA) fixed-
effect
5 16923 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.84, 1.34]
3 All-cause mortality - ALA - SA
by summary risk of bias
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.84, 1.20]
3.1 Low risk of bias 3 5213 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.72, 1.45]
3.2 Moderate/high risk of bias 2 14114 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.71, 1.67]
4 All-cause mortality - ALA - SA
by compliance and study size
5   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 SA - low risk of compliance
bias
3 5811 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.68, 1.63]
4.2 SA - 100+ randomised 5 19327 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.84, 1.20]
5 All-cause mortality - ALA -
subgroup by dose
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.84, 1.20]
5.1 ALA low < 5 g/d 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.80, 1.19]
5.2 ALA high ≥ 5 g/d 4 14490 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.77, 1.75]
6 All-cause mortality - ALA -
subgroup by replacement
5   Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 ALA replacing SFA 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 ALA replacing MUFA 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.80, 1.19]
6.3 ALA replacing n-6 2 13672 Risk Ratio (M-H, Random, 95% CI) 1.37 [0.48, 3.86]
6.4 ALA replacing CHO 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.5 ALA replacing nil/low n-3
placebo
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.6 ALA replacement unclear 2 818 Risk Ratio (M-H, Random, 95% CI) 2.78 [0.29, 26.49]
7 All cause mortality - ALA -
subgroup by intervention type
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.84, 1.20]
7.1 Dietary advice 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Supplemental foods 4 5921 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.82, 1.21]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
7.3 Supplements (capsule) 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.70, 1.64]
7.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 All-cause mortality - ALA -
subgroup by duration
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.84, 1.20]
8.1 Medium duration 1 to < 2
years in study
2 13516 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.71, 1.67]
8.2 Medium-long duration: 2 to
< 4 years in study
3 5811 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.68, 1.63]
8.3 Long duration: ≥ 4 years in
study
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 All-cause mortality - ALA -
subgroup by primary or sec-
ondary prevention
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.84, 1.20]
9.1 Primary CVD prevention 3 14380 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.75, 1.74]
9.2 Secondary CVD prevention 2 4947 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.81, 1.19]
10 All-cause mortality - ALA -
subgroup by statin use
5 16923 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.84, 1.33]
10.1 ALA - ≥ 50% of control
group on statins
2 2543 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.77, 1.34]
10.2 ALA - < 50% of control
group on statins
3 14380 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.75, 1.74]
11 Cardiovascular mortality
(overall) - ALA
4 18619 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.25]
12 CVD mortality - ALA - SA
fixed-effect
4 18619 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.74, 1.25]
13 CVD mortality - ALA - SA by
summary risk of bias
4 18619 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.25]
13.1 Low risk of bias 3 5213 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.70, 1.28]
13.2 Moderate/high risk of bias 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.70]
14 CVD mortality - ALA - SA by
compliance and study size
4 23722 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.78, 1.16]
14.1 SA - low risk of compli-
ance bias
2 5103 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.70, 1.27]
14.2 SA - 100+ randomised 4 18619 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.25]
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15 CVD mortality - ALA - sub-
group by dose
4 18619 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.25]
15.1 ALA low < 5 g/d 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.69, 1.27]
15.2 ALA high ≥ 5 g/d 3 13782 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.62, 1.73]
16 CVD mortality - ALA - sub-
group by replacement
4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 N-3 replacing SFA 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 N-3 replacing MUFA 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.69, 1.27]
16.3 N-3 replacing n-6 2 13672 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.60, 1.70]
16.4 N-3 replacing carbohy-
drates/sugars
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.5 N-3 replacing nil/low n-3
placebo
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.6 Replacement unclear 1 110 Risk Ratio (M-H, Random, 95% CI) 2.69 [0.11, 64.74]
17 CVD mortality - ALA - sub-
group by intervention type
4 18619 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.25]
17.1 Dietary advice 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Supplemental foods 3 5213 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.70, 1.28]
17.3 Supplements (capsule) 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.70]
17.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18 CVD mortality - ALA - sub-
group by duration
4 18619 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.25]
18.1 Medium duration 1 to < 2
years in study
2 13516 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.61, 1.73]
18.2 Medium-long duration: 2
to < 4 years in study
2 5103 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.70, 1.27]
18.3 Long duration: ≥ 4 years in
study
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19 CVD mortality - ALA - sub-
group by primary or secondary
prevention
4 18619 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.25]
19.1 Primary prevention 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.70]
19.2 Secondary prevention 3 5213 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.70, 1.28]
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20 CVD mortality - ALA - sub-
group by statin uses
4 18619 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.25]
20.1 ALA - ≥ 50% of control
group on statins
2 4947 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.70, 1.28]
20.2 ALA - < 50% of control
group on statins
2 13672 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.60, 1.70]
21 Cardiovascular events
(overall) - ALA
5 19327 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
22 CVD events - ALA - SA fixed-
effect
5 19327 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.84, 1.07]
23 CVD events - ALA - SA by
summary risk of bias
5 19327 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
23.1 Low risk of bias 3 5213 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.79, 1.04]
23.2 Moderate/high risk of bias 2 14114 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.84, 1.48]
24 CVD events - ALA - SA by
compliance and study size
5   Risk Ratio (M-H, Random, 95% CI) Subtotals only
24.1 SA - low risk of compli-
ance bias
3 5811 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.79, 1.04]
24.2 SA - 100+ randomised 5 19327 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
25 CVD events - ALA - subgroup
by dose
5 19327 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
25.1 ALA low < 5 g/d 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.79, 1.05]
25.2 ALA high ≥ 5 g/d 4 14490 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.82, 1.40]
26 CVD events - ALA - subgroup
by replacement
5   Risk Ratio (M-H, Random, 95% CI) Subtotals only
26.1 N-3 replacing SFA 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
26.2 N-3 replacing MUFA 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.79, 1.05]
26.3 N-3 replacing n-6 2 13672 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.24, 2.41]
26.4 N-3 replacing carbohy-
drates/sugars
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
26.5 N-3 replacing nil/low n-3
placebo
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
26.6 Replacement unclear 2 818 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.36, 2.43]
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27 CVD events - ALA - subgroup
by intervention type
6 19526 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
27.1 Dietary advice 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
27.2 Supplemental foods 5 6120 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.79, 1.04]
27.3 Supplements (capsule) 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.85, 1.51]
27.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
28 CVD events - ALA - subgroup
by duration
5 19327 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
28.1 Medium duration 1 to < 2
years in study
2 13516 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.86, 1.50]
28.2 Medium-long duration: 2
to < 4 years in study
3 5811 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.79, 1.04]
28.3 Long duration: ≥ 4 years in
study
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
29 CVD events - ALA - subgroup
by primary or secondary pre-
vention
5 19327 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
29.1 Primary prevention 3 14380 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.46, 1.67]
29.2 Secondary prevention 2 4947 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.80, 1.05]
30 CVD events - ALA - subgroup
by statin use
5 19327 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.07]
30.1 ALA - ≥ 50% of control
group on statins
2 4947 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.80, 1.05]
30.2 ALA - < 50% of control
group on statins
3 14380 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.46, 1.67]
31 Coronary heart disease
mortality (overall) - ALA
3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
32 CHD mortality - ALA - SA
fixed-effect
3 18353 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.72, 1.26]
33 CHD mortality - ALA - SA by
summary risk of bias
3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
33.1 Low risk of bias 2 4947 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.67, 1.30]
33.2 Moderate/high risk of bias 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.70]
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34 CHD mortality - ALA - SA by
compliance and study size
3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
34.1 SA - low risk of compli-
ance bias
1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.66, 1.28]
34.2 SA - 100+ randomised 3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
35 CHD mortality - ALA - sub-
group by dose
3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
35.1 ALA low < 5 g/d 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.66, 1.28]
35.2 ALA high ≥ 5 g/d 2 13516 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.61, 1.73]
36 CHD mortality - ALA - sub-
group by replacement
3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
36.1 N-3 replacing SFA 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
36.2 Coronary heart mortality-
ALA
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
36.3 N-3 replacing MUFA 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.66, 1.28]
36.4 N-3 replacing n-6 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.70]
36.5 N-3 replacing carbohy-
drates/sugars
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
36.6 N-3 replacing nil/low n-3
placebo
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
36.7 Replacement unclear 1 110 Risk Ratio (M-H, Random, 95% CI) 2.69 [0.11, 64.74]
37 CHD mortality - ALA - sub-
group by intervention type
3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
37.1 Dietary advice 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
37.2 Supplemental foods 2 4947 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.67, 1.30]
37.3 Supplements (capsule) 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.70]
37.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
38 CHD mortality - ALA - sub-
group by duration
3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
38.1 Medium duration 1 to < 2
years in study
2 13516 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.61, 1.73]
38.2 Medium-long duration: 2
to < 4 years in study
1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.66, 1.28]
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38.3 Long duration: ≥ 4 years in
study
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39 CHD mortality - ALA - sub-
group by primary or secondary
prevention
3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
39.1 Primary prevention of
CVD
1 13406 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.70]
39.2 Secondary prevention of
CVD
2 4947 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.67, 1.30]
40 CHD mortality - ALA - sub-
group by statin use
3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
40.1 ALA - ≥ 50% of control
group on statins
2 4947 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.67, 1.30]
40.2 ALA - < 50% of control
group on statins
1 13406 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.70]
41 CHD mortality - ALA - sub-
group by CAD history
3 18353 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.72, 1.26]
41.1 Previous CAD 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.66, 1.28]
41.2 No previous CAD 2 13516 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.61, 1.73]
42 Coronary heart disease
events (overall) - ALA
4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
43 CHD events - ALA - SA fixed-
effect
4 19061 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.82, 1.21]
44 CHD events - ALA - SA by
summary risk of bias
4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
44.1 Low risk of bias 2 4947 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.71, 1.15]
44.2 Moderate/high risk of bias 2 14114 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.86, 1.67]
45 CHD events - ALA - SA by
compliance and study size
4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
45.1 SA - low risk of compli-
ance bias
2 5545 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.73, 1.17]
45.2 SA - 100+ randomised 4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
46 CHD events - ALA - sub-
group by dose
4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
46.1 ALA low < 5 g/d 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.72, 1.17]
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46.2 ALA high ≥ 5 g/d 3 14224 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.84, 1.61]
47 CHD events - ALA - sub-
group by replacement
4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
47.1 N-3 replacing SFA 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
47.2 N-3 replacing MUFA 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.72, 1.17]
47.3 N-3 replacing n-6 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.85, 1.65]
47.4 N-3 replacing carbohy-
drates/sugars
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
47.5 N-3 replacing nil/low n-3
placebo
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
47.6 Replacement unclear 2 818 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.08, 5.81]
48 CHD events - ALA - sub-
group by intervention type
4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
48.1 Dietary advice 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
48.2 Supplemental foods 3 5655 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.72, 1.16]
48.3 Supplements (capsule) 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.85, 1.65]
48.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
49 CHD events - ALA - sub-
group by duration
4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
49.1 Medium duration 1 to < 2
years in study
2 13516 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.34, 2.58]
49.2 Medium-long duration: 2
to < 4 years in study
2 5545 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.73, 1.17]
49.3 Long duration: ≥ 4 years in
study
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
50 CHD events - ALA - sub-
group by primary or secondary
prevention
4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
50.1 Primary prevention 2 14114 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.86, 1.67]
50.2 Secondary prevention 2 4947 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.71, 1.15]
51 CHD events - ALA - sub-
group by statin use
4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
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51.1 ALA - ≥ 50% of control
group on statins
2 4947 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.71, 1.15]
51.2 ALA - < 50% of control
group on statins
2 14114 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.86, 1.67]
52 CHD events - ALA - sub-
group by CAD history
4 19061 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.82, 1.22]
52.1 Previous CAD 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.72, 1.17]
52.2 No previous CAD 3 14224 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.84, 1.61]
53 Stroke (overall) - ALA 5 19327 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.66, 2.01]
54 Stroke - ALA - SA fixed-effect 5 19327 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.71, 2.13]
55 Stroke - ALA - SA by summa-
ry risk of bias
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.66, 2.01]
55.1 Low risk of bias 3 5213 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.45, 2.09]
55.2 Moderate/high risk of bias 2 14114 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.62, 3.13]
56 Stroke - ALA - SA by compli-
ance and study size
5 25138 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.66, 1.64]
56.1 SA - low risk of compli-
ance bias
3 5811 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.39, 1.87]
56.2 SA - 100+ randomised 5 19327 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.66, 2.01]
57 Stroke - ALA - subgroup by
dose
5   Risk Ratio (M-H, Random, 95% CI) Subtotals only
57.1 ALA low < 5 g/d 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.39, 2.15]
57.2 ALA high ≥ 5 g/d 4 14490 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.65, 2.85]
58 Stroke - ALA - subgroup by
replacement
5   Risk Ratio (M-H, Random, 95% CI) Subtotals only
58.1 N-3 replacing SFA 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
58.2 N-3 replacing MUFA 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.39, 2.15]
58.3 N-3 replacing n-6 2 13672 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.53, 3.01]
58.4 N-3 replacing carbohy-
drates/sugars
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
58.5 N-3 replacing nil/low n-3
placebo
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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58.6 Replacement unclear 2 818 Risk Ratio (M-H, Random, 95% CI) 1.79 [0.31, 10.17]
59 Stroke - ALA - subgroup by
intervention type
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.66, 2.01]
59.1 Dietary advice 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
59.2 Supplemental foods 4 5921 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.46, 2.03]
59.3 Supplements (capsule) 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.62, 3.36]
59.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
60 Stroke - ALA - subgroup by
duration
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.66, 2.01]
60.1 Medium duration 1 to < 2
years in study
2 13516 Risk Ratio (M-H, Random, 95% CI) 1.56 [0.70, 3.44]
60.2 Medium-long duration: 2
to < 4 years in study
3 5811 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.39, 1.87]
60.3 Long duration: ≥ 4 years in
study
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
61 Stroke - ALA - subgroup by
primary or secondary preven-
tion
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.66, 2.01]
61.1 Primary prevention 3 14380 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.57, 2.74]
61.2 Secondary prevention 2 4947 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.47, 2.34]
62 Stroke - ALA - subgroup by
statin use
5 19327 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.71, 2.18]
62.1 ALA - ≥ 50% of control
group on statins
2 4947 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.56, 2.77]
62.2 ALA - < 50% of control
group on statins
3 14380 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.57, 2.74]
63 Stroke - ALA - subgroup by
stroke type
3 13782 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.65, 3.01]
63.1 Ischaemic stroke - ALA 3 13782 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.65, 3.01]
63.2 Haemorrhagic stroke -
ALA
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
64 Arrythmia (overall) - ALA 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.57, 1.10]
64.1 ALA - new arrhythmias 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.57, 1.10]
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
422
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
64.2 ALA - recurrent arrhyth-
mias
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
65 Arrhythmia - ALA - SA by
summary risk of bias
1 4837 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.57, 1.10]
65.1 Low risk of bias 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.57, 1.10]
65.2 Moderate/high risk of bias 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 4.1.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 1 All-cause mortality (overall) - ALA.
Study or subgroup Favours high-
er omega 3
Lower
omega 3 fats
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AlphaOmega - ALA 2010 182/2409 188/2428 81.74% 0.98[0.8,1.19]
FLAX-PAD 2013 1/58 0/52 0.31% 2.69[0.11,64.74]
MARGARIN 2002 3/109 1/157 0.62% 4.32[0.46,41]
Norwegian 1968 43/6716 40/6690 17.02% 1.07[0.7,1.64]
WAHA 2016 1/362 0/346 0.31% 2.87[0.12,70.16]
   
Total (95% CI) 9654 9673 100% 1.01[0.84,1.2]
Total events: 230 (Favours higher omega 3), 229 (Lower omega 3 fats)  
Heterogeneity: Tau2=0; Chi2=2.57, df=4(P=0.63); I2=0%  
Test for overall effect: Z=0.08(P=0.94)  
Favours higher omega 3 200.05 50.2 1 Favours lower omega 3
 
 
Analysis 4.2.   Comparison 4 High vs low ALA omega-3 fat (primary outcomes),
Outcome 2 All-cause mortality - ALA - sensitivity analysis (SA) fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
AlphaOmega - ALA 2010 91/1197 93/1236 68.57% 1.01[0.77,1.33]
FLAX-PAD 2013 1/58 0/52 0.39% 2.69[0.11,64.74]
MARGARIN 2002 3/109 1/157 0.61% 4.32[0.46,41]
Norwegian 1968 43/6716 40/6690 30.03% 1.07[0.7,1.64]
WAHA 2016 1/362 0/346 0.38% 2.87[0.12,70.16]
   
Total (95% CI) 8442 8481 100% 1.06[0.84,1.34]
Total events: 139 (Higher omega 3), 134 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.32, df=4(P=0.68); I2=0%  
Test for overall effect: Z=0.52(P=0.6)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Analysis 4.3.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 3 All-cause mortality - ALA - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.3.1 Low risk of bias  
AlphaOmega - ALA 2010 182/2409 188/2428 81.74% 0.98[0.8,1.19]
FLAX-PAD 2013 1/58 0/52 0.31% 2.69[0.11,64.74]
MARGARIN 2002 3/109 1/157 0.62% 4.32[0.46,41]
Subtotal (95% CI) 2576 2637 82.67% 1.02[0.72,1.45]
Total events: 186 (Higher omega 3), 189 (Lower omega 3)  
Heterogeneity: Tau2=0.02; Chi2=2.05, df=2(P=0.36); I2=2.55%  
Test for overall effect: Z=0.13(P=0.9)  
   
4.3.2 Moderate/high risk of bias  
Norwegian 1968 43/6716 40/6690 17.02% 1.07[0.7,1.64]
WAHA 2016 1/362 0/346 0.31% 2.87[0.12,70.16]
Subtotal (95% CI) 7078 7036 17.33% 1.09[0.71,1.67]
Total events: 44 (Higher omega 3), 40 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.36, df=1(P=0.55); I2=0%  
Test for overall effect: Z=0.4(P=0.69)  
   
Total (95% CI) 9654 9673 100% 1.01[0.84,1.2]
Total events: 230 (Higher omega 3), 229 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.57, df=4(P=0.63); I2=0%  
Test for overall effect: Z=0.08(P=0.94)  
Test for subgroup differences: Chi2=0.05, df=1 (P=0.82), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.4.   Comparison 4 High vs low ALA omega-3 fat (primary outcomes),
Outcome 4 All-cause mortality - ALA - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.4.1 SA - low risk of compliance bias  
AlphaOmega - ALA 2010 182/2409 188/2428 94.49% 0.98[0.8,1.19]
MARGARIN 2002 3/109 1/157 3.67% 4.32[0.46,41]
WAHA 2016 1/362 0/346 1.84% 2.87[0.12,70.16]
Subtotal (95% CI) 2880 2931 100% 1.05[0.68,1.63]
Total events: 186 (Higher omega 3), 189 (Lower omega 3)  
Heterogeneity: Tau2=0.04; Chi2=2.1, df=2(P=0.35); I2=4.59%  
Test for overall effect: Z=0.22(P=0.82)  
   
4.4.2 SA - 100+ randomised  
AlphaOmega - ALA 2010 182/2409 188/2428 81.74% 0.98[0.8,1.19]
FLAX-PAD 2013 1/58 0/52 0.31% 2.69[0.11,64.74]
MARGARIN 2002 3/109 1/157 0.62% 4.32[0.46,41]
Norwegian 1968 43/6716 40/6690 17.02% 1.07[0.7,1.64]
WAHA 2016 1/362 0/346 0.31% 2.87[0.12,70.16]
Subtotal (95% CI) 9654 9673 100% 1.01[0.84,1.2]
Total events: 230 (Higher omega 3), 229 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.57, df=4(P=0.63); I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.08(P=0.94)  
Test for subgroup differences: Chi2=0.03, df=1 (P=0.86), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.5.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 5 All-cause mortality - ALA - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.5.1 ALA low < 5 g/d  
AlphaOmega - ALA 2010 182/2409 188/2428 81.74% 0.98[0.8,1.19]
Subtotal (95% CI) 2409 2428 81.74% 0.98[0.8,1.19]
Total events: 182 (Higher omega 3), 188 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.25(P=0.81)  
   
4.5.2 ALA high ≥ 5 g/d  
FLAX-PAD 2013 1/58 0/52 0.31% 2.69[0.11,64.74]
MARGARIN 2002 3/109 1/157 0.62% 4.32[0.46,41]
Norwegian 1968 43/6716 40/6690 17.02% 1.07[0.7,1.64]
WAHA 2016 1/362 0/346 0.31% 2.87[0.12,70.16]
Subtotal (95% CI) 7245 7245 18.26% 1.16[0.77,1.75]
Total events: 48 (Higher omega 3), 41 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.03, df=3(P=0.57); I2=0%  
Test for overall effect: Z=0.7(P=0.48)  
   
Total (95% CI) 9654 9673 100% 1.01[0.84,1.2]
Total events: 230 (Higher omega 3), 229 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.57, df=4(P=0.63); I2=0%  
Test for overall effect: Z=0.08(P=0.94)  
Test for subgroup differences: Chi2=0.54, df=1 (P=0.46), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 4.6.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 6 All-cause mortality - ALA - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.6.1 ALA replacing SFA  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.6.2 ALA replacing MUFA  
AlphaOmega - ALA 2010 182/2409 188/2428 100% 0.98[0.8,1.19]
Subtotal (95% CI) 2409 2428 100% 0.98[0.8,1.19]
Favours high ALA 1000.01 100.1 1 Favours low ALA
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 182 (Higher omega 3), 188 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.25(P=0.81)  
   
4.6.3 ALA replacing n-6  
MARGARIN 2002 3/109 1/157 17.43% 4.32[0.46,41]
Norwegian 1968 43/6716 40/6690 82.57% 1.07[0.7,1.64]
Subtotal (95% CI) 6825 6847 100% 1.37[0.48,3.86]
Total events: 46 (Higher omega 3), 41 (Lower omega 3)  
Heterogeneity: Tau2=0.29; Chi2=1.43, df=1(P=0.23); I2=29.93%  
Test for overall effect: Z=0.59(P=0.56)  
   
4.6.4 ALA replacing CHO  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.6.5 ALA replacing nil/low n-3 placebo  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.6.6 ALA replacement unclear  
FLAX-PAD 2013 1/58 0/52 50.29% 2.69[0.11,64.74]
WAHA 2016 1/362 0/346 49.71% 2.87[0.12,70.16]
Subtotal (95% CI) 420 398 100% 2.78[0.29,26.49]
Total events: 2 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.98); I2=0%  
Test for overall effect: Z=0.89(P=0.37)  
Test for subgroup differences: Chi2=1.19, df=1 (P=0.55), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.7.   Comparison 4 High vs low ALA omega-3 fat (primary outcomes),
Outcome 7 All cause mortality - ALA - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.7.1 Dietary advice  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.7.2 Supplemental foods  
AlphaOmega - ALA 2010 182/2409 188/2428 81.74% 0.98[0.8,1.19]
FLAX-PAD 2013 1/58 0/52 0.31% 2.69[0.11,64.74]
MARGARIN 2002 3/109 1/157 0.62% 4.32[0.46,41]
Favours high ALA 1000.01 100.1 1 Favours low ALA
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
WAHA 2016 1/362 0/346 0.31% 2.87[0.12,70.16]
Subtotal (95% CI) 2938 2983 82.98% 0.99[0.82,1.21]
Total events: 187 (Higher omega 3), 189 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.48, df=3(P=0.48); I2=0%  
Test for overall effect: Z=0.06(P=0.95)  
   
4.7.3 Supplements (capsule)  
Norwegian 1968 43/6716 40/6690 17.02% 1.07[0.7,1.64]
Subtotal (95% CI) 6716 6690 17.02% 1.07[0.7,1.64]
Total events: 43 (Higher omega 3), 40 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.31(P=0.75)  
   
4.7.4 Any combination  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 9654 9673 100% 1.01[0.84,1.2]
Total events: 230 (Higher omega 3), 229 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.57, df=4(P=0.63); I2=0%  
Test for overall effect: Z=0.08(P=0.94)  
Test for subgroup differences: Chi2=0.1, df=1 (P=0.76), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.8.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 8 All-cause mortality - ALA - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.8.1 Medium duration 1 to < 2 years in study  
FLAX-PAD 2013 1/58 0/52 0.31% 2.69[0.11,64.74]
Norwegian 1968 43/6716 40/6690 17.02% 1.07[0.7,1.64]
Subtotal (95% CI) 6774 6742 17.33% 1.09[0.71,1.67]
Total events: 44 (Higher omega 3), 40 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.32, df=1(P=0.57); I2=0%  
Test for overall effect: Z=0.39(P=0.7)  
   
4.8.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - ALA 2010 182/2409 188/2428 81.74% 0.98[0.8,1.19]
MARGARIN 2002 3/109 1/157 0.62% 4.32[0.46,41]
WAHA 2016 1/362 0/346 0.31% 2.87[0.12,70.16]
Subtotal (95% CI) 2880 2931 82.67% 1.05[0.68,1.63]
Total events: 186 (Higher omega 3), 189 (Lower omega 3)  
Heterogeneity: Tau2=0.04; Chi2=2.1, df=2(P=0.35); I2=4.59%  
Test for overall effect: Z=0.22(P=0.82)  
   
4.8.3 Long duration: ≥ 4 years in study  
Favours [high ALA] 1000.01 100.1 1 Favours low ALA
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 9654 9673 100% 1.01[0.84,1.2]
Total events: 230 (Higher omega 3), 229 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.57, df=4(P=0.63); I2=0%  
Test for overall effect: Z=0.08(P=0.94)  
Test for subgroup differences: Chi2=0.01, df=1 (P=0.91), I2=0%  
Favours [high ALA] 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.9.   Comparison 4 High vs low ALA omega-3 fat (primary outcomes),
Outcome 9 All-cause mortality - ALA - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.9.1 Primary CVD prevention  
MARGARIN 2002 3/109 1/157 0.62% 4.32[0.46,41]
Norwegian 1968 43/6716 40/6690 17.02% 1.07[0.7,1.64]
WAHA 2016 1/362 0/346 0.31% 2.87[0.12,70.16]
Subtotal (95% CI) 7187 7193 17.95% 1.14[0.75,1.74]
Total events: 47 (Higher omega 3), 41 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.75, df=2(P=0.42); I2=0%  
Test for overall effect: Z=0.63(P=0.53)  
   
4.9.2 Secondary CVD prevention  
AlphaOmega - ALA 2010 182/2409 188/2428 81.74% 0.98[0.8,1.19]
FLAX-PAD 2013 1/58 0/52 0.31% 2.69[0.11,64.74]
Subtotal (95% CI) 2467 2480 82.05% 0.98[0.81,1.19]
Total events: 183 (Higher omega 3), 188 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.39, df=1(P=0.53); I2=0%  
Test for overall effect: Z=0.21(P=0.84)  
   
Total (95% CI) 9654 9673 100% 1.01[0.84,1.2]
Total events: 230 (Higher omega 3), 229 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.57, df=4(P=0.63); I2=0%  
Test for overall effect: Z=0.08(P=0.94)  
Test for subgroup differences: Chi2=0.43, df=1 (P=0.51), I2=0%  
Favours [high ALA] 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.10.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 10 All-cause mortality - ALA - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.10.1 ALA - ≥ 50% of control group on statins  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AlphaOmega - ALA 2010 91/1197 93/1236 68.99% 1.01[0.77,1.33]
FLAX-PAD 2013 1/58 0/52 0.53% 2.69[0.11,64.74]
Subtotal (95% CI) 1255 1288 69.52% 1.02[0.77,1.34]
Total events: 92 (Higher omega 3), 93 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.36, df=1(P=0.55); I2=0%  
Test for overall effect: Z=0.13(P=0.9)  
   
4.10.2 ALA - < 50% of control group on statins  
MARGARIN 2002 3/109 1/157 1.05% 4.32[0.46,41]
Norwegian 1968 43/6716 40/6690 28.91% 1.07[0.7,1.64]
WAHA 2016 1/362 0/346 0.52% 2.87[0.12,70.16]
Subtotal (95% CI) 7187 7193 30.48% 1.14[0.75,1.74]
Total events: 47 (Higher omega 3), 41 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.75, df=2(P=0.42); I2=0%  
Test for overall effect: Z=0.63(P=0.53)  
   
Total (95% CI) 8442 8481 100% 1.05[0.84,1.33]
Total events: 139 (Higher omega 3), 134 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.32, df=4(P=0.68); I2=0%  
Test for overall effect: Z=0.45(P=0.65)  
Test for subgroup differences: Chi2=0.2, df=1 (P=0.65), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 4.11.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 11 Cardiovascular mortality (overall) - ALA.
Study or subgroup Favours high-
er omega 3
Lower
omega 3 fats
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AlphaOmega - ALA 2010 78/2409 84/2428 74.35% 0.94[0.69,1.27]
FLAX-PAD 2013 1/58 0/52 0.68% 2.69[0.11,64.74]
MARGARIN 2002 1/109 1/157 0.9% 1.44[0.09,22.78]
Norwegian 1968 27/6716 27/6690 24.08% 1[0.58,1.7]
   
Total (95% CI) 9292 9327 100% 0.96[0.74,1.25]
Total events: 107 (Favours higher omega 3), 112 (Lower omega 3 fats)  
Heterogeneity: Tau2=0; Chi2=0.53, df=3(P=0.91); I2=0%  
Test for overall effect: Z=0.3(P=0.76)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 4.12.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 12 CVD mortality - ALA - SA fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
AlphaOmega - ALA 2010 78/2409 84/2428 74.66% 0.94[0.69,1.27]
FLAX-PAD 2013 1/58 0/52 0.47% 2.69[0.11,64.74]
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
MARGARIN 2002 1/109 1/157 0.73% 1.44[0.09,22.78]
Norwegian 1968 27/6716 27/6690 24.14% 1[0.58,1.7]
   
Total (95% CI) 9292 9327 100% 0.96[0.74,1.25]
Total events: 107 (Higher omega 3), 112 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.53, df=3(P=0.91); I2=0%  
Test for overall effect: Z=0.29(P=0.77)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 4.13.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 13 CVD mortality - ALA - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.13.1 Low risk of bias  
AlphaOmega - ALA 2010 78/2409 84/2428 74.35% 0.94[0.69,1.27]
FLAX-PAD 2013 1/58 0/52 0.68% 2.69[0.11,64.74]
MARGARIN 2002 1/109 1/157 0.9% 1.44[0.09,22.78]
Subtotal (95% CI) 2576 2637 75.92% 0.95[0.7,1.28]
Total events: 80 (Higher omega 3), 85 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.51, df=2(P=0.77); I2=0%  
Test for overall effect: Z=0.34(P=0.74)  
   
4.13.2 Moderate/high risk of bias  
Norwegian 1968 27/6716 27/6690 24.08% 1[0.58,1.7]
Subtotal (95% CI) 6716 6690 24.08% 1[0.58,1.7]
Total events: 27 (Higher omega 3), 27 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.01(P=0.99)  
   
Total (95% CI) 9292 9327 100% 0.96[0.74,1.25]
Total events: 107 (Higher omega 3), 112 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.53, df=3(P=0.91); I2=0%  
Test for overall effect: Z=0.3(P=0.76)  
Test for subgroup differences: Chi2=0.02, df=1 (P=0.88), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.14.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 14 CVD mortality - ALA - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.14.1 SA - low risk of compliance bias  
AlphaOmega - ALA 2010 78/2409 84/2428 42.42% 0.94[0.69,1.27]
MARGARIN 2002 1/109 1/157 0.51% 1.44[0.09,22.78]
Subtotal (95% CI) 2518 2585 42.94% 0.94[0.7,1.27]
Total events: 79 (Higher omega 3), 85 (Lower omega 3)  
Favours high ALA 1000.01 100.1 1 Favours low ALA
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=0.09, df=1(P=0.76); I2=0%  
Test for overall effect: Z=0.4(P=0.69)  
   
4.14.2 SA - 100+ randomised  
AlphaOmega - ALA 2010 78/2409 84/2428 42.42% 0.94[0.69,1.27]
FLAX-PAD 2013 1/58 0/52 0.39% 2.69[0.11,64.74]
MARGARIN 2002 1/109 1/157 0.51% 1.44[0.09,22.78]
Norwegian 1968 27/6716 27/6690 13.74% 1[0.58,1.7]
Subtotal (95% CI) 9292 9327 57.06% 0.96[0.74,1.25]
Total events: 107 (Higher omega 3), 112 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.53, df=3(P=0.91); I2=0%  
Test for overall effect: Z=0.3(P=0.76)  
   
Total (95% CI) 11810 11912 100% 0.95[0.78,1.16]
Total events: 186 (Higher omega 3), 197 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.64, df=5(P=0.99); I2=0%  
Test for overall effect: Z=0.49(P=0.63)  
Test for subgroup differences: Chi2=0.01, df=1 (P=0.92), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.15.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 15 CVD mortality - ALA - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.15.1 ALA low < 5 g/d  
AlphaOmega - ALA 2010 78/2409 84/2428 74.35% 0.94[0.69,1.27]
Subtotal (95% CI) 2409 2428 74.35% 0.94[0.69,1.27]
Total events: 78 (Higher omega 3), 84 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.43(P=0.67)  
   
4.15.2 ALA high ≥ 5 g/d  
FLAX-PAD 2013 1/58 0/52 0.68% 2.69[0.11,64.74]
MARGARIN 2002 1/109 1/157 0.9% 1.44[0.09,22.78]
Norwegian 1968 27/6716 27/6690 24.08% 1[0.58,1.7]
Subtotal (95% CI) 6883 6899 25.65% 1.04[0.62,1.73]
Total events: 29 (Higher omega 3), 28 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.42, df=2(P=0.81); I2=0%  
Test for overall effect: Z=0.13(P=0.89)  
   
Total (95% CI) 9292 9327 100% 0.96[0.74,1.25]
Total events: 107 (Higher omega 3), 112 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.53, df=3(P=0.91); I2=0%  
Test for overall effect: Z=0.3(P=0.76)  
Test for subgroup differences: Chi2=0.11, df=1 (P=0.74), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Analysis 4.16.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 16 CVD mortality - ALA - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.16.1 N-3 replacing SFA  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.16.2 N-3 replacing MUFA  
AlphaOmega - ALA 2010 78/2409 84/2428 100% 0.94[0.69,1.27]
Subtotal (95% CI) 2409 2428 100% 0.94[0.69,1.27]
Total events: 78 (Higher omega 3), 84 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.43(P=0.67)  
   
4.16.3 N-3 replacing n-6  
MARGARIN 2002 1/109 1/157 3.58% 1.44[0.09,22.78]
Norwegian 1968 27/6716 27/6690 96.42% 1[0.58,1.7]
Subtotal (95% CI) 6825 6847 100% 1.01[0.6,1.7]
Total events: 28 (Higher omega 3), 28 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.07, df=1(P=0.8); I2=0%  
Test for overall effect: Z=0.04(P=0.97)  
   
4.16.4 N-3 replacing carbohydrates/sugars  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.16.5 N-3 replacing nil/low n-3 placebo  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.16.6 Replacement unclear  
FLAX-PAD 2013 1/58 0/52 100% 2.69[0.11,64.74]
Subtotal (95% CI) 58 52 100% 2.69[0.11,64.74]
Total events: 1 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.61(P=0.54)  
Test for subgroup differences: Chi2=0.47, df=1 (P=0.79), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
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Analysis 4.17.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 17 CVD mortality - ALA - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.17.1 Dietary advice  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.17.2 Supplemental foods  
AlphaOmega - ALA 2010 78/2409 84/2428 74.35% 0.94[0.69,1.27]
FLAX-PAD 2013 1/58 0/52 0.68% 2.69[0.11,64.74]
MARGARIN 2002 1/109 1/157 0.9% 1.44[0.09,22.78]
Subtotal (95% CI) 2576 2637 75.92% 0.95[0.7,1.28]
Total events: 80 (Higher omega 3), 85 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.51, df=2(P=0.77); I2=0%  
Test for overall effect: Z=0.34(P=0.74)  
   
4.17.3 Supplements (capsule)  
Norwegian 1968 27/6716 27/6690 24.08% 1[0.58,1.7]
Subtotal (95% CI) 6716 6690 24.08% 1[0.58,1.7]
Total events: 27 (Higher omega 3), 27 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.01(P=0.99)  
   
4.17.4 Any combination  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 9292 9327 100% 0.96[0.74,1.25]
Total events: 107 (Higher omega 3), 112 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.53, df=3(P=0.91); I2=0%  
Test for overall effect: Z=0.3(P=0.76)  
Test for subgroup differences: Chi2=0.02, df=1 (P=0.88), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.18.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 18 CVD mortality - ALA - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.18.1 Medium duration 1 to < 2 years in study  
FLAX-PAD 2013 1/58 0/52 0.68% 2.69[0.11,64.74]
Norwegian 1968 27/6716 27/6690 24.08% 1[0.58,1.7]
Subtotal (95% CI) 6774 6742 24.76% 1.02[0.61,1.73]
Total events: 28 (Higher omega 3), 27 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.37, df=1(P=0.54); I2=0%  
Test for overall effect: Z=0.09(P=0.93)  
Favours [high ALA] 1000.01 100.1 1 Favours low ALA
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
4.18.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - ALA 2010 78/2409 84/2428 74.35% 0.94[0.69,1.27]
MARGARIN 2002 1/109 1/157 0.9% 1.44[0.09,22.78]
Subtotal (95% CI) 2518 2585 75.24% 0.94[0.7,1.27]
Total events: 79 (Higher omega 3), 85 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.09, df=1(P=0.76); I2=0%  
Test for overall effect: Z=0.4(P=0.69)  
   
4.18.3 Long duration: ≥ 4 years in study  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 9292 9327 100% 0.96[0.74,1.25]
Total events: 107 (Higher omega 3), 112 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.53, df=3(P=0.91); I2=0%  
Test for overall effect: Z=0.3(P=0.76)  
Test for subgroup differences: Chi2=0.07, df=1 (P=0.78), I2=0%  
Favours [high ALA] 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.19.   Comparison 4 High vs low ALA omega-3 fat (primary outcomes),
Outcome 19 CVD mortality - ALA - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.19.1 Primary prevention  
Norwegian 1968 27/6716 27/6690 24.08% 1[0.58,1.7]
Subtotal (95% CI) 6716 6690 24.08% 1[0.58,1.7]
Total events: 27 (Higher omega 3), 27 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.01(P=0.99)  
   
4.19.2 Secondary prevention  
AlphaOmega - ALA 2010 78/2409 84/2428 74.35% 0.94[0.69,1.27]
FLAX-PAD 2013 1/58 0/52 0.68% 2.69[0.11,64.74]
MARGARIN 2002 1/109 1/157 0.9% 1.44[0.09,22.78]
Subtotal (95% CI) 2576 2637 75.92% 0.95[0.7,1.28]
Total events: 80 (Higher omega 3), 85 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.51, df=2(P=0.77); I2=0%  
Test for overall effect: Z=0.34(P=0.74)  
   
Total (95% CI) 9292 9327 100% 0.96[0.74,1.25]
Total events: 107 (Higher omega 3), 112 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.53, df=3(P=0.91); I2=0%  
Test for overall effect: Z=0.3(P=0.76)  
Test for subgroup differences: Chi2=0.02, df=1 (P=0.88), I2=0%  
Favours [high ALA] 1000.01 100.1 1 Favours low ALA
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Analysis 4.20.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 20 CVD mortality - ALA - subgroup by statin uses.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.20.1 ALA - ≥ 50% of control group on statins  
AlphaOmega - ALA 2010 78/2409 84/2428 74.35% 0.94[0.69,1.27]
FLAX-PAD 2013 1/58 0/52 0.68% 2.69[0.11,64.74]
Subtotal (95% CI) 2467 2480 75.02% 0.94[0.7,1.28]
Total events: 79 (Higher omega 3), 84 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.42, df=1(P=0.52); I2=0%  
Test for overall effect: Z=0.37(P=0.71)  
   
4.20.2 ALA - < 50% of control group on statins  
MARGARIN 2002 1/109 1/157 0.9% 1.44[0.09,22.78]
Norwegian 1968 27/6716 27/6690 24.08% 1[0.58,1.7]
Subtotal (95% CI) 6825 6847 24.98% 1.01[0.6,1.7]
Total events: 28 (Higher omega 3), 28 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.07, df=1(P=0.8); I2=0%  
Test for overall effect: Z=0.04(P=0.97)  
   
Total (95% CI) 9292 9327 100% 0.96[0.74,1.25]
Total events: 107 (Higher omega 3), 112 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.53, df=3(P=0.91); I2=0%  
Test for overall effect: Z=0.3(P=0.76)  
Test for subgroup differences: Chi2=0.05, df=1 (P=0.83), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 4.21.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 21 Cardiovascular events (overall) - ALA.
Study or subgroup Favours high-
er omega 3
Lower
omega 3 fats
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AlphaOmega - ALA 2010 319/2409 352/2428 78.63% 0.91[0.79,1.05]
FLAX-PAD 2013 5/58 4/52 0.98% 1.12[0.32,3.95]
MARGARIN 2002 2/109 9/157 0.68% 0.32[0.07,1.45]
Norwegian 1968 99/6716 87/6690 19.01% 1.13[0.85,1.51]
WAHA 2016 3/362 4/346 0.7% 0.72[0.16,3.18]
   
Total (95% CI) 9654 9673 100% 0.95[0.83,1.07]
Total events: 428 (Favours higher omega 3), 456 (Lower omega 3 fats)  
Heterogeneity: Tau2=0; Chi2=3.95, df=4(P=0.41); I2=0%  
Test for overall effect: Z=0.89(P=0.38)  
Favours higher omega 3 50.2 20.5 1 Favours lower omega 3
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Analysis 4.22.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 22 CVD events - ALA - SA fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
AlphaOmega - ALA 2010 319/2409 352/2428 77.32% 0.91[0.79,1.05]
FLAX-PAD 2013 5/58 4/52 0.93% 1.12[0.32,3.95]
MARGARIN 2002 2/109 9/157 1.63% 0.32[0.07,1.45]
Norwegian 1968 99/6716 87/6690 19.22% 1.13[0.85,1.51]
WAHA 2016 3/362 4/346 0.9% 0.72[0.16,3.18]
   
Total (95% CI) 9654 9673 100% 0.95[0.84,1.07]
Total events: 428 (Higher omega 3), 456 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.95, df=4(P=0.41); I2=0%  
Test for overall effect: Z=0.87(P=0.38)  
Favours [high ALA] 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.23.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 23 CVD events - ALA - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.23.1 Low risk of bias  
AlphaOmega - ALA 2010 319/2409 352/2428 78.63% 0.91[0.79,1.05]
FLAX-PAD 2013 5/58 4/52 0.98% 1.12[0.32,3.95]
MARGARIN 2002 2/109 9/157 0.68% 0.32[0.07,1.45]
Subtotal (95% CI) 2576 2637 80.29% 0.91[0.79,1.04]
Total events: 326 (Higher omega 3), 365 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.94, df=2(P=0.38); I2=0%  
Test for overall effect: Z=1.37(P=0.17)  
   
4.23.2 Moderate/high risk of bias  
Norwegian 1968 99/6716 87/6690 19.01% 1.13[0.85,1.51]
WAHA 2016 3/362 4/346 0.7% 0.72[0.16,3.18]
Subtotal (95% CI) 7078 7036 19.71% 1.12[0.84,1.48]
Total events: 102 (Higher omega 3), 91 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.35, df=1(P=0.55); I2=0%  
Test for overall effect: Z=0.76(P=0.45)  
   
Total (95% CI) 9654 9673 100% 0.95[0.83,1.07]
Total events: 428 (Higher omega 3), 456 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.95, df=4(P=0.41); I2=0%  
Test for overall effect: Z=0.89(P=0.38)  
Test for subgroup differences: Chi2=1.66, df=1 (P=0.2), I2=39.72%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
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Analysis 4.24.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 24 CVD events - ALA - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.24.1 SA - low risk of compliance bias  
AlphaOmega - ALA 2010 319/2409 352/2428 98.27% 0.91[0.79,1.05]
MARGARIN 2002 2/109 9/157 0.85% 0.32[0.07,1.45]
WAHA 2016 3/362 4/346 0.88% 0.72[0.16,3.18]
Subtotal (95% CI) 2880 2931 100% 0.9[0.79,1.04]
Total events: 324 (Higher omega 3), 365 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.93, df=2(P=0.38); I2=0%  
Test for overall effect: Z=1.43(P=0.15)  
   
4.24.2 SA - 100+ randomised  
AlphaOmega - ALA 2010 319/2409 352/2428 78.63% 0.91[0.79,1.05]
FLAX-PAD 2013 5/58 4/52 0.98% 1.12[0.32,3.95]
MARGARIN 2002 2/109 9/157 0.68% 0.32[0.07,1.45]
Norwegian 1968 99/6716 87/6690 19.01% 1.13[0.85,1.51]
WAHA 2016 3/362 4/346 0.7% 0.72[0.16,3.18]
Subtotal (95% CI) 9654 9673 100% 0.95[0.83,1.07]
Total events: 428 (Higher omega 3), 456 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.95, df=4(P=0.41); I2=0%  
Test for overall effect: Z=0.89(P=0.38)  
Test for subgroup differences: Chi2=0.22, df=1 (P=0.64), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.25.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 25 CVD events - ALA - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.25.1 ALA low < 5 g/d  
AlphaOmega - ALA 2010 319/2409 352/2428 78.63% 0.91[0.79,1.05]
Subtotal (95% CI) 2409 2428 78.63% 0.91[0.79,1.05]
Total events: 319 (Higher omega 3), 352 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.26(P=0.21)  
   
4.25.2 ALA high ≥ 5 g/d  
FLAX-PAD 2013 5/58 4/52 0.98% 1.12[0.32,3.95]
MARGARIN 2002 2/109 9/157 0.68% 0.32[0.07,1.45]
Norwegian 1968 99/6716 87/6690 19.01% 1.13[0.85,1.51]
WAHA 2016 3/362 4/346 0.7% 0.72[0.16,3.18]
Subtotal (95% CI) 7245 7245 21.37% 1.07[0.82,1.4]
Total events: 109 (Higher omega 3), 104 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.89, df=3(P=0.41); I2=0%  
Test for overall effect: Z=0.51(P=0.61)  
   
Total (95% CI) 9654 9673 100% 0.95[0.83,1.07]
Total events: 428 (Higher omega 3), 456 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.95, df=4(P=0.41); I2=0%  
Favours higher omega 3 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.89(P=0.38)  
Test for subgroup differences: Chi2=1.06, df=1 (P=0.3), I2=6.05%  
Favours higher omega 3 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 4.26.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 26 CVD events - ALA - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.26.1 N-3 replacing SFA  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.26.2 N-3 replacing MUFA  
AlphaOmega - ALA 2010 319/2409 352/2428 100% 0.91[0.79,1.05]
Subtotal (95% CI) 2409 2428 100% 0.91[0.79,1.05]
Total events: 319 (Higher omega 3), 352 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.26(P=0.21)  
   
4.26.3 N-3 replacing n-6  
MARGARIN 2002 2/109 9/157 32.11% 0.32[0.07,1.45]
Norwegian 1968 99/6716 87/6690 67.89% 1.13[0.85,1.51]
Subtotal (95% CI) 6825 6847 100% 0.76[0.24,2.41]
Total events: 101 (Higher omega 3), 96 (Lower omega 3)  
Heterogeneity: Tau2=0.49; Chi2=2.6, df=1(P=0.11); I2=61.56%  
Test for overall effect: Z=0.47(P=0.64)  
   
4.26.4 N-3 replacing carbohydrates/sugars  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.26.5 N-3 replacing nil/low n-3 placebo  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.26.6 Replacement unclear  
FLAX-PAD 2013 5/58 4/52 58.28% 1.12[0.32,3.95]
WAHA 2016 3/362 4/346 41.72% 0.72[0.16,3.18]
Subtotal (95% CI) 420 398 100% 0.93[0.36,2.43]
Total events: 8 (Higher omega 3), 8 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.2, df=1(P=0.65); I2=0%  
Test for overall effect: Z=0.15(P=0.88)  
Favours high ALA 1000.01 100.1 1 Favours low ALA
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for subgroup differences: Chi2=0.1, df=1 (P=0.95), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.27.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 27 CVD events - ALA - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.27.1 Dietary advice  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.27.2 Supplemental foods  
AlphaOmega - ALA 2010 319/2409 352/2428 78.63% 0.91[0.79,1.05]
Dodin 2005 0/101 0/98   Not estimable
FLAX-PAD 2013 5/58 4/52 0.98% 1.12[0.32,3.95]
MARGARIN 2002 2/109 9/157 0.68% 0.32[0.07,1.45]
WAHA 2016 3/362 4/346 0.7% 0.72[0.16,3.18]
Subtotal (95% CI) 3039 3081 80.99% 0.91[0.79,1.04]
Total events: 329 (Higher omega 3), 369 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.04, df=3(P=0.56); I2=0%  
Test for overall effect: Z=1.4(P=0.16)  
   
4.27.3 Supplements (capsule)  
Norwegian 1968 99/6716 87/6690 19.01% 1.13[0.85,1.51]
Subtotal (95% CI) 6716 6690 19.01% 1.13[0.85,1.51]
Total events: 99 (Higher omega 3), 87 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.86(P=0.39)  
   
4.27.4 Any combination  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 9755 9771 100% 0.95[0.83,1.07]
Total events: 428 (Higher omega 3), 456 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.95, df=4(P=0.41); I2=0%  
Test for overall effect: Z=0.89(P=0.38)  
Test for subgroup differences: Chi2=1.91, df=1 (P=0.17), I2=47.75%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
439
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Analysis 4.28.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 28 CVD events - ALA - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.28.1 Medium duration 1 to < 2 years in study  
FLAX-PAD 2013 5/58 4/52 0.98% 1.12[0.32,3.95]
Norwegian 1968 99/6716 87/6690 19.01% 1.13[0.85,1.51]
Subtotal (95% CI) 6774 6742 19.99% 1.13[0.86,1.5]
Total events: 104 (Higher omega 3), 91 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.99); I2=0%  
Test for overall effect: Z=0.88(P=0.38)  
   
4.28.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - ALA 2010 319/2409 352/2428 78.63% 0.91[0.79,1.05]
MARGARIN 2002 2/109 9/157 0.68% 0.32[0.07,1.45]
WAHA 2016 3/362 4/346 0.7% 0.72[0.16,3.18]
Subtotal (95% CI) 2880 2931 80.01% 0.9[0.79,1.04]
Total events: 324 (Higher omega 3), 365 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.93, df=2(P=0.38); I2=0%  
Test for overall effect: Z=1.43(P=0.15)  
   
4.28.3 Long duration: ≥ 4 years in study  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 9654 9673 100% 0.95[0.83,1.07]
Total events: 428 (Higher omega 3), 456 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.95, df=4(P=0.41); I2=0%  
Test for overall effect: Z=0.89(P=0.38)  
Test for subgroup differences: Chi2=2.02, df=1 (P=0.15), I2=50.61%  
Favours [high ALA] 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.29.   Comparison 4 High vs low ALA omega-3 fat (primary outcomes),
Outcome 29 CVD events - ALA - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.29.1 Primary prevention  
MARGARIN 2002 2/109 9/157 0.68% 0.32[0.07,1.45]
Norwegian 1968 99/6716 87/6690 19.01% 1.13[0.85,1.51]
WAHA 2016 3/362 4/346 0.7% 0.72[0.16,3.18]
Subtotal (95% CI) 7187 7193 20.39% 0.87[0.46,1.67]
Total events: 104 (Higher omega 3), 100 (Lower omega 3)  
Heterogeneity: Tau2=0.14; Chi2=2.89, df=2(P=0.24); I2=30.76%  
Test for overall effect: Z=0.41(P=0.68)  
   
4.29.2 Secondary prevention  
AlphaOmega - ALA 2010 319/2409 352/2428 78.63% 0.91[0.79,1.05]
FLAX-PAD 2013 5/58 4/52 0.98% 1.12[0.32,3.95]
Favours [high ALA] 1000.01 100.1 1 Favours low ALA
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 2467 2480 79.61% 0.92[0.8,1.05]
Total events: 324 (Higher omega 3), 356 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%  
Test for overall effect: Z=1.23(P=0.22)  
   
Total (95% CI) 9654 9673 100% 0.95[0.83,1.07]
Total events: 428 (Higher omega 3), 456 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.95, df=4(P=0.41); I2=0%  
Test for overall effect: Z=0.89(P=0.38)  
Test for subgroup differences: Chi2=0.02, df=1 (P=0.89), I2=0%  
Favours [high ALA] 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.30.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 30 CVD events - ALA - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.30.1 ALA - ≥ 50% of control group on statins  
AlphaOmega - ALA 2010 319/2409 352/2428 78.63% 0.91[0.79,1.05]
FLAX-PAD 2013 5/58 4/52 0.98% 1.12[0.32,3.95]
Subtotal (95% CI) 2467 2480 79.61% 0.92[0.8,1.05]
Total events: 324 (Higher omega 3), 356 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%  
Test for overall effect: Z=1.23(P=0.22)  
   
4.30.2 ALA - < 50% of control group on statins  
MARGARIN 2002 2/109 9/157 0.68% 0.32[0.07,1.45]
Norwegian 1968 99/6716 87/6690 19.01% 1.13[0.85,1.51]
WAHA 2016 3/362 4/346 0.7% 0.72[0.16,3.18]
Subtotal (95% CI) 7187 7193 20.39% 0.87[0.46,1.67]
Total events: 104 (Higher omega 3), 100 (Lower omega 3)  
Heterogeneity: Tau2=0.14; Chi2=2.89, df=2(P=0.24); I2=30.76%  
Test for overall effect: Z=0.41(P=0.68)  
   
Total (95% CI) 9654 9673 100% 0.95[0.83,1.07]
Total events: 428 (Higher omega 3), 456 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.95, df=4(P=0.41); I2=0%  
Test for overall effect: Z=0.89(P=0.38)  
Test for subgroup differences: Chi2=0.02, df=1 (P=0.89), I2=0%  
Favours higher omega 3 50.2 20.5 1 Favours lower omega 3
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Analysis 4.31.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 31 Coronary heart disease mortality (overall) - ALA.
Study or subgroup Favours high-
er omega 3
Lower
omega 3 fats
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AlphaOmega - ALA 2010 66/2409 72/2428 71.78% 0.92[0.66,1.28]
FLAX-PAD 2013 1/58 0/52 0.77% 2.69[0.11,64.74]
Norwegian 1968 27/6716 27/6690 27.45% 1[0.58,1.7]
   
Total (95% CI) 9183 9170 100% 0.95[0.72,1.26]
Total events: 94 (Favours higher omega 3), 99 (Lower omega 3 fats)  
Heterogeneity: Tau2=0; Chi2=0.47, df=2(P=0.79); I2=0%  
Test for overall effect: Z=0.35(P=0.72)  
Favours higher omega 3 1000.01 100.1 1 Favours lower omega 3
 
 
Analysis 4.32.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 32 CHD mortality - ALA - SA fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
AlphaOmega - ALA 2010 66/2409 72/2428 72.23% 0.92[0.66,1.28]
FLAX-PAD 2013 1/58 0/52 0.53% 2.69[0.11,64.74]
Norwegian 1968 27/6716 27/6690 27.24% 1[0.58,1.7]
   
Total (95% CI) 9183 9170 100% 0.95[0.72,1.26]
Total events: 94 (Higher omega 3), 99 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.47, df=2(P=0.79); I2=0%  
Test for overall effect: Z=0.34(P=0.73)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 4.33.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 33 CHD mortality - ALA - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.33.1 Low risk of bias  
AlphaOmega - ALA 2010 66/2409 72/2428 71.78% 0.92[0.66,1.28]
FLAX-PAD 2013 1/58 0/52 0.77% 2.69[0.11,64.74]
Subtotal (95% CI) 2467 2480 72.55% 0.93[0.67,1.3]
Total events: 67 (Higher omega 3), 72 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.43, df=1(P=0.51); I2=0%  
Test for overall effect: Z=0.41(P=0.68)  
   
4.33.2 Moderate/high risk of bias  
Norwegian 1968 27/6716 27/6690 27.45% 1[0.58,1.7]
Subtotal (95% CI) 6716 6690 27.45% 1[0.58,1.7]
Total events: 27 (Higher omega 3), 27 (Lower omega 3)  
Heterogeneity: Not applicable  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.01(P=0.99)  
   
Total (95% CI) 9183 9170 100% 0.95[0.72,1.26]
Total events: 94 (Higher omega 3), 99 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.47, df=2(P=0.79); I2=0%  
Test for overall effect: Z=0.35(P=0.72)  
Test for subgroup differences: Chi2=0.04, df=1 (P=0.84), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 4.34.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 34 CHD mortality - ALA - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.34.1 SA - low risk of compliance bias  
AlphaOmega - ALA 2010 66/2409 72/2428 100% 0.92[0.66,1.28]
Subtotal (95% CI) 2409 2428 100% 0.92[0.66,1.28]
Total events: 66 (Higher omega 3), 72 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.47(P=0.64)  
   
4.34.2 SA - 100+ randomised  
AlphaOmega - ALA 2010 66/2409 72/2428 71.78% 0.92[0.66,1.28]
FLAX-PAD 2013 1/58 0/52 0.77% 2.69[0.11,64.74]
Norwegian 1968 27/6716 27/6690 27.45% 1[0.58,1.7]
Subtotal (95% CI) 9183 9170 100% 0.95[0.72,1.26]
Total events: 94 (Higher omega 3), 99 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.47, df=2(P=0.79); I2=0%  
Test for overall effect: Z=0.35(P=0.72)  
Test for subgroup differences: Chi2=0.02, df=1 (P=0.9), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 4.35.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 35 CHD mortality - ALA - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.35.1 ALA low < 5 g/d  
AlphaOmega - ALA 2010 66/2409 72/2428 71.78% 0.92[0.66,1.28]
Subtotal (95% CI) 2409 2428 71.78% 0.92[0.66,1.28]
Total events: 66 (Higher omega 3), 72 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.47(P=0.64)  
   
4.35.2 ALA high ≥ 5 g/d  
FLAX-PAD 2013 1/58 0/52 0.77% 2.69[0.11,64.74]
Norwegian 1968 27/6716 27/6690 27.45% 1[0.58,1.7]
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 6774 6742 28.22% 1.02[0.61,1.73]
Total events: 28 (Higher omega 3), 27 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.37, df=1(P=0.54); I2=0%  
Test for overall effect: Z=0.09(P=0.93)  
   
Total (95% CI) 9183 9170 100% 0.95[0.72,1.26]
Total events: 94 (Higher omega 3), 99 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.47, df=2(P=0.79); I2=0%  
Test for overall effect: Z=0.35(P=0.72)  
Test for subgroup differences: Chi2=0.1, df=1 (P=0.75), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 4.36.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 36 CHD mortality - ALA - subgroup by replacement.
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.36.1 N-3 replacing SFA  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (High omega 3), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.36.2 Coronary heart mortality- ALA  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (High omega 3), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.36.3 N-3 replacing MUFA  
AlphaOmega - ALA 2010 66/2409 72/2428 100% 0.92[0.66,1.28]
Subtotal (95% CI) 2409 2428 100% 0.92[0.66,1.28]
Total events: 66 (High omega 3), 72 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.47(P=0.64)  
   
4.36.4 N-3 replacing n-6  
Norwegian 1968 27/6716 27/6690 100% 1[0.58,1.7]
Subtotal (95% CI) 6716 6690 100% 1[0.58,1.7]
Total events: 27 (High omega 3), 27 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.01(P=0.99)  
   
4.36.5 N-3 replacing carbohydrates/sugars  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (High omega 3), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Favours high ALA 1000.01 100.1 1 Favours low ALA
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Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.36.6 N-3 replacing nil/low n-3 placebo  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (High omega 3), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.36.7 Replacement unclear  
FLAX-PAD 2013 1/58 0/52 100% 2.69[0.11,64.74]
Subtotal (95% CI) 58 52 100% 2.69[0.11,64.74]
Total events: 1 (High omega 3), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.61(P=0.54)  
Test for subgroup differences: Chi2=0.47, df=1 (P=0.79), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.37.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 37 CHD mortality - ALA - subgroup by intervention type.
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.37.1 Dietary advice  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (High omega 3), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.37.2 Supplemental foods  
AlphaOmega - ALA 2010 66/2409 72/2428 71.78% 0.92[0.66,1.28]
FLAX-PAD 2013 1/58 0/52 0.77% 2.69[0.11,64.74]
Subtotal (95% CI) 2467 2480 72.55% 0.93[0.67,1.3]
Total events: 67 (High omega 3), 72 (Control)  
Heterogeneity: Tau2=0; Chi2=0.43, df=1(P=0.51); I2=0%  
Test for overall effect: Z=0.41(P=0.68)  
   
4.37.3 Supplements (capsule)  
Norwegian 1968 27/6716 27/6690 27.45% 1[0.58,1.7]
Subtotal (95% CI) 6716 6690 27.45% 1[0.58,1.7]
Total events: 27 (High omega 3), 27 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.01(P=0.99)  
   
4.37.4 Any combination  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (High omega 3), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 9183 9170 100% 0.95[0.72,1.26]
Total events: 94 (High omega 3), 99 (Control)  
Favours high ALA 1000.01 100.1 1 Favours low ALA
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Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=0.47, df=2(P=0.79); I2=0%  
Test for overall effect: Z=0.35(P=0.72)  
Test for subgroup differences: Chi2=0.04, df=1 (P=0.84), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.38.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 38 CHD mortality - ALA - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.38.1 Medium duration 1 to < 2 years in study  
FLAX-PAD 2013 1/58 0/52 0.77% 2.69[0.11,64.74]
Norwegian 1968 27/6716 27/6690 27.45% 1[0.58,1.7]
Subtotal (95% CI) 6774 6742 28.22% 1.02[0.61,1.73]
Total events: 28 (Higher omega 3), 27 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.37, df=1(P=0.54); I2=0%  
Test for overall effect: Z=0.09(P=0.93)  
   
4.38.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - ALA 2010 66/2409 72/2428 71.78% 0.92[0.66,1.28]
Subtotal (95% CI) 2409 2428 71.78% 0.92[0.66,1.28]
Total events: 66 (Higher omega 3), 72 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.47(P=0.64)  
   
4.38.3 Long duration: ≥ 4 years in study  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 9183 9170 100% 0.95[0.72,1.26]
Total events: 94 (Higher omega 3), 99 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.47, df=2(P=0.79); I2=0%  
Test for overall effect: Z=0.35(P=0.72)  
Test for subgroup differences: Chi2=0.1, df=1 (P=0.75), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 4.39.   Comparison 4 High vs low ALA omega-3 fat (primary outcomes),
Outcome 39 CHD mortality - ALA - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.39.1 Primary prevention of CVD  
Norwegian 1968 27/6716 27/6690 27.45% 1[0.58,1.7]
Subtotal (95% CI) 6716 6690 27.45% 1[0.58,1.7]
Total events: 27 (Higher omega 3), 27 (Lower omega 3)  
Favours higher omega 3 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.01(P=0.99)  
   
4.39.2 Secondary prevention of CVD  
AlphaOmega - ALA 2010 66/2409 72/2428 71.78% 0.92[0.66,1.28]
FLAX-PAD 2013 1/58 0/52 0.77% 2.69[0.11,64.74]
Subtotal (95% CI) 2467 2480 72.55% 0.93[0.67,1.3]
Total events: 67 (Higher omega 3), 72 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.43, df=1(P=0.51); I2=0%  
Test for overall effect: Z=0.41(P=0.68)  
   
Total (95% CI) 9183 9170 100% 0.95[0.72,1.26]
Total events: 94 (Higher omega 3), 99 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.47, df=2(P=0.79); I2=0%  
Test for overall effect: Z=0.35(P=0.72)  
Test for subgroup differences: Chi2=0.04, df=1 (P=0.84), I2=0%  
Favours higher omega 3 1 Favours lower omega 3
 
 
Analysis 4.40.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 40 CHD mortality - ALA - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.40.1 ALA - ≥ 50% of control group on statins  
AlphaOmega - ALA 2010 66/2409 72/2428 71.78% 0.92[0.66,1.28]
FLAX-PAD 2013 1/58 0/52 0.77% 2.69[0.11,64.74]
Subtotal (95% CI) 2467 2480 72.55% 0.93[0.67,1.3]
Total events: 67 (Higher omega 3), 72 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.43, df=1(P=0.51); I2=0%  
Test for overall effect: Z=0.41(P=0.68)  
   
4.40.2 ALA - < 50% of control group on statins  
Norwegian 1968 27/6716 27/6690 27.45% 1[0.58,1.7]
Subtotal (95% CI) 6716 6690 27.45% 1[0.58,1.7]
Total events: 27 (Higher omega 3), 27 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.01(P=0.99)  
   
Total (95% CI) 9183 9170 100% 0.95[0.72,1.26]
Total events: 94 (Higher omega 3), 99 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.47, df=2(P=0.79); I2=0%  
Test for overall effect: Z=0.35(P=0.72)  
Test for subgroup differences: Chi2=0.04, df=1 (P=0.84), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Analysis 4.41.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 41 CHD mortality - ALA - subgroup by CAD history.
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.41.1 Previous CAD  
AlphaOmega - ALA 2010 66/2409 72/2428 71.78% 0.92[0.66,1.28]
Subtotal (95% CI) 2409 2428 71.78% 0.92[0.66,1.28]
Total events: 66 (High omega 3), 72 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.47(P=0.64)  
   
4.41.2 No previous CAD  
FLAX-PAD 2013 1/58 0/52 0.77% 2.69[0.11,64.74]
Norwegian 1968 27/6716 27/6690 27.45% 1[0.58,1.7]
Subtotal (95% CI) 6774 6742 28.22% 1.02[0.61,1.73]
Total events: 28 (High omega 3), 27 (Control)  
Heterogeneity: Tau2=0; Chi2=0.37, df=1(P=0.54); I2=0%  
Test for overall effect: Z=0.09(P=0.93)  
   
Total (95% CI) 9183 9170 100% 0.95[0.72,1.26]
Total events: 94 (High omega 3), 99 (Control)  
Heterogeneity: Tau2=0; Chi2=0.47, df=2(P=0.79); I2=0%  
Test for overall effect: Z=0.35(P=0.72)  
Test for subgroup differences: Chi2=0.1, df=1 (P=0.75), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.42.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 42 Coronary heart disease events (overall) - ALA.
Study or subgroup Favours high-
er omega 3
Lower
omega 3 fats
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AlphaOmega - ALA 2010 121/2409 133/2428 64.43% 0.92[0.72,1.17]
FLAX-PAD 2013 1/58 3/52 0.79% 0.3[0.03,2.78]
Norwegian 1968 75/6716 63/6690 34.39% 1.19[0.85,1.65]
WAHA 2016 1/362 0/346 0.39% 2.87[0.12,70.16]
   
Total (95% CI) 9545 9516 100% 1[0.82,1.22]
Total events: 198 (Favours higher omega 3), 199 (Lower omega 3 fats)  
Heterogeneity: Tau2=0; Chi2=3.05, df=3(P=0.38); I2=1.59%  
Test for overall effect: Z=0.03(P=0.98)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Analysis 4.43.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 43 CHD events - ALA - SA fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
AlphaOmega - ALA 2010 121/2409 133/2428 66.48% 0.92[0.72,1.17]
FLAX-PAD 2013 1/58 3/52 1.59% 0.3[0.03,2.78]
Norwegian 1968 75/6716 63/6690 31.68% 1.19[0.85,1.65]
WAHA 2016 1/362 0/346 0.26% 2.87[0.12,70.16]
   
Total (95% CI) 9545 9516 100% 1[0.82,1.21]
Total events: 198 (Higher omega 3), 199 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.05, df=3(P=0.38); I2=1.59%  
Test for overall effect: Z=0.03(P=0.98)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 4.44.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 44 CHD events - ALA - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.44.1 Low risk of bias  
AlphaOmega - ALA 2010 121/2409 133/2428 64.43% 0.92[0.72,1.17]
FLAX-PAD 2013 1/58 3/52 0.79% 0.3[0.03,2.78]
Subtotal (95% CI) 2467 2480 65.22% 0.91[0.71,1.15]
Total events: 122 (Higher omega 3), 136 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.96, df=1(P=0.33); I2=0%  
Test for overall effect: Z=0.82(P=0.41)  
   
4.44.2 Moderate/high risk of bias  
Norwegian 1968 75/6716 63/6690 34.39% 1.19[0.85,1.65]
WAHA 2016 1/362 0/346 0.39% 2.87[0.12,70.16]
Subtotal (95% CI) 7078 7036 34.78% 1.2[0.86,1.67]
Total events: 76 (Higher omega 3), 63 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.29, df=1(P=0.59); I2=0%  
Test for overall effect: Z=1.06(P=0.29)  
   
Total (95% CI) 9545 9516 100% 1[0.82,1.22]
Total events: 198 (Higher omega 3), 199 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.05, df=3(P=0.38); I2=1.59%  
Test for overall effect: Z=0.03(P=0.98)  
Test for subgroup differences: Chi2=1.8, df=1 (P=0.18), I2=44.45%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
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Analysis 4.45.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 45 CHD events - ALA - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.45.1 SA - low risk of compliance bias  
AlphaOmega - ALA 2010 121/2409 133/2428 99.44% 0.92[0.72,1.17]
WAHA 2016 1/362 0/346 0.56% 2.87[0.12,70.16]
Subtotal (95% CI) 2771 2774 100% 0.92[0.73,1.17]
Total events: 122 (Higher omega 3), 133 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.49, df=1(P=0.49); I2=0%  
Test for overall effect: Z=0.66(P=0.51)  
   
4.45.2 SA - 100+ randomised  
AlphaOmega - ALA 2010 121/2409 133/2428 64.43% 0.92[0.72,1.17]
FLAX-PAD 2013 1/58 3/52 0.79% 0.3[0.03,2.78]
Norwegian 1968 75/6716 63/6690 34.39% 1.19[0.85,1.65]
WAHA 2016 1/362 0/346 0.39% 2.87[0.12,70.16]
Subtotal (95% CI) 9545 9516 100% 1[0.82,1.22]
Total events: 198 (Higher omega 3), 199 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.05, df=3(P=0.38); I2=1.59%  
Test for overall effect: Z=0.03(P=0.98)  
Test for subgroup differences: Chi2=0.24, df=1 (P=0.62), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.46.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 46 CHD events - ALA - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.46.1 ALA low < 5 g/d  
AlphaOmega - ALA 2010 121/2409 133/2428 64.43% 0.92[0.72,1.17]
Subtotal (95% CI) 2409 2428 64.43% 0.92[0.72,1.17]
Total events: 121 (Higher omega 3), 133 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.48)  
   
4.46.2 ALA high ≥ 5 g/d  
FLAX-PAD 2013 1/58 3/52 0.79% 0.3[0.03,2.78]
Norwegian 1968 75/6716 63/6690 34.39% 1.19[0.85,1.65]
WAHA 2016 1/362 0/346 0.39% 2.87[0.12,70.16]
Subtotal (95% CI) 7136 7088 35.57% 1.16[0.84,1.61]
Total events: 77 (Higher omega 3), 66 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.74, df=2(P=0.42); I2=0%  
Test for overall effect: Z=0.9(P=0.37)  
   
Total (95% CI) 9545 9516 100% 1[0.82,1.22]
Total events: 198 (Higher omega 3), 199 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.05, df=3(P=0.38); I2=1.59%  
Test for overall effect: Z=0.03(P=0.98)  
Test for subgroup differences: Chi2=1.31, df=1 (P=0.25), I2=23.38%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Analysis 4.47.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 47 CHD events - ALA - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.47.1 N-3 replacing SFA  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.47.2 N-3 replacing MUFA  
AlphaOmega - ALA 2010 121/2409 133/2428 100% 0.92[0.72,1.17]
Subtotal (95% CI) 2409 2428 100% 0.92[0.72,1.17]
Total events: 121 (Higher omega 3), 133 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.48)  
   
4.47.3 N-3 replacing n-6  
Norwegian 1968 75/6716 63/6690 100% 1.19[0.85,1.65]
Subtotal (95% CI) 6716 6690 100% 1.19[0.85,1.65]
Total events: 75 (Higher omega 3), 63 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1(P=0.32)  
   
4.47.4 N-3 replacing carbohydrates/sugars  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.47.5 N-3 replacing nil/low n-3 placebo  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.47.6 Replacement unclear  
FLAX-PAD 2013 1/58 3/52 63.31% 0.3[0.03,2.78]
WAHA 2016 1/362 0/346 36.69% 2.87[0.12,70.16]
Subtotal (95% CI) 420 398 100% 0.69[0.08,5.81]
Total events: 2 (Higher omega 3), 3 (Lower omega 3)  
Heterogeneity: Tau2=0.58; Chi2=1.29, df=1(P=0.26); I2=22.74%  
Test for overall effect: Z=0.35(P=0.73)  
Test for subgroup differences: Chi2=1.63, df=1 (P=0.44), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
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Analysis 4.48.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 48 CHD events - ALA - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.48.1 Dietary advice  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.48.2 Supplemental foods  
AlphaOmega - ALA 2010 121/2409 133/2428 64.43% 0.92[0.72,1.17]
FLAX-PAD 2013 1/58 3/52 0.79% 0.3[0.03,2.78]
WAHA 2016 1/362 0/346 0.39% 2.87[0.12,70.16]
Subtotal (95% CI) 2829 2826 65.61% 0.91[0.72,1.16]
Total events: 123 (Higher omega 3), 136 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.46, df=2(P=0.48); I2=0%  
Test for overall effect: Z=0.77(P=0.44)  
   
4.48.3 Supplements (capsule)  
Norwegian 1968 75/6716 63/6690 34.39% 1.19[0.85,1.65]
Subtotal (95% CI) 6716 6690 34.39% 1.19[0.85,1.65]
Total events: 75 (Higher omega 3), 63 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1(P=0.32)  
   
4.48.4 Any combination  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 9545 9516 100% 1[0.82,1.22]
Total events: 198 (Higher omega 3), 199 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.05, df=3(P=0.38); I2=1.59%  
Test for overall effect: Z=0.03(P=0.98)  
Test for subgroup differences: Chi2=1.59, df=1 (P=0.21), I2=37.23%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.49.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 49 CHD events - ALA - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.49.1 Medium duration 1 to < 2 years in study  
FLAX-PAD 2013 1/58 3/52 0.79% 0.3[0.03,2.78]
Norwegian 1968 75/6716 63/6690 34.39% 1.19[0.85,1.65]
Subtotal (95% CI) 6774 6742 35.19% 0.94[0.34,2.58]
Total events: 76 (Higher omega 3), 66 (Lower omega 3)  
Heterogeneity: Tau2=0.29; Chi2=1.43, df=1(P=0.23); I2=30.28%  
Test for overall effect: Z=0.12(P=0.91)  
Favours [high ALA] 1000.01 100.1 1 Favours low ALA
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
4.49.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - ALA 2010 121/2409 133/2428 64.43% 0.92[0.72,1.17]
WAHA 2016 1/362 0/346 0.39% 2.87[0.12,70.16]
Subtotal (95% CI) 2771 2774 64.81% 0.92[0.73,1.17]
Total events: 122 (Higher omega 3), 133 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.49, df=1(P=0.49); I2=0%  
Test for overall effect: Z=0.66(P=0.51)  
   
4.49.3 Long duration: ≥ 4 years in study  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 9545 9516 100% 1[0.82,1.22]
Total events: 198 (Higher omega 3), 199 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.05, df=3(P=0.38); I2=1.59%  
Test for overall effect: Z=0.03(P=0.98)  
Test for subgroup differences: Chi2=0, df=1 (P=0.97), I2=0%  
Favours [high ALA] 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.50.   Comparison 4 High vs low ALA omega-3 fat (primary outcomes),
Outcome 50 CHD events - ALA - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.50.1 Primary prevention  
Norwegian 1968 75/6716 63/6690 34.39% 1.19[0.85,1.65]
WAHA 2016 1/362 0/346 0.39% 2.87[0.12,70.16]
Subtotal (95% CI) 7078 7036 34.78% 1.2[0.86,1.67]
Total events: 76 (Higher omega 3), 63 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.29, df=1(P=0.59); I2=0%  
Test for overall effect: Z=1.06(P=0.29)  
   
4.50.2 Secondary prevention  
AlphaOmega - ALA 2010 121/2409 133/2428 64.43% 0.92[0.72,1.17]
FLAX-PAD 2013 1/58 3/52 0.79% 0.3[0.03,2.78]
Subtotal (95% CI) 2467 2480 65.22% 0.91[0.71,1.15]
Total events: 122 (Higher omega 3), 136 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.96, df=1(P=0.33); I2=0%  
Test for overall effect: Z=0.82(P=0.41)  
   
Total (95% CI) 9545 9516 100% 1[0.82,1.22]
Total events: 198 (Higher omega 3), 199 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.05, df=3(P=0.38); I2=1.59%  
Test for overall effect: Z=0.03(P=0.98)  
Test for subgroup differences: Chi2=1.8, df=1 (P=0.18), I2=44.45%  
Favours [high ALA] 1000.01 100.1 1 Favours low ALA
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Analysis 4.51.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 51 CHD events - ALA - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.51.1 ALA - ≥ 50% of control group on statins  
AlphaOmega - ALA 2010 121/2409 133/2428 64.43% 0.92[0.72,1.17]
FLAX-PAD 2013 1/58 3/52 0.79% 0.3[0.03,2.78]
Subtotal (95% CI) 2467 2480 65.22% 0.91[0.71,1.15]
Total events: 122 (Higher omega 3), 136 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.96, df=1(P=0.33); I2=0%  
Test for overall effect: Z=0.82(P=0.41)  
   
4.51.2 ALA - < 50% of control group on statins  
Norwegian 1968 75/6716 63/6690 34.39% 1.19[0.85,1.65]
WAHA 2016 1/362 0/346 0.39% 2.87[0.12,70.16]
Subtotal (95% CI) 7078 7036 34.78% 1.2[0.86,1.67]
Total events: 76 (Higher omega 3), 63 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.29, df=1(P=0.59); I2=0%  
Test for overall effect: Z=1.06(P=0.29)  
   
Total (95% CI) 9545 9516 100% 1[0.82,1.22]
Total events: 198 (Higher omega 3), 199 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=3.05, df=3(P=0.38); I2=1.59%  
Test for overall effect: Z=0.03(P=0.98)  
Test for subgroup differences: Chi2=1.8, df=1 (P=0.18), I2=44.45%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 4.52.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 52 CHD events - ALA - subgroup by CAD history.
Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.52.1 Previous CAD  
AlphaOmega - ALA 2010 121/2409 133/2428 64.43% 0.92[0.72,1.17]
Subtotal (95% CI) 2409 2428 64.43% 0.92[0.72,1.17]
Total events: 121 (High omega 3), 133 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.48)  
   
4.52.2 No previous CAD  
FLAX-PAD 2013 1/58 3/52 0.79% 0.3[0.03,2.78]
Norwegian 1968 75/6716 63/6690 34.39% 1.19[0.85,1.65]
WAHA 2016 1/362 0/346 0.39% 2.87[0.12,70.16]
Subtotal (95% CI) 7136 7088 35.57% 1.16[0.84,1.61]
Total events: 77 (High omega 3), 66 (Control)  
Heterogeneity: Tau2=0; Chi2=1.74, df=2(P=0.42); I2=0%  
Test for overall effect: Z=0.9(P=0.37)  
   
Total (95% CI) 9545 9516 100% 1[0.82,1.22]
Favours high ALA 1000.01 100.1 1 Favours low ALA
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Study or subgroup High omega 3 Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 198 (High omega 3), 199 (Control)  
Heterogeneity: Tau2=0; Chi2=3.05, df=3(P=0.38); I2=1.59%  
Test for overall effect: Z=0.03(P=0.98)  
Test for subgroup differences: Chi2=1.31, df=1 (P=0.25), I2=23.38%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.53.   Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 53 Stroke (overall) - ALA.
Study or subgroup Favours high-
er omega 3
Lower
omega 3 fats
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AlphaOmega - ALA 2010 10/2409 11/2428 42.84% 0.92[0.39,2.15]
FLAX-PAD 2013 3/58 1/52 6.28% 2.69[0.29,25.06]
MARGARIN 2002 0/109 2/157 3.42% 0.29[0.01,5.93]
Norwegian 1968 13/6716 9/6690 43.38% 1.44[0.62,3.36]
WAHA 2016 1/362 1/346 4.08% 0.96[0.06,15.22]
   
Total (95% CI) 9654 9673 100% 1.15[0.66,2.01]
Total events: 27 (Favours higher omega 3), 24 (Lower omega 3 fats)  
Heterogeneity: Tau2=0; Chi2=1.92, df=4(P=0.75); I2=0%  
Test for overall effect: Z=0.48(P=0.63)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 4.54.   Comparison 4 High vs low ALA omega-3 fat
(primary outcomes), Outcome 54 Stroke - ALA - SA fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 43.05% 1.11[0.47,2.62]
FLAX-PAD 2013 3/58 1/52 4.57% 2.69[0.29,25.06]
MARGARIN 2002 0/109 2/157 8.89% 0.29[0.01,5.93]
Norwegian 1968 13/6716 9/6690 39.06% 1.44[0.62,3.36]
WAHA 2016 1/362 1/346 4.43% 0.96[0.06,15.22]
   
Total (95% CI) 9649 9678 100% 1.23[0.71,2.13]
Total events: 28 (Higher omega 3), 23 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.57, df=4(P=0.81); I2=0%  
Test for overall effect: Z=0.74(P=0.46)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Analysis 4.55.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 55 Stroke - ALA - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.55.1 Low risk of bias  
AlphaOmega - ALA 2010 10/2409 11/2428 42.84% 0.92[0.39,2.15]
FLAX-PAD 2013 3/58 1/52 6.28% 2.69[0.29,25.06]
MARGARIN 2002 0/109 2/157 3.42% 0.29[0.01,5.93]
Subtotal (95% CI) 2576 2637 52.54% 0.97[0.45,2.09]
Total events: 13 (Higher omega 3), 14 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.44, df=2(P=0.49); I2=0%  
Test for overall effect: Z=0.09(P=0.93)  
   
4.55.2 Moderate/high risk of bias  
Norwegian 1968 13/6716 9/6690 43.38% 1.44[0.62,3.36]
WAHA 2016 1/362 1/346 4.08% 0.96[0.06,15.22]
Subtotal (95% CI) 7078 7036 47.46% 1.39[0.62,3.13]
Total events: 14 (Higher omega 3), 10 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.08, df=1(P=0.78); I2=0%  
Test for overall effect: Z=0.79(P=0.43)  
   
Total (95% CI) 9654 9673 100% 1.15[0.66,2.01]
Total events: 27 (Higher omega 3), 24 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.92, df=4(P=0.75); I2=0%  
Test for overall effect: Z=0.48(P=0.63)  
Test for subgroup differences: Chi2=0.4, df=1 (P=0.53), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.56.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 56 Stroke - ALA - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.56.1 SA - low risk of compliance bias  
AlphaOmega - ALA 2010 10/2409 11/2428 28.5% 0.92[0.39,2.15]
MARGARIN 2002 0/109 2/157 2.27% 0.29[0.01,5.93]
WAHA 2016 1/362 1/346 2.72% 0.96[0.06,15.22]
Subtotal (95% CI) 2880 2931 33.48% 0.85[0.39,1.87]
Total events: 11 (Higher omega 3), 14 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.53, df=2(P=0.77); I2=0%  
Test for overall effect: Z=0.4(P=0.69)  
   
4.56.2 SA - 100+ randomised  
AlphaOmega - ALA 2010 10/2409 11/2428 28.5% 0.92[0.39,2.15]
FLAX-PAD 2013 3/58 1/52 4.18% 2.69[0.29,25.06]
MARGARIN 2002 0/109 2/157 2.27% 0.29[0.01,5.93]
Norwegian 1968 13/6716 9/6690 28.85% 1.44[0.62,3.36]
WAHA 2016 1/362 1/346 2.72% 0.96[0.06,15.22]
Subtotal (95% CI) 9654 9673 66.52% 1.15[0.66,2.01]
Total events: 27 (Higher omega 3), 24 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.92, df=4(P=0.75); I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.48(P=0.63)  
   
Total (95% CI) 12534 12604 100% 1.04[0.66,1.64]
Total events: 38 (Higher omega 3), 38 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=2.83, df=7(P=0.9); I2=0%  
Test for overall effect: Z=0.16(P=0.87)  
Test for subgroup differences: Chi2=0.37, df=1 (P=0.54), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.57.   Comparison 4 High vs low ALA omega-3 fat
(primary outcomes), Outcome 57 Stroke - ALA - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.57.1 ALA low < 5 g/d  
AlphaOmega - ALA 2010 10/2409 11/2428 100% 0.92[0.39,2.15]
Subtotal (95% CI) 2409 2428 100% 0.92[0.39,2.15]
Total events: 10 (Higher omega 3), 11 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.2(P=0.84)  
   
4.57.2 ALA high ≥ 5 g/d  
FLAX-PAD 2013 3/58 1/52 10.99% 2.69[0.29,25.06]
MARGARIN 2002 0/109 2/157 5.98% 0.29[0.01,5.93]
Norwegian 1968 13/6716 9/6690 75.89% 1.44[0.62,3.36]
WAHA 2016 1/362 1/346 7.14% 0.96[0.06,15.22]
Subtotal (95% CI) 7245 7245 100% 1.36[0.65,2.85]
Total events: 17 (Higher omega 3), 13 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.46, df=3(P=0.69); I2=0%  
Test for overall effect: Z=0.81(P=0.42)  
Test for subgroup differences: Chi2=0.47, df=1 (P=0.49), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 4.58.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 58 Stroke - ALA - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.58.1 N-3 replacing SFA  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.58.2 N-3 replacing MUFA  
AlphaOmega - ALA 2010 10/2409 11/2428 100% 0.92[0.39,2.15]
Subtotal (95% CI) 2409 2428 100% 0.92[0.39,2.15]
Favours high ALA 1000.01 100.1 1 Favours low ALA
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 10 (Higher omega 3), 11 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.2(P=0.84)  
   
4.58.3 N-3 replacing n-6  
MARGARIN 2002 0/109 2/157 8.13% 0.29[0.01,5.93]
Norwegian 1968 13/6716 9/6690 91.87% 1.44[0.62,3.36]
Subtotal (95% CI) 6825 6847 100% 1.26[0.53,3.01]
Total events: 13 (Higher omega 3), 11 (Lower omega 3)  
Heterogeneity: Tau2=0.03; Chi2=1.02, df=1(P=0.31); I2=1.94%  
Test for overall effect: Z=0.53(P=0.6)  
   
4.58.4 N-3 replacing carbohydrates/sugars  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.58.5 N-3 replacing nil/low n-3 placebo  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.58.6 Replacement unclear  
FLAX-PAD 2013 3/58 1/52 60.6% 2.69[0.29,25.06]
WAHA 2016 1/362 1/346 39.4% 0.96[0.06,15.22]
Subtotal (95% CI) 420 398 100% 1.79[0.31,10.17]
Total events: 4 (Higher omega 3), 2 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.33, df=1(P=0.57); I2=0%  
Test for overall effect: Z=0.66(P=0.51)  
Test for subgroup differences: Chi2=0.56, df=1 (P=0.75), I2=0%  
Favours high ALA 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.59.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 59 Stroke - ALA - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.59.1 Dietary advice  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.59.2 Supplemental foods  
AlphaOmega - ALA 2010 10/2409 11/2428 42.84% 0.92[0.39,2.15]
FLAX-PAD 2013 3/58 1/52 6.28% 2.69[0.29,25.06]
MARGARIN 2002 0/109 2/157 3.42% 0.29[0.01,5.93]
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
WAHA 2016 1/362 1/346 4.08% 0.96[0.06,15.22]
Subtotal (95% CI) 2938 2983 56.62% 0.97[0.46,2.03]
Total events: 14 (Higher omega 3), 15 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.44, df=3(P=0.7); I2=0%  
Test for overall effect: Z=0.09(P=0.93)  
   
4.59.3 Supplements (capsule)  
Norwegian 1968 13/6716 9/6690 43.38% 1.44[0.62,3.36]
Subtotal (95% CI) 6716 6690 43.38% 1.44[0.62,3.36]
Total events: 13 (Higher omega 3), 9 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.84(P=0.4)  
   
4.59.4 Any combination  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 9654 9673 100% 1.15[0.66,2.01]
Total events: 27 (Higher omega 3), 24 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.92, df=4(P=0.75); I2=0%  
Test for overall effect: Z=0.48(P=0.63)  
Test for subgroup differences: Chi2=0.48, df=1 (P=0.49), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 4.60.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 60 Stroke - ALA - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.60.1 Medium duration 1 to < 2 years in study  
FLAX-PAD 2013 3/58 1/52 6.28% 2.69[0.29,25.06]
Norwegian 1968 13/6716 9/6690 43.38% 1.44[0.62,3.36]
Subtotal (95% CI) 6774 6742 49.66% 1.56[0.7,3.44]
Total events: 16 (Higher omega 3), 10 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.26, df=1(P=0.61); I2=0%  
Test for overall effect: Z=1.09(P=0.27)  
   
4.60.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - ALA 2010 10/2409 11/2428 42.84% 0.92[0.39,2.15]
MARGARIN 2002 0/109 2/157 3.42% 0.29[0.01,5.93]
WAHA 2016 1/362 1/346 4.08% 0.96[0.06,15.22]
Subtotal (95% CI) 2880 2931 50.34% 0.85[0.39,1.87]
Total events: 11 (Higher omega 3), 14 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.53, df=2(P=0.77); I2=0%  
Test for overall effect: Z=0.4(P=0.69)  
   
4.60.3 Long duration: ≥ 4 years in study  
Favours [high ALA] 1000.01 100.1 1 Favours low ALA
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 9654 9673 100% 1.15[0.66,2.01]
Total events: 27 (Higher omega 3), 24 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.92, df=4(P=0.75); I2=0%  
Test for overall effect: Z=0.48(P=0.63)  
Test for subgroup differences: Chi2=1.13, df=1 (P=0.29), I2=11.19%  
Favours [high ALA] 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.61.   Comparison 4 High vs low ALA omega-3 fat (primary outcomes),
Outcome 61 Stroke - ALA - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.61.1 Primary prevention  
MARGARIN 2002 0/109 2/157 3.42% 0.29[0.01,5.93]
Norwegian 1968 13/6716 9/6690 43.38% 1.44[0.62,3.36]
WAHA 2016 1/362 1/346 4.08% 0.96[0.06,15.22]
Subtotal (95% CI) 7187 7193 50.88% 1.25[0.57,2.74]
Total events: 14 (Higher omega 3), 12 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.06, df=2(P=0.59); I2=0%  
Test for overall effect: Z=0.56(P=0.58)  
   
4.61.2 Secondary prevention  
AlphaOmega - ALA 2010 10/2409 11/2428 42.84% 0.92[0.39,2.15]
FLAX-PAD 2013 3/58 1/52 6.28% 2.69[0.29,25.06]
Subtotal (95% CI) 2467 2480 49.12% 1.05[0.47,2.34]
Total events: 13 (Higher omega 3), 12 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.78, df=1(P=0.38); I2=0%  
Test for overall effect: Z=0.12(P=0.9)  
   
Total (95% CI) 9654 9673 100% 1.15[0.66,2.01]
Total events: 27 (Higher omega 3), 24 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.92, df=4(P=0.75); I2=0%  
Test for overall effect: Z=0.48(P=0.63)  
Test for subgroup differences: Chi2=0.09, df=1 (P=0.76), I2=0%  
Favours [high ALA] 1000.01 100.1 1 Favours low ALA
 
 
Analysis 4.62.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 62 Stroke - ALA - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.62.1 ALA - ≥ 50% of control group on statins  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AlphaOmega - EPA+DHA 2010 11/2404 10/2433 42.84% 1.11[0.47,2.62]
FLAX-PAD 2013 3/58 1/52 6.28% 2.69[0.29,25.06]
Subtotal (95% CI) 2462 2485 49.12% 1.25[0.56,2.77]
Total events: 14 (Higher omega 3), 11 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.52, df=1(P=0.47); I2=0%  
Test for overall effect: Z=0.54(P=0.59)  
   
4.62.2 ALA - < 50% of control group on statins  
MARGARIN 2002 0/109 2/157 3.42% 0.29[0.01,5.93]
Norwegian 1968 13/6716 9/6690 43.38% 1.44[0.62,3.36]
WAHA 2016 1/362 1/346 4.08% 0.96[0.06,15.22]
Subtotal (95% CI) 7187 7193 50.88% 1.25[0.57,2.74]
Total events: 14 (Higher omega 3), 12 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.06, df=2(P=0.59); I2=0%  
Test for overall effect: Z=0.56(P=0.58)  
   
Total (95% CI) 9649 9678 100% 1.25[0.71,2.18]
Total events: 28 (Higher omega 3), 23 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.57, df=4(P=0.81); I2=0%  
Test for overall effect: Z=0.78(P=0.44)  
Test for subgroup differences: Chi2=0, df=1 (P=1), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 4.63.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 63 Stroke - ALA - subgroup by stroke type.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.63.1 Ischaemic stroke - ALA  
FLAX-PAD 2013 3/58 1/52 11.83% 2.69[0.29,25.06]
MARGARIN 2002 0/109 2/157 6.43% 0.29[0.01,5.93]
Norwegian 1968 13/6716 9/6690 81.73% 1.44[0.62,3.36]
Subtotal (95% CI) 6883 6899 100% 1.4[0.65,3.01]
Total events: 16 (Higher omega 3), 12 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.39, df=2(P=0.5); I2=0%  
Test for overall effect: Z=0.85(P=0.39)  
   
4.63.2 Haemorrhagic stroke - ALA  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 6883 6899 100% 1.4[0.65,3.01]
Total events: 16 (Higher omega 3), 12 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.39, df=2(P=0.5); I2=0%  
Test for overall effect: Z=0.85(P=0.39)  
Test for subgroup differences: Not applicable  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Analysis 4.64.   Comparison 4 High vs low ALA omega-3 fat
(primary outcomes), Outcome 64 Arrythmia (overall) - ALA.
Study or subgroup Favours high-
er omega 3
Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.64.1 ALA - new arrhythmias  
AlphaOmega - ALA 2010 62/2409 79/2428 100% 0.79[0.57,1.1]
Subtotal (95% CI) 2409 2428 100% 0.79[0.57,1.1]
Total events: 62 (Favours higher omega 3), 79 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.4(P=0.16)  
   
4.64.2 ALA - recurrent arrhythmias  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Favours higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 2409 2428 100% 0.79[0.57,1.1]
Total events: 62 (Favours higher omega 3), 79 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.4(P=0.16)  
Test for subgroup differences: Not applicable  
Favours higher omega 3 20.5 1.50.7 1 Favours lower omega 3
 
 
Analysis 4.65.   Comparison 4 High vs low ALA omega-3 fat (primary
outcomes), Outcome 65 Arrhythmia - ALA - SA by summary risk of bias.
Study or subgroup Favours high-
er omega 3
Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.65.1 Low risk of bias  
AlphaOmega - ALA 2010 62/2409 79/2428 100% 0.79[0.57,1.1]
Subtotal (95% CI) 2409 2428 100% 0.79[0.57,1.1]
Total events: 62 (Favours higher omega 3), 79 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.4(P=0.16)  
   
4.65.2 Moderate/high risk of bias  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Favours higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 2409 2428 100% 0.79[0.57,1.1]
Total events: 62 (Favours higher omega 3), 79 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.4(P=0.16)  
Test for subgroup differences: Not applicable  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Comparison 5.   High vs low ALA omega-3 fat (secondary outcomes)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 MACCEs - ALA 1 110 Risk Ratio (M-H, Random,
95% CI)
1.12 [0.32, 3.95]
2 Myocardial infarction (overall) - ALA 3 18353 Risk Ratio (M-H, Random,
95% CI)
1.00 [0.76, 1.32]
3 Total MI - ALA - subgroup by fatality 3   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
3.1 Fatal MI 2 4947 Risk Ratio (M-H, Random,
95% CI)
0.95 [0.62, 1.46]
3.2 Non-fatal MI 3 5213 Risk Ratio (M-H, Random,
95% CI)
0.52 [0.15, 1.77]
4 Angina - ALA 2 13516 Risk Ratio (M-H, Random,
95% CI)
1.41 [0.75, 2.64]
5 Revascularisation - ALA 1   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
5.1 CABG - ALA 1 266 Risk Ratio (M-H, Random,
95% CI)
0.29 [0.01, 5.93]
5.2 Angioplasty - ALA 0 0 Risk Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
5.3 Any revascularisation - ALA 1 266 Risk Ratio (M-H, Random,
95% CI)
0.72 [0.07, 7.84]
6 Peripheral arterial disease - ALA 1   Risk Ratio (M-H, Random,
95% CI)
Subtotals only
7 Body weight, kg - ALA 4 664 Mean Difference (IV, Ran-
dom, 95% CI)
-1.49 [-4.17, 1.18]
8 Weight, kg - ALA - sensitivity analysis (SA) fixed-
effect
4 664 Mean Difference (IV, Fixed,
95% CI)
0.17 [-0.61, 0.96]
9 Weight, kg - ALA - SA by summary risk of bias 4   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
9.1 Low risk of bias 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
9.2 Moderate/high risk of bias 4 664 Mean Difference (IV, Ran-
dom, 95% CI)
-1.49 [-4.17, 1.18]
10 Weight, kg - ALA - SA by compliance and study
size
3   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
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No. of
partici-
pants
Statistical method Effect size
10.1 SA - low risk of compliance bias 3 629 Mean Difference (IV, Ran-
dom, 95% CI)
-1.59 [-4.47, 1.30]
10.2 SA - 100+ randomised 3 629 Mean Difference (IV, Ran-
dom, 95% CI)
-1.59 [-4.47, 1.30]
11 Weight, kg - ALA - subgroup by dose 4   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
11.1 ALA low < 5 g/d 3 485 Mean Difference (IV, Ran-
dom, 95% CI)
-0.71 [-3.31, 1.90]
11.2 ALA high > 5 g/d 1 179 Mean Difference (IV, Ran-
dom, 95% CI)
-4.20 [-7.61, -0.79]
12 Weight, kg - ALA - subgroup by intervention
type
4   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
12.1 Dietary advice 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
12.2 Supplemental foods 3 526 Mean Difference (IV, Ran-
dom, 95% CI)
-1.23 [-5.27, 2.80]
12.3 Supplement (capsule) 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
12.4 Any combination 1 138 Mean Difference (IV, Ran-
dom, 95% CI)
-1.98 [-5.89, 1.92]
13 Weight, kg - ALA - subgroup by replacement 4   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
13.1 ALA replacing SFA 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
13.2 ALA replacing MUFA 1 138 Mean Difference (IV, Ran-
dom, 95% CI)
-1.98 [-5.89, 1.92]
13.3 ALA replacing n-6 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
13.4 ALA replacing carbs/sugars 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
13.5 ALA replacing nil/low n-3 placebo 1 35 Mean Difference (IV, Ran-
dom, 95% CI)
-0.30 [-10.57, 9.97]
13.6 Replacement unclear 2 491 Mean Difference (IV, Ran-
dom, 95% CI)
-1.43 [-6.26, 3.39]
14 Weight, kg - ALA - subgroup by duration 4   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
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studies
No. of
partici-
pants
Statistical method Effect size
14.1 Medium duration 1 to < 2 years in study 4 664 Mean Difference (IV, Ran-
dom, 95% CI)
-1.49 [-4.17, 1.18]
14.2 Medium-long duration: 2 to < 4 years in
study
0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
14.3 Long duration ≥ 4 years in study 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
15 Weight, kg - ALA - subgroup by statin use 4   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
15.1 ALA - ≥ 50% of control group on statins 1 35 Mean Difference (IV, Ran-
dom, 95% CI)
-0.30 [-10.57, 9.97]
15.2 ALA - < 50% of control group on statins 1 138 Mean Difference (IV, Ran-
dom, 95% CI)
-1.98 [-5.89, 1.92]
15.3 ALA - use of statins unclear 2 491 Mean Difference (IV, Ran-
dom, 95% CI)
-1.43 [-6.26, 3.39]
16 Weight, kg - ALA - subgroup by primary or sec-
ondary prevention
4   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
16.1 Low CVD risk 3 629 Mean Difference (IV, Ran-
dom, 95% CI)
-1.59 [-4.47, 1.30]
16.2 Moderate CVD risk 1 35 Mean Difference (IV, Ran-
dom, 95% CI)
-0.30 [-10.57, 9.97]
16.3 High CVD risk 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
17 Body mass index, kg/m2 - ALA 3 1581 Mean Difference (IV, Ran-
dom, 95% CI)
-0.42 [-1.53, 0.69]
18 BMI, kg/m2 - ALA - SA fixed-effect 3 1581 Mean Difference (IV, Fixed,
95% CI)
0.12 [-0.06, 0.30]
19 BMI, kg/m2 - ALA - SA by summary risk of bias 3   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
19.1 Low risk of bias 2 1402 Mean Difference (IV, Ran-
dom, 95% CI)
0.15 [-0.04, 0.33]
19.2 Moderate/high risk of bias 1 179 Mean Difference (IV, Ran-
dom, 95% CI)
-1.5 [-2.86, -0.14]
20 BMI, kg/m2 - ALA - SA by compliance and
study size
3   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
20.1 SA - low risk of compliance bias 3 1581 Mean Difference (IV, Ran-
dom, 95% CI)
-0.42 [-1.53, 0.69]
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studies
No. of
partici-
pants
Statistical method Effect size
20.2 SA - 100+ randomised 3 1581 Mean Difference (IV, Ran-
dom, 95% CI)
-0.42 [-1.53, 0.69]
21 BMI, kg/m2 - ALA - subgroup by dose 3   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
21.1 ALA low < 5 g/d 1 1260 Mean Difference (IV, Ran-
dom, 95% CI)
0.15 [-0.03, 0.33]
21.2 ALA high > 5 g/d 2 321 Mean Difference (IV, Ran-
dom, 95% CI)
-1.12 [-2.24, 0.01]
22 BMI, kg/m2 - ALA - subgroup by intervention
type
3   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
22.1 Dietary advice 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
22.2 Supplemental foods 3 1581 Mean Difference (IV, Ran-
dom, 95% CI)
-0.42 [-1.53, 0.69]
22.3 Supplement (capsule) 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
22.4 Any combination 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
23 BMI, kg/m2 - ALA - subgroup by replacement 3 1581 Mean Difference (IV, Ran-
dom, 95% CI)
-0.42 [-1.53, 0.69]
23.1 ALA replacing SFA 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
23.2 ALA replacing MUFA 1 1260 Mean Difference (IV, Ran-
dom, 95% CI)
0.15 [-0.03, 0.33]
23.3 ALA replacing n-6 1 142 Mean Difference (IV, Ran-
dom, 95% CI)
-0.3 [-2.29, 1.69]
23.4 ALA replacing carbs/sugars 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
23.5 ALA replacing nil/low n-3 placebo 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
23.6 Replacement unclear 1 179 Mean Difference (IV, Ran-
dom, 95% CI)
-1.5 [-2.86, -0.14]
24 BMI, kg/m2 - ALA - subgroup by duration 3   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
24.1 Medium duration 1 to < 2 years in study 1 179 Mean Difference (IV, Ran-
dom, 95% CI)
-1.5 [-2.86, -0.14]
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studies
No. of
partici-
pants
Statistical method Effect size
24.2 Medium-long duration: 2 to < 4 years in
study
2 1402 Mean Difference (IV, Ran-
dom, 95% CI)
0.15 [-0.04, 0.33]
24.3 Long duration ≥ 4 years in study 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
25 BMI, kg/m2 - ALA - subgroup by statin use 3   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
25.1 ALA - ≥ 50% of control group on statins 1 1260 Mean Difference (IV, Ran-
dom, 95% CI)
0.15 [-0.03, 0.33]
25.2 ALA - < 50% of control group on statins 1 142 Mean Difference (IV, Ran-
dom, 95% CI)
-0.3 [-2.29, 1.69]
25.3 ALA - use of statins unclear 1 179 Mean Difference (IV, Ran-
dom, 95% CI)
-1.5 [-2.86, -0.14]
26 BMI, kg/m2 - ALA - subgroup by primary or
secondary preventionA
3   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
26.1 Primary prevention of CVD 2 321 Mean Difference (IV, Ran-
dom, 95% CI)
-1.12 [-2.24, 0.01]
26.2 Secondary prevention of CVD 1 1260 Mean Difference (IV, Ran-
dom, 95% CI)
0.15 [-0.03, 0.33]
27 Other measures of adiposity - ALA 4   Mean Difference (IV, Fixed,
95% CI)
Subtotals only
27.1 Visceral adipose tissue, cm2 1 35 Mean Difference (IV, Fixed,
95% CI)
27.0 [-21.28, 75.28]
27.2 Subcutaneous adipose tissue, cm2 1 35 Mean Difference (IV, Fixed,
95% CI)
0.0 [0.0, 0.0]
27.3 Waist circumference, cm 3 629 Mean Difference (IV, Fixed,
95% CI)
-1.59 [-3.10, -0.07]
28 Total cholesterol, serum, mmoL/L - ALA 6 2164 Mean Difference (IV, Ran-
dom, 95% CI)
-0.09 [-0.23, 0.05]
29 TC, mmoL/L - ALA - SA fixed-effect 6 2164 Mean Difference (IV, Fixed,
95% CI)
-0.10 [-0.17, -0.03]
30 TC, mmoL/L - ALA - SA by summary risk of
bias
6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
30.1 Low risk of bias 3 1436 Mean Difference (IV, Ran-
dom, 95% CI)
0.00 [-0.13, 0.14]
30.2 Moderate/high risk of bias 3 728 Mean Difference (IV, Ran-
dom, 95% CI)
-0.19 [-0.36, -0.01]
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
467
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
31 TC, mmoL/L - ALA - SA by compliance and
study size
4   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
31.1 SA - low risk of compliance bias 4 2045 Mean Difference (IV, Ran-
dom, 95% CI)
-0.10 [-0.25, 0.05]
31.2 SA - 100+ randomised 4 2045 Mean Difference (IV, Ran-
dom, 95% CI)
-0.10 [-0.25, 0.05]
32 TC, mmoL/L - ALA - subgroup by dose 6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
32.1 ALA low < 5 g/d 3 1759 Mean Difference (IV, Ran-
dom, 95% CI)
-0.07 [-0.24, 0.09]
32.2 ALA high > 5 g/d 3 405 Mean Difference (IV, Ran-
dom, 95% CI)
-0.13 [-0.47, 0.21]
33 TC, mmoL/L - ALA - subgroup by intervention
type
6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
33.1 Dietary advice 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
33.2 Supplemental foods 6 2164 Mean Difference (IV, Ran-
dom, 95% CI)
-0.09 [-0.23, 0.05]
33.3 Supplement (capsule) 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
33.4 Any combination 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
34 TC, mmoL/L - ALA - subgroup by replacement 6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
34.1 ALA replacing SFA 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
34.2 ALA replacing MUFA 1 1210 Mean Difference (IV, Ran-
dom, 95% CI)
-0.02 [-0.13, 0.09]
34.3 ALA replacing n-6 1 142 Mean Difference (IV, Ran-
dom, 95% CI)
0.14 [-0.10, 0.38]
34.4 ALA replacing carbs/sugars 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
34.5 ALA replacing nil/low n-3 placebo 1 35 Mean Difference (IV, Ran-
dom, 95% CI)
0.30 [-0.30, 0.90]
34.6 Replacement unclear 3 777 Mean Difference (IV, Ran-
dom, 95% CI)
-0.21 [-0.31, -0.11]
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35 TC, mmoL/L - ALA - subgroup by duration 6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
35.1 Medium duration 1 to < 2 years in study 4 812 Mean Difference (IV, Ran-
dom, 95% CI)
-0.20 [-0.33, -0.07]
35.2 Medium-long duration: 2 to < 4 years in
study
2 1352 Mean Difference (IV, Ran-
dom, 95% CI)
0.02 [-0.12, 0.16]
35.3 Long duration ≥ 4 years in study 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
36 TC, mmoL/L - ALA - subgroup by statin use 6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
36.1 ALA - ≥ 50% of control group on statins 3 1329 Mean Difference (IV, Ran-
dom, 95% CI)
-0.02 [-0.15, 0.11]
36.2 ALA - < 50% of control group on statins 1 142 Mean Difference (IV, Ran-
dom, 95% CI)
0.14 [-0.10, 0.38]
36.3 ALA - use of statins unclear 2 693 Mean Difference (IV, Ran-
dom, 95% CI)
-0.21 [-0.30, -0.11]
37 TC, mmoL/L - ALA - subgroup by primary or
secondary preventionA
6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
37.1 Primary prevention of CVD 4 870 Mean Difference (IV, Ran-
dom, 95% CI)
-0.09 [-0.30, 0.12]
37.2 Secondary prevention of CVD 2 1294 Mean Difference (IV, Ran-
dom, 95% CI)
-0.03 [-0.14, 0.08]
38 Triglycerides, fasting, serum, mmoL/L - ALA 6 1776 Mean Difference (IV, Ran-
dom, 95% CI)
-0.03 [-0.11, 0.05]
39 TG, fasting, mmoL/L - ALA - SA fixed-effect 6 1776 Mean Difference (IV, Fixed,
95% CI)
-0.03 [-0.11, 0.05]
40 TG, fasting, mmoL/L- ALA - SA by summary
risk of bias
6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
40.1 Low risk of bias 3 1436 Mean Difference (IV, Ran-
dom, 95% CI)
0.03 [-0.13, 0.19]
40.2 Moderate/high risk of bias 3 340 Mean Difference (IV, Ran-
dom, 95% CI)
-0.05 [-0.18, 0.09]
41 TG, fasting, mmoL/L- ALA - SA by compliance
and study size
4   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
41.1 SA - low risk of compliance bias 4 1657 Mean Difference (IV, Ran-
dom, 95% CI)
-0.05 [-0.13, 0.04]
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41.2 SA - 100+ randomised 4 1657 Mean Difference (IV, Ran-
dom, 95% CI)
-0.05 [-0.13, 0.04]
42 TG, fasting, mmoL/L - ALA - subgroup by dose 6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
42.1 ALA low < 5 g/d 3 1371 Mean Difference (IV, Ran-
dom, 95% CI)
-0.07 [-0.16, 0.03]
42.2 ALA high > 5 g/d 3 405 Mean Difference (IV, Ran-
dom, 95% CI)
0.05 [-0.09, 0.19]
43 TG, fasting, mmoL/L- ALA - subgroup by inter-
vention type
6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
43.1 Dietary advice 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
43.2 Supplemental foods 5 1650 Mean Difference (IV, Ran-
dom, 95% CI)
-0.01 [-0.10, 0.07]
43.3 Supplement (capsule) 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
43.4 Any combination 1 126 Mean Difference (IV, Ran-
dom, 95% CI)
-0.12 [-0.33, 0.09]
44 TG, fasting, mmoL/L-AL - subgroup by re-
placementA
6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
44.1 ALA replacing SFA 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
44.2 ALA replacing MUFA 2 1336 Mean Difference (IV, Ran-
dom, 95% CI)
-0.07 [-0.17, 0.02]
44.3 ALA replacing n-6 1 142 Mean Difference (IV, Ran-
dom, 95% CI)
0.13 [-0.16, 0.42]
44.4 ALA replacing carbs/sugars 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
44.5 ALA replacing nil/low n-3 placebo 1 35 Mean Difference (IV, Ran-
dom, 95% CI)
0.30 [-0.39, 0.99]
44.6 Replacement unclear 2 263 Mean Difference (IV, Ran-
dom, 95% CI)
0.04 [-0.15, 0.23]
45 TG, fasting, mmoL/L- ALA - subgroup by dura-
tion
6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
45.1 Medium duration 1 to < 2 years in study 4 424 Mean Difference (IV, Ran-
dom, 95% CI)
-0.01 [-0.15, 0.12]
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45.2 Medium-long duration: 2 to < 4 years in
study
2 1352 Mean Difference (IV, Ran-
dom, 95% CI)
-0.01 [-0.17, 0.15]
45.3 Long duration ≥ 4 years in study 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
46 TG, fasting, mmoL/L - ALA - subgroup by
statin use
6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
46.1 ALA - ≥ 50% of control group on statins 3 1329 Mean Difference (IV, Ran-
dom, 95% CI)
0.03 [-0.17, 0.23]
46.2 ALA - < 50% of control group on statins 2 268 Mean Difference (IV, Ran-
dom, 95% CI)
-0.02 [-0.26, 0.23]
46.3 ALA - use of statins unclear 1 179 Mean Difference (IV, Ran-
dom, 95% CI)
-0.02 [-0.20, 0.16]
47 TG, fasting, mmoL/L- ALA - subgroup by pri-
mary or secondary prevention
6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
47.1 Primary prevention 4 482 Mean Difference (IV, Ran-
dom, 95% CI)
-0.02 [-0.14, 0.11]
47.2 Secondary prevention 2 1294 Mean Difference (IV, Ran-
dom, 95% CI)
0.02 [-0.22, 0.25]
48 High-density lipoprotein, serum, mmoL/L -
ALA
6 1776 Mean Difference (IV, Ran-
dom, 95% CI)
-0.02 [-0.08, 0.03]
49 HDL, mmoL/L - ALA - SA fixed-effect 6 1776 Mean Difference (IV, Fixed,
95% CI)
-0.02 [-0.05, 0.00]
50 HDL, mmoL/L - ALA - SA by summary risk of
bias
6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
50.1 Low risk of bias 3 1436 Mean Difference (IV, Ran-
dom, 95% CI)
-0.03 [-0.06, 0.00]
50.2 Moderate/high risk of bias 3 340 Mean Difference (IV, Ran-
dom, 95% CI)
0.04 [-0.14, 0.22]
51 HDL, mmoL/L - ALA - SA by compliance and
study size
4   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
51.1 SA - low risk of compliance bias 4 1657 Mean Difference (IV, Ran-
dom, 95% CI)
-0.02 [-0.08, 0.04]
51.2 SA - 100+ randomised 4 1657 Mean Difference (IV, Ran-
dom, 95% CI)
-0.02 [-0.08, 0.04]
52 HDL, mmoL/L - ALA - subgroup by dose 6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
52.1 ALA low < 5 g/d 3 1371 Mean Difference (IV, Ran-
dom, 95% CI)
0.06 [-0.08, 0.19]
52.2 ALA high > 5 g/d 3 405 Mean Difference (IV, Ran-
dom, 95% CI)
-0.07 [-0.12, -0.01]
53 HDL, mmoL/L - ALA - subgroup by interven-
tion type
6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
53.1 Dietary advice 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
53.2 Supplemental foods 5 1650 Mean Difference (IV, Ran-
dom, 95% CI)
-0.03 [-0.06, -0.00]
53.3 Supplement (capsule) 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
53.4 Any combination 1 126 Mean Difference (IV, Ran-
dom, 95% CI)
0.15 [0.01, 0.29]
54 HDL, mmoL/L - ALA - subgroup by replace-
ment
6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
54.1 ALA replacing SFA 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
54.2 ALA replacing MUFA 2 1336 Mean Difference (IV, Ran-
dom, 95% CI)
0.05 [-0.11, 0.22]
54.3 ALA replacing n-6 1 142 Mean Difference (IV, Ran-
dom, 95% CI)
-0.04 [-0.11, 0.03]
54.4 ALA replacing carbs/sugars 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
54.5 ALA replacing nil/low n-3 placebo 1 35 Mean Difference (IV, Ran-
dom, 95% CI)
0.10 [-0.17, 0.37]
54.6 Replacement unclear 2 263 Mean Difference (IV, Ran-
dom, 95% CI)
-0.09 [-0.17, -0.02]
55 HDL, mmoL/L - ALA - subgroup by duration 6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
55.1 Medium duration 1 to < 2 years in study 4 424 Mean Difference (IV, Ran-
dom, 95% CI)
-0.00 [-0.13, 0.13]
55.2 Medium-long duration: 2 to < 4 years in
study
2 1352 Mean Difference (IV, Ran-
dom, 95% CI)
-0.02 [-0.05, 0.00]
55.3 Long duration ≥ 4 years in study 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
56 HDL, mmoL/L - ALA - subgroup by statin use 6   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
56.1 ALA - ≥ 50% of control group on statins 3 1329 Mean Difference (IV, Ran-
dom, 95% CI)
-0.03 [-0.09, 0.03]
56.2 ALA - < 50% of control group on statins 2 268 Mean Difference (IV, Ran-
dom, 95% CI)
0.05 [-0.14, 0.23]
56.3 ALA - use of statins unclear 1 179 Mean Difference (IV, Ran-
dom, 95% CI)
-0.09 [-0.20, 0.02]
57 HDL, mmoL/L - ALA - subgroup by primary or
secondary prevention
7   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
57.1 Low CVD risk 2 305 Mean Difference (IV, Ran-
dom, 95% CI)
0.03 [-0.21, 0.26]
57.2 Moderate CVD risk 2 177 Mean Difference (IV, Ran-
dom, 95% CI)
-0.03 [-0.10, 0.04]
57.3 High CVD risk 3 1368 Mean Difference (IV, Ran-
dom, 95% CI)
-0.03 [-0.08, 0.03]
58 Low-density lipoprotein, serum, mmoL/L -
ALA
7 2201 Mean Difference (IV, Ran-
dom, 95% CI)
-0.05 [-0.15, 0.04]
59 LDL, mmoL/L - ALA - SA fixed-effect 7 2201 Mean Difference (IV, Fixed,
95% CI)
-0.05 [-0.11, 0.00]
60 LDL, mmoL/L - ALA - SA by summary risk of
bias
7   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
60.1 Low risk of bias 3 1350 Mean Difference (IV, Ran-
dom, 95% CI)
0.02 [-0.05, 0.10]
60.2 Moderate/high risk of bias 4 851 Mean Difference (IV, Ran-
dom, 95% CI)
-0.14 [-0.22, -0.06]
61 LDL, mmoL/L - ALA - SA by compliance and
study size
5   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
61.1 SA - low risk of compliance bias 5 2085 Mean Difference (IV, Ran-
dom, 95% CI)
-0.05 [-0.16, 0.06]
61.2 SA - 100+ randomised 5 2085 Mean Difference (IV, Ran-
dom, 95% CI)
-0.05 [-0.16, 0.06]
62 LDL, mmoL/L - ALA - subgroup by dose 7   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
62.1 ALA low < 5 g/d 4 1796 Mean Difference (IV, Ran-
dom, 95% CI)
-0.06 [-0.17, 0.05]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
62.2 ALA high > 5 g/d 3 405 Mean Difference (IV, Ran-
dom, 95% CI)
-0.04 [-0.28, 0.19]
63 LDL, mmoL/L - ALA - subgroup by interven-
tion type
7   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
63.1 Dietary advice 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
63.2 Supplemental foods 6 2075 Mean Difference (IV, Ran-
dom, 95% CI)
-0.06 [-0.17, 0.05]
63.3 Supplement (capsule) 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
63.4 Any combination 1 126 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [-0.25, 0.25]
64 LDL, mmoL/L - ALA - subgroup by replace-
ment
7   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
64.1 ALA replacing SFA 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
64.2 ALA replacing MUFA 2 1250 Mean Difference (IV, Ran-
dom, 95% CI)
0.01 [-0.07, 0.09]
64.3 ALA replacing n-6 1 142 Mean Difference (IV, Ran-
dom, 95% CI)
0.14 [-0.08, 0.36]
64.4 ALA replacing carbs/sugars 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
64.5 ALA replacing nil/low n-3 placebo 1 32 Mean Difference (IV, Ran-
dom, 95% CI)
-0.10 [-0.59, 0.39]
64.6 Replacement unclear 3 777 Mean Difference (IV, Ran-
dom, 95% CI)
-0.16 [-0.24, -0.07]
65 LDL, mmoL/L - ALA - subgroup by duration 7   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
65.1 Medium duration 1 to < 2 years in study 5 935 Mean Difference (IV, Ran-
dom, 95% CI)
-0.14 [-0.22, -0.06]
65.2 Medium-long duration: 2 to < 4 years in
study
2 1266 Mean Difference (IV, Ran-
dom, 95% CI)
0.03 [-0.06, 0.13]
65.3 Long duration ≥ 4 years in study 0 0 Mean Difference (IV, Ran-
dom, 95% CI)
0.0 [0.0, 0.0]
66 LDL, mmoL/L - ALA - subgroup by statin use 7   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
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studies
No. of
partici-
pants
Statistical method Effect size
66.1 ALA - ≥ 50% of control group on statins 3 1240 Mean Difference (IV, Ran-
dom, 95% CI)
0.00 [-0.08, 0.08]
66.2 ALA - < 50% of control group on statins 2 268 Mean Difference (IV, Ran-
dom, 95% CI)
0.08 [-0.09, 0.24]
66.3 ALA - use of statins unclear 2 693 Mean Difference (IV, Ran-
dom, 95% CI)
-0.16 [-0.25, -0.07]
67 LDL, mmoL/L - ALA - subgroup by primary or
secondary prevention
7   Mean Difference (IV, Ran-
dom, 95% CI)
Subtotals only
67.1 Primary prevention of CVD 5 993 Mean Difference (IV, Ran-
dom, 95% CI)
-0.08 [-0.20, 0.05]
67.2 Secondary prevention of CVD 2 1208 Mean Difference (IV, Ran-
dom, 95% CI)
0.01 [-0.08, 0.09]
 
 
Analysis 5.1.   Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 1 MACCEs - ALA.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
FLAX-PAD 2013 5/58 4/52 100% 1.12[0.32,3.95]
   
Total (95% CI) 58 52 100% 1.12[0.32,3.95]
Total events: 5 (Higher omega 3), 4 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.18(P=0.86)  
Favours higher omega 3 20.5 1.50.7 1 Favours lower omega 3
 
 
Analysis 5.2.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 2 Myocardial infarction (overall) - ALA.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AlphaOmega - ALA 2010 90/2409 101/2428 54.44% 0.9[0.68,1.19]
FLAX-PAD 2013 1/58 3/52 1.53% 0.3[0.03,2.78]
Norwegian 1968 75/6716 63/6690 44.03% 1.19[0.85,1.65]
   
Total (95% CI) 9183 9170 100% 1[0.76,1.32]
Total events: 166 (Higher omega 3), 167 (Lower omega 3)  
Heterogeneity: Tau2=0.02; Chi2=2.7, df=2(P=0.26); I2=25.95%  
Test for overall effect: Z=0.01(P=0.99)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Analysis 5.3.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 3 Total MI - ALA - subgroup by fatality.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.3.1 Fatal MI  
AlphaOmega - ALA 2010 39/2409 42/2428 98.19% 0.94[0.61,1.44]
FLAX-PAD 2013 1/58 0/52 1.81% 2.69[0.11,64.74]
Subtotal (95% CI) 2467 2480 100% 0.95[0.62,1.46]
Total events: 40 (Higher omega 3), 42 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.42, df=1(P=0.52); I2=0%  
Test for overall effect: Z=0.22(P=0.83)  
   
5.3.2 Non-fatal MI  
AlphaOmega - ALA 2010 51/2409 59/2428 71.48% 0.87[0.6,1.26]
FLAX-PAD 2013 0/58 3/52 14.15% 0.13[0.01,2.43]
MARGARIN 2002 0/109 4/157 14.37% 0.16[0.01,2.93]
Subtotal (95% CI) 2576 2637 100% 0.52[0.15,1.77]
Total events: 51 (Higher omega 3), 66 (Lower omega 3)  
Heterogeneity: Tau2=0.51; Chi2=2.9, df=2(P=0.24); I2=30.92%  
Test for overall effect: Z=1.04(P=0.3)  
Test for subgroup differences: Chi2=0.84, df=1 (P=0.36), I2=0%  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 5.4.   Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 4 Angina - ALA.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
FLAX-PAD 2013 1/58 0/52 3.93% 2.69[0.11,64.74]
Norwegian 1968 22/6716 16/6690 96.07% 1.37[0.72,2.61]
   
Total (95% CI) 6774 6742 100% 1.41[0.75,2.64]
Total events: 23 (Higher omega 3), 16 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=0.17, df=1(P=0.68); I2=0%  
Test for overall effect: Z=1.06(P=0.29)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 5.5.   Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 5 Revascularisation - ALA.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.5.1 CABG - ALA  
MARGARIN 2002 0/109 2/157 100% 0.29[0.01,5.93]
Subtotal (95% CI) 109 157 100% 0.29[0.01,5.93]
Total events: 0 (Higher omega 3), 2 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.81(P=0.42)  
   
5.5.2 Angioplasty - ALA  
Favours higher omega 3 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.5.3 Any revascularisation - ALA  
MARGARIN 2002 1/109 2/157 100% 0.72[0.07,7.84]
Subtotal (95% CI) 109 157 100% 0.72[0.07,7.84]
Total events: 1 (Higher omega 3), 2 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.27(P=0.79)  
Favours higher omega 3 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 5.6.   Comparison 5 High vs low ALA omega-3 fat
(secondary outcomes), Outcome 6 Peripheral arterial disease - ALA.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Norwegian 1968 2/6716 8/6690 0% 0.25[0.05,1.17]
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 5.7.   Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 7 Body weight, kg - ALA.
Study or subgroup Favours high-
er omega 3
Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 21.17% -4.2[-7.61,-0.79]
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 5.61% -0.3[-10.57,9.97]
MENU 2016 34 -6.8 (8.2) 32 -7 (7.9) 19.23% 0.2[-3.68,4.08]
MENU 2016 35 -8.1 (7.1) 37 -4.3 (6.1) 22.7% -3.8[-6.86,-0.74]
WAHA 2016 156 -0.3 (3.9) 156 -1 (3.9) 31.28% 0.76[-0.09,1.61]
   
Total *** 328   336   100% -1.49[-4.17,1.18]
Heterogeneity: Tau2=5.76; Chi2=14.6, df=4(P=0.01); I2=72.59%  
Test for overall effect: Z=1.09(P=0.27)  
Favours higher omega 3 52.5-5 -2.5 0 Favours lower omega 3
 
 
Analysis 5.8.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 8 Weight, kg - ALA - sensitivity analysis (SA) fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 5.24% -4.2[-7.61,-0.79]
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 0.58% -0.3[-10.57,9.97]
Favours higher omega 3 52.5-5 -2.5 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
MENU 2016 35 -8.1 (7.1) 37 -4.3 (6.1) 6.51% -3.8[-6.86,-0.74]
MENU 2016 34 -6.8 (8.2) 32 -7 (7.9) 4.05% 0.2[-3.68,4.08]
WAHA 2016 156 -0.3 (3.9) 156 -1 (3.9) 83.62% 0.76[-0.09,1.61]
   
Total *** 328   336   100% 0.17[-0.61,0.96]
Heterogeneity: Tau2=0; Chi2=14.6, df=4(P=0.01); I2=72.59%  
Test for overall effect: Z=0.44(P=0.66)  
Favours higher omega 3 52.5-5 -2.5 0 Favours lower omega 3
 
 
Analysis 5.9.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 9 Weight, kg - ALA - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.9.1 Low risk of bias  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.9.2 Moderate/high risk of bias  
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 21.17% -4.2[-7.61,-0.79]
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 5.61% -0.3[-10.57,9.97]
MENU 2016 34 -6.8 (8.2) 32 -7 (7.9) 19.23% 0.2[-3.68,4.08]
MENU 2016 35 -8.1 (7.1) 37 -4.3 (6.1) 22.7% -3.8[-6.86,-0.74]
WAHA 2016 156 -0.3 (3.9) 156 -1 (3.9) 31.28% 0.76[-0.09,1.61]
Subtotal *** 328   336   100% -1.49[-4.17,1.18]
Heterogeneity: Tau2=5.76; Chi2=14.6, df=4(P=0.01); I2=72.59%  
Test for overall effect: Z=1.09(P=0.27)  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
 
 
Analysis 5.10.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 10 Weight, kg - ALA - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.10.1 SA - low risk of compliance bias  
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 22.7% -4.2[-7.61,-0.79]
MENU 2016 34 -6.8 (8.2) 32 -7 (7.9) 20.77% 0.2[-3.68,4.08]
MENU 2016 35 -8.1 (7.1) 37 -4.3 (6.1) 24.2% -3.8[-6.86,-0.74]
WAHA 2016 156 -0.3 (3.9) 156 -1 (3.9) 32.32% 0.76[-0.09,1.61]
Subtotal *** 310   319   100% -1.59[-4.47,1.3]
Heterogeneity: Tau2=6.52; Chi2=14.59, df=3(P=0); I2=79.43%  
Test for overall effect: Z=1.08(P=0.28)  
   
5.10.2 SA - 100+ randomised  
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 22.7% -4.2[-7.61,-0.79]
MENU 2016 35 -8.1 (7.1) 37 -4.3 (6.1) 24.2% -3.8[-6.86,-0.74]
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
MENU 2016 34 -6.8 (8.2) 32 -7 (7.9) 20.77% 0.2[-3.68,4.08]
WAHA 2016 156 -0.3 (3.9) 156 -1 (3.9) 32.32% 0.76[-0.09,1.61]
Subtotal *** 310   319   100% -1.59[-4.47,1.3]
Heterogeneity: Tau2=6.52; Chi2=14.59, df=3(P=0); I2=79.43%  
Test for overall effect: Z=1.08(P=0.28)  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
 
 
Analysis 5.11.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 11 Weight, kg - ALA - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.11.1 ALA low < 5 g/d  
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 5.64% -0.3[-10.57,9.97]
MENU 2016 35 -8.1 (7.1) 37 -4.3 (6.1) 28.03% -3.8[-6.86,-0.74]
MENU 2016 34 -6.8 (8.2) 32 -7 (7.9) 22.7% 0.2[-3.68,4.08]
WAHA 2016 156 -0.3 (3.9) 156 -1 (3.9) 43.63% 0.76[-0.09,1.61]
Subtotal *** 243   242   100% -0.71[-3.31,1.9]
Heterogeneity: Tau2=3.85; Chi2=7.94, df=3(P=0.05); I2=62.21%  
Test for overall effect: Z=0.53(P=0.6)  
   
5.11.2 ALA high > 5 g/d  
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 100% -4.2[-7.61,-0.79]
Subtotal *** 85   94   100% -4.2[-7.61,-0.79]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.41(P=0.02)  
Test for subgroup differences: Chi2=2.55, df=1 (P=0.11), I2=60.71%  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
 
 
Analysis 5.12.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 12 Weight, kg - ALA - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.12.1 Dietary advice  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.12.2 Supplemental foods  
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 37.68% -4.2[-7.61,-0.79]
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 11.88% -0.3[-10.57,9.97]
WAHA 2016 156 -0.3 (3.9) 156 -1 (3.9) 50.44% 0.76[-0.09,1.61]
Subtotal *** 259   267   100% -1.23[-5.27,2.8]
Heterogeneity: Tau2=8.21; Chi2=7.65, df=2(P=0.02); I2=73.87%  
Test for overall effect: Z=0.6(P=0.55)  
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.12.3 Supplement (capsule)  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.12.4 Any combination  
MENU 2016 34 -6.8 (8.2) 32 -7 (7.9) 45.38% 0.2[-3.68,4.08]
MENU 2016 35 -8.1 (7.1) 37 -4.3 (6.1) 54.62% -3.8[-6.86,-0.74]
Subtotal *** 69   69   100% -1.98[-5.89,1.92]
Heterogeneity: Tau2=4.82; Chi2=2.52, df=1(P=0.11); I2=60.25%  
Test for overall effect: Z=1(P=0.32)  
Test for subgroup differences: Chi2=0.07, df=1 (P=0.79), I2=0%  
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Analysis 5.13.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 13 Weight, kg - ALA - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.13.1 ALA replacing SFA  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.13.2 ALA replacing MUFA  
MENU 2016 34 -6.8 (8.2) 32 -7 (7.9) 45.38% 0.2[-3.68,4.08]
MENU 2016 35 -8.1 (7.1) 37 -4.3 (6.1) 54.62% -3.8[-6.86,-0.74]
Subtotal *** 69   69   100% -1.98[-5.89,1.92]
Heterogeneity: Tau2=4.82; Chi2=2.52, df=1(P=0.11); I2=60.25%  
Test for overall effect: Z=1(P=0.32)  
   
5.13.3 ALA replacing n-6  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.13.4 ALA replacing carbs/sugars  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.13.5 ALA replacing nil/low n-3 placebo  
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 100% -0.3[-10.57,9.97]
Subtotal *** 18   17   100% -0.3[-10.57,9.97]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.06(P=0.95)  
   
5.13.6 Replacement unclear  
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 44.22% -4.2[-7.61,-0.79]
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
WAHA 2016 156 -0.3 (3.9) 156 -1 (3.9) 55.78% 0.76[-0.09,1.61]
Subtotal *** 241   250   100% -1.43[-6.26,3.39]
Heterogeneity: Tau2=10.69; Chi2=7.63, df=1(P=0.01); I2=86.9%  
Test for overall effect: Z=0.58(P=0.56)  
Test for subgroup differences: Chi2=0.1, df=1 (P=0.95), I2=0%  
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Analysis 5.14.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 14 Weight, kg - ALA - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.14.1 Medium duration 1 to < 2 years in study  
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 21.17% -4.2[-7.61,-0.79]
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 5.61% -0.3[-10.57,9.97]
MENU 2016 35 -8.1 (7.1) 37 -4.3 (6.1) 22.7% -3.8[-6.86,-0.74]
MENU 2016 34 -6.8 (8.2) 32 -7 (7.9) 19.23% 0.2[-3.68,4.08]
WAHA 2016 156 -0.3 (3.9) 156 -1 (3.9) 31.28% 0.76[-0.09,1.61]
Subtotal *** 328   336   100% -1.49[-4.17,1.18]
Heterogeneity: Tau2=5.76; Chi2=14.6, df=4(P=0.01); I2=72.59%  
Test for overall effect: Z=1.09(P=0.27)  
   
5.14.2 Medium-long duration: 2 to < 4 years in study  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.14.3 Long duration ≥ 4 years in study  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Not applicable  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
 
 
Analysis 5.15.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 15 Weight, kg - ALA - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.15.1 ALA - ≥ 50% of control group on statins  
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 100% -0.3[-10.57,9.97]
Subtotal *** 18   17   100% -0.3[-10.57,9.97]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.06(P=0.95)  
   
5.15.2 ALA - < 50% of control group on statins  
MENU 2016 34 -6.8 (8.2) 32 -7 (7.9) 45.38% 0.2[-3.68,4.08]
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
MENU 2016 35 -8.1 (7.1) 37 -4.3 (6.1) 54.62% -3.8[-6.86,-0.74]
Subtotal *** 69   69   100% -1.98[-5.89,1.92]
Heterogeneity: Tau2=4.82; Chi2=2.52, df=1(P=0.11); I2=60.25%  
Test for overall effect: Z=1(P=0.32)  
   
5.15.3 ALA - use of statins unclear  
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 44.22% -4.2[-7.61,-0.79]
WAHA 2016 156 -0.3 (3.9) 156 -1 (3.9) 55.78% 0.76[-0.09,1.61]
Subtotal *** 241   250   100% -1.43[-6.26,3.39]
Heterogeneity: Tau2=10.69; Chi2=7.63, df=1(P=0.01); I2=86.9%  
Test for overall effect: Z=0.58(P=0.56)  
Test for subgroup differences: Chi2=0.1, df=1 (P=0.95), I2=0%  
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Analysis 5.16.   Comparison 5 High vs low ALA omega-3 fat (secondary outcomes),
Outcome 16 Weight, kg - ALA - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.16.1 Low CVD risk  
Dodin 2005 85 65.3 (11.2) 94 69.5 (12.1) 22.7% -4.2[-7.61,-0.79]
MENU 2016 35 -8.1 (7.1) 37 -4.3 (6.1) 24.2% -3.8[-6.86,-0.74]
MENU 2016 34 -6.8 (8.2) 32 -7 (7.9) 20.77% 0.2[-3.68,4.08]
WAHA 2016 156 -0.3 (3.9) 156 -1 (3.9) 32.32% 0.76[-0.09,1.61]
Subtotal *** 310   319   100% -1.59[-4.47,1.3]
Heterogeneity: Tau2=6.52; Chi2=14.59, df=3(P=0); I2=79.43%  
Test for overall effect: Z=1.08(P=0.28)  
   
5.16.2 Moderate CVD risk  
HERO 2009 18 92 (17.1) 17 92.3 (13.8) 100% -0.3[-10.57,9.97]
Subtotal *** 18   17   100% -0.3[-10.57,9.97]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.06(P=0.95)  
   
5.16.3 High CVD risk  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=0.06, df=1 (P=0.81), I2=0%  
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Analysis 5.17.   Comparison 5 High vs low ALA omega-3 fat
(secondary outcomes), Outcome 17 Body mass index, kg/m2 - ALA.
Study or subgroup Favours high-
er omega 3
Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
AlphaOmega - ALA 2010 630 0.1 (1.5) 630 -0.1 (1.8) 51.23% 0.15[-0.03,0.33]
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 29.23% -1.5[-2.86,-0.14]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 19.54% -0.3[-2.29,1.69]
   
Total *** 764   817   100% -0.42[-1.53,0.69]
Heterogeneity: Tau2=0.62; Chi2=5.7, df=2(P=0.06); I2=64.93%  
Test for overall effect: Z=0.74(P=0.46)  
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
 
 
Analysis 5.18.   Comparison 5 High vs low ALA omega-3 fat
(secondary outcomes), Outcome 18 BMI, kg/m2 - ALA - SA fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
AlphaOmega - ALA 2010 630 0.1 (1.5) 630 -0.1 (1.8) 97.42% 0.15[-0.03,0.33]
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 1.76% -1.5[-2.86,-0.14]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 0.82% -0.3[-2.29,1.69]
   
Total *** 764   817   100% 0.12[-0.06,0.3]
Heterogeneity: Tau2=0; Chi2=5.7, df=2(P=0.06); I2=64.93%  
Test for overall effect: Z=1.27(P=0.2)  
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
 
 
Analysis 5.19.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 19 BMI, kg/m2 - ALA - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.19.1 Low risk of bias  
AlphaOmega - ALA 2010 630 0.1 (1.5) 630 -0.1 (1.8) 99.16% 0.15[-0.03,0.33]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 0.84% -0.3[-2.29,1.69]
Subtotal *** 679   723   100% 0.15[-0.04,0.33]
Heterogeneity: Tau2=0; Chi2=0.19, df=1(P=0.66); I2=0%  
Test for overall effect: Z=1.57(P=0.12)  
   
5.19.2 Moderate/high risk of bias  
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 100% -1.5[-2.86,-0.14]
Subtotal *** 85   94   100% -1.5[-2.86,-0.14]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.16(P=0.03)  
Test for subgroup differences: Chi2=5.51, df=1 (P=0.02), I2=81.85%  
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Analysis 5.20.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 20 BMI, kg/m2 - ALA - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.20.1 SA - low risk of compliance bias  
AlphaOmega - ALA 2010 630 0.1 (1.5) 630 -0.1 (1.8) 51.23% 0.15[-0.03,0.33]
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 29.23% -1.5[-2.86,-0.14]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 19.54% -0.3[-2.29,1.69]
Subtotal *** 764   817   100% -0.42[-1.53,0.69]
Heterogeneity: Tau2=0.62; Chi2=5.7, df=2(P=0.06); I2=64.93%  
Test for overall effect: Z=0.74(P=0.46)  
   
5.20.2 SA - 100+ randomised  
AlphaOmega - ALA 2010 630 0.1 (1.5) 630 -0.1 (1.8) 51.23% 0.15[-0.03,0.33]
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 29.23% -1.5[-2.86,-0.14]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 19.54% -0.3[-2.29,1.69]
Subtotal *** 764   817   100% -0.42[-1.53,0.69]
Heterogeneity: Tau2=0.62; Chi2=5.7, df=2(P=0.06); I2=64.93%  
Test for overall effect: Z=0.74(P=0.46)  
Test for subgroup differences: Not applicable  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
 
 
Analysis 5.21.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 21 BMI, kg/m2 - ALA - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.21.1 ALA low < 5 g/d  
AlphaOmega - ALA 2010 630 0.1 (1.5) 630 -0.1 (1.8) 100% 0.15[-0.03,0.33]
Subtotal *** 630   630   100% 0.15[-0.03,0.33]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.61(P=0.11)  
   
5.21.2 ALA high > 5 g/d  
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 68.08% -1.5[-2.86,-0.14]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 31.92% -0.3[-2.29,1.69]
Subtotal *** 134   187   100% -1.12[-2.24,0.01]
Heterogeneity: Tau2=0; Chi2=0.95, df=1(P=0.33); I2=0%  
Test for overall effect: Z=1.95(P=0.05)  
Test for subgroup differences: Chi2=4.75, df=1 (P=0.03), I2=78.96%  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
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Analysis 5.22.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 22 BMI, kg/m2 - ALA - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.22.1 Dietary advice  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.22.2 Supplemental foods  
AlphaOmega - ALA 2010 630 0.1 (1.5) 630 -0.1 (1.8) 51.23% 0.15[-0.03,0.33]
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 29.23% -1.5[-2.86,-0.14]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 19.54% -0.3[-2.29,1.69]
Subtotal *** 764   817   100% -0.42[-1.53,0.69]
Heterogeneity: Tau2=0.62; Chi2=5.7, df=2(P=0.06); I2=64.93%  
Test for overall effect: Z=0.74(P=0.46)  
   
5.22.3 Supplement (capsule)  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.22.4 Any combination  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
 
 
Analysis 5.23.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 23 BMI, kg/m2 - ALA - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.23.1 ALA replacing SFA  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.23.2 ALA replacing MUFA  
AlphaOmega - ALA 2010 630 0.1 (1.5) 630 -0.1 (1.8) 51.23% 0.15[-0.03,0.33]
Subtotal *** 630   630   51.23% 0.15[-0.03,0.33]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.61(P=0.11)  
   
5.23.3 ALA replacing n-6  
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 19.54% -0.3[-2.29,1.69]
Subtotal *** 49   93   19.54% -0.3[-2.29,1.69]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.3(P=0.77)  
   
5.23.4 ALA replacing carbs/sugars  
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.23.5 ALA replacing nil/low n-3 placebo  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.23.6 Replacement unclear  
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 29.23% -1.5[-2.86,-0.14]
Subtotal *** 85   94   29.23% -1.5[-2.86,-0.14]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.16(P=0.03)  
   
Total *** 764   817   100% -0.42[-1.53,0.69]
Heterogeneity: Tau2=0.62; Chi2=5.7, df=2(P=0.06); I2=64.93%  
Test for overall effect: Z=0.74(P=0.46)  
Test for subgroup differences: Chi2=5.7, df=1 (P=0.06), I2=64.93%  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
 
 
Analysis 5.24.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 24 BMI, kg/m2 - ALA - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.24.1 Medium duration 1 to < 2 years in study  
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 100% -1.5[-2.86,-0.14]
Subtotal *** 85   94   100% -1.5[-2.86,-0.14]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.16(P=0.03)  
   
5.24.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - ALA 2010 630 0.1 (1.5) 630 -0.1 (1.8) 99.16% 0.15[-0.03,0.33]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 0.84% -0.3[-2.29,1.69]
Subtotal *** 679   723   100% 0.15[-0.04,0.33]
Heterogeneity: Tau2=0; Chi2=0.19, df=1(P=0.66); I2=0%  
Test for overall effect: Z=1.57(P=0.12)  
   
5.24.3 Long duration ≥ 4 years in study  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=5.51, df=1 (P=0.02), I2=81.85%  
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Analysis 5.25.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 25 BMI, kg/m2 - ALA - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.25.1 ALA - ≥ 50% of control group on statins  
AlphaOmega - ALA 2010 630 0.1 (1.5) 630 -0.1 (1.8) 100% 0.15[-0.03,0.33]
Subtotal *** 630   630   100% 0.15[-0.03,0.33]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.61(P=0.11)  
   
5.25.2 ALA - < 50% of control group on statins  
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 100% -0.3[-2.29,1.69]
Subtotal *** 49   93   100% -0.3[-2.29,1.69]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.3(P=0.77)  
   
5.25.3 ALA - use of statins unclear  
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 100% -1.5[-2.86,-0.14]
Subtotal *** 85   94   100% -1.5[-2.86,-0.14]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.16(P=0.03)  
Test for subgroup differences: Chi2=5.7, df=1 (P=0.06), I2=64.93%  
Favours higher omega 3 2010-20 -10 0 Favours lower omega 3
 
 
Analysis 5.26.   Comparison 5 High vs low ALA omega-3 fat (secondary outcomes),
Outcome 26 BMI, kg/m2 - ALA - subgroup by primary or secondary preventionA.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.26.1 Primary prevention of CVD  
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 68.08% -1.5[-2.86,-0.14]
MARGARIN 2002 49 0.2 (1.4) 93 0.5 (9.6) 31.92% -0.3[-2.29,1.69]
Subtotal *** 134   187   100% -1.12[-2.24,0.01]
Heterogeneity: Tau2=0; Chi2=0.95, df=1(P=0.33); I2=0%  
Test for overall effect: Z=1.95(P=0.05)  
   
5.26.2 Secondary prevention of CVD  
AlphaOmega - ALA 2010 630 0.1 (1.5) 630 -0.1 (1.8) 100% 0.15[-0.03,0.33]
Subtotal *** 630   630   100% 0.15[-0.03,0.33]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.61(P=0.11)  
Test for subgroup differences: Chi2=4.75, df=1 (P=0.03), I2=78.96%  
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Analysis 5.27.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 27 Other measures of adiposity - ALA.
Study or subgroup Favours high-
er omega 3
Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
5.27.1 Visceral adipose tissue, cm2  
HERO 2009 18 194.6 (73.5) 17 167.6 (72.2) 100% 27[-21.28,75.28]
Subtotal *** 18   17   100% 27[-21.28,75.28]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.1(P=0.27)  
   
5.27.2 Subcutaneous adipose tissue, cm2  
HERO 2009 18 7.5 (0) 17 -28.1 (0)   Not estimable
Subtotal *** 18   17   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.27.3 Waist circumference, cm  
Dodin 2005 85 1.7 (6.8) 94 3.4 (6.2) 62.67% -1.7[-3.61,0.21]
MENU 2016 35 -6 (5.9) 37 -4 (6.1) 29.86% -2[-4.77,0.77]
MENU 2016 34 -7 (11.7) 32 -8 (11.3) 7.47% 1[-4.54,6.54]
WAHA 2016 156 2.3 (0) 156 1.9 (0)   Not estimable
Subtotal *** 310   319   100% -1.59[-3.1,-0.07]
Heterogeneity: Tau2=0; Chi2=0.94, df=2(P=0.63); I2=0%  
Test for overall effect: Z=2.05(P=0.04)  
Favours higher omega 3 52.5-5 -2.5 0 Favours lower omega 3
 
 
Analysis 5.28.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 28 Total cholesterol, serum, mmoL/L - ALA.
Study or subgroup Favours high-
er omega 3
Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
AlphaOmega - ALA 2010 605 -0.3 (1) 605 -0.3 (1) 27.33% -0.02[-0.13,0.09]
Dodin 2005 85 5.7 (0.7) 94 6 (0.7) 18.84% -0.3[-0.51,-0.09]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 5.33% -0.3[-0.86,0.26]
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 4.66% 0.3[-0.3,0.9]
MARGARIN 2002 49 -0.2 (0.7) 93 -0.4 (0.7) 16.61% 0.14[-0.1,0.38]
WAHA 2016 260 -0.2 (0.7) 254 -0 (0.6) 27.24% -0.18[-0.29,-0.07]
   
Total *** 1060   1104   100% -0.09[-0.23,0.05]
Heterogeneity: Tau2=0.02; Chi2=13.4, df=5(P=0.02); I2=62.69%  
Test for overall effect: Z=1.25(P=0.21)  
Favours higher omega 3 0.40.2-0.4 -0.2 0 Favours lower omega 3
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Analysis 5.29.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 29 TC, mmoL/L - ALA - SA fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
AlphaOmega - ALA 2010 605 -0.3 (1) 605 -0.3 (1) 39.45% -0.02[-0.13,0.09]
Dodin 2005 85 5.7 (0.7) 94 6 (0.7) 10.78% -0.3[-0.51,-0.09]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 1.56% -0.3[-0.86,0.26]
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 1.33% 0.3[-0.3,0.9]
MARGARIN 2002 49 -0.2 (0.7) 93 -0.4 (0.7) 8.2% 0.14[-0.1,0.38]
WAHA 2016 260 -0.2 (0.7) 254 -0 (0.6) 38.68% -0.18[-0.29,-0.07]
   
Total *** 1060   1104   100% -0.1[-0.17,-0.03]
Heterogeneity: Tau2=0; Chi2=13.4, df=5(P=0.02); I2=62.69%  
Test for overall effect: Z=2.8(P=0.01)  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
 
 
Analysis 5.30.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 30 TC, mmoL/L - ALA - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.30.1 Low risk of bias  
AlphaOmega - ALA 2010 605 -0.3 (1) 605 -0.3 (1) 68.48% -0.02[-0.13,0.09]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 5.87% -0.3[-0.86,0.26]
MARGARIN 2002 49 -0.2 (0.7) 93 -0.4 (0.7) 25.66% 0.14[-0.1,0.38]
Subtotal *** 697   739   100% 0[-0.13,0.14]
Heterogeneity: Tau2=0; Chi2=2.53, df=2(P=0.28); I2=20.81%  
Test for overall effect: Z=0.07(P=0.95)  
   
5.30.2 Moderate/high risk of bias  
Dodin 2005 85 5.7 (0.7) 94 6 (0.7) 35.51% -0.3[-0.51,-0.09]
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 7.52% 0.3[-0.3,0.9]
WAHA 2016 260 -0.2 (0.7) 254 -0 (0.6) 56.97% -0.18[-0.29,-0.07]
Subtotal *** 363   365   100% -0.19[-0.36,-0.01]
Heterogeneity: Tau2=0.01; Chi2=3.61, df=2(P=0.16); I2=44.65%  
Test for overall effect: Z=2.1(P=0.04)  
Test for subgroup differences: Chi2=2.84, df=1 (P=0.09), I2=64.8%  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
 
 
Analysis 5.31.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 31 TC, mmoL/L - ALA - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.31.1 SA - low risk of compliance bias  
AlphaOmega - ALA 2010 605 -0.3 (1) 605 -0.3 (1) 30.24% -0.02[-0.13,0.09]
Dodin 2005 85 5.7 (0.7) 94 6 (0.7) 21.04% -0.3[-0.51,-0.09]
MARGARIN 2002 49 -0.2 (0.7) 93 -0.4 (0.7) 18.59% 0.14[-0.1,0.38]
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
WAHA 2016 260 -0.2 (0.7) 254 -0 (0.6) 30.14% -0.18[-0.29,-0.07]
Subtotal *** 999   1046   100% -0.1[-0.25,0.05]
Heterogeneity: Tau2=0.02; Chi2=11.21, df=3(P=0.01); I2=73.23%  
Test for overall effect: Z=1.28(P=0.2)  
   
5.31.2 SA - 100+ randomised  
AlphaOmega - ALA 2010 605 -0.3 (1) 605 -0.3 (1) 30.24% -0.02[-0.13,0.09]
Dodin 2005 85 5.7 (0.7) 94 6 (0.7) 21.04% -0.3[-0.51,-0.09]
MARGARIN 2002 49 -0.2 (0.7) 93 -0.4 (0.7) 18.59% 0.14[-0.1,0.38]
WAHA 2016 260 -0.2 (0.7) 254 -0 (0.6) 30.14% -0.18[-0.29,-0.07]
Subtotal *** 999   1046   100% -0.1[-0.25,0.05]
Heterogeneity: Tau2=0.02; Chi2=11.21, df=3(P=0.01); I2=73.23%  
Test for overall effect: Z=1.28(P=0.2)  
Test for subgroup differences: Chi2=0, df=1 (P=1), I2=0%  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
 
 
Analysis 5.32.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 32 TC, mmoL/L - ALA - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.32.1 ALA low < 5 g/d  
AlphaOmega - ALA 2010 605 -0.3 (1) 605 -0.3 (1) 46.92% -0.02[-0.13,0.09]
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 6.37% 0.3[-0.3,0.9]
WAHA 2016 260 -0.2 (0.7) 254 -0 (0.6) 46.71% -0.18[-0.29,-0.07]
Subtotal *** 883   876   100% -0.07[-0.24,0.09]
Heterogeneity: Tau2=0.01; Chi2=5.65, df=2(P=0.06); I2=64.62%  
Test for overall effect: Z=0.91(P=0.36)  
   
5.32.2 ALA high > 5 g/d  
Dodin 2005 85 5.7 (0.7) 94 6 (0.7) 40.55% -0.3[-0.51,-0.09]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 20.84% -0.3[-0.86,0.26]
MARGARIN 2002 49 -0.2 (0.7) 93 -0.4 (0.7) 38.61% 0.14[-0.1,0.38]
Subtotal *** 177   228   100% -0.13[-0.47,0.21]
Heterogeneity: Tau2=0.06; Chi2=7.62, df=2(P=0.02); I2=73.74%  
Test for overall effect: Z=0.76(P=0.45)  
Test for subgroup differences: Chi2=0.09, df=1 (P=0.77), I2=0%  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
 
 
Analysis 5.33.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 33 TC, mmoL/L - ALA - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.33.1 Dietary advice  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Not applicable  
   
5.33.2 Supplemental foods  
AlphaOmega - ALA 2010 605 -0.3 (1) 605 -0.3 (1) 27.33% -0.02[-0.13,0.09]
Dodin 2005 85 5.7 (0.7) 94 6 (0.7) 18.84% -0.3[-0.51,-0.09]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 5.33% -0.3[-0.86,0.26]
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 4.66% 0.3[-0.3,0.9]
MARGARIN 2002 49 -0.2 (0.7) 93 -0.4 (0.7) 16.61% 0.14[-0.1,0.38]
WAHA 2016 260 -0.2 (0.7) 254 -0 (0.6) 27.24% -0.18[-0.29,-0.07]
Subtotal *** 1060   1104   100% -0.09[-0.23,0.05]
Heterogeneity: Tau2=0.02; Chi2=13.4, df=5(P=0.02); I2=62.69%  
Test for overall effect: Z=1.25(P=0.21)  
   
5.33.3 Supplement (capsule)  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.33.4 Any combination  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Not applicable  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
 
 
Analysis 5.34.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 34 TC, mmoL/L - ALA - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.34.1 ALA replacing SFA  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.34.2 ALA replacing MUFA  
AlphaOmega - ALA 2010 605 -0.3 (1) 605 -0.3 (1) 100% -0.02[-0.13,0.09]
Subtotal *** 605   605   100% -0.02[-0.13,0.09]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.35(P=0.72)  
   
5.34.3 ALA replacing n-6  
MARGARIN 2002 49 -0.2 (0.7) 93 -0.4 (0.7) 100% 0.14[-0.1,0.38]
Subtotal *** 49   93   100% 0.14[-0.1,0.38]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.13(P=0.26)  
   
5.34.4 ALA replacing carbs/sugars  
Subtotal *** 0   0   Not estimable
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.34.5 ALA replacing nil/low n-3 placebo  
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 100% 0.3[-0.3,0.9]
Subtotal *** 18   17   100% 0.3[-0.3,0.9]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.98(P=0.33)  
   
5.34.6 Replacement unclear  
Dodin 2005 85 5.7 (0.7) 94 6 (0.7) 21.14% -0.3[-0.51,-0.09]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 3.05% -0.3[-0.86,0.26]
WAHA 2016 260 -0.2 (0.7) 254 -0 (0.6) 75.82% -0.18[-0.29,-0.07]
Subtotal *** 388   389   100% -0.21[-0.31,-0.11]
Heterogeneity: Tau2=0; Chi2=1.08, df=2(P=0.58); I2=0%  
Test for overall effect: Z=4.22(P<0.0001)  
Test for subgroup differences: Chi2=12.32, df=1 (P=0.01), I2=75.66%  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
 
 
Analysis 5.35.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 35 TC, mmoL/L - ALA - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.35.1 Medium duration 1 to < 2 years in study  
Dodin 2005 85 5.7 (0.7) 94 6 (0.7) 28.99% -0.3[-0.51,-0.09]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 5.46% -0.3[-0.86,0.26]
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 4.7% 0.3[-0.3,0.9]
WAHA 2016 260 -0.2 (0.7) 254 -0 (0.6) 60.85% -0.18[-0.29,-0.07]
Subtotal *** 406   406   100% -0.2[-0.33,-0.07]
Heterogeneity: Tau2=0; Chi2=3.75, df=3(P=0.29); I2=20.03%  
Test for overall effect: Z=2.92(P=0)  
   
5.35.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - ALA 2010 605 -0.3 (1) 605 -0.3 (1) 73.62% -0.02[-0.13,0.09]
MARGARIN 2002 49 -0.2 (0.7) 93 -0.4 (0.7) 26.38% 0.14[-0.1,0.38]
Subtotal *** 654   698   100% 0.02[-0.12,0.16]
Heterogeneity: Tau2=0; Chi2=1.39, df=1(P=0.24); I2=27.95%  
Test for overall effect: Z=0.31(P=0.75)  
   
5.35.3 Long duration ≥ 4 years in study  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=5.08, df=1 (P=0.02), I2=80.33%  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
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Analysis 5.36.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 36 TC, mmoL/L - ALA - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.36.1 ALA - ≥ 50% of control group on statins  
AlphaOmega - ALA 2010 605 -0.3 (1) 605 -0.3 (1) 90.71% -0.02[-0.13,0.09]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 5.01% -0.3[-0.86,0.26]
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 4.28% 0.3[-0.3,0.9]
Subtotal *** 666   663   100% -0.02[-0.15,0.11]
Heterogeneity: Tau2=0; Chi2=2.06, df=2(P=0.36); I2=2.85%  
Test for overall effect: Z=0.32(P=0.75)  
   
5.36.2 ALA - < 50% of control group on statins  
MARGARIN 2002 49 -0.2 (0.7) 93 -0.4 (0.7) 100% 0.14[-0.1,0.38]
Subtotal *** 49   93   100% 0.14[-0.1,0.38]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.13(P=0.26)  
   
5.36.3 ALA - use of statins unclear  
Dodin 2005 85 5.7 (0.7) 94 6 (0.7) 21.8% -0.3[-0.51,-0.09]
WAHA 2016 260 -0.2 (0.7) 254 -0 (0.6) 78.2% -0.18[-0.29,-0.07]
Subtotal *** 345   348   100% -0.21[-0.3,-0.11]
Heterogeneity: Tau2=0; Chi2=0.97, df=1(P=0.32); I2=0%  
Test for overall effect: Z=4.1(P<0.0001)  
Test for subgroup differences: Chi2=9.71, df=1 (P=0.01), I2=79.4%  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
 
 
Analysis 5.37.   Comparison 5 High vs low ALA omega-3 fat (secondary outcomes),
Outcome 37 TC, mmoL/L - ALA - subgroup by primary or secondary preventionA.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.37.1 Primary prevention of CVD  
Dodin 2005 85 5.7 (0.7) 94 6 (0.7) 28.51% -0.3[-0.51,-0.09]
HERO 2009 18 4.9 (0.8) 17 4.6 (1) 9.26% 0.3[-0.3,0.9]
MARGARIN 2002 49 -0.2 (0.7) 93 -0.4 (0.7) 26.12% 0.14[-0.1,0.38]
WAHA 2016 260 -0.2 (0.7) 254 -0 (0.6) 36.11% -0.18[-0.29,-0.07]
Subtotal *** 412   458   100% -0.09[-0.3,0.12]
Heterogeneity: Tau2=0.03; Chi2=9.86, df=3(P=0.02); I2=69.59%  
Test for overall effect: Z=0.81(P=0.42)  
   
5.37.2 Secondary prevention of CVD  
AlphaOmega - ALA 2010 605 -0.3 (1) 605 -0.3 (1) 96.21% -0.02[-0.13,0.09]
FLAX-PAD 2013 43 4.2 (1.3) 41 4.5 (1.3) 3.79% -0.3[-0.86,0.26]
Subtotal *** 648   646   100% -0.03[-0.14,0.08]
Heterogeneity: Tau2=0; Chi2=0.94, df=1(P=0.33); I2=0%  
Test for overall effect: Z=0.55(P=0.58)  
Test for subgroup differences: Chi2=0.21, df=1 (P=0.64), I2=0%  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
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Analysis 5.38.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 38 Triglycerides, fasting, serum, mmoL/L - ALA.
Study or subgroup Favours high-
er omega 3
Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
AlphaOmega - ALA 2010 605 -0.1 (1) 605 -0 (1) 52.2% -0.06[-0.17,0.05]
Dodin 2005 85 1.2 (0.5) 94 1.2 (0.7) 18.79% -0.02[-0.2,0.16]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 5.38% 0.2[-0.14,0.54]
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.35% 0.3[-0.39,0.99]
MARGARIN 2002 49 0.2 (0.8) 93 0.1 (0.9) 7.61% 0.13[-0.16,0.42]
MENU 2016 65 1.1 (0.6) 61 1.3 (0.6) 14.67% -0.12[-0.33,0.09]
   
Total *** 865   911   100% -0.03[-0.11,0.05]
Heterogeneity: Tau2=0; Chi2=4.79, df=5(P=0.44); I2=0%  
Test for overall effect: Z=0.69(P=0.49)  
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
 
 
Analysis 5.39.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 39 TG, fasting, mmoL/L - ALA - SA fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
AlphaOmega - ALA 2010 605 -0.1 (1) 605 -0 (1) 52.2% -0.06[-0.17,0.05]
Dodin 2005 85 1.2 (0.5) 94 1.2 (0.7) 18.79% -0.02[-0.2,0.16]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 5.38% 0.2[-0.14,0.54]
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.35% 0.3[-0.39,0.99]
MARGARIN 2002 49 0.2 (0.8) 93 0.1 (0.9) 7.61% 0.13[-0.16,0.42]
MENU 2016 65 1.1 (0.6) 61 1.3 (0.6) 14.67% -0.12[-0.33,0.09]
   
Total *** 865   911   100% -0.03[-0.11,0.05]
Heterogeneity: Tau2=0; Chi2=4.79, df=5(P=0.44); I2=0%  
Test for overall effect: Z=0.69(P=0.49)  
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
 
 
Analysis 5.40.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 40 TG, fasting, mmoL/L- ALA - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.40.1 Low risk of bias  
AlphaOmega - ALA 2010 605 -0.1 (1) 605 -0 (1) 59.71% -0.06[-0.17,0.05]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 17.52% 0.2[-0.14,0.54]
MARGARIN 2002 49 0.2 (0.8) 93 0.1 (0.9) 22.77% 0.13[-0.16,0.42]
Subtotal *** 697   739   100% 0.03[-0.13,0.19]
Heterogeneity: Tau2=0.01; Chi2=3.1, df=2(P=0.21); I2=35.57%  
Test for overall effect: Z=0.35(P=0.73)  
   
5.40.2 Moderate/high risk of bias  
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Dodin 2005 85 1.2 (0.5) 94 1.2 (0.7) 53.99% -0.02[-0.2,0.16]
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 3.88% 0.3[-0.39,0.99]
MENU 2016 65 1.1 (0.6) 61 1.3 (0.6) 42.13% -0.12[-0.33,0.09]
Subtotal *** 168   172   100% -0.05[-0.18,0.09]
Heterogeneity: Tau2=0; Chi2=1.53, df=2(P=0.46); I2=0%  
Test for overall effect: Z=0.72(P=0.47)  
Test for subgroup differences: Chi2=0.53, df=1 (P=0.47), I2=0%  
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
 
 
Analysis 5.41.   Comparison 5 High vs low ALA omega-3 fat (secondary outcomes),
Outcome 41 TG, fasting, mmoL/L- ALA - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.41.1 SA - low risk of compliance bias  
AlphaOmega - ALA 2010 605 -0.1 (1) 605 -0 (1) 55.97% -0.06[-0.17,0.05]
Dodin 2005 85 1.2 (0.5) 94 1.2 (0.7) 20.15% -0.02[-0.2,0.16]
MARGARIN 2002 49 0.2 (0.8) 93 0.1 (0.9) 8.16% 0.13[-0.16,0.42]
MENU 2016 65 1.1 (0.6) 61 1.3 (0.6) 15.72% -0.12[-0.33,0.09]
Subtotal *** 804   853   100% -0.05[-0.13,0.04]
Heterogeneity: Tau2=0; Chi2=2.05, df=3(P=0.56); I2=0%  
Test for overall effect: Z=1.09(P=0.28)  
   
5.41.2 SA - 100+ randomised  
AlphaOmega - ALA 2010 605 -0.1 (1) 605 -0 (1) 55.97% -0.06[-0.17,0.05]
Dodin 2005 85 1.2 (0.5) 94 1.2 (0.7) 20.15% -0.02[-0.2,0.16]
MARGARIN 2002 49 0.2 (0.8) 93 0.1 (0.9) 8.16% 0.13[-0.16,0.42]
MENU 2016 65 1.1 (0.6) 61 1.3 (0.6) 15.72% -0.12[-0.33,0.09]
Subtotal *** 804   853   100% -0.05[-0.13,0.04]
Heterogeneity: Tau2=0; Chi2=2.05, df=3(P=0.56); I2=0%  
Test for overall effect: Z=1.09(P=0.28)  
Test for subgroup differences: Not applicable  
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
 
 
Analysis 5.42.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 42 TG, fasting, mmoL/L - ALA - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.42.1 ALA low < 5 g/d  
AlphaOmega - ALA 2010 605 -0.1 (1) 605 -0 (1) 76.52% -0.06[-0.17,0.05]
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.98% 0.3[-0.39,0.99]
MENU 2016 65 1.1 (0.6) 61 1.3 (0.6) 21.5% -0.12[-0.33,0.09]
Subtotal *** 688   683   100% -0.07[-0.16,0.03]
Heterogeneity: Tau2=0; Chi2=1.36, df=2(P=0.51); I2=0%  
Test for overall effect: Z=1.33(P=0.18)  
   
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.42.2 ALA high > 5 g/d  
Dodin 2005 85 1.2 (0.5) 94 1.2 (0.7) 59.12% -0.02[-0.2,0.16]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 16.93% 0.2[-0.14,0.54]
MARGARIN 2002 49 0.2 (0.8) 93 0.1 (0.9) 23.95% 0.13[-0.16,0.42]
Subtotal *** 177   228   100% 0.05[-0.09,0.19]
Heterogeneity: Tau2=0; Chi2=1.58, df=2(P=0.45); I2=0%  
Test for overall effect: Z=0.74(P=0.46)  
Test for subgroup differences: Chi2=1.85, df=1 (P=0.17), I2=45.98%  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
 
 
Analysis 5.43.   Comparison 5 High vs low ALA omega-3 fat (secondary outcomes),
Outcome 43 TG, fasting, mmoL/L- ALA - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.43.1 Dietary advice  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.43.2 Supplemental foods  
AlphaOmega - ALA 2010 605 -0.1 (1) 605 -0 (1) 61.17% -0.06[-0.17,0.05]
Dodin 2005 85 1.2 (0.5) 94 1.2 (0.7) 22.02% -0.02[-0.2,0.16]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 6.31% 0.2[-0.14,0.54]
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.58% 0.3[-0.39,0.99]
MARGARIN 2002 49 0.2 (0.8) 93 0.1 (0.9) 8.92% 0.13[-0.16,0.42]
Subtotal *** 800   850   100% -0.01[-0.1,0.07]
Heterogeneity: Tau2=0; Chi2=3.91, df=4(P=0.42); I2=0%  
Test for overall effect: Z=0.28(P=0.78)  
   
5.43.3 Supplement (capsule)  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.43.4 Any combination  
MENU 2016 65 1.1 (0.6) 61 1.3 (0.6) 100% -0.12[-0.33,0.09]
Subtotal *** 65   61   100% -0.12[-0.33,0.09]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.13(P=0.26)  
Test for subgroup differences: Chi2=0.88, df=1 (P=0.35), I2=0%  
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
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Analysis 5.44.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 44 TG, fasting, mmoL/L-AL - subgroup by replacementA.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.44.1 ALA replacing SFA  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.44.2 ALA replacing MUFA  
AlphaOmega - ALA 2010 605 -0.1 (1) 605 -0 (1) 78.07% -0.06[-0.17,0.05]
MENU 2016 65 1.1 (0.6) 61 1.3 (0.6) 21.93% -0.12[-0.33,0.09]
Subtotal *** 670   666   100% -0.07[-0.17,0.02]
Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.62); I2=0%  
Test for overall effect: Z=1.47(P=0.14)  
   
5.44.3 ALA replacing n-6  
MARGARIN 2002 49 0.2 (0.8) 93 0.1 (0.9) 100% 0.13[-0.16,0.42]
Subtotal *** 49   93   100% 0.13[-0.16,0.42]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.88(P=0.38)  
   
5.44.4 ALA replacing carbs/sugars  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.44.5 ALA replacing nil/low n-3 placebo  
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 100% 0.3[-0.39,0.99]
Subtotal *** 18   17   100% 0.3[-0.39,0.99]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.86(P=0.39)  
   
5.44.6 Replacement unclear  
Dodin 2005 85 1.2 (0.5) 94 1.2 (0.7) 72.7% -0.02[-0.2,0.16]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 27.3% 0.2[-0.14,0.54]
Subtotal *** 128   135   100% 0.04[-0.15,0.23]
Heterogeneity: Tau2=0; Chi2=1.22, df=1(P=0.27); I2=18.17%  
Test for overall effect: Z=0.41(P=0.68)  
Test for subgroup differences: Chi2=3.33, df=1 (P=0.34), I2=9.8%  
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
 
 
Analysis 5.45.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 45 TG, fasting, mmoL/L- ALA - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.45.1 Medium duration 1 to < 2 years in study  
Dodin 2005 85 1.2 (0.5) 94 1.2 (0.7) 44.93% -0.02[-0.2,0.16]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 14.72% 0.2[-0.14,0.54]
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 3.86% 0.3[-0.39,0.99]
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
MENU 2016 65 1.1 (0.6) 61 1.3 (0.6) 36.48% -0.12[-0.33,0.09]
Subtotal *** 211   213   100% -0.01[-0.15,0.12]
Heterogeneity: Tau2=0; Chi2=3.29, df=3(P=0.35); I2=8.76%  
Test for overall effect: Z=0.17(P=0.87)  
   
5.45.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - ALA 2010 605 -0.1 (1) 605 -0 (1) 75.76% -0.06[-0.17,0.05]
MARGARIN 2002 49 0.2 (0.8) 93 0.1 (0.9) 24.24% 0.13[-0.16,0.42]
Subtotal *** 654   698   100% -0.01[-0.17,0.15]
Heterogeneity: Tau2=0.01; Chi2=1.45, df=1(P=0.23); I2=30.9%  
Test for overall effect: Z=0.17(P=0.86)  
   
5.45.3 Long duration ≥ 4 years in study  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=0, df=1 (P=0.98), I2=0%  
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
 
 
Analysis 5.46.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 46 TG, fasting, mmoL/L - ALA - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.46.1 ALA - ≥ 50% of control group on statins  
AlphaOmega - ALA 2010 605 -0.1 (1) 605 -0 (1) 68.07% -0.06[-0.17,0.05]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 24.23% 0.2[-0.14,0.54]
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 7.71% 0.3[-0.39,0.99]
Subtotal *** 666   663   100% 0.03[-0.17,0.23]
Heterogeneity: Tau2=0.01; Chi2=2.89, df=2(P=0.24); I2=30.74%  
Test for overall effect: Z=0.3(P=0.76)  
   
5.46.2 ALA - < 50% of control group on statins  
MARGARIN 2002 49 0.2 (0.8) 93 0.1 (0.9) 41.62% 0.13[-0.16,0.42]
MENU 2016 65 1.1 (0.6) 61 1.3 (0.6) 58.38% -0.12[-0.33,0.09]
Subtotal *** 114   154   100% -0.02[-0.26,0.23]
Heterogeneity: Tau2=0.01; Chi2=1.89, df=1(P=0.17); I2=47.09%  
Test for overall effect: Z=0.13(P=0.9)  
   
5.46.3 ALA - use of statins unclear  
Dodin 2005 85 1.2 (0.5) 94 1.2 (0.7) 100% -0.02[-0.2,0.16]
Subtotal *** 85   94   100% -0.02[-0.2,0.16]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.21(P=0.83)  
Test for subgroup differences: Chi2=0.15, df=1 (P=0.93), I2=0%  
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
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Analysis 5.47.   Comparison 5 High vs low ALA omega-3 fat (secondary outcomes),
Outcome 47 TG, fasting, mmoL/L- ALA - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.47.1 Primary prevention  
Dodin 2005 85 1.2 (0.5) 94 1.2 (0.7) 44.3% -0.02[-0.2,0.16]
HERO 2009 18 2.1 (1.3) 17 1.8 (0.7) 3.18% 0.3[-0.39,0.99]
MARGARIN 2002 49 0.2 (0.8) 93 0.1 (0.9) 17.95% 0.13[-0.16,0.42]
MENU 2016 65 1.1 (0.6) 61 1.3 (0.6) 34.57% -0.12[-0.33,0.09]
Subtotal *** 217   265   100% -0.02[-0.14,0.11]
Heterogeneity: Tau2=0; Chi2=2.75, df=3(P=0.43); I2=0%  
Test for overall effect: Z=0.28(P=0.78)  
   
5.47.2 Secondary prevention  
AlphaOmega - ALA 2010 605 -0.1 (1) 605 -0 (1) 70.42% -0.06[-0.17,0.05]
FLAX-PAD 2013 43 1.9 (0.9) 41 1.7 (0.7) 29.58% 0.2[-0.14,0.54]
Subtotal *** 648   646   100% 0.02[-0.22,0.25]
Heterogeneity: Tau2=0.02; Chi2=1.99, df=1(P=0.16); I2=49.76%  
Test for overall effect: Z=0.14(P=0.89)  
Test for subgroup differences: Chi2=0.07, df=1 (P=0.8), I2=0%  
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
 
 
Analysis 5.48.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 48 High-density lipoprotein, serum, mmoL/L - ALA.
Study or subgroup Favours low-
er omega 3
Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
AlphaOmega - ALA 2010 605 0.1 (0.3) 605 0.2 (0.3) 33.71% -0.02[-0.05,0.01]
Dodin 2005 85 1.7 (0.4) 94 1.8 (0.4) 14.75% -0.09[-0.2,0.02]
FLAX-PAD 2013 43 1.1 (0.3) 41 1.2 (0.3) 14.75% -0.1[-0.21,0.01]
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 3.59% 0.1[-0.17,0.37]
MARGARIN 2002 49 0.1 (0.2) 93 0.1 (0.2) 22.74% -0.04[-0.11,0.03]
MENU 2016 65 1.7 (0.4) 61 1.6 (0.4) 10.46% 0.15[0.01,0.29]
   
Total *** 865   911   100% -0.02[-0.08,0.03]
Heterogeneity: Tau2=0; Chi2=10.58, df=5(P=0.06); I2=52.75%  
Test for overall effect: Z=0.91(P=0.36)  
Favours lower omega 3 0.50.25-0.5 -0.25 0 Favours higher omega 3
 
 
Analysis 5.49.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 49 HDL, mmoL/L - ALA - SA fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
AlphaOmega - ALA 2010 605 0.1 (0.3) 605 0.2 (0.3) 73.68% -0.02[-0.05,0.01]
Dodin 2005 85 1.7 (0.4) 94 1.8 (0.4) 5.11% -0.09[-0.2,0.02]
FLAX-PAD 2013 43 1.1 (0.3) 41 1.2 (0.3) 5.11% -0.1[-0.21,0.01]
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 0.83% 0.1[-0.17,0.37]
MARGARIN 2002 49 0.1 (0.2) 93 0.1 (0.2) 12.21% -0.04[-0.11,0.03]
MENU 2016 65 1.7 (0.4) 61 1.6 (0.4) 3.04% 0.15[0.01,0.29]
   
Total *** 865   911   100% -0.02[-0.05,0]
Heterogeneity: Tau2=0; Chi2=10.58, df=5(P=0.06); I2=52.75%  
Test for overall effect: Z=1.94(P=0.05)  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
 
 
Analysis 5.50.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 50 HDL, mmoL/L - ALA - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.50.1 Low risk of bias  
AlphaOmega - ALA 2010 605 0.1 (0.3) 605 0.2 (0.3) 76.15% -0.02[-0.05,0.01]
FLAX-PAD 2013 43 1.1 (0.3) 41 1.2 (0.3) 7.22% -0.1[-0.21,0.01]
MARGARIN 2002 49 0.1 (0.2) 93 0.1 (0.2) 16.63% -0.04[-0.11,0.03]
Subtotal *** 697   739   100% -0.03[-0.06,0]
Heterogeneity: Tau2=0; Chi2=2.16, df=2(P=0.34); I2=7.5%  
Test for overall effect: Z=1.96(P=0.05)  
   
5.50.2 Moderate/high risk of bias  
Dodin 2005 85 1.7 (0.4) 94 1.8 (0.4) 40.29% -0.09[-0.2,0.02]
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 23.05% 0.1[-0.17,0.37]
MENU 2016 65 1.7 (0.4) 61 1.6 (0.4) 36.67% 0.15[0.01,0.29]
Subtotal *** 168   172   100% 0.04[-0.14,0.22]
Heterogeneity: Tau2=0.02; Chi2=7.72, df=2(P=0.02); I2=74.1%  
Test for overall effect: Z=0.46(P=0.65)  
Test for subgroup differences: Chi2=0.59, df=1 (P=0.44), I2=0%  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
 
 
Analysis 5.51.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 51 HDL, mmoL/L - ALA - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.51.1 SA - low risk of compliance bias  
AlphaOmega - ALA 2010 605 0.1 (0.3) 605 0.2 (0.3) 40.51% -0.02[-0.05,0.01]
Dodin 2005 85 1.7 (0.4) 94 1.8 (0.4) 18.41% -0.09[-0.2,0.02]
MARGARIN 2002 49 0.1 (0.2) 93 0.1 (0.2) 27.92% -0.04[-0.11,0.03]
MENU 2016 65 1.7 (0.4) 61 1.6 (0.4) 13.16% 0.15[0.01,0.29]
Subtotal *** 804   853   100% -0.02[-0.08,0.04]
Heterogeneity: Tau2=0; Chi2=7.74, df=3(P=0.05); I2=61.25%  
Test for overall effect: Z=0.53(P=0.6)  
   
5.51.2 SA - 100+ randomised  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
AlphaOmega - ALA 2010 605 0.1 (0.3) 605 0.2 (0.3) 40.51% -0.02[-0.05,0.01]
Dodin 2005 85 1.7 (0.4) 94 1.8 (0.4) 18.41% -0.09[-0.2,0.02]
MARGARIN 2002 49 0.1 (0.2) 93 0.1 (0.2) 27.92% -0.04[-0.11,0.03]
MENU 2016 65 1.7 (0.4) 61 1.6 (0.4) 13.16% 0.15[0.01,0.29]
Subtotal *** 804   853   100% -0.02[-0.08,0.04]
Heterogeneity: Tau2=0; Chi2=7.74, df=3(P=0.05); I2=61.25%  
Test for overall effect: Z=0.53(P=0.6)  
Test for subgroup differences: Not applicable  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
 
 
Analysis 5.52.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 52 HDL, mmoL/L - ALA - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.52.1 ALA low < 5 g/d  
AlphaOmega - ALA 2010 605 0.1 (0.3) 605 0.2 (0.3) 50.51% -0.02[-0.05,0.01]
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 16.66% 0.1[-0.17,0.37]
MENU 2016 65 1.7 (0.4) 61 1.6 (0.4) 32.83% 0.15[0.01,0.29]
Subtotal *** 688   683   100% 0.06[-0.08,0.19]
Heterogeneity: Tau2=0.01; Chi2=6.24, df=2(P=0.04); I2=67.97%  
Test for overall effect: Z=0.83(P=0.41)  
   
5.52.2 ALA high > 5 g/d  
Dodin 2005 85 1.7 (0.4) 94 1.8 (0.4) 22.79% -0.09[-0.2,0.02]
FLAX-PAD 2013 43 1.1 (0.3) 41 1.2 (0.3) 22.78% -0.1[-0.21,0.01]
MARGARIN 2002 49 0.1 (0.2) 93 0.1 (0.2) 54.43% -0.04[-0.11,0.03]
Subtotal *** 177   228   100% -0.07[-0.12,-0.01]
Heterogeneity: Tau2=0; Chi2=1.12, df=2(P=0.57); I2=0%  
Test for overall effect: Z=2.5(P=0.01)  
Test for subgroup differences: Chi2=2.82, df=1 (P=0.09), I2=64.58%  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
 
 
Analysis 5.53.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 53 HDL, mmoL/L - ALA - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.53.1 Dietary advice  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.53.2 Supplemental foods  
AlphaOmega - ALA 2010 605 0.1 (0.3) 605 0.2 (0.3) 67.42% -0.02[-0.05,0.01]
Dodin 2005 85 1.7 (0.4) 94 1.8 (0.4) 7.36% -0.09[-0.2,0.02]
FLAX-PAD 2013 43 1.1 (0.3) 41 1.2 (0.3) 7.36% -0.1[-0.21,0.01]
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 1.24% 0.1[-0.17,0.37]
MARGARIN 2002 49 0.1 (0.2) 93 0.1 (0.2) 16.61% -0.04[-0.11,0.03]
Subtotal *** 800   850   100% -0.03[-0.06,-0]
Heterogeneity: Tau2=0; Chi2=4.34, df=4(P=0.36); I2=7.83%  
Test for overall effect: Z=2.17(P=0.03)  
   
5.53.3 Supplement (capsule)  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.53.4 Any combination  
MENU 2016 65 1.7 (0.4) 61 1.6 (0.4) 100% 0.15[0.01,0.29]
Subtotal *** 65   61   100% 0.15[0.01,0.29]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.12(P=0.03)  
Test for subgroup differences: Chi2=6.4, df=1 (P=0.01), I2=84.37%  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
 
 
Analysis 5.54.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 54 HDL, mmoL/L - ALA - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.54.1 ALA replacing SFA  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.54.2 ALA replacing MUFA  
AlphaOmega - ALA 2010 605 0.1 (0.3) 605 0.2 (0.3) 58.29% -0.02[-0.05,0.01]
MENU 2016 65 1.7 (0.4) 61 1.6 (0.4) 41.71% 0.15[0.01,0.29]
Subtotal *** 670   666   100% 0.05[-0.11,0.22]
Heterogeneity: Tau2=0.01; Chi2=5.55, df=1(P=0.02); I2=81.99%  
Test for overall effect: Z=0.61(P=0.54)  
   
5.54.3 ALA replacing n-6  
MARGARIN 2002 49 0.1 (0.2) 93 0.1 (0.2) 100% -0.04[-0.11,0.03]
Subtotal *** 49   93   100% -0.04[-0.11,0.03]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.13(P=0.26)  
   
5.54.4 ALA replacing carbs/sugars  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.54.5 ALA replacing nil/low n-3 placebo  
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 100% 0.1[-0.17,0.37]
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Subtotal *** 18   17   100% 0.1[-0.17,0.37]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.74(P=0.46)  
   
5.54.6 Replacement unclear  
Dodin 2005 85 1.7 (0.4) 94 1.8 (0.4) 50% -0.09[-0.2,0.02]
FLAX-PAD 2013 43 1.1 (0.3) 41 1.2 (0.3) 50% -0.1[-0.21,0.01]
Subtotal *** 128   135   100% -0.09[-0.17,-0.02]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.9); I2=0%  
Test for overall effect: Z=2.46(P=0.01)  
Test for subgroup differences: Chi2=4.12, df=1 (P=0.25), I2=27.16%  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
 
 
Analysis 5.55.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 55 HDL, mmoL/L - ALA - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.55.1 Medium duration 1 to < 2 years in study  
Dodin 2005 85 1.7 (0.4) 94 1.8 (0.4) 29.75% -0.09[-0.2,0.02]
FLAX-PAD 2013 43 1.1 (0.3) 41 1.2 (0.3) 29.75% -0.1[-0.21,0.01]
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 14.41% 0.1[-0.17,0.37]
MENU 2016 65 1.7 (0.4) 61 1.6 (0.4) 26.09% 0.15[0.01,0.29]
Subtotal *** 211   213   100% -0[-0.13,0.13]
Heterogeneity: Tau2=0.01; Chi2=10.26, df=3(P=0.02); I2=70.75%  
Test for overall effect: Z=0.05(P=0.96)  
   
5.55.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - ALA 2010 605 0.1 (0.3) 605 0.2 (0.3) 85.78% -0.02[-0.05,0.01]
MARGARIN 2002 49 0.1 (0.2) 93 0.1 (0.2) 14.22% -0.04[-0.11,0.03]
Subtotal *** 654   698   100% -0.02[-0.05,0]
Heterogeneity: Tau2=0; Chi2=0.28, df=1(P=0.6); I2=0%  
Test for overall effect: Z=1.72(P=0.09)  
   
5.55.3 Long duration ≥ 4 years in study  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=0.09, df=1 (P=0.77), I2=0%  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
 
 
Analysis 5.56.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 56 HDL, mmoL/L - ALA - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.56.1 ALA - ≥ 50% of control group on statins  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
AlphaOmega - ALA 2010 605 0.1 (0.3) 605 0.2 (0.3) 71.25% -0.02[-0.05,0.01]
FLAX-PAD 2013 43 1.1 (0.3) 41 1.2 (0.3) 23.7% -0.1[-0.21,0.01]
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 5.05% 0.1[-0.17,0.37]
Subtotal *** 666   663   100% -0.03[-0.09,0.03]
Heterogeneity: Tau2=0; Chi2=2.86, df=2(P=0.24); I2=30%  
Test for overall effect: Z=1.05(P=0.29)  
   
5.56.2 ALA - < 50% of control group on statins  
MARGARIN 2002 49 0.1 (0.2) 93 0.1 (0.2) 55.2% -0.04[-0.11,0.03]
MENU 2016 65 1.7 (0.4) 61 1.6 (0.4) 44.8% 0.15[0.01,0.29]
Subtotal *** 114   154   100% 0.05[-0.14,0.23]
Heterogeneity: Tau2=0.01; Chi2=5.78, df=1(P=0.02); I2=82.7%  
Test for overall effect: Z=0.48(P=0.63)  
   
5.56.3 ALA - use of statins unclear  
Dodin 2005 85 1.7 (0.4) 94 1.8 (0.4) 100% -0.09[-0.2,0.02]
Subtotal *** 85   94   100% -0.09[-0.2,0.02]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.65(P=0.1)  
Test for subgroup differences: Chi2=1.7, df=1 (P=0.43), I2=0%  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
 
 
Analysis 5.57.   Comparison 5 High vs low ALA omega-3 fat (secondary outcomes),
Outcome 57 HDL, mmoL/L - ALA - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.57.1 Low CVD risk  
Dodin 2005 85 1.7 (0.4) 94 1.8 (0.4) 51.76% -0.09[-0.2,0.02]
MENU 2016 65 1.7 (0.4) 61 1.6 (0.4) 48.24% 0.15[0.01,0.29]
Subtotal *** 150   155   100% 0.03[-0.21,0.26]
Heterogeneity: Tau2=0.02; Chi2=7.22, df=1(P=0.01); I2=86.15%  
Test for overall effect: Z=0.22(P=0.83)  
   
5.57.2 Moderate CVD risk  
HERO 2009 18 1.5 (0.4) 17 1.4 (0.4) 6.49% 0.1[-0.17,0.37]
MARGARIN 2002 49 0.1 (0.2) 93 0.1 (0.2) 93.51% -0.04[-0.11,0.03]
Subtotal *** 67   110   100% -0.03[-0.1,0.04]
Heterogeneity: Tau2=0; Chi2=1, df=1(P=0.32); I2=0.27%  
Test for overall effect: Z=0.9(P=0.37)  
   
5.57.3 High CVD risk  
Ahn 2016 38 1.2 (0.3) 36 1.1 (0.3) 12.61% 0.05[-0.1,0.2]
AlphaOmega - ALA 2010 605 0.1 (0.3) 605 0.2 (0.3) 66.69% -0.02[-0.05,0.01]
FLAX-PAD 2013 43 1.1 (0.3) 41 1.2 (0.3) 20.7% -0.1[-0.21,0.01]
Subtotal *** 686   682   100% -0.03[-0.08,0.03]
Heterogeneity: Tau2=0; Chi2=2.99, df=2(P=0.22); I2=33.19%  
Test for overall effect: Z=0.96(P=0.34)  
Test for subgroup differences: Chi2=0.21, df=1 (P=0.9), I2=0%  
Favours higher omega 3 10.5-1 -0.5 0 Favours lower omega 3
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Analysis 5.58.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 58 Low-density lipoprotein, serum, mmoL/L - ALA.
Study or subgroup Favours high-
er omega 3
Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
AlphaOmega - ALA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 29.13% 0.01[-0.07,0.09]
Dodin 2005 85 3.5 (0.7) 94 3.6 (0.7) 14.18% -0.19[-0.39,0.01]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 4.23% -0.1[-0.53,0.33]
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 3.33% -0.1[-0.59,0.39]
MARGARIN 2002 49 -0.4 (0.6) 93 -0.5 (0.7) 12.23% 0.14[-0.08,0.36]
MENU 2016 65 3 (0.8) 61 3 (0.6) 10.17% 0[-0.25,0.25]
WAHA 2016 260 -0.2 (0.5) 254 -0 (0.6) 26.73% -0.15[-0.25,-0.05]
   
Total *** 1080   1121   100% -0.05[-0.15,0.04]
Heterogeneity: Tau2=0.01; Chi2=11.05, df=6(P=0.09); I2=45.7%  
Test for overall effect: Z=1.14(P=0.25)  
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
 
 
Analysis 5.59.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 59 LDL, mmoL/L - ALA - SA fixed-e2ect.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
AlphaOmega - ALA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 45.17% 0.01[-0.07,0.09]
Dodin 2005 85 3.5 (0.7) 94 3.6 (0.7) 8.06% -0.19[-0.39,0.01]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 1.69% -0.1[-0.53,0.33]
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 1.3% -0.1[-0.59,0.39]
MARGARIN 2002 49 -0.4 (0.6) 93 -0.5 (0.7) 6.42% 0.14[-0.08,0.36]
MENU 2016 65 3 (0.8) 61 3 (0.6) 4.94% 0[-0.25,0.25]
WAHA 2016 260 -0.2 (0.5) 254 -0 (0.6) 32.43% -0.15[-0.25,-0.05]
   
Total *** 1080   1121   100% -0.05[-0.11,0]
Heterogeneity: Tau2=0; Chi2=11.05, df=6(P=0.09); I2=45.7%  
Test for overall effect: Z=1.88(P=0.06)  
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
 
 
Analysis 5.60.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 60 LDL, mmoL/L - ALA - SA by summary risk of bias.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.60.1 Low risk of bias  
AlphaOmega - ALA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 84.77% 0.01[-0.07,0.09]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 3.18% -0.1[-0.53,0.33]
MARGARIN 2002 49 -0.4 (0.6) 93 -0.5 (0.7) 12.05% 0.14[-0.08,0.36]
Subtotal *** 654   696   100% 0.02[-0.05,0.1]
Heterogeneity: Tau2=0; Chi2=1.49, df=2(P=0.47); I2=0%  
Favours higher omega 3 0.40.2-0.4 -0.2 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=0.57(P=0.57)  
   
5.60.2 Moderate/high risk of bias  
Dodin 2005 85 3.5 (0.7) 94 3.6 (0.7) 17.24% -0.19[-0.39,0.01]
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 2.77% -0.1[-0.59,0.39]
MENU 2016 65 3 (0.8) 61 3 (0.6) 10.58% 0[-0.25,0.25]
WAHA 2016 260 -0.2 (0.5) 254 -0 (0.6) 69.4% -0.15[-0.25,-0.05]
Subtotal *** 426   425   100% -0.14[-0.22,-0.06]
Heterogeneity: Tau2=0; Chi2=1.51, df=3(P=0.68); I2=0%  
Test for overall effect: Z=3.35(P=0)  
Test for subgroup differences: Chi2=8.05, df=1 (P=0), I2=87.57%  
Favours higher omega 3 0.40.2-0.4 -0.2 0 Favours lower omega 3
 
 
Analysis 5.61.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 61 LDL, mmoL/L - ALA - SA by compliance and study size.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.61.1 SA - low risk of compliance bias  
AlphaOmega - ALA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 29.26% 0.01[-0.07,0.09]
Dodin 2005 85 3.5 (0.7) 94 3.6 (0.7) 16.47% -0.19[-0.39,0.01]
MARGARIN 2002 49 -0.4 (0.6) 93 -0.5 (0.7) 14.51% 0.14[-0.08,0.36]
MENU 2016 65 3 (0.8) 61 3 (0.6) 12.33% 0[-0.25,0.25]
WAHA 2016 260 -0.2 (0.5) 254 -0 (0.6) 27.44% -0.15[-0.25,-0.05]
Subtotal *** 1021   1064   100% -0.05[-0.16,0.06]
Heterogeneity: Tau2=0.01; Chi2=10.97, df=4(P=0.03); I2=63.53%  
Test for overall effect: Z=0.88(P=0.38)  
   
5.61.2 SA - 100+ randomised  
AlphaOmega - ALA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 29.26% 0.01[-0.07,0.09]
Dodin 2005 85 3.5 (0.7) 94 3.6 (0.7) 16.47% -0.19[-0.39,0.01]
MARGARIN 2002 49 -0.4 (0.6) 93 -0.5 (0.7) 14.51% 0.14[-0.08,0.36]
MENU 2016 65 3 (0.8) 61 3 (0.6) 12.33% 0[-0.25,0.25]
WAHA 2016 260 -0.2 (0.5) 254 -0 (0.6) 27.44% -0.15[-0.25,-0.05]
Subtotal *** 1021   1064   100% -0.05[-0.16,0.06]
Heterogeneity: Tau2=0.01; Chi2=10.97, df=4(P=0.03); I2=63.53%  
Test for overall effect: Z=0.88(P=0.38)  
Test for subgroup differences: Chi2=0, df=1 (P=1), I2=0%  
Favours higher omega 3 0.20.1-0.2 -0.1 0 Favours lower omega 3
 
 
Analysis 5.62.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 62 LDL, mmoL/L - ALA - subgroup by dose.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.62.1 ALA low < 5 g/d  
AlphaOmega - ALA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 42.48% 0.01[-0.07,0.09]
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 4.57% -0.1[-0.59,0.39]
MENU 2016 65 3 (0.8) 61 3 (0.6) 14.19% 0[-0.25,0.25]
WAHA 2016 260 -0.2 (0.5) 254 -0 (0.6) 38.75% -0.15[-0.25,-0.05]
Subtotal *** 903   893   100% -0.06[-0.17,0.05]
Heterogeneity: Tau2=0.01; Chi2=6.18, df=3(P=0.1); I2=51.48%  
Test for overall effect: Z=1.05(P=0.29)  
   
5.62.2 ALA high > 5 g/d  
Dodin 2005 85 3.5 (0.7) 94 3.6 (0.7) 41.51% -0.19[-0.39,0.01]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 19.84% -0.1[-0.53,0.33]
MARGARIN 2002 49 -0.4 (0.6) 93 -0.5 (0.7) 38.65% 0.14[-0.08,0.36]
Subtotal *** 177   228   100% -0.04[-0.28,0.19]
Heterogeneity: Tau2=0.02; Chi2=4.86, df=2(P=0.09); I2=58.87%  
Test for overall effect: Z=0.37(P=0.71)  
Test for subgroup differences: Chi2=0.01, df=1 (P=0.92), I2=0%  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
 
 
Analysis 5.63.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 63 LDL, mmoL/L - ALA - subgroup by intervention type.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.63.1 Dietary advice  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.63.2 Supplemental foods  
AlphaOmega - ALA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 30.84% 0.01[-0.07,0.09]
Dodin 2005 85 3.5 (0.7) 94 3.6 (0.7) 16.52% -0.19[-0.39,0.01]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 5.29% -0.1[-0.53,0.33]
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 4.19% -0.1[-0.59,0.39]
MARGARIN 2002 49 -0.4 (0.6) 93 -0.5 (0.7) 14.45% 0.14[-0.08,0.36]
WAHA 2016 260 -0.2 (0.5) 254 -0 (0.6) 28.72% -0.15[-0.25,-0.05]
Subtotal *** 1015   1060   100% -0.06[-0.17,0.05]
Heterogeneity: Tau2=0.01; Chi2=10.87, df=5(P=0.05); I2=53.99%  
Test for overall effect: Z=1.12(P=0.26)  
   
5.63.3 Supplement (capsule)  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.63.4 Any combination  
MENU 2016 65 3 (0.8) 61 3 (0.6) 100% 0[-0.25,0.25]
Subtotal *** 65   61   100% 0[-0.25,0.25]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=0.19, df=1 (P=0.66), I2=0%  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
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Analysis 5.64.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 64 LDL, mmoL/L - ALA - subgroup by replacement.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.64.1 ALA replacing SFA  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.64.2 ALA replacing MUFA  
AlphaOmega - ALA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 90.14% 0.01[-0.07,0.09]
MENU 2016 65 3 (0.8) 61 3 (0.6) 9.86% 0[-0.25,0.25]
Subtotal *** 627   623   100% 0.01[-0.07,0.09]
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.94); I2=0%  
Test for overall effect: Z=0.22(P=0.82)  
   
5.64.3 ALA replacing n-6  
MARGARIN 2002 49 -0.4 (0.6) 93 -0.5 (0.7) 100% 0.14[-0.08,0.36]
Subtotal *** 49   93   100% 0.14[-0.08,0.36]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.25(P=0.21)  
   
5.64.4 ALA replacing carbs/sugars  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
5.64.5 ALA replacing nil/low n-3 placebo  
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 100% -0.1[-0.59,0.39]
Subtotal *** 16   16   100% -0.1[-0.59,0.39]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.4(P=0.69)  
   
5.64.6 Replacement unclear  
Dodin 2005 85 3.5 (0.7) 94 3.6 (0.7) 19.1% -0.19[-0.39,0.01]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 4.01% -0.1[-0.53,0.33]
WAHA 2016 260 -0.2 (0.5) 254 -0 (0.6) 76.89% -0.15[-0.25,-0.05]
Subtotal *** 388   389   100% -0.16[-0.24,-0.07]
Heterogeneity: Tau2=0; Chi2=0.19, df=2(P=0.91); I2=0%  
Test for overall effect: Z=3.55(P=0)  
Test for subgroup differences: Chi2=10.85, df=1 (P=0.01), I2=72.35%  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
 
 
Analysis 5.65.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 65 LDL, mmoL/L - ALA - subgroup by duration.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.65.1 Medium duration 1 to < 2 years in study  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Dodin 2005 85 3.5 (0.7) 94 3.6 (0.7) 16.64% -0.19[-0.39,0.01]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 3.49% -0.1[-0.53,0.33]
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 2.68% -0.1[-0.59,0.39]
MENU 2016 65 3 (0.8) 61 3 (0.6) 10.21% 0[-0.25,0.25]
WAHA 2016 260 -0.2 (0.5) 254 -0 (0.6) 66.98% -0.15[-0.25,-0.05]
Subtotal *** 469   466   100% -0.14[-0.22,-0.06]
Heterogeneity: Tau2=0; Chi2=1.54, df=4(P=0.82); I2=0%  
Test for overall effect: Z=3.38(P=0)  
   
5.65.2 Medium-long duration: 2 to < 4 years in study  
AlphaOmega - ALA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 82.02% 0.01[-0.07,0.09]
MARGARIN 2002 49 -0.4 (0.6) 93 -0.5 (0.7) 17.98% 0.14[-0.08,0.36]
Subtotal *** 611   655   100% 0.03[-0.06,0.13]
Heterogeneity: Tau2=0; Chi2=1.17, df=1(P=0.28); I2=14.74%  
Test for overall effect: Z=0.67(P=0.5)  
   
5.65.3 Long duration ≥ 4 years in study  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=7.07, df=1 (P=0.01), I2=85.86%  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
 
 
Analysis 5.66.   Comparison 5 High vs low ALA omega-3 fat (secondary
outcomes), Outcome 66 LDL, mmoL/L - ALA - subgroup by statin use.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.66.1 ALA - ≥ 50% of control group on statins  
AlphaOmega - ALA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 93.79% 0.01[-0.07,0.09]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 3.51% -0.1[-0.53,0.33]
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 2.69% -0.1[-0.59,0.39]
Subtotal *** 621   619   100% 0[-0.08,0.08]
Heterogeneity: Tau2=0; Chi2=0.42, df=2(P=0.81); I2=0%  
Test for overall effect: Z=0.08(P=0.94)  
   
5.66.2 ALA - < 50% of control group on statins  
MARGARIN 2002 49 -0.4 (0.6) 93 -0.5 (0.7) 56.52% 0.14[-0.08,0.36]
MENU 2016 65 3 (0.8) 61 3 (0.6) 43.48% 0[-0.25,0.25]
Subtotal *** 114   154   100% 0.08[-0.09,0.24]
Heterogeneity: Tau2=0; Chi2=0.68, df=1(P=0.41); I2=0%  
Test for overall effect: Z=0.94(P=0.35)  
   
5.66.3 ALA - use of statins unclear  
Dodin 2005 85 3.5 (0.7) 94 3.6 (0.7) 19.9% -0.19[-0.39,0.01]
WAHA 2016 260 -0.2 (0.5) 254 -0 (0.6) 80.1% -0.15[-0.25,-0.05]
Subtotal *** 345   348   100% -0.16[-0.25,-0.07]
Heterogeneity: Tau2=0; Chi2=0.13, df=1(P=0.72); I2=0%  
Test for overall effect: Z=3.53(P=0)  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for subgroup differences: Chi2=9.83, df=1 (P=0.01), I2=79.65%  
Favours higher omega 3 21-2 -1 0 Favours lower omega 3
 
 
Analysis 5.67.   Comparison 5 High vs low ALA omega-3 fat (secondary outcomes),
Outcome 67 LDL, mmoL/L - ALA - subgroup by primary or secondary prevention.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.67.1 Primary prevention of CVD  
Dodin 2005 85 3.5 (0.7) 94 3.6 (0.7) 21.73% -0.19[-0.39,0.01]
HERO 2009 16 2.4 (0.6) 16 2.5 (0.8) 5.51% -0.1[-0.59,0.39]
MARGARIN 2002 49 -0.4 (0.6) 93 -0.5 (0.7) 19% 0.14[-0.08,0.36]
MENU 2016 65 3 (0.8) 61 3 (0.6) 16.03% 0[-0.25,0.25]
WAHA 2016 260 -0.2 (0.5) 254 -0 (0.6) 37.73% -0.15[-0.25,-0.05]
Subtotal *** 475   518   100% -0.08[-0.2,0.05]
Heterogeneity: Tau2=0.01; Chi2=6.96, df=4(P=0.14); I2=42.52%  
Test for overall effect: Z=1.23(P=0.22)  
   
5.67.2 Secondary prevention of CVD  
AlphaOmega - ALA 2010 562 -0.4 (0.7) 562 -0.4 (0.7) 96.39% 0.01[-0.07,0.09]
FLAX-PAD 2013 43 2.3 (1.1) 41 2.4 (0.9) 3.61% -0.1[-0.53,0.33]
Subtotal *** 605   603   100% 0.01[-0.08,0.09]
Heterogeneity: Tau2=0; Chi2=0.24, df=1(P=0.62); I2=0%  
Test for overall effect: Z=0.14(P=0.88)  
Test for subgroup differences: Chi2=1.22, df=1 (P=0.27), I2=18.32%  
Favours higher omega 3 0.50.25-0.5 -0.25 0 Favours lower omega 3
 
 
Comparison 6.   High vs low ALA omega-3 fats (tertiary outcomes)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Blood pressure, mmHg - ALA 4   Mean Difference (IV, Random,
95% CI)
Subtotals only
1.1 Systolic BP - ALA 4 1671 Mean Difference (IV, Random,
95% CI)
-0.87 [-4.48, 2.75]
1.2 Diastolic BP - ALA 4 1671 Mean Difference (IV, Random,
95% CI)
-1.42 [-4.40, 1.57]
2 Serious adverse events - ALA 2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Any serious adverse events 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Bleeding 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 GI hospitalisation 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2.4 Pulmonary embolus or DVT 1 708 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.01, 7.80]
2.5 Thrombophleibitis 1 13406 Risk Ratio (M-H, Random, 95% CI) 1.59 [0.72, 3.51]
2.6 Urolithiasis 1 13406 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.47, 1.36]
3 Side effects - ALA 5   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Dropouts due to side effects 5 3480 Risk Ratio (M-H, Random, 95% CI) 2.10 [0.66, 6.71]
3.2 Abdominal pain or discomfort 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Diarrhoea 1 708 Risk Ratio (M-H, Random, 95% CI) 3.82 [0.82, 17.88]
3.4 Nausea 1 110 Risk Ratio (M-H, Random, 95% CI) 6.29 [0.33, 118.93]
3.5 Any gastrointestinal side effect - ALA 4 3450 Risk Ratio (M-H, Random, 95% CI) 2.06 [0.62, 6.80]
3.6 Pain (joint, lumbar, muscle pain) 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.7 All side effects combined 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Dropouts - ALA 6 3663 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.92, 1.25]
 
 
Analysis 6.1.   Comparison 6 High vs low ALA omega-3 fats
(tertiary outcomes), Outcome 1 Blood pressure, mmHg - ALA.
Study or subgroup Higher omega 3 Lower omega 3 Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
6.1.1 Systolic BP - ALA  
AlphaOmega - ALA 2010 632 -0.2 (20) 632 -2.3 (21.3) 39.11% 2.05[-0.23,4.33]
Dodin 2005 85 120.6 (14.4) 94 120.8 (17.1) 26.39% -0.2[-4.82,4.42]
FLAX-PAD 2013 45 136.2 (25.5) 41 145.6 (21.8) 10.21% -9.4[-19.39,0.59]
MARGARIN 2002 49 -2.9 (14.7) 93 -0.2 (14.5) 24.28% -2.7[-7.76,2.36]
Subtotal *** 811   860   100% -0.87[-4.48,2.75]
Heterogeneity: Tau2=7.36; Chi2=7.15, df=3(P=0.07); I2=58.03%  
Test for overall effect: Z=0.47(P=0.64)  
   
6.1.2 Diastolic BP - ALA  
AlphaOmega - ALA 2010 632 -1.8 (10.3) 632 -2.7 (10.3) 33.94% 0.96[-0.18,2.1]
Dodin 2005 85 75.5 (10.9) 94 76.1 (11.9) 24.68% -0.6[-3.94,2.74]
FLAX-PAD 2013 45 71.8 (11.4) 41 78.5 (9.6) 19.95% -6.7[-11.14,-2.26]
MARGARIN 2002 49 0.7 (11.9) 93 1.9 (11.6) 21.42% -1.2[-5.28,2.88]
Subtotal *** 811   860   100% -1.42[-4.4,1.57]
Heterogeneity: Tau2=6.51; Chi2=11.63, df=3(P=0.01); I2=74.2%  
Test for overall effect: Z=0.93(P=0.35)  
Favours higher omega 3 105-10 -5 0 Favours lower omega 3
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Analysis 6.2.   Comparison 6 High vs low ALA omega-3 fats
(tertiary outcomes), Outcome 2 Serious adverse events - ALA.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.2.1 Any serious adverse events  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
6.2.2 Bleeding  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
6.2.3 GI hospitalisation  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
6.2.4 Pulmonary embolus or DVT  
WAHA 2016 0/362 1/346 100% 0.32[0.01,7.8]
Subtotal (95% CI) 362 346 100% 0.32[0.01,7.8]
Total events: 0 (Higher omega 3), 1 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.7(P=0.48)  
   
6.2.5 Thrombophleibitis  
Norwegian 1968 16/6716 10/6690 100% 1.59[0.72,3.51]
Subtotal (95% CI) 6716 6690 100% 1.59[0.72,3.51]
Total events: 16 (Higher omega 3), 10 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.16(P=0.25)  
   
6.2.6 Urolithiasis  
Norwegian 1968 24/6716 30/6690 100% 0.8[0.47,1.36]
Subtotal (95% CI) 6716 6690 100% 0.8[0.47,1.36]
Total events: 24 (Higher omega 3), 30 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.83(P=0.41)  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
 
 
Analysis 6.3.   Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 3 Side e2ects - ALA.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.3.1 Dropouts due to side effects  
AlphaOmega - ALA 2010 18/1197 21/1236 42.09% 0.89[0.47,1.65]
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Dodin 2005 10/85 5/94 34.77% 2.21[0.79,6.21]
FLAX-PAD 2013 0/58 0/52   Not estimable
HERO 2009 1/26 0/24 10.59% 2.78[0.12,65.08]
WAHA 2016 13/362 0/346 12.55% 25.81[1.54,432.5]
Subtotal (95% CI) 1728 1752 100% 2.1[0.66,6.71]
Total events: 42 (Higher omega 3), 26 (Lower omega 3)  
Heterogeneity: Tau2=0.73; Chi2=7.86, df=3(P=0.05); I2=61.83%  
Test for overall effect: Z=1.25(P=0.21)  
   
6.3.2 Abdominal pain or discomfort  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
6.3.3 Diarrhoea  
WAHA 2016 8/362 2/346 100% 3.82[0.82,17.88]
Subtotal (95% CI) 362 346 100% 3.82[0.82,17.88]
Total events: 8 (Higher omega 3), 2 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.7(P=0.09)  
   
6.3.4 Nausea  
FLAX-PAD 2013 3/58 0/52 100% 6.29[0.33,118.93]
Subtotal (95% CI) 58 52 100% 6.29[0.33,118.93]
Total events: 3 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.23(P=0.22)  
   
6.3.5 Any gastrointestinal side effect - ALA  
AlphaOmega - ALA 2010 9/1197 10/1236 38.38% 0.93[0.38,2.28]
Dodin 2005 8/101 6/98 36.07% 1.29[0.47,3.59]
FLAX-PAD 2013 3/58 0/52 12.38% 6.29[0.33,118.93]
WAHA 2016 13/362 0/346 13.17% 25.81[1.54,432.5]
Subtotal (95% CI) 1718 1732 100% 2.06[0.62,6.8]
Total events: 33 (Higher omega 3), 16 (Lower omega 3)  
Heterogeneity: Tau2=0.76; Chi2=7.17, df=3(P=0.07); I2=58.14%  
Test for overall effect: Z=1.18(P=0.24)  
   
6.3.6 Pain (joint, lumbar, muscle pain)  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
6.3.7 All side effects combined  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 3), 0 (Lower omega 3)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours higher omega 3 100.1 50.2 20.5 1 Favours lower omega 3
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Analysis 6.4.   Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 4 Dropouts - ALA.
Study or subgroup Higher omega 3 Lower omega 3 Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
AlphaOmega - ALA 2010 189/1197 191/1236 68.26% 1.02[0.85,1.23]
Dodin 2005 26/101 17/98 7.86% 1.48[0.86,2.56]
FLAX-PAD 2013 15/58 11/52 5.01% 1.22[0.62,2.42]
HERO 2009 7/26 5/24 2.31% 1.29[0.47,3.53]
MENU 2016 13/82 12/81 4.47% 1.07[0.52,2.2]
WAHA 2016 38/362 34/346 12.11% 1.07[0.69,1.66]
   
Total (95% CI) 1826 1837 100% 1.08[0.92,1.25]
Total events: 288 (Higher omega 3), 270 (Lower omega 3)  
Heterogeneity: Tau2=0; Chi2=1.9, df=5(P=0.86); I2=0%  
Test for overall effect: Z=0.93(P=0.35)  
Favours higher omega 3 20.5 1.50.7 1 Favours lower omega 3
 
 
A D D I T I O N A L   T A B L E S
 
Risk of bias
element
Criteria for low risk of bias Criteria for
unclear
Criteria for high risk of bias
Selection
bias: ran-
dom se-
quence gen-
eration
The study authors needed to have described the method used
to generate the allocation sequence in sufficient detail to al-
low an assessment of whether it should produce comparable
groups. For example "the randomisation sequence was com-
puter generated". We allowed that a good method of randomi-
sation was strongly implied if the authors discussed stratifica-
tion and/or blocking. Therefore, if the authors were not explic-
it about their randomisation method but did describe stratifica-
tion or blocking we assessed this as corresponding to low risk.
The study
authors
have not de-
scribed their
method in
sufficient de-
tail for the
assessment
of whether
it would pro-
duce compa-
rable groups.
For example,
the authors
state "the tri-
al was ran-
domised"
and provide
no further in-
formation.
The randomisation method was
assessed as not truly random,
and may not produce compara-
ble groups.
Selection
bias: allo-
cation con-
cealment
The study authors needed to have described the method used
to conceal allocation sequence in sufficient detail to determine
whether the allocations could have been foreseen in advance
of, or during, enrolment. Good methods included putting allo-
cation codes in opaque sealed envelopes (ideally prepared by
someone outside the treatment or assessment teams and se-
quentially numbered), using a telephone allocation system af-
ter the participants had consented to participate or providing a
The authors
gave insuf-
ficient de-
tail as to
method.
The allocation was known in ad-
vance of participants consenting
to take part in the study.
Table 1.   Risk of bias assessment methods in greater detail 
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random number that links to a specific set of capsules prepared
and distributed centrally or by an arms-length pharmacist.
Perfor-
mance bias:
blinding of
participants
and person-
nel
The study authors needed to have described all measures used,
if any, to blind study participants and personnel from knowl-
edge of which intervention a participant received. Ideally, they
should also have provided information relating to whether the
intended blinding was effective. For example, the authors could
say "both the intervention and placebo capsules looked and
tasted the same." However, if the study authors did not provide
information on whether the blinding was effective, but suffi-
cient detail was given on a good method of blinding, then it was
assumed that the blinding was effective and the risk of bias was
low.
Insufficient
methodolog-
ical details
were provid-
ed e.g. "the
study was
blinded."
The study was unblinded or
where blinding was broken, e.g.
"the capsules were visually iden-
tical but the participants report-
ed a strong fishy flavour in the in-
tervention group only."
Detection
bias: blind-
ing of out-
come as-
sessment
Study authors needed to have described measures used, if any,
to blind outcome assessors from knowledge of which interven-
tion a participant received. Ideally, they should also have pro-
vided information relating to whether the intended blinding
was effective. For example, the authors could say "the outcome
assessors had no knowledge of the group allocation, and both
the intervention and placebo capsules looked and tasted the
same so the self-assessment scales were also blinded." Howev-
er if the study authors did not provide information on whether
the blinding was effective, but sufficient detail was given on a
good method of blinding of the assessors, then it was assumed
that the blinding was effective and the risk of bias is low. All bio-
chemical assessment (lipids, glucose, CRP, insulin, PSA, etc.)
were considered at low risk of detection bias if outcome asses-
sor blinding or double blinding was stated.
Insufficient
methodolog-
ical details
were provid-
ed e.g. "the
study was
blinded."
The study was unblinded or
blinding was broken, e.g. for a
self-assessment measure "the
capsules were visually identical
but the participants reported a
strong fishy flavour in the inter-
vention group only."
Because the level of blinding
could vary by outcome assess-
ment of risk of bias was based
on blinding of the review's pri-
mary outcome(s). Where prima-
ry outcomes had different assess-
ments we opted for the higher
risk of bias but noted that that
risk of bias was lower for other
outcomes.
Attrition
bias: incom-
plete out-
come data
The study authors needed to describe the completeness of out-
come data for each main outcome, including attrition and ex-
clusions from the analysis. They needed to report the num-
ber of attrition/exclusions, the numbers in each group at each
time point, reasons for attrition/exclusion and any re-inclusions
in analyses. Ideally, they would report how they imputed any
missing data e.g. last observation carried forward. There need-
ed to be a reasonable balance of attrition/exclusions between
study arms and ≤ 20% of the sample should be lost over a year.
The authors
didn't state
reasons for
attrition/ex-
clusion, or
were unclear
about the
numbers
lost to attri-
tion/exclu-
sion in each
study arm.
The authors demonstrated a sub-
stantial difference in the rates of
attrition/exclusions between the
study arms and/or > 20% of the
baseline sample was lost over a
year (> 10% over 6 months).
Reporting
bias: selec-
tive out-
come re-
porting
The study authors needed to have published their trial proto-
col or trials registry entry before the end of the study's recruit-
ment period i.e. prospectively. They needed to have reported
on all of the primary and secondary outcomes listed in the pro-
tocol/registry entry. Reporting additional secondary outcomes
in the results paper(s), although not ideal, was deemed to still
be low risk.
No trial pro-
tocol or tri-
als registry
entry was
found, it was
registered
retrospec-
tively, or
the dates of
registration
and partici-
pant recruit-
The study authors did not re-
port at least one primary or sec-
ondary outcome listed in the pro-
tocol/registry entry or the results
paper(s) reported a primary out-
come that was not listed at all in
the protocol or not listed as a pri-
mary outcome in the protocol.
Table 1.   Risk of bias assessment methods in greater detail  (Continued)
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ment were
unclear.
Other
sources of
bias: atten-
tion bias
The study authors needed to have reported that participants
in all study arms received the same amount of attention and
time from researchers and clinical teams. For example, "All par-
ticipants attended the clinic for a baseline assessment which
took 2 hours. They were then followed with monthly telephone
calls, and finally attended for a 6 month assessment at the clin-
ic which took 1 hour." If the study only differed by the content
of the capsules, and the assessment schedule was not stated to
differ between the two arms, it was assumed to be at low risk.
The authors
did not state
the attention
each arm re-
ceived.
Participants in different arms
received different amounts of
attention. For example "the in-
tervention group only attend-
ed for additional assessments at
months 2, 4, and 6" or "the rates
of relapse differed substantially
between the groups which led to
differing amounts of treatment
time and attention," or "the in-
tervention group received a 40
minute dietary education ses-
sion."
Other
sources of
bias: limited
compliance
The study authors needed to have reported on the level of com-
pliance in all arms in sufficient detail to determine whether the
study results were robust. We followed a flow chart to make this
determination. A statistically significant difference between the
intervention and control groups in a body measure of at least
50% of the text fatty acids. Where no body measures were re-
ported then estimated compliance needed to be greater than
64% (proportion complying multiplied by compliance thresh-
old).
Compliance
not report-
ed or not in
a way that
could be in-
terpreted.
Measures of compliance were re-
ported but fell below the appro-
priate thresholds.
Other
sources of
bias: other
In the absence of any additional issues this item was coded
"low risk of bias"
— If fraud concerns had been raised
and the paper had been with-
drawn, or the author had been
found guilty of fraud by a legal or
medical entity the paper was ex-
cluded from the review. However
if fraud concerns were raised, but
the journal had not withdrawn
the paper, and the author had
not been formally sanctioned;
then the study was included in
the review, but concerns were
raised here, and the risk of bias
for this item was high.
Table 1.   Risk of bias assessment methods in greater detail  (Continued)
CRP: C-reactive protein; PSA: prostate specific antigen.
 
 
Variable assessed P value
LCn3 dose 0.61
ALA dose 0.91
Omega-6 dose 0.81
Total PUFA dose 0.82
Duration, months 0.68
Table 2.   Meta-regression results for cardiovascular mortalitya 
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Primary or secondary CVD prevention 0.88
Food or capsule 0.54
Risk of bias 0.94
Food or capsule
+ LCn3 dose
+ duration
0.70
0.96
0.69
Table 2.   Meta-regression results for cardiovascular mortalitya  (Continued)
ALA: alpha-linolenic acid; CVD: cardiovascular disease; LCn3: long-chain omega-3 fatty acids; PUFA: poly-unsaturated fatty acids.
aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary or
secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on cardiovascular mortality. We
ran the meta-regression using all included trials that reported this outcome in this review, and its sister reviews (update of Hooper 2018,
and Abdelhamid 2018). For each variable the P value presented represents probability that the relationship was due to chance (as we
had limited power we assumed a true relationship when P < 0.10). Meta-regression was of each variable singly, plus a multivariate meta-
regression of the 3 single variables with lowest P values. See methods for further information.
 
 
Variable assessed P value
LCn3 dose 0.91
ALA dose 0.70
omega-6 dose 0.34
Total PUFA dose 0.34
Duration, months 0.62
Primary or secondary CVD prevention 0.78
Food or capsule 0.83
Risk of bias 0.24
Risk of bias
+ PUFA dose
+ Omega-6 dose
0.25
0.87
0.83
Table 3.   Meta-regression results for cardiovascular eventsa 
ALA: alpha-linolenic acid; CVD: cardiovascular disease; LCn3: long-chain omega-3 fatty acids; PUFA: poly-unsaturated fatty acids.
aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary or
secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on cardiovascular events. We
ran the meta-regression using all included trials that reported this outcome in this review, and its sister reviews (update of Hooper 2018,
and Abdelhamid 2018). For each variable the P value presented represents probability that the relationship was due to chance (as we
had limited power we assumed a true relationship when P < 0.10). Meta-regression was of each variable singly, plus a multivariate meta-
regression of the 3 single variables with lowest P values. See methods for further information.
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Variable assessed P value
LCn3 dose 0.94
ALA dose 0.93
Omega-6 dose 0.66
Total PUFA dose 0.64
Duration, months 0.41
Primary or secondary CVD prevention 0.63
Food or capsule 0.78
Risk of bias 0.89
Duration
+ Primary or secondary prevention
+ PUFA dose
0.73
0.90
0.76
Table 4.   Meta-regression results for CHD deathsa 
ALA: alpha-linolenic acid; CVD: cardiovascular disease; LCn3: long-chain omega-3 fatty acids; PUFA: poly-unsaturated fatty acids.
aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary or
secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on CHD mortality. We ran the meta-
regression using all included trials that reported this outcome in this review, and its sister reviews (update of Hooper 2018, and Abdelhamid
2018). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power
we assumed a true relationship when P < 0.10). Meta-regression was of each variable singly, plus a multivariate meta-regression of the 3
single variables with lowest P values. See methods for further information.
 
 
Variable assessed P value
LCn3 dose 0.68
ALA dose 0.23
Omega-6 dose 0.84
Total PUFA dose 0.79
Duration, months 0.87
Primary or secondary CVD prevention 0.42
Food or capsule 0.91
Risk of bias 0.98
ALA dose
+ Prim or sec prev
0.32
0.46
Table 5.   Metaregression results for CHD eventsa 
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+ LCn3 dose 0.86
Table 5.   Metaregression results for CHD eventsa  (Continued)
ALA: alpha-linolenic acid; CVD: cardiovascular disease; LCn3: long-chain omega-3 fatty acids; PUFA: poly-unsaturated fatty acids.
aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary or
secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on CHD events. We ran the meta-
regression using all included trials that reported this outcome in this review, and its sister reviews (update of Hooper 2018, and Abdelhamid
2018). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power
we assumed a true relationship when P < 0.10). Meta-regression was of each variable singly, plus a multivariate meta-regression of the 3
single variables with lowest P values. See methods for further information.
 
 
Variable assessed P value Coefficient sign where P < 0.10
LCn3 dose 0.42 —
ALA dose 0.81 —
Omega-6 dose 0.19 —
Total PUFA dose 0.21 —
Duration, months 0.012 Negative (greater effect with shorter dura-
tion)
Primary or secondary CVD prevention 0.04 Positive (greater effect with secondary pre-
vention)
Food or capsule 0.21 —
Risk of bias 0.25 —
Duration
+ primary or secondary prevention
+ omega-6
0.21
0.67
0.38
—
Table 6.   Metaregression results for strokea 
ALA: alpha-linolenic acid; CVD: cardiovascular disease; LCn3: long-chain omega-3 fatty acids; PUFA: poly-unsaturated fatty acids.
aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary or
secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on stroke. We ran the meta-
regression using all included trials that reported this outcome in this review, and its sister reviews (update of Hooper 2018, and Abdelhamid
2018). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power
we assumed a true relationship when P < 0.10). Meta-regression was of each variable singly, plus a multivariate meta-regression of the 3
single variables with lowest P values. See methods for further information.
 
 
Variable assessed P value Coefficient sign where P < 0.10
LCn3 dose 0.06 Negative (greater effect at lower dose)
ALA dose 0.67 —
Omega-6 dose 0.59 —
Table 7.   Meta-regression results for arrhythmiasa 
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Total PUFA dose 0.54 —
Duration, months 0.16 —
Primary or secondary CVD prevention 0.07 Negative (greater effect with primary pre-
vention)
Food or capsule 0.82 —
Risk of bias 0.51 —
LCn3 dose
+ Primary secondary prevention
+ duration
0.09
0.12
0.46
—
Table 7.   Meta-regression results for arrhythmiasa  (Continued)
ALA: alpha-linolenic acid; CVD: cardiovascular disease; LCn3: long-chain omega-3 fatty acids; PUFA: poly-unsaturated fatty acids.
aRandom-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary or
secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on arrhythmia. We ran the meta-
regression using all included trials that reported this outcome in this review, and its sister reviews (update of Hooper 2018, and Abdelhamid
2018). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power
we assumed a true relationship when P < 0.10). Meta-regression was of each variable singly, plus a multivariate meta-regression of the 3
single variables with lowest P values. See methods for further information.
 
 
Balk 2016 Aung 2018 This review 
No. of
people
experi-
encing
events
RR (95% CI) No, of
people
experi-
encing
events
RR (95% CI) No. of
people
experi-
encing
events
RR (95% CI)
All-cause mortali-
ty
8480 0.97 (0.92 to 1.03) — Not assessed 8647 0.98 (0.93 to 1.03)
Cardiovascular
deaths
3799 0.92 (0.82 to 1.02) — Not assessed 4763 0.95 (0.87 to 1.03)
CVD events (MAC-
CEs in Balk 2016)
8085 0.96 (0.91 to 1.02) 12001 0.97 (0.93 to 1.01) 15614 0.99 (0.94 to 1.04)
CHD deaths — Not pooled 2695 0.93, (0.83 to 1.03) 1791 0.93 (0.79 to 1.09)
CHD events — Not assessed 6273 0.96, (0.90 to 1.01) 5865 0.93 (0.88 to 0.97)
Stroke 1467 0.98 (0.88 to 1.09) 1713 1.03 (0.93 to 1.13) 1871 1.06 (0.96, 1.16)
Arrhythmia — Not pooled — Not assessed 3788 0.97 (0.90 to 1.05)
Table 8.   Comparison of the results of LCn3 interventions in this review with Balk 2016 and Aung 2018a  (Continued)
CHD: coronary heart disease; CI: confidence interval; CVD: cardiovascular disease; MACCE: major adverse cerebrovascular or cardiovas-
cular event; RR: risk ratio.
aMeta-analysis of effects of LCn3 in Balk 2016 and Aung 2018 systematic reviews, comparing their findings with our findings for our primary
outcomes.
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
520
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
 
A P P E N D I C E S
Appendix 1. Medline (Ovid) search strategy run in 2002 for the previous version of this review.
1 exp Fish Oils/
2 exp Linseed Oil/
3 linolenic acids/ or exp alpha-linolenic acid/
4 exp Fatty Acids, Omega-3/
5 (fish adj5 (diet$ or nutrit$ or oil$ or supplement$)).tw.
6 (oil$ adj3 (cod$ or marin$ or rapeseed$ or canola$)).tw.
7 (omega-3 or omega3).tw.
8 (eicosapentaen$ or icosapentaen$).tw.
9 docosahexaen$.tw.
10 (Linolen$ or alpha-linolen$ or alphalinolen$).tw.
11 (maxepa$ or omacor$).tw.
12 (trout or kipper$ or salmon or mackerel$ or tuna or tunafish or sardine$ or pilchard$ or herring$).tw.
13 flax$.tw.
14 rapeseed$.tw.
15 canola$.tw.
16 alphalinolen$.tw.
17 perilla$.tw.
18 linolen$.tw.
19 linseed$.tw.
20 maxepa$.tw.
21 (oil$ adj3 colza).tw.
22 (marin$ adj3 (lipid$ or oil$)).tw.
23 naudicelle$.tw.
24 sild.tw.
25 (clupe$ adj3 hareng$).tw.
26 whitebait$.tw.
27 sprat$.tw.
28 brisling$.tw.
29 (salmo adj3 trut$).tw.
30 bloater.tw.
31 scomb$.tw.
32 conger$.tw.
33 tunny.tw.
34 tuna-fish.tw.
35 thunnus$.tw.
36 swordfish$.tw.
37 xiphias$.tw.
38 dogfish.tw.
39 scyliorhinus$.tw.
40 (crab or crabs).tw.
41 (cancer adj3 pagurus).tw.
42 (laks or lax).tw.
43 exp Flax/
44 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or
27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
45 randomized controlled trial.pt.
46 controlled clinical trial.pt.
47 randomized.ab.
48 placebo.ab.
49 clinical trials as topic.sh.
50 randomly.ab.
51 trial.ti.
52 50 or 47 or 51 or 46 or 45 or 48 or 49
53 (animals not (human and animals)).sh.
54 52 not 53
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55 44 and 54
56 (20$ not (2000$ or 2001$)).ed.
57 55 and 56
Appendix 2. Searches run in July 2016 to update the omega-3 review
CENTRAL
#1 MeSH descriptor: [Fish Oils] explode all trees
#2 MeSH descriptor: [Linseed Oil] this term only
#3 MeSH descriptor: [Linolenic Acids] this term only
#4 MeSH descriptor: [Fatty Acids, Omega-3] explode all trees
#5 (fish near/3 oil*)
#6 (oil* near/3 (cod* or marin*))
#7 (omega-3 or omega3 or (omega* near/5 fat*))
#8 eicosapentaen*
#9 docosahexaen*
#10 (oil* near/3 (flax* or rapeseed* or canola*))
#11 (Linolen* or alpha-linolen* or alphalinolen*)
#12 (perilla* or linseed* or maxepa*)
#13 (oil* near/3 (rape or colza))
#14 (marin* near/3 lipid*)
#15 (naudicelle* or herring* or sild)
#16 (clupe* near/3 hareng*)
#17 (whitebait or sardine* or sardina* or pilchard* or sprat* or brisling*)
#18 (salmo* near/3 trut*)
#19 (trout or bloater or kipper* or salmon or mackerel* or scomb* or conger* or tuna or tunny or tunafish or tuna-fish)
#20 (thunnus* or swordfish* or xiphias* or dogfish or scyliorrhinus*)
#21 (crab or crabs or (cancer pagarus))
#22 (DHA or EPA)
#23 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or
#22 Publication Year from 2002 to 2016
#24 MeSH descriptor: [Salmoniformes] explode all trees
#25 MeSH descriptor: [Tuna] this term only
#26 MeSH descriptor: [alpha-Linolenic Acid] this term only
#27 MeSH descriptor: [Flax] this term only
#28 (fish near/3 (diet* or capsul* or nutrit* or supplement*))
#29 (icosapentaen* or docosapentaen*)
#30 (oil* near/3 (purslane or mustard* or candlenut* or stillingia or walnut*))
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#31 (laks or lax)
#32 (ALA or DPA)
#33 (algal near oil*)
#34 #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33
#35 #23 or #34
MEDLINE Ovid
1. exp Fish Oils/
2. Linseed Oil/
3. linolenic acids/ or alpha-linolenic acid/
4. Flax/
5. exp Fatty Acids, Omega-3/
6. (fish adj3 (diet* or nutrit* or oil* or supplement*)).ti,ab.
7. (oil* adj3 (cod* or marin*)).ti,ab.
8. (omega-3 or omega3 or (omega* adj5 fat*)).ti,ab.
9. eicosapentaen*.ti,ab.
10. docosahexaen*.ti,ab.
11. (oil* adj3 (flax* or rapeseed* or canola*)).ti,ab.
12. (Linolen* or alpha-linolen* or alphalinolen*).ti,ab.
13. (perilla* or linseed* or maxepa*).ti,ab.
14. (oil* adj3 (rape or colza)).ti,ab.
15. (marin* adj3 lipid*).ti,ab.
16. (naudicelle* or herring* or sild).ti,ab.
17. (clupe* adj3 hareng*).ti,ab.
18. (whitebait or sardine* or sardina* or pilchard* or sprat* or brisling*).ti,ab.
19. (salmo* adj3 trut*).ti,ab.
20. (trout or bloater or kipper* or salmon or mackerel* or scomb* or conger* or tuna or tunny or tunafish or tuna-fish).ti,ab.
21. (thunnus* or swordfish* or xiphias* or dogfish or scyliorrhinus* or laks or lax).ti,ab.
22. (crab or crabs or cancer pagarus).ti,ab.
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. randomized controlled trial.pt.
25. controlled clinical trial.pt.
26. randomized.ab.
27. placebo.ab.
28. clinical trials as topic.sh.
29. randomly.ab.
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30. trial.ti.
31. 24 or 25 or 26 or 27 or 28 or 29 or 30
32. exp animals/ not humans.sh.
33. 31 not 32
34. 23 and 33
35. limit 34 to ed=20020201-20160721
36. exp salmoniformes/ or tuna/
37. (fish adj3 capsul*).ti,ab.
38. icosapentaen*.ti,ab.
39. docosapentaen*.ti,ab.
40. (oil* adj3 (purslane or mustard* or candlenut* or stillingia or walnut*)).ti,ab.
41. 36 or 37 or 38 or 39 or 40
42. 33 and 41
43. 35 or 42
Embase Ovid
1. exp salmoniformes/ or tuna/
2. fish oil/
3. linseed oil/
4. linolenic acid/
5. Flax/
6. omega 3 fatty acid/
7. (fish adj3 (diet* or nutrit* or oil* or supplement*)).ti,ab.
8. (oil* adj3 (cod* or marin*)).ti,ab.
9. (omega-3 or omega3 or (omega* adj5 fat*)).ti,ab.
10. (eicosapentaen* or icosapentaen*).ti,ab.
11. docosahexaen*.ti,ab.
12. (oil* adj3 (flax* or rapeseed* or canola*)).ti,ab.
13. (Linolen* or alpha-linolen* or alphalinolen*).ti,ab.
14. (perilla* or linseed* or maxepa*).ti,ab.
15. (marin* adj3 lipid*).ti,ab.
16. (naudicelle* or herring* or sild).ti,ab.
17. (clupe* adj3 hareng*).ti,ab.
18. (whitebait or sardine* or sardina* or pilchard* or sprat* or brisling*).ti,ab.
19. (salmo* adj3 trut*).ti,ab.
20. (trout or bloater or kipper* or salmon or mackerel* or scomb* or conger* or tuna or tunny or tunafish or tuna-fish).ti,ab.
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21. (thunnus* or swordfish* or xiphias* or dogfish or scyliorrhinus* or laks or lax).ti,ab.
22. (crab or crabs or (cancer adj3 pagarus)).ti,ab.
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. random$.tw.
25. placebo$.tw.
26. (doubl$ adj blind$).tw.
27. (singl$ adj blind$).tw.
28. double blind procedure/
29. randomized controlled trial/
30. single blind procedure/
31. 24 or 25 or 26 or 27 or 28 or 29 or 30
32. (animal/ or nonhuman/) not human/
33. 31 not 32
34. 23 and 33
35. (2002* or 2003* or 2004* or 2005* or 2006* or 2007* or 2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015* or
2016*).dd,em.
36. 34 and 35
37. exp salmonine/
38. (fish adj3 capsul*).ti,ab.
39. docosapentaen*.ti,ab.
40. (ALA or DHA or DPA or EPA).ti,ab.
41. (algal adj oil*).ti,ab.
42. 37 or 38 or 39 or 40 or 41
43. 33 and 42
44. 36 or 43
Appendix 3. Searches run in April 2017 for allied reviews
These searches were developed and run to collect relevant trials for the systematic reviews on omega-6 fats (the update of Hooper 2018)
and on total PUFA fats (Abdelhamid 2018) on health. They are shown here as these searches were run with the searches for this review,
the identified titles and abstracts de-duplicated and combined, so that we assessed titles and abstracts for all three reviews together.
These searches were each run from database inception, due to the widening of the inclusion criteria, then de-duplicated with each other.
The RCT filter for MEDLINE is the Cochrane sensitivity and precision-maximising RCT filter, and for Embase, terms as recommended in the
Cochrane Handbook have been applied (Lefebvre 2011).
CENTRAL
#1 MeSH descriptor: [Fatty Acids, Essential] explode all trees
#2 MeSH descriptor: [Fatty Acids, Unsaturated] this term only
#3 ((polyunsaturat* or poly-unsaturat*) near/3 fat*)
#4 (poly* adj4 unsat* near/4 fatty acid*)
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#5 PUFA
#6 MeSH descriptor: [Fatty Acids, Omega-6] explode all trees
#7 omega-6
#8 (n-6 near/4 acid*) or ("n 6" near/4 acid*)
#9 linoleic acid*
#10 MeSH descriptor: [Corn Oil] this term only
#11 MeSH descriptor: [Cottonseed Oil] this term only
#12 MeSH descriptor: [Olive Oil] this term only
#13 MeSH descriptor: [Safflower Oil] this term only
#14 MeSH descriptor: [Sesame Oil] this term only
#15 MeSH descriptor: [Soybean Oil] this term only
#16 ((corn or maize or mazola) near/4 oil*)
#17 (cottonseed* or (cotton next seed*))
#18 (olive near/4 oil*)
#19 (safflower near/4 oil*)
#20 (sesame near/4 oil*)
#21 ((soy bean or soybean) near/4 (oil* or fat*))
#22 (so?a near/4 oil*)
#23 so?aoil*
#24 (soy near/4 oil*)
#25 (sunflower near/4 oil*)
#26 helianth*
#27 (grapeseed near/4 oil*)
#28 (canola near/4 oil*)
#29 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or
#22 or #23 or #24 or #25 or #26 or #27 or #28
MEDLINE Ovid
1. exp fatty acids, essential/
2. fatty acids, unsaturated/
3. ((polyunsaturat* or poly-unsaturat*) adj3 fat*).ti,ab.
4. (poly* adj4 unsat* adj4 fatty acid*).ti,ab.
5. PUFA.ti,ab.
6. exp fatty acids, omega-6/
7. omega-6.ti,ab.
8. (n-6 adj4 acid*).ti,ab.
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9. linoleic acid*.ti,ab.
10. corn oil/ or cottonseed oil/ or olive oil/ or safflower oil/ or sesame oil/ or soybean oil/
11. ((corn or maize or mazola) adj4 oil*).ti,ab.
12. (cottonseed* or (cotton adj seed*)).ti,ab.
13. (olive adj4 oil*).ti,ab.
14. (safflower adj4 oil*).ti,ab.
15. (sesame adj4 oil*).ti,ab.
16. ((soy bean or soybean) adj4 (oil* or fat*)).ti,ab.
17. (so?a adj4 oil*).ti,ab.
18. so?aoil*.ti,ab.
19. (soy adj4 oil*).ti,ab.
20. (sunflower adj4 oil*).ti,ab.
21. helianth*.ti,ab.
22. (grapeseed adj4 oil*).ti,ab.
23. (canola adj4 oil*).ti,ab.
24. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. randomized controlled trial.pt.
26. controlled clinical trial.pt.
27. randomized.ab.
28. placebo.ab.
29. clinical trials as topic.sh.
30. randomly.ab.
31. trial.ti.
32. 25 or 26 or 27 or 28 or 29 or 30 or 31
33. exp animals/ not humans.sh.
34. 32 not 33
35. 24 and 34
Embase Ovid
1. exp essential fatty acid/
2. unsaturated fatty acid/ or docosapentaenoic acid/ or omega 6 fatty acid/ or polyunsaturated fatty acid/
3. ((polyunsaturat* or poly-unsaturat*) adj3 fat*).ti,ab.
4. (poly* adj4 unsat* adj4 fatty acid*).ti,ab.
5. PUFA.ti,ab.
6. omega-6.ti,ab.
7. (n-6 adj4 acid*).ti,ab.
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8. linoleic acid*.ti,ab.
9. edible oil/ or canola oil/ or corn oil/ or cotton seed oil/ or olive oil/ or safflower oil/ or safflower oil plus soybean oil/ or sesame seed
oil/ or soybean oil/ or sunflower oil/
10. ((corn or maize or mazola) adj4 oil*).ti,ab.
11. (cottonseed* or (cotton adj seed*)).ti,ab.
12. (olive adj4 oil*).ti,ab.
13. (safflower adj4 oil*).ti,ab.
14. (sesame adj4 oil*).ti,ab.
15. ((soy bean or soybean) adj4 (oil* or fat*)).ti,ab.
16. (so?a adj4 oil*).ti,ab.
17. so?aoil*.ti,ab.
18. (soy adj4 oil*).ti,ab.
19. (sunflower adj4 oil*).ti,ab.
20. helianth*.ti,ab.
21. (grapeseed adj4 oil*).ti,ab.
22. (canola adj4 oil*).ti,ab.
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. double blind procedure/
25. single blind procedure/
26. randomized controlled trial/
27. ((double* or single*) adj blind*).ti,ab.
28. (random* or placebo*).ti,ab.
29. 24 or 25 or 26 or 27 or 28
30. (animal/ or nonhuman/) not human/
31. 29 not 30
32. 23 and 31
F E E D B A C K
Interpretation of e2ect estimates, 18 July 2018
Summary
I am not clear how the quoted RRs and CIs in the abstract support statements of no effect in one part but statements of effect in another
part. It seems that throughout the CIs comprehensively span unity. For example, how is a statement of 'probably reduces risk of CHD
mortality' supported by the metrics '(1.1% to 1.0%, RR 0.95, 95% CI 0.72 to 1.26, 18,353 participants; 193 CHD deaths, 3 RCTs'? That seems
like an entirely null result.
Reply
Thank you for your query.
We described the process of deciding whether there was “little or no effect”, or a positive or negative effect, in the methods section of the
review (under “Summary of findings table”).
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It was agreed with the World Health Organization (WHO) Nutrition Guidance Expert Advisory Group (NUGAG) Subgroup on Diet and Health,
who commissioned this review as part of a wider set that an effect size of 8% (either way, so RR > 1.08 or < 0.92) in the point estimate of the
risk ratio would suggest benefit or harm. Presence or absence of effect is decided on the basis of the pre-stated outcome measure, here
RR. This quality of this finding was assessed through the GRADE process (which is represented in the Summary of Findings tables).
• Wide confidence intervals lead to downgrading for imprecision,• changes in results in sensitivity analyses lead to downgrading for risk of bias,• skewed funnel plots or knowledge of quantities of missing data lead to downgrading for publication bias,• heterogeneity of results (high I2) lead to downgrading for inconsistency, and• limited representativeness of included populations lead to downgrading for indirectness.
We used absolute risk or NNT to describe the scale of effect where an effect was suggested – this could be large or small (all in this review
were very small).
You are absolutely correct in pointing out that this means that ALA intake probably makes little or no difference to CHD mortality. We
apologise for this confusion, which resulted from us using an earlier cut-oC of 7% to consider effectiveness. The effect for CV events is
still “ALA intake may reduce the risk of cardiovascular events but by a very small amount (from 4.8 to 4.7%)” even though the effect is RR
0.95 (95% CI 0.83 to 1.07) as the sensitivity analysis limiting to studies at low summary risk of bias suggested a 9% reduction in risk (RR
0.91, 95% CI 0.79 to 1.04, I2 = 0%). Effects of ALA on arrhythmia are clearer (main analysis suggests RR 0.79, 95% CI 0.57 to 1.10, moderate
quality evidence).
This finding has now been corrected in the review.
Thank you for your keen eye! We hope this clarifies how decisions were made and effects expressed within the review (and the review
series).
Contributors
Feedback submitted by: Bruce Neal
Response by Lee Hooper, contact author of review, and Bill Cayley, feedback editor of Cochrane Heart
Dosing and conclusions, 19 July 2018
Summary
Most of the CVD OR ranges listed for lcN3 data showed zones of significant OR benefit. No dosing information was included. I question the
study's "conclusions", and believe that a more sensitive analysis of the data could easily show benefit in terms of CVD risk reduction.
Reply
Thank you for your comments, and your attention to the question of dosing. While with any intervention it certainly might seem plausible
that a higher dose would be more likely to show benefit than a lower dose, this was not borne out in the studies that met inclusion criteria
for this Review. As outlined in the Summary of Findings Tables, and summarized in the Abstract, the authors “found no evidence of dose-
response or duration effects for any primary outcome, but there was a suggestion of greater protection in participants with lower baseline
omega-6 intake across outcomes.”
Contributors
Feedback submitted by: TR Morris
Response by Lee Hooper, contact author of review, and Bill Cayley, feedback editor of Cochrane Heart
W H A T ' S   N E W
 
Date Event Description
28 November 2018 Feedback has been incorporated We have responded to feedback by two parties.
28 November 2018 Amended Effects of alpha-linolenic acid on coronary heart disease mortal-
ity now correctly interpreted as "little or no effect" as effect size
was < 8%.
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Date Event Description
Effects of long-chain omega-3 and alpha-linolenic acid on serum
high-density lipoprotein reinterpreted as "little or no effect" as
changes were < 5% of baseline.
Study flow corrected.
28 November 2018 New citation required but conclusions
have not changed
The amendments did not change our conclusions.
 
H I S T O R Y
Protocol first published: Issue 2, 1999
Review first published: Issue 4, 2004
 
Date Event Description
13 March 2018 New citation required and conclusions
have changed
This update now reports arrhythmia (atrial fibrillation) and car-
diovascular mortality data. Data now included from 79 RCTs
(112,059 participants) lasting at least one year, of which 25 were
at low summary risk of bias.
We added the following outcomes to the list of primary out-
comes upon the request of World Health Organization (WHO) Nu-
trition Guidance Expert Advisory Group (NUGAG) Subgroup on
Diet and Health.
1. Cardiovascular mortality.
2. Arrhyhtmia (new and recurrent).
We altered inclusion criteria to include only RCTs of at least 12
months' duration (rather than 6 months as previously), and we
excluded cohort studies.
We are assessing effects of long-chain omega-3 fats separately
from effects of alpha-linolenic acid (as planned in the previously
published version).
27 April 2017 New search has been performed Electronic searches updated to 27 April 2017
14 March 2012 Amended Additional tables re-numbered
16 October 2011 New search has been performed Searches updated to July 2011.
Cohort studies not included in this update, and previously in-
cluded cohort studies and related text have been removed.
Previously included trials where we know that no deaths or pri-
mary or secondary health events occurred were removed.
New secondary outcomes added (fatal and non-fatal arrhyth-
mias, and diabetes)
Cardiovascular mortality added as a primary outcome.
9 September 2008 Amended Converted to new review format.
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Date Event Description
1 August 2004 New citation required and conclusions
have changed
Substantive amendment
 
C O N T R I B U T I O N S   O F   A U T H O R S
LH and CDS conceived and led the original version of this review; LH, CDS, HM and HVW were authors of the original version of this review.
LH designed the searches, and CB developed, refined, ran and de-duplicated them. ASA, TJB, JSB, PB, GCT, KHOD, HVW, FS and LH screened
titles and abstracts; ASA, JSB, PB, GCT and LH assessed full-text papers for inclusion; LH, PB and JSB searched trials registers and assessed
entries for inclusion; LH and ASA located full texts, managed assessment and collection of titles, abstracts and full texts, data extraction
and risk of bias assessment. All authors carried out data extraction and assessed risk of bias. LH, KHOD and JSB designed risk of bias
assessment; JSB, KHOD, TJB, ASA and LH wrote to study authors; LH, KHOD, JSB, TJB and ASA carried out data checks; JSB, TJB, LH and ASA
tabulated intake and status data. FS, KHOD, JSB, HVW, CDS and LH provided methodological support. ASA, FKA and LH entered data into
RevMan and ran meta-analyses, ASA and LH carried out sensitivity and subgroup analyses, and LH the meta-regression. ASA wrote the first
draW of the review and LH the WHO NUGAG Subgroup on Diet and Health report; both carried out GRADE assessment and interpretation.
All authors critically read and commented on the final draW and agreed on it for submission.
D E C L A R A T I O N S   O F   I N T E R E S T
ASA: none known.
TJB: none known.
JSB: none known.
PB: none known.
GCT: none known.
HJM: none known.
KHOD: none known.
FKA: none known.
CDS: none known.
HVW: none known.
FS: none known.
LH: none known.
S O U R C E S   O F   S U P P O R T
Internal sources• University of East Anglia, UK.• Cochrane Heart Group, UK.
This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Heart Group. The
views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Pro-
gramme, NIHR, NHS or the Department of Health, UK
External sources• World Health Organization nutrition guidance expert advisory group (NUGAG), Not specified.
WHO NUGAG Subgroup on Diet and Health requested and funded the update and extension of this review.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
Differences between the previous version of this review (2004) and this update (2018):
• Authors altered. The Acknowledgments recognise authors of the previous version who chose not to participate in this update.• Background updated.• Objectives: primary objective altered from 'Do dietary or supplemental omega-3 fatty acids alter total mortality, cardiovascular
events, cancers or other adverse events?' to 'Do long-chain omega-3 (LCn3, fish-based omega-3 fats) or ALA (plant-based omega-3 fats)
fats alter risk of all-cause mortality, cardiovascular deaths, cardiovascular events, coronary heart disease deaths, coronary heart dis-
ease events, stroke, arrhythmia, adiposity and lipids?' This change in emphasis, which we anticipated in the original review, focuses on
long-chain omega-3 fats (EPA, DHA, DPA) and ALA separately. We discuss changes in outcomes assessed below.
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• Secondary questions: we added assessment of effects of omega-3 fats (including both LCn3 and ALA) as a secondary question.• Types of studies included: included RCTs had to be at least one year in duration in the update (the limit was six months in the original
review). We excluded cohort studies from the update.• Types of outcomes: primary outcomes assessed were updated, removing cancers and adverse events as primary outcomes and
adding cardiovascular deaths, coronary heart disease deaths and events, stroke and arrhythmia (atrial fibrillation) as primary out-
comes. Adiposity and lipids were added as key secondary outcomes. Cancer outcomes and other non-cardiovascular outcomes, in-
cluding diabetes, were assessed in separate reviews (Abdelhamid 2018; Abdelhamid 2017; Brown 2017; Hanson 2017a; Hanson 2017b;
Jimoh 2017; Thorpe 2017).• Secondary outcomes: we added new secondary outcomes (major adverse cardiac or cerebrovascular events (MACCEs), myocardial
infarction, sudden cardiac death, angina, heart failure, peripheral arterial disease, re-vascularisation and acute coronary syndrome).
Blood pressure (a secondary outcome in the original review) became a tertiary outcome in the update. We dropped urinary thrombox-
ane and participant fatty acid data as secondary outcomes but collected fatty acid data to help assess compliance.• Risk of bias: we updated this review to incorporate the Cochrane 'Risk of bias' tool (for all included studies). We slightly updated our
assessment of summary risk of bias from low summary risk when "allocation concealment was adequate, and participant, provider
and outcome assessor blinding were all coded 'yes'" to low summary risk for a supplement or capsule type trial where "we judged
randomisation, allocation concealment, blinding of participants and personnel, and blinding of outcome assessors to be adequate" and
for a dietary advice or all-food provided type trial where "we judged randomisation, allocation concealment, and blinding of outcome
assessors to be adequate".• Subgroup analyses: in the update we carried out separate subgroup analyses for LCn3 and ALA studies. Subgrouping in the update
was as in the original review (by dose, dietary or supplemental source and trial duration), with the addition of some new subgroups.
We added new subgroup analyses at the request of the WHO NUGAG Subgroup on Diet and Health.* Replacement of SFA, MUFA, omega-6 fats, fat mixture, carbohydrates or sugars, non-fat or no placebo (or unclear) by LCn3 or ALA.* Primary prevention versus secondary prevention of CVD.* Statin use (< 50% of control group on statins, ≥ 50% of control group on statins, use of statins unclear).* Baseline LCn3 or ALA intake.• Sensitivity analyses: updated for this review. Limiting analyses to studies at low summary risk of bias was continued in the update
from the original review, and we added sensitivity analyses by study size (retaining only trials that randomised at least 100 participants
across all study arms), fixed-effect meta-analysis and compliance (retaining only studies at low risk of compliance bias, this latter at
the request of WHO NUGAG Subgroup on Diet and Health).• Heterogeneity: the original review used Cochran's test while the update used I2. This reflects current best methodology.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Dietary Supplements;  Arrhythmias, Cardiac  [epidemiology];  Cardiovascular Diseases  [diet therapy]  [mortality]  [*prevention & control];
  Cause of Death;  Coronary Disease  [mortality];  Docosahexaenoic Acids  [therapeutic use];  Eicosapentaenoic Acid  [therapeutic use];  Fatty
Acids, Omega-3  [adverse eCects]  [*therapeutic use];  Primary Prevention;  Randomized Controlled Trials as Topic;  Secondary Prevention;
  Stroke  [epidemiology];  Treatment Outcome;  alpha-Linolenic Acid  [therapeutic use]
MeSH check words
Adult; Humans
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